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ABSTRACT 
 This monograph presents a five-step treatment protocol to prevent and reverse Peripheral 
Neuropathy (PN)/Peripheral Arterial Disease (PAD), based on the following systemic medical 
principle: at the present time, removal of cause is a necessary, but not necessarily sufficient, 
condition for restorative treatment to be effective.  Implementation of the five-step PN/PAD 
treatment protocol is as follows: 
FIVE-STEP TREATMENT PROTOCOL TO PREVENT AND REVERSE PN/PAD 
 
 Step 1: Obtain a detailed medical and habit/exposure history from the patient.   
 Step 2: Administer written and clinical performance and behavioral tests to assess the 
severity of the higher-level symptoms and degradation of executive functions 
 Step 3: Administer laboratory tests (blood, urine, imaging, etc) 
 Step 4: Eliminate ongoing PN/PAD contributing factors 
 Step 5: Implement PN/PAD treatments 
 
 
 This individually-tailored PN/PAD treatment protocol can be implemented with the data 
currently available in the biomedical literature.  Additionally, while the methodology 
developed for this study was applied to comprehensive identification of diagnostics, contributing 
factors, and treatments for PN/PAD, it is general and applicable to any chronic disease/condition 
that, like PN/PAD, has an associated substantial research literature. Thus, the protocol and 
methodology developed to prevent or reverse PN/PAD can be used to prevent or reverse any 
chronic disease (with the possible exceptions of individuals with strong genetic predispositions 
to the disease in question or who have suffered irreversible damage from the disease). 
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PREFACE 
 Why was this monograph written, what are its contents, what is new, who is the intended 
audience, and how will readers benefit from it? 
Motivation 
 Non-communicable diseases have overtaken communicable diseases as the leading cause 
of global mortality.  The impacts of non-communicable disease expansion on healthcare and 
associated costs have been dramatic.  In the USA, these costs, and how to deal with them, have 
become a central political issue. 
 The mainstream medical approach emphasizes treatments over prevention for non-
communicable diseases.  Given the expansion of non-communicable diseases, the present 
treatment-dominant approach is insufficient.  More balance between treatment and prevention is 
required.    Eliminating the actionable foundational causes of these diseases is at least as 
important as applying new treatments, if there is to be any hope for full or partial reversal of non-
communicable diseases.  
 Toward that end, I developed the following systemic medical principle that would form 
the bedrock of a healing protocol for diseases: At the present time, removal of cause is a 
necessary, but not necessarily sufficient, condition for restorative treatment to be effective 
(where "removal" encompasses "neutralization" in those cases where actual "removal" is not 
possible, and "restoration" encompasses restoration of health to the organ/tissue as well as 
restoration of function).  To prevent disease, the actionable foundational causes that underlie the 
disease symptoms need to be identified and removed as comprehensively, thoroughly, and 
rapidly as possible.  To reverse disease (if irreversible damage has not been done and genetic 
predisposition to the disease in question is not a dominant factor), the preventive steps above 
need to be implemented as well.  If the preventive protocols alone are inadequate for reversing 
disease progression, they need to be augmented by treatments.  The first step in either disease 
prevention or reversal is to identify the full spectrum of potential foundational 
causes/contributing factors for the disease(s) of interest. 
 The present monograph identifies a wide spectrum of PN/PAD contributing factors, 
treatments, biomarkers, and symptoms/related diseases.  It shows linkages among these 
categories, and especially the impacts of contributing factors and treatments on biomarkers and 
symptoms.  The final product is a PN/PAD treatment protocol that can be tailored to the 
individual. 
Contents 
 The overall theme of the present monograph is preventing and reversing PN/PAD based 
on the systemic medical principle described above.  The specific focus of the present monograph 
is identifying, categorizing, and analyzing the existing PN/PAD contributing factors and 
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treatments, and potential PN/PAD treatments.  Identification of these existing and potential 
PN/PAD contributing factors, and potential PN/PAD treatments is based on analysis of many 
thousands of biomedical journal articles from the premier biomedical literature. 
 Moreover, identifying both PN/PAD contributing factors and treatments, in concert with 
identifying their impacts on specific PN/PAD biomarkers, symptoms, behaviors, performance, 
etc, allows PN/PAD treatment protocols to be tailored to each person's unique condition.  This 
monograph presents the comprehensive PN/PAD treatment protocol I have developed, and 
provides illustrative examples of how the PN/PAD treatment protocol would be implemented.  
Sufficient data and text are presented to make this monograph self-contained. 
 There is a lengthy section in the present monograph describing  
1) the text mining/information technology advances that allowed the existing PN/PAD 
contributing factors, and existing and potential PN/PAD treatments to be extracted efficiently 
from the large numbers of  journal articles retrieved from the premier biomedical literature, and  
2) the impacts of these contributing factors and treatments extracted from the literature.   
 Major advances were made in the text mining approach for extracting both existing and 
potential  treatments, and existing contributing factors, from the biomedical literature (and their 
impacts).  These advances could be applied to identifying existing and potential foundational 
causes for any disease from the literature as well. 
Novelty 
 While the individual existing and potential PN/PAD treatments identified in this 
monograph are "known", in the sense that they exist scattered throughout the published literature 
(although the potential PN/PAD treatments have not been previously associated with PN/PAD in 
the literature), they have not been integrated to the extent they are integrated in this monograph.  
The new "insights" in this monograph are:  
 1) the sheer number of existing PN/PAD contributing factors, and existing and potential 
PN/PAD treatments;  
 2) the sheer number of potential combinations of PN/PAD contributing factors and 
treatments that have to be identified and researched (many of whose individual components have 
not yet been identified); 
 3) the sheer number of PN/PAD biomarkers and symptoms that can be used as 
diagnostics to identify causes and treatments for individual patients; 
 4) the approach for discovering treatments from the non-PN/PAD literature, which allows 
both the re-purposing of drugs that have been used for treating other diseases and identification 
of non-drug substances that will correct the abnormal PN/PAD biomarker values and symptoms; 
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 5) the PN/PAD treatment protocol that can be tailored to any individual patient. 
Audience 
 There are three communities to whom this monograph is targeted.  First is the "PN/PAD 
prevention and reversal" community.  This encompasses the public health community, the 
PN/PAD research community, medical practitioners involved clinically with PN/PAD prevention 
and reversal, healthcare support personnel for PN/PAD patients, and individuals interested in 
what the present approach has to offer (they should heed the warnings in the Disclaimer).  The 
PN/PAD treatment taxonomies and discussions in Chapter 2, and the treatment protocol in 
Chapter 3, should be of particular interest to this community.   
 Second is the text mining and information technology community.  This would cover the 
full spectrum of researchers interested in extraction of useful information from any type of text, 
since the techniques developed in this monograph can be readily adapted to extracting useful 
information from myriad types of biomedical and non-biomedical text.  The concepts, 
algorithms, and discussions in Chapter 6 should be of special interest to this community. 
 Third is the broader medical and health policy community.  While the findings in the 
present monograph relate specifically to PN/PAD prevention and reversal, the methodology is 
applicable to prevention and reversal of any disease that has an associated substantial research 
literature. 
Benefits 
 The interested reader of this monograph will gain a deeper understanding of the main 
contributing factors to, and treatments for, PN/PAD.  The reader will also gain an understanding 
of the broad spectrum of rigorous actions required to prevent and/or reverse PN/PAD.   Finally, 
and most importantly, the motivated reader will see that much of what is required to prevent and 
reverse PN/PAD may be available in the here and now (for those who have not suffered 
irreversible damage or do not have an overwhelming genetic predisposition for PN/PAD)! 
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EXECUTIVE SUMMARY 
ES-1.  Overview 
 The treatment protocol proposed for prevention and reversal of PN/PAD in the present 
monograph is based on the following systemic medical principle [Kostoff, Porter, Buchtel, 
2018]: At the present time, removal of cause is a necessary, but not necessarily sufficient, 
condition for restorative treatment to be effective.  This principle is general, and applicable to 
prevention and reversal of any disease.  The methodology that has been developed based on this 
principle is general, and applicable to any disease as well. 
 To prevent any disease, the foundational causes that underlie the disease symptoms and 
biomarkers need to be identified and removed as comprehensively, thoroughly, and rapidly as 
possible. To reverse any disease (if irreversible damage from the disease has not been done and 
strong genetic predisposition to the disease is not a dominant factor), the preventive steps above 
need to be implemented, and treatments to reverse the disease progression need to be applied. 
 The efficacy of the methodology for preventing and reversing any disease depends on 
how thoroughly the foundational causes, treatments, biomarkers, and symptoms of the disease of 
interest have been identified.  In the present monograph, a wide spectrum of existing PN/PAD 
foundational causes has been identified using a Literature-Related Discovery and Innovation 
(LRDI) methodology (see Chapter 6 for details of methodology).  Additionally, a wide spectrum 
of existing (and a few newly discovered) PN/PAD treatments and PN/PAD symptoms and 
biomarkers has been identified.  Combining these results allows development of a PN/PAD 
treatment protocol that can be tailored to individual patients. Most importantly, this PN/PAD 
treatment protocol (based on the systemic medical principal described above) is available with 
the information at our disposal today! 
For a more detailed overview, see Chapter 1. 
ES-2.  Results 
ES-2A. Existing PN/PAD Contributing Factors 
 Table 7A-1 contains a list of the ~840 existing contributing factors (in the present 
monograph, 'cause' and 'contributing factor' are used interchangeably) identified in this study, 
and the numbers of records in which they appear, highest first.  The top fifty of these 
contributing factors are shown in Table 2B-1.  Because these are the highest frequency 
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Table 2B-1 - Top Fifty Existing PN/PAD Contributing Factors 
#RECORDS CONTRIBUTING FACTOR 
2507 chemotherapy 
2265 smoking 













393 alcohol consumption 





340 peripheral nerve injury 
337 lifestyle 
332 leprosy 







201 chronic constriction injury 
196 docetaxel 







125 advanced glycosylation end products 
121 capecitabine 
121 tuberculosis 
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Categorization and analysis of these contributing factors will be shown in the next section. 
ES-2B. Factor Matrix of Existing Contributing Factors 
 Figure 2B-1 in the Excel workbook located under the same URL as the present 
monograph (FIGURES_FOR_MONOGRAPH.xlsx - listed under View/Open on the link page) 
contains a factor matrix of the existing PN/PAD contributing factors (click on first tab FIG 2B-
1).  The 29 factor headings are shown below in Table 2B-2.  This listing provides a convenient 
taxonomy for categorizing the myriad contributing factors identified.  Figure 2B-1 lists the 
specific contributing factors that had the strongest influence in determining the theme of each of 
the 29 factors. 
 The main broad categories include:  
-drugs (e.g., antiretroviral, chemotherapy, antifungal, antibiotics, antiarrythmic/cardiovascular, 
statins [PN only]), 
-pesticides/herbicides (e.g., dioxin, Chlorophenoxy herbicides, trichlorophenol, Paraquat, 
Trichlorfon, dichlorvos, mipafox, organophosphate pesticides, malathion, chlorpyrifos), 
-infectious agents (e.g., bacteria, mycobacteria, viruses),  
-occupational/industrial chemicals (e.g., organic solvents, hydrocarbons, dithiocarbamates, 
benzene, organotin, methyl n-butyl ketone),  
-environmental pollutants (e.g., heavy metals, persistent organic pollutants, air pollution, 
bisphenol A),  
-induced injury (e.g., lysophosphatidic acid, N-methyl-D-aspartate, Freund's adjuvant, partial 
sciatic nerve ligation),  
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Table 2B-2 - Factor Matrix-based Categories for PN/PAD Contributing Factors 
FACTOR HEADING 
FACTOR 1 - HIGHLY ACTIVE ANTIRETROVIRAL THERAPY 
FACTOR 2 - CHEMOTHERAPY, ESPECIALLY TAXANES 
FACTOR 3 - ANTIFUNGAL DRUGS 
FACTOR 4 -  
FACTOR 5A - CHEMOTHERAPY, CHRONIC MYELOGENOUS LEUKEMIA 
FACTOR 5B - MYCOBACTERIA 
FACTOR 6 - CHEMOTHERAPY, PROTEASOME INHIBITORS 
FACTOR 7 - ALIPHATIC HYDROCARBONS 
FACTOR 8 - HEPATITIS VIRUS AND DRUGS 
FACTOR 9 - VIRUSES 
FACTOR 10 - ORGANOPHOSPHATE PESTICIDES 
FACTOR 11 - ANTIVIRAL DRUGS FOR AIDS 
FACTOR 12A - OCCUPATIONAL CHEMICALS 
FACTOR 12B - INFECTIOUS AGENTS 
FACTOR 13 - ANTIARRHYTHMIC DRUGS 
FACTOR 14 - ORGANIC SOLVENTS 
FACTOR 15 - FLUOROQUINOLONE ANTIBIOTICS, FOCUSED ON TUBERCULOSIS 
FACTOR 16 - BACTERIA AND INDUSTRIAL CHEMICALS 
FACTOR 17 - BACTERIA AND CHRONIC MYELOGENOUS LEUKEMIA DRUGS 
FACTOR 18 - HEAVY METALS 
FACTOR 19A - ENVIRONMENTAL POLLUTANTS 
FACTOR 19B - HYDROCARBONS, MAINLY ALIPHATIC SOLVENTS 
FACTOR 20 - HERBICIDES 
FACTOR 21 - VACCINES 
FACTOR 22 - CHEMOTHERAPY, ESPECIALLY VINCA ALKALOIDS AND TAXANES 
FACTOR 23A - DITHIOCARBAMATES 
FACTOR 23B - HYDROCARBONS, ESPECIALLY TOXIC ALCOHOLS 
FACTOR 24 - CHEMOTHERAPY 
FACTOR 25A - INDUCED INJURY 
FACTOR 25B - LIFESTYLE 
 
ES-2C. Contributing Factors-Contributing Factors Matrix 
 To display the inter-relationships among the PN/PAD causes, all the causes identified are 
matrixed together in Figure 2B-2 (Excel Workbook).  The cell numbers reflect the co-
occurrences of the two causes defining the cell.  Thus, smoking co-occurs with high cholesterol 
diet in 397 records (third column, second row).   
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ES-2D.  Contributing Factors Related to PN and to PAD 
 While many of the contributing factors applied relatively equally to PN and PAD, some 
were focused exclusively on PN and others on PAD.  To identify the relative contributions, the 
symptoms/diseases related to PN and to PAD were aggregated separately.  Table 7A-4 shows the 
numbers of records in which the contributing factors co-occur with PN and with PAD.  The top 
fifty are shown in Table 2B-5. 
 Causes shared more or less equally between PN and PAD include infections, trauma, 
alcohol, radiation, anasthesia, antibiotics, advanced glycation end products, Hepatitis C virus, 
spinal cord injury, burn, high fat diet, inactivity, environmental factors, arsenic, 
lipopolysaccaride, drug abuse, etc.  Causes weighted toward PN include chemotherapy agents, 
radiation therapy, statins, chronic constriction injury, tuberculosis, antiviral agents, 
mycobacterium, pesticides, solvents, acrylamide, acetone, occupational exposures, etc.  Causes 
weighted toward PAD include smoking, high cholesterol diet, dialysis, sedentary, lifestyle, air 
pollution, atenolol, etc. 
Table 2B-5 - Contributing Factors Relevant to PN and to PAD 
#RECORDS CAUSE #PN RECORDS #PAD RECORDS 
2507 chemotherapy 2315 119 
2265 smoking 275 2124 
1140 High cholesterol diet 261 1004 
985 paclitaxel 874 69 
821 HIV-1 696 134 
745 dialysis 139 643 
708 infections 391 393 
683 viruses 548 182 
570 cisplatin 515 20 
570 trauma 269 260 
545 depression 326 251 
524 oxaliplatin 499 1 
508 hemodialysis 105 428 
503 Bortezomib 473 32 
442 alcohol 232 230 
412 statins 43  
393 alcohol consumption 266 147 
378 highly active antiretroviral therapy 344 37 
361 radiation 189 134 
357 anesthesia 157 139 
351 thalidomide 333 56 
347 vincristine 328 11 
340 peripheral nerve injury 229 18 
337 lifestyle 78 283 
332 leprosy 206 19 
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329 radiation therapy 245 50 
324 taxanes 303 7 
323 cyclophosphamide 288 80 
314 hepatitis 267 142 
296 Streptozotocin 273 40 
230 carboplatin 215 5 
217 platinum 194 6 
201 chronic constriction injury 179 1 
196 docetaxel 183 4 
186 Hepatitis C Virus 155 107 
184 antibiotics 101 102 
162 doxorubicin 148 17 
149 Arsenic 78 73 
148 stavudine 143 3 
140 5-fluorouracil 130 3 
131 sedentary 34 108 
125 advanced glycosylation end products 74 74 
121 capecitabine 103  
121 tuberculosis 101 22 
119 zidovudine 115 4 
118 Iatrogenic 55 37 
118 Taxol 103 3 
 
ES-2E. Existing PN/PAD Treatments 
 Table 7A-5 contains a list of the existing PN/PAD treatments identified in this study, and 
the numbers of records in which they appear, highest first.  The top fifty of these treatments are 
shown in Table 2C-1.  Because these are the highest frequency treatments, many will be very 
general.   
Table 2C-1 - Top Fifty Existing PN/PAD Treatments 








1308 artery bypass grafting 
1228 angioplasty 
828 stents 
812 growth factor 
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541 endovascular treatment 




450 bypass surgery 
449 diet 






349 vascular endothelial growth factor 
337 antiplatelet therapy 
317 opioid 
288 supplementation 
266 coronary intervention 








207 vitamin B12 
206 nerve growth factor 
190 smoking cessation 
189 Spinal Cord Stimulation 
172 Gene therapy 
 
ES-2F. Factor Matrix of Existing Treatments 
 Figure 2C-1 in the Excel workbook located under the same URL as the present 
monograph (FINAL_FIGURES.xlsx - listed under View/Open on the link page) contains a factor 
matrix of the existing PN/PAD  (click on FIG 2C-1).  The thirty factor headings are shown below 
in Table 2C-2.  This listing provides a convenient taxonomy for categorizing the myriad 
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treatments identified.  Figure 2C-1 lists the specific treatments that had the strongest influence in 
determining the theme of each of the thirty factors. 
 The main categories include:  
-drugs (e.g., antidepressants, anticonvulsants, opioids, muscle relaxants, 
antiplatelet/antithrombotic/anticoagulant agents, calcium channel blockers, antihypertensive 
agents, serotinin reuptake inhibitors, endocannabinoid deactivation inhibitors, cannabinoids, 
dipeptidyl peptidase-4 inhibitors, etc); 
-surgery (e.g., angioplasty, arterial bypass, stents, revascularization, amputation, spinal cord 
stimulation, deep brain stimulation, etc) 
-supplements (e.g., omega-3 fatty acids, fish oil, antioxidants, Vitamin E, Vitamin C, Vitamin 
B12, alpha lipoic acid, biotin, Vitamin D, magnesium, etc)  
-herbs (e.g., herbal medicines, Chinese herbs, Buyang Huanwu decoctionn Guizhi-shaoyao-
zhimu decoction, Huoxue Kangyuan decoction, Plantaginis Semen, Aucubin, Goshajinkigan, 
kampo, etc)  
-angiogenesis (growth factors, cell therapy, etc) 
 Table 2C-2 - Factor Matrix-based Categories for PN/PAD Treatments 
FACTOR HEADING 
FACTOR 1 - ANTIDEPRESSANTS/ANTICONVULSANTS/OPIODS 
FACTOR 2 - ANTIPLATELET/ANTITHROMBOTIC THERAPY 
FACTOR 3 - ENDOCANNABINOID DEACTIVATION INHIBITORS 
FACTOR 4 - ANTIHYPERTENSIVE AGENTS 
FACTOR 5 - SEROTININ REUPTAKE INHIBITORS 
FACTOR 6 - CANNABINOIDS/ANGIOGENESIS 
FACTOR 7 - MUSCLE RELAXANTS 
FACTOR 8 - ENDOVASCULAR TREATMENT 
FACTOR 9A - CANNABINOIDS 
FACTOR 9B - ANGIOGENESIS/GROWTH FACTORS/CELL THERAPY 
FACTOR 10 - ANTICOAGULANTS 
FACTOR 11 - ANTIEPILEPTICS/ANTICONVULSANTS 
FACTOR 12 - ANTIHYPERTENSIVE AGENTS, ESPECIALLY ACE INHIBITORS 
FACTOR 13 - PERIPHERAL NERVE REGENERATION AND PROTECTION 
FACTOR 14 - OMEGA-3 FATTY ACIDS 
FACTOR 15 - LOW-DENSITY LIPOPROTEIN REDUCTION THERAPY, ESPECIALLY STATINS 
FACTOR 16 - NEUROPATHIC PAIN MANAGEMENT, ESPECIALLY OPIOIDS 
FACTOR 17 - REPURPOSED THERAPIES FOR NEUROPATHY 
FACTOR 18 - CALCIUM CHANNEL ANTAGONISTS 
FACTOR 19 - CXCR4 ANTAGONISTS FOR NEUROPATHIC PAIN 
FACTOR 20 - PHENOLS 
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FACTOR 21 - PROSTACYCLIN ANALOGUES 
FACTOR 22A - GROWTH FACTORS 
FACTOR 22B - CELL THERAPY 
FACTOR 23 - GLYCOSAMINOGLYCANS 
FACTOR 24 - HERBAL MEDICINE 
FACTOR 25 - ANALGESICS/NSAIDs 
FACTOR 26 - SUPPLEMENTATION 
FACTOR 27A - ANTIPLATELET/ANTITHROMBOTIC THERAPY 
FACTOR 27B - ANTITHROMBOTIC/ANTICOAGULANT AGENTS 
 
ES-2G. Treatment-Treatment Matrix  
 To display the inter-relationships among the PN/PAD treatments, all the treatments 
identified  are matrixed together in Figure 2C-2 (Excel Workbook).  The cell numbers reflect the 
co-occurrences of the two treatments defining the cell.  Thus, walking co-occurs with drug in 
122 records (second column, sixth row).   
ES-2H. Treatments related to PN and to PAD 
 While many of the treatments applied relatively equally to PN and PAD, some were 
focused exclusively on PN and others on PAD.  To identify the relative contributions, the 
symptoms/diseases related to PN and to PAD were aggregated separately.  Table 7A-8 shows the 
numbers of records in which the treatments co-occur with PN and with PAD.  The top fifty are 
shown in Table 2C-5. 
Table 2C-5 - Top Fifty Treatments Relevant to PN and to PAD 
#RECORDS TREATMENT #PN RECORDS #PAD RECORDS 
5105 surgery 1172 3427 
3638 drug 2279 1321 
2402 amputation 591 2064 
1920 revascularization 56 1839 
1766 inhibitor 951 813 
1358 walking 304 1058 
1328 exercise 229 1124 
1308 artery bypass grafting 59 1154 
1228 angioplasty 23 1149 
828 stents 7 751 
812 growth factor 377 426 
754 insulin 467 465 
745 dialysis 139 643 
632 medications 320 338 
588 operation 122 374 
576 aspirin 33 552 
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567 analgesic 479 61 
541 endovascular treatment 3 499 
507 vascular surgery 17 466 
499 implantation 69 393 
489 angiogenesis 56 439 
459 rehabilitation 149 262 
450 bypass surgery 13 421 
449 diet 239 233 
447 glycemic control 333 247 
420 Ligation 274 110 
411 corticosteroid 328 148 
382 catheter 41 297 
370 statin  333 
353 Clopidogrel 8 345 
349 vascular endothelial growth factor 105 257 
337 antiplatelet therapy 4 330 
317 opioid 271 28 
288 supplementation 160 124 
266 coronary intervention  261 
252 antihypertensive agents 36 238 
242 Gabapentin 235 16 
240 PNS 166 23 
233 endarterectomy 2 222 
233 pregabalin 230 5 
228 antidepressant 203 27 
221 anticoagulant 24 196 
215 Cilostazol 6 211 
207 vitamin B12 160 50 
206 nerve growth factor 170 8 
190 smoking cessation 9 184 
189 Spinal Cord Stimulation 122 84 
172 Gene therapy 37 128 
172 IL-6 75 95 
167 heparin 15 146 
 
 Treatments shared more or less equally between PN and PAD include insulin, growth 
factors, diet, antioxidants, folic acid, carnitine, cannabis, DHA, etc.  Treatments weighted toward 
PN include analgesics, opioids, gabapentin, pregabalin, antidepressants, Vitamin B12, capsaicin, 
morphine, zidovudine, amitryptiline, alpha lipoic acid, carbamazapine, anthracycline, thiamine , 
etc.  Treatments weighted toward PAD include revascularization, exercise, walking, artery 
bypass grafting, angioplasty, stents, aspirin, endovascular treatment, vascular surgery, 
angiogenesis, catheter, statins, clopidogrel, antiplatelet therapy, antihypertensive agents, 
warfarin, etc. 
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ES-2I.  Potential PN/PAD Treatments from LRDI Discovery 
 The LRDI Discovery method outlined in section 6B5 and presented in detail in Appendix 
6-1 was used to identify potential PN/PAD treatment candidates.  Even with the abbreviated 
query shown, hundreds of potential PN/PAD treatment candidates were retrieved (mid-August 
2019), and thousands more could have been easily obtained with an expanded query.  Ten of the 
candidates that were evaluated and validated for Discovery are shown in Table 2C-6.  While 
combinations of two biomarkers were the criteria for retrieving potential PN/PAD treatment 
candidates, the impacts of the treatment on myriad other biomarkers were included in the 
retrieved article as well.  All the biomarkers impacted by the candidate treatment (listed in the 
abstract) are shown in parentheses after the quoted material. 
Table 2C-6 - Potential Treatments for PN/PAD 
1. Dendrobium nobile Lindl 
"DNLA [Dendrobium nobile Lindl. alkaloids] protects mice from CCl4 induced liver injury, 
probably through the activation of the Nrf2 signaling pathway." [Li, Shiyue; Zhou, Jinxin; Xu, 
Shangfu; et al, 2019] 
(biomarkers altered: oxidative stress, Nrf2, alanine aminotransferase, aspartate aminotransferase, 
malondialdehyde) 
2. CPUY192018 
" CPUY192018 exhibited cytoprotective effects by enhancing the Nrf2-ARE regulated 
antioxidant system and diminished the LPS-induced inflammatory response by hindering the 
ROS-mediated activation of the NF-kappaB pathway.....  by activating Nrf2, CPUY192018 
treatment balanced renal oxidative stress and suppressed inflammatory responses." [Lu, Meng-
Chen; Zhao, Jing; Liu, Yu-Ting; et al, 2019] 
(biomarkers: inflammation, oxidative stress, Nrf2, ROS, NF-kappaB) 
3. Swertiamarin OR Gentiana macrophylla Pall 
"Collectively, Swe [Swertiamarin] could be considered as a promising protective agent against 
cerebral I/R injury through suppressing oxidative stress by activation of the Nrf2 protective 
pathway." [Wang, H. et al, 2019] 
(biomarkers: apoptosis, oxidative stress, ROS, Nrf2, NQO1, HO-1) 
4. Malva sylvestris 
"MS [Malva sylvestris] extract can protect the kidney against toxic effects of gentamicin, and 
thus, the degree of harmful effects of nephrotoxicity on remote organs including the liver will 
be decreased." [Mohamadi Yarijani, Z. et al, 2019] 
(biomarkers: oxidative stress, creatinine, urea-nitrogen, aspartate aminotransferase, alanine 
aminotransferase, alkaline phosphatase, malondialdehyde, inflammation, TNF-alpha, ICAM-1) 
5. Avenathramide C 
"Avn C [Avenathramide C] protects normal human skin fibroblasts against oxidative stress 
and inflammatory response through NF-kappaB inhibition and Nrf2/HO-1 activation " 
[Wang, C. and Eskiw, C.H, 2019] 
(biomarkers: oxidative stress, free radical levels, inflammation, tumor necrosis factor-alpha, NF-
kappaB, HO-1, Nrf2) 
6. SK-119 OR (E)-5-oxo-1-(4-((2,4,6-trihydroxybenzylidene)amino)phenyl)pyrrolidine-3-
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carboxylic acid 
" Nrf2 Activation by SK-119 [(E)-5-oxo-1-(4-((2,4,6-
trihydroxybenzylidene)amino)phenyl)pyrrolidine-3-carboxylic acid] Attenuates Oxidative 
Stress, UVB, and LPS-Induced Damage " [Kahremany, S. et al, 2019] 
(biomarkers: oxidative stress, Nrf2, inflammation, apoptosis) 
7. pristimerin 
" Pris [pristimerin] exerted protective activity against LPS-induced ALI [acute lung injury] via 
anti-oxidant, anti-inflammatory and anti-apoptotic pathways " [Shaaban, A.A. et al, 2018] 
(biomarkers: inflammation, myeloperoxidase, lesions, oxidative stress, tumor necrosis factor-
alpha, interleukin-6, apoptosis, Bax, caspase-3, Bcl2) 
8. Astilbin 
" Astilbin ameliorates cisplatin-induced nephrotoxicity through reducing oxidative stress and 
inflammation. " [Wang, S.-W. et al, 2018] 
(biomarkers: oxidative stress, inflammation, apoptosis, ROS, NRF2, TNF-alpha, NF-kappaB, 
iNOS, COX-2) 
9. Ac-YVAD-cmk 
" Pharmacological [Ac-YVAD-cmk] Inhibition of Caspase-1 Ameliorates Cisplatin-Induced 
Nephrotoxicity through Suppression of Apoptosis, Oxidative Stress, and Inflammation in 
Mice. " [Kim, J.-Y. et al, 2018] 
(biomarkers: caspase-1, blood urea nitrogen, creatinine, caspase-3, apoptosis, oxidative stress,  
inflammation) 
10. Pterostilbene 
" Protective Effects of Pterostilbene Against Myocardial Ischemia/Reperfusion Injury in 
Rats." [Wu, M. et al, 2017] 
(biomarkers: lactate dehydrogenase, creatine kinase-MB, oxidative stress, inflammation, Gas6, 
Axl, Bcl-2, Bax, apoptosis) 
 
 
ES-2J. Existing PN/PAD Characteristics 
 Table 7A-9a contains a list of the 757 existing biomarkers identified in this study, and the 
numbers of records in which they appear, highest first.  The top fifty of these biomarkers are 
shown in Table 2D-1a.  Because these are the highest frequency biomarkers, many will be very 
general.   





2277 nerve conduction velocity 
2038 ankle brachial index 
1549 blood pressure 
1402 stenosis 
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1156 body mass index 
1142 neurotoxic 
1139 total cholesterol 
1138 blood glucose levels 
1091 degeneration 
1061 hemoglobin A1c 








671 growth factor 
640 Schwann cell 
616 demyelination 
610 pain-free walking distance 




495 low-density lipoprotein cholesterol 
489 angiogenesis 
455 axonal degeneration 
435 Systolic blood pressure 
426 circulation 
425 high-density lipoprotein cholesterol 
419 oxidative stress 
413 plaque 
412 occlusions 
402 albumin level 
399 glomerular filtration rate 
391 ventricular ejection fraction 
382 calcification 
365 nerve damage 
354 neurodegeneration 
349 IgM 




 Areas emphasized include neurotoxicity, neurodegeneration, inflammation, oxidative 
stress, demyelination, angiogenesis, circulation, calcification. 
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 Table 7A-9b contains a list of the existing symptoms/diseases identified in this study, and 
the numbers of records in which they appear, highest first.  The top fifty of these 
symptoms/diseases  are shown in Table 2D-1b.  Because these are the highest frequency 
contributing factors, many will be very general.   
Table 2D-1b - Top Fifty Existing PN/PAD Symptoms/Diseases 
#RECORDS SYMPTOM/DISEASE  
17050 neuropathy 
13577 peripheral neuropathy 
9627 diabetes mellitus 
9078 artery disease 
8114 peripheral artery disease 






2861 neuropathic pain 
2612 stroke 
2152 diabetic peripheral neuropathy 
2071 infection 
2056 myocardial infarction 
2051 cardiovascular disease 
1983 intermittent claudication 
1913 polyneuropathy 
1796 coronary artery disease 
1585 heart disease 
1571 type 2 diabetes mellitus 
1547 critical limb ischemia 
1533 diabetic foot ulcer 
1519 Disorder 
1440 heart failure 
1135 weakness 
879 neutropenia 
878 cerebrovascular disease 
833 sensory neuropathy 
832 retinopathy 




747 renal failure 
731 thrombosis 
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705 ataxia 
675 abdominal aortic aneurysm 
660 nephropathy 
645 angina 
645 renal disease 
625 Congestive heart failure 
623 multiple myeloma 




613 chronic kidney disease 
612 vasculitis 
607 ischemic heart disease 
 
 Diabetes, hypertension, infection, and obesity are of particular note. 
ES-2K. Factor Matrix of Characteristics 
 Figure 2D-1a in the Excel workbook contains a factor matrix of the existing PN/PAD 
biomarkers.  The 28 factor headings are shown below in Table 2D-2a.  This listing provides a 
convenient taxonomy for categorizing the myriad biomarkers  identified.  Figure 2D-1a lists the 
specific biomarkers that had the strongest influence in determining the theme of each of the 28  
factors.  
Table 2D-2a - Factor Matrix-based Categories for PN/PAD Biomarkers 
FACTOR HEADING 
FACTOR 1 - PLASMA LIPIDS 
FACTOR 2 - PROINFLAMMATORY CYTOKINES 
FACTOR 3 - miRNA 
FACTOR 4 - HEME BIOSYNTHESIS DEFICIENCY 
FACTOR 5 - OXIDATIVE STRESS 
FACTOR 6 - FIBRIN DEPOSITION 
FACTOR 7A - GROWTH FACTORS 
FACTOR 7B - ADVANCED GLYCATION END PRODUCTS 
FACTOR 8 - KALLIKREIN-KININ SYSTEM 
FACTOR 9 - APOLIPOPROTEINS 
FACTOR 10 - FATTY ACIDS 
FACTOR 11 - KIDNEY FILTERING 
FACTOR 12 - PLATELET AGGREGATION 
FACTOR 13 - PROINFLAMMATORY MONOCYTES 
FACTOR 14 - AXONAL DEGENERATION 
FACTOR 15 - MATRIX METALLOPROTEINASES 
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FACTOR 16 - ANTIBODIES 
FACTOR 17 - VASCULAR CALCIFICATION 
FACTOR 18 - B12/FOLATE DEFICIENCIES 
FACTOR 19 - ENDOTHELIAL DYSFUNCTION 
FACTOR 20 - ARTERIAL STIFFNESS 
FACTOR 21 - RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS AND LIGANDS 
FACTOR 22 - INSULIN DEFICIENCY 
FACTOR 23A - CELL ADHESION MOLECULES 
FACTOR 23B - ANTI-INFLAMMATORY CYTOKINES 
FACTOR 24 - OXIDATIVE STRESS 
FACTOR 25 - CARDIOVASCULAR DISEASE BIOMARKERS 
FACTOR 26 - VIRAL DAMAGE MARKERS 
 
  Figure 2D-1b contains a factor matrix of the existing PN/PAD 
symptoms/diseases.  The 15 factor headings are shown below in in Table 2D-2b.  This listing 
provides a convenient taxonomy for categorizing the myriad symptoms/diseases identified.  
Figure 2D-1b lists the specific symptoms/diseases that had the strongest influence in determining 
the theme of each of the 15 factors. 
Table 2D-2b - Factor Matrix-based Categories for PN/PAD Symptoms/Diseases 
FACTOR HEADINGS 
FACTOR 1 - REDUCED NEUROMUSCULAR CONTROL 
FACTOR 2 - NON-PAIN DIABETES-RELATED SYMPTOMS/DISEASES 
FACTOR 3 - MOTOR NEURON DISEASES 
FACTOR 4 - NEUROPATHIC PAIN 
FACTOR 5 - CANCER TREATMENT SIDE EFFECTS 
FACTOR 6 - EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS 
FACTOR 7 - POEMS SYNDROME 
FACTOR 8 - ASSOCIATED MAJOR ORGAN DISEASES 
FACTOR 9 - POLYNEUROPATHY 
FACTOR 10 - ISCHEMIA 
FACTOR 11 - DIABETIC NEUROPATHY 
FACTOR 12 - INFECTION-RELATED AUTOIMMUNE DISEASES 
FACTOR 13 - CARDIOVASCULAR DISEASES 
FACTOR 14 - MYOCARDIAL INFARCTION SYMPTOMS 
FACTOR 15 - ARTERY DISEASE 
 
ES-2L. Biomarker-Biomarker Matrix  
 To display the inter-relationships among the PN/PAD biomarkers, all the biomarkers  
identified are matrixed together in Figure 2D-2 (Excel Workbook).  The cell numbers reflect the 
co-occurrences of the two biomarkers defining the cell.   
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                                                                                                                
Executive Summary                                                                                                                                                    26 
ES-2M. Biomarkers related to PN and to PAD 
 While many of the biomarkers applied relatively equally to PN and PAD, some were 
focused more strongly on PN and others on PAD.  To identify the relative contributions, the 
biomarkers related to PN and to PAD were aggregated separately.  Table 7A-12 shows the 
numbers of records in which the biomarkers co-occur with PN and with PAD.  The top fifty are 
shown in Table 2D-5. 
Table 2D-5 - Top Fifty Biomarkers Relevant to PN and to PAD 
#RECORDS TREATMENT #PN RECORDS #PAD RECORDS 
2638 lesions 985 1503 
2536 inflammation 1445 1143 
2320 toxicity 2077 186 
2277 nerve conduction velocity 2003 183 
2038 ankle brachial index 93 1984 
1549 blood pressure 334 1362 
1402 stenosis 72 1274 
1156 body mass index 378 868 
1142 neurotoxic 980 37 
1139 total cholesterol 261 1003 
1138 blood glucose levels 685 625 
1091 degeneration 874 167 
1061 hemoglobin A1c 663 646 
932 blood flow 167 802 
856 marker 321 558 
841 proteins 568 245 
748 atrophy 633 93 
747 dorsal root ganglia 631 28 
704 creatinine 230 550 
700 oxygen 184 536 
693 lipoprotein 117 625 
671 growth factor 318 344 
640 Schwann cell 506 25 
616 demyelination 536 56 
610 pain-free walking distance 17 598 
549 C reactive protein 68 507 
538 calcium 249 274 
516 cytokine 289 211 
499 triglycerides 158 410 
495 low-density lipoprotein cholesterol 70 461 
489 angiogenesis 56 439 
455 axonal degeneration 402 73 
435 Systolic blood pressure 88 392 
426 circulation 86 362 
425 high-density lipoprotein cholesterol 105 386 
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419 oxidative stress 223 212 
413 plaque 22 382 
412 occlusions 3 358 
402 albumin level 162 304 
399 glomerular filtration rate 95 338 
391 ventricular ejection fraction 33 366 
382 calcification 45 346 
365 nerve damage 238 32 
354 neurodegeneration 305 42 
349 IgM 325 46 
345 tumour necrosis factor-alpha 225 126 
344 sodium 229 114 
329 lipids 92 255 
322 heart rate 133 204 
318 edema 205 120 
 
 Biomarkers shared more or less equally between PN and PAD include inflammation, 
blood glucose levels, hemoglobin A1c, growth factor, calcium, oxidative stress, nitric oxide, IL-
6, reactive oxygen species, acetylcholine, lactate, urea, antioxidants, lipid peroxidation, advanced 
glycation end products, etc.  Biomarkers weighted toward PN include nerve conduction velocity, 
neurotoxicity, atrophy, Schwann cell, demyelination, axonal degeneration, CD4, nerve fiber 
density, etc.  Biomarkers weighted toward PAD include ankle brachial index, blood flow, pain-
free walking distance, low density lipoprotein cholesterol, occlusions, ventricular ejection 
fraction, calcification, fibrinogen, carotid artery intima-media thickness, platelet aggregation, 
pulse pressure, etc. 
ES-2N. Biomarkers Selected for Protocol 
 The final number of biomarkers identified in the present study was 757 (Table 7A-9a).  
To reduce this number of biomarkers to a manageable amount for the treatment protocol, a 
number of thematic categories were generated based on the results of the biomarker factor matrix 
(Figure 2D-1a) and other inputs.  Then, phrases were selected to populate these categories based 
in part on 1) their rankings in the biomarker factor matrix, and on 2) their applicability to 
PN/PAD or PN or PAD (Table 7A-12), as discussed at the end of section 2D4. 
 Table 2D-6 contains the final list of biomarkers selected for the protocol.  While each 
biomarker is listed for one category, many of the biomarkers will be applicable to multiple 
categories.  The biomarkers highlighted in red are the highest priority for each category, based 
on the criteria described above. 
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Table 2D-6 - Final List of Biomarkers for Treatment Protocol 





ANTIBODIES IgG antibodies 
ANTIBODIES autoantibodies 
ANTIBODIES anti-ganglioside antibodies 
ANTIBODIES demyelination 
ANTIBODIES monoclonal antibodies 
ANTIBODIES glucuronic acid 
ANTIBODIES Chlamydia pneumoniae 
ANTIBODIES antinuclear antibodies 
ART STIFFNESS arterial stiffness 
ART STIFFNESS pulse wave velocity 
ART STIFFNESS pulse pressure 
ART STIFFNESS vascular stiffness 









CALCIFICATION alkaline phosphatase 
ENDOTHELIAL DYSFUNCTION nitric oxide 
ENDOTHELIAL DYSFUNCTION l-arginine 
ENDOTHELIAL DYSFUNCTION nitric oxide synthase 
ENDOTHELIAL DYSFUNCTION arginine 
ENDOTHELIAL DYSFUNCTION endothelin-1 
FOLATE DEFICIENCY folic acid 
FOLATE DEFICIENCY folate deficiency 
FOLATE DEFICIENCY methionine 
FOLATE DEFICIENCY S-adenosylmethionine 
FOLATE DEFICIENCY HCY 
FOLATE DEFICIENCY cysteine 
FOLATE DEFICIENCY methylmalonic acid 
FOLATE DEFICIENCY asymmetric dimethylarginine 
GROWTH FACTORS growth factor 
GROWTH FACTORS vascular endothelial growth factor 
GROWTH FACTORS fibroblast growth factor 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                                                                                                                
Executive Summary                                                                                                                                                    29 
GROWTH FACTORS hepatocyte growth factor 
GROWTH FACTORS nerve growth factor 
GROWTH FACTORS fibroblast growth factor 23 
GROWTH FACTORS blood flow 
GROWTH FACTORS transforming growth factor beta 
INFLAMMATION C reactive protein 
INFLAMMATION IL-6 
INFLAMMATION Tumour necrosis factor-alpha 
INFLAMMATION IL1-beta 










INFLAMMATION Interferon gamma 
INFLAMMATION TGFbeta 
INFLAMMATION IL-2 
INFLAMMATION matrix metalloproteinase 2 





KIDNEY FUNCTION urea 
KIDNEY FUNCTION blood urea nitrogen 
KIDNEY FUNCTION creatinine 
KIDNEY FUNCTION white blood cell 
KIDNEY FUNCTION uric acid 
KIDNEY FUNCTION bilirubin 
KIDNEY FUNCTION glomerular filtration rate 
LIPIDS high-density lipoprotein cholesterol 
LIPIDS total cholesterol 
LIPIDS triglycerides 
LIPIDS low-density lipoprotein cholesterol 
LIPIDS fibrinogen 
LIPIDS Lipoprotein(a) 
LIPIDS hemoglobin A1c 
NEURODEGENERATION myelinated fibers 
NEURODEGENERATION dorsal root ganglia 
NEURODEGENERATION nerve conduction velocity 
NEURODEGENERATION Schwann cell 
NEURODEGENERATION fiber loss 
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NEURODEGENERATION atrophy 
NEURODEGENERATION nerve fiber density 
OXIDATIVE STRESS Reactive oxygen species 
OXIDATIVE STRESS glutathione 
OXIDATIVE STRESS superoxide dismutase 
OXIDATIVE STRESS malondialdehyde 
OXIDATIVE STRESS advanced glycation end products 
OXIDATIVE STRESS catalase 
OXIDATIVE STRESS glutathione peroxidase 
OXIDATIVE STRESS iNOS 
OXIDATIVE STRESS Hydrogen peroxide 
OXIDATIVE STRESS peroxynitrite 
OXIDATIVE STRESS NADPH oxidases 
OXIDATIVE STRESS TBARS 
OXIDATIVE STRESS 4-hydroxy-2-nonenal 
OXIDATIVE STRESS Nrf2 
OXIDATIVE STRESS isoprostane 
OXIDATIVE STRESS NOx 
OXIDATIVE STRESS heme oxygenase 1 
OXIDATIVE STRESS oxidized low-density lipoprotein 
OXIDATIVE STRESS lipid hydroperoxides 
OXIDATIVE STRESS PON-1 
OXIDATIVE STRESS 3-nitrotyrosine 
OXIDATIVE STRESS adenosine triphosphate 
OXIDATIVE STRESS creatine kinase 
PLATELET ACTIVATION arachidonic acid 
PLATELET ACTIVATION adenosine diphosphate 
PLATELET ACTIVATION P-selectin 
PLATELET ACTIVATION prothrombin 
PLATELET ACTIVATION thrombin 
PLATELET ACTIVATION L-selectin 






RAGE thromboxane A2 
RAGE phosphatidylinositol 3-kinase 
RAGE adenosine monophosphate 
RAGE caspase 3 
 
 The biomarkers highlighted in red are only a suggestion for testing prioritization.  There 
is not strong consensus in the literature for many of these biomarkers, and clinicians should 
substitute biomarkers for testing they deem more appropriate.  Also, there may be categories 
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listed that some clinicians believe are not relevant to specific patients, based on their medical 
histories.  The biomarkers in these categories could be eliminated, thereby reducing the number 
of tests required.  Conversely, there could be categories not listed in Table 2D-6 that clinicians 
believe are important for specific patients.  Biomarkers for these categories should be added as 
required.  Three such categories not emphasized in Table 2D-6 are heavy metals, infections, and 
Vitamin deficiencies. 
 Heavy metals that can impact various segments of PN/PAD adversely include arsenic, 
cadmium, lead, mercury, and thallium.  Infections/infectious agents that can impact various 
segments of PN/PAD adversely include human immunodeficiency virus (HIV), Aggregatibacter 
actinomycetemcomitans, Borrelia burgdorferi, Brucella spp., C. pneumoniae, Campylobacter 
jejuni, Campylobacter rectus, Chlamydia pneumoniae., Chryseomonas, Clostridium botulinum, 
Collinsella, Corynebacterium diphtheriae, Cytomegalovirus, Eikenella corrodens, Epstein-Barr 
virus, Eubacterium, Fusobacterium nucleatum, H. influenzae, Helicobacter pylori, Hepatitis C 
virus, Herpes simplex virus, Human T-cell lymphotropic virus, M. pneumoniae, Mycobacterium 
leprae, Mycobacterium tuberculosis, Parvimonas micra, Parvimonas micros, Porphyromonas 
gingivalis, Prevotella intermedia, Prevotella nigrescens, Rabies virus, Roseburia, Streptococcus, 
Tannerella forsythia, Treponema denticola, Varicella-zoster virus, Veillonella, West Nile Virus 
[Brizzi and Lyons, 2014; Budzynski et al, 2016].  Vitamin deficiencies include, but are not 
limited to, Vitamins B-1, B-12, C, D, E. 
ES-2O. Matrix of PN/PAD Causes vs Biomarkers 
 Figure 2E-1 (Excel Workbook) displays the co-occurrences between the existing 
PN/PAD contributing factors and biomarkers. The cell numbers reflect the co-occurrences of the 
contributing factor and biomarker defining the cell.   
 The matrix is relatively dense starting at the upper left, and becomes increasingly sparse 
going to the lower right.  There are approximately 630,000 cells in the matrix, of which about 
16,000 have entries.  That's an occupancy rate of slightly more than two percent.  Why is this 
important?  The cell numbers reflect, in part, the amount of research effort devoted (reported) to 
examining the relationship between the cause and the biomarker defining the cell.  Cells that are 
blank may reflect that research has not been done on the cause and biomarker combination, and 
therefore could be excluding another potential cause.  The message to be taken from this 
observation is far more research could be conducted on identifying potential causes if more 
biomarkers were included in the investigations. 
ES-2P. Matrix of PN/PAD Treatments vs Biomarkers  
 Figure 2F-1 (Excel Workbook) displays the co-occurrences between the existing 
PN/PAD treatments and biomarkers. The cell numbers reflect the co-occurrences of the 
treatment and biomarker defining the cell.   
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ES-3.  Treatment Protocol to Prevent and Reverse PN/PAD 
 
 This section summarizes the recommended treatment protocol for preventing and 
reversing AD.  There are five steps in the full treatment protocol, as shown in the following: 
FIVE-STEP TREATMENT PROTOCOL TO PREVENT AND REVERSE PN/PAD 
 
            Step 1: Obtain a detailed medical and habit/exposure history from the patient.   
 Step 2: Administer written and clinical performance and behavioral tests to assess the 
severity of the higher-level symptoms and degradation of functions 
 Step 3: Administer laboratory tests (blood, urine, imaging, etc) 
 Step 4: Eliminate ongoing PN/PAD contributing factors 
 Step 5: Implement PN/PAD treatments 
 
  
 These five steps will now be described in more detail. 
 Step 1. The first step in the protocol is to obtain a detailed medical and habit/exposure 
history from the PN/PAD patient.  The patient would be provided a detailed questionnaire 
focusing mainly on practices and exposures that are potential PN/PAD contributing factors.  The 
contributing factor component of the questionnaire would be based on Table 7A-1, or, 
preferably, on a similar, but even more extensive, table derived from an expanded study.   
 Step 2. The second step in the protocol is to administer written and clinical performance 
and behavioral tests to assess the severity of the higher-level symptoms.  This would include 
tests for sensing, pain, gait, endurance, strength, etc, and for anxiety, depression, cognitive 
dysfunction, etc.    The latter group of mood-related tests would have some overlap with the 
medical history on the initial questionnaire. 
 Step 3. The third step in the protocol is administration of laboratory tests (blood, urine, 
imaging, etc).  Any abnormalities shown by these tests would help prioritize the PN/PAD 
contributing factors to be eliminated and PN/PAD treatments to be implemented.  Table 2D-6 
contains the PN/PAD biomarkers selected for initial laboratory tests in the PN/PAD protocol.  
These PN/PAD biomarkers reflect the PN/PAD pathological themes and the major themes from 
the PN/PAD biomarker factor matrix (Figure 2D-1a).  Based on the laboratory test results, the 
health practitioner could require further tests to gain detailed information on problematic areas. 
 Step 4. The fourth step in the protocol is to eliminate ongoing PN/PAD contributing 
factors.  Unfortunately, as Figure 2E-1 shows, each PN/PAD contributing factor typically 
impacts many PN/PAD biomarkers, and each PN/PAD biomarker is typically impacted by many 
PN/PAD contributing factors.  Thus, in the general case, PN/PAD biomarker values' 
abnormalities in the lab tests will not be uniquely related to specific PN/PAD contributing 
factors.   
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 To circumvent this problem, a combined 'direct-identification' and 'reverse-engineering' 
approach that has the virtue of simplicity is proposed.  The 'direct-identification' component 
consists of eliminating the PN/PAD contributing factors the patient listed on the initial 
medical/exposure questionnaire.  The 'reverse-engineering' component  
 1) identifies all the patient's PN/PAD biomarkers with abnormal laboratory test values,  
 2) identifies the number of these abnormal PN/PAD biomarkers impacted by each 
PN/PAD contributing factor, then  
 3) prioritizes the PN/PAD contributing factors for elimination according to the number of 
PN/PAD biomarkers impacted by the PN/PAD contributing factors.   
See section 3B4 to show how this prioritization, and further sub-prioritizations, would operate. 
 The recommended prioritization above is based on numbers of PN/PAD biomarkers  
impacted by each PN/PAD contributing factor.  It does not: 
 1) distinguish between one record describing the impact (for a particular PN/PAD 
contributing factor) or ten records describing the impact, 
 2) distinguish among the strengths of impact described in different records, irrespective 
of the number of records describing the impact, 
 3) weight the PN/PAD biomarkers by relative importance,  
 4) incorporate the effects of contributing factor synergies.   
This additional information could be used by the healthcare practitioner to modify the 
prioritization illustrated above. 
 In addition, there are some cases where 'reverse-engineering' may be more 
straightforward.  For example, high serum or urine readings of heavy metals (such as cadmium 
or mercury) would identify specific targets for elimination.  These would be the exception rather 
than the rule, in terms of  specificity. 
 The above prioritization approach would serve as a proxy for the more comprehensive 
elimination of all 'low-hanging fruit' PN/PAD contributing factors, shown in Table 3B-2.  To the 
degree possible, the patient should strive to eliminate as many of these 'low-hanging fruit' 
PN/PAD contributing factors as possible.  The combination of 1) lack of knowledge about 
harmful exposures (limiting what can be answered on the initial medical/exposure questionnaire) 
and 2) incompleteness of PN/PAD characteristics measured will result in 3) PN/PAD 
contributing factors not being identified through the complete testing/evaluation process.  
Eliminating as many of the 'low-hanging fruit' PN/PAD contributing factors as possible will 
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compensate partially for this lack of knowledge.  Many of these items are under the patient's 
control, and can be readily eliminated, with proper motivation and discipline.  
Table 3B-2 - "Low-Hanging Fruit" Causes for Elimination 
"LOW-HANGING FRUIT" RECOMMENDATIONS 
 
1) curb the dietary excesses, and remove the dietary deficiencies, identified in Table 7A-1, the 
medical questionnaire, and the lab tests;  
2) eliminate food additives to the extent knowable and possible, including those dietary excesses 
that derive from food additives (excessive fat, sugar, salt);  
3) minimize high temperature cooking and the subsequent increases in advanced glycation end 
products from certain susceptible foods, heterocyclic amines, acrylamide, and polycyclic 
aromatic hydrocarbons; 
4) reverse the sedentary behavior patterns identified;  
5) remove the foundational impediments to better sleep;  
6) eliminate the use of 'recreational' drugs, including smoking and excessive alcohol;  
7) eliminate the use of medicinal drugs shown to be potential PN/PAD contributing factors from 
Table 7A-1, unless these drugs are absolutely necessary; 
8) minimize exposures to some hydrocarbons, such as n-hexane, methyl-n-butyl ketone, carbon 
disulfide, acrylamide, ethylene oxide, trichloroethylene, kerosene, polycyclic aromatic 
hydrocarbons (including those found in smoke), etc; 
9) minimize exposures to some neurotoxic solvents, especially organic solvents;  
10) minimize inhalation and ingestion exposures to pesticides, herbicides, insecticides, and 
fungicides;  
11) minimize exposures to heavy metals in food, in water, and in the air; 
12) minimize exposure to particulates, especially air pollution;  
13) minimize exposures to ionizing radiation and non-ionizing non-visible radiation (such as cell 
phones, cell towers, WiFi, smart meters, etc.);  
14) minimize chronic stress (mental/emotional/psychological); 
 
 
  There is an implicit assumption in some/many of these PN/PAD contributing 
factor elimination recommendations of a treatment implementation.  For example, elimination of 
a high-fat diet (PN/PAD contributing factor) implies adoption of a low-fat diet (PN/PAD 
treatment).   
 Step 5. The fifth step in the protocol is to implement PN/PAD treatments.  Because of 
risk associated with implementation of even single PN/PAD treatments, and the lack of 
knowledge of how overall risk increases (or decreases) because of treatment combination 
synergies, it is highly recommended that the lowest-risk treatments be implemented initially in 
parallel with required higher-risk treatments 
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 Even among low-risk PN/PAD treatments, some prioritization may be possible.  The 
approach recommended parallels that for eliminating PN/PAD contributing factors in Step 4.  
The approach is a hybrid of 'direct-identification' and 'reverse-engineering'.  The 'direct-
identification' component consists of identifying the patient's PN/PAD contributing factors from 
the medical/exposure questionnaire.  Where applicable, PN/PAD treatments that are positive 
behaviors/habits would be substituted for the negative PN/PAD contributing factors under the 
patient's control.  Thus, if the patient is eating a high AGEs diet, the PN/PAD 'treatment' would 
consist of substituting a low AGEs diet.  If the patient is participating in minimal physical  
activities, he/she would be encouraged to participate in more physical activities. 
 The 'reverse-engineering' component' would be based on the laboratory tests.  In parallel 
with the approach in Step 4, PN/PAD treatments would be prioritized based on the number of 
abnormal PN/PAD biomarkers they would impact.  The caveats of step 4 about relying on 
numbers of biomarkers impacted would apply here as well. 
  The specific PN/PAD treatments employed would be selected based on the 
medical questionnaire results, the clinical sensorimotor evaluation, and the lab tests results.  
Some of the following PN/PAD lowest-risk treatments shown in Table 3B-3 would (in practice) 
be substitutions for the PN/PAD contributing factors eliminated; others would be new activities 
implemented.   
Table 3B-3 - Lowest-Risk Treatments 
 Exercise (such as aerobic exercise, walking, resistance training, treadmill, calisthenics, 
stretching, balancing) 
 Sleep Improvement (such as quiet environment, minimal light, minimal food before 
bedtime, maintain regular sleep schedule) 
 Stress Reduction (such as tai chi, yoga, massage, aromatherapy, accupuncture, 
accupressure, sensory stimulation, physiotherapy, massage, reflexology, meditation) 
 Diet - Choose foods high in 
o polyphenols (such as cloves, star anise, capers, curry powder, ginger, 
cinnamon,  peppermint, oregano, sage, rosemary, thyme, basil, cocoa, tea, red 
wine, chokeberries, elderberries, blueberries, plums, cherries, black currants, 
blackberries, strawberries, raspberries, grapes, flaxseeds, celery seeds, 
chestnuts, hazelnuts, pecans, almonds, walnuts, olives, artichokes, chicory, red 
onion, spinach, broccoli,  apples, pomegranates, peaches, apricots, olive oil, 
canola oil), especially flavonoids (such as apples, blueberries, strawberries, red 
grapes, cabbage, broccoli, onions, capers, dark chocolate, cocoa, tea, red wine), 
isoflavones/genistein (such as soybeans, natto, tempeh, tofu, miso), and 
anthocyanins (such as blackberries, black currants, blueberries, strawberries, 
cranberries, eggplant, cherries, prunes, raisins, and the darker versions of 
raspberries, cabbage, plums, radish, grapes, plums, apples, beans, beets, 
cabbage, onions, pears, wines) 
o Unrefined carbohydrates (such as whole grains, legumes, fruits, and uncooked 
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vegetables) 
o DHA/omega-3 fatty acid (such as salmon, herring, mackerel, anchovy, sardine, 
trout, shark, swordfish, mussel, sea bass, pollock, whiting, flounder, sole, 
lobster, halibut, carp, oyster, crab, mullet, tuna, perch, snapper, shrimp, 
octopus) 
o Vitamin B12/Folate (such as meat [beef liver, lamb, beef], fish [sardines, 
mackerel, salmon], dairy [feta cheese, cottage cheese], eggs, legumes 
[chickpeas, fermented soy, pinto beans, lentils], fruit [banana, avocado], 
vegetables [spinach, parsley, broccoli, beets, turnip, asparagus,]) 
o Vitamin C (such as fruits [guavas, acerola cherry, kiwifruit, rose hips, 
strawberries, oranges, papayas, vegetables [bell peppers, broccoli, tomatoes, 
snow peas, kale]) 
o Vitamin D (such as fish [sardines, salmon, mackerel, tuna], liver [beef, calf, cod 
liver oil], dairy [milk, yogurt]; most importantly, sunlight on exposed skin) 
o Vitamin E (such as seeds [sunflower seeds, pumpkin seeds], nuts [almonds, 
hazelnuts, pine nuts], fish [abalone, salmon, trout], fruit [avocado, mango, 
kiwifruit], vegetables [red peppers, turnip greens, spinach, chard, squash, 
broccoli]) 
o lycopene (such as tomatoes, guavas, watermelon, papaya, grapefruit), 
o oleic acid (such as nuts [almonds, peanuts, pecans, cashews, pistachios, 
hazelnuts] seeds [sesame, sunflower], avocados, olives, and vegetable oils 
[safflower, almond, olive, sesame, sunflower]), 
o luteolin (such as dried oregano, celery seed, hot peppers, peppermint, sage, 
rosemary, juniper berries, thyme, radicchio, chinese celery), 
o quercetin (such as capers, lovage leaves, elderberry juice, dock leaves, raddish 
leaves, arugula, dill weed, coriander, and fennel, cilantro, banana peppers, 
juniper berries, oregano, onions, carob flour, radicchio, red leaf lettuce, onions, 
watercress, raw, asparagus, kale, okra, cocoa powder, chia seeds)  
o sulforaphane (such as broccoli sprouts, broccoli, cauliflower, kale, brussels 
sprouts, cabbage, collards, arugula, turnips) 
o resveratrol (such as red wine, red grapes, peanut butter, pistachios, cocoa 
powder, dark chocolate, strawberries, blueberries, bilberries, cranberries) 
o epigallocatechin-3-gallate (such as green tea, black tea, carob powder, apples, 
blackberries). 
 
   
 
Caveats on diet: 
 Many toxic/harmful substances enter the food supply during all phases of food 
growth, distribution, and processing.  While foods should be selected to maximize 
the amounts of healing nutrients identified above, care must be taken to minimize 
the level of toxic additions to the food in parallel. 
 Low-temperature cooking should be used to minimize production of AGEs and 
other harmful products (nitrosamines, polycyclic aromatic hydrocarbons, and 
acrylamides) during the cooking process. 
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 Only low-mercury wild-caught fish should be used; these tend to be smaller fish, 
lower on the food chain. 
 Grass-fed animals with no exogenous growth hormones or antibiotics should be 
used, if possible, since these harmful products could be passed through to the 
consumer.  
 For fruits and vegetables normally eaten with skin, those that have not been 
sprayed with harmful pesticides and other toxic chemicals should be used. 
 Heavy metals are a contributing factor for many neurodegenerative diseases, 
including AD.  One source of heavy metal bioaccumulation in the body is through 
the food supply.  Heavy metals can occur naturally in the soil in which food is 
grown, they can concentrate abnormally in soils from nearby industrial pollution 
or from precipitation of air pollution, they can preferentially absorb in different 
types of food, and, depending on the type of food, can be absorbed from the food 
processing and manufacturing process.  Any of the above foods selected for 
PN/PAD prevention or treatment purposes should have heavy metal 
concentrations as low as possible. 
 A note about these dietary recommendations.  In Table 7A-5, herbs and plant extracts are 
associated with large numbers of records.  One of the major reasons for this is their copious use 
in Traditional Chinese Medicine, which had significant representation in the PN/PAD database.  
Some of the concoctions that contained these substances had adverse side effects, which 
removed them from the desired low-risk category.  Also, independent verification of many of 
these concoctions' impacts was not readily available.  Therefore, they are not in the first-tier 
recommendations. 
 Additionally, many of these plant extracts, almost by definition, are not whole foods.  
The present monograph recommends whole foods containing the desired chemicals and nutrients 
(listed in Table 7A-5) preferentially in the above list.  The full spectrum of phytochemicals 
contained in whole foods acts synergistically with the fragmented chemicals listed to provide far 
more protection.  As stated in [Liu, 2003]: "the additive and synergistic effects of 
phytochemicals in fruit and vegetables are responsible for their potent antioxidant and anticancer 
activities, and that the benefit of a diet rich in fruit and vegetables is attributed to the complex 
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ES-4. Health Policy 
 The above PN/PAD treatment protocol has been developed based mainly on medical 
findings, especially as reported in the premier biomedical literature.  Financial and 
political/policy considerations were not taken into account.   
 The protocol contains implicit assumptions that patients will be able to 
 1) pay for any expensive drugs (if necessary),  
 2) afford pesticide-free, and other harmful-chemical-free, foods,  
 3) leave jobs where the working environment is toxic,  
 4) move from residences where the environment is toxic, etc.   
 This flexibility might not be available to many patients with limited income and/or 
limited assets. 
 There is also the implicit assumption that, if one has sufficient assets and flexibility, 
toxin-free environments can be found and toxin-free lifestyles can be achieved.  This assumption 
is open to question, as shown by the following example.   
 Probably the key exogenous contributing factor to the development of PN/PAD (and 
many other chronic diseases) is the incorporation of technology in all aspects of modern life 
without adequate regulation and safety testing [Kostoff, 2015; Kostoff, 2016].  To compound the 
problem, some/many of these new technologies are effectively mandated by government, and 
impossible to avoid, even if the PN/PAD patient is wealthy.  One example follows, but it is 
reflective of myriad other technologies contributing in part to PN/PAD. 
 Wireless radiation technology has become ubiquitous in modern life (cell phones, WiFi, 
smart meters, etc.).  Research has shown that wireless radiation in the cell phone radiofrequency 
part of the spectrum contributes to oxidative stress and inflammation [Kostoff and Lau, 2017; 
Chauhan et al, 2017; Kesari et al, 2013], among many other adverse effects.  As the present  
PN/PAD study results show, oxidative stress and inflammation are key PN/PAD characteristics.  
Chronic exposure to wireless radiation would be a factor contributing to increase the incidence of 
PN/PAD (and many other chronic diseases in which these two characteristics are important). 
 Wireless radiation technology requires an infrastructure.  For cell phones, the major 
infrastructure is cell towers.  The Telecommunications Act of 1996 effectively mandates the 
construction of cell towers with no opposition allowed based on health considerations.  As of this 
writing, the FCC is attempting to implement similar effective mandates for the next generation of 
mobile wireless technology, known as 5G.  A million or more 'short' cell towers (in the USA 
alone) would be required for 5G implementation, since the propagation of radiation energy at the 
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high frequencies characteristic of 5G is poor, and the distances between 'short' cell towers is 
relatively small by necessity.   
 This means that populated areas will be blanketed (around the clock) with 3GHz-30GHz 
(or higher) radiofrequency radiation, in addition to the lower frequency radiation emitted from 
today's installed cell towers.  This is a range of the frequency spectrum essentially untested for 
adverse health effects, especially over the long-term in humans, and especially in combination 
with other toxic stimuli [Kostoff and Lau, 2017].  It is no different in principle from a contractor 
proposing to spray the populated areas of the USA with Agent Orange around the clock, and the 
relevant government regulatory agency stating that no opposition to the spraying is allowed 
based on health considerations.  In effect, the USA Federal government is 
promoting/mandating an increase in rates of PN/PAD, with the potential of this increase being 
very large. 
 Thus, there is a dichotomy in the relevant USA Federal policy.  On the one hand, the 
Federal government is investing heavily in biomedical research to treat and reverse PN/PAD.  
On the other hand, the Federal government is allowing essentially unrestricted and inadequately 
regulated expansion of technologies that are important contributing factors to PN/PAD.  
Metaphorically, the Federal government is drilling holes in the floor of the boat at the same time 
they are pumping water out of the boat!  These policies are diametrically opposed, and will limit 
the effectiveness of any PN/PAD treatment protocol, no matter how strictly followed. 
ES-5. Near-Term Implementation of Findings 
 To gain operational experience with exploiting the findings in this monograph, clinical 
trials should be started in the near future.  Given the limitations in knowing exposures to many 
potential PN/PAD contributing factors outlined above, these trials could start with incorporating 
the "low-hanging fruit" contributing factors that have been identified previously.  These are 
potential PN/PAD contributing factors that could be estimated or measured relatively easily.  If 
elimination of these PN/PAD contributing factors does not yield the results desired, then low-risk 
treatments could be instituted. 
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 Chapter 1 describes  
 Basic principles of the treatment protocol 
 Present and projected incidence and prevalence of Peripheral Neuropathy (PN)/Peripheral 
Arterial Disease (PAD) in our society 
 Rationale for combining PN and PAD 
 Mainstream medical approach to treating this disease 
 Relationship of proposed approach to some segments of the mainstream medical 
approach.   
This  chapter ends with an outline of the monograph's structure and contents. 
1B. Basic Principles of Treatment Protocol 
 The treatment protocol proposed for prevention and reversal of PN/PAD in the present 
monograph is based on the following systemic medical principle [Kostoff, Porter, Buchtel, 
2018]: At the present time, removal of cause is a necessary, but not necessarily sufficient, 
condition for restorative treatment to be effective.  This principle is general, and applicable to 
prevention and reversal of any disease.  The methodology that has been developed based on this 
principle is general, and applicable to any disease as well. 
 To prevent any disease, the foundational causes that underlie the disease symptoms and 
biomarkers need to be identified and removed as comprehensively, thoroughly, and rapidly as 
possible. To reverse any disease (if irreversible damage from the disease has not been done and 
strong genetic predisposition to the disease is not a dominant factor), the preventive steps above 
need to be implemented, and treatments to reverse the disease progression need to be applied. 
 The efficacy of the methodology for preventing and reversing any disease depends on 
how thoroughly the foundational causes, treatments, biomarkers, and symptoms of the disease of 
interest have been identified.  In the present monograph, a wide spectrum of existing PN/PAD 
foundational contributing factors has been identified.  Additionally, a wide spectrum of existing 
(and a few newly discovered) PN/PAD treatments and PN/PAD symptoms and biomarkers has 
been identified.  Combining these results allows development of a PN/PAD treatment protocol 
that can be tailored to individual patients. Most importantly, this PN/PAD treatment protocol 
(based on the systemic medical principal described above) is available with the information at 
our disposal today!  
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1C.  Present and Projected PN/PAD Incidence and Prevalence 
1C1. PN 
 PN refers to the range of clinical syndromes that involve damage to the peripheral 
nervous system, including motor, sensory, and autonomic fibers [Shields RW, 2010; NINDS, 
2019].  If one nerve is damaged, the condition is referred to as mononeuropathy. If many nerves 
are involved, it is called polyneuropathy [UCSF, 2019]. 
 Estimates of PN prevalence vary widely.   
 Watson and Dyck: the prevalence of PN in the general population is 2.4% and increases 
with age to an estimated 8% in those older than 55 years [Watson and Dyck, 2015];  
 Foundation for PN: an estimated thirty million Americans suffer from some type of PN 
[FPN, 2019]; 
 Western Neuropathy Association and University of California at San Francisco (UCSF): 
more than twenty million Americans suffer from some sort of PN [WNA, 2019; UCSF, 
2019]; 
 Cioroiu and Brannagan: "Peripheral neuropathy is thought to affect approximately 24 % 
of the population over age 70" [Cioroiu and Brannagan, 2014]. 
The most prevalent types of PN are diabetic (~60%), ideopathic (~23%), chemotherapy-induced 
(~10%), HIV/AIDS-induced (~2%), other (~5%) [FPN, 2019]. 
 More detailed information about symptoms, biomarkers, diagnoses, causes, treatments, 
and epidemiology of PN can be found in the following comprehensive PN review articles [e.g., 
Barrell and Smith, 2019; Saporta and Shy, 2015; Pascuzzi, 2009; England and Asbury, 2004; 
Hughes, 2002; Watson and Dyck, 2015; Hanewinckel, Ikram, and van Doorn, 2016] and in the 
following PN books [e.g., Donofrio, 2012; Smith and Bromberg, 2005; Barohn, 2013; 
Herskovitz, Scelsa, and Schaumburg, 2010; Thomas and Dyck, 2005; Dyck et al, 2010]. 
1C2. PAD 
 PAD is a circulatory problem involving narrowing of the peripheral arteries serving the 
legs, stomach, arms and head, affecting arteries in the legs most commonly [AHA, 2019; MC, 
2019].  It is one of a number of terms used commonly to refer to arterial occlusive disease of the 
lower and upper extremities, including peripheral vascular disease (PVD), peripheral arterial 
occlusive disease, and arteriosclerosis obliterans [Campia, Gerhard-Herman, Piazza, et al, 2019] 
Estimates of PAD prevalence vary somewhat.   
 PAD  affects around 13% of the Western population who are more than 50 years old 
[Morley, Sharma, Horsch et al, 2018];  
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 PAD has a reported prevalence of 15% in Australia, the USA, and other Western 
countries, and up to 30% when studied in older populations [Conte and Vale, 2018];  
 PAD affects 12% to 20% of Americans 60 years and older, increasing to nearly 50% in 
those 85 years and older. Prevalence increases dramatically with age, and PAD 
disproportionately affects black persons. The global disease burden exceeds 200 million 
persons worldwide, and PAD increased in prevalence by 23.5% between 2000 and 2010 
[Firnhaber and Powell, 2019]; 
 PAD prevalence in the United States is low in people 50 years and younger, while PAD 
rates  increase sharply with age, reaching approximately 20% in octogenarians [Campia, 
Gerhard-Herman, Piazza, et al, 2019]; 
 PAD prevalence globally was ~118 million cases in 2017 and the number of incident 
cases was ~11 million, with two thirds of PAD prevalent cases being asymptomatic.  
Furthermore, PAD caused 515,600 years lived with disability. In 2017, ~70,000 people 
died from PAD, which represents ~56% increase compared with 2007 [Kengne and 
Echouffo-Tcheugui, 2019]. 
 More detailed information about symptoms, diagnoses, causes, treatments, and 
epidemiology of PAD can be found in the following comprehensive PAD review articles [e.g., 
Firnhaber and Powell, 2019; Campia, Gerhard-Herman, Piazza, et al, 2019; Conte and Vale, 
2018; Morley, Sharma, Horsch et al, 2018; Gerhard-Herman, Gornik, Barrett, et al, 2017] and in 
the following PAD books [e.g., Mohler and Jaff (Eds), 2017; Alonso, McManus, and Fisher, 
2010; Kevil, Bir, and Pattillo, 2013; Zemaitis, Bah, Boll et al, 2019]. 
 These projections may be strong under-estimates.  PN and PAD have environmental 
components.  There have been many potentially harmful and effectively un-regulated high-
technology additions to the environment in the past few decades [Kostoff, Porter, and Buchtel, 
2018; Kostoff, 2015] (e.g., wireless radiation, vaccine combinations, agricultural chemicals, etc., 
have expanded greatly).  Because of latency delays, inadequate time has elapsed to show 
linkages between these potentially harmful environmental additions and changes in the incidence 
of PN/PAD in human populations.  As will be shown in the present monograph, the adverse 
impact of (for example) recent potentially harmful environmental and dietary additions on 
PN/PAD biomarkers and symptoms ominously portends increased incidence and prevalence of 
PN/PAD in the future. 
 Many of the toxic stimuli that are contributing factors to PN/PAD also contribute to many 
other serious diseases [Kostoff, 2015].  Many of these diseases can be fatal, and may not have 
the multi-decadal latencies associated with some forms of PN and especially with PAD.  Thus, 
these lethal diseases serve to cull out people who would have been high-risk candidates for 
PN/PAD had they lived.  This culling out of high-risk individuals artificially depresses and 
masks the real incidence of PN/PAD had these high-risk people survived. 
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1D. Combining PN and PAD 
 Most of the PN or PAD contributing factor or treatment references examined addressed 
each disease/condition as a separate entity.  However, since poor peripheral blood circulation 
characteristic of many forms of PAD would restrict adequate transport of nutrients (especially 
oxygen) to the peripheral neural system, potentially causing severe damage and destruction to the 
peripheral neural system, an argument could be made that PN and PAD should be treated as a 
combined entity.  What is the evidence in the biomedical literature for this argument? 
 "pathological alterations in chronic ischaemic neuropathy may be due to the combined 
effects of acute ischaemia/reperfusion and chronic hypoxia." [Nukada, vanRij, Packer et 
al, 1996]; 
 "These results support the presence of a mild sensory axonopathy in subjects with 
peripheral arterial disease." [Ugalde, Wineinger, Kappagoda et al, 1998]; 
 "There is a predominantly sensory neuropathy associated with chronic and critical limb 
ischemia. Neuropathic symptoms are often obscured by the effects of ischemia on other 
tissues. The neurophysiologic changes suggest that the underlying pathophysiology is a 
distal axonopathy affecting nerve fibers of all sizes. Measures of blood flow in the leg 
correlate with neurologic symptom scores, examination scores, and electrophysiologic 
testing." [Weinberg DH, Simovic D, Isner et al, 2001]; 
 "Patients with peripheral vascular disease are susceptible to neuropathy from chronic 
hypoxia." [Toursarkissian, Connaughton, D'Ayala et al, 2002]; 
 "chronic peripheral arterial occlusive disease causes axonal degeneration, resulting in 
axonal polyneuropathy." [Weber and Ziegler, 2002]; 
 "ischemia-related impairment in lower extremity nerve function may contribute to 
functional impairment and decline in people with PAD." [McDermott, 2015]; 
 "Subgroup analysis points towards a PAD-associated peripheral neuropathy independent 
of diabetes." [Lang, Schober, Rolke et al, 2006]; 
 "Incidence of CI-DSN [Chronic Idiopathic Distal Symmetric Neuropathy] is higher in 
individuals carrying vascular conditions. In men, the presence at baseline of peripheral 
artery disease is associated with a threefold increase in the risk of developing CI-DSN." 
[Baldereschi, Inzitari, Di Carlo et al, 2013];  
 "Chronic ischemia in patients with peripheral arterial disease (PAD) represents a 
common medical problem. Neuropathic changes and pain caused by chronic ischemia are 
often found in the lower extremities of these patients. Pain in patients with chronic 
critical limb ischemia fulfill the criteria of neuropathic pain." [Lang, 2015]; 
 The message from these studies, and many other similar studies not referenced, is clear.  
Restricted circulation characteristic of PAD deprives the peripheral nerves (and other peripheral 
micro and macro-structures) of adequate nutrients for optimal functioning and survival, 
especially, but not limited to, oxygen.  This deprivation of adequate nutrient supplies to critical 
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organs, cells, and other biological structures, and the resulting pathology, is not limited to PN.  In 
essentially every previous LRDI study I have performed examining myriad chronic diseases, 
poor blood circulation and the attendant nutrient deprivation to critical structures, has been a 
(typically under-emphasized) causal factor in the disease development and progression.  Intake 
of the highest quality nutrients, by whatever route, will have limited effect on biological structure 
health if the logistics transport system (veins and arteries) is 1) not able to deliver these nutrients 
to the appropriate structures in a timely manner and is 2) not able to dispose of the metabolic 
waste products in a timely manner as well. 
1E. Mainstream Medical Approach for PN/PAD 
1E1. PN 
 The mainstream medical approach (and limitations) for PN is reflected in the 
comprehensive PN review articles and books cited above, and is addressed in more detail in the 
Background chapter, sections 5C1, 5C3, and 5E.  While there are modest variations among 
authors, the treatments presented can be categorized in three main categories: related disease 
treatments; lifestyle changes; pain management.  The selection of treatments depends on the 
perceived main causes of PN, if known. 
 Thus, if a patient has diabetes (which is associated with painful PN), emphasis is placed 
on addressing control/reversal of the diabetes.  This is typically accomplished with a 
combination of lifestyle changes (especially dietary) and drugs.  Other lifestyle changes may 
include the use of walking aids, and strict attention to proper foot care and proper footwear. 
 Pain management occupies much of the treatment literature for PN.  It is mainly drug-
based, with potential addition of dietary supplements.  The main drug categories appear to be 
anticonvulsants, antidepressants, supplements, topicals, and analgesics. 
1E2. PAD 
 The mainstream medical approach for PAD is reflected in the comprehensive PAD 
review articles and books cited above, and is addressed in more detail in the Background chapter, 
sections 5C2, 5C4, and 5E.  However, the AHA/ACC guidelines referenced above [Gerhard-
Herman, Gornik, Barrett et al, 2017] reflect a mainstream consensus approach to diagnosis and 
treatment of PAD, and these guidelines overlap strongly with recommendations contained in the 
referenced review articles and books. 
 For treatment, four broad categories are suggested in the AHA/ACC guidelines [Gerhard-
Herman, Gornik, Barrett et al, 2017]: lifestyle changes; pharmacotherapy; exercise; surgery.  The 
above reference suggests combination of some or all of the following, based in the results of the 
comprehensive diagnostic techniques: 
 Antiplatelet, Statin, Antihypertensive Agents, and Oral Anticoagulation 
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 Smoking Cessation 
 Glycemic Control 
 Cilostazol, Pentoxifylline, and Chelation Therapy 
 Homocysteine Lowering 
 Influenza Vaccination 
 Structured Exercise Therapy 
 Prevention of wounds through patient education, foot examination, and prompt 
recognition of foot infection 
 Endovascular surgical approaches 
1E3. Limitations of high-technology mainstream medical approach 
 While lifestyle changes form part of the mainstream PN/PAD treatment protocol, 
including elimination of well-known causative factors, for the most part the mainstream PN/PAD 
treatment protocols are centered on pharmacotherapy and surgery.  These typically high-
technology treatments focus on removing/suppressing PN/PAD pathological symptoms, rather 
than removing the causes of these symptoms.  These treatments (in the absence of 
comprehensive cause removal) have minimal success in reversing PN/PAD because they violate 
the systemic medical principle that forms the basis of the prevention and reversal  methodology 
in this monograph. 
 The strategy of identifying symptoms as pathological mechanisms that must be 
suppressed or removed for healing is a mainstay of Western Medicine.  However, another 
perspective is to view these symptoms in a positive light, as having two basic functions: serve as 
a warning signal that dysfunction exists and actions need to be taken to remove the cause of this 
dysfunction, and serve as a protective mechanism.  
 There are many examples in the biomedical literature supporting the concept of disease 
symptoms as warning signals and protective mechanisms, as shown by the following: 
EXAMPLES OF DISEASE SYMPTOMS AS PROTECTIVE MECHANISMS 
 
 "the down-regulation of energy metabolism in AD is a protective response of the neurons to 
the reduced level of nutrient and oxygen supply in the microenvironment" [Sun, Feng, Liang 
et al, 2012]; 
 "Neurofibrillary tangle formation as a protective response to oxidative stress in Alzheimer’s 
Disease" [Nunomura, Takeda, Moreira et al, 2009]; 
 "Autophagy is a protective response to the oxidative damage to endplate chondrocytes in 
intervertebral disc" [Chen, Lv, Li et al, 2017]; 
 "loss of appetite in the acute phase of illness is indeed an adaptive, protective response that 
improves cell recycling (autophagy) and detoxification" [Schutz, Bally, Stanga et al, 2014]; 
 "Cataract is a self-defence reaction to protect the retina from oxidative damage" [Wegner and  
Khoramnia, 2011]. 
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 Along these same lines, Bredesen states in his 2017 book [Bredesen, 2017]: "Alzheimer's 
disease is actually a protective response to, specifically, three different processes: inflammation, 
suboptimal levels of nutrients and other synapse-supporting molecules, and toxic exposures."  
Other AD researchers have drawn similar conclusions.  If Bredesen's view that the AD 
symptoms serve as a protective response against more serious damage is correct, then the 
mainline drug-based AD treatment approach of removing these pathologies/symptoms without 
removing their foundational causes comprehensively in parallel  
 1) effectively removes the protective shield reflected by these pathologies/symptoms and 
 2) exacerbates the progression of AD! 
These conclusions are applicable to most, if not all, chronic diseases. 
1F. Approach Proposed in Present Monograph 
 The approach to prevention and reversal of PN/PAD proposed in the present monograph 
is based on the following systemic medical principle: At the present time, removal of cause is a 
necessary, but not necessarily sufficient, condition for restorative treatment of disease to be 
effective. To prevent PN/PAD, or any disease, the foundational causes that underlie the disease 
symptoms need to be identified and removed as comprehensively, thoroughly, and rapidly as 
possible. To reverse PN/PAD (if irreversible damage has not been done and strong genetic 
predisposition to PN/PAD is not a dominant factor), the preventive steps above need to be 
implemented, and treatments to reverse progression (if necessary) need to be applied.  
 The approach in the present monograph is not constrained by hypotheses based primarily 
on symptoms/pathological mechanisms.  Symptoms, pathological mechanisms, and other 
abnormal PN/PAD characteristics are used as a guidepost to identify causes to be eliminated and 
treatments to be implemented for individual patients.  The present approach is based on cause 
and effect as evidenced in the premier biomedical literature.  PN/PAD characteristics that exist in 
the biomedical literature are identified as comprehensively as possible, and then adverse changes 
in the values of these PN/PAD characteristics are related to potential underlying foundational 
causes .  Preferably, the research findings will identify the biological mechanisms that link a 
foundational cause to its impact(s) on PN/PAD characteristics.  However, even in the absence of 
such mechanisms, the linkage is retained.  Beneficial changes in the values of these PN/PAD 
characteristics are related to potential treatments, again, whether or not the biological 
mechanisms that link treatments to positive impacts have been identified. 
 In the present monograph, the treatments identified cover research over the past ~thirty 
years.  Treatments that have 'failed' in human clinical trials are not excluded.  My  reading of 
thousands of abstracts on laboratory experiments and clinical trials of potential PN/PAD 
treatments has shown 
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 1) in vitro experiments typically performed on cells tend to have reasonably positive 
outcomes, at least for those papers that surface in the peer-reviewed published literature; 
 2) in vivo experiments typically performed on rodents (but other small animals as well) 
tend to also have reasonably positive outcomes, albeit somewhat less than in vitro experiments; 
 3) when these potential treatments reach the human clinical trial stage, especially the later 
phases, the success rates plummet! 
 The explanation for this discrepancy given most often is the species difference.  Humans 
are different from rodents et al, and their physiological responses to stimuli are different as well.  
However, the toxic experiential and exposure background differences between humans who live 
in the real-world sea of myriad toxic exposures and animals who live in the very controlled 
environment of the laboratory are rarely, if ever, discussed.   
 As the present monograph will show, there are many hundreds of potential causes for 
PN/PAD (ranging from Lifestyle to Occupational/Environmental exposures).  For a given 
individual, some causes have happened in the past, and are no longer happening, but their 
damage trail remains.  Other causes are ongoing, have caused damage, and continue to cause 
damage.   
 Why would anyone expect a human being with such a toxic history to respond to a 
potential treatment the same way that a laboratory animal raised in a controlled environment 
would respond to that treatment?  Furthermore, why would anyone expect a human being 
with such a toxic history to respond to a potential treatment the same way that another human 
being without such a toxic burden would respond to that treatment? 
 Consider the example of Dr. Terri Wahls, an M.D. who was able to reverse her own case 
of Multiple Sclerosis (MS) [Kostoff, 2012; Kostoff, 2015].  She used two main types of 
treatments: lifestyle changes (mainly dietary) to reverse the MS and neuromuscular electrical 
stimulation (NMES) to reverse the damage resulting from MS.  It was only when her diet 
achieved near-pristine status that the NMES produced positive effects.   
 While Dr. Wahls' experience represents one data point only, it is a very powerful data 
point.  Consider its implications.  Suppose a clinical trial were conducted to evaluate the 
potential for NMES to reverse the damage from MS.  Suppose further that Dr. Wahls' dietary-
dominant contributing factor to MS and her reaction to NMES were typical of the participants in 
such a clinical trial.  If the participants did not address their diet during the clinical trial, they 
would not respond positively to the NMES (as was the case for Dr. Wahls initially).  The trial 
would be interpreted as a failure of NMES.  However, in this hypothetical example, the 
NMES ineffectiveness is not the reason for the clinical trial's lack of success.  Failure to remove 
the cause of the disease and subsequent damage is the problem! 
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 Failure to remove cause as a reason for the very limited success of myriad PN/PAD 
treatments in the clinical trials of the past three decades cannot be ruled out.  That is why even 
so-called 'failed' treatments in the present full-spectrum study of existing PN/PAD treatments 
have been included.  It cannot be stated conclusively which treatments failed because 1) they 
were intrinsically ineffective or 2) their beneficial effects were overwhelmed by the strong 
negative effects of the ongoing causes remaining operable.  In fact, it is unknown whether 
comprehensive, timely, and thorough removal of the relevant PN/PAD causes by themselves 
would have obviated the need for many of these PN/PAD treatments! 
 For the comprehensive treatment process contained in this monograph, the first step in 
both PN/PAD prevention and reversal protocols is to identify the full spectrum of existing 
PN/PAD foundational causes/contributing factors.  The second step (in parallel with the 
elimination of the actionable causes identified in the first step) is to identify existing and 
potential PN/PAD treatments that can be implemented to accelerate PN/PAD reversal.  The 
remainder of the present monograph identifies a wide spectrum of existing PN/PAD foundational 
causes, existing and potential treatments, and PN/PAD 'characteristics' impacted by both 
PN/PAD causes and treatments.  Then, these PN/PAD foundational causes, treatments, and 
characteristics are integrated, and a treatment protocol for preventing and reversing PN/PAD 
tailored to the individual is presented. 
1G. Structure of Remaining Monograph Chapters 
 *Chapter 2 presents Results, Discussion, and Conclusions from the PN/PAD study.   
 *Chapter 3 integrates the findings to outline an individualized Treatment Protocol for 
preventing and reversing PN/PAD, in selected cases.   
 *Chapter 4 contains Suggested Further Research, based on both the deficiencies and 
opportunities identified by this study.   
 *Chapter 5 contains the Background for the present study, including definitions of key 
terms.   
 *Chapter 6 presents the detailed Methodology used to identify existing and potential 
PN/PAD treatments, and existing PN/PAD contributing factors and characteristics.   
 *Chapter 7 contains full Tables.   
 *Chapter 8 contains the References for each chapter, and a comprehensive Bibliography 
of myriad PN/PAD references. 
References - Chapter 1 
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Chapter 2 
RESULTS, DISCUSSION, AND CONCLUSIONS 
2A. Overview 
 This chapter presents the results of data analyses, discussion of the findings, and 
conclusions.  It contains lists of the existing PN/PAD causes, treatments, and characteristics.  
These lists undergo factor analyses, and the resultant factor matrices showing the myriad 
categories intrinsic to each list are presented.  Beyond this factor matrix step, only the biomarker 
component of characteristics will be used.  Square matrices of causes-causes, treatments-
treatments, and biomarkers-biomarkers are then presented, to allow identification of closely 
related items in the same category.  For PN/PAD treatments, illustrative examples of potential 
PN/PAD treatment discoveries are also presented. 
 Two matrices are then shown that link the existing PN/PAD causes, treatments, and 
biomarkers.  The first matrix shows causes vs biomarkers, and the second matrix shows 
treatments vs biomarkers.  Sample strings of data from each matrix are extracted to show how 
the matrix would be interpreted and used in practice.  Finally, matrices of causes, treatments, and 
biomarkers vs PN and PAD display the approximate number of records of each item that could 
be assigned to PN and PAD. 
2B. PN/PAD Causes 
2B1. List of Existing PN/PAD Contributing Factors 
 Table 7A-1 contains a list of the ~840 existing contributing factors identified in this 
study, and the numbers of records in which they appear, highest first.  The top fifty of these 
contributing factors are shown in Table 2B-1.  Because these are the highest frequency 
contributing factors, many will be very general.   
 The usual practice when listing contributing factors, treatments, and characteristics in a 
document is to provide one or more references for each item listed.  Because of the voluminous 
numbers of existing PN/PAD contributing factors, treatments, and characteristics identified in 
this study, thousands of references would be required.  The approach that will be taken here is to 
list the search query in Pubmed format for any of these items, and the interested user can run the 
query to identify all the PN/PAD records in Pubmed that contain the item of interest.  This 
allows the user to view all the evidence for selection of the item, not one or two selected 
references.  It also insures the user will have access to the latest references containing the item, 
and not limited to references published months before the publication date of the monograph.  
For those who wish to use Thomson Reuters for this purpose, convert the Pubmed query to 
Thomson Reuters format. 
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 To access the Pubmed records containing the item of interest, use the following: 
{item of interest} 
AND 
(peripheral neuropathy [mh:noexp] OR "peripheral neuropathy" [tiab] OR peripheral arterial 
disease [mh] OR "peripheral arterial disease" [tiab] OR "peripheral vascular disease" [tiab]) 
 One caveat.  Thomson Reuters-Medline does not recognize the MeSH Heading 
"Peripheral Neuropathy".  Instead, the MeSH Heading "Peripheral Nervous System Diseases" 
has to be substituted for the MeSH Heading "Peripheral Neuropathy" in Thompson Reuters. 
 So, if one wants to find the references showing Bortezomib as a contributing factor to 
PN/PAD, one would enter the following query into Pubmed: 
Bortezomib 
AND 
(peripheral neuropathy [mh:noexp] OR "peripheral neuropathy" [tiab] OR peripheral arterial 
disease [mh] OR "peripheral arterial disease" [tiab] OR "peripheral vascular disease" [tiab]) 
Table 2B-1 - Top Fifty Existing PN/PAD Contributing Factors 
#RECORDS CONTRIBUTING FACTOR 
2507 chemotherapy 
2265 smoking 













393 alcohol consumption 
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347 vincristine 
340 peripheral nerve injury 
337 lifestyle 
332 leprosy 







201 chronic constriction injury 
196 docetaxel 
















Categorization and analysis of these contributing factors will be shown in the next section. 
2B2. Factor Matrix of Existing Causes 
 Figure 2B-1 in the Excel workbook located under the same URL as the present 
monograph (FIGURES_FOR_MONOGRAPH.xlsx - listed under View/Open on the link page) 
contains a factor matrix of the existing PN/PAD contributing factors (click on first tab FIG 2B-
1).  The 29 factor headings are shown below in Table 2B-2.  This listing provides a convenient 
taxonomy for categorizing the myriad contributing factors identified.  Figure 2B-1 lists the 
specific contributing factors that had the strongest influence in determining the theme of each of 
the 29 factors. 
 One of the challenges in combining the literatures for two different (but related) 
diseases/conditions is that some (very few) of the treatments for PAD are contributing factors to 
PN.  Statins are one example, and modifications were made to compensate for this fact.  Statins 
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are a direct contributing factor to PN in a modest number of applications.  PN's main symptoms 
are numbness, tingling, and pain, and PN patients experience one or more of these symptoms.  
 Presence of these symptoms adversely impacts the quality and volume of walking, and 
therefore contributes to an increase in sedentary living (everything else being equal).  Sedentary 
living is a direct contributing factor to PAD.  Therefore, statins can be viewed as an indirect 
contributing factor to PAD.  In summary, statins serve three roles: a direct treatment for PAD, a 
direct contributing factor to PN, and an indirect contributing factor to PAD.  Since indirect 
contributing factors were not addressed in the present study, some modifications to the statin 
numbers were required to provide a more accurate picture. 
 Statins initially constituted Factor 4 in Figure 2B-2.  However, this was misleading for 
the above reasons, so this factor was removed.  For any of the treatments specific to PAD that 
contributed directly to PN, the PN contributing factor numbers should be substituted for the 
present treatment contributing factor numbers, and viewed as indirect contributing factors.   
 The main broad categories include:  
-drugs (e.g., antiretroviral, chemotherapy, antifungal, antibiotics, antiarrythmic/cardiovascular, 
statins [PN only]), 
-pesticides/herbicides (e.g., dioxin, Chlorophenoxy herbicides, trichlorophenol, Paraquat, 
Trichlorfon, dichlorvos, mipafox, organophosphate pesticides, malathion, chlorpyrifos), 
-infectious agents (e.g., bacteria, mycobacteria, viruses),  
-occupational/industrial chemicals (e.g., organic solvents, hydrocarbons, dithiocarbamates, 
benzene, organotin, methyl n-butyl ketone),  
-environmental pollutants (e.g., heavy metals, persistent organic pollutants, air pollution, 
bisphenol A),  
-induced injury (e.g., lysophosphatidic acid, N-methyl-D-aspartate, Freund's adjuvant, partial 
sciatic nerve ligation),  
-lifestyle (e.g., excess alcohol, recreational drugs, smoking, sedentary, high cholesterol diet) 
 Almost 60% of the total contributing factors were not included under the factors in Figure 
2B-1, because of the factor loading values used to determine the cutoffs.  Many had factor 
loadings too small to influence the themes of the factors, and the remainder were unit frequency 
(only terms with record frequencies greater than or equal to two were used to generate the factor 
matrix).  The bulk of those not shown under the specific factors were chemicals and drugs, with 
a few related to lifestyle.  However, even though a contributing factor had little influence in 
determining the theme of a factor, it could be very important in its impact on PN/PAD. 
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Table 2B-2 - Factor Matrix-based Categories for PN/PAD Contributing Factors 
FACTOR HEADING 
FACTOR 1 - HIGHLY ACTIVE ANTIRETROVIRAL THERAPY 
FACTOR 2 - CHEMOTHERAPY, ESPECIALLY TAXANES 
FACTOR 3 - ANTIFUNGAL DRUGS 
FACTOR 4 -  
FACTOR 5A - CHEMOTHERAPY, CHRONIC MYELOGENOUS LEUKEMIA 
FACTOR 5B - MYCOBACTERIA 
FACTOR 6 - CHEMOTHERAPY, PROTEASOME INHIBITORS 
FACTOR 7 - ALIPHATIC HYDROCARBONS 
FACTOR 8 - HEPATITIS VIRUS AND DRUGS 
FACTOR 9 - VIRUSES 
FACTOR 10 - ORGANOPHOSPHATE PESTICIDES 
FACTOR 11 - ANTIVIRAL DRUGS FOR AIDS 
FACTOR 12A - OCCUPATIONAL CHEMICALS 
FACTOR 12B - INFECTIOUS AGENTS 
FACTOR 13 - ANTIARRHYTHMIC DRUGS 
FACTOR 14 - ORGANIC SOLVENTS 
FACTOR 15 - FLUOROQUINOLONE ANTIBIOTICS, FOCUSED ON TUBERCULOSIS 
FACTOR 16 - BACTERIA AND INDUSTRIAL CHEMICALS 
FACTOR 17 - BACTERIA AND CHRONIC MYELOGENOUS LEUKEMIA DRUGS 
FACTOR 18 - HEAVY METALS 
FACTOR 19A - ENVIRONMENTAL POLLUTANTS 
FACTOR 19B - HYDROCARBONS, MAINLY ALIPHATIC SOLVENTS 
FACTOR 20 - HERBICIDES 
FACTOR 21 - VACCINES 
FACTOR 22 - CHEMOTHERAPY, ESPECIALLY VINCA ALKALOIDS AND TAXANES 
FACTOR 23A - DITHIOCARBAMATES 
FACTOR 23B - HYDROCARBONS, ESPECIALLY TOXIC ALCOHOLS 
FACTOR 24 - CHEMOTHERAPY 
FACTOR 25A - INDUCED INJURY 
FACTOR 25B - LIFESTYLE 
 
2B3. Causes-Causes Matrix 
 To display the inter-relationships among the PN/PAD causes, all the causes identified are 
matrixed together in Figure 2B-2 (Excel Workbook).  The cell numbers reflect the co-
occurrences of the two causes defining the cell.  Thus, smoking co-occurs with high cholesterol 
diet in 397 records (third column, second row).   
 As an example of all causes that co-occur with a selected cause, Tables 7A-2 and 7A-3 
show all causes that co-occur with with the phrases 'chemotherapy' and 'lifestyle', respectively.  
The top fifty causes from Tables 7A-2 and 7A-3 are shown in Tables 2B-3 and 2B-4, 
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respectively.  The first column represents the total number of records for the specific cause, the 
second column is the cause name, and the third column is the number of records in which the 
cause co-occurs with 'chemotherapy'. 
 In Table 2B-3, the bulk of the other causes are chemotherapuutic agents, although other 
related terms such as radiation and depression are mentioned as well.  Table 2B-4 covers a much 
broader range of concepts than Table 2B-3, since 'lifestyle' is a much broader concept than 
'chemotherapy'.  To understand the associations in more detail, the specific records enumerated 
in each cell of interest must be evaluated.  The reader can manipulate the matrix in Figure 2B-2 
to evaluate terms and relationships of personal interest. 
 It should be emphasized that 'chemotherapy' and 'lifestyle' are phrases that occur in the 
database.  In these tables, they do not reflect category headings.  As an example, 'smoking' co-
occurs with 'lifestyle' 108 times, even though 'smoking' occurs in 2265 records in the total 
PN/PAD database, and 'lifestyle' occurs 337 times in the total PN/PAD database.  Smoking is an 
obvious component of lifestyle, but it only co-occurs with the word 'lifestyle' about 5% of the 
time that the word 'smoking' occurs in the total database.  Interestingly, 'smoking' co-occurs with 
the word 'lifestyle' about 1/3 the time that 'lifestyle' appears in the total database.  Given that 
caveat, these co-occurrences give some idea of what a chemotherapy category would reflect and 
what a lifestyle category would reflect. 
Table 2B-3 - Top Fifty Co-occurrences of Chemotherapy with other Causes 
#RECORDS CAUSE #CO-OCCURENCES 
2507 chemotherapy 2507 
985 paclitaxel 630 
570 cisplatin 392 
524 oxaliplatin 347 
324 taxanes 223 
347 vincristine 190 
329 radiation therapy 166 
230 carboplatin 161 
217 platinum 156 
503 Bortezomib 144 
196 docetaxel 133 
361 radiation 115 
323 cyclophosphamide 112 
140 5-fluorouracil 97 
162 doxorubicin 95 
351 thalidomide 93 
118 Taxol 70 
121 capecitabine 69 
86 alkaloids 64 
76 Vinca alkaloids 60 
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96 gemcitabine 59 
76 vinorelbine 50 
74 etoposide 50 
111 methotrexate 46 
63 bevacizumab 45 
56 epirubicin 41 
54 ifosfamide 40 
62 fluorouracil 40 
61 eribulin 38 
60 cancer therapy 34 
545 depression 33 
90 proteasome inhibitors 31 
46 irinotecan 30 
821 HIV-1 28 
96 drug-induced 28 
708 infections 27 
37 vinblastine 26 
31 bleomycin 25 
58 ixabepilone 23 
91 melphalan 21 
683 viruses 20 
184 antibiotics 20 
23 mitomycin C 18 
39 trastuzumab 17 
110 lenalidomide 17 
22 suramin 16 
49 acetone 16 
 
In Table 2B-3, specific chemotherapy agents tend to co-occur with chemotherapy when they 
appear in the PN/PAD database. 
Table 2B-4 - Top Fifty Co-occurrences of Lifestyle with other Causes 
#RECORDS CAUSE #CO-OCCURENCES 
337 lifestyle 337 
2265 smoking 108 
131 sedentary 44 
1140 High cholesterol diet 35 
442 alcohol 18 
545 depression 11 
59 inactivity 11 
393 alcohol consumption 10 
2507 chemotherapy 9 
745 dialysis 6 
361 radiation 4 
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570 trauma 3 
329 radiation therapy 3 
31 bleomycin 2 
821 HIV-1 2 
708 infections 2 
96 malnutrition 2 
60 cancer therapy 2 
12 red meat 2 
683 viruses 2 
28 vitamin D deficient 2 
43 bariatric surgery 2 
85 renal transplantation 2 
83 axotomy 2 
83 liver transplant 2 
125 advanced glycosylation end products 2 
73 coronary angioplasty 2 
66 high fat diet 2 
5 salt intake 2 
46 irinotecan 1 
20 folate deficient 1 
296 Streptozotocin 1 
82 burn 1 
11 cocaine 1 
18 organic solvent 1 
21 Drug Abuse 1 
74 etoposide 1 
324 taxanes 1 
37 interferon-alpha 1 
985 paclitaxel 1 
67 solvents 1 
570 cisplatin 1 
118 Iatrogenic 1 
65 Zinc 1 
49 environmental factors 1 
 
 In Table 2B-4, while myriad lifestyle problems are mentioned at the higher frequencies 
(e.g., smoking, inactivity, recreational substances, poor diet), sedentary living stands out by co-
occuring with lifestyle a significant fraction of the time it appears in the PN/PAD database.  At 




Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                                                                                                                
   Chapter 2 - Results/Discussion                                                                                                                              57 
2B4.  Contributing Factors Related to PN and to PAD 
 While many of the contributing factors applied relatively equally to PN and PAD, some 
were focused exclusively on PN and others on PAD.  To identify the relative contributions, the 
symptoms/diseases related to PN and to PAD were aggregated separately.  Table 7A-4 shows the 
numbers of records in which the contributing factors co-occur with PN and with PAD.  The top 
fifty are shown in Table 2B-5. 
 Causes shared more or less equally between PN and PAD include infections, trauma, 
alcohol, radiation, anasthesia, antibiotics, advanced glycation end products, Hepatitis C virus, 
spinal cord injury, burn, high fat diet, inactivity, environmental factors, arsenic, 
lipopolysaccaride, drug abuse, etc.  Causes weighted toward PN include chemotherapy agents, 
radiation therapy, statins, chronic constriction injury, tuberculosis, antiviral agents, 
mycobacterium, pesticides, solvents, acrylamide, acetone, occupational exposures, etc.  Causes 
weighted toward PAD include smoking, high cholesterol diet, dialysis, sedentary, lifestyle, air 
pollution, atenolol, etc. 
Table 2B-5 - Contributing Factors Relevant to PN and to PAD 
#RECORDS CAUSE #PN RECORDS #PAD RECORDS 
2507 chemotherapy 2315 119 
2265 smoking 275 2124 
1140 High cholesterol diet 261 1004 
985 paclitaxel 874 69 
821 HIV-1 696 134 
745 dialysis 139 643 
708 infections 391 393 
683 viruses 548 182 
570 cisplatin 515 20 
570 trauma 269 260 
545 depression 326 251 
524 oxaliplatin 499 1 
508 hemodialysis 105 428 
503 Bortezomib 473 32 
442 alcohol 232 230 
412 statins 43  
393 alcohol consumption 266 147 
378 highly active antiretroviral therapy 344 37 
361 radiation 189 134 
357 anesthesia 157 139 
351 thalidomide 333 56 
347 vincristine 328 11 
340 peripheral nerve injury 229 18 
337 lifestyle 78 283 
332 leprosy 206 19 
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329 radiation therapy 245 50 
324 taxanes 303 7 
323 cyclophosphamide 288 80 
314 hepatitis 267 142 
296 Streptozotocin 273 40 
230 carboplatin 215 5 
217 platinum 194 6 
201 chronic constriction injury 179 1 
196 docetaxel 183 4 
186 Hepatitis C Virus 155 107 
184 antibiotics 101 102 
162 doxorubicin 148 17 
149 Arsenic 78 73 
148 stavudine 143 3 
140 5-fluorouracil 130 3 
131 sedentary 34 108 
125 advanced glycosylation end products 74 74 
121 capecitabine 103  
121 tuberculosis 101 22 
119 zidovudine 115 4 
118 Iatrogenic 55 37 
118 Taxol 103 3 
 
2C. PN/PAD Treatments 
2C1. List of Existing PN/PAD Treatments 
 Table 7A-5 contains a list of the existing PN/PAD treatments identified in this study, and 
the numbers of records in which they appear, highest first.  The top fifty of these treatments are 
shown in Table 2C-1.  Because these are the highest frequency treatments, many will be very 
general.  The references are identified using the same method as the contributing factors in 
section 2B-1. 
Table 2C-1 - Top Fifty Existing PN/PAD Treatments 








1308 artery bypass grafting 
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1228 angioplasty 
828 stents 







541 endovascular treatment 




450 bypass surgery 
449 diet 






349 vascular endothelial growth factor 
337 antiplatelet therapy 
317 opioid 
288 supplementation 
266 coronary intervention 








207 vitamin B12 
206 nerve growth factor 
190 smoking cessation 
189 Spinal Cord Stimulation 
172 Gene therapy 
 
Categorization and analysis of these treatments will be shown in the next section. 
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2C2. Factor Matrix of Existing Treatments 
 Figure 2C-1 in the Excel workbook located under the same URL as the present 
monograph (FINAL_FIGURES.xlsx - listed under View/Open on the link page) contains a factor 
matrix of the existing PN/PAD  (click on FIG 2C-1).  The thirty factor headings are shown below 
in Table 2C-2.  This listing provides a convenient taxonomy for categorizing the myriad 
treatments identified.  Figure 2C-1 lists the specific treatments that had the strongest influence in 
determining the theme of each of the thirty factors. 
 The main categories include:  
-drugs (e.g., antidepressants, anticonvulsants, opioids, muscle relaxants, 
antiplatelet/antithrombotic/anticoagulant agents, calcium channel blockers, antihypertensive 
agents, serotinin reuptake inhibitors, endocannabinoid deactivation inhibitors, cannabinoids, 
dipeptidyl peptidase-4 inhibitors, etc); 
-surgery (e.g., angioplasty, arterial bypass, stents, revascularization, amputation, spinal cord 
stimulation, deep brain stimulation, etc) 
-supplements (e.g., omega-3 fatty acids, fish oil, antioxidants, Vitamin E, Vitamin C, Vitamin 
B12, alpha lipoic acid, biotin, Vitamin D, magnesium, etc)  
-herbs (e.g., herbal medicines, Chinese herbs, Buyang Huanwu decoctionn Guizhi-shaoyao-
zhimu decoction, Huoxue Kangyuan decoction, Plantaginis Semen, Aucubin, Goshajinkigan, 
kampo, etc)  
-angiogenesis (growth factors, cell therapy, etc) 
 Almost 75% of the total treatments were not included under the factors in Figure 2C-1, 
because of the factor loading values used to determine the cutoffs.  Many had factor loadings too 
low to influence the themes of the factors, and the remainder were unit frequency.  The bulk of 
those not shown under the specific factors were drugs, herbs/plants, neural stimulation (rTMS, 
TENS, accupuncture, massage, EMF radiation, shock wave, ultrasound, etc), with a few related 
to lifestyle.  Even though a treatment had little influence in determining the theme of a factor, it 
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Table 2C-2 - Factor Matrix-based Categories for PN/PAD Treatments 
FACTOR HEADING 
FACTOR 1 - ANTIDEPRESSANTS/ANTICONVULSANTS/OPIODS 
FACTOR 2 - ANTIPLATELET/ANTITHROMBOTIC THERAPY 
FACTOR 3 - ENDOCANNABINOID DEACTIVATION INHIBITORS 
FACTOR 4 - ANTIHYPERTENSIVE AGENTS 
FACTOR 5 - SEROTININ REUPTAKE INHIBITORS 
FACTOR 6 - CANNABINOIDS/ANGIOGENESIS 
FACTOR 7 - MUSCLE RELAXANTS 
FACTOR 8 - ENDOVASCULAR TREATMENT 
FACTOR 9A - CANNABINOIDS 
FACTOR 9B - ANGIOGENESIS/GROWTH FACTORS/CELL THERAPY 
FACTOR 10 - ANTICOAGULANTS 
FACTOR 11 - ANTIEPILEPTICS/ANTICONVULSANTS 
FACTOR 12 - ANTIHYPERTENSIVE AGENTS, ESPECIALLY ACE INHIBITORS 
FACTOR 13 - PERIPHERAL NERVE REGENERATION AND PROTECTION 
FACTOR 14 - OMEGA-3 FATTY ACIDS 
FACTOR 15 - LOW-DENSITY LIPOPROTEIN REDUCTION THERAPY, ESPECIALLY STATINS 
FACTOR 16 - NEUROPATHIC PAIN MANAGEMENT, ESPECIALLY OPIOIDS 
FACTOR 17 - REPURPOSED THERAPIES FOR NEUROPATHY 
FACTOR 18 - CALCIUM CHANNEL ANTAGONISTS 
FACTOR 19 - CXCR4 ANTAGONISTS FOR NEUROPATHIC PAIN 
FACTOR 20 - PHENOLS 
FACTOR 21 - PROSTACYCLIN ANALOGUES 
FACTOR 22A - GROWTH FACTORS 
FACTOR 22B - CELL THERAPY 
FACTOR 23 - GLYCOSAMINOGLYCANS 
FACTOR 24 - HERBAL MEDICINE 
FACTOR 25 - ANALGESICS/NSAIDs 
FACTOR 26 - SUPPLEMENTATION 
FACTOR 27A - ANTIPLATELET/ANTITHROMBOTIC THERAPY 
FACTOR 27B - ANTITHROMBOTIC/ANTICOAGULANT AGENTS 
 
2C3. Treatment-Treatment Matrix  
 To display the inter-relationships among the PN/PAD treatments, all the treatments 
identified  are matrixed together in Figure 2C-2 (Excel Workbook).  The cell numbers reflect the 
co-occurrences of the two treatments defining the cell.  Thus, walking co-occurs with drug in 
122 records (second column, sixth row).   
 As an example of all treatments that co-occur with a selected treatment, Tables 7A-6 and 
7A-7 show all  that co-occur with with the phrases 'revascularization' and 'growth factor', 
respectively.  The top fifty causes from Tables 7A-6 and 7A-7 are shown in Tables 2C-3 and 2C-
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4, respectively.  The first column represents the total number of records for the specific 
treatment, the second column is the treatment name, and the third column is the number of 
records in which the treatment co-occurs with 'revascularization' or 'growth factor'. 
 In Table 2C-3, the bulk of the other treatments are invasive procedures, although other 
related treatment concepts such as drugs and exercise are mentioned as well.  Table 2C-4 covers 
a much broader range of concepts than Table 2C-3, since 'growth factor' is a much broader 
concept than 'revascularization'.  To understand the associations in more detail, the specific 
records enumerated in each cell of interest must be evaluated.  The reader can manipulate the 
matrix in Figure 2C-2 to evaluate terms and relationships of personal interest. 
 TABLE 2C-3 - Top Fifty Co-occurrences of Revascularization with other 
Treatments 
#RECORDS TREATMENT #CO-OCCURRENCES 
1920 revascularization 1920 
5105 surgery 776 
2402 amputation 615 
1228 angioplasty 403 
828 stents 300 
1308 artery bypass grafting 276 
541 endovascular treatment 178 
450 bypass surgery 127 
507 vascular surgery 121 
1358 walking 120 
3638 drug 119 
1328 exercise 117 
1766 inhibitor 76 
588 operation 73 
576 aspirin 73 
266 coronary intervention 71 
499 implantation 71 
337 antiplatelet therapy 68 
233 endarterectomy 62 
489 angiogenesis 59 
745 dialysis 58 
370 statin 56 
353 Clopidogrel 54 
382 catheter 52 
812 growth factor 51 
215 Cilostazol 44 
632 medications 38 
68 drug-coated balloons 33 
190 smoking cessation 33 
459 rehabilitation 31 
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107 cell therapy 31 
57 nitinol stents 24 
349 vascular endothelial growth factor 22 
754 insulin 21 
252 antihypertensive agents 20 
172 Gene therapy 19 
167 heparin 18 
37 drug-eluting balloons 17 
221 anticoagulant 17 
447 glycemic control 16 
420 Ligation 13 
44 vorapaxar 13 
36 stem cell therapy 13 
35 directional atherectomy 12 
449 diet 11 
110 enzyme inhibitors 11 
131 mononuclear cells 10 
32 Orbital atherectomy 10 
55 antithrombotic therapy 9 
 
In Table 2C-3, the treatments that co-occur with revascularization a significant fraction of the 
time they appear in the PN/PAD database are specific types of vascular surgery (e.g., stents, 
bypass surgery, angioplasty). 
TABLE 2C-4 Top Fifty Co-occurrences of Growth Factor with other Treatments 
#RECORDS TREATMENT # CO-OCCURRENCES 
812 growth factor 812 
349 vascular endothelial growth factor 301 
489 angiogenesis 216 
206 nerve growth factor 174 
3638 drug 103 
1766 inhibitor 85 
5105 surgery 82 
172 Gene therapy 78 
2402 amputation 61 
52 hepatocyte growth factor 52 
51 epidermal growth factor 51 
1920 revascularization 51 
150 hypoxia 31 
420 Ligation 28 
1358 walking 26 
1328 exercise 25 
107 cell therapy 25 
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754 insulin 23 
24 bFGF 22 
42 Neurotrophins 21 
1308 artery bypass grafting 20 
1228 angioplasty 18 
33 neurotrophin-3 18 
52 BDNF 17 
28 GDNF 16 
172 IL-6 15 
131 mononuclear cells 15 
215 Cilostazol 14 
51 Mesenchymal Stem Cells 14 
107 granulocyte colony-stimulating factor 12 
411 corticosteroid 11 
567 analgesic 11 
499 implantation 11 
449 diet 10 
240 PNS 10 
147 capsaicin 10 
24 insulin-like growth factor-I 9 
36 stem cell therapy 9 
167 heparin 9 
78 anthracycline 9 
14 CNTF 8 
189 Spinal Cord Stimulation 8 
317 opioid 7 
17 viral vectors 7 
242 Gabapentin 7 
447 glycemic control 7 
288 supplementation 6 
 
In Table 2C-4, treatments closely related to growth factor are the specific growth factors in the 
PN/PAD database. 
2C4. Treatments related to PN and to PAD 
 While many of the treatments applied relatively equally to PN and PAD, some were 
focused more strongly on PN and others on PAD.  To identify the relative contributions, the 
symptoms/diseases related to PN and to PAD were aggregated separately.  Table 7A-8 shows the 
numbers of records in which the treatments co-occur with PN and with PAD.  The top fifty are 
shown in Table 2C-5. 
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Table 2C-5 - Top Fifty Treatments Relevant to PN and to PAD 
#RECORDS TREATMENT #PN RECORDS #PAD RECORDS 
5105 surgery 1172 3427 
3638 drug 2279 1321 
2402 amputation 591 2064 
1920 revascularization 56 1839 
1766 inhibitor 951 813 
1358 walking 304 1058 
1328 exercise 229 1124 
1308 artery bypass grafting 59 1154 
1228 angioplasty 23 1149 
828 stents 7 751 
812 growth factor 377 426 
754 insulin 467 465 
745 dialysis 139 643 
632 medications 320 338 
588 operation 122 374 
576 aspirin 33 552 
567 analgesic 479 61 
541 endovascular treatment 3 499 
507 vascular surgery 17 466 
499 implantation 69 393 
489 angiogenesis 56 439 
459 rehabilitation 149 262 
450 bypass surgery 13 421 
449 diet 239 233 
447 glycemic control 333 247 
420 Ligation 274 110 
411 corticosteroid 328 148 
382 catheter 41 297 
370 statin  333 
353 Clopidogrel 8 345 
349 vascular endothelial 
growth factor 
105 257 
337 antiplatelet therapy 4 330 
317 opioid 271 28 
288 supplementation 160 124 
266 coronary intervention  261 
252 antihypertensive agents 36 238 
242 Gabapentin 235 16 
240 PNS 166 23 
233 endarterectomy 2 222 
233 pregabalin 230 5 
228 antidepressant 203 27 
221 anticoagulant 24 196 
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215 Cilostazol 6 211 
207 vitamin B12 160 50 
206 nerve growth factor 170 8 
190 smoking cessation 9 184 
189 Spinal Cord Stimulation 122 84 
172 Gene therapy 37 128 
172 IL-6 75 95 
167 heparin 15 146 
 
 Treatments shared more or less equally between PN and PAD include insulin, growth 
factors, diet, antioxidants, folic acid, carnitine, cannabis, DHA, etc.  Treatments weighted toward 
PN include analgesics, opioids, gabapentin, pregabalin, antidepressants, Vitamin B12, capsaicin, 
morphine, zidovudine, amitryptiline, alpha lipoic acid, carbamazapine, anthracycline, thiamine , 
etc.  Treatments weighted toward PAD include revascularization, exercise, walking, artery 
bypass grafting, angioplasty, stents, aspirin, endovascular treatment, vascular surgery, 
angiogenesis, catheter, statins, clopidogrel, antiplatelet therapy, antihypertensive agents, 
warfarin, etc. 
2C5.  Potential PN/PAD Treatments from LRDI Discovery 
 The LRDI Discovery method outlined in section 6B5 and presented in detail in Appendix 
6-1 was used to identify potential PN/PAD treatment candidates.  Even with the abbreviated 
query shown, hundreds of potential PN/PAD treatment candidates were retrieved (mid-August 
2019), and thousands more could have been easily obtained with an expanded query.  Ten of the 
candidates that were evaluated and validated for Discovery are shown in Table 2C-6.  While 
combinations of two biomarkers were the criteria for retrieving potential PN/PAD treatment 
candidates, the impacts of the treatment on myriad other biomarkers were included in the 
retrieved article as well.  All the biomarkers impacted by the candidate treatment (listed in the 
abstract) are shown in parentheses after the quoted material. 
Table 2C-6 - Potential Treatments for PN/PAD 
1. Dendrobium nobile Lindl 
"DNLA [Dendrobium nobile Lindl. alkaloids] protects mice from CCl4 induced liver injury, 
probably through the activation of the Nrf2 signaling pathway." [Li, Shiyue; Zhou, Jinxin; Xu, 
Shangfu; et al, 2019] 
(biomarkers altered: oxidative stress, Nrf2, alanine aminotransferase, aspartate aminotransferase, 
malondialdehyde) 
2. CPUY192018 
" CPUY192018 exhibited cytoprotective effects by enhancing the Nrf2-ARE regulated 
antioxidant system and diminished the LPS-induced inflammatory response by hindering the 
ROS-mediated activation of the NF-kappaB pathway.....  by activating Nrf2, CPUY192018 
treatment balanced renal oxidative stress and suppressed inflammatory responses." [Lu, Meng-
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Chen; Zhao, Jing; Liu, Yu-Ting; et al, 2019] 
(biomarkers: inflammation, oxidative stress, Nrf2, ROS, NF-kappaB) 
3. Swertiamarin OR Gentiana macrophylla Pall 
"Collectively, Swe [Swertiamarin] could be considered as a promising protective agent against 
cerebral I/R injury through suppressing oxidative stress by activation of the Nrf2 protective 
pathway." [Wang, H. et al, 2019] 
(biomarkers: apoptosis, oxidative stress, ROS, Nrf2, NQO1, HO-1) 
4. Malva sylvestris 
"MS [Malva sylvestris] extract can protect the kidney against toxic effects of gentamicin, and 
thus, the degree of harmful effects of nephrotoxicity on remote organs including the liver will 
be decreased." [Mohamadi Yarijani, Z. et al, 2019] 
(biomarkers: oxidative stress, creatinine, urea-nitrogen, aspartate aminotransferase, alanine 
aminotransferase, alkaline phosphatase, malondialdehyde, inflammation, TNF-alpha, ICAM-1) 
5. Avenathramide C 
"Avn C [Avenathramide C] protects normal human skin fibroblasts against oxidative stress 
and inflammatory response through NF-kappaB inhibition and Nrf2/HO-1 activation " 
[Wang, C. and Eskiw, C.H, 2019] 
(biomarkers: oxidative stress, free radical levels, inflammation, tumor necrosis factor-alpha, NF-
kappaB, HO-1, Nrf2) 
6. SK-119 OR (E)-5-oxo-1-(4-((2,4,6-trihydroxybenzylidene)amino)phenyl)pyrrolidine-3-
carboxylic acid 
" Nrf2 Activation by SK-119 [(E)-5-oxo-1-(4-((2,4,6-
trihydroxybenzylidene)amino)phenyl)pyrrolidine-3-carboxylic acid] Attenuates Oxidative 
Stress, UVB, and LPS-Induced Damage " [Kahremany, S. et al, 2019] 
(biomarkers: oxidative stress, Nrf2, inflammation, apoptosis) 
7. pristimerin 
" Pris [pristimerin] exerted protective activity against LPS-induced ALI [acute lung injury] via 
anti-oxidant, anti-inflammatory and anti-apoptotic pathways " [Shaaban, A.A. et al, 2018] 
(biomarkers: inflammation, myeloperoxidase, lesions, oxidative stress, tumor necrosis factor-
alpha, interleukin-6, apoptosis, Bax, caspase-3, Bcl2) 
8. Astilbin 
" Astilbin ameliorates cisplatin-induced nephrotoxicity through reducing oxidative stress and 
inflammation. " [Wang, S.-W. et al, 2018] 
(biomarkers: oxidative stress, inflammation, apoptosis, ROS, NRF2, TNF-alpha, NF-kappaB, 
iNOS, COX-2) 
9. Ac-YVAD-cmk 
" Pharmacological [Ac-YVAD-cmk] Inhibition of Caspase-1 Ameliorates Cisplatin-Induced 
Nephrotoxicity through Suppression of Apoptosis, Oxidative Stress, and Inflammation in 
Mice. " [Kim, J.-Y. et al, 2018] 
(biomarkers: caspase-1, blood urea nitrogen, creatinine, caspase-3, apoptosis, oxidative stress,  
inflammation) 
10. Pterostilbene 
" Protective Effects of Pterostilbene Against Myocardial Ischemia/Reperfusion Injury in 
Rats." [Wu, M. et al, 2017] 
(biomarkers: lactate dehydrogenase, creatine kinase-MB, oxidative stress, inflammation, Gas6, 
Axl, Bcl-2, Bax, apoptosis) 
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2D. PN/PAD Characteristics 
2D1. List of Existing PN/PAD Characteristics 
 Table 7A-9a contains a list of the 757 existing biomarkers identified in this study, and the 
numbers of records in which they appear, highest first.  The top fifty of these biomarkers are 
shown in Table 2D-1a.  Because these are the highest frequency biomarkers, many will be very 
general.   





2277 nerve conduction velocity 
2038 ankle brachial index 
1549 blood pressure 
1402 stenosis 
1156 body mass index 
1142 neurotoxic 
1139 total cholesterol 
1138 blood glucose levels 
1091 degeneration 
1061 hemoglobin A1c 








671 growth factor 
640 Schwann cell 
616 demyelination 
610 pain-free walking distance 




495 low-density lipoprotein cholesterol 
489 angiogenesis 
455 axonal degeneration 
435 Systolic blood pressure 
426 circulation 
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425 high-density lipoprotein cholesterol 
419 oxidative stress 
413 plaque 
412 occlusions 
402 albumin level 
399 glomerular filtration rate 
391 ventricular ejection fraction 
382 calcification 
365 nerve damage 
354 neurodegeneration 
349 IgM 




 Areas emphasized include neurotoxicity, neurodegeneration, inflammation, oxidative 
stress, demyelination, angiogenesis, circulation, calcification. 
 Table 7A-9b contains a list of the existing symptoms/diseases identified in this study, and 
the numbers of records in which they appear, highest first.  The top fifty of these 
symptoms/diseases  are shown in Table 2D-1b.  Because these are the highest frequency 
contributing factors, many will be very general.   
Table 2D-1b - Top Fifty Existing PN/PAD Symptoms/Diseases 
#RECORDS SYMPTOM/DISEASE  
17050 neuropathy 
13577 peripheral neuropathy 
9627 diabetes mellitus 
9078 artery disease 
8114 peripheral artery disease 






2861 neuropathic pain 
2612 stroke 
2152 diabetic peripheral neuropathy 
2071 infection 
2056 myocardial infarction 
2051 cardiovascular disease 
1983 intermittent claudication 
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1913 polyneuropathy 
1796 coronary artery disease 
1585 heart disease 
1571 type 2 diabetes mellitus 
1547 critical limb ischemia 
1533 diabetic foot ulcer 
1519 Disorder 
1440 heart failure 
1135 weakness 
879 neutropenia 
878 cerebrovascular disease 
833 sensory neuropathy 
832 retinopathy 




747 renal failure 
731 thrombosis 
705 ataxia 
675 abdominal aortic aneurysm 
660 nephropathy 
645 angina 
645 renal disease 
625 Congestive heart failure 
623 multiple myeloma 
621 peripheral artery occlusive disease 
618 bleeding 
618 hyperalgesia 
613 chronic kidney disease 
612 vasculitis 
607 ischemic heart disease 
 
 Diabetes, hypertension, infection, and obesity are of particular note. 
2D2. Factor Matrix of Characteristics 
 Figure 2D-1a in the Excel workbook contains a factor matrix of the existing PN/PAD 
biomarkers.  The 28 factor headings are shown below in Table 2D-2a.  This listing provides a 
convenient taxonomy for categorizing the myriad biomarkers  identified.  Figure 2D-1a lists the 
specific biomarkers that had the strongest influence in determining the theme of each of the 28  
factors.  
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Table 2D-2a - Factor Matrix-based Categories for PN/PAD Biomarkers 
FACTOR HEADING 
FACTOR 1 - PLASMA LIPIDS 
FACTOR 2 - PROINFLAMMATORY CYTOKINES 
FACTOR 3 - miRNA 
FACTOR 4 - HEME BIOSYNTHESIS DEFICIENCY 
FACTOR 5 - OXIDATIVE STRESS 
FACTOR 6 - FIBRIN DEPOSITION 
FACTOR 7A - GROWTH FACTORS 
FACTOR 7B - ADVANCED GLYCATION END PRODUCTS 
FACTOR 8 - KALLIKREIN-KININ SYSTEM 
FACTOR 9 - APOLIPOPROTEINS 
FACTOR 10 - FATTY ACIDS 
FACTOR 11 - KIDNEY FILTERING 
FACTOR 12 - PLATELET AGGREGATION 
FACTOR 13 - PROINFLAMMATORY MONOCYTES 
FACTOR 14 - AXONAL DEGENERATION 
FACTOR 15 - MATRIX METALLOPROTEINASES 
FACTOR 16 - ANTIBODIES 
FACTOR 17 - VASCULAR CALCIFICATION 
FACTOR 18 - B12/FOLATE DEFICIENCIES 
FACTOR 19 - ENDOTHELIAL DYSFUNCTION 
FACTOR 20 - ARTERIAL STIFFNESS 
FACTOR 21 - RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS AND LIGANDS 
FACTOR 22 - INSULIN DEFICIENCY 
FACTOR 23A - CELL ADHESION MOLECULES 
FACTOR 23B - ANTI-INFLAMMATORY CYTOKINES 
FACTOR 24 - OXIDATIVE STRESS 
FACTOR 25 - CARDIOVASCULAR DISEASE BIOMARKERS 
FACTOR 26 - VIRAL DAMAGE MARKERS 
 
 About 64% of the total biomarkers were not included under the factors in Figure 2D-1a, 
because of the factor loading values used to determine the cutoffs.  Many had factor loadings too 
small to influence the themes of the factors, and the remainder  were unit frequency.  However, 
even though a biomarker had little influence in determining the theme of a factor, it could be 
very important in its impact on PN/PAD. 
 Figure 2D-1b contains a factor matrix of the existing PN/PAD symptoms/diseases.  The 
15 factor headings are shown below in in Table 2D-2b.  This listing provides a convenient 
taxonomy for categorizing the myriad symptoms/diseases identified.  Figure 2D-1b lists the 
specific symptoms/diseases that had the strongest influence in determining the theme of each of 
the 15 factors. 
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Table 2D-2b - Factor Matrix-based Categories for PN/PAD Symptoms/Diseases 
FACTOR HEADINGS 
FACTOR 1 - REDUCED NEUROMUSCULAR CONTROL 
FACTOR 2 - NON-PAIN DIABETES-RELATED SYMPTOMS/DISEASES 
FACTOR 3 - MOTOR NEURON DISEASES 
FACTOR 4 - NEUROPATHIC PAIN 
FACTOR 5 - CANCER TREATMENT SIDE EFFECTS 
FACTOR 6 - EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS 
FACTOR 7 - POEMS SYNDROME 
FACTOR 8 - ASSOCIATED MAJOR ORGAN DISEASES 
FACTOR 9 - POLYNEUROPATHY 
FACTOR 10 - ISCHEMIA 
FACTOR 11 - DIABETIC NEUROPATHY 
FACTOR 12 - INFECTION-RELATED AUTOIMMUNE DISEASES 
FACTOR 13 - CARDIOVASCULAR DISEASES 
FACTOR 14 - MYOCARDIAL INFARCTION SYMPTOMS 
FACTOR 15 - ARTERY DISEASE 
 
2D3. Biomarker-Biomarker Matrix  
 To display the inter-relationships among the PN/PAD biomarkers, all the biomarkers  
identified are matrixed together in Figure 2D-2 (Excel Workbook).  The cell numbers reflect the 
co-occurrences of the two biomarkers defining the cell.   
 As an example of all biomarkers that co-occur with a selected biomarker, Tables 7A-10 
and 7A-11 show all that co-occur with with the phrases 'angiogenesis' and 'oxidative stress', 
respectively.  The top fifty biomarkers from Tables 7A-10 and 7A-11 are shown in Tables 2D-3 
and 2D-4, respectively.  The first column represents the total number of records for the specific 
biomarker, the second column is the biomarker name, and the third column is the number of 
records in which the biomarker co-occurs with 'angiogenesis' or 'oxidative stress'. 
Table 2D-3 - Top Fifty Biomarkers Co-occurring with Angiogenesis 
#RECORDS BIOMARKER #CO-OCCURRENCES 
489 angiogenesis 489 
671 growth factor 190 
278 vascular endothelial growth factor 131 
932 blood flow 121 
2536 inflammation 64 
700 oxygen 43 
841 proteins 42 
516 cytokine 39 
52 Angiogenic growth factors 39 
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80 fibroblast growth factor 39 
81 Endothelial progenitor cells 36 
318 nitric oxide 32 
2038 ankle brachial index 29 
610 pain-free walking distance 28 
309 apoptosis 28 
52 hepatocyte growth factor 25 
856 marker 21 
2320 toxicity 17 
1138 blood glucose levels 16 
426 circulation 16 
284 endothelial dysfunction 14 
115 nitric oxide synthase 14 
419 oxidative stress 13 
74 matrix metalloproteinase 13 
29 fibroblast growth factor 2 12 
2638 lesions 12 
1549 blood pressure 11 
318 edema 10 
28 CD31 10 
345 tumour necrosis factor-alpha 10 
1402 stenosis 9 
41 CD34 8 
152 Reactive oxygen species 8 
1091 degeneration 7 
413 plaque 7 
52 l-arginine 6 
18 HIF-1alpha 6 
42 thromboangiitis 6 
51 epidermal growth factor 5 
41 transforming growth factor beta 5 
17 CXCR4 5 
748 atrophy 5 
412 occlusions 5 
16 neoangiogenesis 5 
26 miRNA 5 
25 platelet-derived growth factor 5 
2277 nerve conduction velocity 4 
126 vitamin E deficiency 4 
23 integrin 4 
78 transcutaneous oxygen pressure 4 
 
 In Table 2D-3, the most closely related biomarkers are the myriad growth factors.  When 
these growth factors appear in the PN/PAD database, they will co-occur with angiogenesis a 
significant fraction of the time.   
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Table 2D-4 - Top Fifty Biomarkers Co-occurring with Oxidative Stress 
#RECORDS BIOMARKER #CO-OCCURRENCES 
419 oxidative stress 419 
2536 inflammation 117 
700 oxygen 72 
1138 blood glucose levels 60 
152 Reactive oxygen species 53 
119 glutathione 52 
841 proteins 47 
99 antioxidants 46 
309 apoptosis 44 
318 nitric oxide 44 
69 superoxide dismutase 41 
84 malondialdehyde 39 
2277 nerve conduction velocity 37 
69 lipid peroxidation 36 
284 endothelial dysfunction 30 
932 blood flow 30 
693 lipoprotein 30 
747 dorsal root ganglia 27 
856 marker 27 
640 Schwann cell 27 
115 Mitochondrial dysfunction 26 
2320 toxicity 25 
1139 total cholesterol 23 
1091 degeneration 23 
1142 neurotoxic 22 
495 low-density lipoprotein 
cholesterol 
21 
1061 hemoglobin A1c 20 
671 growth factor 20 
549 C reactive protein 20 
65 advanced glycation end product 19 
1549 blood pressure 18 
329 lipids 18 
354 neurodegeneration 18 
538 calcium 17 
345 tumour necrosis factor-alpha 17 
516 cytokine 17 
34 catalase 16 
126 vitamin E deficiency 16 
266 IL-6 16 
185 insulin resistance 15 
26 glutathione peroxidase 14 
115 nitric oxide synthase 14 
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2038 ankle brachial index 14 
33 oxidative damage 14 
1156 body mass index 13 
489 angiogenesis 13 
261 high homocysteine 13 
413 plaque 13 
2638 lesions 12 
616 demyelination 12 
 
 In Table 2D-4, the most closely related biomarkers are measures of oxidation and 
oxidants.  Advanced glycation end products and catalase are closely related as well. To 
understand the associations in more detail, the specific records enumerated in each cell of 
interest must be evaluated.  The reader can manipulate the matrix in Figure 2D-2 to evaluate 
terms and relationships of personal interest. 
2D4. Biomarkers related to PN and to PAD 
 While many of the biomarkers applied relatively equally to PN and PAD, some were 
focused more strongly on PN and others on PAD.  To identify the relative contributions, the 
biomarkers related to PN and to PAD were aggregated separately.  Table 7A-12 shows the 
numbers of records in which the biomarkers co-occur with PN and with PAD.  The top fifty are 
shown in Table 2D-5. 
Table 2D-5 - Top Fifty Biomarkers Relevant to PN and to PAD 
#RECORDS TREATMENT #PN RECORDS #PAD RECORDS 
2638 lesions 985 1503 
2536 inflammation 1445 1143 
2320 toxicity 2077 186 
2277 nerve conduction velocity 2003 183 
2038 ankle brachial index 93 1984 
1549 blood pressure 334 1362 
1402 stenosis 72 1274 
1156 body mass index 378 868 
1142 neurotoxic 980 37 
1139 total cholesterol 261 1003 
1138 blood glucose levels 685 625 
1091 degeneration 874 167 
1061 hemoglobin A1c 663 646 
932 blood flow 167 802 
856 marker 321 558 
841 proteins 568 245 
748 atrophy 633 93 
747 dorsal root ganglia 631 28 
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704 creatinine 230 550 
700 oxygen 184 536 
693 lipoprotein 117 625 
671 growth factor 318 344 
640 Schwann cell 506 25 
616 demyelination 536 56 
610 pain-free walking distance 17 598 
549 C reactive protein 68 507 
538 calcium 249 274 
516 cytokine 289 211 
499 triglycerides 158 410 
495 low-density lipoprotein cholesterol 70 461 
489 angiogenesis 56 439 
455 axonal degeneration 402 73 
435 Systolic blood pressure 88 392 
426 circulation 86 362 
425 high-density lipoprotein cholesterol 105 386 
419 oxidative stress 223 212 
413 plaque 22 382 
412 occlusions 3 358 
402 albumin level 162 304 
399 glomerular filtration rate 95 338 
391 ventricular ejection fraction 33 366 
382 calcification 45 346 
365 nerve damage 238 32 
354 neurodegeneration 305 42 
349 IgM 325 46 
345 tumour necrosis factor-alpha 225 126 
344 sodium 229 114 
329 lipids 92 255 
322 heart rate 133 204 
318 edema 205 120 
 
 Biomarkers shared more or less equally between PN and PAD include inflammation, 
blood glucose levels, hemoglobin A1c, growth factor, calcium, oxidative stress, nitric oxide, IL-
6, reactive oxygen species, acetylcholine, lactate, urea, antioxidants, lipid peroxidation, advanced 
glycation end products, etc.  Biomarkers weighted toward PN include nerve conduction velocity, 
neurotoxicity, atrophy, Schwann cell, demyelination, axonal degeneration, CD4, nerve fiber 
density, etc.  Biomarkers weighted toward PAD include ankle brachial index, blood flow, pain-
free walking distance, low density lipoprotein cholesterol, occlusions, ventricular ejection 
fraction, calcification, fibrinogen, carotid artery intima-media thickness, platelet aggregation, 
pulse pressure, etc. 
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2D5. Biomarkers Selected for Protocol 
 The final number of biomarkers identified in the present study was 757 (Table 7A-9a).  
To reduce this number of biomarkers to a manageable amount for the treatment protocol, a 
number of thematic categories were generated based on the results of the biomarker factor matrix 
(Figure 2D-1a) and other inputs.  Then, phrases were selected to populate these categories based 
in part on 1) their rankings in the biomarker factor matrix, and on 2) their applicability to 
PN/PAD or PN or PAD (Table 7A-12), as discussed at the end of section 2D4. 
 Table 2D-6 contains the final list of biomarkers selected for the protocol.  While each 
biomarker is listed for one category, many of the biomarkers will be applicable to multiple 
categories.  The biomarkers highlighted in red are the highest priority for each category, based 
on the criteria described above. 
Table 2D-6 - Final List of Biomarkers for Treatment Protocol 





ANTIBODIES IgG antibodies 
ANTIBODIES autoantibodies 
ANTIBODIES anti-ganglioside antibodies 
ANTIBODIES demyelination 
ANTIBODIES monoclonal antibodies 
ANTIBODIES glucuronic acid 
ANTIBODIES Chlamydia pneumoniae 
ANTIBODIES antinuclear antibodies 
ART STIFFNESS arterial stiffness 
ART STIFFNESS pulse wave velocity 
ART STIFFNESS pulse pressure 
ART STIFFNESS vascular stiffness 









CALCIFICATION alkaline phosphatase 
ENDOTHELIAL DYSFUNCTION nitric oxide 
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ENDOTHELIAL DYSFUNCTION l-arginine 
ENDOTHELIAL DYSFUNCTION nitric oxide synthase 
ENDOTHELIAL DYSFUNCTION arginine 
ENDOTHELIAL DYSFUNCTION endothelin-1 
FOLATE DEFICIENCY folic acid 
FOLATE DEFICIENCY folate deficiency 
FOLATE DEFICIENCY methionine 
FOLATE DEFICIENCY S-adenosylmethionine 
FOLATE DEFICIENCY HCY 
FOLATE DEFICIENCY cysteine 
FOLATE DEFICIENCY methylmalonic acid 
FOLATE DEFICIENCY asymmetric dimethylarginine 
GROWTH FACTORS growth factor 
GROWTH FACTORS vascular endothelial growth factor 
GROWTH FACTORS fibroblast growth factor 
GROWTH FACTORS hepatocyte growth factor 
GROWTH FACTORS nerve growth factor 
GROWTH FACTORS fibroblast growth factor 23 
GROWTH FACTORS blood flow 
GROWTH FACTORS transforming growth factor beta 
INFLAMMATION C reactive protein 
INFLAMMATION IL-6 
INFLAMMATION Tumour necrosis factor-alpha 
INFLAMMATION IL1-beta 










INFLAMMATION Interferon gamma 
INFLAMMATION TGFbeta 
INFLAMMATION IL-2 
INFLAMMATION matrix metalloproteinase 2 





KIDNEY FUNCTION urea 
KIDNEY FUNCTION blood urea nitrogen 
KIDNEY FUNCTION creatinine 
KIDNEY FUNCTION white blood cell 
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KIDNEY FUNCTION uric acid 
KIDNEY FUNCTION bilirubin 
KIDNEY FUNCTION glomerular filtration rate 
LIPIDS high-density lipoprotein cholesterol 
LIPIDS total cholesterol 
LIPIDS triglycerides 
LIPIDS low-density lipoprotein cholesterol 
LIPIDS fibrinogen 
LIPIDS Lipoprotein(a) 
LIPIDS hemoglobin A1c 
NEURODEGENERATION myelinated fibers 
NEURODEGENERATION dorsal root ganglia 
NEURODEGENERATION nerve conduction velocity 
NEURODEGENERATION Schwann cell 
NEURODEGENERATION fiber loss 
NEURODEGENERATION atrophy 
NEURODEGENERATION nerve fiber density 
OXIDATIVE STRESS Reactive oxygen species 
OXIDATIVE STRESS glutathione 
OXIDATIVE STRESS superoxide dismutase 
OXIDATIVE STRESS malondialdehyde 
OXIDATIVE STRESS advanced glycation end products 
OXIDATIVE STRESS catalase 
OXIDATIVE STRESS glutathione peroxidase 
OXIDATIVE STRESS iNOS 
OXIDATIVE STRESS Hydrogen peroxide 
OXIDATIVE STRESS peroxynitrite 
OXIDATIVE STRESS NADPH oxidases 
OXIDATIVE STRESS TBARS 
OXIDATIVE STRESS 4-hydroxy-2-nonenal 
OXIDATIVE STRESS Nrf2 
OXIDATIVE STRESS isoprostane 
OXIDATIVE STRESS NOx 
OXIDATIVE STRESS heme oxygenase 1 
OXIDATIVE STRESS oxidized low-density lipoprotein 
OXIDATIVE STRESS lipid hydroperoxides 
OXIDATIVE STRESS PON-1 
OXIDATIVE STRESS 3-nitrotyrosine 
OXIDATIVE STRESS adenosine triphosphate 
OXIDATIVE STRESS creatine kinase 
PLATELET ACTIVATION arachidonic acid 
PLATELET ACTIVATION adenosine diphosphate 
PLATELET ACTIVATION P-selectin 
PLATELET ACTIVATION prothrombin 
PLATELET ACTIVATION thrombin 
PLATELET ACTIVATION L-selectin 
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RAGE thromboxane A2 
RAGE phosphatidylinositol 3-kinase 
RAGE adenosine monophosphate 
RAGE caspase 3 
 
2E. Matrix of PN/PAD Causes vs Biomarkers 
 Figure 2E-1 (Excel Workbook) displays the co-occurrences between the existing 
PN/PAD contributing factors and biomarkers. The cell numbers reflect the co-occurrences of the 
contributing factor and biomarker defining the cell.   
 The matrix is relatively dense starting at the upper left, and becomes increasingly sparse 
going to the lower right.  There are approximately 630,000 cells in the matrix, of which about 
16,000 have entries.  That's an occupancy rate of slightly more than two percent.  Why is this 
important?  The cell numbers reflect, in part, the amount of research effort devoted (reported) to 
examining the relationship between the cause and the biomarker defining the cell.  Cells that are 
blank may reflect that research has not been done on the cause and biomarker combination, and 
therefore could be excluding another potential cause.  The message to be taken from this 
observation is far more research could be conducted on identifying potential causes if more 
biomarkers were included in the investigations. 
 As an example of all contributing factors that co-occur with a biomarker, Tables 7A-13 
and 7A-14 show all the causes that co-occur with with the phrases 'oxidative stress' and 'blood 
pressure', respectively.  The top fifty contributing factors from Tables 7A-13 and 7A-14 are 
shown in Tables 2E-1 and 2E-2, respectively.  The first column represents the total number of 
records for the specific contributing factor, the second column is the contributing factor name, 
and the third column is the number of records in which the contributing factor co-occurs with 
'oxidative stress' or 'blood pressure'. 
Table 2E-1 - Top Fifty Causes that Co-occur with Oxidative Stress 
#RECORDS  CAUSE #C0-OCCURRENCES 
2507 chemotherapy 37 
125 advanced glycosylation end products 32 
296 Streptozotocin 31 
2265 smoking 24 
1140 High cholesterol diet 23 
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524 oxaliplatin 16 
985 paclitaxel 11 
149 Arsenic 10 
745 dialysis 9 
503 Bortezomib 9 
347 vincristine 7 
340 peripheral nerve injury 6 
442 alcohol 6 
508 hemodialysis 6 
217 platinum 6 
19 high glucose 6 
66 high fat diet 6 
14 Hydrogen peroxide 6 
570 cisplatin 5 
29 Ischemia-reperfusion 5 
393 alcohol consumption 5 
324 taxanes 5 
201 chronic constriction injury 5 
49 acetone 5 
12 iron overload 4 
18 streptozocin 3 
570 trauma 3 
26 metals 3 
351 thalidomide 3 
196 docetaxel 3 
93 spinal cord injury 3 
86 alkaloids 3 
34 dichloroacetate 3 
9 manganese 3 
9 HFD 2 
9 dithiocarbamates 2 
9 allopurinol 2 
140 5-fluorouracil 2 
29 phenytoin 2 
131 sedentary 2 
83 axotomy 2 
76 Vinca alkaloids 2 
337 lifestyle 2 
73 coronary angioplasty 2 
821 HIV-1 2 
65 Zinc 2 
708 infections 2 
545 depression 2 
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Table 2E-2 - Top Fifty Causes that Co-occur with Blood Pressure 
#RECORDS  CAUSES #CO-OCCURRENCES 
2265 smoking 411 
1140 High cholesterol diet 321 
442 alcohol 55 
337 lifestyle 53 
745 dialysis 52 
508 hemodialysis 44 
393 alcohol consumption 38 
545 depression 27 
131 sedentary 20 
22 atenolol 10 
2507 chemotherapy 9 
357 anesthesia 9 
59 inactivity 9 
15 lisinopril 7 
96 malnutrition 7 
821 HIV-1 6 
14 enalapril 6 
24 cadmium 5 
85 renal transplantation 5 
66 high fat diet 5 
5 salt intake 5 
44 Mercury 5 
985 paclitaxel 4 
683 viruses 4 
39 lead exposure 4 
323 cyclophosphamide 4 
125 advanced glycosylation end 
products 
4 
42 hand-arm vibration 3 
96 drug-induced 3 
570 trauma 3 
708 infections 3 
73 coronary angioplasty 3 
378 highly active antiretroviral 
therapy 
3 
361 radiation 3 
43 bariatric surgery 3 
3 felodipine 3 
324 taxanes 2 
24 immunization 2 
201 chronic constriction injury 2 
196 docetaxel 2 
23 5-hydroxytryptamine 2 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                                                                                                                
   Chapter 2 - Results/Discussion                                                                                                                              83 
28 vitamin D deficient 2 
21 vibration-induced 2 
149 Arsenic 2 
63 bevacizumab 2 
 
 As an example of all biomarkers that co-occur with a contributing factor, Tables 7A-15 
and 7A-16 show all biomarkers impacted by 'high cholesterol diet' and 'sedentary', respectively.  
The top fifty contributing factors from Tables 7A-15 and 7A-16 are shown in Tables 2E-3 and 
2E-4, respectively.   
Table 2E-3 - Top Fifty Biomarkers Co-occurring with High Cholesterol Diet 
#RECORDS BIOMARKER #CO-OCCURRENCES 
1139 total cholesterol 1139 
693 lipoprotein 472 
495 low-density lipoprotein cholesterol 386 
499 triglycerides 340 
425 high-density lipoprotein cholesterol 323 
1549 blood pressure 321 
1156 body mass index 209 
1138 blood glucose levels 191 
1061 hemoglobin A1c 169 
2038 ankle brachial index 164 
435 Systolic blood pressure 133 
329 lipids 116 
549 C reactive protein 96 
2536 inflammation 93 
704 creatinine 90 
308 fibrinogen 72 
402 albumin level 63 
856 marker 60 
125 apolipoprotein 59 
147 lipid profile 57 
175 diastolic blood pressure 51 
1402 stenosis 50 
399 glomerular filtration rate 48 
413 plaque 41 
2638 lesions 39 
261 high homocysteine 39 
185 insulin resistance 39 
96 uric acid 36 
162 glycated haemoglobin 34 
110 waist circumference 33 
94 Lipoprotein(a) 31 
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208 carotid artery intima-media thickness 30 
2277 nerve conduction velocity 28 
27 high total cholesterol 27 
538 calcium 27 
610 pain-free walking distance 27 
92 albumin excretion rate 26 
41 apolipoprotein B 26 
210 fatty acid 23 
419 oxidative stress 23 
104 pulse pressure 22 
841 proteins 22 
266 IL-6 22 
932 blood flow 21 
382 calcification 21 
284 endothelial dysfunction 20 
39 apolipoprotein A-I 20 
251 angiotensin converting enzyme 19 
345 tumour necrosis factor-alpha 18 
36 niacin 17 
 
Table 2E-4 - Top Fifty Biomarkers Co-occurring with Sedentary 
#RECORDS BIOMARKER #CO-OCCURRENCES 
2038 ankle brachial index 31 
1549 blood pressure 20 
1156 body mass index 19 
1139 total cholesterol 10 
1138 blood glucose levels 10 
2536 inflammation 9 
30 body fat 9 
549 C reactive protein 7 
185 insulin resistance 7 
1402 stenosis 6 
1061 hemoglobin A1c 6 
610 pain-free walking distance 6 
425 high-density lipoprotein cholesterol 5 
322 heart rate 5 
932 blood flow 5 
538 calcium 5 
693 lipoprotein 5 
495 low-density lipoprotein cholesterol 5 
208 carotid artery intima-media thickness 5 
110 waist circumference 4 
856 marker 4 
748 atrophy 4 
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700 oxygen 4 
435 Systolic blood pressure 4 
284 endothelial dysfunction 4 
151 arterial stiffness 4 
841 proteins 3 
413 plaque 3 
499 triglycerides 3 
94 Lipoprotein(a) 3 
318 nitric oxide 2 
455 axonal degeneration 2 
329 lipids 2 
20 adenosine triphosphate 2 
308 fibrinogen 2 
2277 nerve conduction velocity 2 
105 plasminogen activator inhibitor-1 2 
222 weight loss 2 
2638 lesions 2 
38 vitamin K 2 
516 cytokine 2 
183 pulse wave velocity 2 
419 oxidative stress 2 
1091 degeneration 2 
147 lipid profile 2 
27 high total cholesterol 2 
125 Vitamin D deficiency 2 
10 low birth weight 2 
32 insulin levels 1 
107 lactate 1 
 
2F. Matrix of PN/PAD Treatments vs Biomarkers  
 Figure 2F-1 (Excel Workbook) displays the co-occurrences between the existing 
PN/PAD treatments and biomarkers. The cell numbers reflect the co-occurrences of the 
treatment and biomarker defining the cell.   
 As an example of all treatments that affect a biomarker, Tables 7A-17 and 7A-18 show 
all the treatments that co-occur with with the phrases 'oxidative stress' and 'blood pressure', 
respectively.  The top fifty treatments from Tables 7A-17 and 7A-18 are shown in Tables 2F-1 
and 2F-2, respectively.  The first column represents the total number of records for the specific 
treatment, the second column is the treatment name, and the third column is the number of 
records in which the treatment co-occurs with 'oxidative stress' or 'blood pressure', respectively. 
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Table 2F-1 - Top Fifty Treatments that Co-occur with Oxidative Stress 
#RECORDS TREATMENT #CO-OCCURRENCES 
3638 drug 49 
99 antioxidants 46 
1766 inhibitor 42 
62 superoxide dismutase 38 
754 insulin 30 
812 growth factor 24 
288 supplementation 21 
1328 exercise 20 
1358 walking 18 
2402 amputation 17 
126 vitamin E 16 
449 diet 16 
25 GSH 15 
349 vascular endothelial growth factor 13 
489 angiogenesis 13 
34 vitamin C 12 
5105 surgery 11 
86 Alpha lipoic acid 11 
745 dialysis 9 
172 IL-6 9 
447 glycemic control 9 
14 antioxidant therapy 9 
150 hypoxia 8 
47 aldose reductase inhibitor 7 
567 analgesic 6 
189 Spinal Cord Stimulation 6 
632 medications 6 
252 antihypertensive agents 6 
206 nerve growth factor 6 
233 pregabalin 5 
80 folic acid 5 
1920 revascularization 5 
28 N-acetylcysteine 5 
190 smoking cessation 5 
67 erythropoietin 5 
25 nicotinamide 5 
541 endovascular treatment 4 
100 haemodialysis 4 
370 statin 4 
12 tempol 4 
1228 angioplasty 4 
266 coronary intervention 4 
242 Gabapentin 4 
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25 curcumin 4 
337 antiplatelet therapy 4 
111 duloxetine 4 
117 Vitamin D 3 
207 vitamin B12 3 
17 interleukin-10 3 
 
Table 2F-2 - Top Fifty Treatments Co-occurring with Blood Pressure 
#RECORDS TREATMENT #CO-OCCURRENCES 
3638 drug 178 
1328 exercise 149 
252 antihypertensive agents 137 
1766 inhibitor 122 
5105 surgery 112 
754 insulin 106 
1358 walking 81 
2402 amputation 74 
447 glycemic control 71 
1920 revascularization 67 
632 medications 58 
745 dialysis 52 
576 aspirin 48 
449 diet 47 
190 smoking cessation 40 
370 statin 36 
1228 angioplasty 30 
337 antiplatelet therapy 29 
110 enzyme inhibitors 29 
353 Clopidogrel 26 
507 vascular surgery 22 
58 angiotensin converting enzyme 
inhibitor 
22 
1308 artery bypass grafting 20 
221 anticoagulant 19 
812 growth factor 18 
459 rehabilitation 16 
33 ramipril 15 
588 operation 12 
233 endarterectomy 12 
22 calcium antagonists 12 
450 bypass surgery 11 
489 angiogenesis 11 
288 supplementation 11 
215 Cilostazol 11 
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59 Testosterone 10 
349 vascular endothelial growth factor 10 
50 C-peptide 10 
27 verapamil 10 
17 amlodipine 10 
117 Vitamin D 9 
59 acetylsalicylic acid 9 
172 Gene therapy 9 
828 stents 9 
50 Nicotine 9 
12 hydrochlorothiazide 9 
28 nifedipine 9 
118 warfarin 8 
16 losartan 8 
21 calcium channel blocker 8 
 
 As an example of all biomarkers affected by a treatment, Tables 7A-19 and 7A-20 show 
all biomarkers impacted by 'exercise' and 'gabapentin', respectively.  The top fifty  biomarkers  
from Tables 7A-19 and 7A-20 are shown in Tables 2F-3 and 2F-4, respectively.   
Table 2F-3 - Top Fifty Biomarkers Co-occurring with Exercise 
#RECORDS BIOMARKER #CO-OCCURRENCES 
610 pain-free walking distance 287 
2038 ankle brachial index 210 
700 oxygen 160 
1549 blood pressure 149 
932 blood flow 124 
322 heart rate 84 
2536 inflammation 67 
1138 blood glucose levels 64 
1402 stenosis 56 
1156 body mass index 53 
1139 total cholesterol 52 
2638 lesions 49 
1061 hemoglobin A1c 46 
70 peak oxygen consumption 43 
693 lipoprotein 40 
495 low-density lipoprotein 
cholesterol 
35 
856 marker 35 
435 Systolic blood pressure 34 
426 circulation 33 
251 angiotensin converting 29 
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enzyme 
489 angiogenesis 28 
329 lipids 28 
549 C reactive protein 26 
2277 nerve conduction velocity 23 
499 triglycerides 23 
78 transcutaneous oxygen 
pressure 
23 
61 oxygen saturation 23 
308 fibrinogen 20 
671 growth factor 20 
284 endothelial dysfunction 20 
419 oxidative stress 20 
318 nitric oxide 20 
185 insulin resistance 19 
425 high-density lipoprotein 
cholesterol 
19 
107 lactate 19 
28 phosphocreatine 19 
748 atrophy 18 
516 cytokine 16 
538 calcium 15 
266 IL-6 15 
262 stenoses 15 
151 arterial stiffness 14 
841 proteins 14 
413 plaque 14 
278 vascular endothelial growth 
factor 
14 
222 weight loss 13 
345 tumour necrosis factor-alpha 12 
95 blood viscosity 12 
168 platelet aggregation 12 
147 lipid profile 11 
 
Table 2F-4 - Top Fifty Biomarkers Co-occurring with Gabapentin 
#RECORDS BIOMARKER #CO-OCCURRENCES 
538 calcium 19 
147 capsaicin 18 
2536 inflammation 15 
1142 neurotoxic 14 
344 sodium 10 
2320 toxicity 9 
747 dorsal root ganglia 8 
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38 Noradrenaline 8 
2277 nerve conduction velocity 6 
318 edema 6 
1138 blood glucose levels 5 
671 growth factor 5 
30 Gamma-aminobutyric acid 5 
65 magnesium 5 
122 mechanical hyperalgesia 5 
119 glutathione 5 
365 nerve damage 4 
419 oxidative stress 4 
195 thermal hyperalgesia 4 
318 nitric oxide 3 
704 creatinine 3 
700 oxygen 3 
263 vitamin B(12) deficiency 3 
206 nerve growth factor 3 
27 cholinesterase 3 
152 Reactive oxygen species 3 
126 glutamate 3 
273 glycoprotein 2 
1139 total cholesterol 2 
222 weight loss 2 
1549 blood pressure 2 
1091 degeneration 2 
54 glial fibrillary acidic protein 2 
322 heart rate 2 
349 IgM 2 
40 myeloperoxidase 2 
70 IL-10 2 
27 cyclooxygenase 2 2 
345 tumour necrosis factor-alpha 2 
128 IL-1beta 2 
25 Iron Deficiency 2 
1156 body mass index 2 
516 cytokine 2 
12 anticardiolipin antibodies 2 
20 folate deficiency 1 
24 aspartate aminotransferase 1 
99 antioxidants 1 
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2G. Under-representation of PN/PAD Causes, Treatments, and Characteristics 
 The previous sections of the present chapter have shown that, while the numbers of 
PN/PAD causes, treatments, and characteristics identified in the present monographs of the 
PN/PAD study are massive compared to any other study in the literature, these numbers are  
 1) a modest fraction of what could theoretically be extracted from the existing PN/PAD 
literature and  
 2) a very modest fraction of what could be extracted from both the existing PN/PAD 
literature and non-PN/PAD literature.   
 There are two main reasons for this.  First, numbers of PN/PAD causes, treatments, and 
characteristics are under-reported in the biomedical literature (especially PN/PAD causes).  
Second, resource limitations restricted the numbers of PN/PAD causes, treatments, and 
characteristics that could be extracted from what is reported in the biomedical literature.  
 There are myriad reasons for under-reporting of PN/PAD causes, treatments, and 
characteristics.  These include: 
• lack of incentives for industry and government to sponsor research on PN/PAD causes 
from industrial products 
• lack of incentives for some journals (especially those with sponsorship from industry or 
government) to publish research on PN/PAD causes from industrial products 
• limited scope and variables measured in many research projects 
 There are also myriad reasons that extraction of PN/PAD causes, treatments, and 
characteristics from those reported in the biomedical literature was limited in the present study.  
Most reasons for limited extraction from the reported data are based on resource and time 
limitations for the study, but process, software, and data limitations played a role as well.  These 
issues are discussed in the remainder of this chapter.  For those readers who want to access the 
PN/PAD treatment protocols directly at this point, they can be found in Chapter 3. 
2G1. Under-reporting of PN/PAD Foundational Causes 
2G1a.  Reduced incentives for sponsoring and reporting PN/PAD foundational causes 
 Chapter 9 of [Kostoff, 2015], and [Kostoff, 2016], contain many caveats showing why 
the numbers of PN/PAD (or any other chronic disease) foundational causes presented in Table 
7A-1 may be vast under-representations of the numbers of PN/PAD operational foundational 
causes.  Summarily, many adverse events are not reported and published in the literature (e.g., 
see references 70-125 of [Kostoff, 2015]), or, if they are reported and published, many are not 
accessed due to inadequate search algorithms.  The under-reporting occurs at the patient, doctor, 
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researcher, journal, corporate, and Federal agency levels, mainly because of myriad incentives 
(and few disincentives) for under-reporting.  See Chapter 9 of [Kostoff, 2015], or [Kostoff, 
2016], for further examples. 
 Under-reporting can be disguised through selective reporting of adverse events.  For 
example, in a previous monograph focusing on AD causes [Kostoff, Zhang, Ma et al, 2017], we 
considered an endogenous substance to be a foundational cause if it was administered 
exogeneously in lab tests for the purpose of better understanding its pathological mechanisms.  
There was a substantial amount of research reported on these intrinsically endogenous 
substances, and they were high-frequency in the literature (large numbers of records).  These 
endogenous substances are typically not major industrial products, and therefore pose no threat 
to any industry if adverse effects are reported.  As an example, in the AD causes monograph, 
there were many studies where Abeta was administered exogenously, in order to study its effects 
under more controlled conditions.  Contrast this high level of effort on Abeta as an exogenous 
contributing factor to AD with the low level of research effort on the myriad harmful 
occupational and environmental substances and radiations. 
 In the same vein, for those foundational causes that are accepted as harmful (smoking, 
excess alcohol, etc), again, there is little reluctance for research funding into adverse effects.  For 
potentially toxic substances that have not yet received public consensus as being harmful, 
industry and government research funds are sparse.  This is reflected by the large number of very 
detailed foundational causes (typically specific chemicals, materials, or radiations) appearing in 
only one or two records in [Kostoff, 2015] and the present study. 
 So, while PN/PAD research on potential foundational causes may appear to be reasonable  
based on overall funding and levels of effort, the research effort/funding is highly skewed toward 
'safe' research on already known harmful substances, and away from substances important to 
industry and government not yet proven to be toxic. 
 Apart from individual and organizational reluctance to identify adverse effects from 
products in which they are involved, a very important consideration limiting sponsor resources 
for identifying new contributing factors is the sheer number of experiments and epidemiological 
studies that would be required for comprehensive evaluation.  This is especially true for the case 
of combinations of contributing factors, where adverse effects from each constituent may only 
show up as part of a combination, or may substantially worsen as part of a combination. 
 The reason few combinations are selected for study derives from combinatorics.  
Consider the number of possible combinations of two and three items in a list of n items.  For n 
variables, and possible combinations of a subset of n consisting of r variables, the number of 
combinations is: C(n,r)=n!/(r!*(n-r)!), where [!] denotes the factorial function.  For large n, and r 
small compared to n, C(n,r)~=n
r
/r!  For large n, C becomes a large number.  How large?  
Consider the following.   
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 It would be useful to identify those substances that, in isolation or in combination, could 
potentially impact PN/PAD or its surrogate endpoints, but have not been studied yet.  There are 
many tens of thousands of items that could be potential candidates for study.  Is there any way to 
narrow those down? 
 [Kostoff, 2015] examined contributing factors to ~4,000 diseases, and identified factors 
that contributed to 1) any of these diseases and 2) a threshold number of diseases.  In [Kostoff, 
2015], on the order of 800 substances that contributed to at least a threshold number of the 
~4,000 diseases were identified.  These 800 pervasive causes constituted about ten percent of the 
total number of causes (90% of which impacted less than the threshold number of diseases) 
identified for the ~4,000 diseases.  The total number of causes identified for all diseases (~8,000) 
might be a good starting point for identifying additional potential PN/PAD causes.  Why is this a 
reasonable assumption? 
 The various systems in the body are inter-related.  The immune system, neural system, 
endocrine system, circulatory system, etc, are linked.  There are research disciplines devoted to 
study of these linked systems (e.g., neuroimmunology, neuroimmunoendocrinology, etc).  Most 
of the ~8,000 causes identified in [Kostoff, 2015] impacted one or more of these inter-related 
systems.  Many of the studies focused on the impact of the test substance on (typically) one 
system only.  It would be reasonable to expect that a substance impacting one of the systems 
above would have some level of impact on the other systems above, with some impacts being 
more significant than others. 
 Thus, the ~8,000 potential causes identified in [Kostoff, 2015], minus those that were 
identified in the present PN/PAD study, would be candidates for evaluation as potential AD 
causes.  Subtracting the ~800 PN/PAD causes identified in the present study from the ~8,000 
causes leaves on the order of ~7,200 items to be examined in isolation.  Assume there were 
another 800 items evaluated for potential impacts on PN/PAD in other studies but were shown 
not to have an effect (in isolation, although we may want to examine them as part of a 
combination).  We are then left with on the order of   
 1) ~7,200 substances to study in combination, and  
 2) ~6,400 of the initial ~7,200 substances to study in isolation.   
This would include the case where the ~800 identified contributing factors in isolation could 
have a stronger effect in combination, for those cases where the combinations have not been 
studied.   
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 The numbers of combinations of two and three for 7,200 test items, C(7200,2), 
C(7200,3), are, according to the formula above for small r: 
 C(7200,2)=~26 million 
 C(7200,3)=~62 billion 
 These numbers are astronomical in any of the cases shown.  Research on each of these 
combinations is a major resource and time effort, in the lab and/or in the field/clinic.  There's no 
way all the combinations, or even the most relevant ones, can be run.  Unfortunately, the myriad 
combinations of potentially toxic stimuli mirror the real world, not the potentially toxic stimuli 
acting in isolation.  And, which combinations are important to a specific individual would be a 
function of that person's unique characteristics, such as genetic makeup. 
2G1b.  Resource limitations to identifying foundational causes 
2G1b1.  Existing foundational causes 
 Additionally, in the initial process of identifying the existing PN/PAD causes listed in 
Table 7A-1, identification of the higher-frequency causes (including some relatively general 
causes) was quite comprehensive.  There were many lower frequency causes identified through 
the linking terms, but the latter process was truncated because of time considerations.  
Unfortunately, as the record frequency of PN/PAD causes decreases, the number of discrete 
PN/PAD causes increases drastically.  These lower frequency PN/PAD causes tended to be 
highly specific in chemical and radiation exposures from industrial practices, medical treatments, 
everyday personal exposures, etc.  Thus, over and above the existing PN/PAD causes that have 
not entered the PN/PAD literature for the reasons described in the previous section, there are 
probably many hundreds of low-frequency PN/PAD causes in the literature that were not 
accessed due to our time/resource limitations. 
2G1b2. Potential foundational causes 
 Another constraint imposed by this study's resource limitations was identification of 
potential PN/PAD foundational causes.  The LRDI approach for identifying potential PN/PAD 
foundational causes (aka literature-related discovery) is analogous to that used for identifying 
potential PN/PAD treatments, shown in section 6B5 and Appendix 6-1.  Non-PN/PAD literatures 
are examined for causes that move the values of PN/PAD characteristics in some desired pre-
determined direction, but these causes have not been identified in the PN/PAD literature.  This 
LRDI-discovery approach was demonstrated in the chronic kidney disease (CKD) LRDI study 
[Kostoff and Patel, 2015].  It was clear from the voluminous retrievals in the CKD study that 
many hundreds of potential CKD contributing factors could be identified with the LRDI 
discovery process, and similar results for identifying PN/PAD causes would be expected from 
application of this LRDI discovery process to the non-PN/PAD biomedical literature. 
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2G1c.  Limited research focus on identifying foundational causes 
 Further, in the epidemiological studies whose focus was on PN/PAD cause identification, 
only a finite number of PN/PAD causes to be identified were the objects of the research.  
PN/PAD causes that were operable, but not search targets, would not be identified. 
2G1d. Research concentration on identifying foundational causes in isolation 
  Also, in both the epidemiology and laboratory studies, very few studies attempted to 
ascertain synergies resulting from combined potential contributing factors.  These included 
factors that, when operating in isolation, produced no or miniscule harmful effects, but when 
operating in combination, produced very harmful effects.  As a recent study shows, the potential 
impacts of contributing factor synergies could be substantial [Kostoff, Goumenou, Tsatsakis, 
2018]. 
2G2. Under-reporting of PN/PAD Treatments 
 It was shown in section 2G1 that under-reporting of causes had two major components: 
technical and disincentives for reporting.  Under-reporting of treatments is mainly due to 
technical reasons, since there are many incentives for sponsorship and publication of PN/PAD 
treatment research. 
2G2a.  Resource constraints 
2G2a1. Existing PN/PAD treatments limited 
 Existing PN/PAD treatments were identified in two ways primarily: visual examination 
of the high-frequency title and abstract phrases, and use of linking phrases (e.g., improve, 
restore, mitigate, etc) to identify low-frequency title and abstract phrases. As in the case of the 
existing PN/PAD causes, the numbers of existing PN/PAD treatments increased drastically as the 
frequency of appearance in the literature decreased.  So, most of the existing PN/PAD treatments 
to be identified were in the region that required linking phrases to access.  Because of resource 
constraints and time limitations, not all of the linking terms identified were used operationally.  
While this approach allowed identification of massive numbers of existing PN/PAD treatments, 
the limited use of linking terms meant that additionally massive numbers of existing PN/PAD 
treatments were not being identified.  An expanded study could overcome this deficiency.  
2G2a2. Potential PN/PAD treatments limited 
 Resource constraints also limited the number of potential PN/PAD treatments that could 
be identified.  These are treatments that influence PN/PAD characteristics in directions desired 
for PN/PAD reversal, and are currently being used for non-PN/PAD diseases.  The LRDI 
discovery approach allows these potential PN/PAD treatments to be readily identified, and 're-
purposed' for PN/PAD application.  Exploratory analysis showed that voluminous treatments 
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from non-PN/PAD literatures had potential to be 're-purposed' for PN/PAD, but only a handful of 
potential PN/PAD treatments were presented in the present proof-of-principle demonstration. 
2G2b. Process, software, and database limitations  
 The linking term approach was indispensible for extracting existing PN/PAD treatments 
from the millions of PN/PAD abstract phrases, but it had intrinsic limitations.  While many 
PN/PAD treatment phrases were in close proximity to linking terms, not all PN/PAD treatment 
phrases were.  Some PN/PAD treatment phrases were slightly outside the four-word range of the 
software abstract phrases, while other PN/PAD treatment phrases were not associated with any 
of the linking terms identified in the present study.   
 The titles were searched initially for existing PN/PAD treatments, and then the abstracts 
were searched.  Unfortunately, there were records in which the existing PN/PAD treatment 
occurred in full-text only, and not in the title or abstract.  Full-text searching would overcome 
this limitation.  However, not all biomedical records are available in full-text on the main 
biomedical databases, and the complexity of searching full-text increases substantially over 
searching titles or abstracts [Kostoff, 2010]. 
2G3. Under-reporting of PN/PAD characteristics 
 The high-frequency PN/PAD characteristics were identified from visual examination of 
the abstract phrases in the retrieved PN/PAD database.  The low frequency PN/PAD 
characteristics were identified and extracted with use of the linking terms developed for 
identifying and extracting treatments and contributing factors. 
2G3a. Process, software, and database limitations  
 Because of time and resource limitations, the characteristics identification process was 
terminated before all linking terms could be examined.  Many of the comments made in the 
previous PN/PAD treatments section apply to PN/PAD characteristics as well. 
 While many PN/PAD characteristics phrases were in close proximity to linking terms, 
not all PN/PAD characteristics phrases were.  Some PN/PAD characteristics phrases were 
slightly outside the four-word range of the software abstract phrases.  In many cases, this was 
because PN/PAD characteristics phrases were used in one long sentence following one linking 
term (e.g., treatment X attenuated characteristic A, characteristic B, characteristic C, etc, where 
only characteristic A would be in the range of the software phrase length).  Other PN/PAD 
characteristics phrases were not associated with any of the linking terms identified in the present 
study.   
 The titles were searched initially for existing PN/PAD characteristics, and then the 
abstracts were searched.  Unfortunately, there were records in which the existing PN/PAD 
characteristics occurred in full-text only, and not in the title or abstract.  This occurred much 
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more frequently than for treatments, since PN/PAD treatments tended to be the focus of the 
research more than the PN/PAD characteristics.  Full-text searching would overcome this 
limitation.  However, not all biomedical records are available in full-text on the main biomedical 
databases, and the complexity of searching full-text increases substantially over searching titles 
or abstracts [Kostoff, 2010]. 
2G3b. Experiment and epidemiology study limitations 
 In order for PN/PAD characteristics to be reported, they need to be identified and 
measured.  Lab experiments targeted a handful of PN/PAD characteristics to be measured, 
typically selected for their relevance to the PN/PAD hypothesis being addressed by the 
researcher.  Epidemiology studies used PN/PAD characteristics identified in medical records or 
stated on questionnaires.  Every additional PN/PAD characteristic that is added to a lab 
experiment or epidemiology study translates into additional time and other resource 
expenditures.  This effectively limits the number and scope of PN/PAD characteristics selected 
for any given lab experiment or epidemiological study. 
 The main point here is the PN/PAD characteristics in the biomedical literature that 
change based on PN/PAD causes or treatments will  be a small fraction of all the PN/PAD 
characteristics that could have been measured and shown to have changed due to PN/PAD causes 
or treatments.  This has strong implications on the populations of the PN/PAD causes-
characteristics or PN/PAD treatments-characteristics matrices.  The matrices presented above, 
massive as they are relative to any others that appear in the PN/PAD literature, are vastly under-
populated because of the limited scope of the epidemiological studies or lab experiments relative 
to breadth of PN/PAD characteristics examined.  
2G3c. Resource limitations on identifying potential PN/PAD characteristics 
 While many hundreds of existing PN/PAD causes and treatments were identified in the 
present study, many hundreds more could have been identified if the limitations described above 
had been removed.  Additionally, many more potential PN/PAD causes and treatments could 
have been identified by using the LRDI process to search non-AD literatures.   
 The same holds true for identifying potential PN/PAD characteristics.  There are 
patterns/groupings of PN/PAD characteristics that could be used to search the non-AD literatures 
for groups of characteristics that include the PN/PAD group patterns, but may also contain other 
characteristics that were not included in the PN/PAD groups in the PN/PAD literature.  
Identifying potential PN/PAD characteristics was not explored in the present study, so it is not 
credible to make estimations of the magnitude of additional PN/PAD characteristics possible 
using this approach. 
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2G4. Impact of under-reporting of PN/PAD causes, treatments, and characteristics 
 What is the real-world impact from the under-reporting of PN/PAD causes, treatments, 
and impacts, as outlined above?  As will be shown in the next chapter on PN/PAD treatment 
protocols, the PN/PAD protocols involve  
 1) measuring relevant PN/PAD characteristics for individual patients,  
 2) identifying causes to be removed based on that patient's PN/PAD characteristics' 
abnormalities, and  
 3) identifying PN/PAD treatments to be implemented based on that patient's PN/PAD 
characteristics' abnormalities.   
Any deficiencies in not identifying, or mis-identifying, PN/PAD characteristics, causes, and 
treatments will translate into deficiencies of these PN/PAD protocols' effectiveness. 
 In the results presented so far in the present chapter, the PN/PAD treatment-biomarker 
(Figure 2F-1) and causes-biomarker matrixes (Figure 2E-1) have their axes ordered starting with 
largest numbers of records at top left, and decreasing numbers of records when proceeding 
rightwards and downwards.  Both types of matrices are dense in the upper left region and very 
sparse in the lower right region.  The PN/PAD treatment-biomarker matrix has a small percent of 
its cells populated with any records.  Even for those cells that contain record numbers, the 
number of records they contain is a very small fraction (on average) of what they could 
theoretically contain.  While an expanded study could increase both the density of the matrix and 
the length of the axes, it would offer little if any insight on the magnitude of the PN/PAD causes 
being suppressed by PN/PAD gatekeepers (e.g., sponsors, journals, etc). 
2H. Conclusions 
 The LRDI-based text mining approach used for this study allowed identification of many 
hundreds of existing PN/PAD characteristics, contributing factors, and treatments, and a handful 
of potential treatments for illustrative purposes.  These are far more characteristics, contributing 
factors, and treatments published in any other PN/PAD study, and they were obtained under the 
most severe resource constraints.  An adequately resourced study could probably double the 
number of these existing PN/PAD items identified, and probably increase the number of 
potential PN/PAD treatments (and contributing factors and biomarkers) by at least an order of 
magnitude. 
 Given the massive numbers of potential contributing factors to PN/PAD, it is difficult to 
see how any treatment approach that does not incorporate full-spectrum elimination of the major 
contributing factors for a given patient can be effective in truly reversing PN/PAD.  Some 
symptom management, especially for the near-term, can be done, but far more is possible. 
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 Successful elimination of the main contributing factors requires three entities: the patient, 
the healthcare provider(s), and the government.  The patient must have the motivation and will to 
heal.  The provider(s) must have the motivation to provide the most accurate information and 
recommendations to the patient.  And, the government must be willing to institute regulations 
that will protect the patient from exposure to many of the known PN/PAD contributing factors.  
All three of the above entities have much room for improvement if PN/PAD reversal is to be 
achieved. 
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 In the present monograph, over 800 PN/PAD causes (depending on how one aggregates 
PN/PAD causes at different levels), over 1100 PN/PAD treatments (again, depending on 
aggregation), and about 1000 PN/PAD characteristics were identified.  As stated repeatedly, an 
expanded study (including recommendations for study process improvement outlined throughout 
this monograph) could double these numbers of existing PN/PAD causes, treatments, and 
characteristics identified, or more.  Additionally,  the LRDI technique could be used to easily 
identify hundreds more potential PN/PAD causes, treatments, and characteristics.   
 Therefore, the challenge for developing a realistic PN/PAD treatment protocol is to  
 1) reduce the numbers of PN/PAD characteristics to be measured, PN/PAD causes to be 
eliminated, and PN/PAD treatments to be implemented from  
 2) the many hundreds of measurable existing and potential PN/PAD characteristics, 
PN/PAD causes, and PN/PAD treatments identified to  
 3) reasonable numbers of PN/PAD characteristics to be measured, PN/PAD causes to be 
eliminated, and PN/PAD treatments to be implemented.  
 The following sections of the present chapter outline the major components of the 
PN/PAD treatment protocol in chronological order.  Adherence to this protocol should restore 
adequate functionality to a substantial number of PN/PAD patients; quantification of this 
hypothesis will require clinical trials for credible estimation.  Strict adherence to this protocol 
should also prevent a substantial number of PN/PAD-prone cases from ever coming to fruition.  
A summary of the complete PN/PAD treatment protocol is contained in section 3B6. 
3B. PN/PAD Treatment Protocol in Chronological Order 
 There are five steps in the full PN/PAD treatment protocol, as shown in Table 3B-1. 
Table 3B-1 - Five-Step Protocol to Prevent and Reverse PN/PAD 
FIVE-STEP PROTOCOL TO PREVENT AND REVERSE PN/PAD 
 
 Step 1: Obtain a detailed medical and habit/exposure history from the patient.   
 Step 2: Administer written and clinical performance tests to assess the severity of the higher-level 
symptoms and degradation of functions 
 Step 3: Administer laboratory tests (blood, urine, imaging, etc) 
 Step 4: Eliminate ongoing PN/PAD contributing factors 
 Step 5: Implement PN/PAD treatments 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                                                                                                                                                             
Chapter 3 - Treatment Protocol                                                                                                                             101 
 These five steps will now be described in more detail. 
3B1. Medical History Questionnaire 
 The first step in the protocol is to obtain a detailed medical and habit/exposure history 
from the PN/PAD patient.  The patient would be provided a detailed questionnaire focusing 
mainly on practices and exposures that are potential PN/PAD contributing factors.  The PN/PAD 
contributing factor component of the questionnaire would be based on Table 7A-1 or, preferably, 
on a similar table derived from an expanded study.  In the latter case, there could be greater than 
1,000 potential contributing factors identified. 
 Most of the questions would not be answerable.  The patient might be able to answer a 
number of questions related to the lifestyle and iatrogenic components of Table 7A-1, and 
perhaps a few of the questions related to the occupational exposures component if these 
exposures were significant.  However, most patients would probably not be able to identify past 
and present exposures to many hundreds of chemicals and radiations that are contributing factors 
to PN/PAD.  The questionnaire would yield some idea of past and present relevant PN/PAD 
contributing factors for the patient, with much to be determined by further testing. 
 Thus, the patient would probably be able to provide some estimate of dietary 
components, sedentary behavior, sleep quality, recreational drug use, major medications taken 
and surgeries experienced, and perhaps exposures to pesticides, ionizing radiation, asbestos, etc, 
as part of their job.  The patient would probably not be able to identify food additives ingested 
when they ate out, chemicals in their home from cleaning and new furniture, particulates and 
chemicals in the air they breathe, exposure to non-ionizing radiations, etc.   
 For those patients whose major PN/PAD contributing factors are in the readily 
identifiable category, their chances of reversing PN/PAD are reasonable (assuming irreversible 
damage has not been done and they do not have an overwhelming genetic predisposition to 
PN/PAD).  For those patients whose major PN/PAD contributing factors are in the non-
identifiable category, complete reversal would be much more of a challenge.  Reversal for them 
may in fact require identification and elimination of far more of the PN/PAD contributing 
factors. 
3B2. Assess Performance Observables 
 The second step in the protocol is to administer written and clinical performance and 
behavioral tests to assess the severity of the higher-level symptoms.  This would include tests for 
sensing, pain, gait, endurance, strength, etc, and for anxiety, depression, cognitive dysfunction, 
etc.  The latter group of mood-related tests might have some overlap with the medical history on 
the initial questionnaire. 
3B3. Administer Laboratory Tests 
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3B3a. Criteria for PN/PAD characteristics laboratory tests 
 The third step in the protocol is administration of laboratory tests (blood, urine, imaging, 
etc).  Any abnormalities shown by these tests would help prioritize the PN/PAD contributing 
factors to be eliminated and PN/PAD treatments to be implemented in the streamlined protocol 
presented in this chapter. 
 In the present study, approximately 1000 PN/PAD characteristics were identified.  
Perhaps 25 percent were treatments and symptoms (whose abnormalities would be reflective of 
PN/PAD, and whose evaluation would be addressed by the procedures in section 3B2).  The 
remaining ~75 percent were estimated to be laboratory-measurable quantities.  It was also 
estimated these numbers of measurable PN/PAD characteristics could be at least doubled in an 
expanded study.  Therefore, for a non-streamlined protocol, this step in the protocol could 
involve the administration of ~1500 lab tests (or more) to identify the full spectrum of 
abnormalities in these measured PN/PAD characteristics. 
 Given costs and other negative aspects of such tests, the number of tests would have to be 
reduced by more than an order of magnitude to be acceptable to both the patient and the 
healthcare practitioner.  In other words, many hundreds of laboratory tests are too large to be 
practical, at the present time.  The present protocol proposes a greatly reduced number of lab 
tests, selected for their ability to cover a wide swath of PN/PAD-related pathologies.  Results 
from these core lab tests will help prioritize PN/PAD causes to be eliminated and PN/PAD 
treatments to be implemented.   
 The protocol approach is cause-and-effect based.  The general biomarkers that tended to 
focus on a broad range of pathophysiological mechanisms (e.g., oxidative stress, inflammation, 
endothelial dysfunction, etc.) were selected, with input from the factor matrix-based 
categorization of key biomarker themes.  Then, for each of the selected general biomarker 
categories, the biomarker-biomarker matrix of Figure 2D-2 was used to identify specific 
measurable biomarkers closely related to the theme of the general biomarker.  
 To reiterate, the final streamlined PN/PAD characteristics selected will encompass the 
pathologies viewed by the PN/PAD research community as important features of PN/PAD.  
Because of the inter-connectedness of major systemic networks (immune system, neural system, 
endocrine system, circulatory system, etc.), one would expect the myriad pathologies associated 
with the factors to have some relationship.  Because of this ripple effect, important PN/PAD 
contributing factors and important PN/PAD treatments are expected to be systemic in their 
impact.  This systemic impact would be reflected by  
 1) important PN/PAD contributing factors producing abnormalities in many of the factor-
driven categories used as the basis for PN/PAD biomarkers selection, and  
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 2) important PN/PAD treatments removing abnormalities in many of the factor-driven 
categories used as the basis for PN/PAD biomarkers selection.   
3B3b. Sample recommendations for PN/PAD biomarkers laboratory tests 
 Based on the criteria for selecting potential PN/PAD biomarkers laboratory tests in the 
previous section, numbers of possible combinations were examined.  Following is the 
combination selected for the present example.  Different practitioners may interpret the source 
data differently, and modify the combinations.  Some practitioners may want to modify the 
combinations to be more focused on PN or on PAD.  Other modifications and additions could be 
expected after an expanded study was conducted. 
 Table 2D-6 contains the PN/PAD biomarkers selected for initial laboratory tests in the 
PN/PAD protocol.  The biomarkers are listed by category, with the highest priority biomarkers 
highlighted in red.  These thematic categories were generated based on the results of the 
biomarker factor matrix (Figure 2D-1a) and other inputs.  Then, phrases were selected to 
populate these categories based in part on 1) their rankings in the biomarker factor matrix, and 
on 2) their applicability to PN/PAD or PN or PAD (Table 7A-12), as discussed at the end of 
section 2D4.  The PN/PAD characteristics are typically not uniquely related to the pathological 
themes.  Usually, any one of the PN/PAD characteristics in the selected group will be related to 
multiple PN/PAD pathologies, and any one of the PN/PAD pathologies will be related to many 
of the PN/PAD characteristics. 
 The biomarkers highlighted in red are only a suggestion for testing prioritization.  There 
is not strong consensus in the literature for many of these biomarkers, and clinicians should 
substitute biomarkers for testing they deem more appropriate.  Also, there may be categories 
listed that some clinicians believe are not relevant to specific patients, based on their medical 
histories.  The biomarkers in these categories could be eliminated, thereby reducing the number 
of tests required.  Conversely, there could be categories not listed in Table 2D-6 that clinicians 
believe are important for specific patients.  Biomarkers for these categories should be added as 
required.  Three such categories not emphasized in Table 2D-6 are heavy metals, infections, and 
Vitamin deficiencies. 
 Heavy metals that can impact various segments of PN/PAD adversely include arsenic, 
cadmium, lead, mercury, and thallium.  Infections/infectious agents that can impact various 
segments of PN/PAD adversely include human immunodeficiency virus (HIV), Aggregatibacter 
actinomycetemcomitans, Borrelia burgdorferi, Brucella spp., C. pneumoniae, Campylobacter 
jejuni, Campylobacter rectus, Chlamydia pneumoniae., Chryseomonas, Clostridium botulinum, 
Collinsella, Corynebacterium diphtheriae, Cytomegalovirus, Eikenella corrodens, Epstein-Barr 
virus, Eubacterium, Fusobacterium nucleatum, H. influenzae, Helicobacter pylori, Hepatitis C 
virus, Herpes simplex virus, Human T-cell lymphotropic virus, M. pneumoniae, Mycobacterium 
leprae, Mycobacterium tuberculosis, Parvimonas micra, Parvimonas micros, Porphyromonas 
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gingivalis, Prevotella intermedia, Prevotella nigrescens, Rabies virus, Roseburia, Streptococcus, 
Tannerella forsythia, Treponema denticola, Varicella-zoster virus, Veillonella, West Nile Virus 
[Brizzi and Lyons, 2014; Budzynski et al, 2016].  Vitamin deficiencies include, but are not 
limited to, Vitamins B-1, B-12, C, D, E. 
3B4. Recommend PN/PAD Contributing Factors to be Eliminated 
3B4a.  Prioritization based on Causes-Biomarkers Matrix 
 The fourth step in the PN/PAD treatment protocol is elimination of as many of the 
ongoing PN/PAD contributing factors as possible.  Once the laboratory tests have been 
completed, the abnormalities in the PN/PAD characteristics' values can be identified.  This 
allows causes to be eliminated and treatments to be implemented. 
 However, identification of unique causes based on abnormal biomarker values is 
extremely difficult.  As Tables 2E-1 and 2E-2 show for oxidative stress and blood pressure, 
respectively there can be many causes that impact a given biomarker adversely.  Thus, 'reverse-
engineering' the abnormal PN/PAD biomarker  values to identify candidate PN/PAD causes for 
elimination will be difficult.  As these tables show, even if only one PN/PAD biomarker had 
abnormal values, there could be tens or hundreds of PN/PAD causes for this abnormality that 
could be identified through 'reverse-engineering' for potential elimination. 
 I propose a combined 'direct-identification' and 'reverse-engineering' approach that has 
the virtue of simplicity.  The 'direct-identification' component consists of eliminating the 
PN/PAD contributing factors the patient listed on the initial medical/exposure questionnaire.  
The 'reverse-engineering' component  
 1) identifies all the patient's PN/PAD biomarkers with abnormal laboratory test values,  
 2) identifies the number of these abnormal PN/PAD biomarkers impacted by each 
PN/PAD contributing factor, then  
 3) prioritizes the PN/PAD contributing factors for elimination according to the number of 
PN/PAD biomarkers impacted by the PN/PAD contributing factors. 
 For example, suppose five of the PN/PAD characteristics measured show abnormal 
values: high AGEs, low ATP, low BDNF, high Homocysteine, high IL-6.  Then, those PN/PAD 
contributing factors  that impacted all five biomarkers would have first priority for elimination, 
those PN/PAD contributing factors that impacted four of the five biomarkers would have second 
priority for elimination, and so on down to PN/PAD contributing factors that impacted any one 
of the biomarkers.   
 The recommended prioritization above is based on numbers of PN/PAD biomarkers 
impacted by each PN/PAD contributing factor.  It does not distinguish between one record 
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describing the impact (for a particular PN/PAD contributing factor) or ten records describing the 
impact.  Irrespective of the number of records describing the impact, it does not distinguish 
among the strengths of impact described in different records.  This additional information could 
be used by the healthcare practitioner to modify the prioritization approach presented above.   
 In addition, there are some cases where 'reverse-engineering' may be more 
straightforward.  For example, high serum or urine readings of heavy metals (e.g., arsenic, 
cadmium, mercury) would identify specific targets for elimination.  These would be the 
exception rather than the rule, in terms of  specificity. 
3B4b.  Prioritization based on "Low-Hanging Fruit" 
 The contributing factors to be eliminated identified from the causes-biomarkers matrix 
may be straight-forward, or they may be unknown in the absence of detailed environmental 
measurements.  Some may be beyond the patient's control, such as fixed cell towers near one's 
residence. 
 Based on Table 7A-1, there are a number of contributing factors that are mainly related to 
lifestyle, and are mainly within one's control to retain or eliminate.  These have been termed 
"Low-Hanging Fruit", since they are probably the 'easiest' contributing factors to eliminate.  
Elimination of the "Low-Hanging Fruit", in parallel with the elimination of the contributing 
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Table 3B-2 - "Low-Hanging Fruit" Causes for Elimination 
LOW-HANGING FRUIT RECOMMENDATIONS 
 
1) curb the dietary excesses, and remove the dietary deficiencies, identified in Table 7A-1, the 
medical questionnaire, and the lab tests;  
2) eliminate food additives to the extent knowable and possible, including those dietary excesses 
that derive from food additives (excessive fat, sugar, salt);  
3) minimize high temperature cooking and the subsequent increases in Advanced Glycation End 
Products from certain susceptible foods, Heterocyclic Amines, Acrylamide, and Polycyclic 
Aromatic Hydrocarbons; 
4) reverse the sedentary behavior patterns identified;  
5) remove the foundational impediments to better sleep;  
6) eliminate the use of 'recreational' drugs, including smoking and excessive alcohol;  
7) eliminate the use of medicinal drugs shown to be potential PN/PAD contributing factors from 
Table 7A-1, unless these drugs are absolutely necessary; 
8) minimize exposures to some hydrocarbons, such as n-hexane, methyl-n-butyl ketone, carbon 
disulfide, acrylamide, ethylene oxide, trichloroethylene, kerosene, polycyclic aromatic 
hydrocarbons (including those found in smoke), etc; 
9) minimize exposures to some neurotoxic solvents, especially organic solvents;  
10) minimize inhalation and ingestion exposures to pesticides, herbicides, insecticides, and 
fungicides;  
11) minimize exposures to heavy metals in food, in water, and in the air; 
12) minimize exposure to particulates, especially air pollution;  
13) minimize exposures to ionizing radiation and non-ionizing non-visible radiation (such as cell 
phones, cell towers, WiFi, smart meters, etc.);  
14) minimize chronic stress (mental/emotional/psychological); 
 
 
3B4c.  Prioritization Based on Remining Indirect Causes 
In the prior two section, the prioritizations were mainly based on removing different types of 
direct causes.  But, there are cases where removing indirect causes would be beneficial. 
 For example, pesticides could be viewed as direct causes of PN/PAD, and they could be 
identified and removed by methods in 3B4a.  Chemotherapy, however, is a direct cause of 
PN/PAD, and its elimination would exacerbate the cancer being treated.  The indirect cause of 
PN/PAD in this case would be the cancer that is necessitating the use of chemotherapy, or, more 
specifically, those contributing factors that, for many people, resulted in the development of 
cancer.  Removing those direct causes of cancer would obviate the need for chemotherapy, and 
and is identical to removing the indirect causes of PN/PAD. 
3B5. Recommend PN/PAD Treatments to be Implemented 
3B5a.  Prioritization based on Treatments-Biomarkers Matrix 
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 The fifth step in the PN/PAD treatment protocol is implementation of the optimal 
number of treatments necessary for reversal.  Once the laboratory tests have been completed, the 
abnormalities in the PN/PAD characteristics' values can be identified.  This allows targeted 
treatments to be implemented. 
 However, identification of unique treatments based on abnormal biomarker values is 
extremely difficult.  As Tables 2F-1 and 2F-2 show for oxidative stress and blood pressure, 
respectively there can be many treatments that impact a given biomarker adversely.  Thus, 
'reverse-engineering' the abnormal PN/PAD biomarker  values to identify candidate PN/PAD 
treatments for implementation will be difficult.  As these tables show, even if only one PN/PAD 
biomarker had abnormal values, there could be tens or hundreds of PN/PAD treatments for this 
abnormality that could be identified through 'reverse-engineering' for potential implementation. 
 I propose a modified 'reverse-engineering' approach that has the virtue of simplicity.  The 
modified 'reverse-engineering' component  
 1) identifies all the patient's PN/PAD biomarkers with abnormal laboratory test values,  
 2) identifies the number of these abnormal PN/PAD biomarkers impacted by each 
PN/PAD treatment, then  
 3) prioritizes the PN/PAD treatments for implementation according to a) the number of 
PN/PAD biomarkers impacted by the PN/PAD treatments and the risk level of the combination 
of treatments selected. 
 For example, suppose five of the PN/PAD characteristics measured show abnormal 
values: high AGEs, low ATP, low BDNF, high Homocysteine, high IL-6.  Then, those PN/PAD 
treatments that impacted all five biomarkers and had low-risk would have first priority for 
elimination, those PN/PAD treatments that impacted four of the five biomarkers and had low-
risk would have second priority for elimination, and so on down to PN/PAD treatments that 
impacted any one of the biomarkers and had low-risk.    
 The recommended prioritization above is based on numbers of PN/PAD biomarkers 
impacted by each PN/PAD treatment and the perceived treatment risk level.  It does not 
distinguish between one record describing the impact (for a particular PN/PADtreatment) or ten 
records describing the impact.  Irrespective of the number of records describing the impact, it 
does not distinguish among the strengths of impact described in different records.  This 
additional information could be used by the healthcare practitioner to modify the prioritization 
approach presented above.   
 In addition, there are some cases where 'reverse-engineering' may be more 
straightforward.  For example, high serum or urine readings of heavy metals (e.g., arsenic, 
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cadmium, mercury) or specific bacteria/viruses would identify specific targets for treatment 
implementation.  These would be the exception rather than the rule, in terms of  specificity. 
3B5b.  Prioritization based on Lowest-Risk Treatment 
 The treatments to be implemented from the treatments-biomarkers matrix may have 
different risk levels calculated in isolation, and perhaps enhanced risk levels when combined.  
 Based on Table 7A-5, there are a number of treatments that are low risk, and are mainly 
within one's control to retain or eliminate.  These have been termed "Lowest-Risk Treatments", 
since they are probably the 'easiest' treatments to implement.  Implementation of these Lowest-
Risk Treatments, in parallel with the implementation of treatments identified by the method of 
the previous section, would be most effective. 
3B5c. Examples of lowest-risk PN/PAD treatments 
 The lowest-risk PN/PAD treatments mentioned in section 3B5b are shown in Table 3B-3.  
They would include, but not be limited to: 
Table 3B-3 - Lowest-Risk Treatments 
 
 Exercise (such as aerobic exercise, walking, resistance training, treadmill, calisthenics, 
stretching, balancing) 
 Sleep Improvement (such as quiet environment, minimal light, minimal food before 
bedtime, maintain regular sleep schedule) 
 Stress Reduction (such as tai chi, yoga, massage, aromatherapy, accupuncture, 
accupressure, sensory stimulation, physiotherapy, massage, reflexology, meditation) 
 Diet - Choose foods high in 
o polyphenols (such as cloves, star anise, capers, curry powder, ginger, 
cinnamon,  peppermint, oregano, sage, rosemary, thyme, basil, cocoa, tea, red 
wine, chokeberries, elderberries, blueberries, plums, cherries, black currants, 
blackberries, strawberries, raspberries, grapes, flaxseeds, celery seeds, 
chestnuts, hazelnuts, pecans, almonds, walnuts, olives, artichokes, chicory, red 
onion, spinach, broccoli,  apples, pomegranates, peaches, apricots, olive oil, 
canola oil), especially flavonoids (such as apples, blueberries, strawberries, red 
grapes, cabbage, broccoli, onions, capers, dark chocolate, cocoa, tea, red wine), 
isoflavones/genistein (such as soybeans, natto, tempeh, tofu, miso), and 
anthocyanins (such as blackberries, black currants, blueberries, strawberries, 
cranberries, eggplant, cherries, prunes, raisins, and the darker versions of 
raspberries, cabbage, plums, radish, grapes, plums, apples, beans, beets, 
cabbage, onions, pears, wines) 
o Unrefined carbohydrates (such as whole grains, legumes, fruits, and uncooked 
vegetables) 
o DHA/omega-3 fatty acid (such as salmon, herring, mackerel, anchovy, sardine, 
trout, shark, swordfish, mussel, sea bass, pollock, whiting, flounder, sole, 
lobster, halibut, carp, oyster, crab, mullet, tuna, perch, snapper, shrimp, 
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octopus) 
o Vitamin B12/Folate (such as meat [beef liver, lamb, beef], fish [sardines, 
mackerel, salmon], dairy [feta cheese, cottage cheese], eggs, legumes 
[chickpeas, fermented soy, pinto beans, lentils], fruit [banana, avocado], 
vegetables [spinach, parsley, broccoli, beets, turnip, asparagus,]) 
o Vitamin C (such as fruits [guavas, acerola cherry, kiwifruit, rose hips, 
strawberries, oranges, papayas, vegetables [bell peppers, broccoli, tomatoes, 
snow peas, kale]) 
o Vitamin D (such as fish [sardines, salmon, mackerel, tuna], liver [beef, calf, cod 
liver oil], dairy [milk, yogurt]; most importantly, sunlight on exposed skin) 
o Vitamin E (such as seeds [sunflower seeds, pumpkin seeds], nuts [almonds, 
hazelnuts, pine nuts], fish [abalone, salmon, trout], fruit [avocado, mango, 
kiwifruit], vegetables [red peppers, turnip greens, spinach, chard, squash, 
broccoli]) 
o lycopene (such as tomatoes, guavas, watermelon, papaya, grapefruit), 
o oleic acid (such as nuts [almonds, peanuts, pecans, cashews, pistachios, 
hazelnuts] seeds [sesame, sunflower], avocados, olives, and vegetable oils 
[safflower, almond, olive, sesame, sunflower]), 
o luteolin (such as dried oregano, celery seed, hot peppers, peppermint, sage, 
rosemary, juniper berries, thyme, radicchio, chinese celery), 
o quercetin (such as capers, lovage leaves, elderberry juice, dock leaves, raddish 
leaves, arugula, dill weed, coriander, and fennel, cilantro, banana peppers, 
juniper berries, oregano, onions, carob flour, radicchio, red leaf lettuce, onions, 
watercress, raw, asparagus, kale, okra, cocoa powder, chia seeds)  
o sulforaphane (such as broccoli sprouts, broccoli, cauliflower, kale, brussels 
sprouts, cabbage, collards, arugula, turnips) 
o resveratrol (such as red wine, red grapes, peanut butter, pistachios, cocoa 
powder, dark chocolate, strawberries, blueberries, bilberries, cranberries) 





Caveats on diet: 
 Many toxic/harmful substances enter the food supply during all phases of food 
growth, distribution, and processing.  While foods should be selected to maximize 
the amounts of healing nutrients identified above, care must be taken to minimize 
the level of toxic additions to the food in parallel. 
 Low-temperature cooking should be used to minimize production of AGEs and 
other harmful products (nitrosamines, polycyclic aromatic hydrocarbons, and 
acrylamides) during the cooking process. 
 Only low-mercury wild-caught fish should be used; these tend to be smaller fish, 
lower on the food chain. 
 Grass-fed animals with no exogenous growth hormones or antibiotics should be 
used, if possible, since these harmful products could be passed through to the 
consumer.  
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 For fruits and vegetables normally eaten with skin, those that have not been 
sprayed with harmful pesticides and other toxic chemicals should be used. 
 Heavy metals are a contributing factor for many neurodegenerative and other 
chronic diseases, including PN/PAD.  One source of heavy metal bioaccumulation 
in the body is through the food supply.  Heavy metals can occur naturally in the 
soil in which food is grown, they can concentrate abnormally in soils from nearby 
industrial pollution or from precipitation of air pollution, they can preferentially 
absorb in different types of food, and, depending on the type of food, can be 
absorbed from the food processing and manufacturing process.  Any of the above 
foods selected for PN/PAD prevention or treatment purposes should have heavy 
metal concentrations as low as possible. 
 
 A note about these dietary recommendations.  In Table 7A-5, herbs and plant extracts are 
associated with large numbers of records.  One of the major reasons for this is their copious use 
in Traditional Chinese Medicine, which had significant representation in our PN/PAD database.  
Some of the concoctions that contained these substances had adverse side effects, which 
removed them from the desired low-risk category.  Also, independent verification of many of 
these concoctions' impacts was not readily available.  Therefore, they are not in the first-tier 
recommendations. 
 Additionally, many of these plant extracts, almost by definition, are not whole foods.  
The present monograph recommends whole foods containing the desired chemicals and nutrients 
(listed in Table 7A-5) preferentially in the above list.  The full spectrum of phytochemicals 
contained in whole foods act synergistically with the fragmented chemicals listed to provide far 
more protection.  As stated in [Liu, 2003]: "the additive and synergistic effects of 
phytochemicals in fruit and vegetables are responsible for their potent antioxidant and anticancer 
activities, and that the benefit of a diet rich in fruit and vegetables is attributed to the complex 
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3B6.  Summary Treatment Protocol to Prevent and Reverse PN/PAD 
 
 This section summarizes the recommended treatment protocol for preventing and 
reversing PN/PAD.  There are five steps in the full treatment protocol, as shown in the following: 
FIVE-STEP TREATMENT PROTOCOL TO PREVENT AND REVERSE PN/PAD 
 
             Step 1: Obtain a detailed medical and habit/exposure history from the patient.   
 Step 2: Administer written and clinical performance and behavioral tests to assess the 
severity of the higher-level symptoms and degradation of functions 
 Step 3: Administer laboratory tests (blood, urine, imaging, etc) 
 Step 4: Eliminate ongoing PN/PAD contributing factors 
 Step 5: Implement PN/PAD treatments 
 
  
 These five steps will now be described in more detail. 
 Step 1. The first step in the protocol is to obtain a detailed medical and habit/exposure 
history from the PN/PAD patient.  The patient would be provided a detailed questionnaire 
focusing mainly on practices and exposures that are potential PN/PAD contributing factors.  The 
contributing factor component of the questionnaire would be based on Table 7A-1, or, 
preferably, on a similar, but even more extensive, table derived from an expanded study.   
 Step 2. The second step in the protocol is to administer written and clinical performance 
and behavioral tests to assess the severity of the higher-level symptoms.  This would include 
tests for sensing, pain, gait, endurance, strength, etc, and for anxiety, depression, cognitive 
dysfunction, etc.    The latter group of mood-related tests would have some overlap with the 
medical history on the initial questionnaire. 
 Step 3. The third step in the protocol is administration of laboratory tests (blood, urine, 
imaging, etc).  Any abnormalities shown by these tests would help prioritize the PN/PAD 
contributing factors to be eliminated and PN/PAD treatments to be implemented.  Table 2D-6 
contains the PN/PAD biomarkers selected for initial laboratory tests in the PN/PAD protocol.  
These PN/PAD biomarkers reflect the PN/PAD pathological themes and the major themes from 
the PN/PAD biomarker factor matrix (Figure 2D-1a).  Based on the laboratory test results, the 
health practitioner could require further tests to gain detailed information on problematic areas. 
 Step 4. The fourth step in the protocol is to eliminate ongoing PN/PAD contributing 
factors.  Unfortunately, as Figure 2E-1 shows, each PN/PAD contributing factor typically 
impacts many PN/PAD biomarkers, and each PN/PAD biomarker is typically impacted by many 
PN/PAD contributing factors.  Thus, in the general case, PN/PAD biomarker values 
abnormalities in the lab tests will not be uniquely related to specific PN/PAD contributing 
factors.   
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 To circumvent this problem, a combined 'direct-identification' and 'reverse-engineering' 
approach that has the virtue of simplicity is proposed.  The 'direct-identification' component 
consists of eliminating the PN/PAD contributing factors the patient listed on the initial 
medical/exposure questionnaire.  The 'reverse-engineering' component  
 1) identifies all the patient's PN/PAD characteristics with abnormal laboratory test values,  
 2) identifies the number of these abnormal PN/PAD characteristics impacted by each 
PN/PAD contributing factor, then  
 3) prioritizes the PN/PAD contributing factors for elimination according to the number of 
PN/PAD characteristics impacted by the PN/PAD contributing factors.   
Section 3B4 shows how this prioritization, and further sub-prioritizations, would operate. 
 The recommended prioritization above is based on numbers of PN/PAD characteristics 
impacted by each PN/PAD contributing factor.  It does not: 
 1) distinguish between one record describing the impact (for a particular PN/PAD 
contributing factor) or ten records describing the impact, 
 2) distinguish among the strengths of impact described in different records, irrespective 
of the number of records describing the impact, 
 3) weight the PN/PAD characteristics by relative importance,  
 4) incorporate the effects of contributing factor synergies.   
This additional information could be used by the healthcare practitioner to modify the 
prioritization illustrated above. 
 In addition, there are some cases where 'reverse-engineering' may be more 
straightforward.  For example, high serum or urine readings of heavy metals (such as cadmium 
or mercury) would identify specific targets for elimination.  These would be the exception rather 
than the rule, in terms of  specificity. 
 The above prioritization approach would serve as a proxy for the more comprehensive 
elimination of all 'low-hanging fruit' PN/PAD contributing factors shown in Table 3B-2.  To the 
degree possible, the patient should strive to eliminate as many of these 'low-hanging fruit' 
PN/PAD contributing factors as possible.  The combination of 1) lack of knowledge about 
harmful exposures (limiting what can be answered on the initial medical/exposure questionnaire) 
and 2) incompleteness of PN/PAD characteristics measured will result in 3) PN/PAD 
contributing factors not being identified through the complete testing/evaluation process.  
Eliminating as many of the 'low-hanging fruit' PN/PAD contributing factors as possible will 
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compensate partially for this lack of knowledge.  Many of these items are under the patient's 
control, and can be readily eliminated, with proper motivation and discipline.  
  There is an implicit assumption in some/many of these PN/PAD contributing 
factor elimination recommendations of a treatment implementation.  For example, elimination of 
a high-fat diet (PN/PAD contributing factor) implies adoption of a low-fat diet (PN/PAD 
treatment).   
 Step 5. The fifth step in the protocol is to implement PN/PAD treatments.  Because of 
risk associated with implementation of single PN/PAD treatments, and the lack of knowledge of 
how overall risk increases because of treatment combination synergies, it is recommended that 
the lowest-risk treatments (e.g., Table 3B-3) be implemented initially in parallel with the 
required higher-risk treatments.   
 Even among low-risk PN/PAD treatments, some prioritization may be possible.  The 
approach recommended parallels that for eliminating PN/PAD contributing factors in Step 4.  
The approach is a hybrid of 'direct-identification' and 'reverse-engineering'.  The 'direct-
identification' component consists of identifying the patient's PN/PAD contributing factors from 
the medical/exposure questionnaire.  Where applicable, PN/PAD treatments that are positive 
behaviors/habits would be substituted for the negative PN/PAD contributing factors under the 
patient's control.  Thus, if the patient is eating a high AGEs diet, the PN/PAD 'treatment' would 
consist of substituting a low AGEs diet.  If the patient is participating in minimal physical  
activities, he/she would be encouraged to participate in more physical activities. 
 The 'reverse-engineering' component' would be based on the laboratory tests.  In parallel 
with the approach in Step 4, PN/PAD treatments would be prioritized based on the number of 
abnormal PN/PAD characteristics they would impact.  The caveats of step 4 about relying on 
numbers of characteristics impacted would apply here as well. 
 The specific PN/PAD treatments employed would be selected based on the medical 
questionnaire results, the clinical sensorimotor evaluation, and the lab tests results.  Some of the 
recommended lowest-risk  PN/PAD treatments would (in practice) be substitutions for the 
PN/PAD contributing factors eliminated; others would be new activities implemented.  See 
Table 3B-3 for a partial list of these lowest-risk treatments.   
3B7. Health policy impact on PN/PAD treatment protocol 
 The above PN/PAD treatment protocol has been developed based mainly on medical 
findings, especially as reported in the premier biomedical literature.  Financial and 
political/policy considerations were not taken into account.   
 The protocol contains implicit assumptions that patients will be able to  
 1) pay for any expensive drugs (if necessary),  
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 2) afford pesticide and other harmful chemical-free foods,  
 3) leave jobs where the working environment is toxic,  
 4) move from residences where the environment is toxic, etc.   
This flexibility might not be available to many patients with limited income and/or limited 
assets. 
 There is also the implicit assumption that, if one has sufficient assets and flexibility, 
toxin-free environments can be found and toxin-free lifestyles can be achieved.  This assumption 
is open to question, as shown by the following example.   
 Probably the key exogenous contributing factor to the development of PN/PAD (and 
many other chronic diseases) is the incorporation of technology in all aspects of modern life 
without adequate regulation and safety testing.  To compound the problem, some/many of these 
new technologies are effectively mandated, and impossible to avoid, even if the PN/PAD patient 
is wealthy. 
 For example, wireless radiation technology has become ubiquitous in modern life (cell 
phones, WiFi, smart meters, etc).  Research has shown that wireless radiation in the cell phone 
radiofrequency part of the spectrum contributes to oxidative stress and inflammation of the brain 
[Kostoff and Lau, 2017; Gulati et al, 2017; Chauhan et al, 2017; Kesari et al, 2013], among many 
other adverse effects.  As our PN/PAD study results show, oxidative stress and inflammation are 
key PN/PAD characteristics.  Chronic exposure to wireless radiation would be a factor 
contributing to increase the incidence of PN/PAD (and many other chronic diseases in which 
these two characteristics are important). 
 Wireless radiation technology requires an infrastructure.  For cell phones, the major 
infrastructure is cell towers.  The Telecommunications Act of 1996 effectively mandates the 
construction of cell towers with no opposition allowed based on health considerations.  As of this 
writing, the FCC is attempting to implement similar effective mandates for the next generation of 
mobile wireless technology, known as 5G.  A million or more 'short' cell towers (in the USA) 
would be required for 5G implementation, since the propagation of radiation energy at the high 
frequencies characteristic of 5G is poor, and the distances between 'short' cell towers is relatively 
small by necessity.   
 This means that populated areas will be blanketed (around the clock) with 3GHz-30GHz 
(or higher) radiofrequency radiation.  This is a range of the frequency spectrum essentially 
untested for adverse health effects, especially over the long-term in humans, and especially in 
combination with other toxic stimuli [Kostoff and Lau, 2017].  It is no different in principle from 
a contractor proposing to spray the populated areas of the USA with Agent Orange around the 
clock, and the relevant government regulatory agency stating that no opposition to the spraying 
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is allowed based on health considerations.  In effect, the USA government is mandating an 
increase in rates of PN/PAD, with the potential of this increase being very large. 
 Thus, we have a dichotomy in the relevant USA Federal policy.  On the one hand, the 
Federal government is investing heavily in biomedical research to treat and reverse PN/PAD.  
On the other hand, the Federal government is allowing essentially unrestricted and inadequately 
regulated expansion of technologies that are important contributing factors to PN/PAD.  
Metaphorically, the Federal government is drilling holes in the floor of the boat at the same time 
it is pumping water out of the boat!  These policies are diametrically opposed, and will limit the 
effectiveness of any PN/PAD treatment protocol, no matter how strictly it is followed. 
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Chapter 4 
SUGGESTED FURTHER RESEARCH 
4A. Identifying Additional PN/PAD Treatments and Contributing Factors 
RECOMMENDATION FOR EXPANDED STUDY 
 
        This present monograph contains numerous recommendations for a follow-on expanded 
study.  The context of the recommendations is typically to identify more (perhaps factors of two 
or three more) PN/PAD treatments, PN/PAD characteristics, and PN/PAD causes/contributing 
factors than are shown in the present monograph. 
        Some of the reviewers of this monograph have questioned why more PN/PAD treatments, 
characteristics, and causes/contributing factors are necessary.  After all, the monograph has 
identified far more PN/PAD treatments, characteristics, and causes/contributing factors than any 
other published paper.  Why are even more PN/PAD treatments, characteristics, and 
causes/contributing factors required and recommended? 
        The answer lies in the status of PN/PAD prevention and reversal.  We have not solved the 
problem of preventing and reversing PN/PAD.  We don't know the full extent of what is 
required to prevent and reverse the full spectrum of PN/PAD cases.  How, then, can we make 
the assumptions that  
 1) the full spectrum of necessary diagnostics for every PN/PAD patient will be found 
within the ~1000 PN/PAD characteristics we have identified in this study,  
 2) the full spectrum of necessary treatments for every PN/PAD patient will be found 
within the ~1200 PN/PAD treatments we have identified in this study, 
 3) the full spectrum of necessary causes to be eliminated for every PN/PAD patient will 
be found within the ~800 PN/PAD causes/contributing factors we have identified in this study? 
        The PN/PAD protocol for preventing and reversing PN/PAD presented in this monograph 
represents a culling of the large numbers of diagnostics, treatments, and causes identified to 
more 'manageable' levels.  It is imperative that this culling process  
 1) starts with the full complement of PN/PAD diagnostics, treatments, and causes 
identified in the biomedical literature, and then  
 2) proceeds to reduce these numbers to levels acceptable to both the healthcare and 
patient communities.   
        I believe that the large numbers of PN/PAD diagnostics, treatments, and causes 
identified in the present monograph will be adequate to prevent and reverse many 
PN/PAD cases.  However, we cannot exclude the possibility that PN/PAD diagnostics, 
treatments, and causes existing in the biomedical literature, but not identified in the present 
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4A1. Identifying Additional Existing PN/PAD Contributing Factors and Treatments  
 The present study is more comprehensive than any of its predecessors with respect to 
identifying existing PN/PAD contributing factors and treatments and their consequences, based 
on the premier biomedical literature.  However, the study has identified only the tip of the 
iceberg of existing PN/PAD  contributing factors and treatments, and their consequences.   
 First, only a modest number of existing PN/PAD contributing factor and treatment 
linking terms were identified due to time and resource limitations.  More research could be done 
to identify additional existing PN/PAD contributing factor and treatment linking terms, as well as 
identify combinations of existing PN/PAD contributing factor and treatment linking terms for 
better precision. 
 Second, not all the existing PN/PAD contributing factor or treatment linking terms 
identified were used to extract existing PN/PAD contributing factors and treatments and their 
impacts from the VP abstracts' phrases.  An arbitrary cutoff of  numbers of existing PN/PAD 
contributing factors and treatments was set.  These limits were deemed adequate to present a 
wide spectrum of existing PN/PAD  contributing factors and treatments without 1) 
overwhelming the reader and 2) prolonging the study unnecessarily.  If more specific existing 
PN/PAD contributing factors or treatments are desired, the remaining linking terms can be used 
to query the VP abstracts for this purpose.  Given the rate at which existing PN/PAD 
contributing factors and treatments were being identified with the linking term approach 
(especially at the lower frequencies of appearance in the biomedical literature), I would estimate 
the number of additional existing PN/PAD contributing factors and treatments possible using this 
approach would double or triple those identified presently.   
 Additionally, in order to access the record containing the existing PN/PAD contributing 
factor or  treatment and its consequence(s), the existing PN/PAD contributing factor or treatment 
linking term had to be physically relatively close to the existing PN/PAD contributing factor or 
treatment impact.  There were numerous records where an abstract sentence was of the form 
'contributing factor X increased  the occurrence of A, B, C, D.....' or 'treatment X reduced the 
occurrence of A, B, C, D.....'.  The software would not have recognized the occurrence of B, C, 
and D because of software phrase length limitations.  This problem could be eliminated by the 
use of Concordance software, where all words within some pre-specified distance of the existing 
PN/PAD contributing factor or treatment linking term would be displayed, and the additional 
existing PN/PAD contributing factor or treatment consequences extracted.   
4A2. Identifying Additional Potential PN/PAD Contributing Factors or Treatments 
 One straightforward way of identifying additional potential PN/PAD contributing factors 
or treatments is with use of the Discovery component of the literature-related discovery and 
innovation (LRDI) approach [Kostoff, 2012; Kostoff and Patel, 2014; Kostoff, Porter, and 
Buchtel, 2018].  Only a handful of these potential PN/PAD treatments (obtained with the LRDI 
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methodology outlined in Chapter 6, and shown in Table 2C-6) were identified in the present 
monograph.  An expanded study could identify many hundreds more of these potential PN/PAD 
treatments using the LRDI methodology, and this LRDI approach could be used to identify 
potential PN/PAD contributing factors and characteristics as well. This concept is discussed 
further in a 2018 monograph on the topic of treatment re-purposing [Kostoff, 2018a]. 
4B. Institute Clinical Trials Combining Removal of Potential PN/PAD Contributing Factors with 
Implementation of PN/PAD Treatments 
 The prevention and treatment protocol for PN/PAD described in Chapter 3 requires 
patient diagnostics measurements, removal of causes based on abnormal diagnostics 
measurements, and implementation of treatments to normalize the abnormal diagnostics 
measurements. 
 To gain operational experience with exploiting the findings in the present monograph, 
clinical trials incorporating the above protocol should be started in the near future.  One of the 
serious limitations in fully implementing the PN/PAD treatment protocol in section 3B6 is 
linking 1) the PN/PAD contributing factors to 2) the PN/PAD characteristics that deviate from 
the norm.  As the results in Chapter 2 show, there are many potential PN/PAD contributing 
factors in our environment and in our daily life to which we are exposed and of which we are 
unaware.  We need to have the capability to measure the exposures to these toxic substances 
experienced by an individual, and section 4C describes a research opportunity to achieve this 
goal. 
 Given the limitations today in identification of personal exposures to many PN/PAD 
contributing factors, near-term clinical trials as recommended above could start with a broad-
based removal of 'low-hanging fruit' PN/PAD causes/contributing factors identified in Table 3B-
2.   
4C. Develop Measurement Devices for Potential PN/PAD Contributing Factor Exposures 
 As stated in section 4B, a key deficiency in implementing comprehensive PN/PAD cause 
removal for any individual is lack of knowledge of the myriad toxic stimuli to which the 
individual is being exposed continually.  What is the full spectrum of potentially toxic chemicals 
in the water we drink, the air we breathe, the food we eat, and in contact with our skin?  Further, 
what is the full spectrum of ionizing and non-ionizing, visible and non-visible, radiations to 
which we are exposed as a function of time?  To answer these questions, we need devices that 1) 
can measure the full range of these toxic stimuli and 2) are convenient and portable.  Producing 
such devices would require an extensive research and development effort, especially devices in a 
form that people would be motivated to wear and use. 
References - Chapter 4
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 This Background section consists of three parts: 1) studies to identify a broad spectrum of 
causes and treatments for PN/PAD; 2) text mining approaches that have been developed for 
identifying existing and potential disease contributing factors and treatments; 3) definitions of 
terms.  Sections 5A-5E address the PN/PAD literature, Section 5F addresses the text mining 
literature, and Section 5G addresses the definitions. 
 PN refers to the range of clinical syndromes that involve damage to the peripheral 
nervous system, including motor, sensory, and autonomic fibers [Shields RW, 2010; NINDS, 
2019].  If one nerve is damaged, the condition is referred to as mononeuropathy. If many nerves 
are involved, it is called polyneuropathy [UCSF, 2019]. 
 PAD is a circulatory problem involving narrowing of the peripheral arteries serving the 
legs, stomach, arms and head, affecting arteries in the legs most commonly [AHA, 2019; MC, 
2019].  It is one of a number of terms used commonly to refer to arterial occlusive disease of the 
lower and upper extremities, including peripheral vascular disease (PVD), peripheral arterial 
occlusive disease, and arteriosclerosis obliterans [Campia, Gerhard-Herman, Piazza, et al, 2019]. 
 Poor peripheral blood circulation characteristic of many forms of PAD restricts adequate 
transport of nutrients (especially oxygen) to the peripheral neural system, potentially causing 
severe damage and destruction to the peripheral neural system and surrounding structures, 
suggesting that PN and PAD should be treated as a combined entity.  Intake of the highest 
quality nutrients, by whatever route, will have limited effect on biological structure health if the 
logistics transport system (veins and arteries) is 1) not able to deliver these nutrients to the 
appropriate structures in a timely manner and is 2) not able to dispose of the metabolic waste 
products in a timely manner as well. 
5B.  Present and Projected PN/PAD Incidence and Prevalence 
5B1. PN 
 Estimates of PN prevalence vary widely.   
 Watson and Dyck: the prevalence of PN in the general population is 2.4% and increases 
with age to an estimated 8% in those older than 55 years [Watson and Dyck, 2015];  
 Foundation for PN: an estimated thirty million Americans suffer from some type of PN 
[FPN, 2019]; 
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 Western Neuropathy Association and University of California at San Francisco (UCSF): 
more than twenty million Americans suffer from some sort of PN [WNA, 2019; UCSF, 
2019].   
The most prevalent types of PN are diabetic (~60%), ideopathic (~23%), chemotherapy-induced 
(~10%), HIV/AIDS-induced (~2%), other (~5%) [FPN, 2019]. 
 More detailed information about symptoms, biomarkers, diagnoses, causes, treatments, 
and epidemiology of PN can be found in the following comprehensive PN review articles [e.g., 
Barrell and Smith, 2019; Pascuzzi, 2009; England and Asbury, 2004; Hughes, 2002; Watson and 
Dyck, 2015] and in the following PN books [e.g., Donofrio, 2012; Smith and Bromberg, 2005; 
Barohn, 2013; Herskovitz, Scelsa, and Schaumburg, 2010; Thomas and Dyck, 2005; Dyck et al, 
2010]. 
5B2. PAD 
 Estimates of PAD prevalence vary somewhat.   
 PAD  affects around 13% of the Western population who are more than 50 years old 
[Morley, Sharma, Horsch et al, 2018];  
 PAD has a reported prevalence of 15% in Australia, the USA, and other Western 
countries, and up to 30% when studied in older populations [Conte and Vale, 2018];  
 PAD affects 12% to 20% of Americans 60 years and older, increasing to nearly 50% in 
those 85 years and older. Prevalence increases dramatically with age, and PAD 
disproportionately affects black persons. The global disease burden exceeds 200 million 
persons worldwide, and PAD increased in prevalence by 23.5% between 2000 and 2010 
[Firnhaber and Powell, 2019]; 
 PAD prevalence in the United States is low in people 50 years and younger, while PAD 
rates  increase sharply with age, reaching approximately 20% in octogenarians [Campia, 
Gerhard-Herman, Piazza, et al, 2019]; 
 PAD prevalence globally was ~118 million cases in 2017 and the number of incident 
cases was ~11 million, with two thirds of PAD prevalent cases being asymptomatic.  
Furthermore, PAD caused 515,600 years lived with disability. In 2017, ~70,000 people 
died from PAD, which represents ~56% increase compared with 2007 [Kengne and 
Echouffo-Tcheugui, 2019]. 
 More detailed information about symptoms, diagnoses, causes, treatments, and 
epidemiology of PAD can be found in the following comprehensive PAD review articles [e.g., 
Firnhaber and Powell, 2019; Campia, Gerhard-Herman, Piazza, et al, 2019; Conte and Vale, 
2018; Morley, Sharma, Horsch et al, 2018; Gerhard-Herman, Gornik, Barrett, et al, 2017] and in 
the following PAD books [e.g., Mohler and Jaff (Eds), 2017; Alonso, McManus, and Fisher, 
2010; Kevil, Bir, and Pattillo, 2013; Zemaitis, Bah, Boll et al, 2019]. 
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 These PN/PAD projections may be strong under-estimates.  They are based mainly on 
extrapolations from the past.  The large causative technology component of these projections 
reflects the adverse effects of established technologies.  The results shown in Chapter 2 reflect 
many recently-implemented technologies that could potentially contribute to PN/PAD.    
 PN and PAD have environmental components.  There have been many potentially 
harmful and effectively un-regulated high-technology additions to the environment in the past 
few decades [Kostoff, Porter, and Buchtel, 2018; Kostoff, 2015] (e.g., wireless radiation, vaccine 
combinations, agricultural chemicals, etc., have expanded greatly).  Because of latency delays 
before serious diseases emerge, inadequate time has elapsed to show linkages between these 
potentially harmful technology additions and changes in the incidence of PN/PAD (or myriad 
other chronic diseases) in human populations.  Additionally, the synergetic adverse effects 
resulting from combinations of these new technologies are unknown, especially when used for 
long time periods [Kostoff, Goumenou, Tsatsakis, 2018].  As will be shown in the present 
monograph, the adverse impact of (for example) recent potentially harmful environmental and 
dietary additions on PN/PAD biomarkers and symptoms ominously portends increased incidence 
and prevalence of PN/PAD in the future. 
 Thus, the appropriate future projections of PN/PAD incidence and prevalence should 
consist of superposition of 1) a trend line reflective of past harmful exposures and positive health 
advances and 2) increasing incidence due to implementation of new potentially harmful 
technologies with decadal latency periods.  The Precautionary Principle dictates that the impacts 
of these newer technologies on PN/PAD characteristics be considered when developing future 
incidence projections, especially in the longer-term. 
 Finally, many of the toxic stimuli that are contributing factors to PN/PAD also contribute 
to many other serious diseases [Kostoff, 2015].  Many of these diseases can be fatal, and may not 
have the multi-decadal latencies associated with some forms of PN and especially with PAD.  
Thus, these lethal diseases serve to cull out people who would have been high-risk candidates for 
PN/PAD had they lived.  This culling out of high-risk individuals artificially depresses and 
masks the real incidence of PN/PAD had these high-risk people survived. 
5C. PN/PAD Contributing Factor and Treatment Studies 
5C1. PN Contributing Factor Studies 
As shown in Chapter 2, there are many published studies focusing on identifying one or a few 
contributing factors to PN.  There are many fewer studies identifying a very broad spectrum of 
disease contributing factors, as was done in the previous LRDI-based prevention and reversal of 
chronic disease studies [Kostoff and Patel, 2015; Kostoff, Porter, and Buchtel, 2018].  The focus 
in the present section is to summarize the results from credible broad spectrum or meta analysis 
studies identifying myriad PN contributing factors. 
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 Results from significant review studies of PN contributing factors are as follows:  
 [Shields, 2010]: "Drugs that can induce polyneuropathies" (Table 1):  
-Antibiotic (Chloramphenicol; Chloroquine; Dapsone; Didanosine; Ethambutol; Ethionamide; 
Isoniazid; Metronidazole; Nitrofurantoin; Savudine; Suramin)   
-Sensorimotor (Zalcitabine)  
-Chemotherapeutic (Cisplatin; Cytarabine; Docetaxel; Paclitaxel; Procarbazine; Vinblastine; 
Vincristine) 
-Cardiovascular (Amiodarone; Captopril; Enalapril; Flecainide; Hydralazine; Perhexiline);  
-Rheumatologic (Allopurinol; Colchicine; Gold; Indomethacin)  
-Miscellaneous  (Disulfiram; Interferon alfa; Lithium; Lovastatin; Phenytoin; Pyridoxine; 
Simvastatin; Thalidomide)  
"Environmental and industrial toxins that cause polyneuropathy" (Table 2): 
-Acrylamide; Allyl chloride; Arsenic; Carbon disulfide; Ethylene oxide; Hexacarbons; Lead; 
Mercury; Organophosphorus esters; Thallium; Trichloroethylene  
 [FPN, 2019]: "There are many causes of peripheral neuropathy, including diabetes, 
chemo-induced neuropathy, hereditary disorders, inflammatory infections, auto-immune 
diseases, protein abnormalities, exposure to toxic chemicals (toxic neuropathy), poor 
nutrition, kidney failure, chronic alcoholism, and certain medications – especially those 
used to treat cancer and HIV/AIDS."  
 [NINDS, 2019]: Causes of symptomatic acquired peripheral neuropathy include: 
-Physical injury (trauma - e.g., automobile accidents, falls, sports, and medical procedures) 
-Diabetes is the leading cause of polyneuropathy in the United States 
-Vascular and blood problems that decrease oxygen supply to the peripheral nerves can lead to 
nerve tissue damage. Diabetes, smoking, and narrowing of the arteries from high blood pressure 
or atherosclerosis (fatty deposits on the inside of blood vessel walls) can lead to neuropathy 
-Systemic (body-wide) autoimmune diseases can directly target nerves or cause problems when 
surrounding tissues compress or entrap nerves 
-Hormonal imbalances can disturb normal metabolic processes, leading to swollen tissues that 
can press on peripheral nerves 
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-Kidney and liver disorders can lead to abnormally high amounts of toxic substances in the blood 
that can damage nerve tissue 
-Nutritional or vitamin imbalances, alcoholism, and exposure to toxins can damage nerves and 
cause neuropathy. Vitamin B12 deficiency and excess vitamin B6 are the best known vitamin-
related causes. Several medications have been shown to occasionally cause neuropathy 
-Certain cancers and benign tumors cause neuropathy; tumors sometimes infiltrate or press on 
nerve fibers. Paraneoplastic syndromes can indirectly cause widespread nerve damage 
-Chemotherapy drugs used to treat cancer cause polyneuropathy in an estimated 30 to 40 percent 
of users. Radiation therapy also can cause nerve damage, sometimes starting months or years 
later 
-Infections can attack nerve tissues and cause neuropathy. Varicella-zoster virus, West Nile 
virus, cytomegalovirus, and herpes simplex target sensory fibers, causing attacks of sharp, 
lightning-like pain. Lyme disease can cause a range of neuropathic symptoms. The human 
immunodeficiency virus (HIV), which causes AIDS, can extensively damage the central and 
peripheral nervous systems.  An estimated 30 percent of people who are HIV-positive develop 
peripheral neuropathy; 20 percent develop distal (away from the center of the body) neuropathic 
pain. 
 [England and Asbury, 2004]: 
Drugs 
-Amiodarone; Chloramphenicol; Chloroquine; Colchicine; Dapsone; Disulfiram; Ethambutol; 
Hydralazine; Isoniazid; Metronidazole; Misonidazole; Nitrofurantoin; Nitrous oxide; 
Nucleosides (ddC, ddI, d4T); Phenytoin; Platinum (cisplatin); Pyridoxine (vitamin B-6); 
Suramin; Taxol; Thalidomide; Vincristine 
Toxins 
-Acrylamide monomer; Acrylamide polymer; Arsenic; Carbon disulphide; Diphtheria toxin; 
Ethylene oxide; Hexacarbons (n-hexane and methyl); Lead; Mercury (metallic and vapour); 
Organophosphates; Thallium; gold (aurothioglucose); perhexilene; allyl chloride; buckthorn 
berries 
 [Saporta and Shy, 2015]: 
Immune-Mediated Neuropathies: inflammatory (Guillain–Barré syndrome, CIDP and variants); 
vasculitic; paraproteinemic; paraneoplastic.  Other neuropathies in which an inflammatory 
component can be identified include some infectious and metabolic neuropathies, including 
diabetic radiculoplexopathy 
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Infectious Neuropathies: Leprosy; HIV; Herpes Zoster; Lyme Disease; Diphtheria 
Toxic Neuropathies:  
-Antineoplastic agents (Vincristine, paclitaxel (Taxol®), cisplatin, suramin, thalidomide) 
-Antimicrobials (Chloroquine, dapsone, isoniazid, metronidazole, nitrofurantoin) 
-Cardiac medications (Amiodarone, perhexiline, hydralazine) 
-Other medications (Colchicine, tacrolimus, gold salts, phenytoin, disulfiram (Antabuse®), 
pyridoxine (vitamin B6)) 
-Heavy metals (Lead, arsenic, mercury, thallium) 
-Chemical compounds (Acrylamide, carbon disulfide, ethylene glycol, hexacarbons, 
organophosphate esters, vacor) 
 [Karam and Dyck, 2015] 
-Toxic Neuropathies Related to Drugs 
--Chemotherapeutic Agents 
---Vinca Alkaloids (vincristine, vinblastine, vinflunine, vinorelbine) 
---Taxanes (paclitaxel, docetaxel, cabazitaxel) 
---Platinum Derivates (cisplatin, carboplatin, oxaliplatin) 
---Bortezomib 
---Thalidomide 
---Other Chemotherapy Agents Less Commonly Associated with Peripheral Neuropathy 
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--Toxic Neuropathies Related to Industrial Agents 
---Carbon Disulfide 
---Dimethylamine Borane 





--Toxic Neuropathies Related to Biotoxins 
---Ciguatera 
---Tetrodotoxin 




--Neuropathies Related to Alcohol 
 There is a thread of common PN risk factors running through the above (and many other) 
full spectrum surveys and meta-analyses.  They can be classified into two types: associated and 
foundational.  The associated risk factors include hypertension, diabetes, obesity, autoimmune 
diseases, kidney and liver disorders, cancers, tumors, and infectious diseases.  The foundational 
risk factors are the many hundreds of foundational contributing factors that were identified in the 
present study. 
 Many of the PN articles in the core database focus on 1) the associated risk factors and 2) 
methods to modify them in a positive direction.  Superficially, the number of associated risk 
factors is a relatively low number of "modifiable" risk factors (the authors of these review 
articles view them as "modifiable").  However, this "low number" is deceptive.  Each of these 
associated risk factors could be classified as a chronic disease.  As our previous LRDI studies on 
reversing chronic disease have shown [Kostoff and Patel, 2015; Kostoff, Porter, and Buchtel, 
2018], as well as our comprehensive pervasive causes of disease study [Kostoff, 2015], there 
tend to be many hundreds of foundational contributing factors for  each of these diseases.  The 
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'treatments' proposed in most of the PN studies tend to be some combination of 
drugs/radiation/surgery for controlling the associated risk factors, sometimes accompanied by 
eliminating a few of the major foundational contributing factors.   
 This is in contrast to the approach of the present monograph, where the full spectrum of 
foundational factors that contribute directly to PN as shown in the core PN biomedical research 
articles are identified and proposed for elimination.  While those foundational factors that 
contribute indirectly to PN through their contribution to the associated risk factors were not 
identified in the present study because of resource and time limitations, they could be identified 
and proposed for elimination in a well-resourced study.  The factors that contribute directly to 
PN are identified through the innovation component of LRDI, and the factors that contribute 
indirectly to PN could be identified through the discovery component of LRDI. 
5C2. PAD Contributing Factor Studies 
 As shown in Chapter 2, there are many published studies focusing on identifying one or a 
few contributing factors to PAD.  There are many fewer studies identifying a very broad 
spectrum of disease contributing factors, as was done in the previous LRDI-based prevention and 
reversal of chronic disease studies [Kostoff and Patel, 2015; Kostoff, Porter, and Buchtel, 2018].  
The focus in the present section is to summarize the results from credible broad spectrum or meta 
analysis studies identifying myriad PAD contributing factors. 
 Results from significant review studies of PAD contributing factors are as follows:  
 [Campia, Gerhard-Herman, Piazza et al, 2019] 
Risk Factors for PAD 
-cigarette smoking is associated with a 2- to 4-fold increased risk of PAD 
-diabetes mellitus is associated with an approximately 2- to 4-fold increase in risk 
-hypertension has reported odds ratios from 1.5 to 2.2 
-association between dyslipidemia and peripheral artery disease appears to be multifaceted 
--higher total cholesterol is associated with increased risk 
--higher high-density lipoprotein (HDL) cholesterol is associated with decreased risk 
 [Firnhaber and Powell, 2019] 
Risk factors include: 
hypertension, diabetes mellitus, chronic kidney disease, hyperlipidemia, and smoking 
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 [Morley, Sharma, Horsch et al, 2018] 
Risk factors include: 
Smoking, diabetes, advancing age, black ethnicity, men are affected at a younger age than 
women, high fasting serum cholesterol level, hypertension, chronic kidney disease, high serum 
homocysteine. 
 [Conte and Vale, 2018] 
Risk Factors 
smoking, hypertension, hyperlipidaemia, diabetes mellitus, obesity, family history of vascular 
disease with smoking being the strongest.  
Novel risk factors include increased inflammatory markers such as C-reactive protein, 
fibrinogen, and plasma homocysteine 
Associated Conditions 
atrial fibrillation; congestive heart failure; obstructive sleep apnoea; chronic kidney disease. 
 [Ruiz-Canela and Martínez-González, 2014] 
Most important risk factors: smoking, diabetes, hypertension, and high low-density lipoprotein-
cholesterol levels. 
Metabolic syndrome, central and abdominal obesity, and poor sleep quality are also risk factors. 
Novel risk factors or biomarkers are low serum 25-hydroxyvitamin D levels, 
hyperhomocysteinemia, low levels of serum bilirubin,total adiponectin, and lipoprotein-
associated phospholipase. Several markers of inflammation, such as serum C-reactive protein 
and interleukin-6, have been found to be associated with symptomatic PAD independently of 
traditional cardiovascular risk factors.  A graded direct dose-response relationship between 
inflammatory markers (C-reactive protein, fibrinogen and leukocyte count) and PAD has been 
found. 
Environmental Risk Factors  
polycyclic aromatic hydrocarbons, Bisphenol A, organochlorine pesticides. 
 [Abdulhannan, Russell, and Homer-Vanniasinkam, 2012]  
 PAD results from any disease causing stenosis or occlusion of the lower limb arteries, 
with atherosclerosis disease being the most common aetiology. 
Risk factors  
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race; male gender; increasing age; smoking; diabetes mellitus; hypertension; dyslipidaemia; 
hypercoagulable and hyperviscous states; hyperhomocysteinaemia; systemic inflammatory 
conditions and chronic renal insufficiency. 
Non-atherosclerotic causes of PAD: 
-Peripheral emboli 
-Aneurysm thrombosis or thromboembolism (aortic, popliteal) 
-Arteritis 
--Takayasu’s disease 
--Thromboangiitis obliterans (Buerger’s disease) 
--Giant cell arteritis 
--Polyarteritis nodosa 
-Fibromuscular dysplasia 
-Prior trauma or irradiation injury 
-Aortic coarctation 
-Endofibrosis of the external iliac artery (iliac artery syndrome in cyclists) 
-Primary vascular tumours 
-Pseudoxanthoma elasticum 
-Young patients 
--Adventitial cyst of the popliteal artery 
--Popliteal entrapment 
--Persistent sciatic artery 
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-Race 
-Type 1 diabetes mellitus 
-Positive family history 
-Genotype 









 There is a thread of common risk factors running through the above (and many other) full 
spectrum surveys and meta-analyses.  They can be classified into two types: associated and 
foundational.  The associated risk factors include hypertension, diabetes, obesity, dyslipidemia, 
renal insufficiency, systemic inflammation, hyperhomocysteinemia.  The foundational risk 
factors identified in the studies referenced above include smoking, poor diet, poor sleep quality, 
but can be expanded to the many hundreds of foundational contributing factors that were 
identified in the present study. 
 Many of the PAD articles in the core database focus on the associated risk factors, and 
methods to modify them in a positive direction.  Superficially, the number of associated risk 
factors is a relatively low number of "modifiable" risk factors (the authors of these review 
articles view them as "modifiable").  However, this "low number" is deceptive.  Each of these 
associated risk factors could be classified as a chronic disease.  As our previous LRDI studies on 
reversing chronic disease have shown [Kostoff and Patel, 2015; Kostoff, Porter, and Buchtel, 
2018], as well as our comprehensive pervasive causes of disease study [Kostoff, 2015], there 
tend to be many hundreds of foundational contributing factors for  each of these diseases.  The 
'treatments' proposed in most of the PAD studies tend to be some combination of drugs, surgery, 
diet, and exercise for controlling the associated risk factors, sometimes accompanied by 
eliminating a few of the major foundational contributing factors.   
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 This is in contrast to the approach of the present monograph, where the full spectrum of 
foundational factors that contribute directly to PAD as shown in the core PAD biomedical 
research articles are identified and proposed for elimination.  While those foundational factors 
that contribute indirectly to PAD through their contribution to the associated risk factors were 
not identified in the present study because of resource and time limitations, they could be 
identified and proposed for elimination in a well-resourced study.  The factors that contribute 
directly to PAD are identified through the innovation component of LRDI, and the factors that 
contribute indirectly to PAD could be identified through the discovery component of LRDI. 
5C3. PN Treatment Studies 
 As shown in Chapter 2, there are many published studies focusing on identifying one or a 
few treatments for PN.  There are many fewer studies identifying a very broad spectrum of 
treatments, as was done in the previous LRDI-based prevention and reversal of chronic disease 
studies [Kostoff and Patel, 2015; Kostoff, Porter, and Buchtel, 2018].  The focus in the present 
section is to summarize the results from credible broad spectrum or meta analysis studies 
identifying myriad PN treatments. 
 Results from significant review studies of PN treatments are as follows:  
 [Shields, 2010] 
"In disorders attributed to underlying medical conditions, management is focused on the medical 
disorder. For example, optimizing glycemic control in diabetic polyneuropathy often stabilizes or 
improves the polyneuropathy." 
"In patients with idiopathic immune-mediated polyneuropathies, specific immune-modulating 
therapies are often recommended (e.g., intravenous gamma globulin (IVIg), plasmapheresis)." 
"Treatment of CIDP may begin with corticosteroid therapy. However, chronic IVIg or 
plasmapheresis, or both, are usually effective and obviate the need for long-term steroid therapy. 
Alternative therapies including azathioprine, cyclophosphamide, cyclosporine, mycophenolate 
mofetil, methotrexate, and rituximab have also been used in patients who have not responded to 
initial standard therapies." 
"Toxic polyneuropathies are managed by discontinuing the offending drug or removing the 
industrial toxin from the patient’s environment." 
Supportive therapies include use of various physical therapy and occupational therapy modalities 
including bracing, aids to ambulation, and ankle-foot orthoses.  
Pain management centers on drugs, such as tricyclic antidepressants and a variety of antiepileptic 
drugs and membrane stabilizers.  Specific drugs include: 
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-Antidepressants (Amitriptyline; Nortriptyline; Imipramine; Desipramine; Duloxetine; 
Venlafaxine)  
-Antiepileptics (Gabapentin; Pregabalin; Carbamazepine; Oxycarbazepine; Lamotrigine; 
Topiramate)  
-Miscellaneous (Mexiletine; Tramadol; Capsaicin) 
All these drugs have side effects, listed in [Shields, 2010].  
 [NINDS, 2019] 
Addressing causes 
healthy lifestyle habits (maintaining optimal weight, avoiding toxic exposures, eating a balanced 
diet,  correcting vitamin deficiencies, stopping smoking, appropriate regular exercise, 
maintaining strict control of blood glucose levels [diabetics]. 
Controlling inflammatory and autoimmune conditions 
immunosuppressive drugs (prednisone, cyclosporine, or azathioprine).  
Plasmapheresis 
Other drugs (rituximab; immunoglobulins, and antibodies). 
Addressing symptoms 
Motor (hand or foot braces; orthopedic shoes; splints; tendon transfers; bone fusions). 
Autonomic (standing up slowly and taking medications to improve blood pressure swings; 
acupuncture, massage, herbal medications, cognitive behavioral or other psychotherapy). 
Sensory (medication; behavioral strategies). 
Medications  
-Antidepressants (Nortriptyline; newer serotonin-norepinephrine reuptake inhibitors such as 
duloxetine hydrochloride).  
-Antiepileptics (gabapentin; pregabalin; topiramate; lamotrigine; carbamazepine; 
oxcarbazepine). 
-Local anesthetics (Lidocaine patches or creams; capsaicin, bupivicaine). 
-Narcotics (tapentadol) 
Surgery (protruding disks; neurosurgical decompression).  
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                                                                                                                
Chapter 5 - Background                                                                                                                                           133 
Transcutaneous electrical nerve stimulation (TENS). 
 [England and Asbury, 2004] 
"Medical causes such as diabetes mellitus, renal insufficiency, hypothyroidism, vitamin B-12 
deficiency, or systemic vasculitis need specific and active treatment. Immunemediated 
neuropathies such as Guillain-Barré syndrome or CIDP respond to specific treatments."  
Medications for pain 
-antiepileptic drugs (gabapentin, carbamazepine),  
-antidepressants (amitriptyline, nortriptyline, and venlafaxine),  
-other (tramadol, lidocaine, opioids) 
Preventive and palliative management (weight reduction, assiduous foot care, good shoes, ankle-
foot orthoses, walking aids, wrist splints).  
 [Watson and Dyck, 2015] 
Neuropathic pain management - combination approach 
Tier 1 
-Anticonvulsants (Gabapentin. Pregabalin) 
-Antidepressants (Amitriptyline, Nortriptyline, Duloxetine) 
-Supplements (a-Lipoic acid, Acetyl-Lcarnitine) 







 The approaches include:  
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-addressing the underlying diseases (e.g., diabetes, hypertension, etc) if known, usually with 
drugs; 
-maintaining healthy lifestyles (diet, exercise, avoiding toxic substances, etc) 
-palliative supportive measures (braces, splints, orthoses, etc) 
-pain management (typically drug-based, although supplemented by complementary therapies in 
some cases) 
 This is in contrast to the approach of the present monograph, where two categories of 
treatments are used: 
-identifying and eliminating the full spectrum of foundational causes that 1) contribute directly to 
PN as shown in the core PN biomedical research articles and 2) contribute indirectly to PN 
through their contribution to the associated risk factors (e.g., diabetes, hypertension, 
inflammation, etc), and  
-implementing treatments that 1) focus directly on PN as shown in the core PN biomedical 
research articles, and 2) focus indirectly on PN through their actions on the associated risk 
factors.   
 The contributing factors and treatments that operate directly on PN are identified through 
the innovation component of LRDI, and the contributing factors and treatments that operate 
indirectly on PN are identified through the discovery component of LRDI. 
5C4. PAD Treatment Studies 
 As shown in Chapter 2, there are many published studies focusing on identifying one or a 
few treatments for PAD.  There are many fewer studies identifying a very broad spectrum of 
treatments, as was done in the previous LRDI-based prevention and reversal of chronic disease 
studies [Kostoff and Patel, 2015; Kostoff, Porter, and Buchtel, 2018].  The focus in the present 
section is to summarize the results from credible broad spectrum or meta analysis studies 
identifying myriad PAD treatments. 
 Results from significant review studies of PAD treatments are as follows:  
 [Gerhard-Herman, Gornik, Barrett, 2017] 
Antiplatelet, Statin, Antihypertensive Agents, and Oral Anticoagulation 
Smoking Cessation 
Glycemic Control 
Cilostazol, Pentoxifylline, and Chelation Therapy 
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Homocysteine Lowering 
Influenza Vaccination 
Structured exercise therapy 
Minimizing tissue loss in patients with PAD 
-Prevention of wounds through patient education, foot examination, and prompt recognition of 
foot infection is important to minimize tissue loss among patients with PAD. 
Revascularization for claudication 
-Endovascular Revascularization for Claudication 
-Surgical Revascularization for Claudication 
management of CLI: 
-Revascularization for CLI 
-Surgical Revascularization for CLI 
-Wound Healing Therapies for CLI 
 [Campia, Gerhard-Herman, Piazza, 2019] 
The goals of medical therapy for PAD include:  
-improvement of limb symptoms,  
-exercise performance, 
-quality of life,  
-reduction of the risk of adverse cardiovascular events and limb events 
Recommended approach of medical therapy for PAD: 
Improvement of symptoms and quality of life 
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Reduction of risk of cardiovascular events 
-Lifestyle modification 
-Tobacco cessation  
-Statins 
-PCSK9 inhibitor (evolocumab) 
-ACE-inhibitors/ARBs 
-Aspirin or a thienopyridine 
-PAR-1 antagonist (vorapaxar) 
-Aspirin + low-dose rivaroxaban 
Reduction of risk of limb events 
-Statins 
-PCSK9 inhibitor (evolocumab) 
-PAR-1 antagonist (vorapaxar) 
-Aspirin + low-dose rivaroxaban 
 [Finhaber and Powell, 2019] 
Lifestyle modification 
-Smoking cessation 
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--angioplasty with stenting 
 [Morley, Sharma, Horsch et al, 2018] 
Primary Care 
Risk factor modification 
Smoking cessation therapy 
HbA1c control 
Blood pressure control 
Clopidogrel (or aspirin) 
Atorvastatin 
Symptom control 
Supervised exercise therapy 
Vasoactive drugs 
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 [Conte and Vale, 2018] 
"The management of PAD focuses on two main goals: improving quality of life by reducing 
symptoms and reducing vascular morbidity and mortality."  








-lipid control with a statin 
-blood pressure lowering with angiotensin converting enzyme inhibitor (ACEI) or angiotensin 
receptor blocker (ARB) therapy 
--ramipril 
-blood glucose control 
-antiplatelet therapy 
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-percutaneous transluminal angioplasty (PTA) with or without stent insertion 
-mechanical thrombectomy 
-surgical bypass procedures. 
 These comprehensive PAD review articles show that the mainline prevention and 
treatment recommendations are relatively few.  The recommendations include Lifestyle 
modifications (smoking cessation, improved diet, supervised exercise), Pharmacotherapy 
(Antiplatelet, Anticoagulant, Antihypertensive, Glycemic control, Lipid control), and Surgery 
(Endovascular, Open surgery). 
 This is in contrast to the approach of the present monograph, where two categories of 
treatments are used: 
-identifying and eliminating the full spectrum of foundational causes that 1) contribute directly 
to PAD as shown in the core PAD biomedical research articles and 2) contribute indirectly to 
PAD through their contribution to the associated risk factors (e.g., diabetes, hypertension, 
inflammation, etc), and  
-implementing treatments that 1) focus directly on PAD as shown in the core PAD biomedical 
research articles, and 2) focus indirectly on PAD through their actions on the associated risk 
factors.   
 The contributing factors and treatments that operate directly on PAD are identified 
through the innovation component of LRDI.  The treatments that operate indirectly on PAD are 
identified through the discovery component of LRDI, and the contributing factors that operate 
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indirectly on PAD could be readily identified through the discovery component of LRDI in a 
well-resourced study. 
5D. Combining PN and PAD 
 Most of the PN or PAD contributing factor or treatment references examined addressed 
each disease/condition as a separate entity.  However, since poor peripheral blood circulation 
characteristic of many forms of PAD would restrict adequate transport of nutrients (especially 
oxygen) to the peripheral neural system, potentially causing severe damage and destruction to the 
peripheral neural system, an argument could be made that PN and PAD should be treated as a 
combined entity.  What is the evidence in the biomedical literature for this argument? 
 "pathological alterations in chronic ischaemic neuropathy may be due to the combined 
effects of acute ischaemia/reperfusion and chronic hypoxia." [Nukada, vanRij, Packer et 
al, 1996]; 
 "These results support the presence of a mild sensory axonopathy in subjects with 
peripheral arterial disease." [Ugalde, Wineinger, Kappagoda et al, 1998]; 
 "There is a predominantly sensory neuropathy associated with chronic and critical limb 
ischemia. Neuropathic symptoms are often obscured by the effects of ischemia on other 
tissues. The neurophysiologic changes suggest that the underlying pathophysiology is a 
distal axonopathy affecting nerve fibers of all sizes. Measures of blood flow in the leg 
correlate with neurologic symptom scores, examination scores, and electrophysiologic 
testing." [Weinberg DH, Simovic D, Isner et al, 2001]; 
 "Patients with peripheral vascular disease are susceptible to neuropathy from chronic 
hypoxia." [Toursarkissian, Connaughton, D'Ayala et al, 2002]; 
 "chronic peripheral arterial occlusive disease causes axonal degeneration, resulting in 
axonal polyneuropathy." [Weber and Ziegler, 2002]; 
 "ischemia-related impairment in lower extremity nerve function may contribute to 
functional impairment and decline in people with PAD." [McDermott, 2015]; 
 "Subgroup analysis points towards a PAD-associated peripheral neuropathy independent 
of diabetes." [Lang, Schober, Rolke et al, 2006]; 
 "Incidence of CI-DSN [Chronic Idiopathic Distal Symmetric Neuropathy] is higher in 
individuals carrying vascular conditions. In men, the presence at baseline of peripheral 
artery disease is associated with a threefold increase in the risk of developing CI-DSN." 
[Baldereschi, Inzitari, Di Carlo et al, 2013];  
 "Chronic ischemia in patients with peripheral arterial disease (PAD) represents a 
common medical problem. Neuropathic changes and pain caused by chronic ischemia are 
often found in the lower extremities of these patients. Pain in patients with chronic 
critical limb ischemia fulfill the criteria of neuropathic pain." [Lang, 2015]; 
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 The message from these studies, and many other similar studies not referenced, is clear.  
Restricted circulation characteristic of PAD deprives the peripheral nerves (and other peripheral 
micro and macro-structures) of adequate nutrients for optimal functioning and survival, 
especially, but not limited to, oxygen.  This deprivation of adequate nutrient supplies to critical 
organs, cells, and other biological structures, and the resulting pathology, is not limited to PN.  In 
essentially every previous LRDI study I have performed examining myriad chronic diseases, 
poor blood circulation and the attendant nutrient deprivation to critical structures, has been a 
(typically under-emphasized) causal factor in the disease development and progression.  Intake 
of the highest quality nutrients, by whatever route, will have limited effect on biological structure 
health if the logistics transport system (veins and arteries) is 1) not able to deliver these nutrients 
to the appropriate structures in a timely manner and is 2) not able to dispose of the metabolic 
waste products in a timely manner as well. 
5E. Limitations of High-Technology Mainstream Medical Approach 
 While lifestyle changes form part of the PN/PAD treatment protocol, including 
elimination of well-known causative factors, for the most part the PN/PAD treatment protocols 
are centered on pharmacotherapy and surgery.  These typically high-technology treatments focus 
on removing/suppressing PN/PAD pathological symptoms, rather than removing the causes of 
these symptoms.  These treatments (in the absence of comprehensive cause removal) have 
minimal success in reversing PN/PAD because they violate the systemic medical principle that 
forms the basis of the prevention and reversal  methodology in this monograph. 
 The strategy of identifying symptoms as pathological mechanisms that must be 
suppressed or removed for healing is a mainstay of Western Medicine.  However, another 
perspective is to view these symptoms in a positive light, as having two basic functions: serve as 
a warning signal that dysfunction exists and actions need to be taken to remove the cause of this 
dysfunction, and serve as a protective mechanism.  
 There are many examples in the biomedical literature supporting the concept of disease 
symptoms as warning signals and protective mechanisms, as shown in the following box: 
 "the down-regulation of energy metabolism in AD is a protective response of the neurons to 
the reduced level of nutrient and oxygen supply in the microenvironment" [Sun, Feng, Liang 
et al, 2012]; 
 "Neurofibrillary tangle formation as a protective response to oxidative stress in Alzheimer’s 
Disease" [Nunomura, Takeda, Moreira et al, 2009]; 
 "Autophagy is a protective response to the oxidative damage to endplate chondrocytes in 
intervertebral disc" [Chen, Lv, Li et al, 2017]; 
 "loss of appetite in the acute phase of illness is indeed an adaptive, protective response that 
improves cell recycling (autophagy) and detoxification" [Schutz, Bally, Stanga et al, 2014]; 
 "Cataract is a self-defence reaction to protect the retina from oxidative damage" [Wegner and  
Khoramnia, 2011]. 
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 Along these same lines, Bredesen states in his 2017 book [Bredesen, 2017]: "Alzheimer's 
disease is actually a protective response to, specifically, three different processes: inflammation, 
suboptimal levels of nutrients and other synapse-supporting molecules, and toxic exposures."  
Other AD researchers have drawn similar conclusions.  If Bredesen's view that the AD 
symptoms serve as a protective response against more serious damage is correct, then the 
mainline drug-based AD treatment approach of removing these pathologies/symptoms without 
removing their foundational causes comprehensively in parallel  
 1) effectively removes the protective shield reflected by these pathologies/symptoms and 
 2) exacerbates the progression of AD! 
These conclusions are applicable to most, if not all, chronic diseases. 
5F. Text Mining to Identify Causes and Treatments for Disease 
5F1. Overview 
 The two main literature-based approaches for identifying existing and potential 
contributing factors to, or treatments for, PN/PAD (or any other disease) are "direct" and 
"indirect": "direct" can be viewed as analogous to Innovation, and "indirect" can be viewed as 
analogous to Discovery [Kostoff and Patel, 2015].  The direct approach identifies e.g. existing 
contributing factors (or treatments) that appear in the same article as PAD (e.g., smoking 
increases the risk for PAD) and link directly to PAD.  The indirect approach identifies e.g. 
potential contributing factors (or treatments) to some disease/symptom other than PAD, then 
links this disease/symptom to PAD (e.g., high-salt diet increases the risk for hypertension, 
hypertension is strongly linked to PAD).   
 In the present PN/PAD monograph, only a handful of potential treatments for PN/PAD 
was presented (Discovery).    Based on the retrieval of potential Discovery candidates by the 
Discovery query, voluminous discoveries of potential PN/PAD treatments (and contributing 
factors as well) are possible. 
5F2. Literature Survey 
 The published text mining approach related most closely to that used in the present 
monograph can be found in our 2018 AD monograph [Kostoff, Porter, Buchtel, 2018] and 
[Kostoff, 2015].  In [Kostoff, 2015], three approaches were used to develop queries for 
identifying foundational causes for all diseases.  The first approach used MeSH Qualifiers 
relevant to identifying foundational causes of disease (e.g., adverse effects, toxicity, 
pathogenicity, poisoning) to retrieve records from Pubmed for analysis.  The second approach 
used generic MeSH terms related relatively unambiguously to foundational causes (e.g., "Drug-
Related Side Effects AND Adverse Reactions"; Abnormalities, Drug Induced; Air Pollutants, 
Occupational; Amphetamine Related Disorders; Carcinogens; Chemical Warfare Agents; 
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Chemically-Induced Disorders, etc) to retrieve the records from Pubmed for analysis.  The third 
approach used text terms (applied to the title field) to retrieve the records from Pubmed for 
analysis.  This title query consisted of two parts: standalone terms (e.g., cardiotoxic*, 
genotoxic*, mutagenic, adverse-outcome, adverse-metabolic-effect*, etc) and terms that are 
intersected with diseases (e.g., (expos* OR induc*) AND (cancer* OR dermatitis)). 
 Other text mining approaches have been developed for generating literature-based 
discovery.  They have been used mainly for identifying potential new treatments for disease, but 
the approaches used for identification of new treatments could be easily modified for 
identification of potential new foundational causes as well (e.g., [Kostoff, Porter, Buchtel, 
2018]).  In the past decade, a number of these semantic relation-based approaches have been 
promulgated:  
 Cohen et al [Cohen, Widdows, Schvaneveldt et al, 2012] use semantic indexing to identify 
empirically sequences of relationships known as 'discovery patterns', such as "drug x 
INHIBITS substance y, substance y CAUSES disease z" that link pharmaceutical substances 
to diseases they are known to treat. These sequences are derived from semantic predications 
extracted from the biomedical literature, and subsequently utilized to direct the search for 
known treatments for a held out set of diseases.  
 Hu et al [Hu, Zhang, Yoo et al, 2010] present a biomedical semantic-based association rule 
system that significantly reduces spurious/useless/biologically irrelevant connections through 
semantic filtering.  
 Miller et al [Miller, Rindflesch, Fiszman et al, 2012] advance the hypothesis of "cortisol as 
part of a mechanistic link elucidating the observed correlation between decreased 
testosterone in aging men and diminished sleep quality".  
 Hristovski et al [Hristovski, Rindflesch, Peterlin, 2013] emphasize semantic relations 
approaches to literature-based discovery. 
 Sang et al [Sang, Yang, Li et al, 2015] develop a supervised learning based approach to 
generate hypotheses from biomedical literature, splitting the traditional processing of 
hypothesis generation with classic ABC model into AB model and BC model.   
 Cameron et al [Cameron, Kavuluru, Rindflesch et al, 2015] implement a context-driven, 
automatic subgraph creation method that captures multifaceted complex associations 
between biomedical concepts; given a pair of concepts, the method automatically generates a 
ranked list of subgraphs, which provide informative and potentially unknown associations 
between such concepts.   
 Kastrin et al [Kastrin, Rindflesch, Hristovski, 2016] mimic the process of literature-based 
discovery as a classification problem on a graph of MeSH terms, using unsupervised and 
supervised link prediction methods for predicting previously unknown connections between 
biomedical concepts.   
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 Further variants on literature-based discovery can be found in the following articles: 
[Ahmed,  2016; Ahmed and Alhashmi, 2014, 2015; Cameron, Kavuluru, Rindflesch et al, 2015; 
Cohen, Widdows, Stephan et al, 2014; Dai, Li, Yang et al, 2019; Dong, Liu, Zhu et al, 2014; 
Gabetta, Larizza, Bellazzi, 2013; Han, Wang, Subhadarshini et al, 2012; Henry and McInnes, 
2017;  Hristovski, Kastrin, Dinevski et al, 2016; Hristovski, Kastrin, Dinevskr et al, 2015; Hur, 
Sullivan, Schuyler et al, 2010; Ittipanuvat, Fujita, Kajikawa et al, 2012; Ittipanuvat, Fujita, 
Sakata et al, 2014; Kastrin, Rindflesch, Hristovski, 2014; Kim and Song, 2019; Korhonen, Guo, 
Baker et al, 2014; Liu, Fu, Jiang, 2016;  Maver, Hristovski, Rindflesch et al, 2013; Miller, 
Rindflesch, Strohl et al, 2012; Ozgur, Xiang, Radev et al, 2010;  Preiss and Stevenson, 2016; 
Preiss and Stevenson, 2017; Preiss, Stevenson, Gaizauskas, 2015; Pyysalo, Baker, Ali et al, 
2019; Rastegar-Mojarad, Elayavilli, Li et al, 2015; Rastegar-Mojarad, Elayavilli, Wang et al, 
2016; Ruch, 2010; Sang, Yang, Liu et al, 2018; Sebastian, 2014; Sebastian, Siew, Orimaye, 
2017a; Sebastian, Siew, Orimaye, 2017b; Smalheiser, 2012; Smalheiser, 2017; Srinivasan, 
Blackburn, Mohamed et al, 2015; Vos, Aarts, van Mulligen et al, 2014;  Workman, Fiszman, 
Rindflesch et al, 2014; Yamazaki, Onodera, Nakayama, 2013; Yang, Ju, Wong et al, 2017]. 
 These approaches achieve neither the breadth nor the volume of Innovation and 
Discovery found in [Kostoff and Patel, 2015; Kostoff, 2015; Kostoff, Porter, and Buchtel, 2018], 
and the present study. 
 Other information technology approaches have been used to identify potential risk 
factors/contributing factors for specific diseases.  They differ from the Discovery approaches 
above because of their focus on identifying the direct causes of disease as defined above.  
Examples of these information technology approaches include: 
 training neural networks to identify risk factors for specific diseases/conditions [Wang, 2002; 
Amin, Agarwal, Beg, 2013; Ushida, Kato, Niwa et al; 2012; Ismaeel and Mikhail, 2016; 
Esfahani and Ghazanfari, 2017],  
 machine learning-based methods to quantify risk factors for diseases/conditions [Barisic, 
Wilhelm, Stambuk et al, 2002; Du and Guo, 2005; Liao X, Kerr D, Morales et al, 2019; 
Berkowitz, Basu, Venkataramani et al, 2019],  
 data based clustering and rule based prediction to identify risk factors for diseases/conditions 
[Rahaman and Hossain, 2013; Pfaff, Weller, Woetzel et al, 2004; Cole, Frankovich, Iyer et 
al, 2013; Gaskin, Pershing, Cole et al, 2016],  
 Bayesian networks to identify risk factors [Rodin, Mosley, Clark et al, 2005; Koskela, 
Ryynanen, Soini, 2010; Zhao and Weng, 2011; Aussem, de Morais, Corbex, 2012; Bertke, 
Meyers, Wurzelbacher et al, 2012; Ben-Assuli and Leshno, 2016; Li, Pang, Li et al, 2019] 
 association rules to identify risk factors [Karaolis, Moutiris, Papaconstantinou et al, 2009; 
Ordonez and Zhao, 2011; Ramezankhani, Pournik, Shahrabi et al, 2015; Li, Zhang, Kang et 
al, 2017]  
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 decision trees to identify risk factors [Samanta, Bird, Kuijpers et al, 2009; Karaolis, Moutiris, 
Hadjipanayi et al, 2010; Marschollek, Goevercin, Rust et al, 2012; Kim, Kim, Won et al, 
2012; Meng, Huang, Rao et al, 2013; Gonoodi, Tayefi, Saberi-Karimian et al, 2019; Shao, 
Chen, Li et al, 2019],  
 text/data mining approaches [Friedman, Liu, Shagina, 2003; Anno, 2004; Tanaka, Aronson, 
Weeber, 2002; Turner, Arsevska, Brant et al, 2018; Pereira, Ito, Fonseca LM et al, 2017], and   
 information technology approaches for identifying adverse events resulting from drugs and 
surgery [Garcia and Guzman, 2008; Golder, Loke, McIntosh, 2008; Golder and Loke, 2009; 
Tanon, Champagne, Contandriopoulos et al, 2010; Egan, MacLean, Sweeting et al, 2012; 
Golder and Loke, 2012; Golder, Loke, Zorzela, 2013; Sampson, Zhang, Morrison et al, 2006; 
Harbour, Fraser, Lefebvre et al, 2014; Waffenschmidt, Janzen, Hausner et al, 2013; 
Damarell, Tieman, Sladek et al, 2011;  McKibbon, Wilczynski, Haynes, 2009; Haase, 
Follmann, Skipka et al, 2007; Golder, Wright, Loke, 2018]. 
5G. Definitions 
5G1. PN/PAD Foundational Cause definition 
 The myriad causes of PN/PAD reported in this monograph are termed "foundational".  A 
PN/PAD foundational cause is a tangible stimulus or behavior that can contribute to a PN/PAD 
symptom or a PN/PAD biomarker/characteristic change that reflects PN/PAD progression.  
Thus, selected drugs, chemicals, radiations, etc are tangible items and are viewed as 
'foundational'.  Diseases/symptoms such as diabetes and hypertension, while associated with or 
related to PN/PAD, are not viewed as 'foundational', since they are not tangible, but rather are 
driven by tangible contributing factors (high salt diet, high fat diet, high refined carbohydrate 
diet, etc).  The expression 'contributing factor' is used interchangeably with 'cause' throughout 
this monograph. 
 A symptom(s)/disease(s) in a person exposed to toxic stimuli is the result of imbalance 
between  the strength of the toxic stimuli and the person's innate ability to neutralize the effects 
of the toxic stimuli, including the genetic factors that were not included in this monograph.  The 
two are not independent; the toxic stimuli can affect the capabilities of the defensive system to 
neutralize incoming toxic stimuli.  Thus, the full spectrum of incoming toxic stimuli can be 
viewed as a "signature" of individual toxic stimuli, with different weightings assigned to each 
toxic stimulus, and the defense can also be viewed as a "signature", with different weightings 
assigned to the health of the body's defensive mechanisms.  Whether a symptom/disease will 
materialize as a result of one or more incoming toxic stimuli depends on whether the defensive 
"signature" is able to neutralize the "signature" of the incoming toxic stimuli. 
 Thus, not every person who eats a high refined carbohydrate diet or undergoes 
chemotherapy for cancer develops PN, but some (more than expected randomly) do.  There were 
a number of cases in the literature where relatively few people were reported to have adverse 
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reactions to a given toxic stimulus.  Identifying the offensive-defensive "signature" relationships 
that allow toxic stimuli to translate into symptoms (within the context of understanding genetic 
polymorphisms and the resulting variations in biological pathways) will play a significant role in 
explaining why some people develop a disease and others do not when exposed to the same 
agent(s).  Understanding the complex web of gene-environment interactions is the central 
challenge of modern medicine; identification of myriad individual toxic stimuli and defensive 
system deficiencies is the first step in this long journey. 
 For purposes of this monograph, a toxic stimulus is termed a (foundational) cause if the 
research author stated/implied/inferred the toxic stimulus was a cause and the information 
presented supported the research author's conclusion.  However, this toxic stimulus was in all 
probability one component of a more complex offensive-defensive "signature" imbalance that 
resulted in the symptom(s) of interest. 
5G2. PN/PAD Treatment definition 
 PN/PAD treatments are actions taken to modify PN/PAD characteristics/ symptoms/ 
biomarkers in desired directions.  The most widely used PN/PAD treatments are myriad drugs 
for attenuating undesired symptoms and/or modifying undesired biomarker/characteristics 
changes.  However, removal of PN/PAD contributing factors could be viewed as PN/PAD 
'treatments' (e.g., cessation of smoking, cessation of excessive alcohol intake, cessation of high-
fat diet, cessation of exposure to harmful chemicals, etc), since this action would modify 
PN/PAD characteristics in desired directions.  Also, substitution of positive practices for 
PN/PAD contributing factors removed could be considered as PN/PAD 'treatments' (e.g., 
drinking more water as a substitute for high-fructose beverages, moving from high air pollution 
environments to low air pollution environments, replacing high-temperature cooking with low-
temperature cooking, etc), again, since they modify PN/PAD characteristics in desired directions. 
5G3. PN/PAD Characteristics definition 
 A PN/PAD characteristic is a measurable quantity associated with a test subject/patient 
whose changes in value may reflect changes in the progression or reversal of PN/PAD.  The 
PN/PAD characteristics can be divided into three main categories as follows:  
 Symptoms (e.g., pain, foot ulcer, muscle weakness, fatigue, numbness, poor balance, 
unsteady gait, etc);  
 Biomarker/metabolic function (e.g., oxidative stress, neuroinflammation, axonal 
degeneration, etc); and  
 Biomarker/metabolic metrics (e.g., C reactive protein, HDL cholesterol, blood glucose level, 
etc).   
 Each of the main categories, especially Symptoms, could be divided into sub-categories, 
if greater clarity is desired. 
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5G4. Linking Term definition 
 Linking terms are words/phrases strongly associated with specific text concepts of 
interest.  Linking terms tend to be more generic than the specific terms that are the main targets 
of text searching.  There are relatively few linking terms compared to the large numbers of 
characteristics, causes, and treatments.  Searching text for the known linking terms will allow the 
desired concepts of interest to be identified. 
 For the causes, treatments, and characteristics of interest in the PN/PAD study, linking 
terms are verbs strongly associated with PN/PAD causes, treatments, and characteristics.  For 
PN/PAD treatments and characteristics in particular, some of the more useful linking terms 
identified included the following: treat*, therap*, prevent*, protect*, improv*, reduc*, attenuat*, 
ameliorat*, enhanc*,  revers*, promot*, alleviat*, inhibit*, remov*, suppress*, mitigat*, restor*, 
lower*, preserv*, regenerat*, rescu*, slow*, neuroprotect*, neurorestorati*, decreas*, increas*, 
eliminat*.   
 Not all these terms are of equal value, or efficiency in identifying the desired text 
concepts.  Some of these terms had higher efficiencies of identifying the PN/PAD treatment 
consequences of interest (PN/PAD characteristics) than others.  Terms like prevent*, protect*, 
improv*, restor*, alleviat*, ameliorat*, mitigat*, etc, almost always gave the desired PN/PAD 
characteristics and the direction in which they changed as a result of PN/PAD treatment.  Terms 
like decreas*, increas*, reduc*, etc, could go either way.  The former group of terms had the 
'sense' of improvement, while the latter group of terms reflected change (positive or negative).   
 Linking terms for identifying PN/PAD causes include: -induced; caused by; induced by; -
contaminated; exposure to; exposure(s) [at end of phrase]; exposed to; poisoning [at end]; -
exposed [at end]; -related; -associated; -infected; abuse*; toxicity; risk factors; deficiency; 
neurotoxicity; risk factor; causes; workers; toxic; occupational; intoxication; toxicities; 
neurotoxic; excessive; deficiencies; contributing factors; worker; contributing factor; occupation; 
overload. 
5G5. Text Mining definition 
 Text mining is the extraction of useful information from large volumes of text.   
 
References - Chapter 5 
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Chapter 6 
METHODOLOGY 
6A. Overview and Strategy 
6A1. Overview 
  There are two main goals of the present study:  
 identify the full spectrum of contributing factors, treatments, and biomarkers/symptoms 
(characteristics) for PN/PAD 
 develop an individually-tailored treatment protocol that could be used for prevention and 
reversal of PN/PAD.   
  The operational objectives that contribute to these goals include:  
 comprehensive identification of existing contributing factors to PN/PAD 
 comprehensive identification of existing treatments available for PN/PAD 
 comprehensive identification/discovery of potential treatments for PN/PAD 
 comprehensive identification of specific existing PN/PAD characteristics impacted by 
each of these existing and potential contributing factors and treatments 
 integration of the above PN/PAD contributing factors and treatments and their impacts to 
generate a protocol that will prevent and reverse PN/PAD, in selected cases.   
 
 Comprehensive identification of potential contributing factors to PN/PAD and 
comprehensive identification of specific potential PN/PAD characteristics impacted by 
each of these existing and potential contributing factors and treatments was not done in 
this study because of resource and time limitations. 
 Assume the existing and potential PN/PAD treatments can be related to their effects on 
the PN/PAD characteristics identified above, existing PN/PAD causes can be related to their 
effects on the same PN/PAD characteristics, and these PN/PAD characteristics are amenable to 
objective and subjective quantification.  Then, a treatment protocol can be generated that 
identifies  
 the amount that measured PN/PAD characteristics deviate from the norm for each 
PN/PAD patient 
 the causes that have to be eliminated to restore the PN/PAD characteristic measurements 
back to the norm 
 the treatments required to restore the PN/PAD characteristics back to the norm.  This 
individually tailored protocol is discussed in more detail in Chapter 3. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                                                                                                                
Chapter 6 - Methodology                                                                                                                                        149 
 The methodology employed in the present monograph identifies existing PN/PAD 
contributing factors, and existing and potential PN/PAD treatments that impact one or more of 
the myriad characteristics associated with PN/PAD, and existing PN/PAD characteristics whose 
values can move in predictable directions when stimulated by PN/PAD contributing factors and 
treatments.      
6A2. Strategy 
Table 6-1 - Approaches Used to Identify Causes/Treatments/Characteristics 
(Biomarkers/Symptoms) 
APPROACH    
VISUAL INSPECTION 
ABSTRACT 
X X X 
LINKING TERMS TITLE X X X 
LINKING TERMS 
ABSTRACT 
X X X 
MESH TERMS 
UNAMBIGUOUS 
X X X 
MESH TERMS QUALIFIERS X X X 
DOT PRODUCT ABSTRACT X   
CATEGORIES-----> CAUSES TREATMENTS CHARACTERISTICS 
 
 The overall conceptual strategy for identifying existing PN/PAD causes, treatments, and 
characteristics was based upon the conceptual strategy used in [Kostoff, Porter, Buchtel, 2018], 
although the implementation of the conceptual strategy differed slightly as knowledge was 
gained during the evolution of the study.   
 The strategy components used in the present study are: 
 Select source database (Medline/Pubmed was selected as the primary source database, 
although the Thomson-Reuters version was used when proximity searching was 
performed). 
 Generate a core PN/PAD database (a Pubmed query was used to generate a core PN/PAD 
database).   
 Retrieve records relevant to PN/PAD treatments, contributing factors, or characteristics 
from the core PN/PAD database (methods will be shown in following sections) 
 Extract existing contributing factors, treatments, and characteristics from retrieved 
records (methods will be shown in following sections) 
 A combination of MeSH-based and text-based examination approaches was used to 
retrieve records relevant to PN/PAD treatments, contributing factors, and characteristics, and to 
extract the desired PN/PAD treatments, contributing factors, and characteristics from these 
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retrieved records.  Table 6-1 summarizes the specific approaches used to identify contributing 
factors, treatments, and characteristics.  Because of resource limitations, not all approaches were 
applied to all targets.  
6B. Methodology for Identifying Existing and Potential PN/PAD Contributing Factors, 
Treatments, and Characteristics 
6B1. Overview 
 As stated above, a MeSH-based approach and a text-based approach were used in tandem 
to identify existing PN/PAD contributing factors, treatments, and characteristics.  The text-based 
approach was developed and used because of the following MeSH-based approach limitations:  
 1) not all Medline records have MeSH terms assigned;  
 2) for those records with MeSH terms, the terms do not always form a comprehensive set;  
 3) for records with MeSH terms, the Qualifiers appended to the Heading are not always 
complete.   
Thus, the text-based approach complements (and overlaps) the MeSH-based approach. 
6B2. Identifying Existing PN/PAD Contributing Factors 
6B2a. Text-based Approach 
6B2a1. Visual Inspection 
 The text-based approach had three components: a visual inspection component, a linking 
term component, and a dot-product component.  The parsed Abstract field, containing about 
4,000,000 phrases reflecting the 43056 records that constituted the core PN/PAD database, was 
used for all three components.  The visual inspection component involved reading the 30,000 
highest frequency Abstract phrases, and selecting those phrases deemed to be candidate 
contributing factors.  The Vantage Point (VP) software [VP, 2019] containing these phrases 
displays both the phrases and the Titles and Abstracts of the records in which they appear.  This 
allows validation of each candidate contributing factor selected. 
6B2a2. Linking Term 
 To identify candidate contributing factors in the lower frequency portion of the parsed 
Abstract field, a text-mining approach was necessary. Linking terms strongly associated with 
contributing factors were generated through visually inspecting many records containing 
foundational contributing factors in the Titles, and identifying those terms that appeared 
frequently with the foundational contributing factors.  The remainder of the parsed Abstract field 
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was searched with use of these linking terms.  The additional candidate contributing factors were 
extracted from the retrieved phrases, and validated as contributing factors. 
 These linking terms included: -induced; caused by; induced by; -contaminated; exposure 
to; exposure(s) [at end of phrase]; exposed to; poisoning [at end]; -exposed [at end]; -related; -
associated; -infected; abuse*; toxicity; risk factors; deficiency; neurotoxicity; risk factor; causes; 
workers; toxic; occupational; intoxication; toxicities; neurotoxic; excessive; deficiencies; 
contributing factors; worker; contributing factor; occupation; overload. 
6B2a3. Dot Product  
 While the visual inspection approach identifies comprehensively the higher-frequency 
foundational causes, the linking term approach is less efficient.  Not all foundational causes are 
associated with the finite list of linking terms used.  Even if a foundational cause is associated (in 
the same Abstract) with a linking term, the software effectively limits the proximity of the 
linking term/foundational cause to four words.  Some foundational causes can be located much 
further away from a linking term than four words in an Abstract.   
 To identify additional foundational causes that may have slipped through the cracks from 
the visual inspection and linking term approaches, the dot product approach was developed.  
Approximately 12,350 potentially toxic substances from myriad other sources (including past 
foundational causes studies, government-approved lists of toxic substances, MeSH-derived 
causes, etc) were generated, and intersected with the ~4,000,000 Abstract phrases in the core 
PN/PAD literature.  While the dot product approach was developed specifically for identifying 
causes, a similar approach could be used for identifying treatments, biomarkers, mechanisms, 
etc. Moreover, given that many authors don't place detailed substances in the Title or Abstract, 
there could be substantial benefits gained by using full-text rather than Abstracts.  
6B2b. MeSH-based Approach 
6B2b1. MeSH Qualifiers 
 MeSH Headings have a number of Qualifiers associated with them to allow focus on 
items of interest. Thus, the MeSH term Cadmium/toxicity allows records to be retrieved related 
to the toxicity of Cadmium.  There were 83 topical MeSH Qualifiers (in Pubmed) used for 
indexing and cataloging in conjunction with MeSH Heading descriptors when this concept was 
developed. All 83 were examined in more or less detail for applicability to identifying 
foundational causes of disease. Four were selected (after extensive validation) as producing 
highly relevant results when used in isolation: adverse effects, toxicity, pathogenicity, poisoning. 
A few limited combinations of the remaining MeSH Qualifiers were examined for the 
streamlined approach, but none were deemed to have sufficient relevance.  All MeSH terms that 
contained at least one of these Qualifiers were extracted, and the related records examined for 
potential foundational causes.  While this MeSH Qualifier linking approach was developed for, 
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and applied to, identifying existing foundational causes, it was easily modified for identifying 
existing treatments and biomarkers, and could be further modified for identifying mechanisms, 
etc. 
6B2b2. MeSH Headings 
 MeSH Headings related relatively unambiguously to foundational causes were identified 
two ways. First, results from past studies were examined, especially [Kostoff, Porter, Buchtel, 
2018; Kostoff and Patel, 2015], and relevant MeSH Headings were extracted. Second, a few of 
the most unambiguous MeSH terms identified from past studies were entered into Pubmed as 
query terms, and all the MeSH terms in the resultant retrieval (i.e., those that co-occurred with 
the entry MeSH terms) were examined for relevance.  The final list of relevant MeSH terms was 
intersected with the total list of MeSH terms in the retrieved database, and the resulting records 
were examined for potential PN/PAD foundational causes.   
 Sample MeSH terms related relatively unambiguously to foundational causes included: 
"Drug-Related Side Effects AND Adverse Reactions"; Abnormalities, Drug Induced; Air 
Pollutants, Occupational; Amphetamine Related Disorders; Carcinogens; Chemical Warfare 
Agents; Chemically-Induced Disorders, etc. 
 Again, while this focused MeSH Heading approach was developed for identifying 
foundational causes, it was adapted to identifying treatments, and could be readily adapted to 
identifying biomarkers, mechanisms, etc. 
6B3. Identifying Existing PN/PAD Treatments 
6B3a. Text-based Approach 
6B3a1. Visual Inspection 
 The text-based approach had two components: a visual inspection component, and a 
linking term component.  The parsed Abstract field, containing about 4,000,000 phrases,  was 
used for both components.  The visual inspection component involved reading the 30,000 highest 
frequency phrases, and selecting those phrases deemed to be candidate treatments.  The Vantage 
Point (VP) software containing these phrases displays both the phrases and the Titles and 
Abstracts of the records in which they appear.  This allows validation of each candidate 
treatment selected. 
6B3a2. Linking Term 
 To identify candidate treatments in the lower frequency portion of the parsed Abstract 
field, a text-mining approach was necessary. Linking terms strongly associated with treatments 
were generated through visually inspecting many records containing treatments in the Titles, and 
identifying those terms that appeared frequently with the treatments.  The remainder of the 
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parsed Abstract field was searched with use of these linking terms.  The additional candidate 
treatments were extracted from the retrieved phrases, and validated as treatments. 
 Some of the more useful linking terms identified included the following: treat*, therap*, 
prevent*, protect*, improv*, reduc*, attenuat*, ameliorat*, enhanc*,  revers*, promot*, alleviat*, 
inhibit*, remov*, suppress*, mitigat*, restor*, lower*, preserv*, regenerat*, rescu*, slow*, 
neuroprotect*, neurorestorati*, decreas*, increas*, eliminat*.   
 Not all these terms are of equal value, or efficiency in identifying the desired text 
concepts.  Some of these terms had higher efficiencies of identifying the PN/PAD treatment 
consequences of interest (PN/PAD characteristics) than others.  Terms like prevent*, protect*, 
improv*, restor*, alleviat*, ameliorat*, mitigat*, etc, almost always were associated with 
treatments, and gave the desired PN/PAD characteristics and the direction in which they changed 
as a result of PN/PAD treatment.  Terms like decreas*, increas*, reduc*, etc, could go either 
way.  The former group of terms had the 'sense' of improvement, while the latter group of terms 
reflected change (positive or negative).   
6B3b. MeSH-based Approach 
6B3b1. MeSH Qualifiers 
 MeSH Headings have a number of Qualifiers associated with them to allow focus on 
items of interest. Thus, the MeSH term Cadmium/toxicity allows records to be retrieved related 
to the toxicity of Cadmium.  There were 83 topical MeSH Qualifiers (in Pubmed) used for 
indexing and cataloging in conjunction with MeSH Heading descriptors when this concept was 
developed. All 83 were examined in more or less detail for applicability to identifying 
treatments.  For the initial Visual Inspection approach query, seven were selected (after extensive 
validation) as producing highly relevant results when used in isolation: diet therapy, drug 
therapy, prevention & control, radiotherapy, surgery, therapeutic use, therapy. A few limited 
combinations of the remaining MeSH Qualifiers were examined for the streamlined approach, 
but none were deemed to have sufficient relevance.  All MeSH terms that contained at least one 
of these Qualifiers were extracted, and the related records examined for treatments.   
6B3b2. MeSH Headings 
 MeSH Headings related relatively unambiguously to treatments were identified two 
ways. First, results from past studies were examined, especially [Kostoff, Porter, Buchtel, 2018; 
Kostoff and Patel, 2015], and relevant MeSH Headings were extracted. Second, a few of the 
most unambiguous MeSH terms identified from past studies were entered into Pubmed as query 
terms, and all the MeSH terms in the resultant retrieval (i.e., those that co-occurred with the entry 
MeSH terms) were examined for relevance.  The final list of relevant MeSH terms was 
intersected with the total list of MeSH terms in the retrieved database, and the resulting records 
were examined for candidate PN/PAD treatments.   
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 Sample MeSH terms related relatively unambiguously to treatments included Treatment 
Outcome, Neuroprotective Agents, Nootropic Agents, Plant Extracts, Phytotherapy, Dietary 
Supplements, Drugs, Chinese Herbal, etc. 
6B4. Identifying Existing PN/PAD Characteristics 
6B4a. Text-based Approach 
6B4a1. Visual Inspection 
 The text-based approach had two components: a visual inspection component, and a 
linking term component.  The parsed Abstract field, containing about 4,000,000 phrases,  was 
used for both components.  The visual inspection component involved reading the 30,000 highest 
frequency phrases, and selecting those phrases deemed to be candidate characteristics.  The 
Vantage Point (VP) software containing these phrases displays both the phrases and the Titles 
and Abstracts of the records in which they appear.  This allows validation of each candidate 
characteristic selected. 
6B4a2. Linking Term 
 To identify candidate characteristics in the lower frequency portion of the parsed Abstract 
field, a text-mining approach was necessary. Linking terms strongly associated with 
characteristics were generated through visually inspecting many records containing 
characteristics in the Titles, and identifying those terms that appeared frequently with the 
characteristics.  The remainder of the parsed Abstract field was searched with use of these 
linking terms.  The additional candidate characteristics were extracted from the retrieved phrases, 
and validated as characteristics. 
 For the streamlined approach, the linking terms used for identifying treatments were 
selected as the linking terms to be used for identifying characteristics.  These linking terms 
included: treat*, therap*, prevent*, protect*, improv*, reduc*, attenuat*, ameliorat*, enhanc*,  
revers*, promot*, alleviat*, inhibit*, remov*, suppress*, mitigat*, restor*, lower*, preserv*, 
regenerat*, rescu*, slow*, neuroprotect*, neurorestorati*, decreas*, increas*, eliminat*.   
6B4b. MeSH-based Approach 
6B4b1. MeSH Qualifiers 
 MeSH Headings have a number of Qualifiers associated with them to allow focus on 
items of interest. Thus, the MeSH term Cadmium/toxicity allows records to be retrieved related 
to the toxicity of Cadmium.  There were 83 topical MeSH Qualifiers (in Pubmed) used for 
indexing and cataloging in conjunction with MeSH Heading descriptors when this concept was 
developed. All 83 were examined in more or less detail for applicability to identifying 
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characteristics. None were identified as being unambiguously related to characteristics, and this 
approach was not pursued further.   
6B4b2. MeSH Headings 
 MeSH Headings related relatively unambiguously to characteristics were identified two 
ways. First, results from past studies were examined, especially [Kostoff, Porter, Buchtel, 2018; 
Kostoff and Patel, 2015], and relevant MeSH Headings were extracted. Second, a few of the 
most unambiguous MeSH terms identified from past studies were entered into Pubmed as query 
terms, and all the MeSH terms in the resultant retrieval (i.e., those that co-occurred with the entry 
MeSH terms) were examined for relevance.  The only MeSH term related relatively 
unambiguously to characteristics was Biomarkers. 
6B4c. Spinoff from Contributing Factor and Treatment Identification Approaches 
 Contributing factor or treatment records typically identify one or more characteristics that 
are impacted by the contributing factor(s) or treatment(s) in the record.  In the present 
streamlined approach, most of the characteristics were identified during the validation process 
for a contributing factor or treatment.  The records were read for validation, and any 
characteristics were then extracted from the record. 
6B5. Identifying Potential PN/PAD Treatments 
 Existing treatments identified in the present monograph were deemed successful when 
they moved the values of characteristics in desired directions.  Thus, if high oxidative stress or 
high inflammation reflected an undesired disease state, then one component of a successful 
treatment for this undesired disease state would be reduction of oxidative stress or reduction of 
inflammation.   One of the outcomes of the present study was identification of myriad 
characteristics and the directions in which they changed as a result of successful treatments. 
 For Discovery (identification of potential PN/PAD treatments), this process is reversed.  
A query is formed consisting of critical characteristics and the directions in which they would be 
changed if successful treatments were applied.  This query is then applied to the full Medline 
database excluding the PN/PAD literature.  Chemicals/radiations/supplements etc, and other 
forms of potential PN/PAD treatments are identified that move these characteristics in desired 
directions, and they are viewed as candidate potential PN/PAD treatments.  A validation is 
performed to insure these candidate potential PN/PAD treatments are not part of the core 
PN/PAD literature. 
 The number of terms in the query could range from one to many.  The more terms in the 
query, the more restricted the retrievals would be in volume and focus.  The fewer terms in the 
query, the greater the chances for radical discovery, but the larger the volume of retrieval to be 
evaluated for validation.   
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 As an example, consider the above case of an undesired disease state, characterized by 
high oxidative stress and high inflammation.  A query would be generated, consisting of "reduce 
oxidative stress AND "reduce inflammation".  All treatments for any disease in Medline (with 
the exception of PN/PAD) that reduced oxidative stress and reduced inflammation would be 
retrieved.  After much experimentation, it was found that queries consisting of combinations of 
two biomarkers (with desired directions of change) provided a good balance between content of 
discovery and volume of retrieval. 
 The detailed methodology that was used in the present study is described in Appendix 6-
1, and in the broader context of treatment re-purposing in [Kostoff, 2018]. 
6B6. Identifying Potential PN/PAD Contributing Factors 
 Potential PN/PAD contributing factors were not identified in the present study because of 
time and resource limitations.  However, the conceptual approach is the same as that for 
identifying potential PN/PAD treatments, with the exception that the directions in which 
characteristics changes are desired are reversed.  In the example provided in section 6B5 for 
treatments, the query for identifying potential contributing factors would be "increase oxidative 
stress" AND "increase inflammation".  All contributing factors for any disease in Medline (with 
the exception of PN/PAD) that increased oxidative stress and increased inflammation would be 
retrieved.   
6B7. Identifying Potential PN/PAD Characteristics 
 Potential PN/PAD characteristics were not identified in the present study because of time 
and resource limitations.  If potential PN/PAD characteristics were desired, the identification 
concept would be to identify patterns of PN/PAD characteristics that tend to co-occur frequently 
in the PN/PAD literature, then use these patterns as a search query in the non-PN/PAD literature.  
New patterns may be identified in the non-PN/PAD literature consisting of the search query 
pattern plus additional characteristics not in the PN/PAD literature.  These additional 
characteristics would then be candidates for discovery as new PN/PAD characteristics that not 
have been identified previously.   
 For example, IL-1 and IL-6 and TNF-alpha and NF-KappaB tend to co-occur in many 
PN/PAD articles relating to inflammation.  These four terms would be combined as a query for 
the non-AD literature: "IL-1 AND IL-6 AND TNF-alpha AND NF-KappaB".  Any records 
retrieved would be examined for additional characteristics, and these additional characteristics 
would be validated if they did not occur in the PN/PAD literature. 
 Myriad other patterns are possible.  For example, existing PN/PAD treatments and 
existing PN/PAD causes move PN/PAD characteristics in known directions.  Non-PN/PAD 
literatures could be searched for characteristics  impacted by these known PN/PAD treatments 
and PN/PAD causes, and not contained in the core PN/PAD literature.  Combinations of these 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                                                                                                                
Chapter 6 - Methodology                                                                                                                                        157 
PN/PAD treatments and PN/PAD causes could be used to increase the likelihood that any new 
characteristics identified would have higher relevance to PN/PAD.   
 As a specific example, consider the following query that was demonstrated in the 
Alzheimer's Disease (AD) study [Kostoff, Porter, Buchtel, 2018]: (high-fat-diet* NEAR/5 
(increas* OR decreas*) AND chitosan NEAR/5 (increas* OR decreas*)) NOT alzheimer*.  This 
will retrieve all records reflecting an increase or decrease of characteristic values (in the non-AD 
literature) due to the presence of the existing AD cause "high-fat-diet" and the existing AD 
treatment "chitosan".  Applying this query to the Medline database leads to the identification of a 
potential AD characteristic "mup17" (major urinary protein 17) [Wang, Zhang, Wang et al, 
2017].  This potential AD characteristic is not found in the AD literature, but it is altered in one 
direction by an existing AD cause, and is altered in the opposing direction by an existing AD 
treatment.  So, it might be a valuable characteristic for AD researchers to track. 
Appendices - Chapter 6 
Appendix 6-1 - PN/PAD Treatment Discovery Query 
6-1a. General strategy 
 As stated in 6B5, a query is formed consisting of critical characteristics and the directions 
in which they would be changed if successful treatments were applied.  This query is then 
applied to the full Medline database excluding the PN/PAD literature.  Chemicals/ radiations/ 
supplements etc, and other forms of potential PN/PAD treatments are identified that move these 
characteristics in desired directions, and they are viewed as candidate potential PN/PAD 
treatments.  A validation is performed to insure these candidate potential PN/PAD treatments are 
not part of the core PN/PAD literature.  
6-1b. Specific approach 
 The most general form of the treatment discovery/repurposing query can incorporate any 
number of characteristics of interest. For PN/PAD, a two biomarker query was deemed adequate 
for demonstration purposes. The generic form of the two biomarker PN/PAD treatment 
discovery/repurposing query is 
(A and B) not (C or D), where 
A is a biomarker and its associated desired direction of change 
B is another biomarker and its associated direction of change 
C is the query used to retrieve the PN/PAD core literature 
D is a list of existing PN/PAD treatments identified in the initial part of the PN/PAD study 
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 Thus, the combination (A and B) retrieves ALL records from the biomedical literature 
that contain potential PN/PAD treatments based on the two desired characteristics A and B, 
while (C or D) subtracts those records and treatments associated with the PN/PAD core 
literature. The remainder is non-PN/PAD records with substances that could be candidate 
potential PN/PAD treatments, based on the requirement that A and B must be present. 
 Twenty of the 757 biomarkers identified in the PN/PAD study (through text mining 
techniques) were selected for the query. The query was run in Thompson-Reuters-Medline, since 
its search engine allows for proximity searching (e.g., [direction] within three words of 
[biomarker], or [direction] near/3 [biomarker]). In modular form, each query term is shown as 
follows: 
6-1b1. PN/PAD Characteristic-Linking Term units 
 #1 - (reduc* OR decreas* OR prevent* OR attenuat* OR suppress* OR  alleviat* OR 
ameliorat*) near/3 "oxidative stress" 
 #2 - (reduc* OR decreas* OR prevent* OR attenuat* OR suppress* OR  alleviat* OR 
ameliorat* OR inhibit*) near/3 "advanced glycation end product*" 
 #3 - (reduc* OR decreas* OR prevent* OR attenuat* OR suppress* OR  alleviat* OR 
ameliorat*) near/3 ("hemoglobin a1c" OR "hba1c") 
 #4 - (increase OR enhanc* OR restor*) near/3 "glomerular filtration rate" 
 #5 - (modulat* OR attenuat* OR reduc* OR inhibit* OR decreas* OR suppress*) near/3 
("il-6" OR "interleukin-6") 
 #6 - (reduc* OR decreas* OR attenuat* OR suppress* OR inhibit*) near/3 "creatine 
kinase" 
 #7 - (attenuat* OR reduc* OR inhibit* OR decreas* OR suppres*) near/3 
"malondialdehyde" 
 #8 - (attenuat* OR reduc* OR inhibit* OR decreas* OR suppres*) near/3 "alkaline 
phosphatase" 
 #9 - (attenuat* OR reduc* OR inhibit* OR decreas* OR suppress*) near/3 
"myeloperoxidase" 
 #10 - (attenuat* OR reduc* OR inhibit* OR decreas* OR suppress*) near/3 "blood urea 
nitrogen" 
 #11 - (attenuat* OR reduc* OR inhibit* OR decreas* OR suppress*) near/3 ("beta 2 
microglobulin" OR "beta-2 microglobulin" OR "beta-2-microglobulin") 
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 #12 - (increas* OR enhanc* OR restor*) near/3 "adenosine triphosphate" 
 #13 - (attenuat* OR reduc* OR inhibit* OR decreas* OR suppress*) near/3 ("pge2" OR 
"Prostaglandin E2") 
 #14 - (attenuat* OR reduc* OR inhibit* OR decreas* OR suppress*) near/3 "cystatin c" 
 #15 - (increas* OR enhanc* OR restor*) near/3 "Nrf2" 
 #16 - (attenuat* OR reduc* OR inhibit* OR decreas* OR suppress*) near/3 "gamma-
glutamyltransferase " 
 #17 - (attenuat* OR reduc* OR inhibit* OR decreas* OR suppress*) near/3 "galectin-3" 
 #18 - (increas* OR enhanc* OR restor*) near/3 "cyclic guanine monophosphate" 
 #19 - (attenuat* OR reduc* OR inhibit* OR decreas* OR suppress*) near/3 "aspartate 
aminotransferase " 
 #20 - (attenuat* OR reduc* OR inhibit* OR decreas*) near/3 "Glutamate 
carboxypeptidase II" 
NOT 
 #21 - peripheral neuropathy [MeSH Heading-NO EXP] OR "peripheral neuropathy" 
[TOPIC] OR peripheral arterial disease [MeSH Heading] OR "peripheral arter* disease" 
[TOPIC] OR "peripheral vascular disease" [TOPIC] 
OR  
Existing Treatments 
#22 - ("revascularization" OR "walking" OR "artery bypass grafting" OR "angioplasty" OR  
"insulin" OR "dialysis" OR "aspirin" OR "endovascular treatment" OR "vascular surgery" OR 
"angiogenesis" OR "glycemic control" OR "corticosteroid" OR "catheter" OR "Clopidogrel" OR 
"thalidomide" OR "vascular endothelial growth factor" OR "balloon angioplasty" OR "CABG" 
OR "Gabapentin" OR "PNS" OR "endarterectomy" OR "pregabalin" OR "Cilostazol" OR 
"vitamin B12" OR "nerve growth factor" OR "smoking cessation" OR "IL-6" OR "heparin" OR 
"adenosine" OR "Electrical stimulation" OR "prednisone" OR "hypoxia" OR "capsaicin" OR 
"morphine" OR "SCS" OR "mononuclear cells" OR "rituximab" OR "Spinal Cord Stimulation" 
OR "vitamin E" OR "zidovudine" OR "plasmapheresis" OR "prednisolone" OR "warfarin" OR 
"Vitamin D" OR "duloxetine" OR "enzyme inhibitors" OR "Acupuncture" OR "pentoxifylline" 
OR "plasma exchange" OR "haemodialysis" OR "antioxidants" OR "IVIG" OR "lidocaine" OR 
"Prostaglandin" OR "gangliosides" OR "Amitriptyline" OR "Alpha lipoic acid" OR 
"carbamazepine" OR "folic acid" OR "anthracycline" OR "GM1" OR "leucovorin" OR 
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"dipyridamole" OR "thiamine" OR "Ticlopidine" OR "methylprednisolone" OR "drug-coated 
balloons" OR "near-infrared" OR "magnesium" OR "Zinc" OR "surgical decompression" OR 
"ethanol" OR "superoxide dismutase" OR "erythropoietin" OR "simvastatin" OR "Acetyl-l-
carnitine" OR "acetylsalicylic acid" OR "hyperbaric oxygen" OR "Testosterone" OR 
"angiotensin converting enzyme inhibitor" OR "nitinol stents" OR "carnitine" OR "Pyridoxine" 
OR "BDNF" OR "hepatocyte growth factor" OR "iloprost" OR "immunosuppressive agents" OR 
"AA" OR "epidermal growth factor" OR "Mesenchymal Stem Cells" OR "peripheral blood 
mononuclear cells" OR "C-peptide" OR "Nicotine" OR "aldose reductase inhibitor" OR 
"atorvastatin" OR "azathioprine" OR "Ketamine" OR "vorapaxar" OR "Neurotrophins" OR 
"clonidine" OR "arginine" OR "ticagrelor" OR "aerobic exercise" OR "antiepileptic drugs" OR 
"valproic acid" OR "drug-eluting balloons" OR "glucocorticoid" OR "apheresis" OR "distal 
bypass" OR "niacin" OR "stem cell therapy" OR "venlafaxine" OR "Cannabinoids" OR 
"directional atherectomy" OR "nitroglycerin" OR "urokinase" OR "vitamin C" OR "ramipril" OR 
"tramadol" OR "Orbital atherectomy" OR "prasugrel" OR "covered stents" OR "l-carnitine" OR 
"progesterone" OR "amifostine" OR "Gamma-aminobutyric acid" OR "lamotrigine" OR 
"Lumbar sympathectomy" OR "Methylcobalamin" OR "phenytoin" OR "propionyl-L-carnitine" 
OR "electroacupuncture" OR "GDNF" OR "HMG-CoA" OR "nifedipine" OR "oxcarbazepine" 
OR "baclofen" OR "glutamine" OR "intermittent pneumatic compression" OR "Mexiletine" OR 
"verapamil" OR "botulinum toxin" OR "diphenhydramine" OR "growth hormone" OR "hormone 
replacement therapy" OR "massage" OR "minocycline" OR "sodium nitroprusside" OR 
"antimicrobial therapy" OR "cannabis" OR "curcumin" OR "GSH" OR "MK-801" OR 
"nicotinamide" OR "opiates" OR "Transcutaneous electrical nerve stimulation" OR "bFGF" OR 
"Goshajinkigan" OR "immunoglobulin therapy" OR "insulin-like growth factor-I" OR "omega-3 
fatty acids" OR "pulse therapy" OR "docosahexaenoic acid" OR "EPO" OR "fish oil" OR 
"hypothermia" OR "alpha-tocopherol" OR "calcium antagonists" OR "cryoplasty" OR "NT-3" 
OR "prostanoids" OR "rapamycin" OR "topiramate" OR "Vitamin B1" OR "calcium channel 
blocker" OR "NSAIDs" OR "oxycodone" OR "phosphodiesterase inhibitor" OR "rivaroxaban" 
OR "tacrolimus" OR "bone marrow mononuclear cells" OR "fentanyl" OR "peripheral nerve 
stimulation" OR "alprostadil" OR "buflomedil" OR "DAPT" OR "ezetimibe" OR "neuroactive 
steroids" OR "neurotrophin-3" OR "phentolamine" OR "serotonin reuptake inhibitors" OR 
"ascorbic acid" OR "balloon dilatation" OR "chelation therapy" OR "eicosapentaenoic acid" OR 
"indomethacin" OR "lithium" OR "muscle stimulation" OR "selenium" OR "amlodipine" OR 
"CXCR4" OR "interleukin-10" OR "laser therapy" OR "mycophenolate mofetil" OR "N-
acetylcysteine" OR "NAC" OR "rifampin" OR "strength training" OR "thienopyridines" OR 
"viral vectors" OR "whole-body vibration" OR "androgen" OR "beraprost sodium" OR 
"ceftriaxone" OR "chlorambucil" OR "Coenzyme Q10" OR "epalrestat" OR "galanin" OR 
"losartan" OR "negative pressure wound therapy" OR "ozone" OR "PGE2" OR "pravastatin" OR 
"RTX" OR "acetaminophen" OR "digoxin" OR "glycosaminoglycan" OR "kampo" OR 
"lisinopril" OR "osteopontin" OR "sildenafil" OR "Streptokinase" OR "abciximab" OR 
"Aldehyde" OR "antioxidant therapy" OR "bivalirudin" OR "cimetidine" OR "CNTF" OR 
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"enalapril" OR "femoropopliteal in-stent restenosis" OR "fluoxetine" OR "memantine" OR 
"myo-inositol" OR "Org 2766" OR "phenylephrine" OR "Picotamide" OR "tapentadol" OR 
"TCA" OR "yohimbine" OR "ACTH" OR "Caffeine" OR "celecoxib" OR "dextromethorphan" 
OR "doxycycline" OR "etanercept" OR "FK506" OR "guanosine" OR "mecobalamin" OR 
"nortriptyline" OR "Olive oil" OR "sulodexide" OR "antihistamines" OR "beta-carotene" OR 
"betaine" OR "cyanocobalamin" OR "Dex" OR "ganglioside GM1" OR "Ginkgo biloba extract" 
OR "hydrochlorothiazide" OR "ketanserin" OR "Lovastatin" OR "prazosin" OR "retinoic acid" 
OR "sodium bicarbonate" OR "tempol" OR "anandamide" OR "chlorthalidone" OR "diclofenac" 
OR "EDTA" OR "phosphatidylcholine" OR "ruboxistaurin" OR "serotonin-norepinephrine 
reuptake inhibitors" OR "tea" OR "benfotiamine" OR "chloroquine" OR "desipramine" OR 
"fenofibrate" OR "glibenclamide" OR "GP IIb/IIIa inhibitors" OR "imipramine" OR "lentivirus" 
OR "melatonin" OR "mesenchymal stromal cells" OR "milnacipran" OR "PAR-1 antagonists" 
OR "plaque excision" OR "Ranitidine" OR "Resveratrol" OR "scrambler therapy" OR "tai chi" 
OR "thiazolidinediones" OR "uridine" OR "vitamin D3" OR "WIN 55,212-2" OR "allopurinol" 
OR "Angiogenic gene therapy" OR "benzodiazepine" OR "captopril" OR "Carvedilol" OR 
"clonazepam" OR "dabigatran" OR "Defibrotide" OR "electromagnetic field" OR "everolimus" 
OR "hydrogen sulfide" OR "levetiracetam" OR "methadone" OR "methylxanthine" OR 
"Paracetamol" OR "perindopril" OR "phlebotomy" OR "sunlight" OR "tafamidis" OR "tolrestat" 
OR "vitamin K antagonist" OR "all-trans retinoic acid" OR "amantadine" OR "Calcitriol" OR 
"D-penicillamine" OR "eptifibatide" OR "external counterpulsation" OR "hydrocortisone" OR 
"ibuprofen" OR "inositol" OR "KU-32" OR "lacosamide" OR "levothyroxine" OR "mannitol" 
OR "manual therapy" OR "Menhaden oil" OR "menthol" OR "muscimol" OR "nicotinic acid" 
OR "osteocalcin" OR "paroxetine" OR "pioglitazone" OR "placenta" OR "Protamine" OR 
"Sitagliptin" OR "taurine" OR "Tetrodotoxin" OR "thiols" OR "tirofiban" OR "TRPA1 
antagonist" OR "7-nitroindazole" OR "acetylcysteine" OR "apixaban" OR "ATS" OR 
"Cannabidiol" OR "capsazepine" OR "coffee" OR "cortical stimulation" OR "cryotherapy" OR 
"DA-9801" OR "dexmedetomidine" OR "diltiazem" OR "factor Xa inhibitors" OR "gamma-
globulin" OR "gamma-linolenic acid" OR "gemfibrozil" OR "Ghrelin" OR "Gliclazide" OR 
"histone deacetylase inhibitors" OR "Huangqi Guizhi Wuwu" OR "interferon-beta" OR 
"Isosorbide dinitrate" OR "linoleic acid" OR "MIRE" OR "neuromuscular electrical stimulation" 
OR "nimodipine" OR "papaverine" OR "Peripheral nerve decompression" OR "PGB" OR 
"plasminogen activators" OR "prostacyclin analogues" OR "quercetin" OR "retigabine" OR 
"riluzole" OR "sirolimus" OR "Viabahn endoprosthesis" OR "acarbose" OR "ancrod" OR 
"atopaxar" OR "Biotin" OR "CB1/CB2 agonist" OR "coumarin" OR "EGb 761" OR "erlotinib" 
OR "HC-030031" OR "hyaluronic acid" OR "hydromorphone" OR "Hydroxocobalamin" OR 
"liraglutide" OR "magnetic fields" OR "marijuana" OR "mesoglycan" OR "naltrexone" OR 
"nebivolol" OR "PARP inhibition" OR "relaxin" OR "salbutamol" OR "Sarpogrelate 
hydrochloride" OR "shockwave therapy" OR "THC" OR "Thiamine pyrophosphate" OR 
"thioctic acid" OR "trimetazidine" OR "Vitamin B complex" OR "Zilver PTX stent" OR 
"acetylcholine-induced" OR "adrenocorticotropic hormone" OR "AMD3100" OR "Bezafibrate" 
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OR "cangrelor" OR "cholinesterase inhibitor" OR "clomipramine" OR "diazepam" OR "drug-
coated stents" OR "edoxaban" OR "epoprostenol" OR "Exendin-4" OR "FAAH inhibitor" OR 
"Flunarizine" OR "Grape" OR "guanethidine" OR "haemodilution" OR "Hematin" OR "Heparin 
cofactor II" OR "hydrotherapy" OR "hydroxychloroquine" OR "hydroxyethyl starch" OR 
"Ibudilast" OR "Jinmaitong" OR "ketorolac" OR "moxibustion" OR "N-methyl-D-aspartate 
receptor antagonists" OR "naftidrofuryl oxalate" OR "NGX-4010" OR "P2Y12 inhibitor" OR 
"pralidoxime" OR "puerarin" OR "repetitive transcranial magnetic stimulation" OR "reteplase" 
OR "rheopheresis" OR "rofecoxib" OR "Sativex" OR "SCH 530348" OR "Shakuyaku-kanzo-to" 
OR "tadalafil" OR "telmisartan" OR "trigonelline" OR "triiodothyronine" OR "URB597" OR 
"VLTS-589" OR "17beta-estradiol" OR "4-methylcatechol" OR "acetazolamide" OR "adrenal 
medullary transplants" OR "agmatine" OR "Aliskiren" OR "allopregnanolone" OR "amikacin" 
OR "anakinra" OR "betamethasone" OR "bosentan" OR "canagliflozin" OR "catechin" OR 
"cefotaxime" OR "chelerythrine" OR "Cinacalcet" OR "ciprostene" OR "dextrorphan" OR 
"dimercaprol" OR "dipyrone" OR "donepezil" OR "doxepin" OR "enoxaparin" OR 
"evolocumab" OR "fluorocitrate" OR "GLP-1 receptor agonists" OR "glyceryl trinitrate" OR 
"hemin" OR "icariin" OR "IGF-II" OR "indobufen" OR "isoproterenol" OR "K-134" OR 
"lafutidine" OR "laser ablation" OR "linolenic acid" OR "Lycopene" OR "Maggot debridement 
therapy" OR "mangafodipir" OR "midodrine" OR "misoprostol" OR "molsidomine" OR "Netrin-
1" OR "orexin-A" OR "percutaneous therapy" OR "pirenzepine" OR "probucol" OR 
"propentofylline" OR "protein kinase C inhibitors" OR "pyridine" OR "pyridostigmine" OR 
"quinidine" OR "Quinine" OR "reflexology" OR "rolipram" OR "ruthenium red" OR "S-Nitroso-
N-acetylpenicillamine" OR "saponins" OR "Sodium nitrite" OR "Tanezumab" OR "Tang-Luo-
Ning" OR "tetrahydrocannabinol" OR "thalamotomy" OR "Thymoquinone" OR "Tizanidine" 
OR "trandolapril" OR "troglitazone" OR "turmeric" OR "unsaturated fatty acids" OR "valsartan" 
OR "Waon therapy" OR "wortmannin" OR "ximelagatran" OR "zenarestat" OR "zonisamide" 
OR "2-(3-mercaptopropyl)pentanedioic acid" OR "2-AG" OR "A23187" OR "actovegin" OR 
"adrenergic agonists" OR "albendazole" OR "alpha-linolenic acid" OR "amiloride" OR 
"antitussive" OR "argatroban" OR "Aucubin" OR "becaplermin" OR "berberine" OR "bone 
marrow stem cells" OR "BPAU" OR "bupivicaine" OR "butyric acid" OR "caloric restriction" 
OR "candesartan" OR "carbenoxolone" OR "carotenoids" OR "caspase inhibitors" OR 
"charcoal" OR "chemical lumbar sympathectomy" OR "chlorpropamide" OR "chondroitinase 
ABC" OR "codeine" OR "cognitive behavior therapy" OR "cyproheptadine" OR "dermatan 
sulfate" OR "desferrioxamine" OR "desvenlafaxine" OR "dietary flaxseed" OR "diflunisal" OR 
"dihydroergotamine" OR "dimethyl fumarate" OR "ellagic acid" OR "epibatidine" OR 
"ethosuximide" OR "Fasudil" OR "fidarestat" OR "fingolimod" OR "fludrocortisone" OR 
"fluvoxamine" OR "fosfomycin" OR "fucoidan" OR "genistein" OR "green tea" OR "H-Wave 
device" OR "hexamethonium" OR "High-mobility group box-1 protein" OR "ifenprodil" OR 
"interferon alfa" OR "irbesartan" OR "ivermectin" OR "JZL184" OR "L-cysteine" OR "Lutonix 
drug-coated balloon" OR "Lyrica" OR "Metanx" OR "mifepristone" OR "mirtazapine" OR "N-
acetyl-l-cysteine" OR "natalizumab" OR "Neostigmine" OR "olesoxime" OR "oxytocin" OR 
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"palmitoylethanolamide" OR "passive exercise" OR "PD98059" OR "pergolide" OR "phenols" 
OR "phosphatidylethanolamine" OR "Photobiomodulation" OR "pifithrin-mu" OR "Plantaginis 
Semen" OR "PLX-PAD" OR "polytetrafluoroethylene-covered stents" OR "probenecid" OR 
"pyrrolidine dithiocarbamate" OR "quinpirole" OR "ranolazine" OR "rotenone" OR "RU38486" 
OR "shear rate therapy" OR "sialidase" OR "Silybin" OR "SKPs" OR "tetrahydrobiopterin" OR 
"thermal ablation" OR "thymosin beta4" OR "Tongxinluo" OR "trimethylamine" OR "TSPO" 
OR "1,5-isoquinolinediol" OR "2,3-dimercapto-1-propanesulfonic acid" OR "2-MPPA)" OR "5-
hydroxydecanoate" OR "Acidic fibroblast growth factor" OR "Aconitum" OR "Acorus calamus" 
OR "adenylate cyclase inhibitor" OR "ALDH Bright Cells" OR "Aleglitazar" OR "alfentanil" 
OR "alogliptin" OR "alpha-conotoxin Vc1.1" OR "alpha2-delta ligands" OR "AM424" OR 
"angelica" OR "anisodamine" OR "Anodyne Therapy System" OR "apomorphine" OR 
"Astragali" OR "Bee venom acupuncture" OR "Bimoclomol" OR "Biolimus" OR "bisoprolol" 
OR "BRX-220" OR "calcium gluconate" OR "calmangafodipir" OR "calpeptin" OR 
"carisoprodol" OR "Cerebrolysin" OR "cicaprost" OR "cinnamaldehyde" OR "Cobalt Chloride" 
OR "controlled reperfusion" OR "Cyclandelate" OR "cytidine" OR "Dark chocolate" OR 
"deferoxamine" OR "DHbetaE)" OR "dietary nitrate" OR "Dihydro-beta-erythroidine" OR 
"dihydropyridines" OR "diluted bee venom" OR "DMSO" OR "docosapentaenoic acid" OR 
"DRG stimulation" OR "DVC1-0101" OR "E2072" OR "egg white hydrolysate" OR "elcatonin" 
OR "electromagnetic neural stimulation" OR "electromagnetic radiation" OR "emodin" OR 
"ergocalciferol" OR "Ethoxyquin" OR "etodolac" OR "excimer laser ablation" OR "fibroblast 
growth factor 1" OR "Flupirtine" OR "fondaparinux" OR "gallic acid" OR "geldanamycin" OR 
"gluthatione" OR "glycyrrhizin" OR "HGF plasmid DNA" OR "hypoxia-inducible factor-
1alpha" OR "HIF-1alpha" OR "intravenous high-dose immunoglobulin" OR "kappa-opioid 
receptor agonist" OR "KRN5500" OR "KU-596" OR "leuprolide acetate" OR "linagliptin" OR 
"Lipid apheresis" OR "local ultrasound" OR "loperamide" OR "LV vectors" OR "maraviroc" OR 
"maximal strength training" OR "MEK inhibitors" OR "melanocortin" OR "metaxalone" OR 
"Methocarbamol" OR "methyl nicotinate" OR "Mibefradil" OR "monochromatic infrared photo 
energy" OR "MSG" OR "nalbuphine" OR "Neomycin" OR "neurofeedback" OR "niflumic acid" 
OR "nitrate consumption" OR "Nitrendipine" OR "nitric oxide donors" OR "norketamine" OR 
"NS1209" OR "nutrient deprivation" OR "Ocimum sanctum" OR "oestradiol" OR "oleic acid" 
OR "orange and blackcurrant juice" OR "Padma 28" OR "Paeoniae Radix" OR "percutaneous 
electrical nerve stimulation" OR "peripheral nerve grafts" OR "PFT-mu" OR "PGE1 alpha-
ciclodestrina" OR "phosphonic acid" OR "Photoablation" OR "physostigmine" OR "pulsed 
infrared light therapy" OR "PXT3003" OR "pyrrolidine-2,5-dione" OR "radiofrequency 
thermocoagulation" OR "retroviral vectors" OR "rimonabant" OR "ropinirole" OR "Rotarex 
thrombectomy" OR "sacubitril/valsartan" OR "saxagliptin" OR "scopolamine" OR "selegiline" 
OR "Selesorb" OR "skin-derived precursors" OR "Snake venoms" OR "Sodium ferulate" OR 
"sodium glutamate" OR "sonothrombolysis" OR "spicamycin derivative" OR "sulforaphane" OR 
"Sumatriptan" OR "TDP1" OR "tiron" OR "tocotrienol" OR "Tranilast" OR "trapidil" OR 
"triamcinolone" OR "trifluoperazine" OR "tropisetron" OR "TX14(A)" OR "U-50,488H" OR 
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"ultrasonic therapy" OR "URB937" OR "vibro-medical insole" OR "1,3-dimethyl-2,6-
dioxopurin-7-yl-alkylcarboxylic acids" OR "11beta-HSD1 inhibitors" OR "25)Mg-PMC16" OR 
"3,3,5-trimethylcyclohexanol" OR "3-Aminobenzamide" OR "4-phenylbutyric acid" OR "5-
phenyl-1-pentyne" OR "7-hydroxy-3,4-dihydrocadalin" OR "8-methoxypsoralen" OR "A-
134974" OR "A-834735" OR "AC591" OR "Acanthopanax" OR "ACEA" OR "acellular dermal 
regenerative tissue" OR "Achyranthis bidentata Blume" OR "acipimox" OR "activation of Nrf2" 
OR "active treadmill walking" OR "ACY-1083" OR "adipose-tissue-derived stem cells" OR 
"AGGF1" OR "aktovegin" OR "Alfa LMW1" OR "alpha-chymotrypsin" OR "Alstonia scholaris" 
OR "AM1241" OR "AM1714" OR "ambroxol" OR "aminoguanidine hydrochloride" OR 
"aminophylline" OR "ampakines" OR "AMPK activators" OR "anthranilic acid" OR "antimycin" 
OR "Apligraf" OR "ARA 290" OR "arm-crank exercise" OR "ascorbyl palmitate" OR "AVP-
923" OR "Azadirachta indica" OR "baicalein" OR "Baicalin" OR "BAIMAI-SAN" OR "BAK-
PLO" OR "bendazac lysine" OR "benserazide" OR "beperminogene perplasmid" OR "beta-
caryophyllene" OR "betulinic acid" OR "bis(maltolato)oxovanadium IV" OR "blueberry" OR 
"blunt microdissection catheter" OR "borneol" OR "bovine lactoferrin" OR "BRL-50481" OR 
"BRLP-42)" OR "bromelain" OR "bushi" OR "Butea monosperma" OR "Buyang Huanwu 
decoction" OR "Caffeic acid phenethyl ester" OR "calciparine" OR "calcium citrate" OR 
"calcium/magnesium infusion" OR "Calmare therapy" OR "Calmidazolium" OR "candoxatril" 
OR "Capnellene" OR "CD31(+) cell transplantation" OR "ceftaroline fosamil (CPT-F)" OR 
"CEP 03" OR "CEP protein adducts" OR "Chamomilla matricaria" OR "chemical ablation" OR 
"chlorogenic acid" OR "Chlorpheniramine" OR "cholecystokinin receptor antagonists" OR 
"cholecystokinin-8" OR "cholesterol-rich diet" OR "chromaffin cell grafts" OR "chuanxiong" 
OR "cinnamamide" OR "cinnamic acid" OR "circulator boot therapy" OR "citicoline" OR 
"COMP-Ang-1" OR "contrast-enhanced sonothrombolysis" OR "copper ions" OR "CQ" OR 
"crenotherapy" OR "Crocin" OR "cromakalim" OR "Crotoxin" OR "CX614" OR "CX729" OR 
"cyclobenzaprine" OR "Cymbalta" OR "Cystamine" OR "cytoflavin" OR "D-sorbitol" OR 
"daidzin" OR "daltroban" OR "danshen root" OR "Deguelin" OR "dexibuprofen" OR "Diallyl 
trisulfide" OR "dielectric barrier discharge plasma" OR "dietary folate intake" OR "dietary 
vitamin E" OR "diethylcarbamazine" OR "dihydrolipoic acid" OR "dimethicone" OR "diphenyl 
diselenide" OR "dronabinol" OR "EAntS-GS" OR "Effexor" OR "Electroconvulsive shock" OR 
"electromagnetic therapy" OR "elinogrel" OR "emfilermin)" OR "Entacapone" OR "Epac-
inhibitor" OR "EPAS1 gene" OR "epicatechin gallate" OR "eplerenone" OR "ergothioneine" OR 
"erucic acid" OR "ESI-09" OR "estradiol valerate" OR "ethanethiol" OR "ethopropazine" OR 
"eugenol" OR "exogenous recombination IL-4" OR "extracorporeal shock wave therapy" OR 
"extract of date fruit" OR "felbamate" OR "Fenfluramine" OR "fenugreek extract" OR "Ferula 
assa-foetida" OR "ferulic acid" OR "Fexofenadine" OR "fluocinolone acetonide" OR "focused 
ultrasound" OR "fumonisin B1" OR "gadolinium chloride" OR "GCSB-5" OR "Gentiopicroside" 
OR "ginsenoside Rb1" OR "Guizhi-shaoyao-zhimu decoction" OR "Hachimi-jio-gan" OR 
"hedysari" OR "hemangioblasts" OR "Huoxue Kangyuan decoction" OR "Hydroxytyrosol" OR 
"hyperforin" OR "hypericin" OR "Ilepatril" OR "imatinib mesylate" OR "increased intake of 
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folate" OR "IND01" OR "INGAP peptide" OR "injectable biomaterial" OR "integrin-linked 
kinase" OR "Intention controlled Myo-Feedback)" OR "interval walking" OR "intrathecal opioid 
infusion" OR "IRE1alpha siRNA" OR "isoprenaline" OR "isopropyl myristate" OR "Isoxsuprine 
hydrochloride" OR "itaconic acid" OR "J147" OR "Jiaweibugan" OR "Juglans regia L." OR 
"kaempferol" OR "Kamishoyosan" OR "ketogenic diet" OR "Kv7 channel activator" OR 
"lactoferrin" OR "leupeptin" OR "levo-corydalmine" OR "Levocarnitine acetyl 150" OR 
"levorphanol" OR "LiCl" OR "ligustrazine" OR "Linalool" OR "Lithospermi radix" OR 
"LM11A-31" OR "lomitapide" OR "Lotrafiban" OR "low frequency acoustic waveform" OR 
"low frequency magnetic fields" OR "low glucose diet" OR "low-frequency contact ultrasound 
debridement" OR "LPP1" OR "Maltol" OR "mangiferin" OR "Manidipine" OR "maprotiline" 
OR "MCC-257" OR "mCPP" OR "MDA19" OR "Me6TREN" OR "meclizine" OR "MenSCs" 
OR "menstrual blood-derived stem cell" OR "metamizol/paracetamol" OR 
"methylsulfonylmethane" OR "metyrapone" OR "microRNA let-7g" OR "mindfulness 
meditation" OR "minoxidil" OR "MnDPDP" OR "MnL4" OR "Momordica cymbalaria" OR 
"monosialotetrahexosylganglioside" OR "monosodium glutamate" OR "morin" OR "MPV-2426" 
OR "N(6)-cyclopentyladenosine" OR "nabilone" OR "naringin" OR "NCX 6550" OR "nefopam" 
OR "neoline" OR "neprilysin" OR "nerve autografts" OR "Neuragen PN" OR "Neurotin" OR 
"NF3" OR "niclosamide" OR "nicorandil" OR "NM-702" OR "Nmnat" OR "Nornicotine" OR 
"NSCs" OR "NT-702" OR "nylidrin" OR "oleanolic acid" OR "OP-1206" OR "pamoic acid" OR 
"pancreatic kininogenase" OR "parthenolide" OR "passive cycling" OR "pCK-HGF-X7" OR 
"PDE4B/7A dual inhibitor" OR "PDE5 inhibitor" OR "PDWHF" OR "pemirolast" OR 
"Peptide5" OR "percutaneous catheter-based therapies" OR "Phenoxodiol" OR "phenoxyphenyl 
pyridines" OR "phenyl-N-tert-butylnitrone" OR "Picrorhiza kurroa" OR "piler-light" OR 
"piperine" OR "piroxican" OR "pitavastatin" OR "placental-derived adherent stromal cells" OR 
"plantar vibration" OR "pneumatic compression boot" OR "polaprezinc" OR "potassium channel 
openers" OR "prifinium bromide" OR "pRLX" OR "Procyclidine" OR "progestins" OR 
"progestogen therapy" OR "Prograf" OR "programmable neuro-stimulator" OR 
"propionylcarnitine" OR "propolis" OR "prosaposin-derived 14-mer peptide" OR 
"proxyphylline" OR "psoralen" OR "Pulsed radiofrequency ablation" OR "pulsed radiofrequency 
neuromodulation" OR "Punica granatum L" OR "Punicalagins" OR "pyrimethamine" OR "QR-
333" OR "Quetiapine" OR "Racemic (R/S)-guaifenesin (1)" OR "rAd5/NR2B" OR 
"Recombinant Sema3A protein" OR "reparixin" OR "Ro5-4864" OR "rosemary" OR 
"Rosmarinic acid" OR "RSR13" OR "rutin" OR "safranal" OR "Salicylaldehyde" OR "salmon 
calcitonin" OR "salsalate" OR "Salvia officinalis" OR "Salvianolic acid B" OR "SAN-Gly" OR 
"Saposhnikovia divaricata Schiskin" OR "SDZ PCO-400" OR "sesame oil" OR "shellac" OR 
"silymarin" OR "SMC therapy" OR "SN gene therapy" OR "sodium hydrosulfide" OR "sodium 
sulfide" OR "sonication" OR "SP600125" OR "spironolactone" OR "SQ22536" OR "SR 
57746A" OR "subsensory electrical stimulation" OR "SVF-enriched fat graft" OR "synthetic 
exendin-4" OR "T-cell-pre-stimulated monocytes" OR "Tanshinone" OR "TAT-CBD3A6K" OR 
"Terbinafine" OR "tetracyclines" OR "tetramethylpyrazine" OR "thenoyltrifluoroacetone" OR 
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"thiorphan" OR "thiosalicylic acid" OR "torsemide" OR "Trehalose" OR "Treprostinil 
diethanolamine" OR "tretinoin" OR "trimethoxy flavone" OR "TRPA1/PDE4B/PDE7A ligand" 
OR "TT saponin" OR "Turpentine" OR "U 69593" OR "ulinastatin" OR "vascular regenerative 
therapy" OR "Vernonia cinerea" OR "vitamin D2" OR "vitamin K2" OR "Vitis vinifera" OR 
"VR-1 receptor modulators" OR "WR1065" OR "Xilonix" OR "xylazine" OR "yang-warming" 
OR "Yiqi Huayu" OR "zaprinast" OR "Zhenqing Capsule" OR "ziconotide") 
 6-1b2. Final Query 
 (#1 AND (#2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 
OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20)) NOT (#21 OR #22) 
 (#2 AND (#3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR 
#13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20)) NOT (#21 OR #22) 
 (#3 AND (#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR 
#14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20)) NOT (#21 OR #22) 
 (#4 AND (#5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR 
#15 OR #16 OR #17 OR #18 OR #19 OR #20)) NOT (#21 OR #22) 
 (#5 AND (#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR 
#16 OR #17 OR #18 OR #19 OR #20)) NOT (#21 OR #22) 
 (#6 AND (#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 
OR #17 OR #18 OR #19 OR #20)) NOT (#21 OR #22) 
 #7 AND (#8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 
OR #18 OR #19 OR #20)) NOT (#21 OR #22) 
 (#8 AND (#9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 
OR #19 OR #20)) NOT (#21 OR #22) 
 (#9 AND (#10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR 
#19 OR #20)) NOT (#21 OR #22) 
 (#10 AND (#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR 
#20)) NOT (#21 OR #22) 
 (#11 AND (#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20)) 
NOT (#21 OR #22) 
 (#12 AND (#13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20)) NOT (#21 
OR #22) 
 (#13 AND (#14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20)) NOT (#21 OR #22) 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                                                                                                                
Chapter 6 - Methodology                                                                                                                                        167 
 (#14 AND (#15 OR #16 OR #17 OR #18 OR #19 OR #20)) NOT (#21 OR #22) 
 (#15 AND (#16 OR #17 OR #18 OR #19 OR #20)) NOT (#21 OR #22) 
 (#16 AND (#17 OR #18 OR #19 OR #20)) NOT (#21 OR #22) 
 (#17 AND (#18 OR #19 OR #20)) NOT (#21 OR #22) 
 (#18 AND (#19 OR #20)) NOT (#21 OR #22) 
 (#19 AND (#20)) NOT (#21 OR #22) 
6-1b3. Treatment Discovery Validation 
 Treatment discovery validation (or contributing factor or characteristic validation) is 
defined as the process of demonstrating that the candidate treatment has not been used or 
proposed for application to PN/PAD.  This will be a function not only of the scope of PN/PAD 
assumed, but which databases are included in the definition of the PN/PAD literature. 
 The present study used the Pubmed version of Medline to retrieve the core PN/PAD 
literature, and used both the Pubmed and Thomson Reuters versions to determine previous use.  
All the treatment discoveries listed in the present monograph were not present in these versions 
of the PN/PAD literature. 
 There could be other ways to define the scope of PN/PAD.  There are also many other 
databases that could be searched for validation purposes, including other literature indexes, 
patent databases, books, magazine articles not indexed in Pubmed or Thomson Reuters, etc.  
Thus, the present validation has to be viewed as limited, even though it is the method used, and 
the databases used, by most (if not all) of the literature-based discovery community.  For 
discovery patenting purposes, or other purposes, more extensive validation and larger numbers of 
databases, may be required. 
 In summary, each candidate potential PN/PAD treatment retrieved using the above query 
required validation before becoming a potential PN/PAD treatment.  The candidate potential 
PN/PAD treatment was intersected with the core PN/PAD literature, and was validated only after 
this intersection showed orthogonality.   
 A final note of interest.  In the AD study [Kostoff, Porter, Buchtel, 2018], five potential 
AD treatment discoveries were shown as an illustrative example (ten were shown in the present 
study, in Chapter 2).  While none of those five were retrieved with the single query used to 
generate the ten illustrative examples in the present monograph, all five turn out to be treatment 
discoveries in the PN/PAD study as well (they passed the final validation step).  In those five 
examples, most of the biomarkers identified that changed in the desired directions were 
applicable to the PN/PAD study as well.  Because of the biomarker identification experience 
gained in the AD study, the PN/PAD study generated about four times the number of biomarkers 
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compared to the AD study.  Most of the AD biomarkers are contained within the list of PN/PAD 
biomarkers, especially those used for the actual AD discovery query. 
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Chapter 7 
TABLES 
Table 7A-1 - Existing PN/PAD Contributing Factors 
(CODE: #REC is the number of records that contain the phrase) 
#REC CONTRIBUTING FACTOR 
2507 chemotherapy 
2265 smoking 













 Statins [PN only] 
393 alcohol consumption 





340 peripheral nerve injury 
337 lifestyle 
332 leprosy 







201 chronic constriction injury 
196 docetaxel 























93 spinal cord injury 
91 melphalan 
91 zalcitabine 




85 renal transplantation 
83 axotomy 
83 liver transplant 
83 N-methyl-D-aspartate 
83 organophosphate pesticides 
82 burn 
81 injury-induced 
76 Vinca alkaloids 
76 vinorelbine 
74 etoposide 
73 coronary angioplasty 
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67 solvents 







61 Mycobacterium leprae 
 Simvastatin [PN only] 













49 environmental factors 
48 n-hexane 
48 occupational exposure 
 Atorvastatin [PN only] 





45 axonal injury 
44 Mercury 
44 metronidazole 
43 bariatric surgery 
43 gluten 
43 lamivudine 
42 hand-arm vibration 
42 levodopa 
39 lead exposure 
39 partial sciatic nerve ligation 
39 trastuzumab 









36 arachidonic acid 
35 2,5-hexanedione 
35 CSA 
35 Freund's adjuvant 
35 HTLV-1 
34 dichloroacetate 










30 carbon monoxide 
30 valproic acid 
29 Chlamydia pneumoniae 
29 Ischemia-reperfusion 
29 phenytoin 
28 cytotoxic agents 




27 varicella zoster virus 
26 dapsone 
26 metals 
26 vitamin B12 deficiencies 
25 cannabis 
25 Epstein Barr virus 
25 Infliximab 
25 Iron Deficiency 
25 neurotoxins 
25 nitrous oxide 
24 cadmium 
24 Campylobacter jejuni 
24 disulfiram 
24 immunization 
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24 purine 
23 5-hydroxytryptamine 
23 copper deficiency 
23 Cytosine Arabinoside 
23 Helicobacter pylori 
23 hepatitis B virus 
23 hypothermia 




22 heavy metals 
22 infectious agents 
22 spine surgery 
22 suramin 
21 Drug Abuse 
21 gp120 





20 epothilone B 
20 folate deficient 





19 high glucose 
19 hyperthermia 
19 protease inhibitors 
19 substance abuse 
19 tamoxifen 
19 tenofovir 
19 traumatic brain injury 
19 tumor necrosis factor (TNF)-alpha 
18 cytarabine 
18 lithium 
























14 Hydrogen peroxide 
14 Leflunomide 
14 mechanical compression 
14 mitoxantrone 
14 Mycobacterium tuberculosis 
13 carbon disulfide 
13 Cremophor EL 
13 etanercept 
13 FK506 





12 Ethylene oxide 
12 galactose 
12 hydroxyurea 
12 iron overload 
12 L-tryptophan 




12 Pseudomonas aeruginosa 
12 red meat 
12 SIV-infected 
12 tobacco smoke 
12 Trypanosoma cruzi 
12 zinc deficient 
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10 cranial irradiation 








10 proton pump inhibitor 
10 sodium arsenite 
10 sodium thiosulfate 
10 tri-ortho-cresyl phosphate 
9 air pollution 
9 allopurinol 
9 cetuximab 













8 abdominal surgery 
8 acetic acid 





8 dietary deficiency 
8 ergotamine tartrate 
8 HCT 
8 head trauma 
8 L-dopa 
8 methyl bromide 
8 nitrofurantoin 
8 pertussis toxin 
8 pollutants 
8 theophylline 
8 vitamin B6 deficiency 
7 Alemtuzumab 
7 amphotericin B 
7 atipamezole 
7 BCNU 






7 estramustine phosphate 
7 feline immunodeficiency virus 
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6 manual work 
6 medication-induced 






































5 Porphyromonas gingivalis 
5 propafenone 
5 riboflavin deficiency 
5 rofecoxib 
5 salt intake 
5 saquinavir 
5 Sleep deprivation 
5 Spirochetes 
5 strontium ranelate 
5 strychnine 






4 allyl isothiocyanate 
4 alpha-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid 
4 anabolic steroids 
4 CCNU 
4 Chloramphenicol 
4 diethylene glycol 
4 diisopropyl phosphorofluoridate 
 Fluvastatin [PN only] 
4 folic acid deficiency 
4 Fotemustine 
4 gold salts 
4 hydralazine 





4 methyl methacrylate 
4 methyl n-butyl ketone 
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4 phorbol 12-myristate 13-acetate 
4 polychlorinated biphenyls 
4 prions 









4 West Nile virus 
3 1,2-diacetylbenzene 
3 2-bp 








3 dimethyl sulfoxide 
3 Enfuvirtide 
3 Ertapenem 
3 estrogen deficiency 




3 gastric surgery 
3 gefitinib 




3 intermittent hypoxia 










3 physical trauma 
3 pirarubicin 
3 piroxicam 
3 Polysorbate 80 
3 pyrethroid 
3 rabies vaccine 







3 Theiler's murine encephalomyelitis 
virus 
















2 cerebral artery occlusion 
2 childhood infection 
2 Chlamydophila pneumoniae 
2 Chlorophenoxy herbicides 
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2 disopyramide 
2 doxifluridine 
2 environmental toxicants 
2 epoxy resins 
2 escitalopram 
2 ethionamide 
2 Ethylene glycol 







2 isonicotinic acid 
2 Karwinskia humboldtiana 
2 lansoprazole 
2 lasalocid sodium 
2 leptin deficiency 
2 levonorgestrel 
2 lopinavir 
2 methyl ethyl ketone 
2 methyllycaconitine 
2 Mitochondrial toxins 
2 MK-2206 
2 moxifloxacin 





2 nerve tissue vaccine 
2 nitroimidazole 
2 organochlorine pesticides 
2 organotin 




2 pentanedioic acid 
2 persistent organic pollutants 
















2 Toxocara canis 




2 ultraviolet irradiation 
2 uracil 
2 vaccination against MD 
2 valganciclovir 
2 vitamin E deficient 











1 1-naphthyl N-methylcarbamate 
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1 3-hydroxyfluorene 








1 Actinobacillus actinomycetemcomitans 
1 Acute nerve injuries 
1 ADI-PEG 20 
1 adverse upper limb postures 







1 androgenic steroids 
1 anti-tetanos vaccination 
1 antimony 
1 aprepitant 





1 bromate intoxication 
1 buckthorn 
1 Bunyaviridae 
1 butyl acetate 
1 C-4 methyl carbonate 
1 C2-ceramide 
1 cacodylic acid 
1 Calmette Guerin (BCG) vaccination 
1 Carbetimer 
1 carbofuran 
1 CGS 21595 
1 chemical warfare agents 
1 Chikungunya virus 
1 chlorinated solvents 
1 chlorofluorocarbon 
1 chromium deficiency 
1 chronic restraint stress 




1 cytolethal distending toxin 
1 darunavir 
1 DEG intoxication 
1 deltamethrin 
1 dextroamphetamine 
1 di-n-butyl-2,2-dichlorovinyl phosphate 
1 diacetylhydrazine 
1 dichlorohydrin 
1 diclofenac sodium 
1 dieldrin 
1 Dimethylamine borane 










1 erythrosin B 
1 ethanolamine 
1 ethyl chloride 
1 Ethylene chlorohydrin 
1 etonogestrel 
1 ferric ammonium citrate 
1 flavivirus 
1 Flecainide acetate 
1 Formic acid 
1 fractalkine-induced 
1 frequent monotonous movements 
1 fuel oils 
1 fungicides 





1 GYKI 52466 
1 Halaven 
1 hantavirus 
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1 Harmine 
1 hazardous chemicals 
1 HCH 
1 HPV vaccine 
1 hydroquinone 
1 ICI 118,551 
1 indocyanine green-loaded boronated 
maltodextrin 
1 indoxacarb 









1 lauric acid 
1 lomefloxacin 
1 lorlatinib 
1 Lyme vaccination 
1 m-tolyl methylcarbamate 
1 MAF intoxication 
1 MBK 
1 MD vaccination 
1 megestrol acetate 
1 metergoline 
1 methomyl 
1 methylcyclopentadienyl manganese 
tricarbonyl 





1 n-propyl bromine 
1 n-propylbromide 
1 naphthoquinone 





1 NP-polySA vaccine 












1 Perfluorooctanoic acid 





1 phosphatidyl ethanolamine 
1 phosphine 
1 photosensitive dyes 
1 phthalates 
1 physical overload 
1 piragliatin 
 Pitavastatin [PN only] 
1 polychlorinated dioxins 





1 radiofrequency radiation 
1 raltitrexed 
1 rapeseed oil 
1 refined carbohydrates 
1 repeated mechanical trauma 





1 S arvensis 
1 S. occidentalis intoxication 
1 samarium 
1 selenium-deficient diet 
1 silicones 
1 Sinemet 
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1 Sodium 3,5,6-trichloropyridin-2-ol 
1 sodium arsenate 
1 sodium bromate 
1 sulfonamide 
1 sulindac 
1 taenia solium 










1 trans fatty acids 
1 trans-nonachlor 
1 traumatic stress 
1 trichlornat 
1 Trichloroethane 













Table 7A-2 - Chemotherapy Co-Occurrences with other Causes 
(CODE: #CO-OCC is the number of co-occurrences of the two phrases)
#REC CAUSE #CO-
OCC 
2507 chemotherapy 2507 
985 paclitaxel 630 
570 cisplatin 392 
524 oxaliplatin 347 
324 taxanes 223 
347 vincristine 190 
329 radiation therapy 166 
230 carboplatin 161 
217 platinum 156 
503 Bortezomib 144 
196 docetaxel 133 
361 radiation 115 
323 cyclophosphamide 112 
140 5-fluorouracil 97 
162 doxorubicin 95 
351 thalidomide 93 
118 Taxol 70 
121 capecitabine 69 
86 alkaloids 64 
76 Vinca alkaloids 60 
96 gemcitabine 59 
76 vinorelbine 50 
74 etoposide 50 
111 methotrexate 46 
63 bevacizumab 45 
56 epirubicin 41 
54 ifosfamide 40 
62 fluorouracil 40 
61 eribulin 38 
60 cancer therapy 34 
545 depression 33 
90 proteasome inhibitors 31 
46 irinotecan 30 
821 HIV-1 28 
96 drug-induced 28 
708 infections 27 
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37 vinblastine 26 
31 bleomycin 25 
58 ixabepilone 23 
91 melphalan 21 
683 viruses 20 
184 antibiotics 20 
23 mitomycin C 18 
39 trastuzumab 17 
110 lenalidomide 17 
22 suramin 16 
49 acetone 16 
570 trauma 16 
27 adriamycin 16 
47 brentuximab 16 
28 cytotoxic agents 14 
18 cytarabine 13 
2265 smoking 13 
378 highly active antiretroviral 
therapy 
12 
332 leprosy 12 
17 Vindesine 12 
442 alcohol 11 
393 alcohol consumption 10 
19 tamoxifen 10 
31 gastrectomy 10 
121 tuberculosis 10 
96 NMDA 10 
201 chronic constriction injury 9 
64 formalin 9 
337 lifestyle 9 
340 peripheral nerve injury 9 
23 Cytosine Arabinoside 8 
11 Ara-C 8 
9 cetuximab 8 
357 anesthesia 7 
19 filgrastim 7 
91 zalcitabine 7 
83 N-methyl-D-aspartate 7 
13 Cremophor EL 7 
38 bone marrow 
transplantation 
7 
118 Iatrogenic 6 
14 mitoxantrone 6 
9 Taxotere 6 
9 topotecan 6 
61 cyclosporin 6 
20 epothilone B 6 
54 anticonvulsant 6 
54 Pyridoxine 6 
6 procarbazine 6 
296 Streptozotocin 6 
25 cannabis 5 
36 2',3'-dideoxycytidine 5 
46 isoniazid 5 
45 axonal injury 5 
148 stavudine 5 
10 cranial irradiation 5 
149 Arsenic 5 
37 interferon-alpha 5 
30 valproic acid 4 
26 metals 4 
59 naloxone 4 
7 pemetrexed 4 
16 interferons 4 
18 lithium 4 
19 hyperthermia 4 
67 solvents 4 
6 nedaplatin 4 
95 antiviral 4 
27 bacterium 4 
46 carfilzomib 4 
119 zidovudine 4 
29 phenytoin 4 
17 amyloid beta 4 
17 voriconazole 4 
10 sodium thiosulfate 4 
4 CCNU 4 
4 lomustine 4 
20 colchicine 3 
19 tumor necrosis factor 
(TNF)-alpha 
3 
22 heavy metals 3 
10 idazoxan 3 
23 hypothermia 3 
11 INH 3 
86 Mycobacterium 3 
745 dialysis 3 
38 herpesviruses 3 
1140 High cholesterol diet 3 
7 Nelarabine 3 
17 fludarabine 3 
17 itraconazole 3 
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12 cabazitaxel 3 
19 etanidazole 3 
93 spinal cord injury 3 
24 purine 3 
7 BCNU 3 
14 aluminum 3 
65 Zinc 3 
314 hepatitis 3 
3 gefitinib 3 
44 metronidazole 2 
43 lamivudine 2 
7 dacarbazine 2 
39 partial sciatic nerve ligation 2 
35 CSA 2 
32 AZT 2 
186 Hepatitis C Virus 2 
31 carrageenan 2 
31 glucocorticoids 2 
6 pertuzumab 2 
26 dapsone 2 
12 Panobinostat 2 
25 nitrous oxide 2 
5 meloxicam 2 
7 posaconazole 2 
21 tacrolimus 2 
5 bendamustine 2 
6 metoclopramide 2 
19 substance abuse 2 
8 nitrofurantoin 2 
107 cytomegalovirus 2 
96 malnutrition 2 
7 Velcade 2 
93 didanosine 2 
83 axotomy 2 
83 liver transplant 2 
82 burn 2 
15 fungi 2 
66 high fat diet 2 
61 Mycobacterium leprae 2 
7 beam radiation 2 
59 Acrylamide 2 
4 Fotemustine 2 
59 inactivity 2 
4 thiotepa 2 
4 Vp-16 2 
3 actinomycin D 2 
3 daunorubicin 2 
49 environmental factors 2 
3 nivolumab 2 
3 pirarubicin 2 
3 Polysorbate 80 2 
3 tegafur 2 
2 MK-2206 2 
6 Sorafenib 1 
44 Mercury 1 
7 methysergide 1 
19 traumatic brain injury 1 
48 n-hexane 1 
21 gp120 1 
7 PNB 1 
9 manganese 1 
12 hydroxyurea 1 
54 linezolid 1 
54 DDI 1 
13 carbon disulfide 1 
8 HCT 1 
10 carbamate 1 
7 sevoflurane 1 




81 injury-induced 1 
28 vitamin D deficient 1 




85 renal transplantation 1 
34 dichloroacetate 1 
125 advanced glycosylation end 
products 
1 
131 sedentary 1 
8 pertussis toxin 1 
508 hemodialysis 1 
18 rifampicin 1 
10 lentivirus 1 
7 estramustine phosphate 1 
8 pollutants 1 
5 strontium ranelate 1 
27 varicella zoster virus 1 
30 carbon monoxide 1 
35 HTLV-1 1 
12 nilotinib 1 
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35 Freund's adjuvant 1 
32 pesticides 1 
7 Alemtuzumab 1 
6 acyclovir 1 




15 H1N1 vaccine 1 
5 depolarization-induced 1 
25 neurotoxins 1 
31 Amiodarone 1 
14 enalapril 1 
14 Ganciclovir 1 
7 fluconazole 1 
14 Hydrogen peroxide 1 
5 MPTP 1 
4 allyl isothiocyanate 1 
35 2,5-hexanedione 1 
12 tobacco smoke 1 
4 hydralazine 1 
4 lactacystin 1 
4 lapatinib 1 
36 arachidonic acid 1 
4 mecamylamine 1 
4 NGF-induced 1 
4 ovariectomy 1 
4 psychological stress 1 
4 Salinomycin 1 
12 Ethylene oxide 1 
4 Toxoplasma 1 
23 5-hydroxytryptamine 1 
12 zinc deficient 1 
3 dactinomycin 1 
12 ethambutol 1 
3 dimethyl sulfoxide 1 
3 fialuridine 1 
38 lipopolysaccharide 1 
29 Ischemia-reperfusion 1 
9 indinavir 1 
13 FK506 1 
3 ruxolitinib 1 
3 Staurosporine 1 
3 sunitinib 1 
6 dideoxyinosine 1 
3 teniposide 1 
3 vorinostat 1 
2 Abraxane 1 
2 altretamine 1 
2 auranofin 1 
2 axitinib 1 
2 hexacarbons 1 
2 hexamethylmelamine 1 
2 methyllycaconitine 1 
6 medication-induced 1 
2 organotin 1 
2 ramucirumab 1 
2 streptomycin 1 
1 1,2-diaminocyclohexane 1 
1 Carbetimer 1 
1 Halaven 1 
1 megestrol acetate 1 
1 N-methylformamide 1 
1 raltitrexed 1 
1 samarium 1 
1 THP 1 





Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                                                                                                                
Chapter 7 - Tables and Figures                                                                                                                               182 
Table 7A-3 - Lifestyle Co-Occurrences with other Causes 
#REC CAUSE #CO-
OCC 
337 lifestyle 337 
2265 smoking 108 
131 sedentary 44 
1140 High cholesterol diet 35 
442 alcohol 18 
545 depression 11 
59 inactivity 11 
393 alcohol consumption 10 
2507 chemotherapy 9 
745 dialysis 6 
361 radiation 4 
570 trauma 3 
329 radiation therapy 3 
31 bleomycin 2 
821 HIV-1 2 
708 infections 2 
96 malnutrition 2 
60 cancer therapy 2 
12 red meat 2 
683 viruses 2 
28 vitamin D deficient 2 
43 bariatric surgery 2 
85 renal transplantation 2 
83 axotomy 2 
83 liver transplant 2 
125 advanced glycosylation end 
products 
2 
73 coronary angioplasty 2 
66 high fat diet 2 
5 salt intake 2 
46 irinotecan 1 
20 folate deficient 1 
296 Streptozotocin 1 
82 burn 1 
11 cocaine 1 
18 organic solvent 1 
21 Drug Abuse 1 
74 etoposide 1 
324 taxanes 1 
37 interferon-alpha 1 
985 paclitaxel 1 
67 solvents 1 
570 cisplatin 1 
118 Iatrogenic 1 
65 Zinc 1 
49 environmental factors 1 
14 Heroin 1 
508 hemodialysis 1 
10 contaminants 1 
14 mechanical compression 1 
9 ritonavir 1 
4 psychological stress 1 
3 physical trauma 1 
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2507 chemotherapy 2315 119 
2265 smoking 275 2124 
1140 High cholesterol diet 261 1004 
985 paclitaxel 874 69 
821 HIV-1 696 134 
745 dialysis 139 643 
708 infections 391 393 
683 viruses 548 182 
570 cisplatin 515 20 
570 trauma 269 260 
545 depression 326 251 
524 oxaliplatin 499 1 
508 hemodialysis 105 428 
503 Bortezomib 473 32 
442 alcohol 232 230 
412 statins 43  
393 alcohol consumption 266 147 
378 
highly active antiretroviral 
therapy 344 37 
361 radiation 189 134 
357 anesthesia 157 139 
351 thalidomide 333 56 
347 vincristine 328 11 
340 peripheral nerve injury 229 18 
337 lifestyle 78 283 
332 leprosy 206 19 
329 radiation therapy 245 50 
324 taxanes 303 7 
323 cyclophosphamide 288 80 
314 hepatitis 267 142 
296 Streptozotocin 273 40 
230 carboplatin 215 5 
217 platinum 194 6 
201 chronic constriction injury 179 1 
196 docetaxel 183 4 
186 Hepatitis C Virus 155 107 
184 antibiotics 101 102 
162 doxorubicin 148 17 
149 Arsenic 78 73 
148 stavudine 143 3 
140 5-fluorouracil 130 3 
131 sedentary 34 108 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                                                                                                                
Chapter 7 - Tables and Figures                                                                                                                               184 
125 
advanced glycosylation end 
products 74 74 
121 capecitabine 103  
121 tuberculosis 101 22 
119 zidovudine 115 4 
118 Iatrogenic 55 37 
118 Taxol 103 3 
111 methotrexate 93 22 
110 lenalidomide 102 19 
107 cytomegalovirus 76 36 
106 arthroplasty 36 48 
96 drug-induced 86 15 
96 gemcitabine 89 3 
96 malnutrition 54 43 
96 NMDA 84 3 
95 antiviral 84 28 
93 didanosine 88 2 
93 spinal cord injury 56 37 
91 melphalan 89 20 
91 zalcitabine 91 2 
90 proteasome inhibitors 79 3 
89 Staphylococcus 33 67 
86 alkaloids 83 3 
86 Mycobacterium 62 4 
85 renal transplantation 32 64 
83 axotomy 42 2 
83 liver transplant 65 17 
83 N-methyl-D-aspartate 64 5 
83 organophosphate pesticides 73 2 
82 burn 46 32 
81 injury-induced 64 2 
76 Vinca alkaloids 75 1 
76 vinorelbine 73 1 
74 etoposide 68 9 
73 coronary angioplasty 6 73 
67 solvents 52 5 
66 high fat diet 41 27 
65 Zinc 44 17 
64 formalin 56 1 
63 bevacizumab 57 4 
62 fluorouracil 57 1 
61 cyclosporin 43 21 
61 eribulin 57 2 
61 Mycobacterium leprae 42 1 
61 simvastatin 19  
60 cancer therapy 45 6 
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59 Acrylamide 49 2 
59 inactivity 23 42 
59 naloxone 50 2 
58 ixabepilone 51 1 
56 epirubicin 55 4 
55 Thallium 21 33 
54 anticonvulsant 49 2 
54 DDI 53 1 
54 ifosfamide 53  
54 linezolid 48 5 
54 Pyridoxine 49 4 
49 acetone 49  
49 environmental factors 23 32 
48 n-hexane 45  
48 occupational exposure 35 2 
47 atorvastatin 6  
47 Borrelia burgdorferi 34 5 
47 brentuximab 45 1 
46 carfilzomib 43 2 
46 irinotecan 43  
46 isoniazid 43 2 
45 axonal injury 32 4 
44 Mercury 28 9 
44 metronidazole 40 3 
43 bariatric surgery 29 12 
43 gluten 39 7 
43 lamivudine 41 4 
42 hand-arm vibration 17 2 
42 levodopa 40 1 
39 lead exposure 29 5 
39 partial sciatic nerve ligation 35  
39 trastuzumab 38 1 
38 bone marrow transplantation 29 7 
38 herpesviruses 23 6 
38 lipopolysaccharide 19 12 
37 interferon-alpha 34 11 
37 nevirapine 36 1 
37 thiamine deficiency 34 4 
37 vaccine 27 10 
37 vinblastine 35 3 
36 2',3'-dideoxycytidine 36  
36 arachidonic acid 7 27 
35 2,5-hexanedione 32  
35 CSA 31 5 
35 Freund's adjuvant 22 1 
35 HTLV-1 32 8 
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34 dichloroacetate 27 9 
34 hip arthroplasty 11 9 
33 bupivacaine 9 8 
32 AZT 31 2 
32 efavirenz 31 3 
32 pesticides 23 5 
31 Amiodarone 24 9 
31 bleomycin 26 4 
31 carrageenan 24  
31 gastrectomy 29 1 
31 glucocorticoids 21 17 
30 carbon monoxide 13 19 
30 valproic acid 27 2 
29 Chlamydia pneumoniae  29 
29 Ischemia-reperfusion 4 27 
29 phenytoin 24 2 
28 cytotoxic agents 25 7 
28 vitamin D deficient 8 23 
27 adriamycin 25 7 
27 bacterium 15 11 
27 insecticide 23  
27 varicella zoster virus 18 6 
26 dapsone 21 1 
26 metals 19 9 
26 vitamin B12 deficiencies 23 3 
25 cannabis 16 10 
25 Epstein Barr virus 20 5 
25 Infliximab 21 6 
25 Iron Deficiency 19 9 
25 neurotoxins 18 2 
25 nitrous oxide 16 4 
24 cadmium 5 16 
24 Campylobacter jejuni 23 1 
24 disulfiram 23  
24 immunization 18 5 
24 purine 19 5 
23 5-hydroxytryptamine 4 18 
23 copper deficiency 16 1 
23 Cytosine Arabinoside 20 2 
23 Helicobacter pylori 9 16 
23 hepatitis B virus 21 10 
23 hypothermia 12 9 
23 mitomycin C 22 1 
22 atenolol 2 20 
22 ciprofloxacin 14 8 
22 fluoroquinolone 19 2 
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22 heavy metals 18 5 
22 infectious agents 11 9 
22 spine surgery 8 5 
22 suramin 20  
21 Drug Abuse 10 16 
21 gp120 20 1 
21 lymphotropic virus 16 6 
21 Retroviruses 15 6 
21 tacrolimus 15 7 
21 vibration-induced 12  
20 colchicine 16 7 
20 epothilone B 19 1 
20 folate deficient 14 6 
20 nutritional deficiency 19 2 
20 pomalidomide 17 4 
19 2',3'-dideoxyinosine 18  
19 etanidazole 18  
19 filgrastim 16 3 
19 high glucose 17 3 
19 hyperthermia 11 2 
19 protease inhibitors 14 8 
19 substance abuse 11 7 
19 tamoxifen 14 4 
19 tenofovir 18 2 
19 traumatic brain injury 14 12 
19 
tumor necrosis factor (TNF)-
alpha 15 4 
18 cytarabine 17  
18 lithium 16  
18 organic solvent 11 3 
18 parasite 12 2 
18 rifampicin 12 3 
18 streptozocin 17 1 
17 amyloid beta 11 3 
17 chlorpyrifos 14  
17 cholecystokinin 16 1 
17 fludarabine 16 1 
17 interferon-gamma 10 3 
17 itraconazole 15 2 
17 Vindesine 17 1 
17 voriconazole 13 3 
16 interferons 14 3 
16 pravastatin 2  
16 syphilis 12 3 
15 cobalt 11 4 
15 fungi 10 4 
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15 H1N1 vaccine 11 4 
15 lisinopril 2 13 
15 Streptokinase 1 12 
14 aluminum 9 3 
14 enalapril 6 9 
14 Ganciclovir 11  
14 Heroin 10 3 
14 Hydrogen peroxide 6 6 
14 Leflunomide 14 1 
14 mechanical compression 9 7 
14 mitoxantrone 14  
14 Mycobacterium tuberculosis 12 1 
13 carbon disulfide 10 3 
13 Cremophor EL 12 1 
13 etanercept 11 4 
13 FK506 8 1 
13 H. pylori 5 9 
13 herbicide 11 1 
13 toluene 12  
12 cabazitaxel 11 1 
12 ethambutol 11 1 
12 Ethylene oxide 9 2 
12 galactose 11  
12 hydroxyurea 11  
12 iron overload 6 6 
12 L-tryptophan 10 1 
12 Lovastatin 4  
12 nilotinib 2 8 
12 Panobinostat 10 1 
12 Phenobarbital 10 1 
12 Pseudomonas aeruginosa 6 10 
12 red meat 4 7 
12 SIV-infected 12  
12 tobacco smoke 2 10 
12 Trypanosoma cruzi 8 1 
12 zinc deficient 12  
11 3'-azido-3'-deoxythymidine 10  
11 almitrine 11 1 
11 Ara-C 10  
11 cigarette smoke  10 
11 cocaine 6 8 
11 Coxsackie 10 1 
11 cyanide 10  
11 enterovirus 7 3 
11 fructose 9 2 
11 hydrogen sulfide 5 6 
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11 INH 10  
11 tellurium 9  
10 carbamate 7  
10 chloroquine 7 3 
10 coal 3 4 
10 contaminants 7 5 
10 cranial irradiation 8  
10 environmental exposure 3 5 
10 hypoxia-induced 3 9 
10 idazoxan 10  
10 lentivirus 7 2 
10 lysophosphatidic acid 7 1 
10 Misonidazole 10  
10 naltrindole 8  
10 phenol 5 2 
10 proton pump inhibitor 4 6 
10 sodium arsenite 10  
10 sodium thiosulfate 8 2 
10 tri-ortho-cresyl phosphate 10 1 
9 air pollution  8 
9 allopurinol 5 5 
9 cetuximab 8  
9 chronic stress 4 4 
9 dithiocarbamates 8  
9 HFD 7 3 
9 indinavir 9  
9 levofloxacin 8  
9 manganese 6 3 
9 methamidophos 9  
9 neuroleptic 5 1 
9 neurotoxicants 7 1 
9 resiniferatoxin 7  
9 ritonavir 7 2 
9 Taxotere 8  
9 topotecan 9 1 
8 abdominal surgery 5 2 
8 acetic acid 6 1 
8 Agent Orange 7 1 
8 amantadine 8 1 
8 antipsychotics 4 5 
8 Clioquinol 2  
8 CS2 6 2 
8 dietary deficiency 8 1 
8 ergotamine tartrate 1 7 
8 HCT 3 5 
8 head trauma 8 4 
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8 L-dopa 8 1 
8 methyl bromide 5  
8 nitrofurantoin 6 1 
8 pertussis toxin 5 3 
8 pollutants 2 6 
8 theophylline 1 6 
8 vitamin B6 deficiency 7 1 
7 Alemtuzumab 7 3 
7 amphotericin B 3 3 
7 atipamezole 6  
7 BCNU 7  
7 beam radiation 5 2 
7 benznidazole 7  
7 ciguatoxin 4  
7 dacarbazine 7  
7 dioxin 6  
7 dust 5  
7 estramustine phosphate 7 1 
7 feline immunodeficiency virus 5 3 
7 fine particulate matter  6 
7 fluconazole 4 2 
7 forskolin 1 3 
7 ipilimumab 7 1 
7 LCIG 7  
7 methanol 5 2 
7 methysergide 7 1 
7 Nelarabine 6  
7 pemetrexed 6  
7 PNB 4  
7 posaconazole 6 1 
7 sevoflurane 6 1 
7 Styrene 5  
7 sweeteners 5 2 
7 tetanus 6  
7 Velcade 7  
6 acyclovir 4 1 
6 adalimumab 4 3 
6 alloxan 6 1 
6 dideoxyinosine 6  
6 entecavir 6 1 
6 flecainide 5  
6 Germanium 5  
6 hydrocarbon 4 2 
6 LPA-induced 5  
6 manual work 4  
6 medication-induced 6 1 
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6 methyl mercury 4  
6 Methylglyoxal 5 2 
6 metoclopramide 6 1 
6 mipafox 6  
6 momelotinib 6  
6 N2O 4  
6 nedaplatin 6  
6 pertuzumab 6  
6 petroleum 5 2 
6 podophyllin 5  
6 procarbazine 6  
6 quinolinic acid 3 3 
6 Sorafenib 4 2 
6 sorbinil 5  
6 sugars 4 2 
5 1-bromopropane 4  
5 
2',3'-didehydro-3'-
deoxythymidine 4  
5 acitretin 4  
5 atazanavir 5 1 
5 bendamustine 4  
5 Brucella 4 1 
5 cerivastatin 1  
5 Chloroform 5  
5 Cryptococcus 2 2 
5 D-glucose 2 3 
5 dasatinib 2 2 
5 depolarization-induced 5  
5 gasoline 4  
5 
gonadotropin-releasing 
hormone 3 2 
5 hydroxychloroquine 5  
5 insulin-induced 4  
5 LY294002 4 1 
5 malathion 5  
5 meloxicam 5  
5 mineralocorticoid 2 3 
5 MPTP 2 1 
5 omeprazole 2 2 
5 palmitate 4 2 
5 Porphyromonas gingivalis  3 
5 propafenone 5  
5 riboflavin deficiency 4  
5 rofecoxib 2 4 
5 salt intake 1 5 
5 saquinavir 5  
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5 Sleep deprivation 4  
5 Spirochetes 4  
5 strontium ranelate 1 4 
5 strychnine 5  
5 traffic accidents 2 1 
5 trichloroethylene 5  
5 zymosan 4 1 
4 
2,3,7,8-tetrachlorodibenzo-p-
dioxin 4 1 
4 2-CdA 4  
4 acrylonitrile 4  




acid 4  
4 anabolic steroids 1 2 
4 CCNU 4  
4 Chloramphenicol 3 1 
4 diethylene glycol 4  
4 
diisopropyl 
phosphorofluoridate 4  
4 fluvastatin 2  
4 folic acid deficiency 3 1 
4 Fotemustine 3  
4 gold salts 4 1 
4 hydralazine 3 1 
4 inorganic mercury 3  
4 lactacystin 4  
4 lapatinib 4  
4 lomustine 4  
4 mecamylamine 4  
4 methyl methacrylate 2 2 
4 methyl n-butyl ketone 4  
4 mustard oil 3  
4 N,N-diethyldithiocarbamate 4  
4 NGF-induced 3  
4 ofloxacin 2 1 
4 ovariectomy 3  
4 p-bromophenylacetylurea 4  
4 paints 4  
4 Perhexiline 4 1 
4 
phorbol 12-myristate 13-
acetate 1 2 
4 polychlorinated biphenyls 3 1 
4 prions 3  
4 psychological stress 4 1 
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4 Salinomycin 4  
4 saxitoxin 2  
4 sertraline 2 2 
4 sofosbuvir 4 3 
4 squatting position 2 1 
4 thiotepa 4 1 
4 Toxoplasma 4  
4 Vp-16 4 1 
4 West Nile virus 4 2 
3 1,2-diacetylbenzene 3  
3 2-bp 3  
3 actinomycin D 3  
3 Bisphenol  3 
3 bradykinin-induced 3 1 
3 carcinogens  2 
3 citalopram 2 2 
3 Corynebacterium 2 1 
3 dactinomycin 2  
3 daunorubicin 3  
3 dimethyl sulfoxide 3 1 
3 Enfuvirtide 3  
3 Ertapenem 2 1 
3 estrogen deficiency  3 
3 ethyl acetate 3  
3 felodipine  3 
3 fialuridine 3  
3 formaldehyde 1  
3 gastric surgery 2 1 
3 gefitinib 3  
3 glue sniffing 1  
3 glues 2  
3 glutamate-induced 3  
3 intermittent hypoxia  3 
3 kainic acid 1  
3 lysophosphatidylcholine 1 2 
3 methamphetamine 1  
3 montelukast 3 2 
3 Mycobacterium avium 2 1 
3 naproxen 2 3 
3 natalizumab 3 2 
3 nivolumab 3  
3 pazopanib 3  
3 phenelzine 3  
3 physical trauma 2 1 
3 pirarubicin 3  
3 piroxicam 2 2 
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3 Polysorbate 80 2  
3 pyrethroid 2  
3 rabies vaccine 1  
3 restraint stress 3  
3 ruxolitinib 3  
3 sotalol 3  
3 Staurosporine 3  
3 sunitinib 2 1 
3 tegafur 3  
3 teniposide 2  
3 
Theiler's murine 
encephalomyelitis virus 1  
3 Treponema denticola  2 
3 undernutrition  3 
3 vorinostat 3 1 
2 1,1,1-trichloroethane 2  
2 1,2-Diethylbenzene 2  
2 Abraxane 2  
2 Adrenaline-induced  2 
2 altretamine 2  
2 ammonium chloride 1 1 
2 amphetamine 1 1 
2 auranofin 1  
2 axitinib 2  
2 benzene 2  
2 benzimidazole 1 1 
2 bexarotene 1  
2 busulfan 2 1 
2 cerebral artery occlusion 2 2 
2 childhood infection  1 
2 Chlamydophila pneumoniae  2 
2 Chlorophenoxy herbicides 2  
2 CNS infections 1 1 
2 daratumumab 2  
2 desogestrel  2 
2 dichlorvos 1  
2 Diethylbenzene 1  
2 Diphenylhydantoin 2 1 
2 disopyramide 1 1 
2 doxifluridine 2 1 
2 environmental toxicants 1  
2 epoxy resins  2 
2 escitalopram 1 1 
2 ethionamide 2  
2 Ethylene glycol 1  
2 ferric chloride  2 
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2 HDI 2  
2 hexacarbons 2  
2 hexamethylmelamine 2  
2 hydrazine 1  
2 Ibrutinib 2 1 
2 imidazole 2 1 
2 isonicotinic acid 2  
2 Karwinskia humboldtiana 1  
2 lansoprazole 2  
2 lasalocid sodium 1  
2 leptin deficiency 1 1 
2 levonorgestrel  1 
2 lopinavir 2 1 
2 methyl ethyl ketone 2  
2 methyllycaconitine 1 1 
2 Mitochondrial toxins 2  
2 MK-2206 2  
2 moxifloxacin 2  
2 
mumps measles rubella 
vaccination 2  
2 mycotoxins 2  
2 N-methylolacrylamide 1  
2 NaHS 1 1 
2 naphthalene 2  
2 nerve tissue vaccine 1  
2 nitroimidazole 2  
2 organochlorine pesticides 1 1 
2 organotin 2  
2 pancuronium bromide 2  
2 Paraquat 2  
2 Pefloxacin 2  
2 pembrolizumab 2  
2 pentanedioic acid 2  
2 persistent organic pollutants 1 1 
2 phenylmethylsulfonyl fluoride 2  
2 poliovirus 2  
2 ponatinib  1 
2 procainamide 2  
2 quinolone 2  
2 raltegravir 2  
2 ramucirumab 2  
2 recreational drugs 2 1 
2 REMSD 2  
2 romidepsin 2  
2 sepsis-induced  1 
2 streptomycin 2  
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2 surgery-induced 2  
2 TBE 2  
2 Teriflunomide 2 2 
2 Toxocara canis  2 
2 Treponema pallidum 2  
2 Trichlorfon 2  
2 trichlorophenol 2 1 
2 Trichloropropane 2  
2 ultraviolet irradiation  1 
2 uracil 2  
2 vaccination against MD 2 1 
2 valganciclovir 2  
2 vitamin E deficient 1  
2 western diet  2 
2 xenobiotic 2  
2 xylene 2  
1 1,2,4-triethylbenzene) 1  
1 1,2-diaminocyclohexane 1  
1 1,3-diethylbenzene 1  
1 1,4-diethylbenzene 1  
1 1-hydroxyphenanthrene  1 
1 1-naphthyl N-methylcarbamate 1  
1 
2,2-dichlorovinyl dibutyl 




methylcarbamate) 1  
1 2,4,5-T 1 1 
1 2,4-dichlorophenoxy 1  
1 2,4-dinitrophenol 1  
1 2-bromopropane 1  
1 2-hydroxyfluorene  1 
1 2-hydroxyphenanthrene  1 
1 
3,4-
dihydroxyphenylglycolaldehyde 1  
1 3,4-dimethyl-2,5-hexanedione 1  
1 
3-(2-carboxypiperazin-4-
yl)propyl-1-phosphonic acid 1  
1 3-hydroxyfluorene  1 
1 3-nitropropionic acid 1  
1 3-NPA 1  
1 acetylhydrazine 1  
1 acetylisoniazid 1  
1 aconitine 1  
1 acrolein 1  
1 Actinobacillus  1 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                                                                                                                
Chapter 7 - Tables and Figures                                                                                                                               197 
actinomycetemcomitans 
1 Acute nerve injuries 1  
1 ADI-PEG 20 1  
1 adverse upper limb postures 1  
1 aerosolize CNS tissue 1  
1 alpha-latrotoxin 1  
1 aminoglycoside-induced 1  
1 amprenavir 1  
1 androgenic steroids  1 
1 anti-tetanos vaccination 1 1 
1 antimony  1 
1 aprepitant 1  
1 atherogenic diet  1 
1 aurothioglucose 1  
1 BMS-275183 1  
1 bromate intoxication 1  
1 buckthorn 1  
1 Bunyaviridae 1  
1 butyl acetate 1  
1 C-4 methyl carbonate 1  
1 C2-ceramide 1  
1 cacodylic acid  1 
1 
Calmette Guerin (BCG) 
vaccination 1  
1 Carbetimer 1  
1 carbofuran 1  
1 CGS 21595 1  
1 chemical warfare agents 1  
1 Chikungunya virus 1  
1 chlorinated solvents 1  
1 chlorofluorocarbon 1  
1 chromium deficiency 1  
1 chronic restraint stress 1  
1 CP intoxication 1  
1 cuprizone 1  
1 Cycloleucine 1  
1 cypermethrin 1  
1 cytolethal distending toxin 1  
1 darunavir 1  
1 DEG intoxication 1  
1 dextroamphetamine 1  
1 
di-n-butyl-2,2-dichlorovinyl 
phosphate 1  
1 diacetylhydrazine 1  
1 dichlorohydrin 1  
1 dieldrin  1 
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1 Dimethylamine borane 1  
1 diquat 1  
1 DMAB 1  
1 DOPEGAL) 1  
1 dronedarone 1  
1 Dursban 1  
1 dyes 1  
1 efalizumab 1 1 
1 Efudex) 1  
1 erythrosin B 1 1 
1 ethanolamine 1 1 
1 ethyl chloride 1  
1 Ethylene chlorohydrin 1  
1 ferric ammonium citrate 1  
1 flavivirus 1  
1 Flecainide acetate 1  
1 Formic acid 1  
1 fractalkine-induced 1  
1 
frequent monotonous 
movements 1  
1 fuel oils 1  
1 gamma rays 1  
1 gemifloxacin 1  
1 gestodene  1 
1 griseofulvin 1  
1 GYKI 52466 1  
1 Halaven 1  
1 hantavirus 1  
1 hazardous chemicals 1  
1 hydroquinone 1  
1 ICI 118,551 1  
1 
indocyanine green-loaded 
boronated maltodextrin  1 
1 indoxacarb 1  
1 isofenphos 1  
1 isopropanol 1  
1 kerosene 1  
1 keyboarding 1  
1 L-tryptophan-induced 1  
1 labetalol  1 
1 lard 1  
1 lauric acid  1 
1 lorlatinib 1  
1 Lyme vaccination 1  
1 m-tolyl methylcarbamate 1  
1 MAF intoxication 1  
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1 MBK 1  
1 MD vaccination 1  
1 megestrol acetate 1 1 
1 metergoline 1  
1 methomyl 1  
1 
methylcyclopentadienyl 
manganese tricarbonyl 1  
1 
N-(2-chloroethyl)-N-ethyl-2-
bromobenzylamine 1  
1 n-heptane 1  
1 N-methylformamide 1  
1 n-propyl bromine 1  
1 naphthoquinone 1  
1 neuropathy-inducing drugs 1  
1 Nimorazole 1  
1 nintedanib 1  
1 nitromethane 1  
1 NP-polySA vaccine 1  
1 
O,O-diethyl O-3,5,6-trichloro-2-
pyridyl phosphorothioate 1  
1 OGD  1 
1 oligomycin 1  
1 OS-induced 1  
1 OspA-vaccinated 1  
1 oxychlordane  1 
1 oxygen-glucose deprivation  1 
1 p,p'-DDE  1 
1 PAHs  1 
1 pantoprazole) 1  
1 perazine 1  
1 Perfluorooctanoic acid  1 
1 
peroxisomal acyl-CoA oxidase 
deficiency 1  
1 PFOA  1 
1 phenothiazine 1  
1 phosphamidon/mevinphos 1  
1 phosphatidyl ethanolamine 1 1 
1 photosensitive dyes 1  
1 phthalates  1 
1 physical overload 1  
1 piragliatin 1  
1 polychlorinated dioxins 1  
1 
Polycyclic aromatic 
hydrocarbons  1 
1 Pralatrexate 1  
1 pronase 1  
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1 propylthiouracil 1  
1 RA-induced 1  
1 raltitrexed 1  
1 rapeseed oil 1 1 
1 refined carbohydrates  1 
1 repeated mechanical trauma 1  
1 repetitive work 1  
1 Repin 1  
1 Revlimid 1  
1 rotenone-induced 1  
1 S arvensis 1  
1 S. occidentalis intoxication 1  
1 samarium 1  
1 selenium-deficient diet 1  
1 silicones 1  
1 Sinemet 1  
1 
Sodium 3,5,6-trichloropyridin-
2-ol 1  
1 sodium arsenate 1  
1 sodium bromate 1  
1 sulfonamide 1  
1 sulindac 1  
1 Tannerella forsythia  1 
1 temozolomide 1  
1 temsirolimus 1  
1 teriparatide 1 1 
1 tert-butylhydroperoxide 1  
1 tetralin) 1  
1 trabectedin  1 
1 trans fatty acids  1 
1 trans-nonachlor  1 
1 traumatic stress  1 
1 trichlornat 1  
1 Trichloroethane 1  
1 trimethyltin 1  
1 triphenyltin 1  
1 TTR-induced 1  
1 tungsten  1 
1 vecuronium bromide 1  
1 X-radiation 1  
1 zileuton 1  
1 Zoloft  1 
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1308 artery bypass grafting 
1228 angioplasty 
828 stents 







541 endovascular treatment 




450 bypass surgery 
449 diet 







vascular endothelial growth 
factor 
337 antiplatelet therapy 
317 opioid 
288 supplementation 
266 coronary intervention 








207 vitamin B12 
206 nerve growth factor 
190 smoking cessation 
189 Spinal Cord Stimulation 









131 mononuclear cells 





117 Vitamin D 
111 duloxetine 
110 anticonvulsants 
110 enzyme inhibitors 














86 Alpha lipoic acid 
80 carbamazepine 
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71 Ticlopidine 
69 methylprednisolone 





63 surgical decompression 
62 ethanol 
62 superoxide dismutase 
61 simvastatin 
59 Acetyl-l-carnitine 
59 acetylsalicylic acid 
59 hyperbaric oxygen 
59 Testosterone 
58 
angiotensin converting enzyme 
inhibitor 
57 nitinol stents 
55 antithrombotic therapy 
55 carnitine 
54 Pyridoxine 
54 steroid therapy 
52 BDNF 
52 hepatocyte growth factor 
52 iloprost 
51 AA 
51 epidermal growth factor 
51 Mesenchymal Stem Cells 
51 













39 aerobic exercise 
38 antiepileptic drugs 
38 valproic acid 
37 anesthetics 
37 drug-eluting balloons 
37 glucocorticoid 
36 apheresis 
36 distal bypass 
36 niacin 
36 stem cell therapy 
36 venlafaxine 
35 Cannabinoids 
35 directional atherectomy 
34 nitroglycerin 
34 urokinase 




32 Orbital atherectomy 
32 prasugrel 




30 Gamma-aminobutyric acid 
30 propionyl-L-carnitine 
29 lamotrigine 














27 serotonin reuptake inhibitors 
27 verapamil 
26 botulinum toxin 
26 diphenhydramine 
26 growth hormone 
26 hormone replacement therapy 
26 massage 
26 minocycline 
26 sodium nitroprusside 
25 antimicrobial therapy 
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24 immunoglobulin therapy 
24 insulin-like growth factor-I 
24 omega-3 fatty acids 
24 pulse therapy 
23 docosahexaenoic acid 
23 fish oil 
23 hypothermia 
22 alpha-tocopherol 





22 Vitamin B1 
21 calcium channel blocker 
21 NSAIDs 
21 oxycodone 
21 phosphodiesterase inhibitor 
21 rivaroxaban 
21 tacrolimus 
20 bone marrow mononuclear cells 
20 fentanyl 





19 neuroactive steroids 
19 phentolamine 
18 ascorbic acid 
18 balloon dilatation 
18 chelation therapy 
18 eicosapentaenoic acid 
18 indomethacin 
18 lithium 





17 laser therapy 
17 mycophenolate mofetil 
17 rifampin 
17 strength training 
17 thienopyridines 
17 viral vectors 
17 whole-body vibration 
16 androgen 
16 beraprost sodium 
16 ceftriaxone 
16 chlorambucil 
16 Coenzyme Q10 


















14 anti-inflammatory agents 










14 herbal medicines 
14 memantine 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                                                                                                                
Chapter 7 - Tables and Figures                                                                                                                               204 
14 myo-inositol 
















13 Olive oil 
13 sulodexide 





























10 mesenchymal stromal cells 
10 milnacipran 
10 PAR-1 antagonists 
10 plaque excision 
10 Ranitidine 
10 Resveratrol 
10 scrambler therapy 
10 tai chi 
10 thiazolidinediones 
10 uridine 
10 vitamin D3 
10 WIN 55,212-2 
9 allopurinol 







9 electromagnetic field 
9 everolimus 
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8 mannitol 
8 manual therapy 
8 Menhaden oil 
8 menthol 
8 muscimol 
























7 factor Xa inhibitors 
7 gamma-globulin 




7 histone deacetylase inhibitors 
7 Huangqi Guizhi Wuwu 
7 interferon-beta 
7 Isosorbide dinitrate 







7 Peripheral nerve decompression 
7 PGB 
7 plasminogen activators 










6 CB1/CB2 agonist 
6 coumarin 
6 EGb 761 
6 erlotinib 
6 HC-030031 













6 Sarpogrelate hydrochloride 
6 shockwave therapy 
6 THC 
6 Thiamine pyrophosphate 
6 thioctic acid 
6 trimetazidine 
6 Vitamin B complex 
6 Zilver PTX stent 
5 acetylcholine-induced 




5 cholinesterase inhibitor 
5 clomipramine 
5 diazepam 
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5 Heparin cofactor II 
5 hydrotherapy 
5 hydroxychloroquine 








5 naftidrofuryl oxalate 
5 NGX-4010 











































4 GLP-1 receptor agonists 








4 laser ablation 
4 linolenic acid 
4 Lycopene 
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4 rolipram 
4 ruthenium red 
4 S-Nitroso-N-acetylpenicillamine 
4 saponins 











4 unsaturated fatty acids 
4 valsartan 












3 adrenergic agonists 
3 albendazole 







3 bone marrow stem cells 
3 BPAU 
3 bupivicaine 
3 butyric acid 




3 caspase inhibitors 
3 charcoal 
3 chemical lumbar sympathectomy 
3 Chinese herbs 
3 chlorpropamide 
3 chondroitinase ABC 
3 codeine 
3 cognitive behavior therapy 
3 CXCR4 antagonist 
3 cyproheptadine 
3 dermatan sulfate 
3 desferrioxamine 
3 desvenlafaxine 
3 dietary flaxseed 
3 diflunisal 
3 dihydroergotamine 
3 dimethyl fumarate 











3 H-Wave device 
3 hexamethonium 
3 High-mobility group box-1 protein 
3 ifenprodil 
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3 palmitoylethanolamide 






3 Plantaginis Semen 
3 PLX-PAD 














3 thermal ablation 










2 Acidic fibroblast growth factor 
2 Aconitum 
2 Acorus calamus 
2 adenylate cyclase inhibitor 




2 alpha-conotoxin Vc1.1 










2 blackcurrant juice 
2 BRX-220 







2 Cobalt Chloride 
2 controlled reperfusion 
2 Cyclandelate 
2 cytidine 
2 Dark chocolate 
2 deferoxamine 
2 DHbetaE) 
2 dietary nitrate 
2 Dihydro-beta-erythroidine 
2 dihydropyridines 
2 diluted bee venom 
2 Dioscoreae rhizoma 
2 DMSO 
2 docosapentaenoic acid 
2 DRG stimulation 
2 DVC1-0101 
2 E2072 










2 fibroblast growth factor 1 
2 Flupirtine 
2 fondaparinux 
2 gallic acid 
2 geldanamycin 
2 gluthatione 
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2 glycyrrhizin 







2 kappa-opioid receptor agonist 
2 KRN5500 
2 KU-596 
2 leuprolide acetate 
2 linagliptin 
2 loperamide 
2 LV vectors 
2 maraviroc 
2 maximal strength training 




2 methyl nicotinate 
2 Mibefradil 
2 
monochromatic infrared photo 
energy 




2 niflumic acid 
2 nitrate consumption 
2 pyrrolidine-2,5-dione 














acellular dermal regenerative 
tissue 
1 Achyranthis bidentata Blume 
1 acipimox 
1 activation of Nrf2 
1 active treadmill walking 
1 ACY-1083 
1 adipose-tissue-derived stem cells 
1 AGGF1 
1 aktovegin 
1 Alfa LMW1 
1 alpha-chymotrypsin 




1 aminoguanidine hydrochloride 
1 aminophylline 
1 ampakines 
1 AMPK activators 
1 anthranilic acid 
1 antimycin 
1 Apligraf 
1 ARA 290 
1 arm-crank exercise 
1 ascorbyl palmitate 
1 AVP-923 





1 bendazac lysine 
1 benserazide 
1 beperminogene perplasmid 
1 beta-caryophyllene 
1 betulinic acid 
1 bis(maltolato)oxovanadium IV 
1 blueberry 
1 blunt microdissection catheter 
1 borneol 





1 Butea monosperma 
1 Buyang Huanwu decoction 
1 Caffeic acid phenethyl ester 
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1 calciparine 
1 calcium citrate 
1 calcium/magnesium infusion 




1 ceftaroline fosamil (CPT-F) 
1 CEP 03 
1 CEP protein adducts 
1 Chamomilla matricaria 
1 chemical ablation 






1 cholesterol-rich diet 
1 chromaffin cell grafts 
1 chuanxiong 
1 cinnamamide 
1 cinnamic acid 





















1 danshen root 
1 Deguelin 
1 dexibuprofen 
1 Diallyl trisulfide 
1 
dielectric barrier discharge 
plasma 
1 dietary folate intake 
1 dietary vitamin E 
1 diethylcarbamazine 
1 dihydrolipoic acid 
1 dimethicone 




1 Electroconvulsive shock 





1 EPAS1 gene 
1 epicatechin gallate 
1 eplerenone 
1 ergothioneine 
1 erucic acid 
1 ESI-09 




1 exogenous recombination IL-4 
1 
extracorporeal shock wave 
therapy 
1 extract of date fruit 
1 felbamate 
1 Fenfluramine 
1 fenugreek extract 
1 Ferula assa-foetida 
1 ferulic acid 
1 Fexofenadine 
1 fluocinolone acetonide 
1 fumonisin B1 
1 gadolinium chloride 
1 GCSB-5 
1 Gentiopicroside 
1 ginsenoside Rb1 
1 Guizhi-shaoyao-zhimu decoction 
1 Hachimi-jio-gan 
1 hedysari 
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1 hemangioblasts 





1 imatinib mesylate 
1 immunoadsorber 
1 increased intake of folate 
1 IND01 
1 INGAP peptide 
1 injectable biomaterial 




1 interval walking 
1 intrathecal opioid infusion 
1 IRE1alpha siRNA 
1 isoprenaline 
1 isopropyl myristate 
1 Isoxsuprine hydrochloride 
1 itaconic acid 
1 J147 
1 Jiaweibugan 
1 Juglans regia L. 
1 kaempferol 
1 Kamishoyosan 
1 ketogenic diet 













1 low frequency acoustic waveform 
1 low frequency magnetic fields 
1 low glucose diet 
1 












1 medical herbs 
1 





1 microRNA let-7g 















1 nerve autografts 











1 oleanolic acid 
1 OP-1206 
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1 pamoic acid 
1 pancreatic kininogenase 
1 parthenolide 
1 passive cycling 
1 pCK-HGF-X7 
1 PDE4B/7A dual inhibitor 









1 phenoxyphenyl pyridines 
1 phenyl-N-tert-butylnitrone 








1 plantar vibration 
1 pneumatic compression boot 
1 polaprezinc 
1 potassium channel openers 




1 progestogen therapy 
1 Prograf 
















1 Racemic (R/S)-guaifenesin (1) 
1 rAd5/NR2B 










1 salmon calcitonin 
1 salsalate 
1 Salvia officinalis 
1 Salvianolic acid B 
1 SAN-Gly 
1 Saposhnikovia divaricata Schiskin 
1 SDZ PCO-400 




1 SMC therapy 
1 SN gene therapy 
1 sodium hydrosulfide 




1 SR 57746A 
1 subsensory electrical stimulation 
1 SVF-enriched fat graft 
1 synthetic exendin-4 








1 thiosalicylic acid 
1 torsemide 
1 Trehalose 
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1 Treprostinil diethanolamine 
1 tretinoin 
1 trimethoxy flavone 
1 TRPA1/PDE4B/PDE7A ligand 
1 TT saponin 
1 Turpentine 
1 U 69593 
1 ulinastatin 
1 vascular regenerative therapy 
1 Vernonia cinerea 
1 vitamin D2 
1 vitamin K2 
1 Vitis vinifera 





1 Yiqi Huayu 
1 zaprinast 
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1920 revascularization 1920 
5105 surgery 776 
2402 amputation 615 
1228 angioplasty 403 
828 stents 300 
1308 artery bypass grafting 276 
541 endovascular treatment 178 
450 bypass surgery 127 
507 vascular surgery 121 
1358 walking 120 
3638 drug 119 
1328 exercise 117 
1766 inhibitor 76 
588 operation 73 
576 aspirin 73 
266 coronary intervention 71 
499 implantation 71 
337 antiplatelet therapy 68 
233 endarterectomy 62 
489 angiogenesis 59 
745 dialysis 58 
370 statin 56 
353 Clopidogrel 54 
382 catheter 52 
812 growth factor 51 
215 Cilostazol 44 
632 medications 38 
68 drug-coated balloons 33 
190 smoking cessation 33 
459 rehabilitation 31 
107 cell therapy 31 
57 nitinol stents 24 
349 
vascular endothelial growth 
factor 22 
754 insulin 21 
252 antihypertensive agents 20 
172 Gene therapy 19 
167 heparin 18 
37 drug-eluting balloons 17 
221 anticoagulant 17 
447 glycemic control 16 
420 Ligation 13 
44 vorapaxar 13 
36 stem cell therapy 13 
35 directional atherectomy 12 
449 diet 11 
110 enzyme inhibitors 11 
131 mononuclear cells 10 
32 Orbital atherectomy 10 




17 amlodipine 8 
22 prostanoids 8 
77 dipyridamole 8 
189 Spinal Cord Stimulation 7 
11 chlorthalidone 7 
567 analgesic 7 
52 iloprost 7 
36 distal bypass 7 
118 warfarin 7 
31 covered stents 7 
40 ticagrelor 6 
19 DAPT 6 
58 
angiotensin converting enzyme 
inhibitor 6 
103 pentoxifylline 6 
150 hypoxia 6 
51 Mesenchymal Stem Cells 6 
15 lisinopril 6 
10 plaque excision 5 
59 hyperbaric oxygen 5 
67 near-infrared 5 
172 IL-6 5 




61 simvastatin 5 
8 external counterpulsation 5 
21 rivaroxaban 5 
47 atorvastatin 4 
71 Ticlopidine 4 
52 hepatocyte growth factor 4 
14 abciximab 4 
15 Streptokinase 4 
14 bivalirudin 4 
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21 calcium channel blocker 4 
59 acetylsalicylic acid 4 
22 cryoplasty 4 
160 adenosine 4 
34 nitroglycerin 4 
34 urokinase 4 
30 propionyl-L-carnitine 4 
51 AA 3 
36 apheresis 3 
7 Viabahn endoprosthesis 3 
4 percutaneous therapy 3 
21 phosphodiesterase inhibitor 3 
91 Prostaglandin 3 
6 Zilver PTX stent 3 
5 SCH 530348 3 
100 haemodialysis 3 
27 verapamil 3 
3 Lutonix drug-coated balloon 3 
10 mesenchymal stromal cells 2 
288 supplementation 2 
24 bFGF 2 
36 niacin 2 
14 Aldehyde 2 




103 Acupuncture 2 
5 drug-coated stents 2 
32 prasugrel 2 
10 GP IIb/IIIa inhibitors 2 
19 alprostadil 2 
62 superoxide dismutase 2 
8 eptifibatide 2 
18 balloon dilatation 2 
3 fucoidan 2 
50 Nicotine 2 
3 passive exercise 2 
2 controlled reperfusion 2 
156 prednisone 1 
4 enoxaparin 1 
10 PAR-1 antagonists 1 
156 Electrical stimulation 1 
25 
Transcutaneous electrical nerve 
stimulation 1 
25 nicotinamide 1 
4 probucol 1 
15 osteopontin 1 
39 aerobic exercise 1 
7 acetylcysteine 1 
25 cannabis 1 
17 laser therapy 1 
317 opioid 1 
4 laser ablation 1 
59 Testosterone 1 
4 canagliflozin 1 
4 bosentan 1 
5 reteplase 1 
10 thiazolidinediones 1 
6 trimetazidine 1 
22 rapamycin 1 
55 carnitine 1 
19 ezetimibe 1 
17 thienopyridines 1 
17 viral vectors 1 
33 ramipril 1 
8 tirofiban 1 
5 epoprostenol 1 
9 perindopril 1 
101 plasma exchange 1 
16 androgen 1 
4 evolocumab 1 
9 allopurinol 1 
7 plasminogen activators 1 
14 enalapril 1 
7 cryotherapy 1 
29 Lumbar sympathectomy 1 
9 captopril 1 
9 Carvedilol 1 
4 Cinacalcet 1 
16 losartan 1 
28 N-acetylcysteine 1 
28 nifedipine 1 
12 hydrochlorothiazide 1 
5 P2Y12 inhibitor 1 
4 glyceryl trinitrate 1 
19 buflomedil 1 
7 factor Xa inhibitors 1 
9 everolimus 1 
5 hydrotherapy 1 
15 digoxin 1 
26 diphenhydramine 1 
26 growth hormone 1 
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26 hormone replacement therapy 1 
15 glycosaminoglycan 1 
12 tempol 1 
26 sodium nitroprusside 1 
4 trandolapril 1 
3 argatroban 1 
3 bone marrow stem cells 1 
51 
peripheral blood mononuclear 
cells 1 
18 chelation therapy 1 
14 Picotamide 1 
2 Acidic fibroblast growth factor 1 
2 Biolimus 1 
2 bisoprolol 1 
9 vitamin K antagonist 1 
2 nitrate consumption 1 
1 blunt microdissection catheter 1 
1 cholesterol-rich diet 1 
1 circulator boot therapy 1 




1 spironolactone 1 
1 torsemide 1 
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812 growth factor 812 
349 
vascular endothelial growth 
factor 301 
489 angiogenesis 216 
206 nerve growth factor 174 
3638 drug 103 
1766 inhibitor 85 
5105 surgery 82 
172 Gene therapy 78 
2402 amputation 61 
52 hepatocyte growth factor 52 
51 epidermal growth factor 51 
1920 revascularization 51 
150 hypoxia 31 
420 Ligation 28 
1358 walking 26 
1328 exercise 25 
107 cell therapy 25 
754 insulin 23 
24 bFGF 22 
42 Neurotrophins 21 
1308 artery bypass grafting 20 
1228 angioplasty 18 
33 neurotrophin-3 18 
52 BDNF 17 
28 GDNF 16 
172 IL-6 15 
131 mononuclear cells 15 
215 Cilostazol 14 




411 corticosteroid 11 
567 analgesic 11 
499 implantation 11 
449 diet 10 
240 PNS 10 
147 capsaicin 10 
24 insulin-like growth factor-I 9 
36 stem cell therapy 9 
167 heparin 9 
78 anthracycline 9 
14 CNTF 8 
189 Spinal Cord Stimulation 8 
317 opioid 7 
17 viral vectors 7 
242 Gabapentin 7 
447 glycemic control 7 
288 supplementation 6 
588 operation 6 
103 pentoxifylline 6 
51 
peripheral blood mononuclear 
cells 6 
59 hyperbaric oxygen 6 
59 Acetyl-l-carnitine 5 
20 bone marrow mononuclear cells 5 
576 aspirin 5 
67 erythropoietin 5 
450 bypass surgery 5 
156 Electrical stimulation 5 
233 pregabalin 5 
228 antidepressant 5 
632 medications 5 
382 catheter 4 
65 Zinc 4 
9 Angiogenic gene therapy 4 
22 rapamycin 4 
26 growth hormone 4 
86 Alpha lipoic acid 4 
117 Vitamin D 4 
80 folic acid 3 
12 all-trans retinoic acid 3 
4 Tanezumab 3 
26 diphenhydramine 3 
31 progesterone 3 
4 4-methylcatechol 3 
30 propionyl-L-carnitine 3 
54 Pyridoxine 3 
14 cimetidine 3 
61 simvastatin 3 
541 endovascular treatment 3 
353 Clopidogrel 3 
47 aldose reductase inhibitor 3 
80 carbamazepine 3 
29 lamotrigine 3 
55 carnitine 2 
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78 GM1 2 
118 warfarin 2 
9 electromagnetic field 2 
22 topiramate 2 
190 smoking cessation 2 
87 Amitriptyline 2 
21 tacrolimus 2 
4 Del-1 2 
4 Netrin-1 2 
91 Prostaglandin 2 
7 DA-9801 2 
337 antiplatelet therapy 2 
27 glutamine 2 
52 iloprost 2 
4 IGF-II 2 
507 vascular surgery 2 
2 Acidic fibroblast growth factor 2 
6 erlotinib 2 
16 PGE2 2 
21 NSAIDs 2 
4 wortmannin 2 
828 stents 2 
27 serotonin reuptake inhibitors 2 
15 osteopontin 2 
65 magnesium 2 
25 cannabis 2 
3 PD98059 2 
207 vitamin B12 2 
103 Acupuncture 2 
25 curcumin 2 
2 fibroblast growth factor 1 2 
126 vitamin E 2 
118 plasmapheresis 2 
73 thiamine 2 
111 duloxetine 2 
3 fucoidan 1 
28 electroacupuncture 1 
3 passive exercise 1 
28 oxcarbazepine 1 
14 TCA 1 
25 
Transcutaneous electrical nerve 
stimulation 1 
8 Protamine 1 
98 lidocaine 1 
10 lentivirus 1 
745 dialysis 1 
26 massage 1 
370 statin 1 
17 laser therapy 1 
459 rehabilitation 1 
26 minocycline 1 
59 Testosterone 1 
7 Peripheral nerve decompression 1 
252 antihypertensive agents 1 
13 celecoxib 1 
8 taurine 1 
6 trimetazidine 1 
221 anticoagulant 1 
110 enzyme inhibitors 1 
8 Tetrodotoxin 1 
24 Goshajinkigan 1 
69 methylprednisolone 1 
8 thiols 1 
22 prostanoids 1 
24 omega-3 fatty acids 1 
6 hyaluronic acid 1 
23 docosahexaenoic acid 1 
7 PGB 1 
13 mecobalamin 1 
5 AMD3100 1 
13 Olive oil 1 
31 covered stents 1 
13 sulodexide 1 
62 ethanol 1 
58 
angiotensin converting enzyme 
inhibitor 1 
6 naltrexone 1 
67 near-infrared 1 
28 N-acetylcysteine 1 
6 polyphenol 1 
18 ascorbic acid 1 
18 eicosapentaenoic acid 1 
18 indomethacin 1 
71 Ticlopidine 1 
4 linolenic acid 1 
50 C-peptide 1 
7 dexmedetomidine 1 
21 calcium channel blocker 1 
4 pyridostigmine 1 
7 diltiazem 1 
160 adenosine 1 
6 shockwave therapy 1 
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8 ibuprofen 1 
4 trandolapril 1 
34 nitroglycerin 1 
16 beraprost sodium 1 
41 clonidine 1 
5 Exendin-4 1 
11 ruboxistaurin 1 
51 AA 1 
8 lacosamide 1 
10 benfotiamine 1 
7 Gliclazide 1 
36 apheresis 1 
10 fenofibrate 1 
1 cholesterol-rich diet 1 
40 arginine 1 
4 donepezil 1 
7 interferon-beta 1 
15 acetaminophen 1 
15 kampo 1 
15 sildenafil 1 
38 antiepileptic drugs 1 
4 turmeric 1 
4 unsaturated fatty acids 1 
21 phosphodiesterase inhibitor 1 
3 A23187 1 
38 valproic acid 1 
3 Aucubin 1 
3 becaplermin 1 
6 Hydroxocobalamin 1 
3 carbenoxolone 1 
3 caspase inhibitors 1 
100 haemodialysis 1 
3 
High-mobility group box-1 
protein 1 
6 liraglutide 1 
5 tadalafil 1 
4 protein kinase C inhibitors 1 
3 Photobiomodulation 1 
3 Shakuyaku-kanzo-to 1 
3 Tongxinluo 1 
8 placenta 1 
2 angelica 1 
10 vitamin D3 1 
31 l-carnitine 1 
2 calcium gluconate 1 
30 amifostine 1 
2 gluthatione 1 
2 HGF plasmid DNA 1 
2 LV vectors 1 
30 Gamma-aminobutyric acid 1 
1 adipose-tissue-derived stem cells 1 
1 Apligraf 1 
1 beperminogene perplasmid 1 
1 bis(maltolato)oxovanadium IV 1 
1 CEP 03 1 
1 CEP protein adducts 1 
1 cholecystokinin-8 1 
14 tapentadol 1 
1 Deguelin 1 
1 
dielectric barrier discharge 
plasma 1 
1 EPAS1 gene 1 
29 phenytoin 1 
1 injectable biomaterial 1 
1 Kamishoyosan 1 
1 Lithospermi radix 1 
1 MCC-257 1 
1 NF3 1 
1 pCK-HGF-X7 1 
1 PDE5 inhibitor 1 
18 balloon dilatation 1 
110 anticonvulsants 1 
1 T-cell-pre-stimulated monocytes 1 
1 Tanshinone 1 
99 antioxidants 1 
1 vascular regenerative therapy 1 
1 WR1065 1 
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5105 surgery 1172 3427 
3638 drug 2279 1321 
2402 amputation 591 2064 
1920 revascularization 56 1839 
1766 inhibitor 951 813 
1358 walking 304 1058 
1328 exercise 229 1124 
1308 artery bypass grafting 59 1154 
1228 angioplasty 23 1149 
828 stents 7 751 
812 growth factor 377 426 
754 insulin 467 465 
745 dialysis 139 643 
632 medications 320 338 
588 operation 122 374 
576 aspirin 33 552 
567 analgesic 479 61 
541 endovascular treatment 3 499 
507 vascular surgery 17 466 
499 implantation 69 393 
489 angiogenesis 56 439 
459 rehabilitation 149 262 
450 bypass surgery 13 421 
449 diet 239 233 
447 glycemic control 333 247 
420 Ligation 274 110 
411 corticosteroid 328 148 
382 catheter 41 297 
370 statin  333 
353 Clopidogrel 8 345 
349 vascular endothelial growth 
factor 
105 257 
337 antiplatelet therapy 4 330 
317 opioid 271 28 
288 supplementation 160 124 
266 coronary intervention  261 
252 antihypertensive agents 36 238 
242 Gabapentin 235 16 
240 PNS 166 23 
233 endarterectomy 2 222 
233 pregabalin 230 5 
228 antidepressant 203 27 
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221 anticoagulant 24 196 
215 Cilostazol 6 211 
207 vitamin B12 160 50 
206 nerve growth factor 170 8 
190 smoking cessation 9 184 
189 Spinal Cord Stimulation 122 84 
172 Gene therapy 37 128 
172 IL-6 75 95 
167 heparin 15 146 
160 adenosine 56 106 
156 Electrical stimulation 87 37 
156 prednisone 139 48 
150 hypoxia 52 116 
147 capsaicin 129 14 
144 morphine 121 6 
131 mononuclear cells 59 76 
126 vitamin E 80 42 
119 zidovudine 115 4 
118 plasmapheresis 106 26 
118 prednisolone 90 19 
118 warfarin 14 107 
117 Vitamin D 48 76 
111 duloxetine 110 4 
110 anticonvulsants 105 6 
110 enzyme inhibitors 6 105 
107 cell therapy 4 99 
107 granulocyte colony-stimulating 
factor 
77 25 
103 Acupuncture 90 10 
103 pentoxifylline 14 95 
101 plasma exchange 90 19 
100 haemodialysis 31 77 
99 antioxidants 53 47 
98 IVIG 84 16 
98 lidocaine 71 10 
91 Prostaglandin 29 60 
90 gangliosides 84 6 
87 Amitriptyline 84 5 
86 Alpha lipoic acid 83 11 
80 carbamazepine 70 4 
80 folic acid 33 46 
78 anthracycline 71 4 
78 GM1 73 9 
77 dipyridamole 5 74 
73 thiamine 68 4 
71 Ticlopidine 2 71 
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69 methylprednisolone 52 21 
68 drug-coated balloons 1 66 
67 erythropoietin 46 26 
67 near-infrared 5 61 
65 magnesium 51 13 
65 Zinc 44 17 
63 surgical decompression 49 5 
62 ethanol 55 6 
62 superoxide dismutase 41 21 
61 simvastatin  41 
59 Acetyl-l-carnitine 53 5 
59 acetylsalicylic acid 1 58 
59 hyperbaric oxygen 17 44 
59 Testosterone 27 40 
58 angiotensin converting enzyme 
inhibitor 
6 55 
57 nitinol stents  48 
55 antithrombotic therapy  54 
55 carnitine 25 30 
54 Pyridoxine 49 4 
54 steroid therapy 40 18 
52 BDNF 39 4 
52 hepatocyte growth factor 6 47 
52 iloprost 2 50 
51 AA 9 40 
51 epidermal growth factor 39 8 
51 Mesenchymal Stem Cells 9 39 
51 peripheral blood mononuclear 
cells 
31 21 
50 C-peptide 32 26 
50 Nicotine 13 37 
47 aldose reductase inhibitor 45 5 
47 atorvastatin  41 
47 azathioprine 41 18 
45 Ketamine 39 5 
44 vorapaxar  44 
42 Neurotrophins 32 2 
41 clonidine 33 8 
40 arginine 21 16 
40 ticagrelor  40 
39 aerobic exercise 22 18 
38 antiepileptic drugs 36 2 
38 valproic acid 33 2 
37 anesthetics 24 8 
37 drug-eluting balloons  32 
37 glucocorticoid 29 16 
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36 apheresis 8 29 
36 distal bypass 1 34 
36 niacin 11 26 
36 stem cell therapy 1 33 
36 venlafaxine 34 3 
35 Cannabinoids 32  
35 directional atherectomy  33 
34 nitroglycerin 1 30 
34 urokinase 5 29 
34 vitamin C 12 23 
33 neurotrophin-3 27 3 
33 ramipril  33 
33 tramadol 30 3 
32 Orbital atherectomy  29 
32 prasugrel 1 32 
31 covered stents  29 
31 l-carnitine 14 19 
31 progesterone 25 3 
30 amifostine 23  
30 Gamma-aminobutyric acid 27 2 
30 propionyl-L-carnitine 1 30 
29 lamotrigine 29 2 
29 Lumbar sympathectomy 3 24 
29 Methylcobalamin 29 1 
29 phenytoin 24 2 
28 electroacupuncture 22 3 
28 GDNF 20  
28 N-acetylcysteine 16 9 
28 nifedipine 5 21 
28 oxcarbazepine 28 1 
27 baclofen 22 3 
27 glutamine 25  
27 intermittent pneumatic 
compression 
 26 
27 Mexiletine 27 2 
27 serotonin reuptake inhibitors 21 3 
27 verapamil 4 21 
26 botulinum toxin 20 3 
26 diphenhydramine 25  
26 growth hormone 15 12 
26 hormone replacement therapy 8 19 
26 massage 18 7 
26 minocycline 24 4 
26 sodium nitroprusside 11 17 
25 antimicrobial therapy 15 15 
25 cannabis 16 10 
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25 curcumin 19 7 
25 GSH 17 5 
25 MK-801 19  
25 nicotinamide 22 6 
25 opiates 21 6 
25 Transcutaneous electrical nerve 
stimulation 
16 9 
24 bFGF 10 15 
24 Goshajinkigan 22 1 
24 immunoglobulin therapy 22 1 
24 insulin-like growth factor-I 18 6 
24 omega-3 fatty acids 8 15 
24 pulse therapy 18 8 
23 docosahexaenoic acid 11 12 
23 fish oil 4 18 
23 hypothermia 12 9 
22 alpha-tocopherol 15 7 
22 calcium antagonists 2 21 
22 cryoplasty  19 
22 prostanoids 3 19 
22 rapamycin 15 7 
22 topiramate 21  
22 Vitamin B1 21 3 
21 calcium channel blocker 6 16 
21 NSAIDs 15 6 
21 oxycodone 21 1 
21 phosphodiesterase inhibitor 2 20 
21 rivaroxaban 1 20 
21 tacrolimus 15 7 
20 bone marrow mononuclear cells 1 18 
20 fentanyl 13 3 
20 peripheral nerve stimulation 18 2 
19 alprostadil 4 16 
19 buflomedil 1 18 
19 DAPT  18 
19 ezetimibe  18 
19 neuroactive steroids 15 2 
19 phentolamine 13 4 
18 ascorbic acid 11 6 
18 balloon dilatation  15 
18 chelation therapy 8 11 
18 eicosapentaenoic acid 3 15 
18 indomethacin 10 7 
18 lithium 16  
18 muscle stimulation 9 5 
18 selenium 10 8 
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17 amlodipine 1 17 
17 CXCR4 10 7 
17 interleukin-10 14 4 
17 laser therapy 13 4 
17 mycophenolate mofetil 14 9 
17 rifampin 11 3 
17 strength training 3 13 
17 thienopyridines  17 
17 viral vectors 1 11 
17 whole-body vibration 15 3 
16 androgen 8 5 
16 beraprost sodium 2 15 
16 ceftriaxone 10 2 
16 chlorambucil 16 1 
16 Coenzyme Q10 15 3 
16 deep brain stimulation 12 3 
16 epalrestat 16 1 
16 galanin 9  
16 losartan 2 13 
16 ozone 2 13 
16 PGE2 7 7 
16 pravastatin  14 
16 RTX 11 5 
15 acetaminophen 9 6 
15 digoxin 2 15 
15 glycosaminoglycan 2 14 
15 kampo 13 1 
15 lisinopril 2 13 
15 osteopontin 2 13 
15 sildenafil 7 9 
15 Streptokinase 1 12 
14 abciximab  14 
14 Aldehyde 9 6 
14 anti-inflammatory agents 11 4 
14 antioxidant therapy 3 13 
14 bivalirudin  11 
14 cimetidine 13 1 
14 CNTF 10 2 
14 enalapril 6 9 
14 femoropopliteal in-stent 
restenosis 
 14 
14 Flavonoids 6 8 
14 fluoxetine 11 4 
14 herbal medicines 11 1 
14 memantine 13 1 
14 myo-inositol 12 1 
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14 Org 2766 14  
14 phenylephrine 7 6 
14 Picotamide 1 14 
14 tapentadol 13 1 
14 TCA 10 5 
14 yohimbine 13  
13 ACTH 11  
13 Caffeine 5 9 
13 celecoxib 6 4 
13 dextromethorphan 12 2 
13 doxycycline 11 1 
13 etanercept 11 4 
13 FK506 8 1 
13 guanosine 6 4 
13 mecobalamin 12  
13 nortriptyline 13 1 
13 Olive oil 2 12 
13 sulodexide 1 12 
12 all-trans retinoic acid 9 3 
12 antihistamines 11 3 
12 beta-carotene 2 10 
12 betaine 6 6 
12 cyanocobalamin 11 2 
12 Dex 11  
12 Ginkgo biloba extract 4 8 
12 hydrochlorothiazide 3 10 
12 ketanserin 3 8 
12 Lovastatin  8 
12 prazosin 7 5 
12 sodium bicarbonate 6 7 
12 tempol 5 6 
11 anandamide 7 2 
11 chlorthalidone  11 
11 diclofenac 7 1 
11 EDTA 3 8 
11 phosphatidylcholine 7 3 
11 ruboxistaurin 11 5 
11 tea 4 3 
10 benfotiamine 10  
10 chloroquine 7 3 
10 desipramine 10 2 
10 fenofibrate 7 8 
10 glibenclamide 8 4 
10 GP IIb/IIIa inhibitors  10 
10 imipramine 10  
10 lentivirus 7 2 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                                                                                                                
Chapter 7 - Tables and Figures                                                                                                                               227 
10 melatonin 5 1 
10 mesenchymal stromal cells  10 
10 milnacipran 9  
10 PAR-1 antagonists  10 
10 plaque excision  9 
10 Ranitidine 10  
10 Resveratrol 7 3 
10 scrambler therapy 9  
10 tai chi 10  
10 thiazolidinediones 6 10 
10 uridine 7 3 
10 vitamin D3 3 7 
10 WIN 55,212-2 10  
9 allopurinol 5 5 
9 Angiogenic gene therapy 1 9 
9 benzodiazepine 6 2 
9 captopril  9 
9 Carvedilol 2 8 
9 clonazepam 9  
9 dabigatran  9 
9 Defibrotide 1 9 
9 electromagnetic field 8 1 
9 everolimus 3 5 
9 hydrogen sulfide 4 5 
9 levetiracetam 8  
9 methadone 6 1 
9 methylxanthine 1 8 
9 Paracetamol 7 4 
9 perindopril  9 
9 phlebotomy 1 8 
9 sunlight 6 5 
9 tafamidis 9  
9 tolrestat 9  
9 vitamin K antagonist  8 
8 amantadine 8 1 
8 Calcitriol 1 7 
8 D-penicillamine 7 1 
8 eptifibatide 1 8 
8 external counterpulsation  8 
8 hydrocortisone 7 1 
8 ibuprofen 5 1 
8 inositol 6 2 
8 KU-32 8  
8 lacosamide 8 1 
8 levothyroxine 6 2 
8 mannitol 3 4 
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8 manual therapy 3 1 
8 Menhaden oil 8 2 
8 menthol 5 3 
8 muscimol 7  
8 nicotinic acid 2 6 
8 osteocalcin  7 
8 paroxetine 6 3 
8 pioglitazone 7 5 
8 placenta 2 5 
8 Protamine 2 7 
8 Sitagliptin 3 7 
8 taurine 8 1 
8 Tetrodotoxin 6  
8 thiols 6 3 
8 tirofiban  8 
8 TRPA1 antagonist 8 1 
7 7-nitroindazole 5  
7 acetylcysteine 3 4 
7 apixaban  7 
7 ATS 4 4 
7 Cannabidiol 7 1 
7 capsazepine 5  
7 coffee 2 5 
7 cortical stimulation 5  
7 cryotherapy 2 4 
7 DA-9801 7  
7 dexmedetomidine 6  
7 diltiazem 1 6 
7 factor Xa inhibitors  7 
7 gamma-globulin 4 1 
7 gamma-linolenic acid 6 2 
7 gemfibrozil 2 6 
7 Ghrelin 5 2 
7 Gliclazide 5 3 
7 histone deacetylase inhibitors 7  
7 Huangqi Guizhi Wuwu 5  
7 interferon-beta 6 1 
7 Isosorbide dinitrate 4 3 
7 linoleic acid 3 3 
7 MIRE 7  
7 neuromuscular electrical 
stimulation 
1 4 
7 nimodipine 6 1 
7 papaverine 2 5 
7 Peripheral nerve decompression 7 1 
7 PGB 7  
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7 plasminogen activators 1 6 
7 prostacyclin analogues  7 
7 quercetin 6 2 
7 retigabine 6  
7 riluzole 6 1 
7 sirolimus 1 5 
7 Viabahn endoprosthesis  7 
6 acarbose 3 4 
6 ancrod  6 
6 atopaxar  6 
6 Biotin 5 1 
6 CB1/CB2 agonist 5  
6 coumarin 3 2 
6 EGb 761 1 5 
6 erlotinib 6  
6 HC-030031 5 2 
6 hyaluronic acid 3 2 
6 hydromorphone 4 2 
6 Hydroxocobalamin 4  
6 liraglutide 3 3 
6 magnetic fields 4  
6 marijuana 6  
6 mesoglycan  6 
6 naltrexone 6  
6 nebivolol  6 
6 PARP inhibition 6 1 
6 polyphenol 4 3 
6 relaxin 1 5 
6 salbutamol 3 2 
6 Sarpogrelate hydrochloride 1 6 
6 shockwave therapy 1 6 
6 THC 5 2 
6 Thiamine pyrophosphate 6 1 
6 thioctic acid 6  
6 trimetazidine  6 
6 Vitamin B complex 6  
6 Zilver PTX stent  4 
5 acetylcholine-induced 1 5 
5 adrenocorticotropic hormone 4  
5 AMD3100 4 2 
5 Bezafibrate  5 
5 cangrelor  5 
5 cholinesterase inhibitor 4  
5 clomipramine 4 1 
5 diazepam 4  
5 drug-coated stents  5 
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5 edoxaban  5 
5 epoprostenol  5 
5 Exendin-4 4 1 
5 FAAH inhibitor 4  
5 Flunarizine 1 3 
5 Grape 3  
5 guanethidine 5  
5 haemodilution  5 
5 Hematin 5  
5 Heparin cofactor II  5 
5 hydrotherapy 4 2 
5 hydroxychloroquine 5  
5 hydroxyethyl starch  5 
5 Ibudilast 5 1 
5 Jinmaitong 5 1 
5 ketorolac 3 2 
5 moxibustion 4 1 
5 N-methyl-D-aspartate receptor 
antagonists 
4 1 
5 naftidrofuryl oxalate  5 
5 NGX-4010 5  
5 P2Y12 inhibitor  5 
5 pralidoxime 5  
5 puerarin 4 2 
5 repetitive transcranial magnetic 
stimulation 
4  
5 reteplase  5 
5 rheopheresis 1 4 
5 rofecoxib 2 4 
5 Sativex 5 1 
5 SCH 530348  5 
5 tadalafil 4 2 
5 telmisartan  5 
5 triiodothyronine 1 3 
5 ultrasonic therapy 2 2 
5 URB597 5  
4 17beta-estradiol 3  
4 4-methylcatechol 4  
4 acetazolamide 2 2 
4 adrenal medullary transplants 3  
4 agmatine 4  
4 Aliskiren 1 4 
4 allopregnanolone 3  
4 amikacin 4 1 
4 anakinra 3 1 
4 betamethasone 4  
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4 bosentan  4 
4 canagliflozin  3 
4 catechin 1 2 
4 cefotaxime 1 1 
4 chelerythrine 3 1 
4 Cinacalcet  4 
4 ciprostene  4 
4 Del-1  4 
4 dextrorphan 4  
4 dimercaprol 3  
4 Dioscorea nipponica Makino 4  
4 dipyrone 1 1 
4 donepezil 3 1 
4 doxepin 4 2 
4 enoxaparin  4 
4 evolocumab  4 
4 fluorocitrate 4  
4 GLP-1 receptor agonists 3 3 
4 glyceryl trinitrate  3 
4 hemin 4  
4 icariin 4  
4 IGF-II 3 1 
4 indobufen  4 
4 isoproterenol 2 2 
4 K-134  4 
4 lafutidine 4  
4 laser ablation  3 
4 linolenic acid 3 1 
4 Lycopene 2 2 
4 Maggot debridement therapy  3 
4 mangafodipir 4  
4 midodrine 4 1 
4 misoprostol  4 
4 molsidomine  4 
4 Netrin-1  3 
4 percutaneous therapy  3 
4 pirenzepine 4  
4 probucol  3 
4 propentofylline 4  
4 protein kinase C inhibitors 4 1 
4 pyridine 3  
4 pyridostigmine 3 1 
4 quinidine 3 2 
4 Quinine 3 2 
4 reflexology 4  
4 rolipram 2  
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4 ruthenium red 4  
4 S-Nitroso-N-acetylpenicillamine 4  
4 saponins 2  
4 Sodium nitrite 1 4 
4 Tanezumab 4  
4 Tang-Luo-Ning 4  
4 tetrahydrocannabinol 4 1 
4 thalamotomy 3  
4 Thymoquinone 3 1 
4 Tizanidine 2  
4 trandolapril 2 3 
4 trigonelline 4  
4 troglitazone 1 3 
4 turmeric 1 3 
4 unsaturated fatty acids 2 3 
4 valsartan 1 3 
4 Waon therapy  4 
4 wortmannin 3  
4 ximelagatran 1 4 
4 zenarestat 4  





3 2-AG 3  
3 A23187  2 
3 actovegin 2 1 
3 adrenergic agonists 2  
3 albendazole 1 2 
3 alpha-linolenic acid  3 
3 amiloride 1 2 
3 antitussive 3  
3 argatroban  3 
3 Aucubin 2 1 
3 becaplermin 2 3 
3 berberine 3 2 
3 bone marrow stem cells  3 
3 BPAU 3  
3 bupivicaine 2 2 
3 butyric acid 3 1 
3 caloric restriction 1 2 
3 candesartan 2 2 
3 carbenoxolone 2 1 
3 carotenoids 3  
3 caspase inhibitors 2  
3 charcoal 2  
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3 chemical lumbar sympathectomy  3 
3 Chinese herbs 2  
3 chlorpropamide 3 3 
3 codeine 3 1 
3 cognitive behavior therapy 2 1 
3 CXCR4 antagonist 2 1 
3 cyproheptadine 3  
3 dermatan sulfate  3 
3 desferrioxamine 3  
3 desvenlafaxine 3  
3 dietary flaxseed  3 
3 diflunisal 3  
3 dihydroergotamine 1 3 
3 dimethyl fumarate 3 1 
3 ellagic acid 3  
3 epibatidine 2  
3 ethosuximide 3  
3 Fasudil 1 1 
3 fidarestat 3  
3 fingolimod 3 1 
3 fludrocortisone 3 1 
3 fluvoxamine 2 1 
3 fosfomycin 3  
3 fucoidan  3 
3 genistein 2 2 
3 H-Wave device 3  
3 hexamethonium  2 
3 High-mobility group box-1 protein 2 1 
3 ifenprodil 1 2 
3 interferon alfa 3 3 
3 irbesartan 1 3 
3 ivermectin 2  
3 JZL184 3  
3 L-cysteine 3  
3 Lutonix drug-coated balloon  3 
3 Lyrica 3  
3 Metanx 3  
3 mifepristone 3  
3 mirtazapine 3  
3 natalizumab 3 2 
3 Neostigmine 3  
3 olesoxime 3  
3 orexin-A 3  
3 oxytocin 2 1 
3 palmitoylethanolamide 3 1 
3 passive exercise  2 
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3 PD98059 3  
3 pergolide 2 1 
3 phosphatidylethanolamine 2  
3 Photobiomodulation 3  
3 pifithrin-mu 3  
3 Plantaginis Semen 3  
3 PLX-PAD  3 




3 probenecid 3  
3 pyrrolidine dithiocarbamate 3  
3 quinpirole 3  
3 ranolazine  3 
3 rotenone 3  
3 Shakuyaku-kanzo-to 3  
3 shear rate therapy  3 
3 sialidase 2  
3 SKPs 1  
3 tetrahydrobiopterin 1 2 
3 thermal ablation  2 
3 thymosin beta4 3  
3 Tongxinluo 3  
3 trimethylamine 2 1 
3 TSPO 2 1 




2 2-MPPA) 2  
2 5-hydroxydecanoate 2  
2 Acidic fibroblast growth factor 1 1 
2 Aconitum 2  
2 Acorus calamus 2  
2 adenylate cyclase inhibitor 1 1 
2 ALDH Bright Cells)  2 
2 Aleglitazar 1 1 
2 alfentanil 1 1 
2 alogliptin  2 
2 alpha-conotoxin Vc1.1 2  
2 alpha2-delta ligands 2  
2 AM424 2  
2 angelica 1  
2 anisodamine 1  
2 Anodyne Therapy System 2  
2 apomorphine 2 1 
2 Astragali 1  
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2 Bimoclomol 2 1 
2 Biolimus  1 
2 bisoprolol 1 1 
2 blackcurrant juice  2 
2 BRX-220 2  
2 calcium gluconate 2  
2 calmangafodipir 2  
2 calpeptin 2  
2 carisoprodol 1 1 
2 Cerebrolysin 1  
2 cicaprost  2 
2 cinnamaldehyde 2  
2 Cobalt Chloride 2  
2 controlled reperfusion  2 
2 Cyclandelate  2 
2 cytidine 2  
2 Dark chocolate  2 
2 deferoxamine 2  
2 DHbetaE) 1  
2 dietary nitrate  2 
2 Dihydro-beta-erythroidine 1 1 
2 dihydropyridines  2 
2 diluted bee venom 2  
2 Dioscoreae rhizoma 2  
2 DMSO 2  
2 docosapentaenoic acid  2 
2 DRG stimulation 2  
2 DVC1-0101  2 
2 E2072 2  
2 egg white hydrolysate 2  
2 elcatonin 2  
2 electromagnetic neural 
stimulation 
2  
2 electromagnetic radiation  1 
2 emodin 2  
2 ergocalciferol  1 
2 Ethoxyquin 2  
2 etodolac 2  
2 fibroblast growth factor 1  2 
2 Flupirtine 1 1 
2 fondaparinux  2 
2 gallic acid 2  
2 geldanamycin 1  
2 gluthatione 2  
2 glycyrrhizin 2  
2 HGF plasmid DNA  2 
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2 hypoxia-inducible factor-1alpha 
(HIF-1alpha) 
 2 
2 intravenous high-dose 
immunoglobulin 
2  
2 kappa-opioid receptor agonist 2  
2 KRN5500 2  
2 KU-596 2  
2 leuprolide acetate  1 
2 linagliptin 1 2 
2 loperamide 2  
2 maraviroc 1 1 
2 maximal strength training  2 
2 MEK inhibitors 2  
2 melanocortin 2  
2 metaxalone 1  
2 methyl nicotinate 2  
2 Mibefradil 2  
2 monochromatic infrared photo 
energy 
2  
2 monosodium glutamate 1 1 
2 nalbuphine 2  
2 Neomycin 1  
2 neurofeedback 2  
2 niflumic acid 1 1 
2 nitrate consumption  2 
2 pyrrolidine-2,5-dione 2 1 
2 Snake venoms 2  
1 25)Mg-PMC16 1  
1 3,3,5-trimethylcyclohexanol  1 
1 3-Aminobenzamide 1  
1 4-phenylbutyric acid 1  
1 5-phenyl-1-pentyne 1  
1 7-hydroxy-3,4-dihydrocadalin 1  
1 8-methoxypsoralen  1 
1 A-134974 1  
1 AC591 1  
1 Acanthopanax 1  
1 ACEA 1  
1 acellular dermal regenerative 
tissue 
1 1 
1 Achyranthis bidentata Blume 1  
1 acipimox 1  
1 activation of Nrf2 1  
1 ACY-1083 1  
1 AGGF1  1 
1 aktovegin  1 
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1 Alfa LMW1  1 
1 alpha-chymotrypsin 1  
1 Alstonia scholaris 1  
1 AM1714 1  
1 aminoguanidine hydrochloride 1  
1 aminophylline  1 
1 ampakines 1  
1 AMPK activators 1  
1 anthranilic acid 1  
1 antimycin 1  
1 Apligraf 1  
1 ARA 290 1  
1 arm-crank exercise  1 
1 ascorbyl palmitate 1  
1 AVP-923 1 1 
1 Azadirachta indica 1  
1 baicalein 1  
1 Baicalin 1  
1 BAIMAI-SAN 1  
1 BAK-PLO 1  
1 bendazac lysine 1  
1 benserazide 1  
1 beperminogene perplasmid  1 
1 beta-caryophyllene 1  
1 betulinic acid 1  
1 bis(maltolato)oxovanadium IV  1 
1 borneol 1  
1 bovine lactoferrin 1  
1 BRL-50481 1  
1 BRLP-42) 1 1 
1 bromelain 1  
1 bushi 1  
1 Butea monosperma 1  
1 Caffeic acid phenethyl ester 1  
1 calciparine  1 
1 calcium citrate 1  
1 calcium/magnesium infusion 1  
1 Calmare therapy 1  
1 Calmidazolium 1  
1 candoxatril 1  
1 Capnellene 1  
1 ceftaroline fosamil (CPT-F)  1 
1 CEP 03  1 
1 CEP protein adducts  1 
1 Chamomilla matricaria 1  
1 chemical ablation  1 
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1 chlorogenic acid  1 
1 Chlorpheniramine 1  
1 cholecystokinin receptor 
antagonists 
1  
1 cholecystokinin-8 1  
1 cholesterol-rich diet  1 
1 chromaffin cell grafts 1  
1 circulator boot therapy  1 
1 citicoline 1  




1 copper ions 1 1 
1 CQ  1 
1 crenotherapy  1 
1 Crocin 1  
1 cromakalim  1 
1 Crotoxin 1  
1 CX614 1  
1 CX729 1  
1 Cymbalta 1 1 
1 Cystamine 1  
1 cytoflavin 1  
1 D-sorbitol 1  
1 daidzin 1  
1 daltroban  1 
1 Deguelin 1  
1 dexibuprofen 1  
1 dielectric barrier discharge 
plasma 
 1 
1 dietary folate intake  1 
1 dietary vitamin E 1  
1 diethylcarbamazine  1 
1 dihydrolipoic acid 1 1 
1 diphenyl diselenide 1  
1 dronabinol 1  
1 EAntS-GS 1  
1 Effexor 1  
1 Electroconvulsive shock 1  
1 electromagnetic therapy  1 
1 elinogrel  1 
1 emfilermin) 1  
1 Entacapone 1  
1 Epac-inhibitor 1  
1 EPAS1 gene  1 
1 epicatechin gallate 1  
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1 eplerenone 1 1 
1 ergothioneine 1  
1 erucic acid 1  
1 ESI-09 1  
1 estradiol valerate  1 
1 ethanethiol 1  
1 ethopropazine 1  
1 eugenol 1  
1 exogenous recombination IL-4 1  
1 extracorporeal shock wave 
therapy 
1  
1 extract of date fruit 1  
1 felbamate 1  
1 Fenfluramine 1  
1 fenugreek extract 1  
1 Ferula assa-foetida 1  
1 ferulic acid 1  
1 Fexofenadine 1  
1 fluocinolone acetonide 1  
1 fumonisin B1 1  
1 gadolinium chloride 1  
1 GCSB-5 1  
1 Gentiopicroside 1  
1 Guizhi-shaoyao-zhimu decoction 1 1 
1 Hachimi-jio-gan  1 
1 hemangioblasts  1 
1 Hydroxytyrosol 1  
1 hyperforin 1  
1 hypericin 1  
1 Ilepatril 1  
1 imatinib mesylate  1 
1 immunoadsorber 1 1 
1 increased intake of folate  1 
1 IND01 1  
1 INGAP peptide 1  
1 injectable biomaterial  1 
1 interval walking  1 
1 intrathecal opioid infusion 1  
1 IRE1alpha siRNA 1  
1 isoprenaline  1 
1 isopropyl myristate 1  
1 Isoxsuprine hydrochloride  1 
1 itaconic acid  1 
1 J147 1  
1 Jiaweibugan 1  
1 Juglans regia L. 1  
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1 kaempferol 1  
1 Kamishoyosan 1  
1 ketogenic diet 1  
1 Kv7 channel activator 1  
1 lactoferrin 1  
1 levo-corydalmine 1  
1 Levocarnitine acetyl 150 1  
1 levorphanol 1 1 
1 LiCl 1  
1 ligustrazine 1  
1 Linalool 1  
1 Lithospermi radix 1  
1 LM11A-31 1  
1 lomitapide  1 
1 Lotrafiban  1 
1 low frequency acoustic waveform  1 
1 low frequency magnetic fields 1  
1 low glucose diet  1 
1 LPP1 1  
1 Maltol 1  
1 mangiferin 1  
1 Manidipine 1 1 
1 maprotiline 1  
1 MCC-257 1  
1 mCPP 1  
1 MDA19 1  
1 Me6TREN  1 
1 meclizine 1  
1 medical herbs 1  
1 metamizol/paracetamol  1 
1 methylsulfonylmethane 1  
1 metyrapone 1  
1 microRNA let-7g  1 
1 mindfulness meditation 1  
1 minoxidil 1  
1 MnDPDP 1  
1 MnL4 1  
1 Momordica cymbalaria 1  
1 monosialotetrahexosylganglioside 1  
1 morin 1  
1 MPV-2426 1  
1 N(6)-cyclopentyladenosine 1  
1 nabilone 1  
1 naringin 1  
1 NCX 6550  1 
1 nefopam 1  
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1 neoline 1  
1 neprilysin 1  
1 Neuragen PN 1  
1 NF3  1 
1 niclosamide 1  
1 nicorandil 1  
1 NM-702  1 
1 Nmnat) 1  
1 Nornicotine 1  
1 NT-702  1 
1 nylidrin  1 
1 oleanolic acid 1  
1 OP-1206 1 1 
1 pamoic acid 1  
1 pancreatic kininogenase 1  
1 parthenolide 1  
1 pCK-HGF-X7  1 
1 PDE4B/7A dual inhibitor 1  
1 PDE5 inhibitor 1  
1 PDWHF  1 
1 pemirolast 1  
1 Peptide5 1  
1 percutaneous catheter-based 
therapies 
 1 
1 phenols  1 
1 Phenoxodiol 1  
1 phenoxyphenyl pyridines 1  
1 phenyl-N-tert-butylnitrone 1  
1 Picrorhiza kurroa 1  
1 piler-light  1 
1 piperine 1  
1 piroxican 1  
1 pitavastatin  1 
1 placental-derived adherent 
stromal cells 
 1 
1 plantar vibration 1  
1 pneumatic compression boot 1 1 
1 polaprezinc 1  
1 potassium channel openers 1 1 
1 prifinium bromide 1  
1 pRLX  1 
1 Procyclidine 1  
1 progestins  1 
1 progestogen therapy  1 
1 Prograf 1  
1 propolis 1  
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1 prosaposin-derived 14-mer 
peptide 
1  
1 proxyphylline 1  
1 psoralen  1 
1 Pulsed radiofrequency ablation 1  
1 pulsed radiofrequency 
neuromodulation 
1  
1 Punica granatum L 1  
1 Punicalagins 1  
1 pyrimethamine 1  
1 QR-333 1  
1 Quetiapine 1  
1 Racemic (R/S)-guaifenesin (1) 1  
1 rAd5/NR2B 1  
1 Recombinant Sema3A protein 1  
1 reparixin 1  
1 Ro5-4864 1  
1 rosemary 1  
1 Rosmarinic acid 1  
1 RSR13  1 
1 RU38486 1  
1 rutin 1  
1 safranal 1  
1 Salicylaldehyde 1  
1 salmon calcitonin 1  
1 salsalate 1 1 
1 Salvia officinalis 1  
1 Salvianolic acid B 1  
1 SAN-Gly 1  
1 Saposhnikovia divaricata Schiskin 1  
1 SDZ PCO-400  1 
1 sesame oil 1  
1 shellac  1 
1 Silybin 1  
1 silymarin 1 1 
1 SN gene therapy  1 
1 sodium hydrosulfide  1 
1 sodium sulfide  1 
1 SP600125 1  
1 spironolactone  1 
1 SQ22536 1  
1 SR 57746A 1 1 
1 subsensory electrical stimulation 1  
1 synthetic exendin-4 1  
1 T-cell-pre-stimulated monocytes  1 
1 Tanshinone 1  
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1 TAT-CBD3A6K 1  
1 Terbinafine  1 
1 tetracyclines 1  
1 tetramethylpyrazine 1  
1 thenoyltrifluoroacetone  1 
1 thiorphan 1  
1 thiosalicylic acid 1  
1 torsemide  1 
1 Trehalose 1  
1 Treprostinil diethanolamine  1 
1 tretinoin  1 
1 trimethoxy flavone 1  
1 TRPA1/PDE4B/PDE7A ligand 1  
1 TT saponin 1  
1 Turpentine 1 1 
1 U 69593 1  
1 vascular regenerative therapy  1 
1 Vernonia cinerea 1  
1 vitamin K2  1 
1 Vitis vinifera 1  
1 VR-1 receptor modulators 1  
1 WR1065 1  
1 Xilonix  1 
1 yang-warming 1  
1 Yiqi Huayu 1  
1 Zhenqing Capsule 1  
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TABLE 7A-9a - Existing PN/PAD Biomarkers 




2277 nerve conduction 
velocity 
2038 ankle brachial index 
1549 blood pressure 
1402 stenosis 
1156 body mass index 
1142 neurotoxic 
1139 total cholesterol 
1138 blood glucose levels 
1091 degeneration 
1061 hemoglobin A1c 








671 growth factor 
640 Schwann cell 
616 demyelination 
610 pain-free walking 
distance 




495 low-density lipoprotein 
cholesterol 
489 angiogenesis 
455 axonal degeneration 
435 Systolic blood pressure 
426 circulation 
425 high-density lipoprotein 
cholesterol 
419 oxidative stress 
413 plaque 
412 occlusions 
402 albumin level 
399 glomerular filtration rate 
391 ventricular ejection 
fraction 
382 calcification 
365 nerve damage 
354 neurodegeneration 
349 IgM 




322 heart rate 
318 edema 
318 nitric oxide 
309 apoptosis 
308 fibrinogen 
284 endothelial dysfunction 
283 denervation 




263 vitamin B(12) deficiency 
262 stenoses 
261 high homocysteine 
251 angiotensin converting 
enzyme 
247 amyloid 
240 myelinated fibers 
237 vibration perception 
threshold 
222 weight loss 
210 fatty acid 
208 carotid artery intima-
media thickness 
206 nerve growth factor 
202 T-cell 
197 autoantibodies 




185 insulin resistance 
183 pulse wave velocity 
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175 diastolic blood pressure 
170 nerve regeneration 
168 platelet aggregation 
162 glycated haemoglobin 
159 lymphocytes 
158 nerve fiber density 
154 B-cell 
152 Reactive oxygen species 
151 arterial stiffness 
147 capsaicin 
147 lipid profile 




126 vitamin E deficiency 
125 apolipoprotein 
125 Vitamin D deficiency 
123 acetylcholine 
122 mechanical hyperalgesia 
119 glutathione 




115 nitric oxide synthase 
115 white blood cell 
114 creatine 
110 waist circumference 
108 creatinine clearance 
107 lactate 
106 von Willebrand factor 
105 plasminogen activator 
inhibitor-1 
104 pulse pressure 
104 thrombin 
103 urea 
102 atherosclerotic plaque 
102 IgA 
101 vasculopathy 
100 intercellular adhesion 
molecule-1 
99 antioxidants 
98 calcitonin gene-related 
peptide 
96 uric acid 
95 blood viscosity 
94 Lipoprotein(a) 
92 albumin excretion rate 
92 substance P 
84 fiber loss 
84 malondialdehyde 
81 Endothelial progenitor 
cells 
81 orthostatic hypotension 
80 fibrin 
80 fibroblast growth factor 
80 folic acid 
78 transcutaneous oxygen 
pressure 
74 creatine kinase 
74 matrix metalloproteinase 
74 thromboxane 
73 thiamine 
72 systemic sclerosis 
70 IL-10 
70 peak oxygen 
consumption 
69 lipid peroxidation 
69 prostacyclin 
69 superoxide dismutase 
69 troponin 
68 D-dimer 
66 mRNA levels 








64 Red Blood Cell 
61 monoclonal antibodies 
61 oxygen saturation 
61 P-selectin 
60 heat shock 
60 rheumatoid factor 
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55 Ca(2+) 
55 Venous occlusion 
54 glial fibrillary acidic 
protein 
53 chemokines 
53 Tissue Plasminogen 
Activator 
52 Angiogenic growth 
factors 
52 BDNF 
52 hepatocyte growth factor 
52 l-arginine 
52 MetS 
51 cardiac troponin T 
51 epidermal growth factor 
51 glucose metabolism 
51 prothrombin 
50 NF-kappaB 
49 adenosine diphosphate 
49 bone mineral density 










45 neuronal damage 
44 adiponectin 
44 alanine 








41 alkaline phosphatase 
41 apolipoprotein B 
41 CD34 
41 free radicals 
41 N-terminal pro-brain 
natriuretic peptide 







39 apolipoprotein A-I 
39 bacterial infection 
39 cyclic AMP 
39 endothelial damage 
38 connexin 32 
38 glycine 
38 Noradrenaline 
38 vitamin K 
37 blood urea nitrogen 
37 E-selectin 
37 endothelin-1 
37 matrix metalloproteinase 
9 
36 arachidonic acid 
36 heme 





35 interferon gamma 
34 actin 
34 catalase 






33 cerebral ischemia 
33 ferritin 
33 glial activation 
33 hypoperfusion 
33 oxidative damage 
32 anti-MAG antibodies 
32 insulin levels 
32 polyunsaturated fatty 
acids 
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31 parathyroid hormone 
31 progesterone 
30 beta 2 microglobulin 







29 Chlamydia pneumoniae 




28 brain atrophy 
28 carotid-femoral pulse 
wave velocity 
28 CD31 





28 thromboxane A2 
27 antinuclear antibodies 
27 Apolipoprotein E 
27 cholinesterase 




27 high total cholesterol 
27 methylmalonic acid 
27 RAGE 
27 vascular reactivity 
26 Endothelin 
26 glutathione peroxidase 
26 growth hormone 
26 HMG-CoA reductase 
26 Hydrogen peroxide 
26 leptin 
26 miRNA 
25 amyloid beta 
25 cysteine 
25 GP IIb/IIIa 
25 Helicobacter pylori 
25 Iron Deficiency 







23 copper deficiency 






22 Vitamin B1 deficiency 
21 bradykinin 
21 Escherichia coli 
21 glutamic acid 
21 methicillin-resistant 
Staphylococcus aureus 
21 Oxidized low-density 
lipoprotein 
21 prostate-specific antigen 
20 acylcarnitine 
20 adenosine triphosphate 
20 aldosterone 
20 arterial obstruction 
20 CD40 ligand 
20 folate deficiency 
20 insulin-like growth factor 
I 




19 serum calcium 
19 thrombomodulin 
19 vascular calcifications 
18 amyloid fibrils 
18 c-Fos 
18 caspase 3 
18 docosahexaenoic acid 
18 eicosapentaenoic acid 
18 endothelial activation 
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18 estradiol 
18 heme oxygenase 1 
18 HIF-1alpha 
18 luminal diameter 




17 aortic pulse wave 
velocity 
17 arterial compliance 
17 bone density 









17 High-mobility group box 
1 
17 IL-2 
17 lactic acid 
17 lead levels 
17 porphobilinogen 
17 prothrombin time 
16 androgen 




16 phytanic acid 
16 proline 
16 pyridoxal 
15 activated partial 
thromboplastin time 





15 DNA polymerase gamma 
15 osteopontin 
14 anti-GM1 antibody 










13 atheromatous plaque 
13 ceruloplasmin 
13 complement levels 
13 cyclic guanine 
monophosphate 












12 anticardiolipin antibodies 





12 Chondroitin sulfate 
12 hydrogen sulfide 
12 IgE 









11 anti-gliadin antibodies 
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11 Coxsackie 
11 dendritic cells 
11 dipeptidyl peptidase 






11 Myelin breakdown 









10 glycogen synthase 
10 low birth weight 










9 Aortic augmentation 
index 
9 beta-galactosidase 







9 fibrin D-dimer 
9 fungi 
9 heparan sulfate 
9 iodine 




9 vascular stiffness 




















7 aldehyde dehydrogenase 
7 amines 
7 angiotensin II type 1 
7 CD14 
7 coronary calcification 
7 HIV RNA levels 
7 horseradish peroxidase 
7 linoleic acid 








6 arterial elasticity 
6 citrulline 
6 Cu 
6 dimethylarsinic acid 
6 factor XIII 
6 fibroblast growth factor 
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23 
6 FVII 
6 glucuronic acid 
6 GRP78 
6 histone deacetylase 6 
6 IL-18 
6 kallikrein 
6 lipid hydroperoxides 
6 Methylglyoxal 
6 N-acetylglucosamine 
6 neurotoxic esterase 








5 apolipoprotein A-II 








5 Glyoxalase 1 
5 guanosine 
monophosphate 






5 luteinizing hormone 
5 monoamine oxidase 
5 omega-3 index 
5 perforin 
5 phenyl valerate 
5 platelet factor 4 
5 pregnenolone 










4 apolipoprotein B-48 
4 apolipoprotein C-III 







4 erythrocyte aggregation 
4 GHb 
4 glutathione transferase 
4 glycated albumin 
4 homovanillic acid 
4 hydroxymethylbilane 
synthase 









4 nitrogen oxide 
4 Nox2 
4 S100A12 
4 Sirtuin 1 
4 SO2 
4 soluble guanylyl cyclase 
4 succinate dehydrogenase 
4 tetrahydrobiopterin 
4 tissue inhibitors of 
metalloproteinases 
4 ubiquinone 
4 valvular calcification 
4 vasoactive intestinal 
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peptide 
3 acetaldehyde 
3 acyl-CoA oxidase 
3 Allograft inflammatory 
factor-1 
3 arginase 
3 B vitamin deficiency 
3 brain iron accumulation 
3 butyric acid 
3 CFU 
3 chorionic gonadotropin 
3 connective tissue growth 
factor 
3 CXCL10 
3 eosinophil cationic 
protein 
3 factor XII 
3 Fusobacterium 
3 glucagon-like peptide 1 
3 Glucokinase 
3 glutathione reductase 
3 GTP cyclohydrolase 
3 hemosiderin 
3 hydroperoxide 
3 hydroxyl radical 
antioxidant capacity 
3 hyperoxia 






















3 serum nitrate 
3 sTWEAK 
3 trimethylamine 
3 waist-to-height ratio 
3 xanthine oxidase 
2 3-nitrotyrosine 
2 32P 
2 acid phosphatase 
2 adenosine deaminase 
2 adenosine kinase 
2 adenylyl cyclases 
2 agrin 
2 aminolevulinic acid 
2 aminopeptidases 
2 apoB/apoA-I ratio 
2 apolipoprotein A-IV 
2 apolipoprotein AI-CIII-AIV 
gene cluster 
2 aspartic acid 
2 campesterol 
2 carboxymethyl-lysine 
2 Cardiometabolic index 
(CMI) 
2 caspase 9 
2 CCL4 
2 Ceramide antibody levels 




2 docosapentaenoic acid 
2 endostatin 
2 estrone 
2 follicle stimulating 
hormone 
2 glutaredoxin 
2 herpes simplex virus 1 
2 hippuric acid 
2 histone deacetylases 
2 hydroxyproline 
2 Janus kinase 1 
2 JC virus 
2 Ketones 
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2 kininase II 
2 kininogen fractions 
2 kynurenic acid 






2 omentin-1 level 
2 phenylglyoxylic acid 
2 polymorphonuclear 
neutrophils 
2 Prevotella intermedia 
2 protein tyrosine 
phosphatases 
2 pyruvic acid 
2 saturated fatty acid 
2 suPAR level 
2 tachykinins 
2 transcription factor CHOP 
2 TREM-1 


















1 adenylate kinase 
1 aniline hydroxylase 
1 Anti-Mullerian hormone 
1 antiphospholipids-
induced 
1 apolipoprotein D 
1 Apolipoprotein L1 
1 aryl hydrocarbon 
hydroxylases 





1 caspase 12 




1 complement C3b 
1 complex II deficiency 
1 complex IV deficiency 
1 cyclic ADP-ribose 






1 elevated copper 









1 High adiponectin 
1 histone 
acetyltransferases 




1 L-ascorbic acid 
1 lathosterol 
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1 pyruvate carboxylase 
1 S-nitrosoglutathione 
1 sex steroid hormones 
1 ulifloxacin 
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TABLE 7A-9b - Existing PN/PAD Symptoms/Diseases 
# REC SYMPTOM/DISEASE  
17050 neuropathy 
13577 peripheral neuropathy 
9627 diabetes mellitus 
9078 artery disease 
8114 peripheral artery disease 







2861 neuropathic pain 
2612 stroke 
2152 diabetic peripheral 
neuropathy 
2071 infection 
2056 myocardial infarction 
2051 cardiovascular disease 
1983 intermittent claudication 
1913 polyneuropathy 
1796 coronary artery disease 
1585 heart disease 
1571 type 2 diabetes mellitus 
1547 critical limb ischemia 
1533 diabetic foot ulcer 
1519 Disorder 
1440 heart failure 
1135 weakness 
879 neutropenia 
878 cerebrovascular disease 
833 sensory neuropathy 
832 retinopathy 




747 renal failure 
731 thrombosis 
705 ataxia 




645 renal disease 
625 Congestive heart failure 
623 multiple myeloma 




613 chronic kidney disease 
612 vasculitis 
607 ischemic heart disease 
602 restenosis 














433 atrial fibrillation 
417 balance 
412 chronic pain 
400 mononeuropathy 
391 lymphoma 
389 rheumatoid arthritis 
388 End stage renal disease 
387 autonomic neuropathy 
385 dementia 
380 axonal neuropathy 







354 ischemic stroke 
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352 Guillain-Barre syndrome 
345 carpal tunnel syndrome 
343 hyperlipidemia 
332 leprosy 
319 type 1 diabetes mellitus 
314 hepatitis 
308 renal insufficiency 
306 encephalopathy 
305 demyelinating peripheral 
neuropathy 
304 motor neuropathy 
303 Coronary Syndrome 
295 neurological symptoms 
285 neurologic disease 






271 metabolic syndrome 




250 left ventricular 
hypertrophy 







224 diabetic retinopathy 
220 hypotension 
213 multiple sclerosis 
205 coronary disease 
202 paresthesia 
199 constipation 
199 monoclonal gammopathy 
190 proteinuria 
187 diabetic nephropathy 
187 Mixed Cryoglobulinemia 
187 Sjogren's syndrome 
179 nerve dysfunction 






162 angina pectoris 
160 axonopathy 
158 lung disease 
157 Parkinson's disease 
157 renal dysfunction 
152 autoimmune disease 
150 albuminuria 
150 hypoxia 
149 liver disease 
149 sensorimotor neuropathy 
147 hyperplasia 
133 erectile dysfunction 
126 renal impairment 
125 artery calcification 
124 vasculitic neuropathy 
123 amyotrophic lateral 
sclerosis 
123 systemic atherosclerosis 
120 axonal polyneuropathy 
119 hypothyroidism 
119 myocardial ischemia 
117 neurodegenerative 
disease 
113 Alzheimer's disease 
113 POEMS syndrome 
110 atherosclerotic vascular 
disease 
110 Osteoporosis 
107 carotid artery disease 
107 peripheral 
polyneuropathy 
107 reactive hyperemia 
103 neuromuscular disease 
103 optic neuropathy 
102 impaired glucose 
tolerance 
101 endocrinopathy 
101 Macrovascular disease 
88 motor neuron disease 
86 cerebral infarction 
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84 arterial stenosis 












72 complex regional pain 
syndrome 
72 microvascular disease 
70 dysphagia 
70 polyarteritis nodosa 
69 HIV disease 




67 Restless legs syndrome 
66 vascular calcification 
65 hypoglycemic 
65 polyangiitis 





59 metabolic disease 
58 impaired renal function 
56 celiac disease 
56 Crohn's disease 
55 demyelinating disease 
54 coronary atherosclerosis 
54 inflammatory bowel 
disease 
54 macroalbuminuria 
53 sleep apnea 
52 nephrotic syndrome 
51 carotid atherosclerosis 
48 gammopathies 
47 connective tissue disease 
47 proliferative retinopathy 
46 cardiac autonomic 
neuropathy 
43 Buerger's disease 
43 Lyme disease 
41 arteriosclerosis 
obliterans 
41 polyvascular disease 
41 vascular dysfunction 
38 cutaneous vasculitis 
37 Fabry disease 
37 Miller Fisher syndrome 
33 hypercoagulability 
31 hypoalbuminemia 
31 mitochondrial diseases 
31 muscle ischemia 
30 Castleman's disease 
30 diplopia 
30 Hansen's disease 
29 Behcet's disease 
29 chronic liver disease 
28 sicca syndrome 
26 hyperuricemia 
25 gluten sensitivity 
25 peripheral ischemia 
21 Hypereosinophilic 
syndrome 
20 aortic stiffness 
18 coronary artery stenosis 
17 normoalbuminuria 




12 mechanical stress 
12 rheumatoid vasculitis 
11 hypomagnesemia 
11 neurone disease 
10 neurosyphilis 
10 social isolation 
9 low physical activity 
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Table 7A-10 - Angiogenesis Co-Occurrences with other Biomarkers 
# RECORDS BIOMARKER # CO-
OCCURRENCES 
489 angiogenesis 489 
671 growth factor 190 
278 vascular endothelial growth factor 131 
932 blood flow 121 
2536 inflammation 64 
700 oxygen 43 
841 proteins 42 
516 cytokine 39 
52 Angiogenic growth factors 39 
80 fibroblast growth factor 39 
81 Endothelial progenitor cells 36 
318 nitric oxide 32 
2038 ankle brachial index 29 
610 pain-free walking distance 28 
309 apoptosis 28 
52 hepatocyte growth factor 25 
856 marker 21 
2320 toxicity 17 
1138 blood glucose levels 16 
426 circulation 16 
284 endothelial dysfunction 14 
115 nitric oxide synthase 14 
419 oxidative stress 13 
74 matrix metalloproteinase 13 
29 fibroblast growth factor 2 12 
2638 lesions 12 
1549 blood pressure 11 
318 edema 10 
28 CD31 10 
345 tumour necrosis factor-alpha 10 
1402 stenosis 9 
41 CD34 8 
152 Reactive oxygen species 8 
1091 degeneration 7 
413 plaque 7 
52 l-arginine 6 
18 HIF-1alpha 6 
42 thromboangiitis 6 
51 epidermal growth factor 5 
41 transforming growth factor beta 5 
17 CXCR4 5 
748 atrophy 5 
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412 occlusions 5 
16 neoangiogenesis 5 
26 miRNA 5 
25 platelet-derived growth factor 5 
2277 nerve conduction velocity 4 
126 vitamin E deficiency 4 
23 integrin 4 
78 transcutaneous oxygen pressure 4 
168 platelet aggregation 4 
186 proinflammatory cytokine 4 
128 IL-1beta 4 
640 Schwann cell 4 
101 vasculopathy 4 
1156 body mass index 3 
185 insulin resistance 3 
18 heme oxygenase 1 3 
55 Venous occlusion 3 
13 cyclic guanine monophosphate 3 
20 arterial obstruction 3 
6 oxygen radicals 3 
61 monoclonal antibodies 3 
15 osteopontin 3 
99 antioxidants 3 
17 High-mobility group box 1 3 
36 heme 3 
329 lipids 3 
7 neuropilin-1 3 
69 prostacyclin 3 
435 Systolic blood pressure 3 
202 T-cell 3 
33 cerebral ischemia 3 
37 matrix metalloproteinase 9 3 
1061 hemoglobin A1c 3 
266 IL-6 3 
7 thrombospondin 2 
1139 total cholesterol 2 
747 dorsal root ganglia 2 
693 lipoprotein 2 
6 Telomerase 2 
549 C reactive protein 2 
4 angiogenin 2 
16 proline 2 
2 endostatin 2 
53 chemokines 2 
2 Wnt5a 2 
35 IL-8 2 
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354 neurodegeneration 2 
344 sodium 2 
308 fibrinogen 2 
283 denervation 2 
50 NF-kappaB 2 
206 nerve growth factor 2 
49 monocyte chemoattractant 
protein-1 
2 
170 nerve regeneration 2 
123 acetylcholine 2 
119 glutathione 2 
26 growth hormone 2 
107 lactate 2 
106 von Willebrand factor 2 
105 plasminogen activator inhibitor-1 2 
104 thrombin 2 
102 atherosclerotic plaque 2 
100 intercellular adhesion molecule-1 2 
94 Lipoprotein(a) 2 
84 malondialdehyde 2 
39 cyclic AMP 2 
69 lipid peroxidation 2 
66 mRNA levels 2 
65 Zinc 2 
37 E-selectin 2 
37 endothelin-1 2 
28 matrix metalloproteinase 2 2 
9 beta-galactosidase 2 
1142 neurotoxic 1 
616 demyelination 1 
538 calcium 1 
495 low-density lipoprotein cholesterol 1 
24 IL-4 1 
29 acetylcholinesterase 1 
20 insulin-like growth factor I 1 
29 asymmetric dimethylarginine 1 
27 vascular reactivity 1 
154 B-cell 1 
25 cysteine 1 
80 fibrin 1 
48 thymidine 1 
80 folic acid 1 
162 glycated haemoglobin 1 
183 pulse wave velocity 1 
197 autoantibodies 1 
29 laminin 1 
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39 bacterial infection 1 
26 HMG-CoA reductase 1 
14 MMA 1 
70 peak oxygen consumption 1 
26 Hydrogen peroxide 1 
18 estradiol 1 
69 superoxide dismutase 1 
38 connexin 32 1 
17 elastin 1 
114 creatine 1 
65 advanced glycation end product 1 
65 magnesium 1 
33 hypoperfusion 1 
27 cyclooxygenase 2 1 
34 actin 1 
251 angiotensin converting enzyme 1 
261 high homocysteine 1 
61 oxygen saturation 1 
27 RAGE 1 
102 IgA 1 
273 glycoprotein 1 
19 Ccl2 1 
52 MetS 1 
365 nerve damage 1 
58 Neutrophils 1 
12 adipokine 1 
12 arterial calcifications 1 
12 insulin deficiency 1 
10 lysophosphatidic acid 1 
10 Nrf2 1 
41 alkaline phosphatase 1 
9 CD133 1 
9 heparan sulfate 1 
8 glucagon 1 
8 Retroviruses 1 
7 CD14 1 
17 excitotoxicity 1 
7 phosphatidylinositol 3-kinase 1 
135 platelet activation 1 
7 TNFR2 1 
6 kallikrein 1 
402 albumin level 1 
6 prolactin 1 
26 leptin 1 
5 CD16 1 
5 CD86 1 
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5 Glyoxalase 1 1 
5 sphingosine 1 
4 Adrenomedullin 1 
45 neuronal damage 1 
4 IL-22 1 
4 SO2 1 
3 arginase 1 
3 GTP cyclohydrolase 1 
3 NF68 1 
3 serum nitrate 1 
47 glycosylation 1 
2 protein tyrosine phosphatases 1 
18 NADPH oxidases 1 
1 Perlecan 1 
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Table 7A-11 - Oxidative Stress Co-Occurrences with other Biomarkers 
#REC BIOMARKER #CO-
OCC 
419 oxidative stress 419 
2536 inflammation 117 
700 oxygen 72 
1138 blood glucose levels 60 
152 Reactive oxygen 
species 
53 
119 glutathione 52 
841 proteins 47 
99 antioxidants 46 
309 apoptosis 44 
318 nitric oxide 44 
69 superoxide dismutase 41 
84 malondialdehyde 39 
2277 nerve conduction 
velocity 
37 
69 lipid peroxidation 36 
284 endothelial dysfunction 30 
932 blood flow 30 
693 lipoprotein 30 
747 dorsal root ganglia 27 
856 marker 27 




2320 toxicity 25 
1139 total cholesterol 23 
1091 degeneration 23 
1142 neurotoxic 22 
495 low-density lipoprotein 
cholesterol 
21 
1061 hemoglobin A1c 20 
671 growth factor 20 
549 C reactive protein 20 
65 advanced glycation end 
product 
19 
1549 blood pressure 18 
329 lipids 18 
354 neurodegeneration 18 
538 calcium 17 
345 tumour necrosis factor-
alpha 
17 
516 cytokine 17 
34 catalase 16 
126 vitamin E deficiency 16 
266 IL-6 16 
185 insulin resistance 15 
26 glutathione peroxidase 14 
115 nitric oxide synthase 14 
2038 ankle brachial index 14 
33 oxidative damage 14 
1156 body mass index 13 
489 angiogenesis 13 
261 high homocysteine 13 
413 plaque 13 
2638 lesions 12 
616 demyelination 12 
610 pain-free walking 
distance 
12 
278 vascular endothelial 
growth factor 
11 
499 triglycerides 10 
41 free radicals 10 
308 fibrinogen 10 




399 glomerular filtration 
rate 
9 
26 Hydrogen peroxide 9 
23 peroxynitrite 8 
47 glycosylation 8 
36 heme 8 
18 NADPH oxidases 8 
455 axonal degeneration 7 
158 nerve fiber density 7 
426 circulation 7 
14 TBARS 7 
210 fatty acid 7 
10 Nrf2 7 
8 isoprostane 7 
206 nerve growth factor 6 
45 neuronal damage 6 
49 protein kinases 6 
704 creatinine 6 
12 NOx 6 
18 heme oxygenase 1 6 
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151 arterial stiffness 6 
80 folic acid 5 








102 atherosclerotic plaque 5 
51 glucose metabolism 5 
96 uric acid 5 
49 cytochrome c 5 
382 calcification 5 
115 white blood cell 5 
147 lipid profile 5 
21 Oxidized low-density 
lipoprotein 
5 
50 NF-kappaB 5 
6 lipid hydroperoxides 5 
52 l-arginine 5 
154 B-cell 4 
263 vitamin B(12) 
deficiency 
4 




40 myeloperoxidase 4 
60 heat shock 4 
105 plasminogen activator 
inhibitor-1 
4 
37 endothelin-1 4 
208 carotid artery intima-
media thickness 
4 
18 caspase 3 4 
33 ferritin 4 
7 4-hydroxy-2-nonenal 4 




84 fiber loss 4 
6 oxygen radicals 4 
104 pulse pressure 4 
100 intercellular adhesion 
molecule-1 
4 
52 MetS 3 
44 adiponectin 3 
26 leptin 3 
318 edema 3 
147 capsaicin 3 
73 thiamine 3 
128 IL-1beta 3 
42 leucocytes 3 
107 lactate 3 
365 nerve damage 3 
59 nitrogen 3 
123 acetylcholine 3 
19 Ccl2 3 
125 Vitamin D deficiency 3 
125 apolipoprotein 3 
55 Ca(2+) 3 
1402 stenosis 3 
70 IL-10 3 
195 thermal hyperalgesia 3 
13 ceruloplasmin 3 
183 pulse wave velocity 3 
66 mRNA levels 3 
237 vibration perception 
threshold 
3 
27 glutamine 3 
8 paraoxonase-1 3 
106 von Willebrand factor 3 
126 glutamate 3 
21 bradykinin 3 
98 calcitonin gene-related 
peptide 
2 
29 phospholipids 2 
92 substance P 2 
81 Endothelial progenitor 
cells 
2 
28 CD31 2 
74 thromboxane 2 
65 magnesium 2 
65 Zinc 2 
28 Tau 2 
18 selenium 2 
26 growth hormone 2 
61 oxygen saturation 2 
61 P-selectin 2 
27 cyclooxygenase 2 2 
54 glial fibrillary acidic 
protein 
2 
53 chemokines 2 
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52 hepatocyte growth 
factor 
2 
27 RAGE 2 
48 bilirubin 2 
27 vascular reactivity 2 
43 erythrocytes 2 
41 alkaline phosphatase 2 
40 arginine 2 
402 albumin level 2 
40 sorbitol 2 
391 ventricular ejection 
fraction 
2 
16 pyridoxal 2 
322 heart rate 2 
14 MMA 2 
35 HCY 2 
35 IL-8 2 
17 CXCR4 2 
34 actin 2 
283 denervation 2 
29 acetylcholinesterase 2 
240 myelinated fibers 2 
222 weight loss 2 
29 adenine 2 
32 insulin levels 2 
175 diastolic blood 
pressure 
2 
170 nerve regeneration 2 
12 adipokine 2 
162 glycated haemoglobin 2 
159 lymphocytes 2 
8 arterial dilatation 2 
135 platelet activation 2 
126 Transthyretin 2 
8 taurine 2 
17 excitotoxicity 2 
7 neuropilin-1 2 
6 arterial elasticity 2 
6 Cu 2 
104 thrombin 2 
101 vasculopathy 2 
5 galectin-3 2 
4 Nox2 2 
3 hydroxyl radical 
antioxidant capacity 
2 
2 glutaredoxin 2 
25 cysteine 1 
41 transforming growth 
factor beta 
1 
68 D-dimer 1 
40 DBP 1 
40 dopamine 1 
20 folate deficiency 1 
20 insulin-like growth 
factor I 
1 
19 riboflavin 1 
39 bacterial infection 1 
25 Helicobacter pylori 1 
52 Angiogenic growth 
factors 
1 
13 atheromatous plaque 1 
38 glycine 1 




37 blood urea nitrogen 1 
37 E-selectin 1 




19 thrombomodulin 1 
72 systemic sclerosis 1 
14 fos 1 
24 cadmium 1 
15 DNA polymerase 
gamma 
1 
51 cardiac troponin T 1 
28 carotid-femoral pulse 
wave velocity 
1 
94 Lipoprotein(a) 1 
27 high total cholesterol 1 
29 laminin 1 
34 cystatin C 1 
34 histamine 1 
27 methylmalonic acid 1 
14 myo-inositol 1 
20 aldosterone 1 
33 cerebral ischemia 1 
103 urea 1 
33 glial activation 1 
23 transferrin 1 
49 monocyte 1 
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chemoattractant 
protein-1 
15 cholestanol 1 
108 creatinine clearance 1 
22 lipase 1 
58 methionine 1 
58 Neutrophils 1 
26 Endothelin 1 
12 beta-carotene 1 
12 caspases 1 
12 insulin deficiency 1 
110 waist circumference 1 




10 ammonia 1 
29 Chlamydia pneumoniae 1 




9 low testosterone 1 
168 platelet aggregation 1 
30 beta 2 microglobulin 1 
20 CD40 ligand 1 
8 S100 beta 1 
26 HMG-CoA reductase 1 
70 peak oxygen 
consumption 
1 
202 T-cell 1 
247 amyloid 1 
251 angiotensin converting 
enzyme 
1 
6 GRP78 1 
273 glycoprotein 1 
42 thromboangiitis 1 
6 Telomerase 1 
6 transketolase 1 
55 Venous occlusion 1 




4 glutathione transferase 1 
4 metallothionein 1 
17 aortic pulse wave 
velocity 
1 
4 Sirtuin 1 1 
3 acetaldehyde 1 
3 CXCL10 1 
3 glutathione reductase 1 
3 GTP cyclohydrolase 1 
3 hydroperoxide 1 
16 neoangiogenesis 1 
3 iron deposition 1 
3 LXR 1 
3 neurotensin 1 
2 deoxyguanosine 1 
435 Systolic blood pressure 1 
2 miR-130a 1 
2 miR-210 1 




2 TREM-1 1 




1 cyclooxygenase 1 1 
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2638 lesions 985 1503 
2536 inflammation 1445 1143 
2320 toxicity 2077 186 
2277 nerve conduction velocity 2003 183 
2038 ankle brachial index 93 1984 
1549 blood pressure 334 1362 
1402 stenosis 72 1274 
1156 body mass index 378 868 
1142 neurotoxic 980 37 
1139 total cholesterol 261 1003 
1138 blood glucose levels 685 625 
1091 degeneration 874 167 
1061 hemoglobin A1c 663 646 
932 blood flow 167 802 
856 marker 321 558 
841 proteins 568 245 
748 atrophy 633 93 
747 dorsal root ganglia 631 28 
704 creatinine 230 550 
700 oxygen 184 536 
693 lipoprotein 117 625 
671 growth factor 318 344 
640 Schwann cell 506 25 
616 demyelination 536 56 
610 pain-free walking distance 17 598 
549 C reactive protein 68 507 
538 calcium 249 274 
516 cytokine 289 211 
499 triglycerides 158 410 
495 low-density lipoprotein 
cholesterol 
70 461 
489 angiogenesis 56 439 
455 axonal degeneration 402 73 
435 Systolic blood pressure 88 392 
426 circulation 86 362 
425 high-density lipoprotein 
cholesterol 
105 386 
419 oxidative stress 223 212 
413 plaque 22 382 
412 occlusions 3 358 
402 albumin level 162 304 
399 glomerular filtration rate 95 338 
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391 ventricular ejection 
fraction 
33 366 
382 calcification 45 346 
365 nerve damage 238 32 
354 neurodegeneration 305 42 
349 IgM 325 46 
345 tumour necrosis factor-
alpha 
225 126 
344 sodium 229 114 
329 lipids 92 255 
322 heart rate 133 204 
318 edema 205 120 
318 nitric oxide 114 188 
309 apoptosis 203 86 
308 fibrinogen 24 292 
284 endothelial dysfunction 44 251 
283 denervation 202 40 
278 vascular endothelial 
growth factor 
89 202 
273 glycoprotein 187 75 
266 IL-6 107 157 
263 vitamin B(12) deficiency 198 68 
262 stenoses 6 248 
261 high homocysteine 58 215 
251 angiotensin converting 
enzyme 
31 223 
247 amyloid 213 50 
240 myelinated fibers 199 30 
237 vibration perception 
threshold 
225 55 
222 weight loss 162 81 
210 fatty acid 118 92 
208 carotid artery intima-media 
thickness 
12 197 
206 nerve growth factor 170 8 
202 T-cell 152 41 
197 autoantibodies 153 48 
195 thermal hyperalgesia 177 3 
193 CD4 177 19 
186 proinflammatory cytokine 110 72 
185 insulin resistance 76 148 
183 pulse wave velocity 16 158 
175 diastolic blood pressure 41 161 
170 nerve regeneration 87 7 
168 platelet aggregation 10 161 
162 glycated haemoglobin 117 103 
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159 lymphocytes 104 40 
158 nerve fiber density 154 8 
154 B-cell 126 35 
152 Reactive oxygen species 84 68 
151 arterial stiffness 11 132 
147 capsaicin 129 14 
147 lipid profile 53 123 
135 platelet activation 3 134 
128 IL-1beta 83 37 
126 glutamate 98 9 
126 Transthyretin 122 7 
126 vitamin E deficiency 80 42 
125 apolipoprotein 27 96 
125 Vitamin D deficiency 52 81 
123 acetylcholine 74 46 
122 mechanical hyperalgesia 114 2 
119 glutathione 92 24 
118 compound muscle action 
potential 
90 9 
115 Mitochondrial dysfunction 99 16 
115 nitric oxide synthase 63 46 
115 white blood cell 37 81 
114 creatine 69 44 
110 waist circumference 29 93 
108 creatinine clearance 38 83 
107 lactate 59 46 
106 von Willebrand factor 11 99 
105 plasminogen activator 
inhibitor-1 
6 98 
104 pulse pressure 12 96 
104 thrombin 2 99 
103 urea 50 67 
102 atherosclerotic plaque 2 102 
102 IgA 91 18 
101 vasculopathy 51 64 
100 intercellular adhesion 
molecule-1 
20 84 
99 antioxidants 53 47 
98 calcitonin gene-related 
peptide 
73 7 
96 uric acid 26 80 
95 blood viscosity 26 75 
94 Lipoprotein(a) 8 92 
92 albumin excretion rate 55 74 
92 substance P 71 10 
84 fiber loss 76 15 
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84 malondialdehyde 48 35 
81 Endothelial progenitor cells 6 79 
81 orthostatic hypotension 63 30 
80 fibrin 10 70 
80 fibroblast growth factor 17 67 
80 folic acid 33 46 
78 transcutaneous oxygen 
pressure 
5 75 
74 creatine kinase 52 25 
74 matrix metalloproteinase 22 57 
74 thromboxane 3 70 
73 thiamine 68 4 
72 systemic sclerosis 26 49 
70 IL-10 40 28 
70 peak oxygen consumption 12 58 
69 lipid peroxidation 37 31 
69 prostacyclin 6 66 
69 superoxide dismutase 46 23 
69 troponin 5 69 
68 D-dimer 2 68 
66 mRNA levels 45 17 
65 advanced glycation end 
product 
41 39 
65 magnesium 51 13 
65 Zinc 44 17 
64 anti-neutrophil cytoplasmic 
antibody 
58 46 
64 erythrocyte sedimentation 
rate 
47 34 
64 Red Blood Cell 17 47 
61 monoclonal antibodies 41 14 
61 oxygen saturation 7 54 
61 P-selectin 2 60 
60 heat shock 50 10 
60 rheumatoid factor 51 32 
59 acetylsalicylic acid 1 58 
59 nitrogen 25 39 
58 methionine 29 27 
58 Neutrophils 29 31 
55 Ca(2+) 41 10 
55 Venous occlusion 6 53 
54 glial fibrillary acidic protein 41 6 
53 chemokines 32 18 
53 Tissue Plasminogen 
Activator 
 50 
52 Angiogenic growth factors 5 50 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                                                                                                                
Chapter 7 - Tables and Figures                                                                                                                               270 
52 BDNF 39 4 
52 hepatocyte growth factor 6 47 
52 l-arginine 12 36 
52 MetS 7 47 
51 cardiac troponin T 4 51 
51 epidermal growth factor 39 8 
51 glucose metabolism 28 31 
51 prothrombin 8 47 
50 NF-kappaB 34 17 
49 adenosine diphosphate 3 46 
49 bone mineral density 27 30 
49 cytochrome c 45 4 
49 monocyte chemoattractant 
protein-1 
11 31 
49 protein kinases 36 12 
48 bilirubin 27 26 
48 thymidine 43 4 
48 urinary albumin/creatinine 
ratio 
15 42 
47 glycosylation 38 19 
45 neuronal damage 41 12 
44 adiponectin 13 37 
44 alanine 35 11 
44 carbon dioxide 10 31 
44 Mercury 28 9 
43 erythrocytes 20 17 
42 leucocytes 6 37 
42 myelin basic protein 36 3 
42 neuroinflammation 39 3 
42 phosphorus 9 34 
42 thromboangiitis 1 38 
41 alkaline phosphatase 18 22 
41 apolipoprotein B 4 39 
41 CD34 12 31 
41 free radicals 19 25 
41 N-terminal pro-brain 
natriuretic peptide 
1 41 
41 transforming growth factor 
beta 
17 28 
40 arginine 21 16 
40 DBP 7 37 
40 dopamine 26 9 
40 myeloperoxidase 16 29 
40 sorbitol 35 3 
39 apolipoprotein A-I 12 26 
39 bacterial infection 21 22 
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39 cyclic AMP 21 14 
39 endothelial damage 10 34 
38 connexin 32 37  
38 glycine 35 3 
38 Noradrenaline 32 6 
38 vitamin K 3 33 
37 blood urea nitrogen 17 25 
37 E-selectin 8 30 
37 endothelin-1 9 26 
37 matrix metalloproteinase 9 15 25 
36 arachidonic acid 7 27 
36 heme 28 8 
36 IgG antibodies 26 14 
36 niacin 11 26 
35 glycogen 27 5 
35 HCY 10 27 
35 IL-8 8 30 
35 interferon gamma 22 7 
34 actin 21 10 
34 catalase 22 10 
34 cystatin C 7 29 
34 histamine 25 4 
34 Streptococcal 17 20 
33 anti-ganglioside antibodies 29 1 
33 catecholamine 15 11 
33 cerebral ischemia 8 33 
33 ferritin 9 24 
33 glial activation 31 1 
33 hypoperfusion 7 27 
33 oxidative damage 16 16 
32 anti-MAG antibodies 31 1 
32 insulin levels 22 15 
32 polyunsaturated fatty acids 8 21 
31 parathyroid hormone 9 21 
31 progesterone 25 3 
30 beta 2 microglobulin 18 14 
30 body fat 9 22 
30 Gamma-aminobutyric acid 27 2 
29 acetylcholinesterase 21 5 




29 Chlamydia pneumoniae  29 
29 fibroblast growth factor 2 10 20 
29 laminin 19 4 
29 phospholipids 12 20 
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28 albumin/creatinine 7 25 
28 brain atrophy 21 7 
28 carotid-femoral pulse wave 
velocity 
3 23 
28 CD31 4 27 
28 matrix metalloproteinase 2 11 20 
28 Osteoprotegerin 6 27 
28 phosphocreatine 5 24 
28 Tau 20 8 
28 thromboxane A2  27 
27 antinuclear antibodies 23 16 
27 Apolipoprotein E 8 16 
27 cholinesterase 17 1 
27 cyclooxygenase 2 17 9 
27 epinephrine 6 16 
27 GDNF 19  
27 glutamine 25  
27 high total cholesterol 5 26 
27 methylmalonic acid 25 3 
27 RAGE 16 14 
27 vascular reactivity 9 19 
26 Endothelin 8 19 
26 glutathione peroxidase 16 8 
26 growth hormone 15 12 
26 HMG-CoA reductase 10 19 
26 Hydrogen peroxide 11 14 
26 leptin 13 14 
26 miRNA 8 18 
25 amyloid beta 16 6 
25 cysteine 14 11 
25 GP IIb/IIIa  25 
25 Helicobacter pylori 9 18 
25 Iron Deficiency 19 9 
25 platelet-derived growth 
factor 
9 18 
25 sulfatide 23 2 
24 aspartate aminotransferase 17 9 
24 cadmium 5 16 
24 IL-4 14 10 
23 copper deficiency 16 1 
23 immune activation 17 9 
23 integrin 10 11 
23 peroxynitrite 18 6 
23 transferrin 12 12 
22 CD8 19 4 
22 lipase 13 10 
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22 Vitamin B1 deficiency 21 3 
21 bradykinin 6 12 
21 Escherichia coli 14 8 




21 Oxidized low-density 
lipoprotein 
2 17 
21 prostate-specific antigen 19 3 
20 acylcarnitine 10 7 
20 adenosine triphosphate 11 10 
20 aldosterone 6 14 
20 arterial obstruction 2 19 
20 CD40 ligand 3 16 
20 folate deficiency 14 6 
20 insulin-like growth factor I 16 4 
20 thromboxane B2 1 19 
20 transaminases 19 5 
19 Ccl2 10 7 
19 riboflavin 17 1 
19 serum calcium 6 16 
19 thrombomodulin 4 15 
19 vascular calcifications  16 
18 amyloid fibrils 16 2 
18 c-Fos 15  
18 caspase 3 16 1 
18 docosahexaenoic acid 7 11 
18 eicosapentaenoic acid 3 15 
18 endothelial activation 2 16 
18 estradiol 2 15 
18 heme oxygenase 1 11 7 
18 HIF-1alpha 4 17 
18 luminal diameter  18 
18 NADPH oxidases 8 11 
18 renin 7 13 
18 selenium 10 8 
17 5-hydroxytryptamine 4 12 
17 aortic pulse wave velocity 1 17 
17 arterial compliance  17 
17 bone density 10 8 
17 compound motor action 
potential 
12 2 
17 CXCR4 10 7 
17 cytomegalovirus infection 14 6 
17 dehydration 10 5 
17 desmin 15 2 
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17 elastin 3 15 
17 excitotoxicity 14 3 
17 High-mobility group box 1 9 11 
17 IL-2 10 6 
17 lactic acid 8 4 
17 lead levels 10 2 
17 porphobilinogen 17  
17 prothrombin time 4 13 
16 androgen 8 5 
16 factor Xa  16 
16 galanin 9  
16 neoangiogenesis  16 
16 PGE2 7 7 
16 phytanic acid 15  
16 proline 13 4 
16 pyridoxal 10 5 
15 activated partial 
thromboplastin time 
 15 
15 calcium phosphate 4 11 
15 calpain 12 2 
15 cholestanol 15 3 
15 cortisol 4 8 
15 digoxin 2 15 
15 DNA polymerase gamma 14 1 
15 osteopontin 2 13 
14 anti-GM1 antibody 12 3 
14 antithrombin III 3 13 
14 CD68 6 7 
14 choline 8 4 
14 CNTF 10 2 
14 Fas 8 4 
14 fos 9 2 
14 MMA 13 2 
14 myo-inositol 12 1 
14 porphyrin 14 2 
14 TBARS 9 5 
13 atheromatous plaque  12 
13 ceruloplasmin 5 5 
13 complement levels 12 7 
13 cyclic guanine 
monophosphate 
2 8 
13 E. coli 8 6 
13 elastase 2 11 
13 Fetuin-A 2 13 
13 leucine 10 1 
13 Lipoprotein-associated  13 
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phospholipase A2 
13 Neopterin 6 8 
13 RNA levels 11 1 
13 thyroxine 8 4 
13 transglutaminase 11 2 
13 vasopressin 1 10 
12 adipokine 2 10 
12 anticardiolipin antibodies 6 7 
12 arterial calcifications  10 
12 beta-carotene 2 10 
12 C1q 10 4 
12 calcineurin 9 5 
12 caspases 10  
12 Chondroitin sulfate 8 2 
12 hydrogen sulfide 5 7 
12 IgE 10 5 
12 insulin deficiency 12 2 
12 MEP 10  
12 mitogen-activated protein 
kinases 
10 2 
12 NOx 1 11 
12 PBMCs 7 4 
12 Proteus 4 6 
12 sE-selectin 3 10 
12 spirochete 9 1 
11 anti-gliadin antibodies 11 4 
11 Coxsackie 10 1 
11 dendritic cells 3 7 
11 dipeptidyl peptidase 4 8 
11 excitatory amino acids 10 1 




11 histidine 9 1 
11 IL-12 5 6 
11 Myelin breakdown 11  
11 Pseudomonas aeruginosa 6 9 
11 Resistin 3 8 
10 ammonia 6 2 
10 AMPA 10  
10 apolipoprotein(a)  10 
10 cathepsins 5 5 




10 glycogen synthase 10  
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10 low birth weight 3 8 
10 lysophosphatidic acid 7 1 
10 Nrf2 7 2 
10 polyglutamine 10  
10 S-adenosylmethionine 5 5 
10 threonine 9 1 
10 tryptophan 8 1 
9 adenosine monophosphate 4 4 
9 alpha-synuclein 6  
9 anticholinesterase 9 1 
9 Aortic augmentation index  9 
9 beta-galactosidase 5 3 
9 BNP levels 1 9 
9 BSA 8 1 




9 deoxyuridine 9  
9 enolase 7 1 
9 fibrin D-dimer  9 
9 fungi 5 3 
9 heparan sulfate 3 8 
9 iodine 4 5 
9 low testosterone 5 7 
9 phenylalanine 7 2 
9 squalene 7  
9 staphylococcal 5 6 
9 vascular stiffness 1 9 
8 arterial dilatation  7 
8 Aspergillus 3 4 
8 Butyrylcholinesterase 6  
8 CBM 4 4 
8 coagulation activation  8 
8 corticosterone 6  
8 glucagon 6 5 
8 gonadotropin 5 2 
8 inositol 6 2 
8 isoprostane 2 6 
8 leukotrienes 3 4 
8 osteocalcin  7 
8 paraoxonase-1 2 6 
8 phosphates 5 3 
8 Retroviruses 5 3 
8 S100 beta 7 1 
8 somatostatin 8 2 
8 taurine 8 1 
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8 thyrotropin 5 2 
7 4-hydroxy-2-nonenal 1 6 
7 aldehyde dehydrogenase 4 4 
7 amines 4 3 
7 angiotensin II type 1 2 6 
7 CD14 2 5 
7 coronary calcification  7 
7 HIV RNA levels 7  
7 horseradish peroxidase 3 1 
7 linoleic acid 3 3 
7 monomethylarsonic acid 1 6 
7 neuropilin-1 2 4 




7 thrombospondin  7 
7 TNFR2 4 4 
6 alcohols 6 2 
6 arterial elasticity  6 
6 citrulline 3 3 
6 Cu 2 2 
6 dimethylarsinic acid 2 4 
6 factor XIII  6 
6 fibroblast growth factor 23  6 
6 FVII  6 
6 glucuronic acid 6  
6 GRP78 3 2 
6 histone deacetylase 6 6 1 
6 IL-18 3 3 
6 kallikrein  6 
6 lipid hydroperoxides  6 
6 Methylglyoxal 5 2 
6 N-acetylglucosamine 5 1 
6 neurotoxic esterase 6  
6 oxygen radicals 1 3 
6 pentraxin  6 
6 pERK 4 1 
6 prolactin 3 3 
6 quinolinic acid 3 3 
6 Telomerase 2 4 
6 transketolase 6  
5 Acetylcarnitine 1 4 
5 apolipoprotein A-II 1 3 
5 apolipoprotein B-100 1 4 
5 CD11c 1 4 
5 CD16 1 3 
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5 CD86 2 3 
5 cyclin D1 2 1 
5 deoxyhemoglobin  5 
5 dihydrotestosterone 1 4 
5 galectin-3 2 4 
5 Glyoxalase 1 3 2 
5 guanosine monophosphate 1 2 
5 Guanylate Cyclase  4 
5 hyperphosphorylation 4  
5 IL-13 2 4 
5 inosine 2 2 
5 L-selectin  5 
5 lipofuscin 4  
5 luteinizing hormone 2 4 
5 monoamine oxidase 3 2 
5 omega-3 index  5 
5 perforin 4 1 
5 phenyl valerate 5  
5 platelet factor 4  5 
5 pregnenolone 5  
5 pristanic acid 5 1 
5 retinol 1 3 
5 sphingosine 3 1 
5 thiocyanate 3 2 
5 YKL-40  5 
4 Adrenomedullin 2 2 
4 amyloid precursor protein 4 1 
4 angiogenin 2 3 
4 angiotensinogen 1 4 
4 apolipoprotein B-48 1 3 
4 apolipoprotein C-III  4 
4 arterial tonometry index 
(RHI) 
 4 
4 beta-endorphin 3  
4 chromogranin 3 2 
4 dehydroepiandrosterone 3 2 
4 dynactin 4  
4 endopeptidases 3 3 
4 erythrocyte aggregation 2 3 
4 GHb 4 3 
4 glutathione transferase 4  
4 glycated albumin 3 4 




4 IgG4-positive plasma cells 4 2 
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4 IL-17 3 1 
4 IL-22 2 2 
4 indole 2 3 
4 Janus kinase 2 3 1 
4 mannose 3 2 
4 metallothionein 2  
4 myostatin 1 3 
4 nitrogen oxide 1 3 
4 Nox2  4 
4 S100A12  4 
4 Sirtuin 1 2 2 
4 SO2  3 
4 soluble guanylyl cyclase 2  
4 succinate dehydrogenase 3 1 
4 tetrahydrobiopterin 2 2 
4 tissue inhibitors of 
metalloproteinases 
 4 
4 ubiquinone 3 1 
4 valvular calcification  4 
4 vasoactive intestinal 
peptide 
1  
3 acetaldehyde 3  
3 acyl-CoA oxidase 2  
3 Allograft inflammatory 
factor-1 
3  
3 arginase 1 1 
3 B vitamin deficiency 3 1 
3 brain iron accumulation 2 1 
3 butyric acid 3 1 
3 CFU 1 2 
3 chorionic gonadotropin 1 1 
3 connective tissue growth 
factor 
1 2 
3 CXCL10 3  
3 eosinophil cationic protein 3 2 
3 factor XII  3 
3 Fusobacterium 3 3 
3 glucagon-like peptide 1 1 2 
3 Glucokinase 2 2 
3 glutathione reductase 3  
3 GTP cyclohydrolase 1 2 
3 hemosiderin 2 3 
3 hydroperoxide  3 
3 hydroxyl radical antioxidant 
capacity 
 3 
3 hyperoxia  3 
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3 iron deposition 2  
3 kynurenine 2  
3 LXR 3  
3 m-calpain 2  
3 mandelic acid 2 1 
3 methemoglobin 2 2 
3 mu-calpain 3  
3 N-acetylaspartate 3 1 
3 neurite loss 3 1 
3 neurotensin 3 1 




3 Nociceptin 2  
3 phosphatidylserine 1 2 
3 PINK1 3  




3 ryanodine 1 2 
3 S-adenosylhomocysteine 1 2 
3 sCD163 1 2 
3 serum nitrate 1 3 
3 sTWEAK  3 
3 trimethylamine 2 1 
3 waist-to-height ratio 1 2 
3 xanthine oxidase 1 2 
2 3-nitrotyrosine 2  
2 32P 2  
2 acid phosphatase 1  
2 adenosine deaminase 1  
2 adenosine kinase 2  
2 adenylyl cyclases 1  
2 agrin 1  
2 aminolevulinic acid 2  
2 aminopeptidases  2 
2 apoB/apoA-I ratio  2 
2 apolipoprotein A-IV 1 1 
2 apolipoprotein AI-CIII-AIV 
gene cluster 
 2 
2 aspartic acid 2  
2 campesterol 1 1 
2 carboxymethyl-lysine  2 
2 Cardiometabolic index 
(CMI) 
 2 
2 caspase 9 1  
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2 CCL4 2  
2 cyclin-dependent kinase 5 2  
2 deoxyguanosine 2  
2 deoxypyridinoline 2  
2 docosapentaenoic acid  2 
2 endostatin  2 
2 estrone  2 
2 follicle stimulating 
hormone 
2 1 
2 glutaredoxin  2 
2 herpes simplex virus 1 1 1 
2 hippuric acid 1 1 
2 histone deacetylases 1  
2 hydroxyproline 1 2 
2 Janus kinase 1 2  
2 JC virus 2 1 
2 Ketones 2  
2 kininase II  2 
2 kininogen fractions  2 
2 kynurenic acid 2  
2 measles virus 1  
2 midkine  2 
2 miR-130a  2 
2 miR-210  2 
2 miR-27b  2 
2 MuSK 1  
2 omentin-1 level  2 




2 Prevotella intermedia  2 
2 protein tyrosine 
phosphatases 
 2 
2 pyruvic acid 1  
2 saturated fatty acid 2  
2 suPAR level  2 
2 tachykinins 1  
2 transcription factor CHOP 2  
2 TREM-1  2 
2 vitamin C deficiency  2 




1 1,7-dimethylxanthine  1 
1 25-hydroxycholesterol  1 
1 27-hydroxycholesterol  1 
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1 3,4-dihydroxyphenylglycol 1  
1 3,5,3'-triiodothyronine 1  
1 5-bromo-2'-deoxyuridine 1  
1 7-ketocholesterol  1 
1 8-hydroxyguanosine  1 
1 8-oxoguanine 1  
1 adenylate kinase 1  
1 aniline hydroxylase 1  
1 Anti-Mullerian hormone  1 
1 antiphospholipids-induced 1 1 
1 apolipoprotein D 1  
1 Apolipoprotein L1  1 
1 aryl hydrocarbon 
hydroxylases 
1  
1 bacterial endotoxins  1 
1 benzo(a)pyrene 1  
1 beta-mannosidase 1  
1 calcium-dependent protein 
kinase 
1  
1 caspase 12 1  




1 CgA 1 1 
1 complement C3b 1  
1 complex II deficiency 1  
1 complex IV deficiency 1  
1 cyclic ADP-ribose 1  
1 cyclooxygenase 1  1 
1 cystathionine gamma-lyase 1  
1 cysteinylglycine  1 
1 dihydroxyphenylalanine 1  
1 DL-alpha-tocopherol 1  
1 elevated copper 1  
1 Ferric iron 1 1 
1 gamma-glutamylcysteine 1  
1 gamma-tocopherol  1 
1 glutaminase 1  
1 glyceraldehyde 1  
1 glyoxal 1  
1 granzymes 1  
1 hexokinase 1  
1 High adiponectin 1 1 
1 histone acetyltransferases 1  
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1 homocysteic acid  1 
1 hypochlorite  1 
1 isobutanol 1  
1 L-ascorbic acid  1 
1 lathosterol  1 




1 o-xylene  1 
1 oncostatin 1  
1 oxysterols  1 
1 p-cresol  1 
1 p300-CBP-associated factor  1 
1 pancreatic polypeptide 1  
1 Perlecan  1 
1 Peroxiredoxins  1 
1 phosphorylases 1  
1 polyamines  1 
1 polyQ 1  
1 prulifloxacin  1 
1 psychosine 1  
1 pyruvate carboxylase 1  
1 S-nitrosoglutathione  1 
1 sex steroid hormones 1  
1 ulifloxacin  1 
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Table 7A-13 - Causes Co-Occurring with Oxidative Stress 
#REC  CAUSE #C0- 
OCC 





296 Streptozotocin 31 
2265 smoking 24 
1140 High cholesterol 
diet 
23 
524 oxaliplatin 16 
985 paclitaxel 11 
149 Arsenic 10 
745 dialysis 9 
503 Bortezomib 9 
412 statins 7 
347 vincristine 7 
340 peripheral nerve 
injury 
6 
442 alcohol 6 
508 hemodialysis 6 
217 platinum 6 
19 high glucose 6 
66 high fat diet 6 
14 Hydrogen peroxide 6 







247 leading cause 5 
324 taxanes 5 
201 chronic constriction 
injury 
5 
49 acetone 5 
12 iron overload 4 
18 streptozocin 3 
570 trauma 3 
26 metals 3 
351 thalidomide 3 
196 docetaxel 3 
93 spinal cord injury 3 
86 alkaloids 3 
34 dichloroacetate 3 
9 manganese 3 
9 HFD 2 
9 dithiocarbamates 2 
9 allopurinol 2 
140 5-fluorouracil 2 
29 phenytoin 2 
131 sedentary 2 
83 axotomy 2 
76 Vinca alkaloids 2 




821 HIV-1 2 
65 Zinc 2 
708 infections 2 
545 depression 2 
61 simvastatin 2 
683 viruses 2 
22 heavy metals 2 
10 sodium arsenite 2 
30 carbon monoxide 2 





3 Bisphenol 2 
2 epoxy resins 2 
2 Paraquat 2 
30 valproic acid 1 







24 disulfiram 1 
357 anesthesia 1 




47 atorvastatin 1 
10 lentivirus 1 
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11 cyanide 1 
81 injury-induced 1 
314 hepatitis 1 
46 carfilzomib 1 
23 Helicobacter pylori 1 
186 Hepatitis C Virus 1 





7 sevoflurane 1 
64 formalin 1 
6 metoclopramide 1 
45 axonal injury 1 
5 palmitate 1 
22 atenolol 1 
5 Sleep deprivation 1 
12 tobacco smoke 1 
60 cancer therapy 1 
8 dietary deficiency 1 
32 pesticides 1 
31 Amiodarone 1 
58 ixabepilone 1 
42 levodopa 1 
22 infectious agents 1 
54 anticonvulsant 1 
5 zymosan 1 
7 fine particulate 
matter 
1 
20 folate deficient 1 




4 hydralazine 1 





4 prions 1 
96 malnutrition 1 
3 citalopram 1 
16 pravastatin 1 
8 pollutants 1 




1 3-NPA 1 
1 acrolein 1 
1 AlCl3 1 
1 atherogenic diet 1 
1 diquat 1 
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Table 7A-14 - Causes Co-Occurring with Blood Pressure 
#REC  CAUSE #CO-
OCC 
2265 smoking 411 
1140 High cholesterol diet 321 
442 alcohol 55 
337 lifestyle 53 
745 dialysis 52 




412 statins 37 
545 depression 27 
247 leading cause 23 
131 sedentary 20 
22 atenolol 10 
2507 chemotherapy 9 
357 anesthesia 9 
59 inactivity 9 
15 lisinopril 7 
96 malnutrition 7 
821 HIV-1 6 
14 enalapril 6 




66 high fat diet 5 
5 salt intake 5 
44 Mercury 5 
985 paclitaxel 4 
683 viruses 4 
39 lead exposure 4 





28 HMG-CoA reductase 
inhibitors 
4 
61 simvastatin 4 
47 atorvastatin 4 
42 hand-arm vibration 3 
96 drug-induced 3 
570 trauma 3 
708 infections 3 
73 coronary 3 
angioplasty 




361 radiation 3 
43 bariatric surgery 3 
3 felodipine 3 
324 taxanes 2 
24 immunization 2 
201 chronic constriction 
injury 
2 




28 vitamin D deficient 2 
21 vibration-induced 2 
149 Arsenic 2 
63 bevacizumab 2 
314 hepatitis 2 
67 solvents 2 
119 zidovudine 1 
118 Iatrogenic 1 
107 cytomegalovirus 1 
37 interferon-alpha 1 
96 gemcitabine 1 
37 nevirapine 1 
37 thiamine deficiency 1 
19 tenofovir 1 
93 spinal cord injury 1 
7 dust 1 
23 Helicobacter pylori 1 
14 Heroin 1 
89 Staphylococcus 1 
14 Hydrogen peroxide 1 
111 methotrexate 1 
570 cisplatin 1 
524 oxaliplatin 1 
83 liver transplant 1 
18 organic solvent 1 
34 dichloroacetate 1 
11 fructose 1 
7 Alemtuzumab 1 
11 INH 1 
7 sweeteners 1 
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5 mineralocorticoid 1 
6 manual work 1 
340 peripheral nerve 
injury 
1 
332 leprosy 1 
65 Zinc 1 
31 Amiodarone 1 
14 Leflunomide 1 
21 Drug Abuse 1 
61 cyclosporin 1 
7 fine particulate 
matter 
1 
329 radiation therapy 1 
296 Streptozotocin 1 
31 glucocorticoids 1 
30 carbon monoxide 1 
230 carboplatin 1 




56 epirubicin 1 




29 phenytoin 1 
10 contaminants 1 
217 platinum 1 
186 Hepatitis C Virus 1 




6 Methylglyoxal 1 
27 insecticide 1 
11 cyanide 1 
5 omeprazole 1 
9 air pollution 1 




5 gasoline 1 
11 cigarette smoke 1 
148 stavudine 1 
15 cobalt 1 
14 aluminum 1 
11 cocaine 1 
4 paints 1 
3 Bisphenol 1 
121 tuberculosis 1 
3 intermittent hypoxia 1 
2 disopyramide 1 
2 epoxy resins 1 
2 ramucirumab 1 
2 recreational drugs 1 
2 sepsis-induced 1 
2 Teriflunomide 1 
2 western diet 1 
1 antimony 1 




1 PFOA 1 
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Table 7A-15 - Biomarkers Co-Occurring with High Cholesterol Diet 
#REC BIOMARKER #CO-
OCC 
1139 total cholesterol 1139 
693 lipoprotein 472 
495 low-density lipoprotein 
cholesterol 
386 




1549 blood pressure 321 
1156 body mass index 209 
1138 blood glucose levels 191 
1061 hemoglobin A1c 169 
2038 ankle brachial index 164 
435 Systolic blood pressure 133 
329 lipids 116 
549 C reactive protein 96 
2536 inflammation 93 
704 creatinine 90 
308 fibrinogen 72 
402 albumin level 63 
856 marker 60 
125 apolipoprotein 59 
147 lipid profile 57 
175 diastolic blood 
pressure 
51 
1402 stenosis 50 
399 glomerular filtration 
rate 
48 
413 plaque 41 
2638 lesions 39 
261 high homocysteine 39 
185 insulin resistance 39 
96 uric acid 36 
162 glycated haemoglobin 34 
110 waist circumference 33 
94 Lipoprotein(a) 31 
208 carotid artery intima-
media thickness 
30 
2277 nerve conduction 
velocity 
28 
27 high total cholesterol 27 
538 calcium 27 
610 pain-free walking 27 
distance 
92 albumin excretion rate 26 
41 apolipoprotein B 26 
210 fatty acid 23 
419 oxidative stress 23 
104 pulse pressure 22 
841 proteins 22 
266 IL-6 22 
932 blood flow 21 
382 calcification 21 
284 endothelial dysfunction 20 
39 apolipoprotein A-I 20 
251 angiotensin converting 
enzyme 
19 
345 tumour necrosis factor-
alpha 
18 
36 niacin 17 
183 pulse wave velocity 17 
516 cytokine 17 
391 ventricular ejection 
fraction 
17 
426 circulation 16 
237 vibration perception 
threshold 
16 
103 urea 15 
106 von Willebrand factor 15 
95 blood viscosity 14 
125 Vitamin D deficiency 14 
126 vitamin E deficiency 14 
115 white blood cell 14 
108 creatinine clearance 13 
640 Schwann cell 13 
52 MetS 13 
322 heart rate 13 
44 adiponectin 13 
105 plasminogen activator 
inhibitor-1 
13 
102 atherosclerotic plaque 13 
222 weight loss 12 
1091 degeneration 12 
151 arterial stiffness 12 
100 intercellular adhesion 
molecule-1 
11 
26 HMG-CoA reductase 10 
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318 nitric oxide 10 
40 DBP 10 







59 nitrogen 9 
99 antioxidants 9 
168 platelet aggregation 8 
27 Apolipoprotein E 7 
80 folic acid 7 
616 demyelination 7 
671 growth factor 7 
33 ferritin 7 
128 IL-1beta 6 
2320 toxicity 6 
42 phosphorus 6 
455 axonal degeneration 6 




28 Osteoprotegerin 6 
9 squalene 6 
29 phospholipids 6 
37 blood urea nitrogen 6 
1142 neurotoxic 5 
18 endothelial activation 5 
48 bilirubin 5 
41 N-terminal pro-brain 
natriuretic peptide 
5 
53 Tissue Plasminogen 
Activator 
5 
412 occlusions 5 
28 albumin/creatinine 5 
39 endothelial damage 5 
37 E-selectin 5 
22 lipase 5 






65 magnesium 5 
114 creatine 5 
66 mRNA levels 5 
262 stenoses 5 
748 atrophy 4 
747 dorsal root ganglia 4 
44 alanine 4 
119 glutathione 4 
30 body fat 4 
278 vascular endothelial 
growth factor 
4 
68 D-dimer 4 




26 growth hormone 4 
69 lipid peroxidation 4 
74 creatine kinase 4 
72 systemic sclerosis 4 
70 IL-10 4 
42 leucocytes 4 
51 glucose metabolism 4 
18 docosahexaenoic acid 4 
14 antithrombin III 4 
15 cholestanol 4 
23 transferrin 4 
273 glycoprotein 3 
365 nerve damage 3 
197 autoantibodies 3 
193 CD4 3 
700 oxygen 3 
123 acetylcholine 3 
135 platelet activation 3 
18 eicosapentaenoic acid 3 
41 alkaline phosphatase 3 
64 Red Blood Cell 3 
41 transforming growth 
factor beta 
3 
25 Helicobacter pylori 3 
26 glutathione peroxidase 3 
80 fibrin 3 
37 endothelin-1 3 
318 edema 3 
69 superoxide dismutase 3 
354 neurodegeneration 3 
34 cystatin C 3 
21 Oxidized low-density 
lipoprotein 
3 
31 progesterone 3 
28 carotid-femoral pulse 3 
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12 beta-carotene 3 
6 IL-18 3 




40 arginine 2 
15 calcium phosphate 2 
61 P-selectin 2 
489 angiogenesis 2 
38 vitamin K 2 
69 troponin 2 
59 acetylsalicylic acid 2 
309 apoptosis 2 
202 T-cell 2 
36 arachidonic acid 2 
18 selenium 2 
195 thermal hyperalgesia 2 
52 l-arginine 2 
35 HCY 2 
19 serum calcium 2 
34 catalase 2 
27 vascular reactivity 2 
17 aortic pulse wave 
velocity 
2 
69 prostacyclin 2 
51 cardiac troponin T 2 
33 oxidative damage 2 
32 insulin levels 2 
55 Venous occlusion 2 
26 leptin 2 




26 Endothelin 2 





13 Fetuin-A 2 
101 vasculopathy 2 
13 thyroxine 2 
61 monoclonal antibodies 2 




11 Resistin 2 
10 apolipoprotein(a) 2 
159 lymphocytes 2 
6 alcohols 2 
47 glycosylation 2 
5 apolipoprotein A-II 2 
5 luteinizing hormone 2 
43 erythrocytes 2 
5 YKL-40 2 
4 apolipoprotein B-48 2 
4 valvular calcification 2 
3 LXR 2 
3 waist-to-height ratio 2 
2 apolipoprotein AI-CIII-
AIV gene cluster 
2 
2 campesterol 2 
2 Cardiometabolic index 
(CMI) 
2 
38 connexin 32 1 
23 copper deficiency 1 
27 methylmalonic acid 1 
15 osteopontin 1 
58 methionine 1 
58 Neutrophils 1 
52 BDNF 1 
81 Endothelial progenitor 
cells 
1 
20 insulin-like growth 
factor I 
1 
36 IgG antibodies 1 
283 denervation 1 
16 pyridoxal 1 
247 amyloid 1 
35 IL-8 1 
22 CD8 1 
240 myelinated fibers 1 
13 atheromatous plaque 1 
206 nerve growth factor 1 
22 Vitamin B1 deficiency 1 




14 CD68 1 
49 bone mineral density 1 
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170 nerve regeneration 1 
17 arterial compliance 1 
20 thromboxane B2 1 
152 Reactive oxygen 
species 
1 
17 bone density 1 
16 neoangiogenesis 1 
28 phosphocreatine 1 
31 parathyroid hormone 1 
16 PGE2 1 
20 acylcarnitine 1 
19 riboflavin 1 
45 neuronal damage 1 
16 factor Xa 1 




27 antinuclear antibodies 1 
20 CD40 ligand 1 
115 nitric oxide synthase 1 
17 IL-2 1 
44 Mercury 1 
104 thrombin 1 
13 Neopterin 1 
13 RNA levels 1 
102 IgA 1 
12 adipokine 1 
12 arterial calcifications 1 
42 myelin basic protein 1 
12 hydrogen sulfide 1 
12 NOx 1 
42 neuroinflammation 1 
11 Coxsackie 1 
27 cholinesterase 1 
11 Myelin breakdown 1 
17 lactic acid 1 
27 cyclooxygenase 2 1 
10 cathepsins 1 
10 cotinine 1 
9 Aortic augmentation 
index 
1 




9 heparan sulfate 1 
9 low testosterone 1 
84 fiber loss 1 
8 glucagon 1 
8 gonadotropin 1 
8 leukotrienes 1 
8 paraoxonase-1 1 
8 S100 beta 1 
8 thyrotropin 1 
7 angiotensin II type 1 1 
7 coronary calcification 1 
7 HIV RNA levels 1 




41 CD34 1 
6 dimethylarsinic acid 1 
6 factor XIII 1 
6 FVII 1 
6 GRP78 1 
41 free radicals 1 
6 pentraxin 1 




5 dihydrotestosterone 1 
5 lipofuscin 1 
19 thrombomodulin 1 




5 retinol 1 
74 thromboxane 1 
25 sulfatide 1 
4 apolipoprotein C-III 1 
4 beta-endorphin 1 
4 endopeptidases 1 
4 nitrogen oxide 1 
4 ubiquinone 1 
73 thiamine 1 
3 brain iron 
accumulation 
1 
14 TBARS 1 
3 NF68 1 
65 advanced glycation end 
product 
1 
2 apoB/apoA-I ratio 1 
2 apolipoprotein A-IV 1 
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65 Zinc 1 




2 follicle stimulating 
hormone 
1 
2 herpes simplex virus 1 1 
2 midkine 1 
2 omentin-1 level 1 
2 suPAR level 1 
1 25-hydroxycholesterol 1 
1 27-hydroxycholesterol 1 
1 7-ketocholesterol 1 
1 aniline hydroxylase 1 
1 benzo(a)pyrene 1 
1 gamma-tocopherol 1 
1 lathosterol 1 
1 oxysterols 1 
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Table 7A-16 - Biomarkers Co-Occurring with Sedentary 
#REC BIOMARKER #CO-
OCC 
2038 ankle brachial index 31 
1549 blood pressure 20 
1156 body mass index 19 
1139 total cholesterol 10 
1138 blood glucose levels 10 
2536 inflammation 9 
30 body fat 9 
549 C reactive protein 7 
185 insulin resistance 7 
1402 stenosis 6 
1061 hemoglobin A1c 6 
610 pain-free walking distance 6 
425 high-density lipoprotein 
cholesterol 
5 
322 heart rate 5 
932 blood flow 5 
538 calcium 5 
693 lipoprotein 5 
495 low-density lipoprotein 
cholesterol 
5 
208 carotid artery intima-media 
thickness 
5 
110 waist circumference 4 
856 marker 4 
748 atrophy 4 
700 oxygen 4 
435 Systolic blood pressure 4 
284 endothelial dysfunction 4 
151 arterial stiffness 4 
841 proteins 3 
413 plaque 3 
499 triglycerides 3 
94 Lipoprotein(a) 3 
318 nitric oxide 2 
455 axonal degeneration 2 
329 lipids 2 
20 adenosine triphosphate 2 
308 fibrinogen 2 
2277 nerve conduction velocity 2 
105 plasminogen activator 
inhibitor-1 
2 
222 weight loss 2 
2638 lesions 2 
38 vitamin K 2 
516 cytokine 2 
183 pulse wave velocity 2 
419 oxidative stress 2 
1091 degeneration 2 
147 lipid profile 2 
27 high total cholesterol 2 
125 Vitamin D deficiency 2 
10 low birth weight 2 
32 insulin levels 1 
107 lactate 1 
345 tumour necrosis factor-
alpha 
1 
344 sodium 1 
70 peak oxygen consumption 1 
309 apoptosis 1 
80 folic acid 1 
39 apolipoprotein A-I 1 
283 denervation 1 
278 vascular endothelial 
growth factor 
1 
273 glycoprotein 1 
266 IL-6 1 
747 dorsal root ganglia 1 
262 stenoses 1 
104 pulse pressure 1 
251 angiotensin converting 
enzyme 
1 
104 thrombin 1 
240 myelinated fibers 1 
69 lipid peroxidation 1 
704 creatinine 1 
17 arterial compliance 1 
671 growth factor 1 
49 bone mineral density 1 
101 vasculopathy 1 
69 troponin 1 
640 Schwann cell 1 
66 mRNA levels 1 
96 uric acid 1 
489 angiogenesis 1 
118 compound muscle action 
potential 
1 
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175 diastolic blood pressure 1 
170 nerve regeneration 1 
49 monocyte chemoattractant 
protein-1 
1 
51 cardiac troponin T 1 
29 Chlamydia pneumoniae 1 
158 nerve fiber density 1 
65 Zinc 1 
53 Tissue Plasminogen 
Activator 
1 
402 albumin level 1 
84 malondialdehyde 1 
26 growth hormone 1 
16 pyridoxal 1 
16 factor Xa 1 
80 fibrin 1 
42 thromboangiitis 1 
126 vitamin E deficiency 1 
125 apolipoprotein 1 
382 calcification 1 
12 adipokine 1 
9 low testosterone 1 
8 CBM 1 
8 corticosterone 1 
8 gonadotropin 1 
6 pERK 1 
6 prolactin 1 
6 Telomerase 1 
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Table 7A-17 - Treatments Co-Occurring with Oxidative Stress 
#REC TREATMENT #CO-
OCC 
3638 drug 49 
99 antioxidants 46 
1766 inhibitor 42 
62 superoxide dismutase 38 
754 insulin 30 
812 growth factor 24 
288 supplementation 21 
1328 exercise 20 
1358 walking 18 
2402 amputation 17 
126 vitamin E 16 
449 diet 16 
25 GSH 15 
349 vascular endothelial 
growth factor 
13 
489 angiogenesis 13 
34 vitamin C 12 
5105 surgery 11 
86 Alpha lipoic acid 11 
745 dialysis 9 
172 IL-6 9 
447 glycemic control 9 
14 antioxidant therapy 9 
150 hypoxia 8 
47 aldose reductase 
inhibitor 
7 
567 analgesic 6 
189 Spinal Cord 
Stimulation 
6 




206 nerve growth factor 6 
233 pregabalin 5 
80 folic acid 5 
1920 revascularization 5 
28 N-acetylcysteine 5 
190 smoking cessation 5 
67 erythropoietin 5 




100 haemodialysis 4 
370 statin 4 
12 tempol 4 
1228 angioplasty 4 
266 coronary intervention 4 
242 Gabapentin 4 
25 curcumin 4 
337 antiplatelet therapy 4 
111 duloxetine 4 
117 Vitamin D 3 
207 vitamin B12 3 
17 interleukin-10 3 
6 PARP inhibition 3 
36 apheresis 3 
147 capsaicin 3 
16 epalrestat 3 
30 propionyl-L-carnitine 3 
29 Methylcobalamin 3 
9 phlebotomy 3 
27 glutamine 3 
14 Aldehyde 3 
576 aspirin 3 
167 heparin 3 
73 thiamine 3 
8 thiols 3 
14 Flavonoids 3 
382 catheter 2 
317 opioid 2 
160 adenosine 2 
65 magnesium 2 
65 Zinc 2 
18 selenium 2 
13 guanosine 2 
103 Acupuncture 2 
8 TRPA1 antagonist 2 
62 ethanol 2 
17 CXCR4 2 
228 antidepressant 2 
7 acetylcysteine 2 
40 arginine 2 
6 polyphenol 2 
5 puerarin 2 
4 mangafodipir 2 
215 Cilostazol 2 
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36 venlafaxine 2 
11 tea 2 
7 quercetin 2 
16 ozone 2 
8 taurine 2 
29 lamotrigine 2 
61 simvastatin 2 
29 phenytoin 2 
59 Acetyl-l-carnitine 2 
10 melatonin 2 
5 Heparin cofactor II 2 
7 Gliclazide 2 
7 Huangqi Guizhi Wuwu 2 
26 growth hormone 2 
9 allopurinol 2 
6 HC-030031 2 
55 carnitine 2 
450 bypass surgery 2 
420 Ligation 2 
52 hepatocyte growth 
factor 
2 
4 saponins 2 
2 1,5-isoquinolinediol 2 
2 calmangafodipir 2 
71 Ticlopidine 1 
12 beta-carotene 1 
18 chelation therapy 1 




6 nebivolol 1 
59 hyperbaric oxygen 1 





4 Tang-Luo-Ning 1 
54 Pyridoxine 1 
9 sunlight 1 
52 iloprost 1 
51 AA 1 
51 Mesenchymal Stem 
Cells 
1 
51 peripheral blood 
mononuclear cells 
1 
47 atorvastatin 1 
45 Ketamine 1 
5 hydrotherapy 1 
42 Neurotrophins 1 
41 clonidine 1 
1308 artery bypass grafting 1 
6 liraglutide 1 
39 aerobic exercise 1 
38 antiepileptic drugs 1 
38 valproic acid 1 
37 anesthetics 1 
588 operation 1 
507 vascular surgery 1 
22 alpha-tocopherol 1 
6 THC 1 
4 midodrine 1 
11 phosphatidylcholine 1 
8 placenta 1 
11 ruboxistaurin 1 
16 Coenzyme Q10 1 
34 nitroglycerin 1 
353 Clopidogrel 1 
7 nimodipine 1 
4 protein kinase C 
inhibitors 
1 
10 benfotiamine 1 
33 tramadol 1 
7 gamma-linolenic acid 1 
22 rapamycin 1 
10 desipramine 1 
31 l-carnitine 1 
16 pravastatin 1 
30 amifostine 1 
6 thioctic acid 1 
22 topiramate 1 
9 Carvedilol 1 
7 Ghrelin 1 
21 NSAIDs 1 
13 Caffeine 1 
8 KU-32 1 
8 lacosamide 1 
131 mononuclear cells 1 
10 lentivirus 1 
28 oxcarbazepine 1 
13 celecoxib 1 
13 dextromethorphan 1 
10 mesenchymal stromal 1 
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cells 
27 Mexiletine 1 
27 serotonin reuptake 
inhibitors 
1 
110 anticonvulsants 1 
5 Jinmaitong 1 
110 enzyme inhibitors 1 
7 PGB 1 
4 catechin 1 
13 sulodexide 1 
91 Prostaglandin 1 
26 sodium nitroprusside 1 
10 Resveratrol 1 
8 menthol 1 
90 gangliosides 1 
87 Amitriptyline 1 
4 Sodium nitrite 1 
25 opiates 1 
4 anakinra 1 
4 donepezil 1 
80 carbamazepine 1 
14 fluoxetine 1 
24 insulin-like growth 
factor-I 
1 
14 herbal medicines 1 
8 paroxetine 1 
14 myo-inositol 1 
4 Thymoquinone 1 
4 trigonelline 1 
4 turmeric 1 
4 zonisamide 1 
3 amiloride 1 
3 caloric restriction 1 
3 carotenoids 1 
3 dihydroergotamine 1 
3 ellagic acid 1 
3 fludrocortisone 1 
3 Metanx 1 
3 PLX-PAD 1 
3 rotenone 1 
5 pralidoxime 1 
2 Astragali 1 
18 ascorbic acid 1 
2 Dark chocolate 1 
2 deferoxamine 1 
2 egg white hydrolysate 1 
1 3-Aminobenzamide 1 
1 Acanthopanax 1 
1 Achyranthis bidentata 
Blume 
1 
1 activation of Nrf2 1 
1 antimycin 1 
1 ascorbyl palmitate 1 
1 dihydrolipoic acid 1 
1 epicatechin gallate 1 
1 eugenol 1 
1 ferulic acid 1 
1 GCSB-5 1 
1 ginsenoside Rb1 1 
1 hemangioblasts 1 
1 Jiaweibugan 1 
1 Juglans regia L. 1 
1 LiCl 1 
1 Linalool 1 
1 Maltol 1 
1 MnDPDP 1 




1 morin 1 
1 naringin 1 
1 NF3 1 





adherent stromal cells 
1 
1 Punica granatum L 1 
1 Punicalagins 1 
1 QR-333 1 
1 Rosmarinic acid 1 
1 rutin 1 




1 Silybin 1 
1 Vernonia cinerea 1 
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Table 7A-18 - Treatments Co-Occurring with Blood Pressure 
#REC TREATMENT #CO-
OCC 
3638 drug 178 




1766 inhibitor 122 
5105 surgery 112 
754 insulin 106 
1358 walking 81 
2402 amputation 74 
447 glycemic control 71 
1920 revascularization 67 
632 medications 58 
745 dialysis 52 
576 aspirin 48 
449 diet 47 
190 smoking cessation 40 
370 statin 36 
1228 angioplasty 30 
337 antiplatelet therapy 29 
110 enzyme inhibitors 29 
353 Clopidogrel 26 
507 vascular surgery 22 
58 angiotensin converting 
enzyme inhibitor 
22 
1308 artery bypass grafting 20 
221 anticoagulant 19 
812 growth factor 18 
459 rehabilitation 16 
33 ramipril 15 
588 operation 12 
233 endarterectomy 12 
22 calcium antagonists 12 
450 bypass surgery 11 
489 angiogenesis 11 
288 supplementation 11 
215 Cilostazol 11 
59 Testosterone 10 
349 vascular endothelial 
growth factor 
10 
50 C-peptide 10 
27 verapamil 10 
17 amlodipine 10 
117 Vitamin D 9 
59 acetylsalicylic acid 9 
172 Gene therapy 9 
828 stents 9 
50 Nicotine 9 
12 hydrochlorothiazide 9 
28 nifedipine 9 
118 warfarin 8 
16 losartan 8 






103 pentoxifylline 7 
15 lisinopril 7 
9 perindopril 7 
24 omega-3 fatty acids 7 
160 adenosine 6 
14 enalapril 6 
207 vitamin B12 6 
150 hypoxia 5 
126 vitamin E 5 
100 haemodialysis 5 
67 near-infrared 5 
47 atorvastatin 4 
52 hepatocyte growth 
factor 
4 
99 antioxidants 4 
61 simvastatin 4 
420 Ligation 4 
55 antithrombotic therapy 4 
266 coronary intervention 4 
11 chlorthalidone 4 
411 corticosteroid 3 
382 catheter 3 
91 Prostaglandin 3 
52 iloprost 3 
67 erythropoietin 3 
189 Spinal Cord Stimulation 3 
65 magnesium 3 
15 digoxin 3 
77 dipyridamole 3 
156 Electrical stimulation 3 
71 Ticlopidine 3 
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39 aerobic exercise 3 
8 Sitagliptin 3 
10 thiazolidinediones 3 
34 vitamin C 3 
6 nebivolol 3 
147 capsaicin 3 
9 captopril 3 
51 AA 3 
41 clonidine 3 
26 sodium nitroprusside 3 
62 superoxide dismutase 3 
172 IL-6 3 
103 Acupuncture 3 
7 diltiazem 3 
8 Calcitriol 3 
5 telmisartan 3 
567 analgesic 3 
499 implantation 3 
4 trandolapril 3 
3 alpha-linolenic acid 3 
228 antidepressant 2 
9 dabigatran 2 
111 duloxetine 2 
7 apixaban 2 
26 growth hormone 2 
26 hormone replacement 
therapy 
2 
8 pioglitazone 2 
13 Caffeine 2 





36 niacin 2 
80 folic acid 2 




14 antioxidant therapy 2 
22 prostanoids 2 
242 Gabapentin 2 
167 heparin 2 
32 prasugrel 2 
21 rivaroxaban 2 
19 ezetimibe 2 
12 tempol 2 
18 ascorbic acid 2 
10 fenofibrate 2 
59 hyperbaric oxygen 2 
4 valsartan 2 
9 Carvedilol 2 
3 dietary flaxseed 2 
3 irbesartan 2 
2 dietary nitrate 2 
2 dihydropyridines 2 
6 relaxin 1 
37 drug-eluting balloons 1 
37 glucocorticoid 1 
36 apheresis 1 
14 abciximab 1 
4 dimercaprol 1 
206 nerve growth factor 1 
36 venlafaxine 1 
6 hydromorphone 1 
156 prednisone 1 
5 NGX-4010 1 
34 urokinase 1 
6 Hydroxocobalamin 1 
10 vitamin D3 1 
6 liraglutide 1 
33 tramadol 1 
4 canagliflozin 1 
119 zidovudine 1 
5 ketorolac 1 
31 l-carnitine 1 
31 progesterone 1 
8 tirofiban 1 
14 Flavonoids 1 
30 propionyl-L-carnitine 1 
4 quinidine 1 
14 herbal medicines 1 
7 riluzole 1 
29 phenytoin 1 
28 electroacupuncture 1 
17 strength training 1 
17 thienopyridines 1 
107 cell therapy 1 
14 phenylephrine 1 
27 baclofen 1 
4 linolenic acid 1 
27 intermittent pneumatic 
compression 
1 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                                                                                                                
Chapter 7 - Tables and Figures                                                                                                                               300 
17 viral vectors 1 
9 Defibrotide 1 
98 IVIG 1 
98 lidocaine 1 
4 Sodium nitrite 1 
16 beraprost sodium 1 
86 Alpha lipoic acid 1 
26 massage 1 
26 minocycline 1 
80 carbamazepine 1 
10 glibenclamide 1 
4 isoproterenol 1 
6 trimetazidine 1 
4 glyceryl trinitrate 1 
9 methylxanthine 1 
6 Biotin 1 
13 guanosine 1 
73 thiamine 1 
24 bFGF 1 
13 mecobalamin 1 
69 methylprednisolone 1 
13 Olive oil 1 
4 probucol 1 
65 Zinc 1 
5 hydrotherapy 1 
23 fish oil 1 
4 molsidomine 1 
12 beta-carotene 1 
16 deep brain stimulation 1 
62 ethanol 1 
8 menthol 1 
9 vitamin K antagonist 1 




21 NSAIDs 1 
21 oxycodone 1 
55 carnitine 1 
7 nimodipine 1 
12 ketanserin 1 
4 GLP-1 receptor 
agonists 
1 
20 fentanyl 1 
12 prazosin 1 
19 alprostadil 1 
19 buflomedil 1 
12 sodium bicarbonate 1 
8 osteocalcin 1 
51 epidermal growth 
factor 
1 
19 phentolamine 1 
5 edoxaban 1 
18 balloon dilatation 1 
5 Ibudilast 1 
5 epoprostenol 1 
7 gemfibrozil 1 
8 hydrocortisone 1 
4 Tizanidine 1 
45 Ketamine 1 
15 kampo 1 
4 Waon therapy 1 
40 arginine 1 
3 candesartan 1 
3 chlorpropamide 1 
40 ticagrelor 1 
3 dimethyl fumarate 1 
3 fingolimod 1 
3 fludrocortisone 1 
3 ifenprodil 1 
18 muscle stimulation 1 
3 ranolazine 1 
2 bisoprolol 1 
15 osteopontin 1 
18 selenium 1 
2 ergocalciferol 1 
2 HGF plasmid DNA 1 




2 nitrate consumption 1 
1 blueberry 1 
1 cromakalim 1 




1 estradiol valerate 1 
1 Linalool 1 
1 lomitapide 1 
1 low glucose diet 1 
1 SDZ PCO-400 1 
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Table 7A-19 - Biomarkers Co-Occurring with Exercise 
#REC BIOMARKER #CO-
OCC 
610 pain-free walking 
distance 
287 
2038 ankle brachial index 210 
700 oxygen 160 
1549 blood pressure 149 
932 blood flow 124 
322 heart rate 84 
2536 inflammation 67 
1138 blood glucose 
levels 
64 
1402 stenosis 56 
1156 body mass index 53 
1139 total cholesterol 52 
2638 lesions 49 
1061 hemoglobin A1c 46 
70 peak oxygen 
consumption 
43 





856 marker 35 
435 Systolic blood 
pressure 
34 




489 angiogenesis 28 
329 lipids 28 
549 C reactive protein 26 
2277 nerve conduction 
velocity 
23 




61 oxygen saturation 23 
308 fibrinogen 20 




419 oxidative stress 20 
318 nitric oxide 20 





107 lactate 19 
28 phosphocreatine 19 
748 atrophy 18 
516 cytokine 16 
538 calcium 15 
266 IL-6 15 
262 stenoses 15 
151 arterial stiffness 14 
841 proteins 14 





222 weight loss 13 
345 tumour necrosis 
factor-alpha 
12 




147 lipid profile 11 
115 white blood cell 11 
412 occlusions 11 
74 thromboxane 10 
344 sodium 10 
747 dorsal root ganglia 9 
175 diastolic blood 
pressure 
9 
183 pulse wave velocity 9 
283 denervation 9 
52 MetS 9 
402 albumin level 9 
261 high homocysteine 8 
365 nerve damage 8 
69 prostacyclin 7 
42 leucocytes 7 
391 ventricular ejection 
fraction 
7 
152 Reactive oxygen 
species 
7 
210 fatty acid 7 
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158 nerve fiber density 6 
84 malondialdehyde 6 
126 vitamin E deficiency 6 







114 creatine 5 
1091 degeneration 5 








61 P-selectin 5 




52 l-arginine 5 
41 CD34 5 
20 acylcarnitine 5 
382 calcification 4 
74 creatine kinase 4 
80 fibroblast growth 
factor 
4 












69 troponin 4 
147 capsaicin 4 
128 IL-1beta 4 
125 Vitamin D 
deficiency 
4 
51 cardiac troponin T 4 
41 apolipoprotein B 4 










35 glycogen 4 
99 antioxidants 4 
53 Tissue Plasminogen 
Activator 
3 
21 bradykinin 3 
80 fibrin 3 
20 arterial obstruction 3 
96 uric acid 3 
65 magnesium 3 
2320 toxicity 3 
1142 neurotoxic 3 
704 creatinine 3 
69 lipid peroxidation 3 
68 D-dimer 3 




37 E-selectin 3 




27 vascular reactivity 3 




104 pulse pressure 3 
318 edema 3 
115 nitric oxide 
synthase 
3 
309 apoptosis 3 
101 vasculopathy 3 
273 glycoprotein 3 
28 thromboxane A2 3 
36 niacin 3 
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18 NADPH oxidases 2 
52 hepatocyte growth 
factor 
2 
51 glucose metabolism 2 
49 cytochrome c 2 
247 amyloid 2 
240 myelinated fibers 2 









40 arginine 2 
40 DBP 2 
40 myeloperoxidase 2 
126 glutamate 2 
39 endothelial damage 2 
27 high total 
cholesterol 
2 
37 endothelin-1 2 
35 interferon gamma 2 
118 compound muscle 
action potential 
2 
33 oxidative damage 2 
13 elastase 2 
104 thrombin 2 
12 beta-carotene 2 
8 phosphates 2 
32 insulin levels 2 
170 nerve regeneration 2 
94 Lipoprotein(a) 2 
92 albumin excretion 
rate 
2 
20 thromboxane B2 2 




6 kallikrein 2 
5 Acetylcarnitine 2 
5 CD11c 2 
5 CD86 2 







70 IL-10 2 
14 choline 2 
58 Neutrophils 2 
52 Angiogenic growth 
factors 
2 
640 Schwann cell 1 
26 miRNA 1 
20 aldosterone 1 
263 vitamin B(12) 
deficiency 
1 
206 nerve growth factor 1 




193 CD4 1 
20 CD40 ligand 1 
154 B-cell 1 
17 bone density 1 
123 acetylcholine 1 
33 hypoperfusion 1 
119 glutathione 1 
106 von Willebrand 
factor 
1 
15 cortisol 1 




15 digoxin 1 
65 advanced glycation 
end product 
1 
65 Zinc 1 
17 lactic acid 1 
64 Red Blood Cell 1 
19 riboflavin 1 
72 systemic sclerosis 1 
28 Osteoprotegerin 1 
14 antithrombin III 1 
44 alanine 1 
27 cyclooxygenase 2 1 






27 glutamine 1 
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28 carotid-femoral 





17 arterial compliance 1 
27 RAGE 1 
38 vitamin K 1 






43 erythrocytes 1 
26 Endothelin 1 
36 arachidonic acid 1 
66 mRNA levels 1 
36 IgG antibodies 1 
55 Ca(2+) 1 
58 methionine 1 
26 growth hormone 1 
35 IL-8 1 
22 CD8 1 
59 nitrogen 1 
34 catalase 1 
26 Hydrogen peroxide 1 
26 leptin 1 
49 bone mineral 
density 
1 




12 insulin deficiency 1 
12 PBMCs 1 
11 dendritic cells 1 




11 IL-12 1 
11 Myelin breakdown 1 




9 CD133 1 
9 low testosterone 1 
8 CBM 1 
8 corticosterone 1 
8 inositol 1 
50 NF-kappaB 1 
7 CD14 1 
18 c-Fos 1 
6 arterial elasticity 1 




6 Telomerase 1 
16 PGE2 1 
24 IL-4 1 
5 CD16 1 
41 free radicals 1 
22 lipase 1 
5 retinol 1 
4 apolipoprotein C-III 1 
4 myostatin 1 
4 Nox2 1 
3 hydroperoxide 1 




3 methemoglobin 1 
3 N-acetylaspartate 1 
3 serum nitrate 1 
27 Apolipoprotein E 1 
3 xanthine oxidase 1 




2 TREM-1 1 
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Table 7A-20 - Biomarkers Co-Occurring with Gabapentin 
#REC BIOMARKER #CO-
OCC 
538 calcium 19 
147 capsaicin 18 
2536 inflammation 15 
1142 neurotoxic 14 
344 sodium 10 
2320 toxicity 9 
747 dorsal root ganglia 8 
38 Noradrenaline 8 
2277 nerve conduction 
velocity 
6 
318 edema 6 
1138 blood glucose levels 5 








119 glutathione 5 
365 nerve damage 4 




318 nitric oxide 3 
704 creatinine 3 
700 oxygen 3 
263 vitamin B(12) 
deficiency 
3 
206 nerve growth factor 3 
27 cholinesterase 3 
152 Reactive oxygen 
species 
3 
126 glutamate 3 
273 glycoprotein 2 
1139 total cholesterol 2 
222 weight loss 2 
1549 blood pressure 2 
1091 degeneration 2 
54 glial fibrillary acidic 
protein 
2 
322 heart rate 2 
349 IgM 2 
40 myeloperoxidase 2 
70 IL-10 2 
27 cyclooxygenase 2 2 
345 tumour necrosis 
factor-alpha 
2 
128 IL-1beta 2 
25 Iron Deficiency 2 
1156 body mass index 2 








99 antioxidants 1 
18 caspase 3 1 
14 choline 1 
354 neurodegeneration 1 
18 c-Fos 1 
309 apoptosis 1 
19 Ccl2 1 
26 Hydrogen peroxide 1 
283 denervation 1 
278 vascular endothelial 
growth factor 
1 
118 compound muscle 
action potential 
1 




16 galanin 1 
84 malondialdehyde 1 




52 hepatocyte growth 
factor 
1 
14 TBARS 1 
115 nitric oxide synthase 1 
80 folic acid 1 
2638 lesions 1 
856 marker 1 
17 CXCR4 1 
841 proteins 1 
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22 lipase 1 




185 insulin resistance 1 
22 Vitamin B1 
deficiency 
1 
108 creatinine clearance 1 
107 lactate 1 
40 sorbitol 1 
69 lipid peroxidation 1 
48 thymidine 1 




499 triglycerides 1 





34 histamine 1 
49 protein kinases 1 
40 dopamine 1 
44 alanine 1 
65 advanced glycation 
end product 
1 
126 vitamin E deficiency 1 
33 ferritin 1 
16 PGE2 1 
123 acetylcholine 1 
103 urea 1 
44 Mercury 1 
16 androgen 1 
11 fructose 1 
9 deoxyuridine 1 
8 S100 beta 1 
4 beta-endorphin 1 
 
References - Chapter 7  
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            307 
Chapter 8 
REFERENCES AND BIBLIOGRAPHY 
8A. References 
 -8A0. Executive Summary References 
Chauhan P, Verma HN, Sisodia R, Kesari KK.  Microwave radiation (2.45 GHz)-induced 
oxidative stress: Whole-body exposure effect on histopathology of Wistar rats. Electromagnetic 
biology and medicine.  2017; 36:1; 20-30.  
Kahremany S. et al. (2019) Nrf2 Activation by SK-119 Attenuates Oxidative Stress, UVB, and 
LPS-Induced Damage. Skin pharmacology and physiology 32 (4), 173-181 
Kesari KK, Siddiqui MH, Meena R, Verma HN, Kumar S.  Cell phone radiation exposure on 
brain and associated biological systems. Indian journal of experimental biology.  2013; 51:3; 
187-200.    
Kim, J.-Y. et al. (2018) Pharmacological Inhibition of Caspase-1 Ameliorates Cisplatin-Induced 
Nephrotoxicity through Suppression of Apoptosis, Oxidative Stress, and Inflammation in Mice. 
Mediators of inflammation 2018, 6571676 
Kostoff RN, Lau CGY.  Modified health effects of non-ionizing electromagnetic radiation 
combined with other agents reported in the biomedical literature.  Chapter 4 in: Geddes (ed.).  
Microwave Effects on DNA and Proteins.  Springer; 1st ed. 2017 edition (March 15, 2017).  DOI 
10.1007/978-3-319-50289-2_4. 
Kostoff RN, Porter AL, Buchtel HA.  Prevention and reversal of Alzheimer's disease: treatment 
protocol.  Georgia Institute of Technology. 2018. PDF. 
https://smartech.gatech.edu/handle/1853/59311. 
Kostoff RN.  Under-reporting of adverse events in the biomedical literature.  JDIS.  
2016;1(4):10-32.  doi:10.20309/jdis.201623. 
Kostoff RN. Pervasive Causes of Disease. Georgia Institute of Technology. 2015. PDF. 
http://hdl.handle.net/1853/53714  
Li, Shiyue; Zhou, Jinxin; Xu, Shangfu; et al.  Induction of Nrf2 pathway by Dendrobium nobile 
Lindl. alkaloids protects against carbon tetrachloride induced acute liver injury.  Biomedicine & 
pharmacotherapy.  2019.  117; 109073. 
Liu RH. Health benefits of fruit and vegetables are from additive and synergistic combinations of 
phytochemicals. Am J Clin Nutr. 2003; 78:3; 517S-520S. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            308 
Lu, Meng-Chen; Zhao, Jing; Liu, Yu-Ting; et al.  CPUY192018, a potent inhibitor of the Keap1-
Nrf2 protein-protein interaction, alleviates renal inflammation in mice by restricting oxidative 
stress and NF-kappaB activation.  (2019).  Redox biology.  26; 101266.   
Mohamadi Yarijani, Z. et al. (2019) Amelioration of renal and hepatic function, oxidative stress, 
inflammation and histopathologic damages by Malva sylvestris extract in gentamicin induced 
renal toxicity. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 112, 
108635 
Shaaban, A.A. et al. (2018) Protective effect of pristimerin against LPS-induced acute lung 
injury in mice. International immunopharmacology 59, 31-39 
Wang, C. and Eskiw, C.H. (2019) Cytoprotective effects of Avenathramide C against oxidative 
and inflammatory stress in normal human dermal fibroblasts. Scientific reports 9 (1), 2932 
Wang, H. et al. (2019) Neuroprotective Effect of Swertiamain on Cerebral Ischemia/Reperfusion 
Injury by Inducing the Nrf2 Protective Pathway. ACS chemical neuroscience 10 (5), 2276-2286 
Wang, S.-W. et al. (2018) Astilbin ameliorates cisplatin-induced nephrotoxicity through reducing 
oxidative stress and inflammation. Food and chemical toxicology : an international journal 
published for the British Industrial Biological Research Association 114, 227-236 
Wu, M. et al. (2017) Protective Effects of Pterostilbene Against Myocardial 
Ischemia/Reperfusion Injury in Rats. Inflammation 40 (2), 578-588 
 -8A1. Chapter 1 References 
AHA, 2019.  About Peripheral Artery Disease.  American Heart Association.  Dallas, TX. 
https://www.heart.org/en/health-topics/peripheral-artery-disease/about-peripheral-artery-disease-
pad 
Alonso A, McManus DD, Fisher DZ.  Peripheral Vascular Disease 1st Edition.  2010.  Jones and 
Bartlett Learning, Burlington, MA. 
Baldereschi M, Inzitari M, Di Carlo A, Bovis F, Maggi S, Capurso A, Solfrizzi V, Panza F, 
Scafato E, Inzitari D.  Vascular factors predict polyneuropathy in a non-diabetic elderly 
population.  NEUROLOGICAL SCIENCES.  2013; 34:6, 955-962.  DOI: 10.1007/s10072-012-
1167-x. 
Barohn RJ. Peripheral Neuropathies, An Issue of Neurologic Clinics [Special Issue]. Elsevier 
Health Sciences.  11 June 2013. 
Barrell K, Smith, AG.  Peripheral neuropathy.  The Medical clinics of North America. 2019; 
103:2; 383-397. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            309 
Bredesen DE.  The End of Alzheimer's: the First Program to Prevent and Reverse Cognitive 
Decline.  2017.  Avery, New York, NY. 
Campia U, Gerhard-Herman Marie, Piazza G, Goldhaber SZ.  Peripheral Artery Disease: Past, 
Present, and Future.   The American journal of medicine.  2019; 
DOI:10.1016/j.amjmed.2019.04.043. 
Chen K, Lv X, Li W, Yu F, Lin J, Ma J, Xiao D.  Autophagy is a protective response to the 
oxidative damage to endplate chondrocytes in intervertebral disc: implications for the treatment 
of degenerative lumbar disc.  Oxidative Medicine and Cellular Longevity  2017; 2017; Article 
ID: 4041768. 
Cioroiu CM, Brannagan TH.  Peripheral Neuropathy. CURRENT GERIATRICS REPORTS.  
2014; 3:2;  83-90.  DOI: 10.1007/s13670-014-0079-4 
Conte SM, Vale PR.  Peripheral Arterial Disease. (2018).  Heart, lung & circulation.  27:4; 427-
432. 
Donofrio PD.  Textbook of Peripheral Neuropathy.  Springer Publishing Company.  2012. 
Dyck PJ, Klein CJ, Low P, Amrami K.  Companion to Peripheral Neuropathy: Illustrated Cases 
and New Developments.  Elsevier Health Sciences.  2010. 
Emile R. Mohler and Jaff (Eds).  Peripheral Artery Disease 2nd Edition.  2017.  Wiley-
Blackwell, Hoboken, NJ. 
England JD, Asbury AK.  Peripheral neuropathy.  Lancet.  2004; 363:9427; 2151-61. 
Firnhaber JM, Powell CS.  Lower Extremity Peripheral Artery Disease: Diagnosis and 
Treatment.  (2019).  American family physician.  99:6; 362-369. 
FPN, 2019.  Foundation for Peripheral Neuropathy, Buffalo Grove, IL. 
https://www.foundationforpn.org/what-is-peripheral-neuropathy/types-risk-factors/) 
Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher 
LA, Fowkes FGR, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel 
RAG, Regensteiner JG, Schanzer A, Shishehbor MH, Stewart KJ, Treat-Jacobson D, Walsh ME.  
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral 
Artery Disease: Executive Summary: A Report of the American College of 
Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.  
Circulation.  2017; 135:12; e686-e725. 
(https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000470) 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            310 
Hanewinckel R, Ikram MA, van Doorn PA.  Peripheral neuropathies.  
NEUROEPIDEMIOLOGY.  Edited by:Rosano, C; Ikram, MA; Ganguli, M, Eds.  2016; 138; 
263-282.  DOI: 10.1016/B978-0-12-802973-2.00015-X 
Herskovitz S, Scelsa S, Schaumburg H.  Peripheral Neuropathies in Clinical Practice.  Oxford 
University Press, USA.  2010. 
Hughes RAC.  Peripheral neuropathy.  BMJ.  2002; 324:7335; 466-9. 
Karam C, Dyck PJB.  Toxic Neuropathies.  Seminars in neurology.  2015; 35:4; 448-57.  
DOI:10.1055/s-0035-1558977 
Kengne AP, Echouffo-Tcheugui JB.  Differential burden of peripheral artery disease.  The 
Lancet.  2019; 7:8; e980-e981. 
Kevil CG, Bir SC, Pattillo CB.  Peripheral Arterial Disease: Pathophysiology and Therapeutics.  
2013.  Biota Publishing, Princeton, NJ. 
Kostoff RN, Porter AL, Buchtel HA.  Prevention and reversal of Alzheimer's disease: treatment 
protocol.  Georgia Institute of Technology. 2018. PDF. 
https://smartech.gatech.edu/handle/1853/59311. 
Kostoff RN.  Literature-related discovery and innovation - update.  Technological Forecasting 
and Social Change.  79:4.  789-800.   DOI: 10.1016/j.techfore.2012.02.002.  2012. 
Kostoff RN. Pervasive Causes of Disease. Georgia Institute of Technology. 2015. PDF. 
http://hdl.handle.net/1853/53714. 
Lang PM, Schober GM, Rolke R, Wagner S, Hilge R, Offenbacher M, Treede RD, Hoffmann U, 
Irnich D.   Sensory neuropathy and signs of central sensitization in patients with peripheral 
arterial disease.  PAIN.  2006; 124:1-2; 190-200.  DOI: 10.1016/j.pain.2006.04.011. 
Lang PM.  Painful ischemic neuropathy.  NERVENARZT.  2015; 86:2; 151-+.  DOI: 
10.1007/s00115-014-4125-4 
MC, 2019.  Peripheral Artery Disease.  Mayo Clinic.  Rochester, MN. 
https://www.mayoclinic.org/diseases-conditions/peripheral-artery-disease/symptoms-causes/syc-
20350557 
McDermott MM.  Lower Extremity Manifestations of Peripheral Artery Disease The 
Pathophysiologic and Functional Implications of Leg Ischemia.  CIRCULATION RESEARCH.  
2015; 116:9; 1540-1550.  DOI: 10.1161/CIRCRESAHA.114.303517. 
Morley RL, Sharma A, Horsch AD, et al.  Peripheral artery disease.  (2018).  BMJ.  360; j5842. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            311 
NINDS, 2019.  Peripheral Neuropathy Fact Sheet, NINDS.  
(https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Peripheral-
Neuropathy-Fact-Sheet) 
Nukada H, vanRij AM, Packer SGK, McMorran, PD.  Pathology of acute and chronic ischaemic 
neuropathy in atherosclerotic peripheral vascular disease.  BRAIN.  1996; 119:1449-1460. 
Nunomura A., Takeda A, Moreira PI, Castellani RJ, Lee HG, Zhu X, Smith MA, Perry G.  2009.  
Neurofibrillary tangle formation as a protective response to oxidative stress in Alzheimer’s 
Disease. In: Maccioni R.B., Perry G. (eds) Current Hypotheses and Research Milestones in 
Alzheimer's Disease. Springer, Boston, MA DOI https://doi.org/10.1007/978-0-387 
Pascuzzi RM.  Peripheral neuropathy.  The Medical clinics of North America.  2009; 93:2.  317-
42. 
Saporta MA, Shy ME.  Chapter 12: Peripheral Neuropathies.  in Neurobiology of brain 
disorders: biological basis of neurological and psychiatric disorders.  Zigmond MJ, Rowland LP, 
Coyle JT, Eds.  2015; 167-188.  Academic Press Ltd-Elsevier Science Ltd, 24-28 Oval Road, 
London Nw1 7dx, England. 
Schutz P, Bally M, Stanga Z, Keller U.  Loss of appetite in acutely ill medical inpatients: 
physiological response or therapeutic target?  Swiss Medical Weekly.  2014; 144; w13957.  
DOI:10.4414/smw.2014.13957 
Shields RW, 2010.  Peripheral Neuropathy, Cleveland Clinic. 
(http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/neurology/peripheral-
neuropathy/) 
Smith AG, Bromberg MB. Handbook of Peripheral Neuropathy.  Taylor and Francis.  2005. 
Sun J, Feng X, Liang D, Duan Y, Lei H.  Down-regulation of energy metabolism in Alzheimer's 
disease is a protective response of neurons to the microenvironment.  Journal of Alzheimer's 
disease.  2012; 28:2; 389-402.  DOI:10.3233/JAD-2011-111313 
Thomas PK, Dyck PJ.  Peripheral Neuropathy: 2-Volume Set / Edition 4.  Elsevier Health 
Sciences.  2005. 
Toursarkissian B, Connaughton JC, D'Ayala M, Shireman PK, Harrison A, Schoolfield J, Sykes 
MT.  Does lower limb revascularization result in an improvement in sensory perception 
thresholds?  ANNALS OF VASCULAR SURGERY.  2002.  16:3; 309-313.  DOI: 
10.1007/s10016-001-0069-9. 
UCSF, 2019.  Peripheral Neuropathy.  University of California, San Francisco. 
https://www.ucsfhealth.org/conditions/peripheral_neuropathy/ 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            312 
Ugalde V, Wineinger MA, Kappagoda CT, Kilmer DD, Pevec WC, Rosen WS, Rubner D.  
Sensory axonopathy in mild to moderate peripheral arterial disease. AMERICAN JOURNAL OF 
PHYSICAL MEDICINE & REHABILITATION.  1998; 77:1; 59-64.  DOI: 10.1097/00002060-
199801000-00012. 
Watson JC, Dyck PJB.  Peripheral Neuropathy: A Practical Approach to Diagnosis and 
Symptom Management.  MAYO CLINIC PROCEEDINGS.  2015; 90:7; 940-951. 
Weber F, Ziegler A.  Axonal neuropathy in chronic peripheral arterial occlusive disease.  
MUSCLE & NERVE.  2002; 26:4; 471-476.  DOI: 10.1002/mus.10235. 
Wegner A, Khoramnia R.  Cataract is a self-defence reaction to protect the retina from oxidative 
damage.  Medical Hypotheses. 2011; 76:5; 741-4.  DOI:10.1016/j.mehy.2011.02.013 
Weinberg DH, Simovic D, Isner J, Ropper AH.  Chronic ischemic monomelic neuropathy from 
critical limb ischemia.  NEUROLOGY.  2001; 57:6; 1008-1012.  DOI: 10.1212/WNL.57.6.1008. 
WNA, 2019.  Western Neuropathy Association, Sacramento, CA. https://pnhelp.org/neuropathy 
Zemaitis MR, Bah F, Boll JM, Dreyer MA.  Peripheral Arterial Disease.  2019.  StatPearls 
Publishing, Treasure Island, FL. 
 -8A2. Chapter 2 References 
Kahremany, S. et al. (2019) Nrf2 Activation by SK-119 Attenuates Oxidative Stress, UVB, and 
LPS-Induced Damage. Skin pharmacology and physiology 32 (4), 173-181 
Kim, J.-Y. et al. (2018) Pharmacological Inhibition of Caspase-1 Ameliorates Cisplatin-Induced 
Nephrotoxicity through Suppression of Apoptosis, Oxidative Stress, and Inflammation in Mice. 
Mediators of inflammation 2018, 6571676 
Kostoff RN, Goumenou M, Tsatsakis A.  The role of toxic stimuli combinations in determining 
safe exposure limits.  TOXICOLOGY REPORTS.  2018; 5; 1169-1172.   
Kostoff RN, Patel U.  Literature-related discovery and innovation: Chronic Kidney Disease.  
Technological Forecasting and Social Change.  2015;91:341-351.  
http://dx.doi.org/10.1016/j.techfore.2014.09.013. 
Kostoff RN, Zhang Y, Ma J, Porter AL, Buchtel HA.  Prevention and reversal of Alzheimer's 
Disease. Georgia Institute of Technology. 2017. PDF.  
https://smartech.gatech.edu/handle/1853/56646. 
Kostoff RN.  Expanded information retrieval using full text searching.  Journal of Information 
Science.  2010; 36:1; 104-113. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            313 
Kostoff RN.  Under-reporting of adverse events in the biomedical literature.  JDIS.  
2016;1(4):10-32.  doi:10.20309/jdis.201623. 
Kostoff RN. Pervasive Causes of Disease. Georgia Institute of Technology. 2015. PDF. 
http://hdl.handle.net/1853/53714 
Li, Shiyue; Zhou, Jinxin; Xu, Shangfu; et al.  Induction of Nrf2 pathway by Dendrobium nobile 
Lindl. alkaloids protects against carbon tetrachloride induced acute liver injury.  Biomedicine & 
pharmacotherapy.  2019.  117; 109073. 
Lu, Meng-Chen; Zhao, Jing; Liu, Yu-Ting; et al.  CPUY192018, a potent inhibitor of the Keap1-
Nrf2 protein-protein interaction, alleviates renal inflammation in mice by restricting oxidative 
stress and NF-kappaB activation.  (2019).  Redox biology.  26; 101266.   
Mohamadi Yarijani, Z. et al. (2019) Amelioration of renal and hepatic function, oxidative stress, 
inflammation and histopathologic damages by Malva sylvestris extract in gentamicin induced 
renal toxicity. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 112, 
108635 
Shaaban, A.A. et al. (2018) Protective effect of pristimerin against LPS-induced acute lung 
injury in mice. International immunopharmacology 59, 31-39 
Wang, C. and Eskiw, C.H. (2019) Cytoprotective effects of Avenathramide C against oxidative 
and inflammatory stress in normal human dermal fibroblasts. Scientific reports 9 (1), 2932 
Wang, H. et al. (2019) Neuroprotective Effect of Swertiamain on Cerebral Ischemia/Reperfusion 
Injury by Inducing the Nrf2 Protective Pathway. ACS chemical neuroscience 10 (5), 2276-2286 
Wang, S.-W. et al. (2018) Astilbin ameliorates cisplatin-induced nephrotoxicity through reducing 
oxidative stress and inflammation. Food and chemical toxicology : an international journal 
published for the British Industrial Biological Research Association 114, 227-236 
Wu, M. et al. (2017) Protective Effects of Pterostilbene Against Myocardial 
Ischemia/Reperfusion Injury in Rats. Inflammation 40 (2), 578-588 
 -8A3. Chapter 3 References 
Brizzi, Kate T; Lyons, Jennifer L. (2014).  Peripheral nervous system manifestations of 
infectious diseases.  The Neurohospitalist.  4:4; 230-40. 
Budzynski, Jacek; Wisniewska, Joanna; Ciecierski, Marek; Kedzia, Anna. (2016).  Association 
between Bacterial Infection and Peripheral Vascular Disease: A Review.  The International 
journal of angiology : official publication of the International College of Angiology, Inc.  25:1; 
3-13. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            314 
Chauhan P, Verma HN, Sisodia R, Kesari KK. Microwave radiation (2.45 GHz)-induced 
oxidative stress: Whole-body exposure effect on histopathology of Wistar rats. Electromagnetic 
biology and medicine. 2017; 36:1; 20-30. 
Gulati S, Yadav A, Kumar N, Priya K, Aggarwal NK, Gupta R. Phenotypic and genotypic 
characterization of antioxidant enzyme system in human population exposed to radiation from 
mobile towers. Molecular and cellular biochemistry. 2017; 1-9. DOI:10.1007/s11010-017-3150-
6 
Kesari KK, Siddiqui MH, Meena R, Verma HN, Kumar S. Cell phone radiation exposure on 
brain and associated biological systems. Indian journal of experimental biology. 2013; 51:3; 187-
200. 
Kostoff RN, Lau CGY. Modified Health Effects of Non-ionizing Electromagnetic Radiation 
Combined with Other Agents Reported in the Biomedical Literature. Chapter 4 in: Geddes (ed.). 
Microwave Effects on DNA and Proteins. Springer; 1st ed. 2017 edition (March 15, 2017). DOI 
10.1007/978-3-319-50289-2_4. 
Liu RH. Health benefits of fruit and vegetables are from additive and synergistic combinations of 
phytochemicals. Am J Clin Nutr. 2003; 78:3; 517S-520S. 
 -8A4. Chapter 4 References 
Kostoff RN, Patel U.  Literature-related discovery and innovation: Chronic Kidney Disease.  
Technological Forecasting and Social Change.  2015;91:341-351.  
http://dx.doi.org/10.1016/j.techfore.2014.09.013.   
Kostoff RN, Porter AL, Buchtel HA.  Prevention and reversal of Alzheimer's disease: treatment 
protocol.  Georgia Institute of Technology. 2018. PDF. 
https://smartech.gatech.edu/handle/1853/59311. 
Kostoff RN.  Literature-related discovery and innovation - update.  Technological Forecasting 
and Social Change.  79:4.  789-800.   DOI: 10.1016/j.techfore.2012.02.002.  2012. 
Kostoff RN. Treatment Repurposing using Literature-Related Discovery. Georgia Institute of 
Technology. 2018a. PDF. http://hdl.handle. 
 -8A5. Chapter 5 References 
Abdulhannan , Russell DA, Homer-Vanniasinkam S.  Peripheral arterial disease: a literature 
review.  British medical bulletin.  2012; 104; 21-39. 
AHA, 2019.  About Peripheral Artery Disease.  American Heart Association.  Dallas, TX. 
https://www.heart.org/en/health-topics/peripheral-artery-disease/about-peripheral-artery-disease-
pad 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            315 
Ahmed A, Alhashmi SM, Ieee. A Metric for Literature-Based Discovery Methodology 
Evaluation.  2015 Ieee/Acs 12th International Conference of Computer Systems and 
Applications. International Conference on Computer Systems and Applications2015. 
Ahmed A, Alhashmi SM. A Critical Survey on Current Literature-Based Discovery Models. 
Soliman KS, editor2014. 1383-99 p. 
Ahmed A. Literature-Based Discovery: Critical Analysis and Future Directions. International 
Journal of Computer Science and Network Security. 2016;16(7):11-26. 
Amin SU, Agarwal K, Beg R.  Genetic neural network based data mining in prediction of heart 
disease using risk factors.  2013 IEEE Conference on Information and Communication 
Technologies (ICT 2013).  2013;1227-1231.   
Anno S.  GIS/data mining applied for identification of environmental risk factors for diseases.  
Management Information Systems.  2004;8:49-54.   
Aussem A, de Morais SR, Corbex M.  Analysis of nasopharyngeal carcinoma risk factors with 
Bayesian networks.  Artificial Intelligence in Medicine.  2012;54(1):53-62.   
Baldereschi M, Inzitari M, Di Carlo A, Bovis F, Maggi S, Capurso A, Solfrizzi V, Panza F, 
Scafato E, Inzitari D.  Vascular factors predict polyneuropathy in a non-diabetic elderly 
population.  NEUROLOGICAL SCIENCES.  2013; 34:6, 955-962.  DOI: 10.1007/s10072-012-
1167-x. 
Barisic I, Wilhelm V, Stambuk N et al.  Machine learning based analysis of biochemical and 
morphologic parameters in patients with dialysis related amyloidosis.  Croatica Chemica Acta.  
2002;75:4:935-944.   
Barohn RJ. Peripheral Neuropathies, An Issue of Neurologic Clinics [Special Issue]. Elsevier 
Health Sciences.  11 June 2013. 
Barrell K, Smith, AG.  Peripheral neuropathy.  The Medical clinics of North America. 2019; 
103:2; 383-397. 
Ben-Assuli O, Leshno M. Assessing electronic health record systems in emergency departments: 
Using a decision analytic Bayesian model. Health Informatics Journal. 2016;22(3):712-29. 
Berkowitz SA, Basu S, Venkataramani A et al.  Association between access to social service 
resources and cardiometabolic risk factors: a machine learning and multilevel modeling analysis.  
BMJ OPEN.  2019; 9:3; e025281. 
Bertke SJ, Meyers AR, Wurzelbacher SJ et al.  Development and evaluation of a Naive Bayesian 
model for coding causation of workers' compensation claims.  Journal of Safety Research.  
2012;435-6):327-332.   
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            316 
Bredesen DE.  The End of Alzheimer's: the First Program to Prevent and Reverse Cognitive 
Decline.  2017.  Avery, New York, NY. 
Cameron D, Kavuluru R, Rindflesch TC, Sheth AP, Thirunarayan K, Bodenreider O. Context-
driven automatic subgraph creation for literature-based discovery. Journal of Biomedical 
Informatics. 2015;54:141-57. 
Campia U, Gerhard-Herman Marie, Piazza G, Goldhaber SZ.  Peripheral Artery Disease: Past, 
Present, and Future.   The American journal of medicine.  2019; 
DOI:10.1016/j.amjmed.2019.04.043. 
Chen K, Lv X, Li W, Yu F, Lin J, Ma J, Xiao D.  Autophagy is a protective response to the 
oxidative damage to endplate chondrocytes in intervertebral disc: implications for the treatment 
of degenerative lumbar disc.  Oxidative Medicine and Cellular Longevity  2017; 2017; Article 
ID: 4041768. 
Cioroiu CM, Brannagan TH.  Peripheral Neuropathy. CURRENT GERIATRICS REPORTS.  
2014; 3:2;  83-90.  DOI: 10.1007/s13670-014-0079-4 
Cohen T, Widdows D, Schvaneveldt RW, Davies P, Rindflesch TC.  Discovering discovery 
patterns with predication-based semantic indexing.  Journal of Biomedical Informatics.  
2012;45:6:1049-1065.  DOI: 10.1016/j.jbi.2012.07.003.  
Cohen T, Widdows D, Stephan C, Zinner R, Kim J, Rindflesch T, et al. Predicting High-
Throughput Screening Results With Scalable Literature-Based Discovery Methods. Cpt-
Pharmacometrics & Systems Pharmacology. 2014;3(10). 
Cole TS, Frankovich J, Iyer S et al.  Profiling risk factors for chronic uveitis in juvenile 
idiopathic arthritis: a new model for EHR-based research.  Pediatric Rheumatology.  
2013;11:Article Number: 45.   
Conte SM, Vale PR.  Peripheral Arterial Disease. (2018).  Heart, lung & circulation.  27:4; 427-
432. 
Dai ZG, Li Q, Yang G, Wang YN, Liu Y, Zheng ZL, et al. Using literature-based discovery to 
identify candidate genes for the interaction between myocardial infarction and depression. Bmc 
Medical Genetics. 2019;20. 
Damarell RA, Tieman J, Sladek RM, Davidson PM.  Development of a heart failure filter for 
Medline: an objective approach using evidence-based clinical practice guidelines as an 
alternative to hand searching.  BMC Medical Research Methodology.  2011;11:  Article Number: 
12.  DOI: 10.1186/1471-2288-11-12.   
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            317 
Dong WW, Liu YX, Zhu WJ, Mou Q, Wang JL, Hu Y. Simulation of Swanson's Literature-
Based Discovery: Anandamide Treatment Inhibits Growth of Gastric Cancer Cells In Vitro and 
In Silico. Plos One. 2014;9(6). 
Donofrio PD.  Textbook of Peripheral Neuropathy.  Springer Publishing Company.  2012. 
Du JP, Guo WS.  Data mining on patient data.  Proceedings of the 2005 International Conference 
on Neural Networks and Brain.  2005;1-3:84-87.   
Dyck PJ, Klein CJ, Low P, Amrami K.  Companion to Peripheral Neuropathy: Illustrated Cases 
and New Developments.  Elsevier Health Sciences.  2010. 
Egan M, MacLean A, Sweeting H, Hunt K.  Comparing the effectiveness of using generic and 
specific search terms in electronic databases to identify health outcomes for a systematic review: 
a prospective comparative study of literature search methods.  BMJ Open.  2012;2(3):e001043.  
DOI: 10.1136/bmjopen-2012-001043.   
England JD, Asbury AK.  Peripheral neuropathy.  Lancet.  2004; 363:9427; 2151-61. 
Esfahani HA, Ghazanfari M.  Cardiovascular disease detection using a new ensemble classifier.  
IEEE 4TH INTERNATIONAL CONFERENCE ON KNOWLEDGE-BASED ENGINEERING 
AND INNOVATION (KBEI); 2017; 1011-1014. 
Firnhaber JM, Powell CS.  Lower Extremity Peripheral Artery Disease: Diagnosis and 
Treatment.  (2019).  American family physician.  99:6; 362-369. 
FPN, 2019.  Foundation for Peripheral Neuropathy, Buffalo Grove, IL. 
https://www.foundationforpn.org/what-is-peripheral-neuropathy/types-risk-factors/ 
Friedman C, Liu HF, Shagina L.  A vocabulary development and visualization tool based on 
natural language processing and the mining of textual patient reports.  Journal of Biomedical 
Informatics.  2003;36(3):189-201.   
Gabetta M, Larizza C, Bellazzi R. A Unified Medical Language System (UMLS) Based System 
for Literature-Based Discovery in Medicine. In: Lehmann CU, Ammenwerth E, Nohr C, editors. 
Medinfo 2013: Proceedings of the 14th World Congress on Medical and Health Informatics, Pts 
1 and 2. Studies in Health Technology and Informatics. 1922013. p. 412-6. 
Garcia MO, Guzman FA.  Searching for drug-related adverse events in PubMed/medline using 
the MeSH term "Drug Toxicity".  Drug Safety.  2008;31(10):889-889.   
Gaskin GL, Pershing S, Cole TS, Shah NH. Predictive modeling of risk factors and 
complications of cataract surgery. European Journal of Ophthalmology. 2016;26(4):328-37. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            318 
Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher 
LA, Fowkes FGR, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel 
RAG, Regensteiner JG, Schanzer A, Shishehbor MH, Stewart KJ, Treat-Jacobson D, Walsh ME.  
2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral 
Artery Disease: Executive Summary: A Report of the American College of 
Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.  
Circulation.  2017; 135:12; e686-e725. 
(https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000470) 
Golder S, Loke Y, McIntosh HM.  Poor reporting and inadequate searches were apparent in 
systematic reviews of adverse effects.  Journal of Clinical Epidemiology. 2008;61(5):440-448.  
DOI: 10.1016/j.jclinepi.2007.06.005.   
Golder S, Loke YK, Zorzela L.  Some improvements are apparent in identifying adverse effects 
in systematic reviews from 1994 to 2011.  Journal of Clinical Epidemiology.  2013;66(3):253-
260.  DOI: 10.1016/j.jclinepi.2012.09.013.   
Golder S, Loke YK.  Search strategies to identify information on adverse effects: a systematic 
review.  Journal of the Medical Library Association.  2009;97(2):84-92.  DOI: 10.3163/1536-
5050.97.2.004.   
Golder S, Loke YK.  Sensitivity and precision of adverse effects search filters in MEDLINE and 
EMBASE: a case study of fractures with thiazolidinediones.  Health Information and Libraries 
Journal.  2012;29(1):28-38.  DOI: 10.1111/j.1471-1842.2011.00972.x.   
Golder S, Wright K, Loke YK.  The development of search filters for adverse effects of surgical 
interventions in medline and Embase.  HEALTH INFORMATION AND LIBRARIES 
JOURNAL.  2018; 35:2; 121-129. 
Gonoodi K, Tayefi M, Saberi-Karimian M et al.  An assessment of the risk factors for vitamin D 
deficiency using a decision tree model.  DIABETES & METABOLIC SYNDROME-CLINICAL 
RESEARCH & REVIEWS.  2019; 13:3; 1773-1777. 
Haase A, Follmann M, Skipka G, Kirchner H.  Developing search strategies for clinical practice 
guidelines in SUMSearch and Google Scholar and assessing their retrieval performance.  BMC 
Medical Research Methodology.  2007;7:28 
Han X, Wang Z, Subhadarshini A, Karnik S, Strother RM, Hall SD, et al. NOVEL 
TRANSLATIONAL PARADIGM FOR DRUG-DRUG INTERACTION RESEARCH: A 
COMBINATION OF LITERATURE-BASED DISCOVERY, ELECTRONIC MEDICAL 
RECORDS AND IN VITRO DDI SCREENING ASSAYS. Clinical Pharmacology & 
Therapeutics. 2012;91:S47-S. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            319 
Hanewinckel R, Ikram MA, van Doorn PA.  Peripheral neuropathies.  
NEUROEPIDEMIOLOGY.  Edited by:Rosano, C; Ikram, MA; Ganguli, M, Eds.  2016; 138; 
263-282.  DOI: 10.1016/B978-0-12-802973-2.00015-X 
Harbour J, Fraser C, Lefebvre C, Glanville J, Beale S, Boachie C, Duffy S, McCool R, Smith L.  
Reporting methodological search filter performance comparisons: a literature review.  Health 
Information and Libraries Journal.  2014;31(3):176-194.  DOI: 10.1111/hir.12070.   
Henry S, McInnes BT. Literature Based Discovery: Models, methods, and trends. Journal of 
Biomedical Informatics. 2017;74:20-32. 
Herskovitz S, Scelsa S, Schaumburg H.  Peripheral Neuropathies in Clinical Practice.  Oxford 
University Press, USA.  2010. 
Hills AJ, Shalhoub J, Shepherd AC, Davies AH.  Peripheral arterial disease.  British journal of 
hospital medicine.  2009; 70:10; 560-5. 
Hristovski D, Kastrin A, Dinevski D, Burgun A, Ziberna L, Rindflesch TC. Using Literature-
Based Discovery to Explain Adverse Drug Effects. Journal of Medical Systems. 2016;40(8). 
Hristovski D, Kastrin A, Dinevskr D, Rindflesch TC. Constructing a Graph Database for 
Semantic Literature-Based Discovery. In: Sarkar IN, Georgiou A, Marques PMD, editors. 
Medinfo 2015: Ehealth-Enabled Health. Studies in Health Technology and Informatics. 
2162015. p. 1094-. 
Hristovski D, Rindflesch T, Peterlin B.  Using literature-based discovery to identify novel 
therapeutic approaches.  Cardiovasc Hematol Agents Med Chem. 2013;11:1:14-24.   
Hu XH, Zhang XD, Yoo I, Wang XF, Feng JL.  Mining hidden connections among biomedical 
concepts from disjoint biomedical literature sets through semantic-based association rule.  
International Journal of Intelligent Systems.  2010;25:2:207-223.  DOI: 10.1002/int.20396.   
Hughes RAC.  Peripheral neuropathy.  BMJ.  2002; 324:7335; 466-9. 
Hur J, Sullivan KA, Schuyler AD, Hong Y, Pande M, States DJ, et al. Literature-based discovery 
of diabetes- and ROS-related targets. Bmc Medical Genomics. 2010;3. 
Ismaeel AG, Mikhail DY. Effective data mining technique for classification cancers via 
mutations in gene using neural network. International Journal of Advanced Computer Science 
and Applications. 2016;7(7):69-76. 
Ittipanuvat V, Fujita K, Kajikawa Y, Mori J, Sakata I. Finding Linkage between Technology and 
Social Issues: A Literature Based Discovery Approach. Kocaoglu DF, Anderson TR, Daim TU, 
editors2012. 2310-21 p. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            320 
Ittipanuvat V, Fujita K, Sakata I, Kajikawa Y. Finding linkage between technology and social 
issue: A Literature Based Discovery approach. Journal of Engineering and Technology 
Management. 2014;32:160-84. 
Karam C, Dyck PJB.  Toxic Neuropathies.  Seminars in neurology.  2015; 35:4; 448-57.  
DOI:10.1055/s-0035-1558977 
Karaolis M, Moutiris JA, Papaconstantinou L et al.  AKAMAS: Mining association rules using a 
new algorithm for the assessment of the risk of coronary heart events.  2009 9th International 
Conference on Information Technology and Applications in Biomedicine.  2009;514-519.   
Karaolis MA, Moutiris JA, Hadjipanayi D et al.  Assessment of the risk factors of coronary heart 
events based on data mining with decision trees.  IEEE Transactions on Information Technology 
in Biomedicine.  2010;14(3):559-566.   
Kastrin A, Rindflesch TC, Hristovski D. Link Prediction on a network of co-occurring MeSH 
terms: towards literature-based discovery. Methods of Information in Medicine. 2016;55(4):340-
6. 
Kastrin A, Rindflesch TC, Hristovski D. Link Prediction on the Semantic MEDLINE Network 
An Approach to Literature-Based Discovery. In: Dzeroski S, Panov P, Kocev D, Todorovski L, 
editors. Discovery Science, Ds 2014. Lecture Notes in Artificial Intelligence. 87772014. p. 135-
43. 
Kengne AP, Echouffo-Tcheugui JB.  Differential burden of peripheral artery disease.  The 
Lancet.  2019; 7:8; e980-e981. 
Kevil CG, Bir SC, Pattillo CB.  Peripheral Arterial Disease: Pathophysiology and Therapeutics.  
2013.  Biota Publishing, Princeton, NJ. 
Kim TN, Kim JM, Won JC et al.  A decision tree-based approach for identifying urban-rural 
differences in metabolic syndrome risk factors in the adult Korean population.  Journal of 
Endocrinological Investigation.  2012;35(9):847-852.   
Kim YH, Song M. A context-based ABC model for literature-based discovery. Plos One. 
2019;14(4). 
Korhonen A, Guo YF, Baker S, Yetisgen-Yildiz M, Stenius U, Narita M, et al. Improving 
Literature-Based Discovery with Advanced Text Mining. In: DiSerio C, Lio P, Nonis A, 
Tagliaferri R, editors. Computational Intelligence Methods for Bioinformatics and Biostatistics, 
Cibb 2014. Lecture Notes in Bioinformatics. 86232015. p. 89-98. 
Koskela TH, Ryynanen OP, Soini EJ.  Risk factors for persistent frequent use of the primary 
health care services among frequent attenders: A Bayesian approach.  Scandinavian Journal of 
Primary Health Care.  2010;28(1):55-61.   
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            321 
Kostoff RN, Goumenou M, Tsatsakis A.  The role of toxic stimuli combinations in determining 
safe exposure limits.  TOXICOLOGY REPORTS.  2018; 5; 1169-1172.   
Kostoff RN, Patel U.  Literature-related discovery and innovation: Chronic Kidney Disease.  
Technological Forecasting and Social Change.  2015;91:341-351.  
http://dx.doi.org/10.1016/j.techfore.2014.09.013.   
Kostoff RN, Porter AL, Buchtel HA.  Prevention and reversal of Alzheimer's disease: treatment 
protocol.  Georgia Institute of Technology. 2018. PDF. 
https://smartech.gatech.edu/handle/1853/59311. 
Kostoff RN. Literature-related discovery and innovation - update. Technological Forecasting and 
Social Change. 2012;79(4):789-800. 
Kostoff RN. Pervasive Causes of Disease. Georgia Institute of Technology. 2015. PDF. 
http://hdl.handle.net/1853/53714. 
Lang PM, Schober GM, Rolke R, Wagner S, Hilge R, Offenbacher M, Treede RD, Hoffmann U, 
Irnich D.   Sensory neuropathy and signs of central sensitization in patients with peripheral 
arterial disease.  PAIN.  2006; 124:1-2; 190-200.  DOI: 10.1016/j.pain.2006.04.011. 
Lang PM.  Painful ischemic neuropathy.  NERVENARZT.  2015; 86:2; 151-+.  DOI: 
10.1007/s00115-014-4125-4 
Li Q, Zhang Y, Kang H et al.  Mining association rules between stroke risk factors based on the 
Apriori algorithm.  TECHNOLOGY AND HEALTH CARE.  2017; 25; 1; S197-S205. 
Li X, Pang J, Li M et al.  Discover high-risk factor combinations using Bayesian network from 
cohort data of National Stoke Screening in China.  BMC MEDICAL INFORMATICS AND 
DECISION MAKING.  2019; 19; Supplement: 2; 67. 
Liao X, Kerr D, Morales J et al.  Application of Machine Learning to Identify Clustering of 
Cardiometabolic Risk Factors in US Adults.  DIABETES TECHNOLOGY & THERAPEUTICS.  
2019;  21:5; 245-253.  
Liu XY, Fu H, Jiang CY. A Directional Recognition Algorithm of Semantic Relation for 
Literature-Based Discovery. In: Tan Y, Shi Y, Li L, editors. Advances in Swarm Intelligence, 
Icsi 2016, Pt Ii. Lecture Notes in Computer Science. 97132016. p. 281-8. 
Marschollek M, Goevercin M, Rust S et al.  Mining geriatric assessment data for in-patient fall 
prediction models and high-risk subgroups.  BMC Medical Informatics and Decision Making.  
2012;12:  Article Number:19.   
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            322 
Maver A, Hristovski D, Rindflesch TC, Peterlin B. Integration of Data from Omic Studies with 
the Literature-Based Discovery towards Identification of Novel Treatments for 
Neovascularization in Diabetic Retinopathy. Biomed Research International. 2013. 
MC, 2019.  Peripheral Artery Disease.  Mayo Clinic.  Rochester, MN. 
https://www.mayoclinic.org/diseases-conditions/peripheral-artery-disease/symptoms-causes/syc-
20350557 
McDermott MM.  Lower Extremity Manifestations of Peripheral Artery Disease The 
Pathophysiologic and Functional Implications of Leg Ischemia.  CIRCULATION RESEARCH.  
2015; 116:9; 1540-1550.  DOI: 10.1161/CIRCRESAHA.114.303517. 
McKibbon KA, Wilczynski NL, Haynes RB.  Retrieving randomized controlled trials from 
Medline: a comparison of 38 published search filters.  Health Information and Libraries Journal.  
2009;26(3):187-202.   
Meng XH, Huang YX, Rao DP et al.  Comparison of three data mining models for predicting 
diabetes or prediabetes by risk factors.  Kaohsiung Journal of Medical Sciences.  2013;29(2):93-
99.   
Miller CM, Rindflesch TC, Fiszman M, Hristovski D, Shin D, Rosemblat G, Zhang H, Strohl 
KP.  A closed literature-based discovery technique finds a mechanistic link between 
hypogonadism and diminished sleep quality in aging men.  Sleep.  2012;35:2:279-85.   
Miller CM, Rindflesch TC, Strohl KP, Koo BB. LITERATURE-BASED DISCOVERY 
SUGGESTS NEUROMELANIN AND IRON METABOLISM IN RESTLESS LEGS 
SYNDROME. Sleep. 2012;35:A61-A2. 
Morley RL, Sharma A, Horsch AD, Hinchliffe RJ.  Peripheral artery disease.  BMJ.  2018; 360; 
j5842. 
NINDS, 2019.  Peripheral Neuropathy Fact Sheet, NINDS. 
(https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Peripheral-
Neuropathy-Fact-Sheet) 
Nukada H, vanRij AM, Packer SGK, McMorran, PD.  Pathology of acute and chronic ischaemic 
neuropathy in atherosclerotic peripheral vascular disease.  BRAIN.  1996; 119:1449-1460. 
Nunomura A., Takeda A, Moreira PI, Castellani RJ, Lee HG, Zhu X, Smith MA, Perry G.  2009.  
Neurofibrillary tangle formation as a protective response to oxidative stress in Alzheimer’s 
Disease. In: Maccioni R.B., Perry G. (eds) Current Hypotheses and Research Milestones in 
Alzheimer's Disease. Springer, Boston, MA DOI https://doi.org/10.1007/978-0-387 
Ordonez C, Zhao K.  Evaluating association rules and decision trees to predict multiple target 
attributes.  Intelligent Data Analysis.  2011;15(2):173-192.   
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            323 
Ozgur A, Xiang ZS, Radev DR, He YQ. Literature-Based Discovery of IFN-gamma and 
Vaccine-Mediated Gene Interaction Networks. Journal of Biomedicine and Biotechnology. 2010. 
Pascuzzi RM.  Peripheral neuropathy.  The Medical clinics of North America.  2009; 93:2.  317-
42. 
Pereira A, Ito M, Fonseca LM et al.  Testing data mining indications for novel biomarkers and 
risk factors.  ATHEROSCLEROSIS.  2017; 263; E198-E198; PO285. 
Pfaff M, Weller K, Woetzel D et al.  Prediction of cardiovascular risk in hemodialysis patients 
by data mining.  Methods of Information in Medicine.  2004;43:1:106-113.   
Preiss J, Stevenson M, Gaizauskas R. Exploring relation types for literature-based discovery. 
Journal of the American Medical Informatics Association. 2015;22(5):987-92. 
Preiss J, Stevenson M. Quantifying and filtering knowledge generated by literature based 
discovery. Bmc Bioinformatics. 2017;18. 
Preiss J, Stevenson M. The effect of word sense disambiguation accuracy on literature based 
discovery. Bmc Medical Informatics and Decision Making. 2016;16. 
Pyysalo S, Baker S, Ali I, Haselwimmer S, Shah T, Young A, et al. LION LBD: a literature-
based discovery system for cancer biology. Bioinformatics. 2019;35(9):1553-61. 
Rahaman S, Hossain MS.  A Belief Rule Based Clinical Decision Support System to Assess 
Suspicion of Heart Failure from Signs, Symptoms and Risk Factors.  2013 INTERNATIONAL 
CONFERENCE ON INFORMATICS, ELECTRONICS & VISION (ICIEV).  2013. 
Ramezankhani A, Pournik O, Shahrabi J, Azizi F, Hadaegh F. An application of association rule 
mining to extract risk pattern for Type 2 Diabetes using Tehran lipid and glucose study database. 
International Journal of Endocrinology and Metabolism. 2015;13(2). 
Rastegar-Mojarad M, Elayavilli RK, Li DC, Prasad R, Liu HF. A new method for prioritizing 
drug repositioning candidates extracted by literature-based discovery. In: Huan J, Miyano S, 
Shehu A, Hu X, Ma B, Rajasekaran S, et al., editors. Proceedings 2015 Ieee International 
Conference on Bioinformatics and Biomedicine. IEEE International Conference on 
Bioinformatics and Biomedicine-BIBM2015. p. 669-74. 
Rastegar-Mojarad M, Elayavilli RK, Wang LW, Prasad R, Liu HF, Acm. Prioritizing Adverse 
Drug Reaction and Drug Repositioning Candidates Generated by Literature-Based 
Discovery2016. 289-96 p. 
Rodin A, Mosley TH, Clark AG et al.  Mining genetic epidemiology data with Bayesian 
networks application to APOE gene variation and plasma lipid levels.  Journal of Computational 
Biology.  2005;12(1):1-11.   
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            324 
Ruch P. Literature-Based Discovery. Journal of the American Society for Information Science 
and Technology. 2010;61(7):1506-8. 
Ruiz-Canela M, Martinez-Gonzalez MA.  Lifestyle and dietary risk factors for peripheral artery 
disease.  Circulation journal : official journal of the Japanese Circulation Society.  2014; 78:3; 
553-9. 
Samanta B, Bird GL, Kuijpers M et al.  Prediction of periventricular leukomalacia. Part I: 
Selection of hemodynamic features using logistic regression and decision tree algorithms.  
Artificial Intelligence in Medicine.  2009;46(3):201-215.   
Sampson M, Zhang L, Morrison A, Barrowman NJ, Clifford TJ, Platt RW, Klassen TP, Moher 
D.  An alternative to the hand searching gold standard: validating methodological search filters 
using relative recall.  BMC Medical Research Methodology.  2006;6(33).  DOI:10.1186/1471-
2288-6-33.   
Sang ST, Yang ZH, Li ZY, Lin HF. Supervised learning based hypothesis generation from 
biomedical literature. Biomed Research International. 2015. 
Sang ST, Yang ZH, Liu XX, Wang L, Zhang Y, Lin HF, et al. A Knowledge Graph based 
Bidirectional Recurrent Neural Network Method for Literature-based Discovery. In: Zheng H, 
Callejas Z, Griol D, Wang H, Hu X, Schmidt H, et al., editors. Proceedings 2018 Ieee 
International Conference on Bioinformatics and Biomedicine. IEEE International Conference on 
Bioinformatics and Biomedicine-BIBM2018. p. 751-2. 
Saporta MA, Shy ME.  Chapter 12: Peripheral Neuropathies.  in Neurobiology of brain 
disorders: biological basis of neurological and psychiatric disorders.  Zigmond MJ, Rowland LP, 
Coyle JT, Eds.  2015; 167-188.  Academic Press Ltd-Elsevier Science Ltd, 24-28 Oval Road, 
London Nw1 7dx, England. 
Schutz P, Bally M, Stanga Z, Keller U.  Loss of appetite in acutely ill medical inpatients: 
physiological response or therapeutic target?  Swiss Medical Weekly.  2014; 144; w13957.  
DOI:10.4414/smw.2014.13957 
Sebastian Y, Acm. Cluster Links Prediction for Literature Based Discovery Using Latent 
Structure and Semantic Features2014. 1275- p. 
Sebastian Y, Siew EG, Orimaye SO. Emerging approaches in literature-based discovery: 
techniques and performance review. Knowledge Engineering Review. 2017a;32:1-35. 
Sebastian Y, Siew EG, Orimaye SO. Learning the heterogeneous bibliographic information 
network for literature-based discovery. Knowledge-Based Systems. 2017b;115:66-79. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            325 
Shao Z, Chen C, Li W et al.  Assessment of the risk factors in the daily life of stroke patients 
based on an optimized decision tree.   TECHNOLOGY AND HEALTH CARE.  2019; 27; 1; 
S317-S329. 
Shields RW, 2010.  Peripheral Neuropathy, Cleveland Clinic.  
(http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/neurology/peripheral-
neuropathy/) 
Smalheiser NR. Literature-Based Discovery: Beyond the ABCs. Journal of the American Society 
for Information Science and Technology. 2012;63(2):218-24. 
Smalheiser NR. Rediscovering Don Swanson: The Past, Present and Future of Literature-based 
Discovery. Journal of Data and Information Science. 2017;2(4):43-64. 
Smith AG, Bromberg MB. Handbook of Peripheral Neuropathy.  Taylor and Francis.  2005. 
Srinivasan M, Blackburn C, Mohamed M, Sivagami AV, Blum J. Literature-Based Discovery of 
Salivary Biomarkers for Type 2 Diabetes Mellitus. Biomarker Insights. 2015;10:39-45. 
Sun J, Feng X, Liang D, Duan Y, Lei H.  Down-regulation of energy metabolism in Alzheimer's 
disease is a protective response of neurons to the microenvironment.  Journal of Alzheimer's 
disease.  2012; 28:2; 389-402.  DOI:10.3233/JAD-2011-111313 
Tanaka L, Aronson AR, Weeber M.  Mining the epidemiological literature for risk factors and 
incidence data of Kawasaki disease.  AMIA 2002 Symposium, Proceedings: Biomedical 
Informatics: One Discipline.  2002;1178-1178.   
Tanon AA, Champagne F, Contandriopoulos AP, Pomey MP, Vadeboncoeur A, Nguyen, H.  
Patient safety and systematic reviews: finding papers indexed in MEDLINE, EMBASE and 
CINAHL.  Quality & Safety in Health Care.  2010;19(5):452-461.  DOI: 
10.1136/qshc.2008.031401.   
Thomas PK, Dyck PJ.  Peripheral Neuropathy: 2-Volume Set / Edition 4.  Elsevier Health 
Sciences.  2005. 
Toursarkissian B, Connaughton JC, D'Ayala M, Shireman PK, Harrison A, Schoolfield J, Sykes 
MT.  Does lower limb revascularization result in an improvement in sensory perception 
thresholds?  ANNALS OF VASCULAR SURGERY.  2002.  16:3; 309-313.  DOI: 
10.1007/s10016-001-0069-9. 
Turner R, Arsevska E, Brant B et al.  Risk factors for cutaneous myiasis (blowfly strike) in pet 
rabbits in Great Britain based on text-mining veterinary electronic health records.  
PREVENTIVE VETERINARY MEDICINE.  2018; 153; 77-83. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            326 
UCSF, 2019.  Peripheral Neuropathy.  University of California, San Francisco. 
https://www.ucsfhealth.org/conditions/peripheral_neuropathy/ 
Ugalde V, Wineinger MA, Kappagoda CT, Kilmer DD, Pevec WC, Rosen WS, Rubner D.  
Sensory axonopathy in mild to moderate peripheral arterial disease. AMERICAN JOURNAL OF 
PHYSICAL MEDICINE & REHABILITATION.  1998; 77:1; 59-64.  DOI: 10.1097/00002060-
199801000-00012. 
Ushida Y, Kato R, Niwa K et al.  Combinational risk factors of metabolic syndrome identified by 
fuzzy neural network analysis of health-check data.  BMC Medical Informatics and Decision 
Making.  2012;12.  Article Number: 80.   
Vos R, Aarts S, van Mulligen E, Metsemakers J, van Boxtel MP, Verhey F, et al. Finding 
potentially new multimorbidity patterns of psychiatric and somatic diseases: exploring the use of 
literature-based discovery in primary care research. Journal of the American Medical Informatics 
Association. 2014;21(1):139-45. 
Waffenschmidt S, Janzen T, Hausner E, Kaiser T.  Simple search techniques in PubMed are 
potentially suitable for evaluating the completeness of systematic reviews.  Journal of Clinical 
Epidemiology.  2013;66(6):660-665.  DOI: 10.1016/j.jclinepi.2012.11.011.   
Wang WJ.  Quantifying relevance of input features.  Lecture Notes in Computer Science.  
2002;2412:588-593.   
Watson JC, Dyck PJB.  Peripheral Neuropathy: A Practical Approach to Diagnosis and 
Symptom Management.  MAYO CLINIC PROCEEDINGS.  2015; 90:7; 940-951. 
Weber F, Ziegler A.  Axonal neuropathy in chronic peripheral arterial occlusive disease.  
MUSCLE & NERVE.  2002; 26:4; 471-476.  DOI: 10.1002/mus.10235. 
Wegner A, Khoramnia R.  Cataract is a self-defence reaction to protect the retina from oxidative 
damage.  Medical Hypotheses. 2011; 76:5; 741-4.  DOI:10.1016/j.mehy.2011.02.013 
Weinberg DH, Simovic D, Isner J, Ropper AH.  Chronic ischemic monomelic neuropathy from 
critical limb ischemia.  NEUROLOGY.  2001; 57:6; 1008-1012.  DOI: 10.1212/WNL.57.6.1008. 
WNA, 2019.  Western Neuropathy Association, Sacramento, CA. https://pnhelp.org/neuropathy 
Workman TE, Fiszman M, Rindflesch TC, Nahl D. Framing Serendipitous Information-Seeking 
Behavior for Facilitating Literature-Based Discovery: A Proposed Model. Journal of the 
Association for Information Science and Technology. 2014;65(3):501-12. 
Yamazaki S, Onodera N, Nakayama SI. Extraction of the Pharmacological Treatment Features in 
Literature-based Discovery by Applying Cluster Analysis. In: Lehmann CU, Ammenwerth E, 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            327 
Nohr C, editors. Medinfo 2013: Proceedings of the 14th World Congress on Medical and Health 
Informatics, Pts 1 and 2. Studies in Health Technology and Informatics. 1922013. p. 983-. 
Yang HT, Ju JH, Wong YT, Shmulevich I, Chiang JH. Literature-based discovery of new 
candidates for drug repurposing. Briefings in Bioinformatics. 2017;18(3):488-97. 
Zemaitis MR, Bah F, Boll JM, Dreyer MA.  Peripheral Arterial Disease.  2019.  StatPearls 
Publishing, Treasure Island, FL. 
Zhao D, Weng C.  Combining PubMed knowledge and EHR data to develop a weighted 
bayesian network for pancreatic cancer prediction.  Journal of Biomedical Informatics.  
2011;44(5):859-868.   
 -8A6. Chapter 6 References 
Kostoff RN, Porter AL, Buchtel HA.  Prevention and reversal of Alzheimer's disease: treatment 
protocol.  Georgia Institute of Technology. 2018. PDF. 
https://smartech.gatech.edu/handle/1853/59311. 
Kostoff RN. Treatment Repurposing using Literature-Related Discovery. Georgia Institute of 
Technology. 2018. PDF. https://smartech.gatech.edu/handle/1853/60507. 
VP.  Vantage Point.  2019.  wwwtheVantagePointcom, Search Technology, Inc, Norcross, GA 
Wang B, Zhang S, Wang X, Yang S, Jiang Q, Xu Y, Xia W.  Transcriptome analysis of the 
effects of chitosan on the hyperlipidemia and oxidative stress in high-fat diet fed mice.  
International Journal of Biological Macromolecules.  2017; 102; 104-110.   
DOI:10.1016/j.ijbiomac.2017.03.187. 
 -8A7. Chapter 7 References 
8B.  Bibliography 
8B1.  PAD Reviews Bibliography 
 Abaraogu UO, Dall PM, Seenan CA. The Effect of Structured Patient Education on 
Physical Activity in Patients with Peripheral Arterial Disease and Intermittent Claudication: A 
Systematic Review. European journal of vascular and endovascular surgery : the official journal 
of the European Society for Vascular Surgery. 2017;54(1):58-68. 
 Abdellaoui A, Al-Khaffaf H. C-reactive protein (CRP) as a marker in peripheral vascular 
disease. European journal of vascular and endovascular surgery : the official journal of the 
European Society for Vascular Surgery. 2007;34(1):18-22. 
 Abdulhannan P, Russell DA, Homer-Vanniasinkam S. Peripheral arterial disease: a 
literature review. British medical bulletin. 2012;104:21-39. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            328 
 Abdullah K, Bou Dargham B, Steinbrecher M, Sun B, Huiqiang Z, Khalili H, et al. Drug-
Eluting Stents for Treatment of Peripheral Artery Disease. American journal of cardiovascular 
drugs : drugs, devices, and other interventions. 2018;18(3):175-80. 
 Aboyans V, Bjorck M, Brodmann M, Collet J-P, Czerny M, De Carlo M, et al. Questions 
and Answers on Diagnosis and Management of Patients withPeripheral Arterial Diseases: A 
Companion Document of the 2017 ESCGuidelines for the Diagnosis and Treatment of Peripheral 
Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). 
European journal of vascular and endovascular surgery : the official journal of the European 
Society for Vascular Surgery. 2018;55(4):457-64. 
 Aboyans V, Ricco J-B, Bartelink M-LEL, Bjorck M, Brodmann M, Cohnert T, et al. 
Editor's Choice - 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial 
Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European 
journal of vascular and endovascular surgery : the official journal of the European Society for 
Vascular Surgery. 2018;55(3):305-68. 
 Abu Dakka M, Badri H, Al-Khaffaf H. Total knee arthroplasty in patients with peripheral 
vascular disease. The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and 
Ireland. 2009;7(6):362-5. 
 Abul-Khoudoud O. Diagnosis and risk assessment of lower extremity peripheral arterial 
disease. Journal of endovascular therapy : an official journal of the International Society of 
Endovascular Specialists. 2006;13 Suppl 2:II10-8. 
 Adams GL, Khanna PK, Staniloae CS, Abraham JP, Sparrow EM. Optimal techniques 
with the Diamondback 360Â° System achieve effective results for the treatment of peripheral 
arterial disease. Journal of cardiovascular translational research. 2011;4(2):220-9. 
 Aday AW, Everett BM. Dyslipidemia Profiles in Patients with Peripheral Artery Disease. 
Current cardiology reports. 2019;21(6):42. 
 Aggarwal S, Loomba RS, Arora R. Preventive aspects in peripheral artery disease. 
Therapeutic advances in cardiovascular disease. 2012;6(2):53-70. 
 Aggarwal S, Moore RD, Arena R, Marra B, McBride A, Lamb B, et al. Rehabilitation 
Therapy in Peripheral Arterial Disease. The Canadian journal of cardiology. 2016;32(10 Suppl 
2):S374-S81. 
 Agrawal K, Eberhardt RT. Contemporary medical management of peripheral arterial 
disease: a focus on risk reduction and symptom relief for intermittent claudication. Cardiology 
clinics. 2015;33(1):111-37. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            329 
 Aherne T, McHugh S, Kheirelseid EA, Lee MJ, McCaffrey N, Moneley D, et al. 
Comparing Supervised Exercise Therapy to Invasive Measures in the Management of 
Symptomatic Peripheral Arterial Disease. Surgery research and practice. 2015;2015:960402. 
 Ahmed B, Al-Khaffaf H. Prevalence of significant asymptomatic carotid artery disease in 
patients with peripheral vascular disease: a meta-analysis. European journal of vascular and 
endovascular surgery : the official journal of the European Society for Vascular Surgery. 
2009;37(3):262-71. 
 Aizenberg DJ. Cardiovascular Testing in Asymptomatic Patients: Carotid Duplex, 
Cardiac Stress Testing, Screen for Peripheral Arterial Disease. The Medical clinics of North 
America. 2016;100(5):971-9. 
 Al Mheid I, Quyyumi AA. Cell therapy in peripheral arterial disease. Angiology. 
2008;59(6):705-16. 
 Alahdab F, Wang AT, Elraiyah TA, Malgor RD, Rizvi AZ, Lane MA, et al. A systematic 
review for the screening for peripheral arterial disease in asymptomatic patients. Journal of 
vascular surgery. 2015;61(3 Suppl):42S-53S. 
 Al-Bawardy RF, Waldo SW, Rosenfield K. Advances in Percutaneous Therapies for 
Peripheral Artery Disease: Drug-Coated Balloons. Current cardiology reports. 2017;19(10):99. 
 Albayati MA, Shearman CP. Peripheral arterial disease and bypass surgery in the diabetic 
lower limb. The Medical clinics of North America. 2013;97(5):821-34. 
 Ali FN, Carman TL. Medical management for chronic atherosclerotic peripheral arterial 
disease. Drugs. 2012;72(16):2073-85. 
 Allaqaband S, Solis J, Kazemi S, Bajwa T, American Heart A, American College of C. 
Endovascular treatment of peripheral vascular disease. Current problems in cardiology. 
2006;31(11):711-60. 
 Allen JD, Giordano T, Kevil CG. Nitrite and nitric oxide metabolism in peripheral artery 
disease. Nitric oxide : biology and chemistry. 2012;26(4):217-22. 
 Almahameed A, Bhatt DL. Contemporary management of peripheral arterial disease: III. 
Endovascular and surgical management. Cleveland Clinic journal of medicine. 2006;73 Suppl 
4:S45-51. 
 Almahameed A. Peripheral arterial disease: recognition and medical management. 
Cleveland Clinic journal of medicine. 2006;73(7):621-6, 8, 32-4, passim. 
 Alnaeb ME, Alobaid N, Seifalian AM, Mikhailidis DP, Hamilton G. Optical techniques 
in the assessment of peripheral arterial disease. Current vascular pharmacology. 2007;5(1):53-9. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            330 
 Alnaeb ME, Alobaid N, Seifalian AM, Mikhailidis DP, Hamilton G. Statins and 
peripheral arterial disease: potential mechanisms and clinical benefits. Annals of vascular 
surgery. 2006;20(5):696-705. 
 Altit R, Gray WA. New Innovations in Drug-Eluting Stents for Peripheral Arterial 
Disease. Current cardiology reports. 2017;19(11):117. 
 Ambler GK, Radwan R, Hayes PD, Twine CP. Atherectomy for peripheral arterial 
disease. The Cochrane database of systematic reviews. 2014(3):CD006680. 
 Amer MR, Chaturvedula ST, Joshi S, Ingrassia J. Antithrombotic Therapy After 
Revascularization in Patients With Peripheral Arterial Disease: What Is Here, What Is Next. 
Vascular and endovascular surgery. 2019;53(4):325-36. 
 Anand RG, Ventura HO, Mehra MR. Is heart failure more prevalent in patients with 
peripheral arterial disease? A meta-analysis. Congestive heart failure (Greenwich, Conn). 
2007;13(6):319-22. 
 Andras A, Ferket B. Screening for peripheral arterial disease. The Cochrane database of 
systematic reviews. 2014(4):CD010835. 
 Andras A, Hansrani M, Stewart M, Stansby G. Intravascular brachytherapy for peripheral 
vascular disease. The Cochrane database of systematic reviews. 2014(1):CD003504. 
 Andras A, Stansby G, Hansrani M. Homocysteine lowering interventions for peripheral 
arterial disease and bypass grafts. The Cochrane database of systematic reviews. 
2013(7):CD003285. 
 Andreozzi GM. Propionyl l-carnitine: intermittent claudication and peripheral arterial 
disease. Expert opinion on pharmacotherapy. 2009;10(16):2697-707. 
 Annex BH, Beller GA. TOWARDS THE DEVELOPMENT OF NOVEL 
THERAPEUTICS FOR PERIPHERAL ARTERY DISEASE. Transactions of the American 
Clinical and Climatological Association. 2016;127:224-34. 
 Antoniou GA, Fisher RK, Georgiadis GS, Antoniou SA, Torella F. Statin therapy in 
lower limb peripheral arterial disease: Systematic review and meta-analysis. Vascular 
pharmacology. 2014;63(2):79-87. 
 Antonopoulos AG, Thomopoulos M, Trikas A. The role of the angiosome model in 
percutaneous intravascular and surgical reperfusion treatment of peripheral artery disease of the 
lower limbs. Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese. 
2014;55(1):52-7. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            331 
 Antonopoulos AS, Papanikolaou E, Vogiatzi G, Oikonomou E, Tousoulis D. Anti-
inflammatory agents in peripheral arterial disease. Current opinion in pharmacology. 2018;39:1-
8. 
 Arain FA, Cooper LT, Jr. Peripheral arterial disease: diagnosis and management. Mayo 
Clinic proceedings. 2008;83(8):944-49; quiz 9-50. 
 Aranguren XL, Verfaillie CM, Luttun A. Emerging hurdles in stem cell therapy for 
peripheral vascular disease. Journal of molecular medicine (Berlin, Germany). 2009;87(1):3-16. 
 Arif SA, D'Souza J, Gil M, Gim S. Vorapaxar for reduction of thrombotic cardiovascular 
events in myocardial infarction and peripheral artery disease. American journal of health-system 
pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 
2015;72(19):1615-22. 
 Armstrong EJ, Bishu K, Waldo SW. Endovascular Treatment of Infrapopliteal Peripheral 
Artery Disease. Current cardiology reports. 2016;18(4):34. 
 Armstrong EJ, Chhatriwalla AK, Szerlip M, Swaminathan RV, Patel RAG. Late breaking 
trials of 2015 in structural heart disease and peripheral artery disease: Commentary covering 
ACC, EuroPCR, SCAI, TCT, VIVA, ESC, and AHA. Catheterization and cardiovascular 
interventions : official journal of the Society for Cardiac Angiography & Interventions. 
2016;87(6):1020-6. 
 Aronow H, Hiatt WR. The burden of peripheral artery disease and the role of antiplatelet 
therapy. Postgraduate medicine. 2009;121(4):123-35. 
 Aronow H. Peripheral arterial disease in the elderly: recognition and management. 
American journal of cardiovascular drugs : drugs, devices, and other interventions. 
2008;8(6):353-64. 
 Aronow HD, Beckman JA. Parsing Atherosclerosis: The Unnatural History of Peripheral 
Artery Disease. Circulation. 2016;134(6):438-40. 
 Aronow WS. Management of peripheral arterial disease of the lower extremities. 
Comprehensive therapy. 2007;33(4):247-56. 
 Aronow WS. Peripheral arterial disease and abdominal aortic aneurysm in elderly people. 
Minerva medica. 2011;102(6):483-500. 
 Aronow WS. Peripheral arterial disease in the elderly. Clinical interventions in aging. 
2007;2(4):645-54. 
 Aronow WS. Peripheral arterial disease in women. Maturitas. 2009;64(4):204-11. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            332 
 Aronow WS. Peripheral arterial disease. Geriatrics. 2007;62(1):19-25. 
 Askew CD, Parmenter B, Leicht AS, Walker PJ, Golledge J. Exercise & Sports Science 
Australia (ESSA) position statement on exercise prescription for patients with peripheral arterial 
disease and intermittent claudication. Journal of science and medicine in sport. 2014;17(6):623-
9. 
 Aslam F, Haque A, Foody J, Lee LV. Peripheral arterial disease: current perspectives and 
new trends in management. Southern medical journal. 2009;102(11):1141-9. 
 Asongwed ET, Chesbro SB, Karavatas SG. Peripheral arterial disease and the ankle-
brachial index: what home healthcare clinicians need to know. Home healthcare nurse. 
2009;27(3):160-7; quiz 8-9. 
 Astori G, Bambi F, Soldati G, Surder D, Moccetti T. Autologous bone marrow 
mononucleated cell preparation for the clinical treatment of acute myocardial infarction and 
peripheral arterial disease. Cytotherapy. 2011;13(9):1031-5. 
 Atturu G, Homer-Vanniasinkam S, Russell DA. Pharmacology in peripheral arterial 
disease: what the interventional radiologist needs to know. Seminars in interventional radiology. 
2014;31(4):330-7. 
 Au TB, Golledge J, Walker PJ, Haigh K, Nelson M. Peripheral arterial disease - 
diagnosis and management in general practice. Australian family physician. 2013;42(6):397-400. 
 Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC. Lipid-lowering for peripheral 
arterial disease of the lower limb. The Cochrane database of systematic reviews. 
2007(4):CD000123. 
 Azarbal A, Clavijo L, Gaglia MA, Jr. Antiplatelet therapy for peripheral arterial disease 
and critical limb ischemia: guidelines abound, but where are the data? Journal of cardiovascular 
pharmacology and therapeutics. 2015;20(2):144-56. 
 Bailey MA, Griffin KJ, Scott DJA. Clinical assessment of patients with peripheral arterial 
disease. Seminars in interventional radiology. 2014;31(4):292-9. 
 Balaz P, Rokosny S, Bafrnec J, Bjorck M. The role of hybrid procedures in the 
management of peripheral vascular disease. Scandinavian journal of surgery : SJS : official organ 
for the Finnish Surgical Society and the Scandinavian Surgical Society. 2012;101(4):232-7. 
 Balzer KM, Weis-Muller BT. Results of open vascular surgical therapy in chronic 
peripheral arterial disease. VASA Zeitschrift fur Gefasskrankheiten. 2011;40(5):359-67. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            333 
 Banchs Vina H, Claudio H, Mesa M, Lopez-Candales A. Diagnostic Studies for the 
Evaluation of Peripheral Artery Disease. Boletin de la Asociacion Medica de Puerto Rico. 
2015;107(3):42-5. 
 Banerjee A, Fowkes FG, Rothwell PM. Associations between peripheral artery disease 
and ischemic stroke: implications for primary and secondary prevention. Stroke. 
2010;41(9):2102-7. 
 Banerjee S, Sarode K, Vinas A, Banerjee A, Mohammad A, Brilakis ES. The role of 
antiplatelet therapy in patients with peripheral artery disease and lower extremity peripheral 
artery revascularization. Current opinion in cardiology. 2015;30(5):525-35. 
 Barkat M, Torella F, Antoniou GA. Drug-eluting balloon catheters for lower limb 
peripheral arterial disease: the evidence to date. Vascular health and risk management. 
2016;12:199-208. 
 Barochiner J, Aparicio LS, Waisman GD. Challenges associated with peripheral arterial 
disease in women. Vascular health and risk management. 2014;10:115-28. 
 Barriocanal AM, Lopez A, Monreal M, Montane E. Quality assessment of peripheral 
artery disease clinical guidelines. Journal of vascular surgery. 2016;63(4):1091-8. 
 Barshes NR, Grant CL. Advances in the Management of Peripheral Artery Disease. 
Current diabetes reports. 2019;19(7):36. 
 Bartholomew JR, Olin JW. Pathophysiology of peripheral arterial disease and risk factors 
for its development. Cleveland Clinic journal of medicine. 2006;73 Suppl 4:S8-14. 
 Begelman SM, Jaff MR. Noninvasive diagnostic strategies for peripheral arterial disease. 
Cleveland Clinic journal of medicine. 2006;73 Suppl 4:S22-9. 
 Beiswenger AC, Jo A, Harth K, Kumins NH, Shishehbor MH, Kashyap VS. A systematic 
review of the efficacy of aspirin monotherapy versus other antiplatelet therapy regimens in 
peripheral arterial disease. Journal of vascular surgery. 2018;67(6):1922-32.e6. 
 Belkin N, Damrauer SM. Peripheral Arterial Disease Genetics: Progress to Date and 
Challenges Ahead. Current cardiology reports. 2017;19(12):131. 
 Bellmunt S, Roque M, Osorio D, Pardo H, Escudero JR, Bonfill X. Healthcare quality 
indicators of peripheral artery disease based on systematic reviews. European journal of vascular 
and endovascular surgery : the official journal of the European Society for Vascular Surgery. 
2014;48(1):60-9. 
 Bennett PC, Silverman S, Gill PS, Lip GYH. Ethnicity and peripheral artery disease. 
QJM : monthly journal of the Association of Physicians. 2009;102(1):3-16. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            334 
 Bennett PC, Silverman SH, Gill PS, Lip GYH. Peripheral arterial disease and Virchow's 
triad. Thrombosis and haemostasis. 2009;101(6):1032-40. 
 Bentley AJ, Kelechi TJ. Motivators and Barriers to Walking in Older Adults With 
Peripheral Artery Disease. Journal of gerontological nursing. 2018;44(1):43-50. 
 Berger JS, Hiatt WR. Medical therapy in peripheral artery disease. Circulation. 
2012;126(4):491-500. 
 Berti-Hearn L, Elliott B. A closer look at lower extremity peripheral arterial disease. 
Nursing. 2018;48(1):34-41. 
 Bhat TM, Afari ME, Garcia LA. Atherectomy in Peripheral Artery Disease: A Review. 
The Journal of invasive cardiology. 2017;29(4):135-44. 
 Bhat TM, Afari ME, Garcia LA. Neutrophil lymphocyte ratio in peripheral vascular 
disease: a review. Expert review of cardiovascular therapy. 2016;14(7):871-5. 
 Biondi-Zoccai G, Sangiorgi G, D'Ascenzo F, Zuffi A, Lotrionte M, Romagnoli E, et al. 
Drug-eluting balloons for peripheral artery disease: a meta-analysis of 7 randomized clinical 
trials and 643 patients. International journal of cardiology. 2013;168(1):570-1. 
 Biscetti F, Bonadia N, Nardella E, Cecchini AL, Landolfi R, Flex A. The Role of the 
Stem Cells Therapy in the Peripheral Artery Disease. International journal of molecular sciences. 
2019;20(9). 
 Biscetti F, Nardella E, Cecchini AL, Landolfi R, Flex A. The Role of the Microbiota in 
the Diabetic Peripheral Artery Disease. Mediators of inflammation. 2019;2019:4128682. 
 Blinc A, Poredos P. Pharmacological prevention of atherothrombotic events in patients 
with peripheral arterial disease. European journal of clinical investigation. 2007;37(3):157-64. 
 Blum A, Balkan W, Hare JM. Advances in cell-based therapy for peripheral vascular 
disease. Atherosclerosis. 2012;223(2):269-77. 
 Blum AS. Management of dyslipidemia with statins in the patient with peripheral arterial 
disease. Techniques in vascular and interventional radiology. 2006;9(2):50-5. 
 Bonaca MP, Creager MA. Pharmacological treatment and current management of 
peripheral artery disease. Circulation research. 2015;116(9):1579-98. 
 Bondke Persson A, Buschmann EE, Lindhorst R, Troidl K, Langhoff R, Schulte KL, et 
al. Therapeutic arteriogenesis in peripheral arterial disease: combining intervention and passive 
training. VASA Zeitschrift fur Gefasskrankheiten. 2011;40(3):177-87. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            335 
 Bonneau C, Caron NR, Hussain MA, Kayssi A, Verma S, Al-Omran M. Peripheral artery 
disease among Indigenous Canadians: What do we know? Canadian journal of surgery Journal 
canadien de chirurgie. 2018;61(5):305-10. 
 Bosevski M. Peripheral Arterial Disease and Chronic Kidney Disease. Prilozi 
(Makedonska akademija na naukite i umetnostite Oddelenie za medicinski nauki). 
2017;38(2):29-33. 
 Bosevski M. Peripheral arterial disease and diabetes. Prilozi. 2012;33(1):65-78. 
 Bosiers M, Cagiannos C, Deloose K, Verbist J, Peeters P. Drug-eluting stents in the 
management of peripheral arterial disease. Vascular health and risk management. 2008;4(3):553-
9. 
 Botham CM, Bennett WL, Cooke JP. Clinical trials of adult stem cell therapy for 
peripheral artery disease. Methodist DeBakey cardiovascular journal. 2013;9(4):201-5. 
 Botti C, Maione C, Coppola A, Sica V, Cobellis G. Autologous bone marrow cell therapy 
for peripheral arterial disease. Stem cells and cloning : advances and applications. 2012;5:5-14. 
 Brenner I, Parry M, Brown CA. Exercise interventions for patients with peripheral 
arterial disease: a review of the literature. The Physician and sportsmedicine. 2012;40(2):41-55. 
 Brevetti G, Giugliano G, Brevetti L, Hiatt WR. Inflammation in peripheral artery disease. 
Circulation. 2010;122(18):1862-75. 
 Brevetti G, Schiano V, Chiariello M. Cellular adhesion molecules and peripheral arterial 
disease. Vascular medicine (London, England). 2006;11(1):39-47. 
 Brevetti G, Schiano V, Chiariello M. Endothelial dysfunction: a key to the 
pathophysiology and natural history of peripheral arterial disease? Atherosclerosis. 
2008;197(1):1-11. 
 Brostow DP, Hirsch AT, Collins TC, Kurzer MS. The role of nutrition and body 
composition in peripheral arterial disease. Nature reviews Cardiology. 2012;9(11):634-43. 
 Brostow DP, Petrik ML, Starosta AJ, Waldo SW. Depression in patients with peripheral 
arterial disease: A systematic review. European journal of cardiovascular nursing : journal of the 
Working Group on Cardiovascular Nursing of the European Society of Cardiology. 
2017;16(3):181-93. 
 Brownrigg JRW, Hinchliffe RJ, Apelqvist J, Boyko EJ, Fitridge R, Mills JL, et al. 
Effectiveness of bedside investigations to diagnose peripheral artery disease among people with 
diabetes mellitus: a systematic review. Diabetes/metabolism research and reviews. 2016;32 
Suppl 1:119-27. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            336 
 Brownrigg JRW, Schaper NC, Hinchliffe RJ. Diagnosis and assessment of peripheral 
arterial disease in the diabetic foot. Diabetic medicine : a journal of the British Diabetic 
Association. 2015;32(6):738-47. 
 Budzynski J, Wisniewska J, Ciecierski M, Kedzia A. Association between Bacterial 
Infection and Peripheral Vascular Disease: A Review. The International journal of angiology : 
official publication of the International College of Angiology, Inc. 2016;25(1):3-13. 
 Buechel R, Stirnimann A, Zimmer R, Keo H, Groechenig E. Drug-eluting stents and 
drug-coated balloons in peripheral artery disease. VASA Zeitschrift fur Gefasskrankheiten. 
2012;41(4):248-61. 
 Bunte MC, Shishehbor MH. Next Generation Endovascular Therapies in Peripheral 
Artery Disease. Progress in cardiovascular diseases. 2018;60(6):593-9. 
 Busti C, Falcinelli E, Momi S, Gresele P. Matrix metalloproteinases and peripheral 
arterial disease. Internal and emergency medicine. 2010;5(1):13-25. 
 Byrne RA, Joner M, Alfonso F, Kastrati A. Drug-coated balloon therapy in coronary and 
peripheral artery disease. Nature reviews Cardiology. 2014;11(1):13-23. 
 Caldieraro-Bentley AJ, Andrews JO. An integrative review: application of self-efficacy 
instruments for walking in populations with peripheral arterial disease. Journal of vascular 
nursing : official publication of the Society for Peripheral Vascular Nursing. 2013;31(3):118-30. 
 Camargo-Arias E, Aponte-Rodriguez J, Banchs-Pieretti H, Altieri-Nieto PI. Screening for 
Peripheral Arterial Disease. Boletin de la Asociacion Medica de Puerto Rico. 2015;107(3):95-7. 
 Campia U, Gerhard-Herman M, Piazza G, Goldhaber SZ. Peripheral Artery Disease: 
Past, Present, and Future. The American journal of medicine. 2019. 
 Cao P, De Rango P. Endovascular treatment of peripheral artery disease (PAD): so old 
yet so far from evidence! European journal of vascular and endovascular surgery : the official 
journal of the European Society for Vascular Surgery. 2009;37(5):501-3. 
 Carman TL, Fernandez BB, Jr. Contemporary management of peripheral arterial disease: 
II. Improving walking distance and quality of life. Cleveland Clinic journal of medicine. 2006;73 
Suppl 4:S38-44. 
 Carrero JJ, Grimble RF. Does nutrition have a role in peripheral vascular disease? The 
British journal of nutrition. 2006;95(2):217-29. 
 Casillas JM, Troisgros O, Hannequin A, Gremeaux V, Ader P, Rapin A, et al. 
Rehabilitation in patients with peripheral arterial disease. Annals of physical and rehabilitation 
medicine. 2011;54(7):443-61. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            337 
 Cassar A, Poldermans D, Rihal CS, Gersh BJ. The management of combined coronary 
artery disease and peripheral vascular disease. European heart journal. 2010;31(13):1565-72. 
 Cassar K, Bachoo P. Peripheral arterial disease. Clinical evidence. 2006(15):164-76. 
 Cassar K. Peripheral arterial disease. BMJ clinical evidence. 2007;2007. 
 Cassar K. Peripheral arterial disease. BMJ clinical evidence. 2010;2010. 
 Cassar K. Peripheral arterial disease. BMJ clinical evidence. 2011;2011. 
 Cequier A, Carrascosa C, Diez-Tejedor E, Goicoechea M, Gonzalez-Garcia A, Quiles J, 
et al. Comments on the ESC guidelines on the diagnosis and treatment of peripheral artery 
diseases. A report of the Task Force of the Clinical Practice Guidelines Committee of the 
Spanish Society of Cardiology. Revista espanola de cardiologia (English ed). 2012;65(2):119-24. 
 Chan YC, Cheng SW. Drug-eluting stents and balloons in peripheral arterial disease: 
evidence so far. International journal of clinical practice. 2011;65(6):664-8. 
 Charakida M, Masi S, Tousoulis D. Functional, genetic and biochemical biomarkers of 
peripheral arterial disease. Current medicinal chemistry. 2012;19(16):2497-503. 
 Chatterjee S, Bandyopadhyay D, Ghosh RK, Majumdar U, Aneja A, Lavie CJ, et al. 
SGLT-2 Inhibitors and Peripheral Artery Disease: A Statistical Hoax or Reality? Current 
problems in cardiology. 2019;44(7):207-22. 
 Chavan A, Luthe L, Schmuck B. Peripheral vascular disease of iliac and femoro-popliteal 
arteries: state-of-the-art endoluminal revascularization. Der Radiologe. 2010;50(1):16-22. 
 Chen L, Liu H, Yuan M, Lu W, Wang J, Wang T. The roles of interleukins in perfusion 
recovery after peripheral arterial disease. Bioscience reports. 2018;38(1). 
 Chen Q, Shi Y, Wang Y, Li X. Patterns of disease distribution of lower extremity 
peripheral arterial disease. Angiology. 2015;66(3):211-8. 
 Chi Y-W, Jaff MR. Optimal risk factor modification and medical management of the 
patient with peripheral arterial disease. Catheterization and cardiovascular interventions : official 
journal of the Society for Cardiac Angiography & Interventions. 2008;71(4):475-89. 
 Chi Y-W, Jaff MR. Peripheral artery disease and genetics: is there a cause-and-effect 
relationship? Postgraduate medicine. 2010;122(4):170-6. 
 Chi Y-W, Osinbowale O, Milani R. Genetic association studies in peripheral arterial 
disease. The Journal of the Louisiana State Medical Society : official organ of the Louisiana 
State Medical Society. 2011;163(1):30-4, 6-7, 9. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            338 
 Chin JA, Sumpio BE. Diabetes mellitus and peripheral vascular disease: diagnosis and 
management. Clinics in podiatric medicine and surgery. 2014;31(1):11-26. 
 Chioncel V, Brezeanu R, Sinescu C. New Directions in the Management of Peripheral 
Artery Disease. American journal of therapeutics. 2019;26(2):e284-e93. 
 Cho YI, Cho DJ, Rosenson RS. Endothelial shear stress and blood viscosity in peripheral 
arterial disease. Current atherosclerosis reports. 2014;16(4):404. 
 Chong A-Y, So DY. Ticagrelor for the treatment of peripheral arterial disease. Expert 
opinion on investigational drugs. 2014;23(12):1737-43. 
 Christie A, Roditi G. Vascular imaging: the evolving role of the multidisciplinary team 
meeting in peripheral vascular disease. Seminars in interventional radiology. 2014;31(4):320-9. 
 Chrusciel P, Rysz J, Banach M. Defining the role of trimetazidine in the treatment of 
cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease. 
Drugs. 2014;74(9):971-80. 
 Chu TM, Chan YC, Cheng SW. Evidence for treating peripheral arterial diseases with 
biodegradable scaffolds. The Journal of cardiovascular surgery. 2017;58(1):87-94. 
 Chua GT, Chan YC, Cheng SW. Vitamin D status and peripheral arterial disease: 
evidence so far. Vascular health and risk management. 2011;7:671-5. 
 Cilingiroglu M, Patel RAG, Dean LS. Late breaking trials of 2014 in structural heart 
disease and peripheral arterial disease: Commentary covering ACC, EuroPCR, SCAI, TCT, 
VIVA, ESC, and AHA. Catheterization and cardiovascular interventions : official journal of the 
Society for Cardiac Angiography & Interventions. 2015;86(1):80-4. 
 Clement DL, Debuyzere ML. How to treat hypertension in patients with peripheral artery 
disease. Current hypertension reports. 2007;9(3):190-5. 
 Clement DL. Control of hypertension in patients with peripheral artery disease. Blood 
pressure. 2006;15(4):251-2. 
 Clement DL. European Society of Hypertension Scientific Newsletter: control of 
hypertension in patients with peripheral artery disease. Journal of hypertension. 
2006;24(12):2477-8. 
 Clement DL. Treatment of hypertension in patients with peripheral arterial disease: an 
update. Current hypertension reports. 2009;11(4):271-6. 
 Colleran R, Harada Y, Cassese S, Byrne RA. Drug coated balloon angioplasty in the 
treatment of peripheral artery disease. Expert review of medical devices. 2016;13(6):569-82. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            339 
 Collins R, Burch J, Cranny G, Aguiar-Ibanez R, Craig D, Wright K, et al. Duplex 
ultrasonography, magnetic resonance angiography, and computed tomography angiography for 
diagnosis and assessment of symptomatic, lower limb peripheral arterial disease: systematic 
review. BMJ (Clinical research ed). 2007;334(7606):1257. 
 Collins R, Cranny G, Burch J, Aguiar-Ibanez R, Craig D, Wright K, et al. A systematic 
review of duplex ultrasound, magnetic resonance angiography and computed tomography 
angiography for the diagnosis and assessment of symptomatic, lower limb peripheral arterial 
disease. Health technology assessment (Winchester, England). 2007;11(20):iii-iv, xi-xiii, 1-184. 
 Comsa HI, Zdrenghea D, Man SC, Pop D. The role of novel atherosclerosis markers in 
peripheral artery disease: is there a gender difference? Cardiovascular journal of Africa. 
2018;29(5):322-30. 
 Conte SM, Vale PR. Peripheral Arterial Disease. Heart, lung & circulation. 
2018;27(4):427-32. 
 Cooke JP, Wilson AM. Biomarkers of peripheral arterial disease. Journal of the 
American College of Cardiology. 2010;55(19):2017-23. 
 Coppola G, Novo S. Statins and peripheral arterial disease: effects on claudication, 
disease progression, and prevention of cardiovascular events. Archives of medical research. 
2007;38(5):479-88. 
 Coppola G, Romano G, Corrado E, Grisanti RM, Novo S. Peripheral artery disease: 
potential role of ACE-inhibitor therapy. Vascular health and risk management. 2008;4(6):1179-
87. 
 Corrado E, Mignano A, Coppola G. Use of statins in patients with peripheral artery 
disease. Trends in cardiovascular medicine. 2019. 
 Cotard S, Nouni A, Jaquinandi V, Gladu G, Kaladji A, Mahe G. Peripheral artery disease 
in patients younger than 50years old: Which etiology? Annales de cardiologie et d'angeiologie. 
2016;65(4):275-85. 
 Coughlin PA, Rudd JHF. Optimizing medical management in peripheral artery disease. 
The British journal of surgery. 2018;105(9):1079-81. 
 Coutinho T, Rooke TW, Kullo IJ. Arterial dysfunction and functional performance in 
patients with peripheral artery disease: a review. Vascular medicine (London, England). 
2011;16(3):203-11. 
 Couto M, Figueroa A, Sotolongo A, Perez R, Ojeda JM. Endovascular Intervention in the 
Treatment of Peripheral Artery Disease. Boletin de la Asociacion Medica de Puerto Rico. 
2015;107(3):47-51. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            340 
 Crawford F, Welch K, Andras A, Chappell FM. Ankle brachial index for the diagnosis of 
lower limb peripheral arterial disease. The Cochrane database of systematic reviews. 
2016;9:CD010680. 
 Criqui MH, Aboyans V, Allison MA, Denenberg JO, Forbang N, McDermott MM, et al. 
Peripheral Artery Disease and Aortic Disease. Global heart. 2016;11(3):313-26. 
 Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circulation research. 
2015;116(9):1509-26. 
 Cronin O, Morris DR, Walker PJ, Golledge J. The association of obesity with 
cardiovascular events in patients with peripheral artery disease. Atherosclerosis. 
2013;228(2):316-23. 
 Dachun X, Jue L, Liling Z, Yawei X, Dayi H, Pagoto SL, et al. Sensitivity and specificity 
of the ankle--brachial index to diagnose peripheral artery disease: a structured review. Vascular 
medicine (London, England). 2010;15(5):361-9. 
 Das JR, Eberhardt RT. Contemporary risk assessment and cardiovascular outcomes in 
peripheral arterial disease. Cardiovascular & hematological disorders drug targets. 
2013;13(3):185-96. 
 Daskalopoulou SS, Daskalopoulos ME, Mikhailidis DP, Liapis CD. Lipid management 
and peripheral arterial disease. Current drug targets. 2007;8(4):561-70. 
 Davies RSM, Vohra RK, Bradbury AW, Adam DJ. The impact of hormone replacement 
therapy on the pathophysiology of peripheral arterial disease. European journal of vascular and 
endovascular surgery : the official journal of the European Society for Vascular Surgery. 
2007;34(5):569-75. 
 De Buyzere ML, Clement DL. Management of hypertension in peripheral arterial disease. 
Progress in cardiovascular diseases. 2008;50(4):238-63. 
 de Franciscis S, Metzinger L, Serra R. The Discovery of Novel Genomic, 
Transcriptomic, and Proteomic Biomarkers in Cardiovascular and Peripheral Vascular Disease: 
The State of the Art. BioMed research international. 2016;2016:7829174. 
 De Haro J, Acin F, Lopez-Quintana A, Florez A, Martinez-Aguilar E, Varela C. Meta-
analysis of randomized, controlled clinical trials in angiogenesis: gene and cell therapy in 
peripheral arterial disease. Heart and vessels. 2009;24(5):321-8. 
 de Holanda A, Aubourg M, Dubus-Bausiere V, Eveno D, Abraham P. Vascular 
rehabilitation in patients with peripheral arterial disease. Presse medicale (Paris, France : 1983). 
2013;42(6 Pt 1):1032-8. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            341 
 de Mullenheim PY, Chaudru S, Mahe G, Prioux J, Le Faucheur A. Clinical Interest of 
Ambulatory Assessment of Physical Activity and Walking Capacity in Peripheral Artery 
Disease. Scandinavian journal of medicine & science in sports. 2016;26(7):716-30. 
 de Vos LC, Lefrandt JD, Dullaart RPF, Zeebregts CJ, Smit AJ. Advanced glycation end 
products: An emerging biomarker for adverse outcome in patients with peripheral artery disease. 
Atherosclerosis. 2016;254:291-9. 
 De Vries J, De Jongste MJL, Spincemaille G, Staal MJ. Spinal cord stimulation for 
ischemic heart disease and peripheral vascular disease. Advances and technical standards in 
neurosurgery. 2007;32:63-89. 
 Deer TR, Raso LJ. Spinal cord stimulation for refractory angina pectoris and peripheral 
vascular disease. Pain physician. 2006;9(4):347-52. 
 Deer TR. Spinal cord stimulation for the treatment of angina and peripheral vascular 
disease. Current pain and headache reports. 2009;13(1):18-23. 
 Deftereos SG, Vrachatis DA, Tolis C, Giannopoulos G. Invasive treatment in peripheral 
artery disease. Current opinion in pharmacology. 2018;39:113-20. 
 Deitelzweig SB, Hoekstra JW. Peripheral arterial disease and the hospitalist: the rationale 
for early detection and optimal therapy. Journal of hospital medicine. 2008;3 Suppl 2:S4-8. 
 Del Conde I, Benenati JF. Noninvasive Testing in Peripheral Arterial Disease. 
Interventional cardiology clinics. 2014;3(4):469-78. 
 Dellegrottaglie S, Sanz J, Macaluso F, Einstein AJ, Raman S, Simonetti OP, et al. 
Technology Insight: magnetic resonance angiography for the evaluation of patients with 
peripheral artery disease. Nature clinical practice Cardiovascular medicine. 2007;4(12):677-87. 
 DeLoach SS, Mohler ER, 3rd. Peripheral arterial disease: a guide for nephrologists. 
Clinical journal of the American Society of Nephrology : CJASN. 2007;2(4):839-46. 
 Desormais I, Aboyans V, Pesteil F, Lacroix P. Peripheral arterial disease: Treatment. 
Presse medicale (Paris, France : 1983). 2018;47(1):56-61. 
 Devanesan AJ, Laughlan KA, Girn HRS, Homer-Vanniasinkam S. Endothelial progenitor 
cells as a therapeutic option in peripheral arterial disease. European journal of vascular and 
endovascular surgery : the official journal of the European Society for Vascular Surgery. 
2009;38(4):475-81. 
 Dhanoa D, Baerlocher MO, Benko AJ, Benenati JF, Kuo MD, Dariushnia SR, et al. 
Position Statement on Noninvasive Imaging of Peripheral Arterial Disease by the Society of 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            342 
Interventional Radiology and the Canadian Interventional Radiology Association. Journal of 
vascular and interventional radiology : JVIR. 2016;27(7):947-51. 
 Di Minno G, Spadarella G, Cafaro G, Petitto M, Lupoli R, Di Minno A, et al. Systematic 
reviews and meta-analyses for more profitable strategies in peripheral artery disease. Annals of 
medicine. 2014;46(7):475-89. 
 Dinh T, Scovell S, Veves A. Peripheral arterial disease and diabetes: a clinical update. 
The international journal of lower extremity wounds. 2009;8(2):75-81. 
 Drouet L, Bal dit Sollier C, Henry P. The basis of platelets: platelets and 
atherothrombosis: an understanding of the lack of efficacy of aspirin in peripheral arterial disease 
(PAD) and diabetic patients. Drugs. 2010;70 Suppl 1:9-14. 
 Dryden M, Baguneid M, Eckmann C, Corman S, Stephens J, Solem C, et al. 
Pathophysiology and burden of infection in patients with diabetes mellitus and peripheral 
vascular disease: focus on skin and soft-tissue infections. Clinical microbiology and infection : 
the official publication of the European Society of Clinical Microbiology and Infectious 
Diseases. 2015;21 Suppl 2:S27-32. 
 Dua A, Lee CJ. Epidemiology of Peripheral Arterial Disease and Critical Limb Ischemia. 
Techniques in vascular and interventional radiology. 2016;19(2):91-5. 
 Duprez DA. Pharmacological interventions for peripheral artery disease. Expert opinion 
on pharmacotherapy. 2007;8(10):1465-77. 
 Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, et al. 
Definition and evaluation of transient ischemic attack: a scientific statement for healthcare 
professionals from the American Heart Association/American Stroke Association Stroke 
Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular 
Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary 
Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value 
of this statement as an educational tool for neurologists. Stroke. 2009;40(6):2276-93. 
 Eastridge DK. An integrative review of interventions to reduce peripheral arterial disease 
risk factors in African Americans. Journal of vascular nursing : official publication of the Society 
for Peripheral Vascular Nursing. 2009;27(2):31-45. 
 El-Menyar A, Al Suwaidi J, Al-Thani H. Peripheral arterial disease in the Middle East: 
Underestimated predictor of worse outcome. Global cardiology science & practice. 
2013;2013(2):98-113. 
 Enns JE, Yeganeh A, Zarychanski R, Abou-Setta AM, Friesen C, Zahradka P, et al. The 
impact of omega-3 polyunsaturated fatty acid supplementation on the incidence of 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            343 
cardiovascular events and complications in peripheral arterial disease: a systematic review and 
meta-analysis. BMC cardiovascular disorders. 2014;14:70. 
 Erez G, Leitersdorf E. The rationale for using HMG-CoA reductase inhibitors ('statins') 
in peripheral arterial disease. European journal of vascular and endovascular surgery : the official 
journal of the European Society for Vascular Surgery. 2007;33(2):192-201. 
 Espinola-Klein C, Savvidis S, Kopp H. Peripheral artery disease as supplemental 
diagnosis in coronary heart disease--influence on diagnostics, treatment and prognosis. Deutsche 
medizinische Wochenschrift (1946). 2014;139 Suppl 1:S40-2. 
 Espinola-Klein C, Savvidis S. Peripheral arterial disease: epidemiology, symptoms and 
diagnosis. Der Internist. 2009;50(8):919-26. 
 Espinola-Klein C. Anti-Thrombotic Treatment of Patients with Peripheral Artery Disease 
(PAD). Deutsche medizinische Wochenschrift (1946). 2018;143(15):1060-4. 
 Espinola-Klein C. ESC guidelines 2017 on peripheral arterial diseases : Summary of the 
most important recommendations and innovations. Herz. 2017;42(8):721-7. 
 Espinola-Klein C. Peripheral artery disease: basic knowledge. Medizinische 
Monatsschrift fur Pharmazeuten. 2017;40(3):95-7. 
 Espinola-Klein C. Peripheral artery disease: diagnosis. Medizinische Monatsschrift fur 
Pharmazeuten. 2017;40(3):98-9. 
 Espinola-Klein C. Peripheral artery disease: Introduction and conservative treatment. 
Medizinische Monatsschrift fur Pharmazeuten. 2017;40(3):100-1. 
 Fadini GP, Agostini C, Avogaro A. Autologous stem cell therapy for peripheral arterial 
disease meta-analysis and systematic review of the literature. Atherosclerosis. 2010;209(1):10-7. 
 Faglia E. Characteristics of peripheral arterial disease and its relevance to the diabetic 
population. The international journal of lower extremity wounds. 2011;10(3):152-66. 
 Falconer D, Papageorgiou N, Salem K, Lim WY, Katsargyris A, Avgerinos E, et al. 
Nitric oxide donors for peripheral artery disease. Current opinion in pharmacology. 2018;39:77-
85. 
 Falconer TM, Eikelboom JW, Hankey GJ, Norman PE. Management of peripheral 
arterial disease in the elderly: focus on cilostazol. Clinical interventions in aging. 2008;3(1):17-
23. 
 Falluji N, Mukherjee D. Contemporary management of infrapopliteal peripheral arterial 
disease. Angiology. 2011;62(6):490-9. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            344 
 Fanari Z, Weintraub WS. Cost-effectiveness of medical, endovascular and surgical 
management of peripheral vascular disease. Cardiovascular revascularization medicine : 
including molecular interventions. 2015;16(7):421-5. 
 Federman DG, Kravetz JD, Bravata DM, Kirsner RS. Peripheral arterial disease. A 
marker of morbidity and mortality. Postgraduate medicine. 2006;119(2):21-7. 
 Federman DG, Kravetz JD. Peripheral arterial disease: diagnosis, treatment, and systemic 
implications. Clinics in dermatology. 2007;25(1):93-100. 
 Fenton R, Brook-Barclay L, Delaney CL, Spark JI, Miller MD. Do Medications 
Commonly Prescribed to Patients with Peripheral Arterial Disease Have an Effect on Nutritional 
Status? A Review of the Literature. Annals of vascular surgery. 2016;32:145-75. 
 Ferket BS, Spronk S, Colkesen EB, Hunink MGM. Systematic review of guidelines on 
peripheral artery disease screening. The American journal of medicine. 2012;125(2):198-208.e3. 
 Ferreira AC, Macedo FYB. A review of simple, non-invasive means of assessing 
peripheral arterial disease and implications for medical management. Annals of medicine. 
2010;42(2):139-50. 
 Fleischmann D, Hallett RL, Rubin GD. CT angiography of peripheral arterial disease. 
Journal of vascular and interventional radiology : JVIR. 2006;17(1):3-26. 
 Foley TR, Armstrong EJ, Waldo SW. Contemporary evaluation and management of 
lower extremity peripheral artery disease. Heart (British Cardiac Society). 2016;102(18):1436-
41. 
 Foley TR, Waldo SW, Armstrong EJ. Antithrombotic therapy in peripheral artery 
disease. Vascular medicine (London, England). 2016;21(2):156-69. 
 Foley TR, Waldo SW, Armstrong EJ. Medical Therapy in Peripheral Artery Disease and 
Critical Limb Ischemia. Current treatment options in cardiovascular medicine. 2016;18(7):42. 
 Forbang NI, Hughes-Austin JM, Allison MA, Criqui MH. Peripheral artery disease and 
non-coronary atherosclerosis in Hispanics: another paradox? Progress in cardiovascular diseases. 
2014;57(3):237-43. 
 Forster R, Liew A, Bhattacharya V, Shaw J, Stansby G. Gene therapy for peripheral 
arterial disease. The Cochrane database of systematic reviews. 2018;10:CD012058. 
 Forsythe RO, Brownrigg J, Hinchliffe RJ. Peripheral arterial disease and 
revascularization of the diabetic foot. Diabetes, obesity & metabolism. 2015;17(5):435-44. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            345 
 Forsythe RO, Hinchliffe RJ. Management of peripheral arterial disease and the diabetic 
foot. The Journal of cardiovascular surgery. 2014;55(2 Suppl 1):195-206. 
 Fowkes FG, Forster RB, Levin CE, Naidoo NG, Roy A, Shu C, et al. Prioritization of 
treatments for lower extremity peripheral artery disease in low- and middle-income countries. 
International angiology : a journal of the International Union of Angiology. 2017;36(3):203-15. 
 Fowkes FGR, Aboyans V, Fowkes FJI, McDermott MM, Sampson UKA, Criqui MH. 
Peripheral artery disease: epidemiology and global perspectives. Nature reviews Cardiology. 
2017;14(3):156-70. 
 Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. 
Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 
2000 and 2010: a systematic review and analysis. Lancet (London, England). 
2013;382(9901):1329-40. 
 Frangogiannis NG. Cell therapy for peripheral artery disease. Current opinion in 
pharmacology. 2018;39:27-34. 
 Franzone A, Ferrone M, Carotenuto G, Carbone A, Scudiero L, Serino F, et al. The role 
of atherectomy in the treatment of lower extremity peripheral artery disease. BMC surgery. 
2012;12 Suppl 1:S13. 
 Frisbee JC, Goodwill AG, Frisbee SJ, Butcher JT, Wu F, Chantler PD. Microvascular 
perfusion heterogeneity contributes to peripheral vascular disease in metabolic syndrome. The 
Journal of physiology. 2016;594(8):2233-43. 
 Gaddipati VC, Kuriacose R, Copeland R, Bailey BA, Peiris AN. Vitamin D deficiency: 
an increasing concern in peripheral arterial disease. Journal of the American Medical Directors 
Association. 2010;11(5):308-11. 
 Galyfos G, Geropapas G, Stefanidis I, Kerasidis S, Stamatatos I, Kastrisios G, et al. 
Bioabsorbable stenting in peripheral artery disease. Cardiovascular revascularization medicine : 
including molecular interventions. 2015;16(8):480-3. 
 Gandhi S, Weinberg I, Margey R, Jaff MR. Comprehensive medical management of 
peripheral arterial disease. Progress in cardiovascular diseases. 2011;54(1):2-13. 
 Gao W, Wang F, Liu G, Ran X. Systematic review of autologous hemopoietic stem cell 
transplantation for peripheral arterial disease. Zhongguo xiu fu chong jian wai ke za zhi = 
Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive 
surgery. 2011;25(5):610-7. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            346 
 Garcia LA, Lyden SP. Atherectomy for infrainguinal peripheral artery disease. Journal of 
endovascular therapy : an official journal of the International Society of Endovascular 
Specialists. 2009;16(2 Suppl 2):II105-15. 
 Garcia LA. Epidemiology and pathophysiology of lower extremity peripheral arterial 
disease. Journal of endovascular therapy : an official journal of the International Society of 
Endovascular Specialists. 2006;13 Suppl 2:II3-9. 
 Gardner AW, Afaq A. Management of lower extremity peripheral arterial disease. 
Journal of cardiopulmonary rehabilitation and prevention. 2008;28(6):349-57. 
 Gardner AW. Exercise rehabilitation for peripheral artery disease: An exercise 
physiology perspective with special emphasis on the emerging trend of home-based exercise. 
VASA Zeitschrift fur Gefasskrankheiten. 2015;44(6):405-17. 
 Garimella PS, Hart PD, O'Hare A, DeLoach S, Herzog CA, Hirsch AT. Peripheral artery 
disease and CKD: a focus on peripheral artery disease as a critical component of CKD care. 
American journal of kidney diseases : the official journal of the National Kidney Foundation. 
2012;60(4):641-54. 
 Garimella PS, Hirsch AT. Peripheral artery disease and chronic kidney disease: clinical 
synergy to improve outcomes. Advances in chronic kidney disease. 2014;21(6):460-71. 
 Gaudio A, Xourafa A, Rapisarda R, Castellino P, Signorelli SS. Peripheral artery disease 
and osteoporosis: Not only ageâ€‘related (Review). Molecular medicine reports. 
2018;18(6):4787-92. 
 Gavier B, Vazquez F, Gandara E. Antiphospholipid antibodies and lower extremity 
peripheral arterial disease - a systematic review and meta-analysis. VASA Zeitschrift fur 
Gefasskrankheiten. 2016;45(4):325-30. 
 Gebauer K, Reinecke H. PCSK9 inhibition for LDL lowering and beyond - implications 
for patients with peripheral artery disease. VASA Zeitschrift fur Gefasskrankheiten. 
2018;47(3):165-76. 
 Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, 
et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity 
Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart 
Association Task Force on Clinical Practice Guidelines. Journal of the American College of 
Cardiology. 2017;69(11):e71-e126. 
 Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, 
et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            347 
Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart 
Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135(12):e726-e79. 
 Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, 
et al. 2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity 
Peripheral Artery Disease: Executive Summary. Vascular medicine (London, England). 
2017;22(3):NP1-NP43. 
 Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, 
et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity 
Peripheral Artery Disease: Executive Summary: A Report of the American College of 
Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 
2017;135(12):e686-e725. 
 Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, 
et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity 
Peripheral Artery Disease: Executive Summary: A Report of the American College of 
Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of 
the American College of Cardiology. 2017;69(11):1465-508. 
 Germani A, Di Campli C, Pompilio G, Biglioli P, Capogrossi MC. Regenerative therapy 
in peripheral artery disease. Cardiovascular therapeutics. 2009;27(4):289-304. 
 Gersbach P, Gardaz JP, Ferrari E, Haesler E, von Segesser LK. Indications, limits and 
future of epidural spinal cord electrical stimulation for coronary and peripheral artery disease. 
Revue medicale suisse. 2008;4(150):797-804. 
 Gertz ZM, Wilensky RL. Local drug delivery for treatment of coronary and peripheral 
artery disease. Cardiovascular therapeutics. 2011;29(6):e54-66. 
 Ghosh R, Walsh SR, Tang TY, Noorani A, Hayes PD. Gene therapy as a novel 
therapeutic option in the treatment of peripheral vascular disease: systematic review and meta-
analysis. International journal of clinical practice. 2008;62(9):1383-90. 
 Giagtzidis I, Karkos C, Pitoulias G, Papazoglou K. Matrix metalloproteinases and 
peripheral arterial disease. International angiology : a journal of the International Union of 
Angiology. 2015;34(3):195-201. 
 Giannakakis S, Galyfos G, Sachmpazidis I, Kapasas K, Kerasidis S, Stamatatos I, et al. 
Thrombolysis in peripheral artery disease. Therapeutic advances in cardiovascular disease. 
2017;11(4):125-32. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            348 
 Giannopoulos G, Angelidis C, Vogiatzi G, Cleman MW, Deftereos S. Antioxidant 
treatment in peripheral artery disease: the rationale is there, but what about clinical results? 
Current opinion in pharmacology. 2018;39:53-9. 
 Gibler WB. Advances in the Treatment of Stable Coronary Artery Disease and Peripheral 
Artery Disease. Critical pathways in cardiology. 2018;17(2):53-68. 
 Gil de Lamadrid Jose H, Delgado Osorio H. Peripheral Arterial Disease: Surgical 
Treatment. Boletin de la Asociacion Medica de Puerto Rico. 2015;107(3):75-8. 
 Gill R, Shapiro R, Kayler LK. Management of peripheral vascular disease compromising 
renal allograft placement and function: review of the literature with an illustrative case. Clinical 
transplantation. 2011;25(3):337-44. 
 Girn HRS, Orsi NM, Homer-Vanniasinkam S. An overview of cytokine interactions in 
atherosclerosis and implications for peripheral arterial disease. Vascular medicine (London, 
England). 2007;12(4):299-309. 
 Goff DC, Jr., Brass L, Braun LT, Croft JB, Flesch JD, Fowkes FGR, et al. Essential 
features of a surveillance system to support the prevention and management of heart disease and 
stroke: a scientific statement from the American Heart Association Councils on Epidemiology 
and Prevention, Stroke, and Cardiovascular Nursing and the Interdisciplinary Working Groups 
on Quality of Care and Outcomes Research and Atherosclerotic Peripheral Vascular Disease. 
Circulation. 2007;115(1):127-55. 
 Goldsweig AM, Faheem O, Cleman MW, Forrest JK. A balloon-expandable sheath 
facilitates transfemoral TAVR in patients with peripheral vascular disease and tortuosity. 
Therapeutic advances in cardiovascular disease. 2015;9(3):95-102. 
 Golledge J, Biros E, Bingley J, Iyer V, Krishna SM. Epigenetics and Peripheral Artery 
Disease. Current atherosclerosis reports. 2016;18(4):15. 
 Golledge J, Singh TP, Alahakoon C, Pinchbeck J, Yip L, Moxon JV, et al. Meta-analysis 
of clinical trials examining the benefit of structured home exercise in patients with peripheral 
artery disease. The British journal of surgery. 2019;106(4):319-31. 
 Golomb BA, Dang TT, Criqui MH. Peripheral arterial disease: morbidity and mortality 
implications. Circulation. 2006;114(7):688-99. 
 Gorenoi V, Brehm MU, Koch A, Hagen A. Growth factors for angiogenesis in peripheral 
arterial disease. The Cochrane database of systematic reviews. 2017;6:CD011741. 
 Gornik HL, Creager MA. Contemporary management of peripheral arterial disease: I. 
Cardiovascular risk-factor modification. Cleveland Clinic journal of medicine. 2006;73 Suppl 
4:S30-7. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            349 
 Got I. Peripheral vascular disease and diabetic foot. La Revue de medecine interne. 
2008;29 Suppl 2:S249-59. 
 Gouveri E, Papanas N, Hatzitolios AI, Maltezos E. Hypovitaminosis D and peripheral 
arterial disease: emerging link beyond cardiovascular risk factors. European journal of internal 
medicine. 2012;23(8):674-81. 
 Gradoli J, Vidal V, Brady AJ, Facila L. Anticoagulation in Patients with Ischaemic Heart 
Disease and Peripheral Arterial Disease: Clinical Implications of COMPASS Study. European 
cardiology. 2018;13(2):115-8. 
 Grenon SM, Hughes-Fulford M, Rapp J, Conte MS. Polyunsaturated fatty acids and 
peripheral artery disease. Vascular medicine (London, England). 2012;17(1):51-63. 
 Grimaldi V, Schiano C, Casamassimi A, Zullo A, Soricelli A, Mancini FP, et al. Imaging 
techniques to evaluate cell therapy in peripheral artery disease: state of the art and clinical trials. 
Clinical physiology and functional imaging. 2016;36(3):165-78. 
 Grochot-Przeczek A, Dulak J, Jozkowicz A. Therapeutic angiogenesis for 
revascularization in peripheral artery disease. Gene. 2013;525(2):220-8. 
 Guirgis M, Thompson P, Jansen S. Review of aspirin and clopidogrel resistance in 
peripheral arterial disease. Journal of vascular surgery. 2017;66(5):1576-86. 
 Guirguis-Blake JM, Evans CV, Redmond N, Lin JS. Screening for Peripheral Artery 
Disease Using the Ankle-Brachial Index: Updated Evidence Report and Systematic Review for 
the US Preventive Services Task Force. Jama. 2018;320(2):184-96. 
 Gupta NK, Armstrong EJ, Parikh SA. The current state of stem cell therapy for peripheral 
artery disease. Current cardiology reports. 2014;16(2):447. 
 Haas TL, Lloyd PG, Yang H-T, Terjung RL. Exercise training and peripheral arterial 
disease. Comprehensive Physiology. 2012;2(4):2933-3017. 
 Hachiya T. Medical treatment for peripheral arterial disease. Nihon yakurigaku zasshi 
Folia pharmacologica Japonica. 2007;130(5):398-401. 
 Hackam DG, Eikelboom JW. Antithrombotic treatment for peripheral arterial disease. 
Heart (British Cardiac Society). 2007;93(3):303-8. 
 Hackam DG, Sultan NM, Criqui MH. Vascular protection in peripheral artery disease: 
systematic review and modelling study. Heart (British Cardiac Society). 2009;95(13):1098-102. 
 Haigh K, Bingley J, Golledge J, Walker PJ. Peripheral arterial disease - screening in 
general practice. Australian family physician. 2013;42(6):391-5. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            350 
 Hamburg NM, Balady GJ. Exercise rehabilitation in peripheral artery disease: functional 
impact and mechanisms of benefits. Circulation. 2011;123(1):87-97. 
 Hamburg NM, Creager MA. Pathophysiology of Intermittent Claudication in Peripheral 
Artery Disease. Circulation journal : official journal of the Japanese Circulation Society. 
2017;81(3):281-9. 
 Hamburg NM, Leeper NJ. Therapeutic Potential of Modulating MicroRNA in Peripheral 
Artery Disease. Current vascular pharmacology. 2015;13(3):316-23. 
 Hammer A, Steiner S. Gene therapy for therapeutic angiogenesis in peripheral arterial 
disease - a systematic review and meta-analysis of randomized, controlled trials. VASA 
Zeitschrift fur Gefasskrankheiten. 2013;42(5):331-9. 
 Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. 
Jama. 2006;295(5):547-53. 
 Hardman RL, Jazaeri O, Yi J, Smith M, Gupta R. Overview of classification systems in 
peripheral artery disease. Seminars in interventional radiology. 2014;31(4):378-88. 
 Harky A, Maskell P, Burgess M. Anti-platelet and anti-coagulant therapy in peripheral 
arterial disease prior to surgical intervention. Vascular. 2019;27(3):299-311. 
 Harris SK, Roos MG, Landry GJ. Statin use in patients with peripheral arterial disease. 
Journal of vascular surgery. 2016;64(6):1881-8. 
 Haugen S, Casserly IP, Regensteiner JG, Hiatt WR. Risk assessment in the patient with 
established peripheral arterial disease. Vascular medicine (London, England). 2007;12(4):343-
50. 
 Hauguel A, Maurel B, Bague N, Gouaillier-Vulcain F, Costargent A, Chaillou P, et al. 
Management of ambulatory (day case) endovascular procedures for peripheral arterial disease. 
The Journal of cardiovascular surgery. 2017;58(2):293-304. 
 Hawkins BM, Hennebry TA. Local paclitaxel delivery for treatment of peripheral arterial 
disease. Circulation Cardiovascular interventions. 2011;4(3):297-302. 
 Hazarika S, Annex BH. Biomarkers and Genetics in Peripheral Artery Disease. Clinical 
chemistry. 2017;63(1):236-44. 
 Health Quality O. Paclitaxel Drug-Eluting Stents in Peripheral Arterial Disease: A Health 
Technology Assessment. Ontario health technology assessment series. 2015;15(20):1-62. 
 Healy DA, Boyle EM, Clarke Moloney M, Hodnett PA, Scanlon T, Grace PA, et al. 
Contrast-enhanced magnetic resonance angiography in diabetic patients with infra-genicular 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            351 
peripheral arterial disease: systematic review. International journal of surgery (London, 
England). 2013;11(3):228-32. 
 Heikkinen M, Salmenpera M, Lepantalo A, Lepantalo M. Diabetes care for patients with 
peripheral arterial disease. European journal of vascular and endovascular surgery : the official 
journal of the European Society for Vascular Surgery. 2007;33(5):583-91. 
 Hendrikx G, Voo S, Bauwens M, Post MJ, Mottaghy FM. SPECT and PET imaging of 
angiogenesis and arteriogenesis in pre-clinical models of myocardial ischemia and peripheral 
vascular disease. European journal of nuclear medicine and molecular imaging. 
2016;43(13):2433-47. 
 Herraiz-Adillo A, Cavero-Redondo I, Alvarez-Bueno C, Martinez-Vizcaino V, Pozuelo-
Carrascosa DP, Notario-Pacheco B. The accuracy of an oscillometric ankle-brachial index in the 
diagnosis of lower limb peripheral arterial disease: A systematic review and meta-analysis. 
International journal of clinical practice. 2017;71(9). 
 Herrick A. Diagnosis and management of scleroderma peripheral vascular disease. 
Rheumatic diseases clinics of North America. 2008;34(1):89-114; vii. 
 Herten M, Stahlhoff S, Imm B, Schonefeld E, Schwindt A, Torsello GB. Drug-coated 
balloons in the treatment of peripheral artery disease (PAD). History and current level of 
evidence. Der Radiologe. 2016;56(3):240-53. 
 Hess CN, Hiatt WR. Antithrombotic Therapy for Peripheral Artery Disease in 2018. 
Jama. 2018;319(22):2329-30. 
 Hess CN, Norgren L, Ansel GM, Capell WH, Fletcher JP, Fowkes FGR, et al. A 
Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on 
Revascularization: A TASC (InterSociety Consensus for the Management of Peripheral Artery 
Disease) Initiative. Circulation. 2017;135(25):2534-55. 
 Heuschmid M, Ketelsen D, Brechtel K. Advanced interventional techniques and therapies 
in the treatment of peripheral artery disease below the knee. RoFo : Fortschritte auf dem Gebiete 
der Rontgenstrahlen und der Nuklearmedizin. 2012;184(7):607-17. 
 Hiatt WR, Armstrong EJ, Larson CJ, Brass EP. Pathogenesis of the limb manifestations 
and exercise limitations in peripheral artery disease. Circulation research. 2015;116(9):1527-39. 
 Hiatt WR, Krantz MJ. Masterclass series in peripheral arterial disease. Antiplatelet 
therapy for peripheral arterial disease and claudication. Vascular medicine (London, England). 
2006;11(1):55-60. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            352 
 Hiatt WR, Rogers RK, Brass EP. The treadmill is a better functional test than the 6-
minute walk test in therapeutic trials of patients with peripheral artery disease. Circulation. 
2014;130(1):69-78. 
 Hills AJ, Shalhoub J, Shepherd AC, Davies AH. Peripheral arterial disease. British 
journal of hospital medicine (London, England : 2005). 2009;70(10):560-5. 
 Hinchliffe RJ, Andros G, Apelqvist J, Bakker K, Friederichs S, Fiedrichs S, et al. A 
systematic review of the effectiveness of revascularization of the ulcerated foot in patients with 
diabetes and peripheral arterial disease. Diabetes/metabolism research and reviews. 2012;28 
Suppl 1:179-217. 
 Hinchliffe RJ, Brownrigg JRW, Andros G, Apelqvist J, Boyko EJ, Fitridge R, et al. 
Effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral 
artery disease: a systematic review. Diabetes/metabolism research and reviews. 2016;32 Suppl 
1:136-44. 
 Hiramoto JS, Teraa M, de Borst GJ, Conte MS. Interventions for lower extremity 
peripheral artery disease. Nature reviews Cardiology. 2018;15(6):332-50. 
 Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. 
ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial 
disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from 
the American Association for Vascular Surgery/Society for Vascular Surgery, Society for 
Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, 
Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines 
(Writing Committee to Develop Guidelines for the Management of Patients With Peripheral 
Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary 
Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; 
TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 
2006;113(11):e463-654. 
 Ho CY, Shanahan CM. Medial Arterial Calcification: An Overlooked Player in 
Peripheral Arterial Disease. Arteriosclerosis, thrombosis, and vascular biology. 2016;36(8):1475-
82. 
 Hobeika MJ, Thompson RW, Muhs BE, Brooks PC, Gagne PJ. Matrix metalloproteinases 
in peripheral vascular disease. Journal of vascular surgery. 2007;45(4):849-57. 
 Hoyer C, Sandermann J, Petersen LJ. The toe-brachial index in the diagnosis of 
peripheral arterial disease. Journal of vascular surgery. 2013;58(1):231-8. 
 Hu Y-z, Zhu J-a, Jiang Y-g, Hu B. Ultrasound microbubble contrast agents: application 
to therapy for peripheral vascular disease. Advances in therapy. 2009;26(4):425-34. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            353 
 Hunter MR, Cahoon WD, Jr., Lowe DK. Angiotensin-converting enzyme inhibitors for 
intermittent claudication associated with peripheral arterial disease. The Annals of 
pharmacotherapy. 2013;47(11):1552-7. 
 Hur DJ, Kizilgul M, Aung WW, Roussillon KC, Keeley EC. Frequency of coronary 
artery disease in patients undergoing peripheral artery disease surgery. The American journal of 
cardiology. 2012;110(5):736-40. 
 Husmann M, Jacomella V, Thalhammer C, Amann-Vesti BR. Markers of arterial 
stiffness in peripheral arterial disease. VASA Zeitschrift fur Gefasskrankheiten. 2015;44(5):341-
8. 
 Huysman E, Mathieu C. Diabetes and peripheral vascular disease. Acta chirurgica 
Belgica. 2009;109(5):587-94. 
 Imanishi T, Akasaka T. MicroRNAs in peripheral artery disease. Current topics in 
medicinal chemistry. 2013;13(13):1589-95. 
 Inampudi C, Akintoye E, Ando T, Briasoulis A. Angiogenesis in peripheral arterial 
disease. Current opinion in pharmacology. 2018;39:60-7. 
 Inglis SC, Hermis A, Shehab S, Newton PJ, Lal S, Davidson PM. Peripheral arterial 
disease and chronic heart failure: a dangerous mix. Heart failure reviews. 2013;18(4):457-64. 
 Ismaeel A, Brumberg RS, Kirk JS, Papoutsi E, Farmer PJ, Bohannon WT, et al. 
Oxidative Stress and Arterial Dysfunction in Peripheral Artery Disease. Antioxidants (Basel, 
Switzerland). 2018;7(10). 
 Ix JH, Criqui MH. Epidemiology and diagnosis of peripheral arterial disease in patients 
with chronic kidney disease. Advances in chronic kidney disease. 2008;15(4):378-83. 
 Jaff MR, Nelson T, Ferko N, Martinson M, Anderson LH, Hollmann S. Endovascular 
Interventions for Femoropopliteal Peripheral Artery Disease: A Network Meta-Analysis of 
Current Technologies. Journal of vascular and interventional radiology : JVIR. 
2017;28(12):1617-27.e1. 
 Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, Razavi M, et al. An update on 
methods for revascularization and expansion of the TASC lesion classification to include below-
the-knee arteries: A supplement to the inter-society consensus for the management of peripheral 
arterial disease (TASC II): The TASC steering committee. Catheterization and cardiovascular 
interventions : official journal of the Society for Cardiac Angiography & Interventions. 
2015;86(4):611-25. 
 Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, Razavi M, et al. An Update on 
Methods for Revascularization and Expansion of the TASC Lesion Classification to Include 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            354 
Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of 
Peripheral Arterial Disease (TASC II). Journal of endovascular therapy : an official journal of 
the International Society of Endovascular Specialists. 2015;22(5):663-77. 
 Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, Razavi M, et al. An Update on 
Methods for Revascularization and Expansion of the TASC Lesion Classification to Include 
Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of 
Peripheral Arterial Disease (TASC II). Vascular medicine (London, England). 2015;20(5):465-
78. 
 Johnston LE, Stewart BT, Yangni-Angate H, Veller M, Upchurch GR, Jr., Gyedu A, et 
al. Peripheral Arterial Disease in Sub-Saharan Africa: A Review. JAMA surgery. 
2016;151(6):564-72. 
 Jones WS, Annex BH. Growth factors for therapeutic angiogenesis in peripheral arterial 
disease. Current opinion in cardiology. 2007;22(5):458-63. 
 Jones WS, Dolor RJ, Hasselblad V, Vemulapalli S, Subherwal S, Schmit K, et al. 
Comparative effectiveness of endovascular and surgical revascularization for patients with 
peripheral artery disease and critical limb ischemia: systematic review of revascularization in 
critical limb ischemia. American heart journal. 2014;167(4):489-98.e7. 
 Jover E, Marin F, Roldan V, Montoro-Garcia S, Valdes M, Lip GYH. Atherosclerosis 
and thromboembolic risk in atrial fibrillation: focus on peripheral vascular disease. Annals of 
medicine. 2013;45(3):274-90. 
 Jude EB, Eleftheriadou I, Tentolouris N. Peripheral arterial disease in diabetes--a review. 
Diabetic medicine : a journal of the British Diabetic Association. 2010;27(1):4-14. 
 Jurado JA, Bashir R, Burket MW. Radiation-induced peripheral artery disease. 
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac 
Angiography & Interventions. 2008;72(4):563-8. 
 Kakkar AM, Abbott JD. Percutaneous versus surgical management of lower extremity 
peripheral artery disease. Current atherosclerosis reports. 2015;17(2):479. 
 Kapetanios D, Karkos C, Giagtzidis I, Papazoglou K, Kiroplastis K, Spyridis C. Vascular 
calcification biomarkers and peripheral arterial disease. International angiology : a journal of the 
International Union of Angiology. 2016;35(5):455-9. 
 Kaplovitch E, Rannelli L, Anand SS. Antithrombotics in stable peripheral artery disease. 
Vascular medicine (London, England). 2019;24(2):132-40. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            355 
 Karanth VK, Karanth TK, Karanth L. Lumbar sympathectomy techniques for critical 
lower limb ischaemia due to non-reconstructable peripheral arterial disease. The Cochrane 
database of systematic reviews. 2016;12:CD011519. 
 Kassimis G, Spiliopoulos S, Katsanos K, Tsetis D, Krokidis ME. Bioresorbable scaffolds 
in peripheral arterial disease. Expert review of cardiovascular therapy. 2014;12(4):443-50. 
 Katsanos K, Spiliopoulos S, Saha P, Diamantopoulos A, Karunanithy N, Krokidis M, et 
al. Comparative Efficacy and Safety of Different Antiplatelet Agents for Prevention of Major 
Cardiovascular Events and Leg Amputations in Patients with Peripheral Arterial Disease: A 
Systematic Review and Network Meta-Analysis. PloS one. 2015;10(8):e0135692. 
 Katsiki N, Giannoukas AD, Athyros VG, Mikhailidis DP. Lipid-lowering treatment in 
peripheral artery disease. Current opinion in pharmacology. 2018;39:19-26. 
 Katwal AB, Dokun AO. Peripheral arterial disease in diabetes: is there a role for 
genetics? Current diabetes reports. 2011;11(3):218-25. 
 Kayssi A, Al-Atassi T, Oreopoulos G, Roche-Nagle G, Tan KT, Rajan DK. Drug-eluting 
balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the 
lower limbs. The Cochrane database of systematic reviews. 2016(8):CD011319. 
 Kellogg DL, 3rd, Fisher-Hoch S, McCormick JB, Prasad A. Searching for the Genetic 
Determinants of Peripheral Arterial Disease: A Review of the Literature and Future Directions. 
Cardiology in review. 2019;27(3):145-52. 
 Keswani AN, White CJ. The impact of peripheral arterial disease on patients with 
congestive heart failure. Heart failure clinics. 2014;10(2):327-38. 
 Khan NA, Rahim SA, Anand SS, Simel DL, Panju A. Does the clinical examination 
predict lower extremity peripheral arterial disease? Jama. 2006;295(5):536-46. 
 Khandanpour N, Loke YK, Meyer FJ, Jennings B, Armon MP. Homocysteine and 
peripheral arterial disease: systematic review and meta-analysis. European journal of vascular 
and endovascular surgery : the official journal of the European Society for Vascular Surgery. 
2009;38(3):316-22. 
 Khandanpour N, Willis G, Meyer FJ, Armon MP, Loke YK, Wright AJA, et al. 
Peripheral arterial disease and methylenetetrahydrofolate reductase (MTHFR) C677T mutations: 
A case-control study and meta-analysis. Journal of vascular surgery. 2009;49(3):711-8. 
 Khawaja FJ, Kullo IJ. Novel markers of peripheral arterial disease. Vascular medicine 
(London, England). 2009;14(4):381-92. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            356 
 Khorev NG, Elykomov VA, Zaloznyi DA. Therapeutic cellular angiogenesis in treatment 
of peripheral artery diseases. Angiologiia i sosudistaia khirurgiia = Angiology and vascular 
surgery. 2011;17(2):36-44. 
 Khoury H, Lavoie L, Welner S, Folkerts K. The Burden of Major Adverse Cardiac 
Events and Antiplatelet Prevention in Patients with Coronary or Peripheral Arterial Disease. 
Cardiovascular therapeutics. 2016;34(2):115-24. 
 Kiernan TJ, Hynes BG, Ruggiero NJ, Yan BP, Jaff MR. Comprehensive evaluation and 
medical management of infrainguinal peripheral artery disease: "when to treat, when not to 
treat". Techniques in vascular and interventional radiology. 2010;13(1):2-10. 
 Kim ESH, Wattanakit K, Gornik HL. Using the ankle-brachial index to diagnose 
peripheral artery disease and assess cardiovascular risk. Cleveland Clinic journal of medicine. 
2012;79(9):651-61. 
 Kitrou P, Katsanos K, Karnabatidis D, Reppas L, Brountzos E, Spiliopoulos S. Current 
Evidence and Future Perspectives on Anti-platelet and Statin Pharmacotherapy for Patients with 
Symptomatic Peripheral Arterial Disease. Current vascular pharmacology. 2017;15(5):430-45. 
 Klein AJ, Ross CB. Endovascular treatment of lower extremity peripheral arterial 
disease. Trends in cardiovascular medicine. 2016;26(6):495-512. 
 Kleinegris M-CF, ten Cate H, ten Cate-Hoek AJ. D-dimer as a marker for cardiovascular 
and arterial thrombotic events in patients with peripheral arterial disease. A systematic review. 
Thrombosis and haemostasis. 2013;110(2):233-43. 
 Klonaris C, Patelis N, Drebes A, Matheiken S, Liakakos T. Antiplatelet Treatment in 
Peripheral Arterial Disease: The Role of Novel Antiplatelet Agents. Current pharmaceutical 
design. 2016;22(29):4610-6. 
 Kloos W, Vogel B, Blessing E. MiRNAs in peripheral artery disease - something 
gripping this way comes. VASA Zeitschrift fur Gefasskrankheiten. 2014;43(3):163-70. 
 Knipfer E, Reeps C, Dolezal C, Zimmermann A, Pelisek J, Behrens J, et al. Assessment 
of generic and disease-specific health-related quality of life instruments in peripheral arterial 
disease. VASA Zeitschrift fur Gefasskrankheiten. 2008;37(2):99-115. 
 Knowles JW, Assimes TL, Li J, Quertermous T, Cooke JP. Genetic susceptibility to 
peripheral arterial disease: a dark corner in vascular biology. Arteriosclerosis, thrombosis, and 
vascular biology. 2007;27(10):2068-78. 
 Kobayashi T, Parikh SA, Giri J. Intermittent claudication due to peripheral artery disease: 
best modern medical and endovascular therapeutic approaches. Current cardiology reports. 
2015;17(10):86. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            357 
 Kokkalis E, Aristokleous N, Houston JG. Haemodynamics and Flow Modification Stents 
for Peripheral Arterial Disease: A Review. Annals of biomedical engineering. 2016;44(2):466-
76. 
 Kolossvary E, Jarai Z, Farkas K. Peripheral arterial disease and diabetes related lower 
limb amputations. Presentation of the epidemiological data and the analysis of potentialities in 
preventive strategy. Orvosi hetilap. 2016;157(32):1266-74. 
 Koutakis P, Ismaeel A, Farmer P, Purcell S, Smith RS, Eidson JL, et al. Oxidative stress 
and antioxidant treatment in patients with peripheral artery disease. Physiological reports. 
2018;6(7):e13650. 
 Kownator S. Is it valuable to screen for peripheral arterial disease in patients with 
coronary artery diseases? Presse medicale (Paris, France : 1983). 2009;38(6):973-6. 
 Krajcer Z, Ghosheh B. The role of leading centers for endovascular surgery in education 
and training for endovascular treatment of peripheral vascular disease. The Journal of 
cardiovascular surgery. 2011;52(1):53-6. 
 Krishna SM, Moxon JV, Golledge J. A review of the pathophysiology and potential 
biomarkers for peripheral artery disease. International journal of molecular sciences. 
2015;16(5):11294-322. 
 Krishna SM, Omer SM, Golledge J. Evaluation of the clinical relevance and limitations 
of current pre-clinical models of peripheral artery disease. Clinical science (London, England : 
1979). 2016;130(3):127-50. 
 Krishna SM, Trollope AF, Golledge J. The relevance of epigenetics to occlusive cerebral 
and peripheral arterial disease. Clinical science (London, England : 1979). 2015;128(9):537-58. 
 Kroger K, Espinola-Klein C, Hoffmann U, Kalka C, Lawall H, Weiss N. Peripheral 
Arterial Disease: When is a PCSK9 Inhibitor Useful? Deutsche medizinische Wochenschrift 
(1946). 2018;143(19):1391-6. 
 Kudagi VS, White CJ. Endovascular stents: a review of their use in peripheral arterial 
disease. American journal of cardiovascular drugs : drugs, devices, and other interventions. 
2013;13(3):199-212. 
 Kuhlmann MT, Klocke R, Nikol S. Therapeutic angiogenesis for peripheral artery 
disease: cytokine therapy. VASA Zeitschrift fur Gefasskrankheiten. 2007;36(4):253-60. 
 Kullo IJ, Leeper NJ. The genetic basis of peripheral arterial disease: current knowledge, 
challenges, and future directions. Circulation research. 2015;116(9):1551-60. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            358 
 Kullo IJ, Rooke TW. CLINICAL PRACTICE. Peripheral Artery Disease. The New 
England journal of medicine. 2016;374(9):861-71. 
 Kuznetsov MR, Kosykh IV, Yu TV, Kuznetsova VF, Magnitsky IA. Sulodexide in 
conservative treatment of peripheral arterial diseases. Angiologiia i sosudistaia khirurgiia = 
Angiology and vascular surgery. 2015;21(4):45-51. 
 Lachmann N, Nikol S. Therapeutic angiogenesis for peripheral artery disease: stem cell 
therapy. VASA Zeitschrift fur Gefasskrankheiten. 2007;36(4):241-51. 
 Lane DA, Lip GY. Treatment of hypertension in peripheral arterial disease. The 
Cochrane database of systematic reviews. 2009(4):CD003075. 
 Lane DA, Lip GYH. Treatment of hypertension in peripheral arterial disease. The 
Cochrane database of systematic reviews. 2013(12):CD003075. 
 Lassila R. Role and management of coagulation disorders in peripheral arterial disease. 
Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the 
Scandinavian Surgical Society. 2012;101(2):94-9. 
 Lau JF, Weinberg MD, Olin JW. Peripheral artery disease. Part 1: clinical evaluation and 
noninvasive diagnosis. Nature reviews Cardiology. 2011;8(7):405-18. 
 Lawall H, Bramlage P, Amann B. Stem cell and progenitor cell therapy in peripheral 
artery disease. A critical appraisal. Thrombosis and haemostasis. 2010;103(4):696-709. 
 Lawall H, Bramlage P, Amann B. Treatment of peripheral arterial disease using stem and 
progenitor cell therapy. Journal of vascular surgery. 2011;53(2):445-53. 
 Lawall H, Huppert P, Espinola-Klein C, Zemmrich CS, Ruemenapf G. German guideline 
on the diagnosis and treatment of peripheral artery disease - a comprehensive update 2016. 
VASA Zeitschrift fur Gefasskrankheiten. 2017;46(2):79-86. 
 Leardini-Tristao M, Charles A-L, Lejay A, Pizzimenti M, Meyer A, Estato V, et al. 
Beneficial Effect of Exercise on Cognitive Function during Peripheral Arterial Disease: Potential 
Involvement of Myokines and Microglial Anti-Inflammatory Phenotype Enhancement. Journal 
of clinical medicine. 2019;8(5). 
 Lee K-B, Kim D-I. Clinical application of stem cells for therapeutic angiogenesis in 
patients with peripheral arterial disease. International journal of stem cells. 2009;2(1):11-7. 
 Leeper NJ, Kullo IJ, Cooke JP. Genetics of peripheral artery disease. Circulation. 
2012;125(25):3220-8. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            359 
 Leibecke T, Kagel C, Lubienski A, Peters SO, Jungbluth T, Helmberger T. CTA and 
MRA in peripheral arterial disease--is DSA out? Der Radiologe. 2006;46(11):941-7. 
 Lejay A, Ohana M, Delay C, Georg Y, Girsowicz E, Thaveau F, et al. Cystic adventitial 
pathology as an entity in peripheral arterial disease. The Journal of cardiovascular surgery. 
2016;57(2):282-91. 
 Lejay A, Thaveau F, Girsowicz E, Georg Y, Heim F, Durand B, et al. Stent evolution for 
peripheral arterial disease. The Journal of cardiovascular surgery. 2012;53(1 Suppl 1):171-9. 
 Lemaster K, Jackson D, Goldman D, Frisbee JC. Insidious incrementalism: The silent 
failure of the microcirculation with increasing peripheral vascular disease risk. Microcirculation 
(New York, NY : 1994). 2017;24(2). 
 Lepantalo M, Fiengo L, Biancari F. Peripheral arterial disease in diabetic patients with 
renal insufficiency: a review. Diabetes/metabolism research and reviews. 2012;28 Suppl 1:40-5. 
 Leyon JJ, Jaiveer S, Connolly DL, Babu S. Statin prescription is essential in peripheral 
vascular disease. Journal of vascular and interventional radiology : JVIR. 2010;21(2):175-7, quiz 
8. 
 Li J, Parikh SA. Drug-coated balloons for long lesions in peripheral arterial disease. The 
Journal of cardiovascular surgery. 2017;58(5):698-714. 
 Li Y, Li Z, Chang G, Wang M, Wu R, Wang S, et al. Effect of structured home-based 
exercise on walking ability in patients with peripheral arterial disease: a meta-analysis. Annals of 
vascular surgery. 2015;29(3):597-606. 
 Lichtenberg M. Peripheral artery disease: endovascular therapy. Medizinische 
Monatsschrift fur Pharmazeuten. 2017;40(3):102-6. 
 Lichtenberg MK, Carr JG, Golzar JA. Optical coherence tomography: guided therapy of 
in-stent restenosis for peripheral arterial disease. The Journal of cardiovascular surgery. 
2017;58(4):518-27. 
 Liew NC, Moissinac K, Lee L, Gee T, Zezeman RBHR. Update on the management of 
peripheral arterial disease (PAD). The Medical journal of Malaysia. 2011;66(4):386-8; quiz 9. 
 Liles DR, Kallen MA, Petersen LA, Bush RL. Quality of life and peripheral arterial 
disease. The Journal of surgical research. 2006;136(2):294-301. 
 Lin JB, Phillips EH, Riggins TAE, Sangha GS, Chakraborty S, Lee JY, et al. Imaging of 
small animal peripheral artery disease models: recent advancements and translational potential. 
International journal of molecular sciences. 2015;16(5):11131-77. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            360 
 Lin JS, Olson CM, Johnson ES, Whitlock EP. The ankle-brachial index for peripheral 
artery disease screening and cardiovascular disease prediction among asymptomatic adults: a 
systematic evidence review for the U.S. Preventive Services Task Force. Annals of internal 
medicine. 2013;159(5):333-41. 
 Lin PH, Bechara C, Kougias P, Huynh TT, LeMaire SA, Coselli JS. Assessment of aortic 
pathology and peripheral arterial disease using multidetector computed tomographic 
angiography. Vascular and endovascular surgery. 2008;42(6):583-98. 
 Lindquist J, Schramm K. Drug-Eluting Balloons and Drug-Eluting Stents in the 
Treatment of Peripheral Vascular Disease. Seminars in interventional radiology. 2018;35(5):443-
52. 
 Linsky RA, Korr KS, Sadiq I. Contemporary management of peripheral arterial disease--
a review. Medicine and health, Rhode Island. 2008;91(10):305-8. 
 Lipsitz EC, Kim S. Antithrombotic therapy in peripheral arterial disease. Clinics in 
geriatric medicine. 2006;22(1):183-98, x. 
 Litsky J, Chanda A, Stilp E, Lansky A, Mena C. Critical evaluation of stents in the 
peripheral arterial disease of the superficial femoral artery - focus on the paclitaxel eluting stent. 
Medical devices (Auckland, NZ). 2014;7:149-56. 
 Liu J, Wu Y, Li Z, Li W, Wang S. Endovascular treatment for intermittent claudication in 
patients with peripheral arterial disease: a systematic review. Annals of vascular surgery. 
2014;28(4):977-82. 
 Liu S, Li P, Su H. Four-Limb Blood Pressure Measurement with an Oscillometric 
Device: a Tool for Diagnosing Peripheral Vascular Disease. Current hypertension reports. 
2019;21(2):15. 
 Long A, Bui HT, Journet J, Hadj Henni A. Peripheral arterial disease with lower limb 
claudication: Medical treatment. Journal des maladies vasculaires. 2009;34(5):323-9. 
 Lowry D, Saeed M, Narendran P, Tiwari A. A Review of Distribution of Atherosclerosis 
in the Lower Limb Arteries of Patients With Diabetes Mellitus and Peripheral Vascular Disease. 
Vascular and endovascular surgery. 2018;52(7):535-42. 
 Lu L, Mackay DF, Pell JP. Meta-analysis of the association between cigarette smoking 
and peripheral arterial disease. Heart (British Cardiac Society). 2014;100(5):414-23. 
 Lumsden AB, Rice TW. Medical management of peripheral arterial disease: a therapeutic 
algorithm. Journal of endovascular therapy : an official journal of the International Society of 
Endovascular Specialists. 2006;13 Suppl 2:II19-29. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            361 
 Lyden SP, Joseph D. The clinical presentation of peripheral arterial disease and guidance 
for early recognition. Cleveland Clinic journal of medicine. 2006;73 Suppl 4:S15-21. 
 Lyu X, Li S, Peng S, Cai H, Liu G, Ran X. Intensive walking exercise for lower 
extremity peripheral arterial disease: A systematic review and meta-analysis. Journal of diabetes. 
2016;8(3):363-77. 
 Mackman N, Spronk HMH, Stouffer GA, Ten Cate H. Dual Anticoagulant and 
Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients. 
Arteriosclerosis, thrombosis, and vascular biology. 2018;38(4):726-32. 
 Mahe G, Jaquinandi V. Diagnosis of lower limb peripheral artery disease. Presse 
medicale (Paris, France : 1983). 2018;47(1):47-55. 
 Mahmud E, Cavendish JJ, Salami A. Current treatment of peripheral arterial disease: role 
of percutaneous interventional therapies. Journal of the American College of Cardiology. 
2007;50(6):473-90. 
 Makris GC, Chrysafi P, Little M, Patel R, Bratby M, Wigham A, et al. The role of 
intravascular ultrasound in lower limb revascularization in patients with peripheral arterial 
disease. International angiology : a journal of the International Union of Angiology. 
2017;36(6):505-16. 
 Makris GC, Lattimer CR, Lavida A, Geroulakos G. Availability of supervised exercise 
programs and the role of structured home-based exercise in peripheral arterial disease. European 
journal of vascular and endovascular surgery : the official journal of the European Society for 
Vascular Surgery. 2012;44(6):569-75; discussion 76. 
 Makris KI, Nella AA, Zhu Z, Swanson SA, Casale GP, Gutti TL, et al. 
Mitochondriopathy of peripheral arterial disease. Vascular. 2007;15(6):336-43. 
 Maly R, Chovanec V. Peripheral arterial disease and diabetes. Vnitrni lekarstvi. 
2010;56(4):341-6. 
 Malyar NM, Reinecke H, Freisinger E. Restenosis after endovascular revascularization in 
peripheral artery disease. VASA Zeitschrift fur Gefasskrankheiten. 2015;44(4):257-70. 
 Manfrini O, Amaduzzi PL, Cenko E, Bugiardini R. Prognostic implications of peripheral 
artery disease in coronary artery disease. Current opinion in pharmacology. 2018;39:121-8. 
 Mangi MA, Kahloon R, Elzanaty A, Zafrullah F, Eltahawy E. The Use of Fractional 
Flow Reserve for Physiological Assessment of Indeterminate Lesions in Peripheral Artery 
Disease. Cureus. 2019;11(4):e4445. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            362 
 Manuneedhi Cholan P, Cartland SP, Kavurma MM. NADPH Oxidases, Angiogenesis, 
and Peripheral Artery Disease. Antioxidants (Basel, Switzerland). 2017;6(3). 
 Marcial JM, Perez R, Vargas P, Franqui-Rivera H. Non-Invasive Therapy of Peripheral 
Arterial Disease. Boletin de la Asociacion Medica de Puerto Rico. 2015;107(3):52-7. 
 Mardikar HM, Mukherjee D. Current endovascular treatment of peripheral arterial 
disease. Progress in cardiovascular nursing. 2007;22(1):31-7. 
 Markel A. Statins and peripheral arterial disease. International angiology : a journal of 
the International Union of Angiology. 2015;34(5):416-27. 
 Marmagkiolis K, Sardar P, Mustapha JA, Montero-Baker M, Charitakis K, Iliescu C, et 
al. Transpedal Access for the Management of Complex Peripheral Artery Disease. The Journal 
of invasive cardiology. 2017;29(12):425-9. 
 Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Cutter G, et al. A systematic review 
of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in 
multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2015;21(3):318-31. 
 Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. Journal of the 
American College of Cardiology. 2006;47(5):921-9. 
 Martin D, Wallace D, Crowe M, Rush C, Tosenovsky P, Golledge J. Association of total 
white cell count with mortality and major adverse events in patients with peripheral arterial 
disease: a systematic review. European journal of vascular and endovascular surgery : the official 
journal of the European Society for Vascular Surgery. 2014;47(4):422-32. 
 Masanauskiene E, Naudziunas A. Peripheral arterial disease--an underappreciated clinical 
problem. Medicina (Kaunas, Lithuania). 2008;44(4):328-35. 
 Mascarenhas JV, Albayati MA, Shearman CP, Jude EB. Peripheral arterial disease. 
Endocrinology and metabolism clinics of North America. 2014;43(1):149-66. 
 Mathew RC, Kramer CM. Recent advances in magnetic resonance imaging for peripheral 
artery disease. Vascular medicine (London, England). 2018;23(2):143-52. 
 Matoba S, Matsubara H. Therapeutic angiogenesis for peripheral artery diseases by 
autologous bone marrow cell transplantation. Current pharmaceutical design. 2009;15(24):2769-
77. 
 Matthews EO, Rowbotham SE, Moxon JV, Jones RE, Vega de Ceniga M, Golledge J. 
Meta-analysis of the association between peripheral artery disease and growth of abdominal 
aortic aneurysms. The British journal of surgery. 2017;104(13):1765-74. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            363 
 Mays RJ, Rogers RK, Hiatt WR, Regensteiner JG. Community walking programs for 
treatment of peripheral artery disease. Journal of vascular surgery. 2013;58(6):1678-87. 
 McCann AB, Jaff MR. Treatment strategies for peripheral artery disease. Expert opinion 
on pharmacotherapy. 2009;10(10):1571-86. 
 McCaslin JE, Andras A, Stansby G. Cryoplasty for peripheral arterial disease. The 
Cochrane database of systematic reviews. 2013(8):CD005507. 
 McCaslin JE, Macdonald S, Stansby G. Cryoplasty for peripheral vascular disease. The 
Cochrane database of systematic reviews. 2007(4):CD005507. 
 McDermott MM, Polonsky TS. Home-Based Exercise: A Therapeutic Option for 
Peripheral Artery Disease. Circulation. 2016;134(16):1127-9. 
 McDermott MM. Functional impairment in peripheral artery disease and how to improve 
it in 2013. Current cardiology reports. 2013;15(4):347. 
 McDermott MM. Lower extremity manifestations of peripheral artery disease: the 
pathophysiologic and functional implications of leg ischemia. Circulation research. 
2015;116(9):1540-50. 
 McDermott MM. Medical Management of Functional Impairment in Peripheral Artery 
Disease: A Review. Progress in cardiovascular diseases. 2018;60(6):586-92. 
 McDermott MM. The magnitude of the problem of peripheral arterial disease: 
epidemiology and clinical significance. Cleveland Clinic journal of medicine. 2006;73 Suppl 
4:S2-7. 
 Melfi R, Ricottini E. Antiplatelet therapy for peripheral artery disease. Cardiovascular 
diagnosis and therapy. 2018;8(5):663-77. 
 Meller SM, Stilp E, Walker CN, Mena-Hurtado C. The link between vasculogenic 
erectile dysfunction, coronary artery disease, and peripheral artery disease: role of metabolic 
factors and endovascular therapy. The Journal of invasive cardiology. 2013;25(6):313-9. 
 Menasche P. Cell therapy for peripheral arterial disease. Current opinion in molecular 
therapeutics. 2010;12(5):538-45. 
 Mendes Pedro L. The role of statins in atherosclerotic peripheral arterial disease. Revista 
portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese 
journal of cardiology : an official journal of the Portuguese Society of Cardiology. 2011;30(7-
8):665-73. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            364 
 Mendes-Pinto D, Rodrigues-Machado MdG. Applications of arterial stiffness markers in 
peripheral arterial disease. Jornal vascular brasileiro. 2019;18:e20180093. 
 Meneses AL, Ritti-Dias RM, Parmenter B, Golledge J, Askew CD. Combined Lower 
Limb Revascularisation and Supervised Exercise Training for Patients with Peripheral Arterial 
Disease: A Systematic Review of Randomised Controlled Trials. Sports medicine (Auckland, 
NZ). 2017;47(5):987-1002. 
 Menke J, Larsen J. Meta-analysis: Accuracy of contrast-enhanced magnetic resonance 
angiography for assessing steno-occlusions in peripheral arterial disease. Annals of internal 
medicine. 2010;153(5):325-34. 
 Met R, Bipat S, Legemate DA, Reekers JA, Koelemay MJW. Diagnostic performance of 
computed tomography angiography in peripheral arterial disease: a systematic review and meta-
analysis. Jama. 2009;301(4):415-24. 
 Meyersohn NM, Walker TG, Oliveira GR. Advances in axial imaging of peripheral 
vascular disease. Current cardiology reports. 2015;17(10):87. 
 Mikita J. Peripheral arterial disease. Orvosi hetilap. 2006;147(16):723-30. 
 Mikroulis D, Papanas N, Maltezos E, Bougioukas G. Angiogenic growth factors in the 
treatment of peripheral arterial disease. Current vascular pharmacology. 2007;5(3):195-209. 
 Milani RV, Lavie CJ. The role of exercise training in peripheral arterial disease. Vascular 
medicine (London, England). 2007;12(4):351-8. 
 Miyamoto M, Takagi H, Kubota Y, Tetsuka A, Tara S, Shimizu W, et al. Frontline of 
vascular regenerative therapy for refractory peripheral arterial diseases. Nihon Jibiinkoka Gakkai 
kaiho. 2015;118(11):1281-8. 
 Mohler E, 3rd, Giri J, Acc, Aha. Management of peripheral arterial disease patients: 
comparing the ACC/AHA and TASC-II guidelines. Current medical research and opinion. 
2008;24(9):2509-22. 
 Mohler ER, 3rd. Combination antiplatelet therapy in patients with peripheral arterial 
disease: is the best therapy aspirin, clopidogrel, or both? Catheterization and cardiovascular 
interventions : official journal of the Society for Cardiac Angiography & Interventions. 2009;74 
Suppl 1:S1-6. 
 Mohler ER, 3rd. Therapy insight: peripheral arterial disease and diabetes--from 
pathogenesis to treatment guidelines. Nature clinical practice Cardiovascular medicine. 
2007;4(3):151-62. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            365 
 Moloney E, O'Connor J, Craig D, Robalino S, Chrysos A, Javanbakht M, et al. 
Systematic Review of Economic Models Used to Compare Techniques for Detecting Peripheral 
Arterial Disease. PharmacoEconomics - open. 2019;3(1):21-30. 
 Morcos R, Louka B, Tseng A, Misra S, McBane R, Esser H, et al. The Evolving 
Treatment of Peripheral Arterial Disease through Guideline-Directed Recommendations. Journal 
of clinical medicine. 2018;7(1). 
 Morley RL, Sharma A, Horsch AD, Hinchliffe RJ. Peripheral artery disease. BMJ 
(Clinical research ed). 2018;360:j5842. 
 Morris DR, Rodriguez AJ, Moxon JV, Cunningham MA, McDermott MM, Myers J, et al. 
Association of lower extremity performance with cardiovascular and all-cause mortality in 
patients with peripheral artery disease: a systematic review and meta-analysis. Journal of the 
American Heart Association. 2014;3(4). 
 Movahed M-R, Amani F, Stinis C, Kubaska SM, 3rd. Combined peripheral and coronary 
artery percutaneous intervention in patients with significant coronary and peripheral vascular 
disease. Case reports and review. The Journal of invasive cardiology. 2006;18(5):E157-61. 
 Mughal NA, Russell DA, Ponnambalam S, Homer-Vanniasinkam S. Gene therapy in the 
treatment of peripheral arterial disease. The British journal of surgery. 2012;99(1):6-15. 
 Muir RL. Peripheral arterial disease: Pathophysiology, risk factors, diagnosis, treatment, 
and prevention. Journal of vascular nursing : official publication of the Society for Peripheral 
Vascular Nursing. 2009;27(2):26-30. 
 Mukherjee D, Cho L. Peripheral arterial disease: considerations in risks, diagnosis, and 
treatment. Journal of the National Medical Association. 2009;101(10):999-1008. 
 Mukherjee D, Eagle K. The importance of early diagnosis and treatment in peripheral 
arterial disease: insights from the PARTNERS and REACH registries. Current vascular 
pharmacology. 2010;8(3):293-300. 
 Muller MD, Reed AB, Leuenberger UA, Sinoway LI. Physiology in medicine: peripheral 
arterial disease. Journal of applied physiology (Bethesda, Md : 1985). 2013;115(9):1219-26. 
 Murakami A. Hybrid Operations in Patients with Peripheral Arterial Disease. Annals of 
vascular diseases. 2018;11(1):57-65. 
 Myers SA, Huben NB, Yentes JM, McCamley JD, Lyden ER, Pipinos II, et al. 
Spatiotemporal Changes Posttreatment in Peripheral Arterial Disease. Rehabilitation research 
and practice. 2015;2015:124023. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            366 
 Naghi J, Yalvac EA, Pourdjabbar A, Ang L, Bahadorani J, Reeves RR, et al. New 
developments in the clinical use of drug-coated balloon catheters in peripheral arterial disease. 
Medical devices (Auckland, NZ). 2016;9:161-74. 
 Nayak KR, Cavendish JJ. Risk reduction with clopidogrel in the management of 
peripheral arterial disease. Vascular health and risk management. 2007;3(3):289-97. 
 Neves SE. Anesthesia for Patients with Peripheral Vascular Disease and Cardiac 
Dysfunction. Anesthesiology clinics. 2016;34(4):775-95. 
 Nfor T, Allaqaband S, Bajwa T. Increasing role of interventional cardiologists for 
peripheral vascular disease. Current problems in cardiology. 2014;39(8):255-311. 
 Ng VG, Mena C, Pietras C, Lansky AJ. Local delivery of paclitaxel in the treatment of 
peripheral arterial disease. European journal of clinical investigation. 2015;45(3):333-45. 
 Ngu NL, McEvoy M. Environmental tobacco smoke and peripheral arterial disease: A 
review. Atherosclerosis. 2017;266:113-20. 
 Nguyen LL. Percutaneous treatment of peripheral vascular disease: the role of diabetes 
and inflammation. Journal of vascular surgery. 2007;45 Suppl A:A149-57. 
 Nicolau JC, Baracioli LM, Giugliano RP. Ticagrelor for the prevention of ischemic 
events in patients with prior myocardial infarction and peripheral artery disease. Expert opinion 
on pharmacotherapy. 2018;19(9):1013-9. 
 Nielsen YJW. Whole-body MR angiography in patients with peripheral arterial disease. 
Danish medical bulletin. 2010;57(12):B4231. 
 Nikol S. Therapeutic angiogenesis for peripheral artery disease: gene therapy. VASA 
Zeitschrift fur Gefasskrankheiten. 2007;36(3):165-73. 
 Nikol S. Therapeutic angiogenesis using gene transfer and stem cell therapy in peripheral 
artery disease. Deutsche medizinische Wochenschrift (1946). 2011;136(14):672-4. 
 Nirala N, Periyasamy R, Kumar A. Noninvasive Diagnostic Methods for Better 
Screening of Peripheral Arterial Disease. Annals of vascular surgery. 2018;52:263-72. 
 Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR, et al. Inter-
society consensus for the management of peripheral arterial disease. International angiology : a 
journal of the International Union of Angiology. 2007;26(2):81-157. 
 Nosova EV, Conte MS, Grenon SM. Advancing beyond the "heart-healthy diet" for 
peripheral arterial disease. Journal of vascular surgery. 2015;61(1):265-74. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            367 
 Noukeu LC, Wolf J, Yuan B, Banerjee S, Nguyen KT. Nanoparticles for Detection and 
Treatment of Peripheral Arterial Disease. Small (Weinheim an der Bergstrasse, Germany). 
2018;14(32):e1800644. 
 Novakovic M, Jug B, Lenasi H. Clinical impact of exercise in patients with peripheral 
arterial disease. Vascular. 2017;25(4):412-22. 
 Nsengiyumva V, Fernando ME, Moxon JV, Krishna SM, Pinchbeck J, Omer SM, et al. 
The association of circulating 25-hydroxyvitamin D concentration with peripheral arterial 
disease: A meta-analysis of observational studies. Atherosclerosis. 2015;243(2):645-51. 
 O'Donnell ME, Reid JA, Lau LL, Hannon RJ, Lee B. Optimal management of peripheral 
arterial disease for the non-specialist. The Ulster medical journal. 2011;80(1):33-41. 
 Oka RK. Peripheral arterial disease in older adults: management of cardiovascular 
disease risk factors. The Journal of cardiovascular nursing. 2006;21(5 Suppl 1):S15-20. 
 Okamoto S, Iida O, Mano T. Current Perspective on Hemodialysis Patients with 
Peripheral Artery Disease. Annals of vascular diseases. 2017;10(2):88-91. 
 Okeke E, Dokun AO. Role of genetics in peripheral arterial disease outcomes; 
significance of limb-salvage quantitative locus-1 genes. Experimental biology and medicine 
(Maywood, NJ). 2018;243(2):190-7. 
 Olin JW, Allie DE, Belkin M, Bonow RO, Casey DE, Jr., Creager MA, et al. 
ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 performance measures for adults with 
peripheral artery disease. A Report of the American College of Cardiology Foundation/American 
Heart Association Task Force on Performance Measures, the American College of Radiology, 
the Society for Cardiac Angiography and Interventions, the Society for Interventional Radiology, 
the Society for Vascular Medicine, the Society for Vascular Nursing, and the Society for 
Vascular Surgery (Writing Committee to Develop Clinical Performance Measures for Peripheral 
Artery Disease). Vascular medicine (London, England). 2010;15(6):481-512. 
 Olin JW, White CJ, Armstrong EJ, Kadian-Dodov D, Hiatt WR. Peripheral Artery 
Disease: Evolving Role of Exercise, Medical Therapy, and Endovascular Options. Journal of the 
American College of Cardiology. 2016;67(11):1338-57. 
 Olinic D-M, Spinu M, Olinic M, Homorodean C, Tataru D-A, Liew A, et al. 
Epidemiology of peripheral artery disease in Europe: VAS Educational Paper. International 
angiology : a journal of the International Union of Angiology. 2018;37(4):327-34. 
 Olinic D-M, Tataru DA, Homorodean C, Spinu M, Olinic M. Antithrombotic treatment in 
peripheral artery disease. VASA Zeitschrift fur Gefasskrankheiten. 2018;47(2):99-108. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            368 
 Ono T, Nakamura M. Peripheral artery disease: treatment overview. Nihon rinsho 
Japanese journal of clinical medicine. 2014;72(7):1294-7. 
 Osinbowale OO, Milani RV. Benefits of exercise therapy in peripheral arterial disease. 
Progress in cardiovascular diseases. 2011;53(6):447-53. 
 Ouma GO, Jonas RA, Usman MHU, Mohler ER, 3rd. Targets and delivery methods for 
therapeutic angiogenesis in peripheral artery disease. Vascular medicine (London, England). 
2012;17(3):174-92. 
 Owen AR, Roditi GH. Peripheral arterial disease: the evolving role of non-invasive 
imaging. Postgraduate medical journal. 2011;87(1025):189-98. 
 Ozaki Y, Imanishi T, Akasaka T. Inflammatory Biomarkers in Peripheral Artery Disease: 
Diagnosis, Prognosis, and Therapeutic Challenges. Current medicinal chemistry. 
2015;22(23):2744-53. 
 Ozdemir BA, Brownrigg JR, Jones KG, Thompson MM, Hinchliffe RJ. Systematic 
review of screening investigations for peripheral arterial disease in patients with diabetes 
mellitus. Surgical technology international. 2013;23:51-8. 
 Pacilli A, Faggioli G, Stella A, Pasquinelli G. An update on therapeutic angiogenesis for 
peripheral vascular disease. Annals of vascular surgery. 2010;24(2):258-68. 
 Panico A, Jafferani A, Shah F, Dieter RS. Advances in peripheral arterial disease 
endovascular revascularization. Cardiology clinics. 2015;33(1):89-98. 
 Papia G, Mayer P, Kelton D, Queen D, Elliott JA, Kuhnke JL. Just leg pain? Think again: 
What health leaders must know about peripheral arterial disease. Healthcare management forum. 
2015;28(6 Suppl):S5-9. 
 Paquissi FC. The role of inflammation in cardiovascular diseases: the predictive value of 
neutrophil-lymphocyte ratio as a marker in peripheral arterial disease. Therapeutics and clinical 
risk management. 2016;12:851-60. 
 Paraskevas KI, Baker DM, Vrentzos GE, Mikhailidis DP. The role of fibrinogen and 
fibrinolysis in peripheral arterial disease. Thrombosis research. 2008;122(1):1-12. 
 Paraskevas KI, Giannoukas AD, Mikhailidis DP. Renal function impairment in peripheral 
arterial disease: an important parameter that should not be neglected. Annals of vascular surgery. 
2009;23(5):690-9. 
 Paravastu SCV, Mendonca D, Da Silva A. Beta blockers for peripheral arterial disease. 
The Cochrane database of systematic reviews. 2008(4):CD005508. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            369 
 Paravastu SCV, Mendonca DA, da Silva A. Beta blockers for peripheral arterial disease. 
European journal of vascular and endovascular surgery : the official journal of the European 
Society for Vascular Surgery. 2009;38(1):66-70. 
 Paravastu SCV, Mendonca DA, Da Silva A. Beta blockers for peripheral arterial disease. 
The Cochrane database of systematic reviews. 2013(9):CD005508. 
 Parmenter BJ, Dieberg G, Phipps G, Smart NA. Exercise training for health-related 
quality of life in peripheral artery disease: a systematic review and meta-analysis. Vascular 
medicine (London, England). 2015;20(1):30-40. 
 Parmenter BJ, Dieberg G, Smart NA. Exercise training for management of peripheral 
arterial disease: a systematic review and meta-analysis. Sports medicine (Auckland, NZ). 
2015;45(2):231-44. 
 Parmenter BJ, Mavros Y, Ritti Dias R, King S, Fiatarone Singh M. Resistance training as 
a treatment for older persons with peripheral artery disease: a systematic review and meta-
analysis. British journal of sports medicine. 2019. 
 Parvar SL, Fitridge R, Dawson J, Nicholls SJ. Medical and lifestyle management of 
peripheral arterial disease. Journal of vascular surgery. 2018;68(5):1595-606. 
 Patel T, Baydoun H, Patel NK, Tripathi B, Nanavaty S, Savani S, et al. Peripheral arterial 
disease in women: The gender effect. Cardiovascular revascularization medicine : including 
molecular interventions. 2019. 
 Patelis N, Karaolanis G, Kouvelos GN, Hart C, Metheiken S. The effect of exercise on 
coagulation and fibrinolysis factors in patients with peripheral arterial disease. Experimental 
biology and medicine (Maywood, NJ). 2016;241(15):1699-707. 
 Pattillo CB, Bir S, Rajaram V, Kevil CG. Inorganic nitrite and chronic tissue ischaemia: a 
novel therapeutic modality for peripheral vascular diseases. Cardiovascular research. 
2011;89(3):533-41. 
 Peach G, Griffin M, Jones KG, Thompson MM, Hinchliffe RJ. Diagnosis and 
management of peripheral arterial disease. BMJ (Clinical research ed). 2012;345:e5208. 
 Pearce L, Ghosh J, Counsell A, Serracino-Inglott F. Cilostazol and peripheral arterial 
disease. Expert opinion on pharmacotherapy. 2008;9(15):2683-90. 
 Pearson TL. Peripheral arterial disease. Simple screening tool could diagnose more cases. 
Advance for nurse practitioners. 2006;14(7):47-8, 50. 
 Pedersen BL, Baekgaard N, Quistorff B. Muscle mitochondrial function in patients with 
type 2 diabetes mellitus and peripheral arterial disease: implications in vascular surgery. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            370 
European journal of vascular and endovascular surgery : the official journal of the European 
Society for Vascular Surgery. 2009;38(3):356-64. 
 Peker A, Balendran B, Paraskevopoulos I, Krokidis M. Demystifying the Use of Self-
Expandable Interwoven Nitinol Stents in Femoropopliteal Peripheral Arterial Disease. Annals of 
vascular surgery. 2019. 
 Peterson S, Hasenbank M, Silvestro C, Raina S. IN.PACT Admiral drug-coated balloon: 
Durable, consistent and safe treatment for femoropopliteal peripheral artery disease. Advanced 
drug delivery reviews. 2017;112:69-77. 
 Piaggesi A, Vallini V, Iacopi E, Tedeschi A, Scatena A, Goretti C, et al. Iloprost in the 
management of peripheral arterial disease in patients with diabetes mellitus. Minerva 
cardioangiologica. 2011;59(1):101-8. 
 Pineda JRET, Kim ESH, Osinbowale OO. Impact of pharmacologic interventions on 
peripheral artery disease. Progress in cardiovascular diseases. 2015;57(5):510-20. 
 Piscione F, Piccolo R, De Rosa R, Chiariello M. Assessment of quality of life in patients 
with peripheral arterial disease: a problem left ahead. Giornale italiano di cardiologia (2006). 
2009;10(4):216-24. 
 Poku E, Duncan R, Keetharuth A, Essat M, Phillips P, Woods HB, et al. Patient-reported 
outcome measures in patients with peripheral arterial disease: a systematic review of 
psychometric properties. Health and quality of life outcomes. 2016;14(1):161. 
 Pollak AW, Norton PT, Kramer CM. Multimodality imaging of lower extremity 
peripheral arterial disease: current role and future directions. Circulation Cardiovascular 
imaging. 2012;5(6):797-807. 
 Poredos P, Jezovnik M, Kalodiki E, Andreozzi G, Antignani PL, Clement D, et al. 
Medical management of patients with peripheral arterial disease. International angiology : a 
journal of the International Union of Angiology. 2015;34(1):75-93. 
 Poredos P, Jezovnik MK. Antiplatelet and antithrombotic treatment of patients with 
peripheral arterial disease. International angiology : a journal of the International Union of 
Angiology. 2010;29(1):20-6. 
 Poredos P, Jezovnik MK. Is aspirin still the drug of choice for management of patients 
with peripheral arterial disease? VASA Zeitschrift fur Gefasskrankheiten. 2013;42(2):88-95. 
 Pysna A, Bem R, Nemcova A, Fejfarova V, Jirkovska A, Hazdrova J, et al. Endothelial 
Progenitor Cells Biology in Diabetes Mellitus and Peripheral Arterial Disease and their 
Therapeutic Potential. Stem cell reviews. 2019;15(2):157-65. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            371 
 Qanadli SD, Laswed T, Denys A, Doenz F. CT-angiography of peripheral arterial 
diseases: principle and current indications. Revue medicale suisse. 2006;2(73):1731-5. 
 Rac-Albu M, Iliuta L, Guberna SM, Sinescu C. The role of ankle-brachial index for 
predicting peripheral arterial disease. Maedica. 2014;9(3):295-302. 
 Rafnsson SB, Deary IJ, Fowkes FGR. Peripheral arterial disease and cognitive function. 
Vascular medicine (London, England). 2009;14(1):51-61. 
 Rajaee S, Hurtado CM, Sumpio B. Drug-Eluting Stents: New Tools for the 
Armamentarium Against Peripheral Arterial Disease. Surgical technology international. 
2015;27:200-7. 
 Rajagopalan S, Mihai G. Perspectives on optimizing trial design and endpoints in 
peripheral arterial disease: a case for imaging-based surrogates as endpoints of functional 
efficacy. Cardiology clinics. 2011;29(3):419-31. 
 Rajamanickam A, Krishnan P. History and Physical Examination in Diagnosis of 
Peripheral Artery Disease. Interventional cardiology clinics. 2014;3(4):461-7. 
 Ramacciotti E, Castelli V, Jr., Walenga J, Fareed J. Medical management of stable 
peripheral artery disease: the COMPASS trial. Perspectives from a vascular standpoint. 
International angiology : a journal of the International Union of Angiology. 2018;37(4):255-60. 
 Ramirez JL, Drudi LM, Grenon SM. Review of biologic and behavioral risk factors 
linking depression and peripheral artery disease. Vascular medicine (London, England). 
2018;23(5):478-88. 
 Ransohoff JD, Wu JC. Imaging stem cell therapy for the treatment of peripheral arterial 
disease. Current vascular pharmacology. 2012;10(3):361-73. 
 Raparelli V, Proietti M, Napoleone L, Bucci T, Talerico G, Pignataro FS, et al. 
Asymptomatic peripheral artery disease and antiplatelet management. VASA Zeitschrift fur 
Gefasskrankheiten. 2014;43(5):309-25. 
 Raval Z, Losordo DW. Cell therapy of peripheral arterial disease: from experimental 
findings to clinical trials. Circulation research. 2013;112(9):1288-302. 
 Raza A, Harwood A, Totty J, Smith G, Chetter I. Extracorporeal Shockwave Therapy for 
Peripheral Arterial Disease: A Review of the Potential Mechanisms of Action. Annals of 
vascular surgery. 2017;45:294-8. 
 Regensteiner JG, Stewart KJ. Established and evolving medical therapies for claudication 
in patients with peripheral arterial disease. Nature clinical practice Cardiovascular medicine. 
2006;3(11):604-10. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            372 
 Rerkasem K, Kosachunhanun N, Sony K, Inpankaew N, Mani R. Underrecognized 
Peripheral Arterial Disease in Patients With Diabetes Mellitus in Thailand: We Must Consider 
Neuroischemic Foot Ulcers From This Fallout. The international journal of lower extremity 
wounds. 2015;14(2):132-5. 
 Rhee SY, Kim YS. Peripheral Arterial Disease in Patients with Type 2 Diabetes Mellitus. 
Diabetes & metabolism journal. 2015;39(4):283-90. 
 Rice TW, Lumsden AB. Optimal medical management of peripheral arterial disease. 
Vascular and endovascular surgery. 2006;40(4):312-27. 
 RieSs HC, Debus ES, Schwaneberg T, Hischke S, Maier J, Bublitz M, et al. Indicators of 
outcome quality in peripheral arterial disease revascularisations - a Delphi expert consensus. 
VASA Zeitschrift fur Gefasskrankheiten. 2018;47(6):491-7. 
 Rigato M, Monami M, Fadini GP. Autologous Cell Therapy for Peripheral Arterial 
Disease: Systematic Review and Meta-Analysis of Randomized, Nonrandomized, and 
Noncontrolled Studies. Circulation research. 2017;120(8):1326-40. 
 Ripa RS, Kjaer A, Hesse B. Non-invasive imaging for subclinical coronary 
atherosclerosis in patients with peripheral artery disease. Current atherosclerosis reports. 
2014;16(6):415. 
 Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. The 
Cochrane database of systematic reviews. 2007(1):CD003748. 
 Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. The 
Cochrane database of systematic reviews. 2008(1):CD003748. 
 Rontoyanni VG, Nunez Lopez O, Fankhauser GT, Cheema ZF, Rasmussen BB, Porter C. 
Mitochondrial Bioenergetics in the Metabolic Myopathy Accompanying Peripheral Artery 
Disease. Frontiers in physiology. 2017;8:141. 
 Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss LK, et al. 2011 
ACCF/AHA focused update of the guideline for the management of patients with peripheral 
artery disease (updating the 2005 guideline): a report of the American College of Cardiology 
Foundation/American Heart Association Task Force on Practice Guidelines: developed in 
collaboration with the Society for Cardiovascular Angiography and Interventions, Society of 
Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. 
Journal of vascular surgery. 2011;54(5):e32-58. 
 Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss LK, et al. 2011 
ACCF/AHA focused update of the guideline for the management of patients with peripheral 
artery disease (updating the 2005 guideline): a report of the American College of Cardiology 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            373 
Foundation/American Heart Association Task Force on Practice Guidelines: developed in 
collaboration with the Society for Cardiovascular Angiography and Interventions, Society of 
Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. 
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac 
Angiography & Interventions. 2012;79(4):501-31. 
 Rosero EB, Kane K, Clagett GP, Timaran CH. A systematic review of the limitations and 
approaches to improve detection and management of peripheral arterial disease in Hispanics. 
Journal of vascular surgery. 2010;51(4 Suppl):27S-35S. 
 Roy TL, Forbes TL, Dueck AD, Wright GA. MRI for peripheral artery disease: 
Introductory physics for vascular physicians. Vascular medicine (London, England). 
2018;23(2):153-62. 
 Rubin BG. Plaque excision in the treatment of peripheral arterial disease. Perspectives in 
vascular surgery and endovascular therapy. 2006;18(1):47-52. 
 Ruiz-Aragon J, Marquez Calderon S. Effectiveness of lumbar sympathectomy in the 
treatment of occlusive peripheral vascular disease in lower limbs: systematic review. Medicina 
clinica. 2010;134(11):477-82. 
 Ruiz-Canela M, Martinez-Gonzalez MA. Lifestyle and dietary risk factors for peripheral 
artery disease. Circulation journal : official journal of the Japanese Circulation Society. 
2014;78(3):553-9. 
 Safar ME. Arterial stiffness and peripheral arterial disease. Advances in cardiology. 
2007;44:199-211. 
 Saha HHT, Leskinen YKJ, Salenius JP, Lahtela JT. Peripheral vascular disease in 
diabetic peritoneal dialysis patients. Peritoneal dialysis international : journal of the International 
Society for Peritoneal Dialysis. 2007;27 Suppl 2:S210-4. 
 Said ZH, Lerakis S. The role of magnetic resonance angiography in peripheral artery 
disease. Current opinion in pharmacology. 2018;39:129-33. 
 Salameh MJ, Ratchford EV. Update on peripheral arterial disease and claudication 
rehabilitation. Physical medicine and rehabilitation clinics of North America. 2009;20(4):627-56. 
 Salisbury DL, Brown RJ, Bronas UG, Kirk LN, Treat-Jacobson D. Measurement of 
peripheral blood flow in patients with peripheral artery disease: Methods and considerations. 
Vascular medicine (London, England). 2018;23(2):163-71. 
 Samies JH, Gehling M, Serena TE, Yaakov RA. Use of a fluorescence angiography 
system in assessment of lower extremity ulcers in patients with peripheral arterial disease: A 
review and a look forward. Seminars in vascular surgery. 2015;28(3-4):190-4. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            374 
 Sampson UKA, Fowkes FGR, McDermott MM, Criqui MH, Aboyans V, Norman PE, et 
al. Global and regional burden of death and disability from peripheral artery disease: 21 world 
regions, 1990 to 2010. Global heart. 2014;9(1):145-58.e21. 
 Sanada F, Taniyama Y, Kanbara Y, Otsu R, Ikeda-Iwabu Y, Carracedo M, et al. Gene 
therapy in peripheral artery disease. Expert opinion on biological therapy. 2015;15(3):381-90. 
 Sanada F, Taniyama Y, Muratsu J, Otsu R, Shimizu H, Rakugi H, et al. Gene-
Therapeutic Strategies Targeting Angiogenesis in Peripheral Artery Disease. Medicines (Basel, 
Switzerland). 2018;5(2). 
 Sapelkin SV, Kharazov AF. Advanced position in the conservative treatment of patients 
with peripheral arterial disease. Khirurgiia. 2013(4):68-73. 
 Sapelkin SV, Kuznetsov MR. Conservative treatment of patients with peripheral artery 
diseases: possibilities and existing problems. Angiologiia i sosudistaia khirurgiia = Angiology 
and vascular surgery. 2016;22(4):169-75. 
 Sarode K, Spelber DA, Bhatt DL, Mohammad A, Prasad A, Brilakis ES, et al. Drug 
delivering technology for endovascular management of infrainguinal peripheral artery disease. 
JACC Cardiovascular interventions. 2014;7(8):827-39. 
 Savill P. Early diagnosis of peripheral arterial disease can save limbs. The Practitioner. 
2012;256(1755):19-21, 2-3. 
 Schaper NC, Andros G, Apelqvist J, Bakker K, Lammer J, Lepantalo M, et al. Diagnosis 
and treatment of peripheral arterial disease in diabetic patients with a foot ulcer. A progress 
report of the International Working Group on the Diabetic Foot. Diabetes/metabolism research 
and reviews. 2012;28 Suppl 1:218-24. 
 Schiattarella GG, Perrino C, Magliulo F, Carbone A, Bruno AG, De Paulis M, et al. 
Physical activity in the prevention of peripheral artery disease in the elderly. Frontiers in 
physiology. 2014;5:12. 
 Schillinger M, Minar E. Percutaneous treatment of peripheral artery disease: novel 
techniques. Circulation. 2012;126(20):2433-40. 
 Schirmang TC, Ahn SH, Murphy TP, Dubel GJ, Soares GM. Peripheral arterial disease: 
update of overview and treatment. Medicine and health, Rhode Island. 2009;92(12):398-402. 
 Schmehl J, Tepe G. Current status of bare and drug-eluting stents in infrainguinal 
peripheral vascular disease. Expert review of cardiovascular therapy. 2008;6(4):531-8. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            375 
 Schmit K, Dolor RJ, Jones WS, Vemulapalli S, Hasselblad V, Subherwal S, et al. 
Comparative effectiveness review of antiplatelet agents in peripheral artery disease. Journal of 
the American Heart Association. 2014;3(6):e001330. 
 Schnorr B, Albrecht T. Drug-coated balloons and their place in treating peripheral arterial 
disease. Expert review of medical devices. 2013;10(1):105-14. 
 Schocke M, Esterhammer R, Greiner A. High-energy phosphate metabolism in the 
exercising muscle of patients with peripheral arterial disease. VASA Zeitschrift fur 
Gefasskrankheiten. 2008;37(3):199-210. 
 Schorr EN, Treat-Jacobson D. Methods of symptom evaluation and their impact on 
peripheral artery disease (PAD) symptom prevalence: a review. Vascular medicine (London, 
England). 2013;18(2):95-111. 
 Schramm K, Rochon PJ. Gender Differences in Peripheral Vascular Disease. Seminars in 
interventional radiology. 2018;35(1):9-16. 
 Schulte KL. Peripheral arterial disease: secondary prevention, medical therapy, 
revascularization. Der Internist. 2009;50(8):927-35. 
 Sebastianski M, Makowsky MJ, Dorgan M, Tsuyuki RT. Paradoxically lower prevalence 
of peripheral arterial disease in South Asians: a systematic review and meta-analysis. Heart 
(British Cardiac Society). 2014;100(2):100-5. 
 Sen I, Agarwal S, Tharyan P, Forster R. Lumbar sympathectomy versus prostanoids for 
critical limb ischaemia due to non-reconstructable peripheral arterial disease. The Cochrane 
database of systematic reviews. 2018;4:CD009366. 
 Serrano Hernando FJ, Martin Conejero A. Peripheral artery disease: pathophysiology, 
diagnosis and treatment. Revista espanola de cardiologia. 2007;60(9):969-82. 
 Sethi SS, Lee MS. Drug-Coated Balloons for Infrainguinal Peripheral Artery Disease. 
The Journal of invasive cardiology. 2016;28(7):281-6. 
 Sfyri P, Matsakas A. Crossroads between peripheral atherosclerosis, western-type diet 
and skeletal muscle pathophysiology: emphasis on apolipoprotein E deficiency and peripheral 
arterial disease. Journal of biomedical science. 2017;24(1):42. 
 Shabani Varaki E, Gargiulo GD, Penkala S, Breen PP. Peripheral vascular disease 
assessment in the lower limb: a review of current and emerging non-invasive diagnostic 
methods. Biomedical engineering online. 2018;17(1):61. 
 Shah DJ, Brown B, Kim RJ, Grizzard JD. Magnetic resonance evaluation of peripheral 
arterial disease. Cardiology clinics. 2007;25(1):185-212, vii. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            376 
 Shah S, Antoniou GA, Torella F. Evidence-based analysis of peripheral arterial disease 
screening based on the WHO criteria. International angiology : a journal of the International 
Union of Angiology. 2017;36(4):299-305. 
 Shammas NW. Epidemiology, classification, and modifiable risk factors of peripheral 
arterial disease. Vascular health and risk management. 2007;3(2):229-34. 
 Shamoun F, Sural N, Abela G. Peripheral artery disease: therapeutic advances. Expert 
review of cardiovascular therapy. 2008;6(4):539-53. 
 Shamoun FE, Fankhauser GT, Mookadam M. Vascular medicine: aortic and peripheral 
arterial disease. Primary care. 2013;40(1):169-77. 
 Shanmugasundaram M, Murugapandian S, Truong HT, Lotun K, Banerjee S. Drug-
coated balloon in peripheral artery disease. Cardiovascular revascularization medicine : 
including molecular interventions. 2019;20(4):338-43. 
 Shanmugasundaram M, Ram VK, Luft UC, Szerlip M, Alpert JS. Peripheral arterial 
disease--what do we need to know? Clinical cardiology. 2011;34(8):478-82. 
 Sharma AM, Norton PT, Zhu D. Conditions presenting with symptoms of peripheral 
arterial disease. Seminars in interventional radiology. 2014;31(4):281-91. 
 Sheldon RD, Roseguini BT, Laughlin MH, Newcomer SC. New insights into the 
physiologic basis for intermittent pneumatic limb compression asa therapeutic strategy for 
peripheral artery disease. Journal of vascular surgery. 2013;58(6):1688-96. 
 Shen R, Wiegers SE, Glaser R. The evaluation of cardiac and peripheral arterial disease 
in patients with diabetes mellitus. Endocrine research. 2007;32(3):109-42. 
 Sherman W, Mazouz C, Deans R, Patel AN. Commercialization of trials for peripheral 
artery disease. Cytotherapy. 2011;13(10):1157-61. 
 Shimamura M, Nakagami H, Koriyama H, Morishita R. Gene therapy and cell-based 
therapies for therapeutic angiogenesis in peripheral artery disease. BioMed research 
international. 2013;2013:186215. 
 Shimamura M, Nakagami H, Taniyama Y, Morishita R. Gene therapy for peripheral 
arterial disease. Expert opinion on biological therapy. 2014;14(8):1175-84. 
 Sibley RC, 3rd, Reis SP, MacFarlane JJ, Reddick MA, Kalva SP, Sutphin PD. 
Noninvasive Physiologic Vascular Studies: A Guide to Diagnosing Peripheral Arterial Disease. 
Radiographics : a review publication of the Radiological Society of North America, Inc. 
2017;37(1):346-57. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            377 
 Sieggreen M. A contemporary approach to peripheral arterial disease. The Nurse 
practitioner. 2006;31(7):14-8, 23-5; quiz 6-7. 
 Signorelli SS, Anzaldi M, Fiore V. Inflammation in peripheral arterial disease (PAD). 
Current pharmaceutical design. 2012;18(28):4350-7. 
 Signorelli SS, Fiore V, Malaponte G. Inflammation and peripheral arterial disease: the 
value of circulating biomarkers (Review). International journal of molecular medicine. 
2014;33(4):777-83. 
 Signorelli SS, Katsiki N. Oxidative Stress and Inflammation: Their Role in the 
Pathogenesis of Peripheral Artery Disease with or Without Type 2 Diabetes Mellitus. Current 
vascular pharmacology. 2018;16(6):547-54. 
 Signorelli SS, Mazzarino MC, Spandidos DA, Malaponte G. Proinflammatory circulating 
molecules in peripheral arterial disease. International journal of molecular medicine. 
2007;20(3):279-86. 
 Signorelli SS. How to Treat Patients with Essential Hypertension and Peripheral Arterial 
Disease. Current pharmaceutical design. 2017;23(31):4598-602. 
 Sigvant B, Lundin F, Wahlberg E. The Risk of Disease Progression in Peripheral Arterial 
Disease is Higher than Expected: A Meta-Analysis of Mortality and Disease Progression in 
Peripheral Arterial Disease. European journal of vascular and endovascular surgery : the official 
journal of the European Society for Vascular Surgery. 2016;51(3):395-403. 
 Sillesen H, Falk E. Peripheral artery disease (PAD) screening in the asymptomatic 
population: why, how, and who? Current atherosclerosis reports. 2011;13(5):390-5. 
 Simmons A, Steffen K, Sanders S. Medical therapy for peripheral arterial disease. 
Current opinion in cardiology. 2012;27(6):592-7. 
 Simmons A, Steffen K. Peripheral arterial disease in women. Reviews in cardiovascular 
medicine. 2011;12(3):123-31. 
 Singer DRJ, Kite A. Management of hypertension in peripheral arterial disease: does the 
choice of drugs matter? European journal of vascular and endovascular surgery : the official 
journal of the European Society for Vascular Surgery. 2008;35(6):701-8. 
 Singh KP, Patel MR, Kandzari DE, Zidar JP. Peripheral arterial disease: an overview of 
endovascular therapies and contemporary treatment strategies. Reviews in cardiovascular 
medicine. 2006;7(2):55-68. 
 Singh TP, Morris DR, Smith S, Moxon JV, Golledge J. Systematic Review and Meta-
Analysis of the Association Between C-Reactive Protein and Major Cardiovascular Events in 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            378 
Patients with Peripheral Artery Disease. European journal of vascular and endovascular surgery : 
the official journal of the European Society for Vascular Surgery. 2017;54(2):220-33. 
 Sirico G, Spadera L, De Laurentis M, Brevetti G. Carotid artery disease and stroke in 
patients with peripheral arterial disease. The role of inflammation. Monaldi archives for chest 
disease = Archivio Monaldi per le malattie del torace. 2009;72(1):10-7. 
 Smadja D, Silvestre JS, Levy BI. Genic and cellular therapy for peripheral arterial 
diseases. Transfusion clinique et biologique : journal de la Societe francaise de transfusion 
sanguine. 2013;20(2):211-20. 
 Smith L. Identifying and managing peripheral arterial disease. Nursing times. 
2012;108(43):12-4. 
 Smolderen KG, Gosch K, Patel M, Jones WS, Hirsch AT, Beltrame J, et al. PORTRAIT 
(Patient-Centered Outcomes Related to Treatment Practices in Peripheral Arterial Disease: 
Investigating Trajectories): Overview of Design and Rationale of an International Prospective 
Peripheral Arterial Disease Study. Circulation Cardiovascular quality and outcomes. 
2018;11(2):e003860. 
 Sneider EB, Nowicki PT, Messina LM. Regenerative medicine in the treatment of 
peripheral arterial disease. Journal of cellular biochemistry. 2009;108(4):753-61. 
 Sobieszczyk P, Eisenhauer A. Management of patients after endovascular interventions 
for peripheral artery disease. Circulation. 2013;128(7):749-57. 
 Sontheimer DL. Peripheral vascular disease: diagnosis and treatment. American family 
physician. 2006;73(11):1971-6. 
 Sorensen J, Wilks SA, Jacob AD, Huynh TTT. Screening for peripheral artery disease. 
Seminars in roentgenology. 2015;50(2):139-47. 
 Sotoda Y, Hirooka S, Orita H, Wakabayashi I. Recent Knowledge of Smoking and 
Peripheral Arterial Disease in Lower Extremities. Nihon eiseigaku zasshi Japanese journal of 
hygiene. 2015;70(3):211-9. 
 Spiliopoulos S, Pastromas G. Current status of high on-treatment platelet reactivity in 
patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical 
implications. World journal of cardiology. 2015;7(12):912-21. 
 Squires H, Simpson E, Meng Y, Harnan S, Stevens J, Wong R, et al. A systematic review 
and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol 
nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. 
Health technology assessment (Winchester, England). 2011;15(40):1-210. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            379 
 Srivaratharajah K, Abramson BL. Women and Peripheral Arterial Disease: A Review of 
Sex Differences in Epidemiology, Clinical Manifestations, and Outcomes. The Canadian journal 
of cardiology. 2018;34(4):356-61. 
 Stacy MR, Sinusas AJ. Novel Applications of Radionuclide Imaging in Peripheral 
Vascular Disease. Cardiology clinics. 2016;34(1):167-77. 
 Stacy MR, Zhou W, Sinusas AJ. Radiotracer imaging of peripheral vascular disease. 
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 
2013;54(12):2104-10. 
 Stacy MR, Zhou W, Sinusas AJ. Radiotracer Imaging of Peripheral Vascular Disease. 
Journal of nuclear medicine technology. 2015;43(3):185-92. 
 Stehouwer CDA, Clement D, Davidson C, Diehm C, Elte JW, Lambert M, et al. 
Peripheral arterial disease: a growing problem for the internist. European journal of internal 
medicine. 2009;20(2):132-8. 
 Stephan D, Cordeanu E-M, Mirea C, Faller A, Lejay A, Gaertner S. Place of non-vitamin 
K antagonist oral anticoagulants in anticoagulant-antiplatelet combinations in peripheral artery 
disease. Archives of cardiovascular diseases. 2016;109(11):634-40. 
 Steven S, Daiber A, Dopheide JF, Munzel T, Espinola-Klein C. Peripheral artery disease, 
redox signaling, oxidative stress - Basic and clinical aspects. Redox biology. 2017;12:787-97. 
 Stoica A, Ginghina C. Cardiovascular risk in patients with peripheral vascular diseases. 
Romanian journal of internal medicine = Revue roumaine de medecine interne. 2008;46(4):275-
83. 
 Stone AJ, Kaufman MP. The exercise pressor reflex and peripheral artery disease. 
Autonomic neuroscience : basic & clinical. 2015;188:69-73. 
 Stone PA, Yacoub M. Inflammatory biomarkers in peripheral arterial disease. Seminars 
in vascular surgery. 2014;27(3-4):148-51. 
 Stoner MC, Calligaro KD, Chaer RA, Dietzek AM, Farber A, Guzman RJ, et al. 
Reporting standards of the Society for Vascular Surgery for endovascular treatment of chronic 
lower extremity peripheral artery disease. Journal of vascular surgery. 2016;64(1):e1-e21. 
 Stoner MC, Calligaro KD, Chaer RA, Dietzek AM, Farber A, Guzman RJ, et al. 
Reporting standards of the Society for Vascular Surgery for endovascular treatment of chronic 
lower extremity peripheral artery disease: Executive summary. Journal of vascular surgery. 
2016;64(1):227-8. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            380 
 Suades R, Cosentino F, Badimon L. Glucose-lowering treatment in cardiovascular and 
peripheral artery disease. Current opinion in pharmacology. 2018;39:86-98. 
 Sumpio BE, Forsythe RO, Ziegler KR, van Baal JG, Lepantalo MJA, Hinchliffe RJ. 
Clinical implications of the angiosome model in peripheral vascular disease. Journal of vascular 
surgery. 2013;58(3):814-26. 
 Sun Z. Diagnostic accuracy of multislice CT angiography in peripheral arterial disease. 
Journal of vascular and interventional radiology : JVIR. 2006;17(12):1915-21. 
 Suzuki H, Iso Y. Clinical application of vascular regenerative therapy for peripheral 
artery disease. BioMed research international. 2013;2013:179730. 
 Suzuki J-I, Shimamura M, Suda H, Wakayama K, Kumagai H, Ikeda Y, et al. Current 
therapies and investigational drugs for peripheral arterial disease. Hypertension research : official 
journal of the Japanese Society of Hypertension. 2016;39(4):183-91. 
 Swaminathan A, Vemulapalli S, Patel MR, Jones WS. Lower extremity amputation in 
peripheral artery disease: improving patient outcomes. Vascular health and risk management. 
2014;10:417-24. 
 Szafirska M, Urbanik A, Herman-Sucharska I, Nardzewska-Szczepanik M, Dubis A. 
Three-dimentiolanl moving-table MR angiography in diagnostic of peripheral arteria diseases. 
Przeglad lekarski. 2010;67(4):330-6. 
 Takagi H, Umemoto T, Group A. Association of chronic obstructive pulmonary, 
coronary artery, or peripheral artery disease with abdominal aortic aneurysm rupture. 
International angiology : a journal of the International Union of Angiology. 2017;36(4):322-31. 
 Takagi H, Umemoto T, Group A. Association of peripheral artery disease with abdominal 
aortic aneurysm growth. Journal of vascular surgery. 2016;64(2):506-13. 
 Takagi H, Umemoto T. Associations of coronary and peripheral artery disease with 
presence, expansion, and rupture of abdominal aortic aneurysm - a grin without a cat! VASA 
Zeitschrift fur Gefasskrankheiten. 2017;46(3):151-8. 
 Tamura K, Tsurumi-Ikeya Y, Wakui H, Maeda A, Ohsawa M, Azushima K, et al. 
Therapeutic potential of low-density lipoprotein apheresis in the management of peripheral 
artery disease in patients with chronic kidney disease. Therapeutic apheresis and dialysis : 
official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for 
Apheresis, the Japanese Society for Dialysis Therapy. 2013;17(2):185-92. 
 Tan JWC, Yeo KK, Laird JR. Excimer laser assisted angioplasty for complex 
infrainguinal peripheral artery disease: a 2008 update. The Journal of cardiovascular surgery. 
2008;49(3):329-40. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            381 
 Tanaka M, Taketomi K, Yonemitsu Y. Therapeutic angiogenesis: recent and future 
prospects of gene therapy in peripheral artery disease. Current gene therapy. 2014;14(4):300-8. 
 Tanaka R, Yoshioka K, Takagi H, Schuijf JD, Arakita K. Novel developments in non-
invasive imaging of peripheral arterial disease with CT: experience with state-of-the-art, ultra-
high-resolution CT and subtraction imaging. Clinical radiology. 2019;74(1):51-8. 
 Tang GL, Chin J, Kibbe MR. Advances in diagnostic imaging for peripheral arterial 
disease. Expert review of cardiovascular therapy. 2010;8(10):1447-55. 
 Tatsumi T, Matsubara H. Therapeutic angiogenesis for peripheral arterial disease and 
ischemic heart disease by autologous bone marrow cells implantation. Nihon rinsho Japanese 
journal of clinical medicine. 2006;64(11):2126-34. 
 Tattersall MC, Johnson HM, Mason PJ. Contemporary and optimal medical management 
of peripheral arterial disease. The Surgical clinics of North America. 2013;93(4):761-78, vii. 
 Tehan PE, Santos D, Chuter VH. A systematic review of the sensitivity and specificity of 
the toe-brachial index for detecting peripheral artery disease. Vascular medicine (London, 
England). 2016;21(4):382-9. 
 Teodorescu VJ, Vavra AK, Kibbe MR. Peripheral arterial disease in women. Journal of 
vascular surgery. 2013;57(4 Suppl):18S-26S. 
 Tew GA, Brabyn S, Cook L, Peckham E. The Completeness of Intervention Descriptions 
in Randomised Trials of Supervised Exercise Training in Peripheral Arterial Disease. PloS one. 
2016;11(3):e0150869. 
 Thiruvoipati T, Kielhorn CE, Armstrong EJ. Peripheral artery disease in patients with 
diabetes: Epidemiology, mechanisms, and outcomes. World journal of diabetes. 2015;6(7):961-9. 
 Thomas JC, Vohra RS, Beer S, Bhatti K, Ponnambalam S, Homer-Vanniasinkam S. 
Biomarkers in peripheral arterial disease. Trends in cardiovascular medicine. 2009;19(5):147-51. 
 Thorud JC, Plemmons B, Buckley CJ, Shibuya N, Jupiter DC. Mortality After 
Nontraumatic Major Amputation Among Patients WithDiabetes and Peripheral Vascular 
Disease: A Systematic Review. The Journal of foot and ankle surgery : official publication of the 
American College of Foot and Ankle Surgeons. 2016;55(3):591-9. 
 Thukkani AK, Kinlay S. Endovascular intervention for peripheral artery disease. 
Circulation research. 2015;116(9):1599-613. 
 Tickner A, Klinghard C, Arnold JF, Marmolejo V. Total Contact Cast Use in Patients 
With Peripheral Arterial Disease: A Case Series and Systematic Review. Wounds : a 
compendium of clinical research and practice. 2018;30(2):49-56. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            382 
 Tirziu C, Badila E, Mehic F, Ghiorghe S, Bartos D. The management of patients with 
peripheral arterial disease and intermittent claudication. Actual recommendations. Romanian 
journal of internal medicine = Revue roumaine de medecine interne. 2010;48(3):223-32. 
 Torii S, Kolodgie FD, Virmani R, Finn AV. IN.PACT Admiral drug-coated balloons in 
peripheral artery disease: current perspectives. Medical devices (Auckland, NZ). 2019;12:53-64. 
 Tracey WR, Knight DR. Treatment of peripheral artery disease: an unmet medical need. 
Current opinion in investigational drugs (London, England : 2000). 2009;10(9):899-901. 
 Troidl K, Schaper W. Arteriogenesis versus angiogenesis in peripheral artery disease. 
Diabetes/metabolism research and reviews. 2012;28 Suppl 1:27-9. 
 Tromp G, Kuivaniemi H. Developments in genomics to improve understanding, 
diagnosis and management of aneurysms and peripheral artery disease. European journal of 
vascular and endovascular surgery : the official journal of the European Society for Vascular 
Surgery. 2009;38(6):676-82. 
 Tsigkou V, Siasos G, Rovos K, Tripyla N, Tousoulis D. Peripheral artery disease and 
antiplatelet treatment. Current opinion in pharmacology. 2018;39:43-52. 
 Tsioufis C, Andrikou I, Siasos G, Filis K, Tousoulis D. Anti-hypertensive treatment in 
peripheral artery disease. Current opinion in pharmacology. 2018;39:35-42. 
 Tsui JC, Shi-Wen X. Endothelin-1 in peripheral arterial disease: a potential role in 
muscle damage. Pharmacological research. 2011;63(6):473-6. 
 Tu C, Das S, Baker AB, Zoldan J, Suggs LJ. Nanoscale strategies: treatment for 
peripheral vascular disease and critical limb ischemia. ACS nano. 2015;9(4):3436-52. 
 Tulsyan N, Ouriel K, Kashyap VS. Emerging drugs in peripheral arterial disease. Expert 
opinion on emerging drugs. 2006;11(1):75-90. 
 Tummala S, Scherbel D. Clinical Assessment of Peripheral Arterial Disease in the Office: 
What Do the Guidelines Say? Seminars in interventional radiology. 2018;35(5):365-77. 
 Ueta CB, Gomes KS, Ribeiro MA, Mochly-Rosen D, Ferreira JCB. Disruption of 
mitochondrial quality control in peripheral artery disease: New therapeutic opportunities. 
Pharmacological research. 2017;115:96-106. 
 Ungerleider JL, Christman KL. Concise review: injectable biomaterials for the treatment 
of myocardial infarction and peripheral artery disease: translational challenges and progress. 
Stem cells translational medicine. 2014;3(9):1090-9. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            383 
 Ungprasert P, Thongprayoon C, Kittanamongkolchai W, Srivali N, Cheungpasitporn W. 
Peripheral arterial disease in patients with giant cell arteritis: a meta-analysis. International 
journal of rheumatic diseases. 2016;19(8):819-25. 
 Urasawa K, Sato K, Koshida R, Honma Y. Endovascular therapy for peripheral arterial 
disease. Nihon rinsho Japanese journal of clinical medicine. 2011;69(2):318-21. 
 Vahl A, Elsman B, van Enst A. Diagnostics and treatment of lower extremity peripheral 
arterial disease; guideline and registry. Nederlands tijdschrift voor geneeskunde. 2016;160:D847. 
 Valdivielso P, Ramirez-Bollero J, Perez-Lopez C. Peripheral arterial disease, type 2 
diabetes and postprandial lipidaemia: Is there a link? World journal of diabetes. 2014;5(5):577-
85. 
 Valentine EA, Ochroch EA. 2016 American College of Cardiology/American Heart 
Association Guideline on the Management of Patients With Lower Extremity Peripheral Artery 
Disease: Perioperative Implications. Journal of cardiothoracic and vascular anesthesia. 
2017;31(5):1543-53. 
 van Aalst FM, Verwijmeren L, van Dongen EPA, de Vries J-PPM, de Groot E, Noordzij 
PG. Frailty and functional outcomes after open and endovascular procedures for patients with 
peripheral arterial disease: A systematic review. Journal of vascular surgery. 2019. 
 van den Hoven P, Ooms S, van Manen L, van der Bogt KEA, van Schaik J, Hamming JF, 
et al. A systematic review of the use of near-infrared fluorescence imaging in patients with 
peripheral artery disease. Journal of vascular surgery. 2019;70(1):286-97.e1. 
 van Haelst STW, Peeters Weem SMO, Moll FL, de Borst GJ. Current status and future 
perspectives of bioresorbable stents in peripheral arterial disease. Journal of vascular surgery. 
2016;64(4):1151-9.e1. 
 Varcoe RL. Combination therapy for complex peripheral artery disease: the evidence for 
combining mechanical revascularization with anti-restenotic drug delivery systems. The Journal 
of cardiovascular surgery. 2017;58(5):722-30. 
 Vardi M, Nini A. Near-infrared spectroscopy for evaluation of peripheral vascular 
disease. A systematic review of literature. European journal of vascular and endovascular 
surgery : the official journal of the European Society for Vascular Surgery. 2008;35(1):68-74. 
 Vartanian SM, Conte MS. Surgical intervention for peripheral arterial disease. 
Circulation research. 2015;116(9):1614-28. 
 Vavra AK, Kibbe MR. Women and peripheral arterial disease. Women's health (London, 
England). 2009;5(6):669-83. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            384 
 Vazquez F, Rodger M, Carrier M, Le Gal G, Reny JL, Sofi F, et al. Prothrombin 
G20210A mutation and lower extremity peripheral arterial disease: a systematic review and 
meta-analysis. European journal of vascular and endovascular surgery : the official journal of the 
European Society for Vascular Surgery. 2015;50(2):232-40. 
 Venkatachalam S, Shishehbor MH, Gray BH. Basic data related to endovascular 
management of peripheral arterial disease in critical limb ischemia. Annals of vascular surgery. 
2012;26(7):1039-51. 
 Verim S, Tasci I. Doppler ultrasonography in lower extremity peripheral arterial disease. 
Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir. 2013;41(3):248-
55. 
 Vertes A. Cardiovascular prevention with peripheral artery disease. Orvosi hetilap. 
2007;148(28):1303-9. 
 Violi F, Basili S, Berger JS, Hiatt WR. Antiplatelet therapy in peripheral artery disease. 
Handbook of experimental pharmacology. 2012(210):547-63. 
 Violi F, Hiatt W. A critical review of antiplatelet treatment in peripheral arterial disease. 
Internal and emergency medicine. 2007;2(2):84-7. 
 Violi F, Lip GYH, Basili S. Peripheral artery disease and atrial fibrillation: a potentially 
dangerous combination. Internal and emergency medicine. 2012;7(3):213-8. 
 Vita JA, Hamburg NM. Does endothelial dysfunction contribute to the clinical status of 
patients with peripheral arterial disease? The Canadian journal of cardiology. 2010;26 Suppl 
A:45A-50A. 
 Vitalis A, Lip GYH, Kay M, Vohra RK, Shantsila A. Ethnic differences in the prevalence 
of peripheral arterial disease: a systematic review and meta-analysis. Expert review of 
cardiovascular therapy. 2017;15(4):327-38. 
 Vlachopoulos C, Georgakopoulos C, Koutagiar I, Tousoulis D. Diagnostic modalities in 
peripheral artery disease. Current opinion in pharmacology. 2018;39:68-76. 
 Vogiatzi G, Oikonomou E, Deftereos S, Siasos G, Tousoulis D. Peripheral artery disease: 
a micro-RNA-related condition? Current opinion in pharmacology. 2018;39:105-12. 
 Vos CG, Vahl AC. Anticoagulation and antiplatelet therapy in patients with peripheral 
arterial disease of the femoropopliteal arteries. The Journal of cardiovascular surgery. 
2018;59(2):164-71. 
 Vries MH, Post MJ. Delivering therapeutics in peripheral artery disease: challenges and 
future perspectives. Therapeutic delivery. 2016;7(7):483-93. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            385 
 Vrsalovic M, Presecki AV. Atrial fibrillation and risk of cardiovascular events and 
mortality in patients with symptomatic peripheral artery disease: A meta-analysis of prospective 
studies. Clinical cardiology. 2017;40(12):1231-5. 
 Vrsalovic M, Vucur K, Vrsalovic Presecki A, Fabijanic D, Milosevic M. Impact of 
diabetes on mortality in peripheral artery disease: a meta-analysis. Clinical cardiology. 
2017;40(5):287-91. 
 Vyas MV, Mrkobrada M, Donner A, Hackam DG. Underrepresentation of peripheral 
artery disease in modern cardiovascular trials: systematic review and meta-analysis. International 
journal of cardiology. 2013;168(5):4875-6. 
 Wakabayashi I, Sotoda Y. Alcohol drinking and peripheral arterial disease of lower 
extremity. Nihon Arukoru Yakubutsu Igakkai zasshi = Japanese journal of alcohol studies & 
drug dependence. 2014;49(1):13-27. 
 Ward R, Long C, Patel MR, Jones WS. Antithrombotic therapy in peripheral artery 
disease: A review of the EUCLID trial results and current ongoing trials. Clinical cardiology. 
2018;41(1):137-43. 
 Watson K, Watson BD, Pater KS. Peripheral arterial disease: a review of disease 
awareness and management. The American journal of geriatric pharmacotherapy. 2006;4(4):365-
79. 
 Watts MM. Pharmacology of Peripheral Arterial Disease in the Angio Suite: What Every 
Interventionalist Should Know. Seminars in interventional radiology. 2018;35(5):393-8. 
 Wei B, Qian C, Fang Q, Wang Y. The Prognostic Value of Peripheral Artery Disease in 
Heart Failure: Insights from a Meta-analysis. Heart, lung & circulation. 2016;25(12):1195-202. 
 Weinberg MD, Lau JF, Rosenfield K, Olin JW. Peripheral artery disease. Part 2: medical 
and endovascular treatment. Nature reviews Cardiology. 2011;8(8):429-41. 
 Weiss N. A critical review on the use of lipid apheresis and rheopheresis for treatment of 
peripheral arterial disease and the diabetic foot syndrome. Seminars in dialysis. 2012;25(2):220-
7. 
 Weiss N. Lipid apheresis and rheopheresis for treatment of peripheral arterial disease. 
Atherosclerosis Supplements. 2009;10(5):62-9. 
 Welten GMJM, Schouten O, Chonchol M, Hoeks SE, Bax JJ, Van Domburg RT, et al. 
Prognosis of patients with peripheral arterial disease. The Journal of cardiovascular surgery. 
2009;50(1):109-21. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            386 
 Wen Y, Meng L, Gao Q. Autologous bone marrow cell therapy for patients with 
peripheral arterial disease: a meta-analysis of randomized controlled trials. Expert opinion on 
biological therapy. 2011;11(12):1581-9. 
 Wennberg PW. Approach to the patient with peripheral arterial disease. Circulation. 
2013;128(20):2241-50. 
 Werner M, Scheinert D. Drug eluting devices for critically ill patients: can we apply 
lessons learned from the treatment of peripheral artery disease? Advanced drug delivery reviews. 
2014;77:32-9. 
 Werner M. Angioplasty with drug coated balloons for the treatment of infrainguinal 
peripheral artery disease. VASA Zeitschrift fur Gefasskrankheiten. 2016;45(5):365-72. 
 Werth S, Halbritter K, Mahlmann A, Weiss N. Interventional treament of peripheral 
arterial disease and diabetic angiopathy. Deutsche medizinische Wochenschrift (1946). 
2011;136(40):1994-7. 
 Whayne TF, Mukherjee D. Increased Exercise Favorably Modifies Coronary Artery 
Disease and Peripheral Arterial Disease Outcomes. Current vascular pharmacology. 
2016;14(5):458-65. 
 Whayne TF. A review of the role of anticoagulation in the treatment of peripheral arterial 
disease. The International journal of angiology : official publication of the International College 
of Angiology, Inc. 2012;21(4):187-94. 
 White CJ, Gray WA. Endovascular therapies for peripheral arterial disease: an evidence-
based review. Circulation. 2007;116(19):2203-15. 
 Williams KJ, Babber A, Ravikumar R, Davies AH. Non-Invasive Management of 
Peripheral Arterial Disease. Advances in experimental medicine and biology. 2017;906:387-406. 
 Wilson JF, Laine C, Goldmann D. In the clinic. Peripheral arterial disease. Annals of 
internal medicine. 2007;146(5):ITC3-1-ITC3-16. 
 Wiltz-James LM, Foley J. Hospital Discharge Teaching for Patients with Peripheral 
Vascular Disease. Critical care nursing clinics of North America. 2019;31(1):91-5. 
 Wu C-C, Hung S-C, Kuo K-L, Tarng D-C. Impact of Indoxyl Sulfate on Progenitor Cell-
Related Neovascularization of Peripheral Arterial Disease and Post-Angioplasty Thrombosis of 
Dialysis Vascular Access. Toxins. 2017;9(1). 
 Wulff B, Jungbluth T, Esnaashari H, Franke C, Bruch HP. Surgical management of 
peripheral arterial disease. Operative methods and results. Der Radiologe. 2006;46(11):931-40. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            387 
 Xu J, Sachdev U. The Toll of Vascular Insufficiency: Implications for the Management 
of Peripheral Arterial Disease. Journal of immunology research. 2016;2016:8249015. 
 Yamagishi S-I, Matsui T. Role of Ligands of Receptor for Advanced Glycation End 
Products (RAGE) in Peripheral Artery Disease. Rejuvenation research. 2018;21(5):456-63. 
 Yan BP, Kiernan TJ, Lam YY, Yu CM. Current endovascular therapy for lower 
extremity peripheral arterial disease: indications, outcomes and modalities. Heart Asia. 
2009;1(1):51-7. 
 Yan J, Tie G, Xu TY, Cecchini K, Messina LM. Mesenchymal stem cells as a treatment 
for peripheral arterial disease: current status and potential impact of type II diabetes on their 
therapeutic efficacy. Stem cell reviews. 2013;9(3):360-72. 
 Yang S-L, Zhu L-Y, Han R, Sun L-L, Li J-X, Dou J-T. Pathophysiology of peripheral 
arterial disease in diabetes mellitus. Journal of diabetes. 2017;9(2):133-40. 
 Yevzlin AS, Gimelli G. Diagnosis and treatment of peripheral arterial disease in CKD 
patients. Seminars in dialysis. 2013;26(2):240-51. 
 Yin L, Han Q, Li X, Liu Z. Advances in research on the genetics of peripheral arterial 
disease. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese 
journal of medical genetics. 2015;32(6):890-3. 
 Yokoi H. Atherosclerosis: progress in diagnosis and treatments. Topics: IV. Progress in 
treatments of atherosclerosis; 5. Current management for patient with peripheral artery disease. 
Nihon Naika Gakkai zasshi The Journal of the Japanese Society of Internal Medicine. 
2013;102(2):392-8. 
 Yokoi Y. Global vascular intervention for peripheral vascular disease: endovascular 
integrated approach and future trend. Nihon rinsho Japanese journal of clinical medicine. 
2011;69(2):295-300. 
 Ypsilantis E, Tang TY. Pre-emptive analgesia for chronic limb pain after amputation for 
peripheral vascular disease: a systematic review. Annals of vascular surgery. 2010;24(8):1139-
46. 
 Zagidullin NS, Valeeva KF, Zagidullin SZ, Rezbaeva AG. Possibilities of the use 
Angiotensin converting enzyme inhibitor in peripheral arterial disease. Kardiologiia. 
2010;50(4):92-6. 
 Zakari M, Alsahly M, Koch LG, Britton SL, Katwa LC, Lust RM. Are There Limitations 
to Exercise Benefits in Peripheral Arterial Disease? Frontiers in cardiovascular medicine. 
2018;5:173. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            388 
 Zeller T, Rastan A, Macharzina R, Beschorner U, Noory E. Novel Approaches to the 
Management of Advanced Peripheral Artery Disease: Perspectives on Drug-Coated Balloons, 
Drug-Eluting Stents, and Bioresorbable Scaffolds. Current cardiology reports. 2015;17(9):624. 
 Zeller T, Sixt S, Rastan A. New techniques for endovascular treatment of peripheral 
artery disease with focus on chronic critical limb ischemia. VASA Zeitschrift fur 
Gefasskrankheiten. 2009;38(1):3-12. 
 Zhang Q, Li Y, Wu Z. Research advance of gene therapy for peripheral arterial disease 
using hepatocyte growth factor. Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu 
chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery. 
2006;20(11):1147-50. 
 Zhou B, Poon MC, Pu WT, Han ZC. Therapeutic neovascularization for peripheral 
arterial diseases: advances and perspectives. Histology and histopathology. 2007;22(6):677-86. 
 Zhou X, Yuan P, He Y. Role of microRNAs in peripheral artery disease (review). 
Molecular medicine reports. 2012;6(4):695-700. 
 8B2.  PN Reviews Bibliography 
 Adams D, Cauquil C, Lozeron P. Autonomic peripheral neuropathy. Presse medicale 
(Paris, France : 1983). 2012;41(11):1128-36. 
 Addington J, Freimer M. Chemotherapy-induced peripheral neuropathy: an update on the 
current understanding. F1000Research. 2016;5. 
 Ahmed MA, Muntingh GL, Rheeder P. Perspectives on Peripheral Neuropathy as a 
Consequence of Metformin-Induced Vitamin B12 Deficiency in T2DM. International journal of 
endocrinology. 2017;2017:2452853. 
 Al-Atiyyat N, Obaid A. Management of peripheral neuropathy induced by chemotherapy 
in adults with cancer: a review. International journal of palliative nursing. 2017;23(1):13-7. 
 Alberti P, Cavaletti G. Management of side effects in the personalized medicine era: 
chemotherapy-induced peripheral neuropathy. Methods in molecular biology (Clifton, NJ). 
2014;1175:301-22. 
 Alleman CJM, Westerhout KY, Hensen M, Chambers C, Stoker M, Long S, et al. 
Humanistic and economic burden of painful diabetic peripheral neuropathy in Europe: A review 
of the literature. Diabetes research and clinical practice. 2015;109(2):215-25. 
 Alport AR, Sander HW. Clinical approach to peripheral neuropathy: anatomic 
localization and diagnostic testing. Continuum (Minneapolis, Minn). 2012;18(1):13-38. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            389 
 Amara S. Oral glutamine for the prevention of chemotherapy-induced peripheral 
neuropathy. The Annals of pharmacotherapy. 2008;42(10):1481-5. 
 Anastasi JK, Capili B, Chang M. HIV peripheral neuropathy and foot care management: 
a review of assessment and relevant guidelines. The American journal of nursing. 
2013;113(12):34-40; quiz 1. 
 Ang CD, Alviar MJM, Dans AL, Bautista-Velez GGP, Villaruz-Sulit MVC, Tan JJ, et al. 
Vitamin B for treating peripheral neuropathy. The Cochrane database of systematic reviews. 
2008(3):CD004573. 
 Antonio-Valdiviezo A, Pena-Santos G, Martinez-Torres J. Peripheral neuropathy caused 
by leflunomide. A case reported with a brief review. Revista medica del Instituto Mexicano del 
Seguro Social. 2010;48(5):567-70. 
 Areti A, Yerra VG, Naidu V, Kumar A. Oxidative stress and nerve damage: role in 
chemotherapy induced peripheral neuropathy. Redox biology. 2014;2:289-95. 
 Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in 
multiple myeloma: a comprehensive review of the literature. Blood. 2008;112(5):1593-9. 
 Argyriou AA, Kyritsis AP, Makatsoris T, Kalofonos HP. Chemotherapy-induced 
peripheral neuropathy in adults: a comprehensive update of the literature. Cancer management 
and research. 2014;6:135-47. 
 Argyriou AA, Marmiroli P, Cavaletti G, Kalofonos HP. Epothilone-induced peripheral 
neuropathy: a review of current knowledge. Journal of pain and symptom management. 
2011;42(6):931-40. 
 Argyriou AA, Zolota V, Kyriakopoulou O, Kalofonos HP. Toxic peripheral neuropathy 
associated with commonly used chemotherapeutic agents. Journal of BUON : official journal of 
the Balkan Union of Oncology. 2010;15(3):435-46. 
 Ariga T. The role of sulfoglucuronosyl glycosphingolipids in the pathogenesis of 
monoclonal IgM paraproteinemia and peripheral neuropathy. Proceedings of the Japan Academy 
Series B, Physical and biological sciences. 2011;87(7):386-404. 
 Arnold ML. Steering Peripheral Neuropathy Workup. Physical medicine and 
rehabilitation clinics of North America. 2018;29(4):761-76. 
 Ashwin DP, Chandan GD, Jasleen HK, Rajkumar GC, Rudresh KB, Prashanth R. 
Hereditary sensory and autosomal peripheral neuropathy-type IV: case series and review of 
literature. Oral and maxillofacial surgery. 2015;19(2):117-23. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            390 
 Aziz MT, Good BL, Lowe DK. Serotonin-norepinephrine reuptake inhibitors for the 
management of chemotherapy-induced peripheral neuropathy. The Annals of pharmacotherapy. 
2014;48(5):626-32. 
 Bakogeorgos M, Georgoulias V. Risk-reduction and treatment of chemotherapy-induced 
peripheral neuropathy. Expert review of anticancer therapy. 2017;17(11):1045-60. 
 Bales JG, Meals R. Peripheral neuropathy of the upper extremity: medical comorbidity 
that confounds common orthopedic pathology. Orthopedics. 2009;32(10):758. 
 Baloh RH. Mitochondrial dynamics and peripheral neuropathy. The Neuroscientist : a 
review journal bringing neurobiology, neurology and psychiatry. 2008;14(1):12-8. 
 Barrell K, Smith AG. Peripheral Neuropathy. The Medical clinics of North America. 
2019;103(2):383-97. 
 Beijers AJM, Mols F, Vreugdenhil G. A systematic review on chronic oxaliplatin-
induced peripheral neuropathy and the relation with oxaliplatin administration. Supportive care 
in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 
2014;22(7):1999-2007. 
 Bennett GJ. Pathophysiology and animal models of cancer-related painful peripheral 
neuropathy. The oncologist. 2010;15 Suppl 2:9-12. 
 Benstead TJ, Chalk CH, Parks NE. Treatment for cryoglobulinemic and non-
cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection. The 
Cochrane database of systematic reviews. 2014(12):CD010404. 
 Beran R. Paraesthesia and peripheral neuropathy. Australian family physician. 
2015;44(3):92-5. 
 Berkowitz AL, Samuels MA. The neurology of Sjogren's syndrome and the 
rheumatology of peripheral neuropathy and myelitis. Practical neurology. 2014;14(1):14-22. 
 Bjornard KL, Gilchrist LS, Inaba H, Diouf B, Hockenberry MJ, Kadan-Lottick NS, et al. 
Peripheral neuropathy in children and adolescents treated for cancer. The Lancet Child & 
adolescent health. 2018;2(10):744-54. 
 Bo C, Xue Z, Yi G, Zelin C, Yang B, Zixu W, et al. Assessing the quality of reports 
about randomized controlled trials of acupuncture treatment on Diabetic Peripheral Neuropathy. 
PloS one. 2012;7(7):e38461. 
 Bobylev I, Elter T, Schneider C, Wunderlich G, Zimmer P, Streckmann F, et al. 
Chemotherapy-induced Peripheral Neuropathy. Fortschritte der Neurologie-Psychiatrie. 
2015;83(8):427-36. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            391 
 Bonnet CT, Ray C. Peripheral neuropathy may not be the only fundamental reason 
explaining increased sway in diabetic individuals. Clinical biomechanics (Bristol, Avon). 
2011;26(7):699-706. 
 Brabb T, Carbone L, Snyder J, Phillips N. Institutional animal care and use committee 
considerations for animal models of peripheral neuropathy. ILAR journal. 2014;54(3):329-37. 
 Brami C, Bao T, Deng G. Natural products and complementary therapies for 
chemotherapy-induced peripheral neuropathy: A systematic review. Critical reviews in 
oncology/hematology. 2016;98:325-34. 
 Brannagan TH, 3rd. Current issues in peripheral neuropathy. Journal of the peripheral 
nervous system : JPNS. 2012;17 Suppl 2:1-3. 
 Bredfeldt C, Altschuler A, Adams AS, Portz JD, Bayliss EA. Patient reported outcomes 
for diabetic peripheral neuropathy. Journal of diabetes and its complications. 2015;29(8):1112-8. 
 Brewer JR, Morrison G, Dolan ME, Fleming GF. Chemotherapy-induced peripheral 
neuropathy: Current status and progress. Gynecologic oncology. 2016;140(1):176-83. 
 Bridges CM, Smith EML. What about Alice? Peripheral neuropathy from taxane-
containing treatment for advanced nonsmall cell lung cancer. Supportive care in cancer : official 
journal of the Multinational Association of Supportive Care in Cancer. 2014;22(9):2581-92. 
 Broyl A, Jongen JLM, Sonneveld P. General aspects and mechanisms of peripheral 
neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma. 
Seminars in hematology. 2012;49(3):249-57. 
 Buetti B, Luxon LM. Vestibular involvement in peripheral neuropathy: a review. 
International journal of audiology. 2014;53(6):353-9. 
 Burns JM, Mauermann ML, Burns TM. An easy approach to evaluating peripheral 
neuropathy. The Journal of family practice. 2006;55(10):853-61. 
 Cakici N, Fakkel TM, van Neck JW, Verhagen AP, Coert JH. Systematic review of 
treatments for diabetic peripheral neuropathy. Diabetic medicine : a journal of the British 
Diabetic Association. 2016;33(11):1466-76. 
 Callaghan BC, Price RS, Chen KS, Feldman EL. The Importance of Rare Subtypes in 
Diagnosis and Treatment of Peripheral Neuropathy: A Review. JAMA neurology. 
2015;72(12):1510-8. 
 Campbell G, Skubic MA. Balance and Gait Impairment: Sensor-Based Assessment for 
Patients With Peripheral Neuropathy. Clinical journal of oncology nursing. 2018;22(3):316-25. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            392 
 Canta A, Pozzi E, Carozzi VA. Mitochondrial Dysfunction in Chemotherapy-Induced 
Peripheral Neuropathy (CIPN). Toxics. 2015;3(2):198-223. 
 Carlson K, Ocean AJ. Peripheral neuropathy with microtubule-targeting agents: 
occurrence and management approach. Clinical breast cancer. 2011;11(2):73-81. 
 Carozzi VA, Canta A, Chiorazzi A. Chemotherapy-induced peripheral neuropathy: What 
do we know about mechanisms? Neuroscience letters. 2015;596:90-107. 
 Carrato MR, Coluccia A, Borracci P, Fasano A, Riccio P, Cuomo V. Smoking during 
pregnancy: a risk factor for peripheral neuropathy? Developmental neuroscience. 
2008;30(4):224-30. 
 Carter GT. Rehabilitation management of peripheral neuropathy. Seminars in neurology. 
2005;25(2):229-37. 
 Carvalho LF, Silva AMF, Carvalho AA. The use of antioxidant agents for chemotherapy-
induced peripheral neuropathy treatment in animal models. Clinical and experimental 
pharmacology & physiology. 2017;44(10):971-9. 
 Cascella M, Muzio MR. Potential application of the Kampo medicine goshajinkigan for 
prevention of chemotherapy-induced peripheral neuropathy. Journal of integrative medicine. 
2017;15(2):77-87. 
 Castano A, Bokhari S, Brannagan TH, 3rd, Wynn J, Maurer MS. Technetium 
pyrophosphate myocardial uptake and peripheral neuropathy in a rare variant of familial 
transthyretin (TTR) amyloidosis (Ser23Asn): a case report and literature review. Amyloid : the 
international journal of experimental and clinical investigation : the official journal of the 
International Society of Amyloidosis. 2012;19(1):41-6. 
 Cata JP, Weng HR, Lee BN, Reuben JM, Dougherty PM. Clinical and experimental 
findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva 
anestesiologica. 2006;72(3):151-69. 
 Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of 
multiple myeloma: a review of recent studies. Leukemia & lymphoma. 2010;51(7):1178-87. 
 Chan A, Hertz DL, Morales M, Adams EJ, Gordon S, Tan CJ, et al. Biological predictors 
of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications 
working group overview. Supportive care in cancer : official journal of the Multinational 
Association of Supportive Care in Cancer. 2019. 
 Chaudhry HM, Mauermann ML, Rajkumar SV. Monoclonal Gammopathy-Associated 
Peripheral Neuropathy: Diagnosis and Management. Mayo Clinic proceedings. 2017;92(5):838-
50. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            393 
 Chaudhry V, Russell J, Belzberg A. Decompressive surgery of lower limbs for 
symmetrical diabetic peripheral neuropathy. The Cochrane database of systematic reviews. 
2008(3):CD006152. 
 Chen W, Luo Y-F, Liu J-P. Topical herbal medicine for treatment of diabetic peripheral 
neuropathy: a systematic review of randomized controlled trials. Forschende 
Komplementarmedizin (2006). 2011;18(3):134-45. 
 Chen W, Yang G-Y, Liu B, Manheimer E, Liu J-P. Manual acupuncture for treatment of 
diabetic peripheral neuropathy: a systematic review of randomized controlled trials. PloS one. 
2013;8(9):e73764. 
 Chen W, Zhang Y, Li X, Yang G, Liu JP. Chinese herbal medicine for diabetic peripheral 
neuropathy. The Cochrane database of systematic reviews. 2013(10):CD007796. 
 Chen W, Zhang Y, Liu JP. Chinese herbal medicine for diabetic peripheral neuropathy. 
The Cochrane database of systematic reviews. 2011(6):CD007796. 
 Chiang M-C, Tseng M-T, Pan C-L, Chao C-C, Hsieh S-T. Progress in the treatment of 
small fiber peripheral neuropathy. Expert review of neurotherapeutics. 2015;15(3):305-13. 
 Chowdhury D, Patel N. Approach to a case of autonomic peripheral neuropathy. The 
Journal of the Association of Physicians of India. 2006;54:727-32. 
 Chu SH, Lee YJ, Lee ES, Geng Y, Wang XS, Cleeland CS. Current use of drugs 
affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer 
patients: a systematic review. Supportive care in cancer : official journal of the Multinational 
Association of Supportive Care in Cancer. 2015;23(2):513-24. 
 Chu SH, Lee YJ, Lee YJ, Cleeland CS. Properties of the Measures to Assess Oxaliplatin-
induced Peripheral Neuropathy: A Literature Review. Journal of Korean Academy of Nursing. 
2015;45(6):783-801. 
 Chung T, Prasad K, Lloyd TE. Peripheral neuropathy: clinical and electrophysiological 
considerations. Neuroimaging clinics of North America. 2014;24(1):49-65. 
 Cioroiu C, Weimer LH. Update on Chemotherapy-Induced Peripheral Neuropathy. 
Current neurology and neuroscience reports. 2017;17(6):47. 
 Clair C, Cohen MJ, Eichler F, Selby KJ, Rigotti NA. The Effect of Cigarette Smoking on 
Diabetic Peripheral Neuropathy: A Systematic Review and Meta-Analysis. Journal of general 
internal medicine. 2015;30(8):1193-203. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            394 
 Cliff J, Jorgensen AL, Lord R, Azam F, Cossar L, Carr DF, et al. The molecular genetics 
of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Critical 
reviews in oncology/hematology. 2017;120:127-40. 
 Costantino M, Guaraldi C, Costantino D, De Grazia S, Unfer V. Peripheral neuropathy in 
obstetrics: efficacy and safety of alpha-lipoic acid supplementation. European review for medical 
and pharmacological sciences. 2014;18(18):2766-71. 
 Cox AA, Sagot Y, Hedou G, Grek C, Wilkes T, Vinik AI, et al. Low-Dose Pulsatile 
Interleukin-6 As a Treatment Option for Diabetic Peripheral Neuropathy. Frontiers in 
endocrinology. 2017;8:89. 
 Cundari S, Cavaletti G. Thalidomide chemotherapy-induced peripheral neuropathy: 
actual status and new perspectives with thalidomide analogues derivatives. Mini reviews in 
medicinal chemistry. 2009;9(7):760-8. 
 Curcio KR. Instruments for Assessing Chemotherapy-Induced Peripheral Neuropathy: A 
Review of the Literature. Clinical journal of oncology nursing. 2016;20(2):144-51. 
 De Grandis D. Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral 
neuropathy: a short review. CNS drugs. 2007;21 Suppl 1:39-43; discussion 5-6. 
 Delforge M, Blade J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, et al. Treatment-
related peripheral neuropathy in multiple myeloma: the challenge continues. The Lancet 
Oncology. 2010;11(11):1086-95. 
 Deng B, Jia L, Cheng Z. Radix Astragali-Based Chinese Herbal Medicine for 
Oxaliplatin-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis. Evidence-
based complementary and alternative medicine : eCAM. 2016;2016:2421876. 
 Dentale N, Manfredi R. Therapeutic use of interferons and their toxicity. Focus on 
peripheral neuropathy. Recenti progressi in medicina. 2007;98(6):329-34. 
 Derksen TME, Bours MJL, Mols F, Weijenberg MP. Lifestyle-Related Factors in the 
Self-Management of Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer: A 
Systematic Review. Evidence-based complementary and alternative medicine : eCAM. 
2017;2017:7916031. 
 Desai B, Freeman E, Huang E, Hung A, Knapp E, Breunig IM, et al. Clinical value of 
tapentadol extended-release in painful diabetic peripheral neuropathy. Expert review of clinical 
pharmacology. 2014;7(2):203-9. 
 Desguerre I, Barnerias C, Valayannopoulos V. Peripheral neuropathy as a presentation of 
metabolic disorders in childhood. Revue neurologique. 2007;163(12):1256-9. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            395 
 Diaz PL, Furfari A, Wan BA, Lam H, Charames G, Drost L, et al. Predictive biomarkers 
of chemotherapy-induced peripheral neuropathy: a review. Biomarkers in medicine. 
2018;12(8):907-16. 
 Dimitrova A, Murchison C, Oken B. Acupuncture for the Treatment of Peripheral 
Neuropathy: A Systematic Review and Meta-Analysis. Journal of alternative and complementary 
medicine (New York, NY). 2017;23(3):164-79. 
 Dive D, Lievens I, Moonen G, Wang FC. Diabetic peripheral neuropathy. Revue 
medicale de Liege. 2005;60(5-6):490-7. 
 Dixit S, Maiya A. Diabetic peripheral neuropathy and its evaluation in a clinical scenario: 
a review. Journal of postgraduate medicine. 2014;60(1):33-40. 
 Dobrowsky RT. Targeting the Diabetic Chaperome to Improve Peripheral Neuropathy. 
Current diabetes reports. 2016;16(8):71. 
 Donertas B, Unel CC, Erol K. Cannabinoids and agmatine as potential therapeutic 
alternatives for cisplatin-induced peripheral neuropathy. Journal of experimental pharmacology. 
2018;10:19-28. 
 Donnan J, Ledger S. An update on the treatment and management of diabetic peripheral 
neuropathy. CANNT journal = Journal ACITN. 2006;16(4):32-6; quiz 7-8. 
 Dorsey SG, Morton PG. HIV peripheral neuropathy: pathophysiology and clinical 
implications. AACN clinical issues. 2006;17(1):30-6. 
 Doughty CT, Seyedsadjadi R. Approach to Peripheral Neuropathy for the Primary Care 
Clinician. The American journal of medicine. 2018;131(9):1010-6. 
 Douglas DS, Popko B. Mouse forward genetics in the study of the peripheral nervous 
system and human peripheral neuropathy. Neurochemical research. 2009;34(1):124-37. 
 Dros J, Wewerinke A, Bindels PJ, van Weert HC. Accuracy of monofilament testing to 
diagnose peripheral neuropathy: a systematic review. Annals of family medicine. 2009;7(6):555-
8. 
 Duregon F, Vendramin B, Bullo V, Gobbo S, Cugusi L, Di Blasio A, et al. Effects of 
exercise on cancer patients suffering chemotherapy-induced peripheral neuropathy undergoing 
treatment: A systematic review. Critical reviews in oncology/hematology. 2018;121:90-100. 
 Dworkin RH, Turk DC, Peirce-Sandner S, McDermott MP, Farrar JT, Hertz S, et al. 
Placebo and treatment group responses in postherpetic neuralgia vs. painful diabetic peripheral 
neuropathy clinical trials in the REPORT database. Pain. 2010;150(1):12-6. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            396 
 Egashira N, Kawashiri T, Oishi R. The current state of the drugs for the treatment of 
peripheral neuropathy induced by anticancer drugs. Nihon yakurigaku zasshi Folia 
pharmacologica Japonica. 2010;136(5):275-9. 
 Evans JD, Jacobs TF, Evans EW. Role of acetyl-L-carnitine in the treatment of diabetic 
peripheral neuropathy. The Annals of pharmacotherapy. 2008;42(11):1686-91. 
 Ewertz M, Qvortrup C, Eckhoff L. Chemotherapy-induced peripheral neuropathy in 
patients treated with taxanes and platinum derivatives. Acta oncologica (Stockholm, Sweden). 
2015;54(5):587-91. 
 Farmer KL, Li C, Dobrowsky RT. Diabetic peripheral neuropathy: should a chaperone 
accompany our therapeutic approach? Pharmacological reviews. 2012;64(4):880-900. 
 Fehrenbacher JC. Chemotherapy-induced peripheral neuropathy. Progress in molecular 
biology and translational science. 2015;131:471-508. 
 Feng Y, Schlosser FJ, Sumpio BE. The Semmes Weinstein monofilament examination as 
a screening tool for diabetic peripheral neuropathy. Journal of vascular surgery. 2009;50(3):675-
82, 82.e1. 
 Fernandez C, Mehta Z, Espenlaub A, Ellison N. Chemotherapy-induced peripheral 
neuropathy #197. Journal of palliative medicine. 2014;17(8):965-6. 
 Ferrier J, Pereira V, Busserolles J, Authier N, Balayssac D. Emerging trends in 
understanding chemotherapy-induced peripheral neuropathy. Current pain and headache reports. 
2013;17(10):364. 
 Flatters SJL, Dougherty PM, Colvin LA. Clinical and preclinical perspectives on 
Chemotherapy-Induced Peripheral Neuropathy (CIPN): a narrative review. British journal of 
anaesthesia. 2017;119(4):737-49. 
 Francis DA, Christopher AT, Beasley BD. Conservative treatment of peripheral 
neuropathy and neuropathic pain. Clinics in podiatric medicine and surgery. 2006;23(3):509-30. 
 Freeman R. Autonomic peripheral neuropathy. Lancet (London, England). 
2005;365(9466):1259-70. 
 Freeman R. Autonomic peripheral neuropathy. Neurologic clinics. 2007;25(1):277-301. 
 Freeman R. Newer agents for the treatment of painful diabetic peripheral neuropathy. 
Current diabetes reports. 2005;5(6):409-16. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            397 
 Fuhrmann D, Elsasser H-P. Schwann cell Myc-interacting zinc-finger protein 1 without 
pox virus and zinc finger: epigenetic implications in a peripheral neuropathy. Neural 
regeneration research. 2018;13(9):1534-7. 
 Fukuda Y, Li Y, Segal RA. A Mechanistic Understanding of Axon Degeneration in 
Chemotherapy-Induced Peripheral Neuropathy. Frontiers in neuroscience. 2017;11:481. 
 Gallardo E, Noto Y-I, Simon NG. Ultrasound in the diagnosis of peripheral neuropathy: 
structure meets function in the neuromuscular clinic. Journal of neurology, neurosurgery, and 
psychiatry. 2015;86(10):1066-74. 
 Galuppo M, Giacoppo S, Bramanti P, Mazzon E. Use of natural compounds in the 
management of diabetic peripheral neuropathy. Molecules (Basel, Switzerland). 
2014;19(3):2877-95. 
 Garcia-Cabo C, Moris G. Peripheral neuropathy: an underreported neurologic 
manifestation of inflammatory bowel disease. European journal of internal medicine. 
2015;26(7):468-75. 
 Gewandter JS, Brell J, Cavaletti G, Dougherty PM, Evans S, Howie L, et al. Trial designs 
for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations. 
Neurology. 2018;91(9):403-13. 
 Gewandter JS, Burke L, Cavaletti G, Dworkin RH, Gibbons C, Gover TD, et al. Content 
validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy. 
Muscle & nerve. 2017;55(3):366-72. 
 Gewandter JS, Dworkin RH, Finnerup NB, Mohile NA. Painful chemotherapy-induced 
peripheral neuropathy: lack of treatment efficacy or the wrong clinical trial methodology? Pain. 
2017;158(1):30-3. 
 Gewandter JS, Freeman R, Kitt RA, Cavaletti G, Gauthier LR, McDermott MP, et al. 
Chemotherapy-induced peripheral neuropathy clinical trials: Review and recommendations. 
Neurology. 2017;89(8):859-69. 
 GieSsen-Jung C, von Baumgarten L. Peripheral neuropathy as a side effect of 
chemotherapy and targeted therapy. Deutsche medizinische Wochenschrift (1946). 
2018;113(13):970-8. 
 Gilchrist L. Chemotherapy-induced peripheral neuropathy in pediatric cancer patients. 
Seminars in pediatric neurology. 2012;19(1):9-17. 
 Gomez A, Hoffman JE. Anti Myelin-Associated-Glycoprotein Antibody Peripheral 
Neuropathy Response to Combination Chemoimmunotherapy With Bendamustine/Rituximab in 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            398 
a Patient With Biclonal IgM kappa and IgM lambda: Case Report and Review of the Literature. 
Clinical lymphoma, myeloma & leukemia. 2016;16(7):e101-8. 
 Gonzalez-Duarte A, Cikurel K, Simpson DM. Managing HIV peripheral neuropathy. 
Current HIV/AIDS reports. 2007;4(3):114-8. 
 Goolsby TA, Jakeman B, Gaynes RP. Clinical relevance of metronidazole and peripheral 
neuropathy: a systematic review of the literature. International journal of antimicrobial agents. 
2018;51(3):319-25. 
 Gorshtein A, Levy Y. Intravenous immunoglobulin in therapy of peripheral neuropathy. 
Clinical reviews in allergy & immunology. 2005;29(3):271-9. 
 Goswami C. TRPV1-tubulin complex: involvement of membrane tubulin in the 
regulation of chemotherapy-induced peripheral neuropathy. Journal of neurochemistry. 
2012;123(1):1-13. 
 Grammatico S, Cesini L, Petrucci MT. Managing treatment-related peripheral neuropathy 
in patients with multiple myeloma. Blood and lymphatic cancer : targets and therapy. 2016;6:37-
47. 
 Griffith KA, Merkies ISJ, Hill EE, Cornblath DR. Measures of chemotherapy-induced 
peripheral neuropathy: a systematic review of psychometric properties. Journal of the peripheral 
nervous system : JPNS. 2010;15(4):314-25. 
 Gu Y, Dennis SM. Are falls prevention programs effective at reducing the risk factors for 
falls in people with type-2 diabetes mellitus and peripheral neuropathy: A systematic review with 
narrative synthesis. Journal of diabetes and its complications. 2017;31(2):504-16. 
 Guo X, Sun H, Dong J, Feng Y, Li H, Zhuang R, et al. Does nab-paclitaxel have a higher 
incidence of peripheral neuropathy than solvent-based paclitaxel? Evidence from a systematic 
review and meta-analysis. Critical reviews in oncology/hematology. 2019;139:16-23. 
 Gutierrez-Gutierrez G, Sereno M, Miralles A, Casado-Saenz E, Gutierrez-Rivas E. 
Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and 
treatment strategies. Clinical & translational oncology : official publication of the Federation of 
Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2010;12(2):81-91. 
 Han T, Bai J, Liu W, Hu Y. A systematic review and meta-analysis of alpha-lipoic acid in 
the treatment of diabetic peripheral neuropathy. European journal of endocrinology. 
2012;167(4):465-71. 
 Han Y, Smith MT. Pathobiology of cancer chemotherapy-induced peripheral neuropathy 
(CIPN). Frontiers in pharmacology. 2013;4:156. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            399 
 Haryani H, Fetzer SJ, Wu C-L, Hsu Y-Y. Chemotherapy-Induced Peripheral Neuropathy 
Assessment Tools: A Systematic Review. Oncology nursing forum. 2017;44(3):E111-E23. 
 Hattori A, Sasaki M, Sakuma H, Saito Y, Komaki H, Nakagawa E, et al. Hereditary 
spastic paraplegia associated with congenital cataracts, mental retardation and peripheral 
neuropathy. No to hattatsu = Brain and development. 2010;42(6):454-7. 
 Hattori N. Diagnosis and treatment of peripheral neuropathy induced by ANCA-
associated vasculitis. Brain and nerve = Shinkei kenkyu no shinpo. 2014;66(7):857-62. 
 Hauser W, Bartram C, Bartram-Wunn E, Tolle T. Adverse events attributable to nocebo 
in randomized controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral 
neuropathy: systematic review. The Clinical journal of pain. 2012;28(5):437-51. 
 Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, 
and evaluation of chemotherapy-induced peripheral neuropathy. Seminars in oncology. 
2006;33(1):15-49. 
 Hazari A, Maiya AG, Shivashankara KN, Agouris I, Monteiro A, Jadhav R, et al. 
Kinetics and kinematics of diabetic foot in type 2 diabetes mellitus with and without peripheral 
neuropathy: a systematic review and meta-analysis. SpringerPlus. 2016;5(1):1819. 
 Head KA. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. 
Alternative medicine review : a journal of clinical therapeutic. 2006;11(4):294-329. 
 Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. 
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of 
adult cancers: American Society of Clinical Oncology clinical practice guideline. Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology. 
2014;32(18):1941-67. 
 Hewston P, Deshpande N. Falls and Balance Impairments in Older Adults with Type 2 
Diabetes: Thinking Beyond Diabetic Peripheral Neuropathy. Canadian journal of diabetes. 
2016;40(1):6-9. 
 Hoeijmakers JGJ, Faber CG, Merkies ISJ, Waxman SG. Painful peripheral neuropathy 
and sodium channel mutations. Neuroscience letters. 2015;596:51-9. 
 Hoke A, Ray M. Rodent models of chemotherapy-induced peripheral neuropathy. ILAR 
journal. 2014;54(3):273-81. 
 Hong H-B, Xu R-J. Progress on painful diabetic peripheral neuropathy treated by 
integrative medicine. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = 
Chinese journal of integrated traditional and Western medicine. 2005;25(4):378-82. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            400 
 Hoshino N, Hida K, Ganeko R, Sakai Y. Goshajinkigan for reducing chemotherapy-
induced peripheral neuropathy: protocol for a systematic review and meta-analysis. International 
journal of colorectal disease. 2017;32(5):737-40. 
 Hsu S-Y, Lu C-H, Chen S-Z, Jane S-W. Nursing care of chemotherapy-induced 
peripheral neuropathy. Hu li za zhi The journal of nursing. 2015;62(2):84-8. 
 Hu L-Y, Mi W-L, Wu G-C, Wang Y-Q, Mao-Ying Q-L. Prevention and Treatment for 
Chemotherapy-Induced Peripheral Neuropathy: Therapies Based on CIPN Mechanisms. Current 
neuropharmacology. 2019;17(2):184-96. 
 Hu S, Huang KM, Adams EJ, Loprinzi CL, Lustberg MB. Recent Developments of 
Novel Pharmacologic Therapeutics for Prevention of Chemotherapy-Induced Peripheral 
Neuropathy. Clinical cancer research : an official journal of the American Association for Cancer 
Research. 2019. 
 Huan MC. Laboratory evaluation of peripheral neuropathy. Seminars in neurology. 
2010;30(4):337-49. 
 Hurley RW, Lesley MR, Adams MCB, Brummett CM, Wu CL. Pregabalin as a treatment 
for painful diabetic peripheral neuropathy: a meta-analysis. Regional anesthesia and pain 
medicine. 2008;33(5):389-94. 
 Imataki O, Ohnishi H, Kitanaka A, Kubota Y, Ishida T, Tanaka T. Pancytopenia 
complicated with peripheral neuropathy due to copper deficiency: clinical diagnostic review. 
Internal medicine (Tokyo, Japan). 2008;47(23):2063-5. 
 Innis J. Pain assessment and management for a dialysis patient with diabetic peripheral 
neuropathy. CANNT journal = Journal ACITN. 2006;16(2):12-7, 20-6; quiz 18-9, 27-8. 
 Iqbal Z, Azmi S, Yadav R, Ferdousi M, Kumar M, Cuthbertson DJ, et al. Diabetic 
Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy. Clinical therapeutics. 
2018;40(6):828-49. 
 Ishida H, Shin-Nakai N, Imamura T, Yokoi K, Yoshihara T, Fujii N, et al. A woman 
complicated with immune thrombocytopenic purpura, subclinical Graves disease and peripheral 
neuropathy 5 years after allogeneic bone marrow transplantation. [Rinsho ketsueki] The Japanese 
journal of clinical hematology. 2005;46(10):1123-8. 
 Istenes I, Nagy Z, Demeter J. Chemotherapy-induced peripheral neuropathy: 
characteristics, diagnosis and treatment. Magyar onkologia. 2016;60(2):165-75. 
 Ites KI, Anderson EJ, Cahill ML, Kearney JA, Post EC, Gilchrist LS. Balance 
interventions for diabetic peripheral neuropathy: a systematic review. Journal of geriatric 
physical therapy (2001). 2011;34(3):109-16. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            401 
 Izycki D, Niezgoda A, Kazmierczak M, Nowak-Markwitz E. Chemotherapy-induced 
peripheral neuropathy - epidemiology and pathogenesis. Ginekologia polska. 2016;87(4):293-9. 
 Izycki D, Niezgoda AA, Kazmierczak M, Piorunek T, Izycka N, Karaszewska B, et al. 
Chemotherapy-induced peripheral neuropathy - diagnosis, evolution and treatment. Ginekologia 
polska. 2016;87(7):516-21. 
 Jaggi AS, Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral 
neuropathy. Toxicology. 2012;291(1-3):1-9. 
 Jayabalan B, Low LL. Vitamin B supplementation for diabetic peripheral neuropathy. 
Singapore medical journal. 2016;57(2):55-9. 
 Jeong NY, Shin YH, Jung J. Neuropathic pain in hereditary peripheral neuropathy. 
Journal of exercise rehabilitation. 2013;9(4):397-9. 
 Jiang D-Q, Li M-X, Ma Y-J, Wang Y, Wang Y. Efficacy and safety of prostaglandin E1 
plus lipoic acid combination therapy versus monotherapy for patients with diabetic peripheral 
neuropathy. Journal of clinical neuroscience : official journal of the Neurosurgical Society of 
Australasia. 2016;27:8-16. 
 Jiang D-Q, Xu L-C, Jiang L-L, Li M-X, Wang Y. Fasudil combined with 
methylcobalamin or lipoic acid can improve the nerve conduction velocity in patients with 
diabetic peripheral neuropathy: A meta-analysis. Medicine. 2018;97(27):e11390. 
 Jiang D-Q, Zhao S-H, Li M-X, Jiang L-L, Wang Y, Wang Y. Prostaglandin E1 plus 
methylcobalamin combination therapy versus prostaglandin E1 monotherapy for patients with 
diabetic peripheral neuropathy: A meta-analysis of randomized controlled trials. Medicine. 
2018;97(44):e13020. 
 Jiang M-S, Yuan Y, Gu Z-X, Zhuang S-L. Corneal confocal microscopy for assessment 
of diabetic peripheral neuropathy: a meta-analysis. The British journal of ophthalmology. 
2016;100(1):9-14. 
 Jin HY, Lee KA, Park TS. The impact of glycemic variability on diabetic peripheral 
neuropathy. Endocrine. 2016;53(3):643-8. 
 Jin HY, Park TS. Role of inflammatory biomarkers in diabetic peripheral neuropathy. 
Journal of diabetes investigation. 2018;9(5):1016-8. 
 Jolivalt CG, Frizzi KE, Guernsey L, Marquez A, Ochoa J, Rodriguez M, et al. Peripheral 
Neuropathy in Mouse Models of Diabetes. Current protocols in mouse biology. 2016;6(3):223-
55. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            402 
 Juhn MS, Parsons B, Varvara R, Sadosky A. Pregabalin for painful diabetic peripheral 
neuropathy: strategies for dosing, monotherapy vs. combination therapy, treatment-refractory 
patients, and adverse events. Current medical research and opinion. 2015;31(5):1017-26. 
 Julian T, Glascow N, Syeed R, Zis P. Alcohol-related peripheral neuropathy: a systematic 
review and meta-analysis. Journal of neurology. 2018. 
 Jung M, Rein N, Fuchs B. Physical Therapy for Chemotherapy-induced Peripheral 
Neuropathy in Pediatric Oncology. Klinische Padiatrie. 2016;228(6-07):313-8. 
 Juster-Switlyk K, Smith AG. Updates in diabetic peripheral neuropathy. F1000Research. 
2016;5. 
 Kaley TJ, Deangelis LM. Therapy of chemotherapy-induced peripheral neuropathy. 
British journal of haematology. 2009;145(1):3-14. 
 Kanda T. Peripheral neuropathy and blood-nerve barrier. Rinsho shinkeigaku = Clinical 
neurology. 2009;49(11):959-62. 
 Kandula T, Park SB, Cohn RJ, Krishnan AV, Farrar MA. Pediatric chemotherapy 
induced peripheral neuropathy: A systematic review of current knowledge. Cancer treatment 
reviews. 2016;50:118-28. 
 Kanji JN, Anglin RES, Hunt DL, Panju A. Does this patient with diabetes have large-
fiber peripheral neuropathy? Jama. 2010;303(15):1526-32. 
 Kanzawa-Lee GA, Knoerl R, Donohoe C, Bridges CM, Smith EML. Mechanisms, 
Predictors, and Challenges in Assessing and Managing Painful Chemotherapy-Induced 
Peripheral Neuropathy. Seminars in oncology nursing. 2019;35(3):253-60. 
 Kao DS, Cheng J. Peripheral neuropathy: surgical approaches simplified for the imagers. 
Seminars in musculoskeletal radiology. 2015;19(2):121-9. 
 Kaplan GS, Torcun CC, Grune T, Ozer NK, Karademir B. Proteasome inhibitors in 
cancer therapy: Treatment regimen and peripheral neuropathy as a side effect. Free radical 
biology & medicine. 2017;103:1-13. 
 Karlsson JOG, Andersson RG, Jynge P. Mangafodipir a Selective Cytoprotectant - with 
Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral 
Neuropathy (CIPN). Translational oncology. 2017;10(4):641-9. 
 Kassem LA, Yassin NA. Role of erythropoeitin in prevention of chemotherapy-induced 
peripheral neuropathy. Pakistan journal of biological sciences : PJBS. 2010;13(12):577-87. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            403 
 Kellogg AP, Cheng HT, Pop-Busui R. Cyclooxygenase-2 pathway as a potential 
therapeutic target in diabetic peripheral neuropathy. Current drug targets. 2008;9(1):68-76. 
 Kerckhove N, Collin A, Conde S, Chaleteix C, Pezet D, Balayssac D, et al. 
Chemotherapy-induced peripheral neuropathy: Symptomatology and epidemiology. Bulletin du 
cancer. 2018;105(11):1020-32. 
 Kim PY, Johnson CE. Chemotherapy-induced peripheral neuropathy: a review of recent 
findings. Current opinion in anaesthesiology. 2017;30(5):570-6. 
 Kleopa KA, Sargiannidou I. Connexins, gap junctions and peripheral neuropathy. 
Neuroscience letters. 2015;596:27-32. 
 Kles KA, Vinik AI. Pathophysiology and treatment of diabetic peripheral neuropathy: the 
case for diabetic neurovascular function as an essential component. Current diabetes reviews. 
2006;2(2):131-45. 
 Kluding PM, Bareiss SK, Hastings M, Marcus RL, Sinacore DR, Mueller MJ. Physical 
Training and Activity in People With Diabetic Peripheral Neuropathy: Paradigm Shift. Physical 
therapy. 2017;97(1):31-43. 
 Koeppen S. Treatment of multiple myeloma: thalidomide-, bortezomib-, and 
lenalidomide-induced peripheral neuropathy. Oncology research and treatment. 2014;37(9):506-
13. 
 Kolak A, Staroslawska E, Kubiatowski T, Kieszko D, Cisek P, Patyra KI, et al. 
Chemotherapy induced peripheral neuropathy. Polski merkuriusz lekarski : organ Polskiego 
Towarzystwa Lekarskiego. 2013;35(209):292-6. 
 Kulkarni RR, Pradeep AV, Bairy BK. Disulfiram-induced combined irreversible anterior 
ischemic optic neuropathy and reversible peripheral neuropathy: a prospective case report and 
review of the literature. The Journal of neuropsychiatry and clinical neurosciences. 
2013;25(4):339-42. 
 Kwok T, Ting PT, Wong EK, Brassard A. Peripheral neuropathy for dermatologists: what 
if not diabetic neuropathy? Journal of cutaneous medicine and surgery. 2013;17 Suppl 1:S1-5. 
 Lauria G, Devigili G. Skin biopsy as a diagnostic tool in peripheral neuropathy. Nature 
clinical practice Neurology. 2007;3(10):546-57. 
 Lauria G, Lombardi R, Camozzi F, Devigili G. Skin biopsy for the diagnosis of 
peripheral neuropathy. Histopathology. 2009;54(3):273-85. 
 Lauria G, Lombardi R. Skin biopsy: a new tool for diagnosing peripheral neuropathy. 
BMJ (Clinical research ed). 2007;334(7604):1159-62. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            404 
 Lauria G. Recent developments in the management of peripheral neuropathy using skin 
biopsy. Revue neurologique. 2007;163(12):1266-70. 
 Le Forestier N, Bouche P. Peripheral neuropathy in the elderly. Psychologie & 
neuropsychiatrie du vieillissement. 2006;4(2):109-19. 
 Lee G, Kim SK. Therapeutic Effects of Phytochemicals and Medicinal Herbs on 
Chemotherapy-Induced Peripheral Neuropathy. Molecules (Basel, Switzerland). 2016;21(9). 
 Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. 
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 
2006;24(10):1633-42. 
 Lee YJ, Park S, Kim YW, Park KM, Kim IH, Park JH, et al. Rhabdomyolysis with 
Peripheral Neuropathy: A Case Series and Literature Review. The American journal of case 
reports. 2018;19:1272-8. 
 Lees JG, Makker PGS, Tonkin RS, Abdulla M, Park SB, Goldstein D, et al. Immune-
mediated processes implicated in chemotherapy-induced peripheral neuropathy. European 
journal of cancer (Oxford, England : 1990). 2017;73:22-9. 
 Lehmann HC, Hoke A. Use of engineered Schwann cells in peripheral neuropathy: Hopes 
and hazards. Brain research. 2016;1638(Pt A):97-104. 
 Levine TD, Saperstein DS. Laboratory evaluation of peripheral neuropathy. Neurologic 
clinics. 2013;31(2):363-76. 
 Li L, Hondzinski JM. Select exercise modalities may reverse movement dysfunction 
because of peripheral neuropathy. Exercise and sport sciences reviews. 2012;40(3):133-7. 
 Li L, Zhang S, Dobson J. The contribution of small and large sensory afferents to 
postural control in patients with peripheral neuropathy. Journal of sport and health science. 
2019;8(3):218-27. 
 Li Z, Jin H, Yan Q, Sun L, Wasan HS, Shen M, et al. The Method of Activating Blood 
and Dredging Collaterals for Reducing Chemotherapy-Induced Peripheral Neuropathy: A 
Systematic Review and Meta-Analysis. Evidence-based complementary and alternative medicine 
: eCAM. 2019;2019:1029626. 
 Liang X-c, Piao Y-l. Effect of Chinese materia medica on nerve repair and regeneration 
in diabetic peripheral neuropathy. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe 
zazhi = Chinese journal of integrated traditional and Western medicine. 2011;31(4):564-8. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            405 
 Long CP, Suzuki H, Vitale K. Peripheral Neuropathy Due to Common Variable 
Immunodeficiency: Case Report and Narrative Review. Gerontology & geriatric medicine. 
2019;5:2333721419850644. 
 Lorber M. A case of possible darunavir/ritonavir-induced peripheral neuropathy: case 
description and review of the literature. Journal of the International Association of Providers of 
AIDS Care. 2013;12(3):162-5. 
 Louraki M, Karayianni C, Kanaka-Gantenbein C, Katsalouli M, Karavanaki K. 
Peripheral neuropathy in children with type 1 diabetes. Diabetes & metabolism. 2012;38(4):281-
9. 
 Luczkowska K, Litwinska Z, Paczkowska E, Machalinski B. Pathophysiology of drug-
induce peripheral neuropathy in patients with multiple myeloma. Journal of physiology and 
pharmacology : an official journal of the Polish Physiological Society. 2018;69(2). 
 Lv WS, Zhao WJ, Gong SL, Fang DD, Wang B, Fu ZJ, et al. Serum 25-hydroxyvitamin 
D levels and peripheral neuropathy in patients with type 2 diabetes: a systematic review and 
meta-analysis. Journal of endocrinological investigation. 2015;38(5):513-8. 
 Ma J, Kavelaars A, Dougherty PM, Heijnen CJ. Beyond symptomatic relief for 
chemotherapy-induced peripheral neuropathy: Targeting the source. Cancer. 2018;124(11):2289-
98. 
 Magy L. Changes in the assessment of peripheral neuropathy in the last decade. Revue 
neurologique. 2006;162(12):1279-83. 
 Majithia N, Temkin SM, Ruddy KJ, Beutler AS, Hershman DL, Loprinzi CL. National 
Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and 
lessons. Supportive care in cancer : official journal of the Multinational Association of 
Supportive Care in Cancer. 2016;24(3):1439-47. 
 Malacrida A, Meregalli C, Rodriguez-Menendez V, Nicolini G. Chemotherapy-Induced 
Peripheral Neuropathy and Changes in Cytoskeleton. International journal of molecular sciences. 
2019;20(9). 
 Malik B, Stillman M. Chemotherapy-induced peripheral neuropathy. Current pain and 
headache reports. 2008;12(3):165-74. 
 Malik B, Stillman M. Chemotherapy-induced peripheral neuropathy. Current neurology 
and neuroscience reports. 2008;8(1):56-65. 
 Mangus LM, Dorsey JL, Laast VA, Ringkamp M, Ebenezer GJ, Hauer P, et al. 
Unraveling the pathogenesis of HIV peripheral neuropathy: insights from a simian 
immunodeficiency virus macaque model. ILAR journal. 2014;54(3):296-303. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            406 
 Markman M. Chemotherapy-induced peripheral neuropathy: underreported and 
underappreciated. Current pain and headache reports. 2006;10(4):275-8. 
 Martin TG. Peripheral neuropathy experience in patients with relapsed and/or refractory 
multiple myeloma treated with carfilzomib. Oncology (Williston Park, NY). 2013;27 Suppl 3:4-
10. 
 Massey EW, Stolp KA. Peripheral neuropathy in pregnancy. Physical medicine and 
rehabilitation clinics of North America. 2008;19(1):149-62, vii-viii. 
 Massey RL, Kim HK, Abdi S. Brief review: chemotherapy-induced painful peripheral 
neuropathy (CIPPN): current status and future directions. Canadian journal of anaesthesia = 
Journal canadien d'anesthesie. 2014;61(8):754-62. 
 McCrary JM, Goldstein D, Boyle F, Cox K, Grimison P, Kiernan MC, et al. Optimal 
clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a 
systematic review and Delphi survey. Supportive care in cancer : official journal of the 
Multinational Association of Supportive Care in Cancer. 2017;25(11):3485-93. 
 Melcangi RC, Garcia-Segura LM. Therapeutic approaches to peripheral neuropathy 
based on neuroactive steroids. Expert review of neurotherapeutics. 2006;6(8):1121-5. 
 Mellion M, Gilchrist JM, de la Monte S. Alcohol-related peripheral neuropathy: 
nutritional, toxic, or both? Muscle & nerve. 2011;43(3):309-16. 
 Menezes MP, Ouvrier RA. Peripheral neuropathy associated with mitochondrial disease 
in children. Developmental medicine and child neurology. 2012;54(5):407-14. 
 Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: a persisting challenge in 
paclitaxel-based regimes. European journal of cancer (Oxford, England : 1990). 2006;42(1):24-
30. 
 Miranda-Massari JR, Gonzalez MJ, Jimenez FJ, Allende-Vigo MZ, Duconge J. 
Metabolic correction in the management of diabetic peripheral neuropathy: improving clinical 
results beyond symptom control. Current clinical pharmacology. 2011;6(4):260-73. 
 Modesto-Lowe V, Bojka R, Alvarado C. Cannabis for peripheral neuropathy: The good, 
the bad, and the unknown. Cleveland Clinic journal of medicine. 2018;85(12):943-9. 
 Mohrmann C, Armer J, Hayashi RJ. Challenges Evaluating Chemotherapy-Induced 
Peripheral Neuropathy in Childhood Cancer Survivors. Journal of pediatric oncology nursing : 
official journal of the Association of Pediatric Oncology Nurses. 2017;34(2):106-14. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            407 
 Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau J-L, Mohty M. Peripheral 
neuropathy and new treatments for multiple myeloma: background and practical 
recommendations. Haematologica. 2010;95(2):311-9. 
 Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L. Chemotherapy-induced 
peripheral neuropathy and its association with quality of life: a systematic review. Supportive 
care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 
2014;22(8):2261-9. 
 Montreuil C. The complexity of the diabetic peripheral neuropathy: propositions for 
therapeutic educational interventions. Praxis. 2012;101(21):1371-5. 
 Mora E, Smith EML, Donohoe C, Hertz DL. Vincristine-induced peripheral neuropathy 
in pediatric cancer patients. American journal of cancer research. 2016;6(11):2416-30. 
 Morales-Vidal S, Morgan C, McCoyd M, Hornik A. Diabetic peripheral neuropathy and 
the management of diabetic peripheral neuropathic pain. Postgraduate medicine. 
2012;124(4):145-53. 
 Morawska M, Grzasko N, Kostyra M, Wojciechowicz J, Hus M. Therapy-related 
peripheral neuropathy in multiple myeloma patients. Hematological oncology. 2015;33(4):113-9. 
 Mu Z-P, Wang Y-G, Li C-Q, Lv W-S, Wang B, Jing Z-H, et al. Association Between 
Tumor Necrosis Factor-alpha and Diabetic Peripheral Neuropathy in Patients with Type 2 
Diabetes: a Meta-Analysis. Molecular neurobiology. 2017;54(2):983-96. 
 Muller T, van Laar T, Cornblath DR, Odin P, Klostermann F, Grandas FJ, et al. 
Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal 
delivery. Parkinsonism & related disorders. 2013;19(5):501-7 ; discussion  
 Mustapa A, Justine M, Mohd Mustafah N, Jamil N, Manaf H. Postural Control and Gait 
Performance in the Diabetic Peripheral Neuropathy: A Systematic Review. BioMed research 
international. 2016;2016:9305025. 
 Nakagawa T, Kaneko S. Roles of Transient Receptor Potential Ankyrin 1 in Oxaliplatin-
Induced Peripheral Neuropathy. Biological & pharmaceutical bulletin. 2017;40(7):947-53. 
 Nakagawa T. Roles of TRPA1 in painful peripheral neuropathy. Seikagaku The Journal 
of Japanese Biochemical Society. 2016;88(2):237-9. 
 Nardone A, Schieppati M. Balance control under static and dynamic conditions in 
patients with peripheral neuropathy. Giornale italiano di medicina del lavoro ed ergonomia. 
2007;29(1):101-4. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            408 
 Negi G, Nakkina V, Kamble P, Sharma SS. Heme oxygenase-1, a novel target for the 
treatment of diabetic complications: focus on diabetic peripheral neuropathy. Pharmacological 
research. 2015;102:158-67. 
 Nicolini G, Monfrini M, Scuteri A. Axonal Transport Impairment in Chemotherapy-
Induced Peripheral Neuropathy. Toxics. 2015;3(3):322-41. 
 Nodera H, Izumi Y, Kaji R. Effects of Vitamin B12 in Patients with Amyotrophic Lateral 
Sclerosis and Peripheral Neuropathy. Brain and nerve = Shinkei kenkyu no shinpo. 
2015;67(9):1133-8. 
 O'Brien PD, Hinder LM, Sakowski SA, Feldman EL. ER stress in diabetic peripheral 
neuropathy: A new therapeutic target. Antioxidants & redox signaling. 2014;21(4):621-33. 
 Oh PJ, Kim YL. Effectiveness of Non-Pharmacologic Interventions in Chemotherapy 
Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis. Journal of Korean 
Academy of Nursing. 2018;48(2):123-42. 
 Oishi R, Egashira N. Peripheral neuropathy induced by anticancer drugs. Fukuoka igaku 
zasshi = Hukuoka acta medica. 2013;104(5):71-80. 
 Okuma H, Nagano R, Takagi S. Hemiplegic peripheral neuropathy accompanied with 
multiple cranial nerve palsy. Clinics and practice. 2012;2(2):e40. 
 Ouvrier R, Grew S. Mechanisms of disease and clinical features of mutations of the gene 
for mitofusin 2: an important cause of hereditary peripheral neuropathy with striking clinical 
variability in children and adults. Developmental medicine and child neurology. 2010;52(4):328-
30. 
 Overell JR. Peripheral neuropathy: pattern recognition for the pragmatist. Practical 
neurology. 2011;11(2):62-70. 
 Oya Y. Vasculitic peripheral neuropathy. Brain and nerve = Shinkei kenkyu no shinpo. 
2013;65(11):1299-309. 
 Pachman DR, Barton DL, Watson JC, Loprinzi CL. Chemotherapy-induced peripheral 
neuropathy: prevention and treatment. Clinical pharmacology and therapeutics. 2011;90(3):377-
87. 
 Pachman DR, Watson JC, Lustberg MB, Wagner-Johnston ND, Chan A, Broadfield L, et 
al. Management options for established chemotherapy-induced peripheral neuropathy. 
Supportive care in cancer : official journal of the Multinational Association of Supportive Care 
in Cancer. 2014;22(8):2281-95. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            409 
 Pagano L, Proietto M, Biondi R. Diabetic peripheral neuropathy: reflections and drug-
rehabilitative treatment. Recenti progressi in medicina. 2009;100(7-8):337-42. 
 Paice JA. Clinical challenges: chemotherapy-induced peripheral neuropathy. Seminars in 
oncology nursing. 2009;25(2 Suppl 1):S8-19. 
 Panthi S, Jing X, Gao C, Gao T. Yang-warming method in the treatment of diabetic 
peripheral neuropathy: an updated systematic review and meta-analysis. BMC complementary 
and alternative medicine. 2017;17(1):424. 
 Papanas N, Ziegler D. Emerging drugs for diabetic peripheral neuropathy and 
neuropathic pain. Expert opinion on emerging drugs. 2016;21(4):393-407. 
 Parasoglou P, Rao S, Slade JM. Declining Skeletal Muscle Function in Diabetic 
Peripheral Neuropathy. Clinical therapeutics. 2017;39(6):1085-103. 
 Pareyson D, Piscosquito G, Moroni I, Salsano E, Zeviani M. Peripheral neuropathy in 
mitochondrial disorders. The Lancet Neurology. 2013;12(10):1011-24. 
 Pascuzzi RM. Peripheral neuropathy. The Medical clinics of North America. 
2009;93(2):317-42, vii-viii. 
 Pastre T, Faot F, Westphalen FH, da Rosa RS. Treatment of painful post-traumatic 
peripheral neuropathy with capsaicin in an edentulous patient with extreme resorption in the 
mental region: a case report. The journal of contemporary dental practice. 2008;9(3):106-13. 
 Patte-Mensah C, Mensah-Nyagan AG. Peripheral neuropathy and neurosteroid formation 
in the central nervous system. Brain research reviews. 2008;57(2):454-9. 
 Persson A-K, Hoeijmakers JGJ, Estacion M, Black JA, Waxman SG. Sodium Channels, 
Mitochondria, and Axonal Degeneration in Peripheral Neuropathy. Trends in molecular 
medicine. 2016;22(5):377-90. 
 Piccolo J, Kolesar JM. Prevention and treatment of chemotherapy-induced peripheral 
neuropathy. American journal of health-system pharmacy : AJHP : official journal of the 
American Society of Health-System Pharmacists. 2014;71(1):19-25. 
 Pieber K, Herceg M, Paternostro-Sluga T. Electrotherapy for the treatment of painful 
diabetic peripheral neuropathy: a review. Journal of rehabilitation medicine. 2010;42(4):289-95. 
 Pinzur MS. Diabetic peripheral neuropathy. Foot and ankle clinics. 2011;16(2):345-9. 
 Poupon L, Kerckhove N, Vein J, Lamoine S, Authier N, Busserolles J, et al. Minimizing 
chemotherapy-induced peripheral neuropathy: preclinical and clinical development of new 
perspectives. Expert opinion on drug safety. 2015;14(8):1269-82. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            410 
 Prabodha LBL, Sirisena ND, Dissanayake VHW. Susceptible and Prognostic Genetic 
Factors Associated with Diabetic Peripheral Neuropathy: A Comprehensive Literature Review. 
International journal of endocrinology. 2018;2018:8641942. 
 Pratt RW, Weimer LH. Medication and toxin-induced peripheral neuropathy. Seminars in 
neurology. 2005;25(2):204-16. 
 Premkumar LS, Pabbidi RM. Diabetic peripheral neuropathy: role of reactive oxygen and 
nitrogen species. Cell biochemistry and biophysics. 2013;67(2):373-83. 
 Pulvers JN, Marx G. Factors associated with the development and severity of oxaliplatin-
induced peripheral neuropathy: a systematic review. Asia-Pacific journal of clinical oncology. 
2017;13(6):345-55. 
 Qu L, Liang X-c. Exploration on the relationship between diabetic peripheral neuropathy 
and oxidative stress QU ling and. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe 
zazhi = Chinese journal of integrated traditional and Western medicine. 2007;27(8):764-8. 
 Raghav A, Singh P, Ahmad J. New insights into bioelectronic medicines: A new 
approach to tackle diabetic peripheral neuropathy pain in clinics. Diabetes & metabolic 
syndrome. 2019;13(2):1011-4. 
 Rao DB, Jortner BS, Sills RC. Animal models of peripheral neuropathy due to 
environmental toxicants. ILAR journal. 2014;54(3):315-23. 
 Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, et al. Management 
of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2012;26(4):595-
608. 
 Rivera DR, Ganz PA, Weyrich MS, Bandos H, Melnikow J. Chemotherapy-Associated 
Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review. 
Journal of the National Cancer Institute. 2018;110(2). 
 Robinson CC, Klahr PDS, Stein C, Falavigna M, Sbruzzi G, Plentz RDM. Effects of 
monochromatic infrared phototherapy in patients with diabetic peripheral neuropathy: a 
systematic review and meta-analysis of randomized controlled trials. Brazilian journal of 
physical therapy. 2017;21(4):233-43. 
 Roglio I, Giatti S, Pesaresi M, Bianchi R, Cavaletti G, Lauria G, et al. Neuroactive 
steroids and peripheral neuropathy. Brain research reviews. 2008;57(2):460-9. 
 Rolim LC, da Silva EM, Flumignan RL, Abreu MM, Dib SA. Acetyl-L-carnitine for the 
treatment of diabetic peripheral neuropathy. The Cochrane database of systematic reviews. 
2019;6:CD011265. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            411 
 Rosenberg CJ, Watson JC. Treatment of painful diabetic peripheral neuropathy. 
Prosthetics and orthotics international. 2015;39(1):17-28. 
 Rosenberg NR, Vermeulen M. Should coeliac disease be considered in the work up of 
patients with chronic peripheral neuropathy? Journal of neurology, neurosurgery, and psychiatry. 
2005;76(10):1415-9. 
 Ross MA. Electrodiagnosis of peripheral neuropathy. Neurologic clinics. 
2012;30(2):529-49. 
 Rossor AM, Carr AS, Devine H, Chandrashekar H, Pelayo-Negro AL, Pareyson D, et al. 
Peripheral neuropathy in complex inherited diseases: an approach to diagnosis. Journal of 
neurology, neurosurgery, and psychiatry. 2017;88(10):846-63. 
 Roth T, van Seventer R, Murphy TK. The effect of pregabalin on pain-related sleep 
interference in diabetic peripheral neuropathy or postherpetic neuralgia: a review of nine clinical 
trials. Current medical research and opinion. 2010;26(10):2411-9. 
 Saad M, Tafani C, Psimaras D, Ricard D. Chemotherapy-induced peripheral neuropathy 
in the adult. Current opinion in oncology. 2014;26(6):634-41. 
 Saade NE, Jabbur SJ. Nociceptive behavior in animal models for peripheral neuropathy: 
spinal and supraspinal mechanisms. Progress in neurobiology. 2008;86(1):22-47. 
 Sadosky A, McDermott AM, Brandenburg NA, Strauss M. A review of the epidemiology 
of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied 
neuropathic pain conditions. Pain practice : the official journal of World Institute of Pain. 
2008;8(1):45-56. 
 Saini NY, Bathini V. Large granular lymphocytic leukemia-associated peripheral 
neuropathy. Annals of hematology. 2018;97(8):1501-4. 
 Sakai A. Complications and their management in multiple myeloma patients: bone 
disease, renal impairment and peripheral neuropathy. [Rinsho ketsueki] The Japanese journal of 
clinical hematology. 2012;53(10):1689-98. 
 Samuel BS, Appel SJ. Identifying early signs of peripheral neuropathy among patients 
with diabetes mellitus. The Nurse practitioner. 2016;41(1). 
 Scheel A, Beijers AJM, Mols F, Faber CG, Vreugdenhil G. Chemotherapy-induced 
peripheral neuropathy; impact on quality of life. Nederlands tijdschrift voor geneeskunde. 
2014;158:A7455. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            412 
 Schemmel KE, Padiyara RS, D'Souza JJ. Aldose reductase inhibitors in the treatment of 
diabetic peripheral neuropathy: a review. Journal of diabetes and its complications. 
2010;24(5):354-60. 
 Schloss J, Colosimo M, Vitetta L. Herbal medicines and chemotherapy induced 
peripheral neuropathy (CIPN): A critical literature review. Critical reviews in food science and 
nutrition. 2017;57(6):1107-18. 
 Schloss J, Colosimo M. B Vitamin Complex and Chemotherapy-Induced Peripheral 
Neuropathy. Current oncology reports. 2017;19(12):76. 
 Schloss JM, Colosimo M, Airey C, Masci PP, Linnane AW, Vitetta L. Nutraceuticals and 
chemotherapy induced peripheral neuropathy (CIPN): a systematic review. Clinical nutrition 
(Edinburgh, Scotland). 2013;32(6):888-93. 
 Schneider BP, Hershman DL, Loprinzi C. Symptoms: Chemotherapy-Induced Peripheral 
Neuropathy. Advances in experimental medicine and biology. 2015;862:77-87. 
 Schuler U, Heller S. Chemotherapy-induced peripheral neuropathy and neuropathic pain. 
Schmerz (Berlin, Germany). 2017;31(4):413-25. 
 Sedel F, Barnerias C, Dubourg O, Desguerres I, Lyon-Caen O, Saudubray J-M. 
Peripheral neuropathy and inborn errors of metabolism in adults. Journal of inherited metabolic 
disease. 2007;30(5):642-53. 
 Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, 
prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review 
and meta-analysis. Pain. 2014;155(12):2461-70. 
 Sessions J, Nickerson DS. Biologic Basis of Nerve Decompression Surgery for Focal 
Entrapments in Diabetic Peripheral Neuropathy. Journal of diabetes science and technology. 
2014;8(2):412-8. 
 Shabeeb D, Najafi M, Hasanzadeh G, Hadian MR, Musa AE, Shirazi A. 
Electrophysiological measurements of diabetic peripheral neuropathy: A systematic review. 
Diabetes & metabolic syndrome. 2018;12(4):591-600. 
 Shen H, Zhao J, Liu Y, Sun G. Interactions between and Shared Molecular Mechanisms 
of Diabetic Peripheral Neuropathy and Obstructive Sleep Apnea in Type 2 Diabetes Patients. 
Journal of diabetes research. 2018;2018:3458615. 
 Silberman J, Lonial S. Review of peripheral neuropathy in plasma cell disorders. 
Hematological oncology. 2008;26(2):55-65. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            413 
 Singh R, Kishore L, Kaur N. Diabetic peripheral neuropathy: current perspective and 
future directions. Pharmacological research. 2014;80:21-35. 
 Smith B, Galbiati F, Castelvetri LC, Givogri MI, Lopez-Rosas A, Bongarzone ER. 
Peripheral neuropathy in the Twitcher mouse involves the activation of axonal caspase 3. ASN 
neuro. 2011;3(4). 
 Smith EML, Beck SL, Cohen J. The total neuropathy score: a tool for measuring 
chemotherapy-induced peripheral neuropathy. Oncology nursing forum. 2008;35(1):96-102. 
 Smith RG. Painful diabetic peripheral neuropathy. Journal of the American Podiatric 
Medical Association. 2007;97(5):394-401. 
 Smith SC, Lamping DL, Maclaine GDH. Measuring health-related quality of life in 
diabetic peripheral neuropathy: a systematic review. Diabetes research and clinical practice. 
2012;96(3):261-70. 
 Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Mehta S, Botteman M. 
Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral 
neuropathy. Pain practice : the official journal of World Institute of Pain. 2014;14(2):167-84. 
 Snyder MJ, Gibbs LM, Lindsay TJ. Treating Painful Diabetic Peripheral Neuropathy: An 
Update. American family physician. 2016;94(3):227-34. 
 Sommer C, Lauria G. Skin biopsy in the management of peripheral neuropathy. The 
Lancet Neurology. 2007;6(7):632-42. 
 Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral 
neuropathy: A current review. Annals of neurology. 2017;81(6):772-81. 
 Staff NP, Windebank AJ. Peripheral neuropathy due to vitamin deficiency, toxins, and 
medications. Continuum (Minneapolis, Minn). 2014;20(5 Peripheral Nervous System 
Disorders):1293-306. 
 Staff PO. Correction: manual acupuncture for treatment of diabetic peripheral 
neuropathy: a systematic review of randomized controlled trials. PloS one. 2014;9(3):e91110. 
 Stagg NJ, Shen B-Q, Brunstein F, Li C, Kamath AV, Zhong F, et al. Peripheral 
neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and 
perspectives in translatability from nonclinical toxicology studies to the clinic. Regulatory 
toxicology and pharmacology : RTP. 2016;82:1-13. 
 Stalberg E. Between genetics and biology. Is ENMG useful in peripheral neuropathy 
diagnosis and management? Revue neurologique. 2016;172(10):627-31. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            414 
 Starobova H, Vetter I. Pathophysiology of Chemotherapy-Induced Peripheral 
Neuropathy. Frontiers in molecular neuroscience. 2017;10:174. 
 Stavros K, Simpson DM. Understanding the etiology and management of HIV-associated 
peripheral neuropathy. Current HIV/AIDS reports. 2014;11(3):195-201. 
 Stillman M, Cata JP. Management of chemotherapy-induced peripheral neuropathy. 
Current pain and headache reports. 2006;10(4):279-87. 
 Stino AM, Smith AG. Peripheral neuropathy in prediabetes and the metabolic syndrome. 
Journal of diabetes investigation. 2017;8(5):646-55. 
 Storkebaum E. Peripheral neuropathy via mutant tRNA synthetases: Inhibition of protein 
translation provides a possible explanation. BioEssays : news and reviews in molecular, cellular 
and developmental biology. 2016;38(9):818-29. 
 Streckmann F, Zopf EM, Lehmann HC, May K, Rizza J, Zimmer P, et al. Exercise 
intervention studies in patients with peripheral neuropathy: a systematic review. Sports medicine 
(Auckland, NZ). 2014;44(9):1289-304. 
 Strong AL, Agarwal S, Cederna PS, Levi B. Peripheral Neuropathy and Nerve 
Compression Syndromes in Burns. Clinics in plastic surgery. 2017;44(4):793-803. 
 Stubblefield MD, McNeely ML, Alfano CM, Mayer DK. A prospective surveillance 
model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral 
neuropathy. Cancer. 2012;118(8 Suppl):2250-60. 
 Sun L-Q, Liang X-C. Study on nitric oxide in diabetic peripheral neuropathy and 
traditional Chinese medicine intervention in it. Zhongguo Zhong xi yi jie he za zhi Zhongguo 
Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine. 
2009;29(2):187-90. 
 Suzuki M. Peripheral neuropathy in the elderly. Handbook of clinical neurology. 
2013;115:803-13. 
 Swaminathan A, du Cros P, Seddon JA, Mirgayosieva S, Asladdin R, Dusmatova Z. 
Peripheral neuropathy in a diabetic child treated with linezolid for multidrug-resistant 
tuberculosis: a case report and review of the literature. BMC infectious diseases. 2017;17(1):417. 
 Taguchi K. Role of Transient Receptor Potential Channels in Paclitaxel- and Oxaliplatin-
induced Peripheral Neuropathy. Yakugaku zasshi : Journal of the Pharmaceutical Society of 
Japan. 2016;136(2):287-96. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            415 
 Tanay MAL, Armes J, Ream E. The experience of chemotherapy-induced peripheral 
neuropathy in adult cancer patients: a qualitative thematic synthesis. European journal of cancer 
care. 2017;26(5). 
 Ten Hoope W, Looije M, Lirk P. Regional anesthesia in diabetic peripheral neuropathy. 
Current opinion in anaesthesiology. 2017;30(5):627-31. 
 Teoh D, Smith TJ, Song M, Spirtos NM. Care After Chemotherapy: Peripheral 
Neuropathy, Cannabis for Symptom Control, and Mindfulness. American Society of Clinical 
Oncology educational book American Society of Clinical Oncology Annual Meeting. 
2018;38:469-79. 
 Tesfaye S, Selvarajah D, Gandhi R, Greig M, Shillo P, Fang F, et al. Diabetic peripheral 
neuropathy may not be as its name suggests: evidence from magnetic resonance imaging. Pain. 
2016;157 Suppl 1:S72-80. 
 Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management 
of diabetic peripheral neuropathy. Diabetes/metabolism research and reviews. 2012;28 Suppl 
1:8-14. 
 Tesfaye S, Selvarajah D. The Eurodiab study: what has this taught us about diabetic 
peripheral neuropathy? Current diabetes reports. 2009;9(6):432-4. 
 Tesfaye S. Advances in the management of diabetic peripheral neuropathy. Current 
opinion in supportive and palliative care. 2009;3(2):136-43. 
 Tofthagen C, McAllister RD, Visovsky C. Peripheral neuropathy caused by Paclitaxel 
and docetaxel: an evaluation and comparison of symptoms. Journal of the advanced practitioner 
in oncology. 2013;4(4):204-15. 
 Tofthagen C, Visovsky C, Berry DL. Strength and balance training for adults with 
peripheral neuropathy and high risk of fall: current evidence and implications for future research. 
Oncology nursing forum. 2012;39(5):E416-24. 
 Trivedi JR, Silvestri NJ, Wolfe GI. Treatment of painful peripheral neuropathy. 
Neurologic clinics. 2013;31(2):377-403. 
 Trivedi S, Pandit A, Ganguly G, Das SK. Epidemiology of Peripheral Neuropathy: An 
Indian Perspective. Annals of Indian Academy of Neurology. 2017;20(3):173-84. 
 Truman RW, Ebenezer GJ, Pena MT, Sharma R, Balamayooran G, Gillingwater TH, et 
al. The armadillo as a model for peripheral neuropathy in leprosy. ILAR journal. 
2014;54(3):304-14. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            416 
 Tu Y, Lineaweaver WC, Chen Z, Hu J, Mullins F, Zhang F. Surgical Decompression in 
the Treatment of Diabetic Peripheral Neuropathy: A Systematic Review and Meta-analysis. 
Journal of reconstructive microsurgery. 2017;33(3):151-7. 
 Tu Y, Lineaweaver WC, Zheng X, Chen Z, Mullins F, Zhang F. Burn-related peripheral 
neuropathy: A systematic review. Burns : journal of the International Society for Burn Injuries. 
2017;43(4):693-9. 
 van de Velde ME, Kaspers GL, Abbink FCH, Wilhelm AJ, Ket JCF, van den Berg MH. 
Vincristine-induced peripheral neuropathy in children with cancer: A systematic review. Critical 
reviews in oncology/hematology. 2017;114:114-30. 
 van Nooten F, Treur M, Pantiri K, Stoker M, Charokopou M. Capsaicin 8% Patch Versus 
Oral Neuropathic Pain Medications for the Treatment of Painful Diabetic Peripheral Neuropathy: 
A Systematic Literature Review and Network Meta-analysis. Clinical therapeutics. 
2017;39(4):787-803.e18. 
 Vas PRJ, Edmonds ME. Early recognition of diabetic peripheral neuropathy and the need 
for one-stop microvascular assessment. The lancet Diabetes & endocrinology. 2016;4(9):723-5. 
 Vavra MW, Rubin DI. The peripheral neuropathy evaluation in an office-based 
neurology setting. Seminars in neurology. 2011;31(1):102-14. 
 Velasco R, Bruna J. Chemotherapy-induced peripheral neuropathy: an unresolved issue. 
Neurologia (Barcelona, Spain). 2010;25(2):116-31. 
 Verhulst ALJ, Savelberg HHCM, Vreugdenhil G, Mischi M, Schep G. Whole-Body 
Vibration as a Modality for the Rehabilitation of Peripheral Neuropathies: Implications for 
Cancer Survivors Suffering from Chemotherapy-Induced Peripheral Neuropathy. Oncology 
reviews. 2015;9(1):263. 
 Vilholm OJ, Christensen AA, Zedan AH, Itani M. Drug-induced peripheral neuropathy. 
Basic & clinical pharmacology & toxicology. 2014;115(2):185-92. 
 Visovsky C, Collins M, Abbott L, Aschenbrenner J, Hart C. Putting evidence into 
practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clinical 
journal of oncology nursing. 2007;11(6):901-13. 
 Visovsky C, Haas M, Faiman B, Kurtin S, Shaftic AM, Lyden E, et al. Nurse self-
evaluation of assessment of chemotherapy-induced peripheral neuropathy in patients with 
cancer. Journal of the advanced practitioner in oncology. 2012;3(5):319-25. 
 Visovsky C, Meyer RR, Roller J, Poppas M. Evaluation and management of peripheral 
neuropathy in diabetic patients with cancer. Clinical journal of oncology nursing. 
2008;12(2):243-7. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            417 
 Visovsky C. Acupuncture for the management of chemotherapy-induced peripheral 
neuropathy. Journal of the advanced practitioner in oncology. 2012;3(3):178-81. 
 Visovsky C. Challenges in the conduct of research: chemotherapy-induced peripheral 
neuropathy. Journal of the advanced practitioner in oncology. 2013;4(5):369-71. 
 Vital A, Lepreux S, Vital C. Peripheral neuropathy and parkinsonism: a large clinical and 
pathogenic spectrum. Journal of the peripheral nervous system : JPNS. 2014;19(4):333-42. 
 Waldfogel JM, Nesbit SA, Dy SM, Sharma R, Zhang A, Wilson LM, et al. 
Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: A systematic 
review. Neurology. 2017;88(20):1958-67. 
 Walton DM, Minton SD, Cook AD. The potential of transdermal nitric oxide treatment 
for diabetic peripheral neuropathy and diabetic foot ulcers. Diabetes & metabolic syndrome. 
2018. 
 Wampler MA, Hamolsky D, Hamel K, Melisko M, Topp KS. Case report: painful 
peripheral neuropathy following treatment with docetaxel for breast cancer. Clinical journal of 
oncology nursing. 2005;9(2):189-93. 
 Wang EF, Misra SL, Patel DV. In Vivo Confocal Microscopy of the Human Cornea in 
the Assessment of Peripheral Neuropathy and Systemic Diseases. BioMed research international. 
2015;2015:951081. 
 Wang F, Zhang J, Yu J, Liu S, Zhang R, Ma X, et al. Diagnostic Accuracy of 
Monofilament Tests for Detecting Diabetic Peripheral Neuropathy: A Systematic Review and 
Meta-Analysis. Journal of diabetes research. 2017;2017:8787261. 
 Wang J-F, Wang H-T, Liu Z-G. A research advance on bortezomib-induced peripheral 
neuropathy. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 2012;33(2):157-9. 
 Wang X, Lin H, Xu S, Jin Y, Zhang R. Alpha lipoic acid combined with epalrestat: a 
therapeutic option for patients with diabetic peripheral neuropathy. Drug design, development 
and therapy. 2018;12:2827-40. 
 Wang X-M, Lehky TJ, Brell JM, Dorsey SG. Discovering cytokines as targets for 
chemotherapy-induced painful peripheral neuropathy. Cytokine. 2012;59(1):3-9. 
 Waseem M, Kaushik P, Tabassum H, Parvez S. Role of Mitochondrial Mechanism in 
Chemotherapy-Induced Peripheral Neuropathy. Current drug metabolism. 2018;19(1):47-54. 
 Watson JC, Dyck PJB. Peripheral Neuropathy: A Practical Approach to Diagnosis and 
Symptom Management. Mayo Clinic proceedings. 2015;90(7):940-51. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            418 
 Weimer LH, Sachdev N. Update on medication-induced peripheral neuropathy. Current 
neurology and neuroscience reports. 2009;9(1):69-75. 
 What role for capsaicin in diabetic peripheral neuropathy? Drug and therapeutics bulletin. 
2016;54(8):90-3. 
 White CM, van Doorn PA, Garssen MPJ, Stockley RC. Interventions for fatigue in 
peripheral neuropathy. The Cochrane database of systematic reviews. 2014(12):CD008146. 
 Wickham R. Chemotherapy-induced peripheral neuropathy: a review and implications for 
oncology nursing practice. Clinical journal of oncology nursing. 2007;11(3):361-76. 
 Wickham R. Review of a study of duloxetine for painful chemotherapy-induced 
peripheral neuropathy. Journal of the advanced practitioner in oncology. 2013;4(5):361-8. 
 Wilkes G. Peripheral neuropathy related to chemotherapy. Seminars in oncology nursing. 
2007;23(3):162-73. 
 Willits I, Cole H, Jones R, Dimmock P, Arber M, Craig J, et al. ViibraTip for Testing 
Vibration Perception to Detect Diabetic Peripheral Neuropathy: A NICE Medical Technology 
Guidance. Applied health economics and health policy. 2015;13(4):315-24. 
 Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced 
peripheral neuropathy: prevention and treatment strategies. European journal of cancer (Oxford, 
England : 1990). 2008;44(11):1507-15. 
 Wolff RF, Bala MM, Westwood M, Kessels AG, Kleijnen J. 5% lidocaine medicated 
plaster in painful diabetic peripheral neuropathy (DPN): a systematic review. Swiss medical 
weekly. 2010;140(21-22):297-306. 
 Won JC, Kim SS, Ko KS, Cha B-Y. Current status of diabetic peripheral neuropathy in 
Korea: report of a hospital-based study of type 2 diabetic patients in Korea by the diabetic 
neuropathy study group of the korean diabetes association. Diabetes & metabolism journal. 
2014;38(1):25-31. 
 Won JC, Park TS. Recent Advances in Diagnostic Strategies for Diabetic Peripheral 
Neuropathy. Endocrinology and metabolism (Seoul, Korea). 2016;31(2):230-8. 
 Won SY, Choi B-O, Chung KW, Lee JE. Zebrafish is a central model to dissect the 
peripheral neuropathy. Genes & genomics. 2019. 
 Wooten K. Clinical features and electrodiagnosis of diabetic peripheral neuropathy in the 
dysvascular patient. Physical medicine and rehabilitation clinics of North America. 
2009;20(4):657-76. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            419 
 Wormser GP, Strle F, Shapiro ED, Dattwyler RJ, Auwaerter PG. A critical appraisal of 
the mild axonal peripheral neuropathy of late neurologic Lyme disease. Diagnostic microbiology 
and infectious disease. 2017;87(2):163-7. 
 Wu B-Y, Liu C-T, Su Y-L, Chen S-Y, Chen Y-H, Tsai M-Y. A review of complementary 
therapies with medicinal plants for chemotherapy-induced peripheral neuropathy. 
Complementary therapies in medicine. 2019;42:226-32. 
 Wu J, Zhang X, Zhang B. Efficacy and safety of puerarin injection in treatment of 
diabetic peripheral neuropathy: a systematic review and meta-analysis of randomized controlled 
trials. Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan. 2014;34(4):401-
10. 
 Wu Q, Liang X. Survey of current studies of effects of traditional Chinese medicine on 
nerve growth factor and diabetic peripheral neuropathy. Zhongguo Zhong yao za zhi = Zhongguo 
zhongyao zazhi = China journal of Chinese materia medica. 2010;35(14):1896-9. 
 Wu Q-L, Liang X-C. Survey of current experimental studies of effects of traditional 
Chinese compound recipe on diabetic peripheral neuropathy. Zhongguo Zhong yao za zhi = 
Zhongguo zhongyao zazhi = China journal of Chinese materia medica. 2007;32(9):775-8. 
 Xie B, Wang Q, Zhou C, Wu J, Xu D. Efficacy and Safety of the Injection of the 
Traditional Chinese Medicine Puerarin for the Treatment of Diabetic Peripheral Neuropathy: A 
Systematic Review and Meta-Analysis of 53 Randomized Controlled Trials. Evidence-based 
complementary and alternative medicine : eCAM. 2018;2018:2834650. 
 Xu H-B, Jiang R-H, Chen X-Z, Li L. Chinese herbal medicine in treatment of diabetic 
peripheral neuropathy: a systematic review and meta-analysis. Journal of ethnopharmacology. 
2012;143(2):701-8. 
 Xu Q, Pan J, Yu J, Liu X, Liu L, Zuo X, et al. Meta-analysis of methylcobalamin alone 
and in combination with lipoic acid in patients with diabetic peripheral neuropathy. Diabetes 
research and clinical practice. 2013;101(2):99-105. 
 Xu W-R, Hua B-J. Progress on the treatment of chemotherapy-induced peripheral 
neuropathy by Chinese and Western medicine. Zhongguo Zhong xi yi jie he za zhi Zhongguo 
Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine. 
2008;28(11):1049-52. 
 Yagihashi S. Early diagnosis of peripheral neuropathy in patients with impaired glucose 
tolerance (IGT). Nihon rinsho Japanese journal of clinical medicine. 2005;63 Suppl 6:640-6. 
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
                                      
Chapter 8 - References and Bibliography                                                                                                            420 
 Yang D, Liang X-C. Strategies and Research Progress of Chinese Medicine in Prevention 
and Treatment of Diabetic Peripheral Neuropathy. Chinese journal of integrative medicine. 
2018;24(10):794-800. 
 Yorek MA. Is Fish Oil a Potential Treatment for Diabetic Peripheral Neuropathy? 
Current diabetes reviews. 2018;14(4):339-49. 
 Yorek MA. Vascular Impairment of Epineurial Arterioles of the Sciatic Nerve: 
Implications for Diabetic Peripheral Neuropathy. The review of diabetic studies : RDS. 
2015;12(1-2):13-28. 
 Yu S, Chen Y, Hou X, Xu D, Che K, Li C, et al. Serum Uric Acid Levels and Diabetic 
Peripheral Neuropathy in Type 2 Diabetes: a Systematic Review and Meta-analysis. Molecular 
neurobiology. 2016;53(2):1045-51. 
 Zajaczkowska R, Kocot-Kepska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. 
Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. International journal of 
molecular sciences. 2019;20(6). 
 Zhang Q, Liang X-C. Effects of Mitochondrial Dysfunction via AMPK/PGC-1 alpha 
Signal Pathway on Pathogenic Mechanism of Diabetic Peripheral Neuropathy and the Protective 
Effects of Chinese Medicine. Chinese journal of integrative medicine. 2019;25(5):386-94. 
 Zhao B, Zhao H, Zhao J. Incidence and clinical parameters associated with eribulin 
mesylate-induced peripheral neuropathy. Critical reviews in oncology/hematology. 
2018;128:110-7. 
 Zhao H, Yuan Y, Li Y, Si C-W, Tian G-S, Wang G-Q, et al. Encephalic large arteries 
narrowness and peripheral neuropathy in a patient with adult-onset Still's disease. Rheumatology 
international. 2008;28(12):1261-4. 
 Zheng C, Ou W, Shen H, Zhou Z, Wang J. Combined therapy of diabetic peripheral 
neuropathy with breviscapine and mecobalamin: a systematic review and a meta-analysis of 
Chinese studies. BioMed research international. 2015;2015:680756. 
 Zis P, Grunewald RA, Chaudhuri RK, Hadjivassiliou M. Peripheral neuropathy in 
idiopathic Parkinson's disease: A systematic review. Journal of the neurological sciences. 
2017;378:204-9. 
 Zivkovic SA. Rituximab in the treatment of peripheral neuropathy associated with 
monoclonal gammopathy. Expert review of neurotherapeutics. 2006;6(9):1267-74. 
 Zou L, Gong Y, Liu S, Liang S. Natural compounds acting at P2 receptors alleviate 
peripheral neuropathy. Brain research bulletin. 2018.
Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
Acknowledgements and Author Bio                                                                                                                      421 
ACKNOWLEDGEMENTS 
I appreciate the helpful comments provided over the course of this study by Drs. Alan Porter, 
Gus Buchtel, Loet Leydesdorff, and Mr. Michael Briggs. 
 
 
ABOUT THE AUTHOR 
Ronald Neil Kostoff received a Ph. D. in Aerospace and Mechanical Sciences from Princeton 
University in 1967. He has worked for Bell Laboratories, Department of Energy, Office of Naval 
Research, and MITRE Corp. He invented the Wake Shield for producing high vacuum in low 
orbit, and used in manned space missions for research and development.  He has published over 
200 peer-reviewed articles, served as Guest Editor of four journal Special Issues since 1994, 
obtained two text mining system patents, and currently is a Research Affiliate at Georgia 
Institute of Technology.  
 
He has published on numerous medical topics in the peer-reviewed literature, including: 
 potential treatments for  
o Multiple Sclerosis,  
o Parkinson's Disease,  
o Raynaud's Phenomenon,  
o Cataracts,  
o SARS,  
o Vitreous Restoration,  
o Alzheimer's Disease, and  
o Chronic Kidney Disease; 
 potential causes of Chronic Kidney Disease;  
 potential causes of Alzheimer's Disease;   
 potential impacts of Electromagnetic Fields on health; and  
 synergistic effects of toxic stimuli combinations 
 
His recent publications in toxicology have shown that regulatory exposure limits to toxic stimuli 
are, on average, orders of magnitude too high compared to exposures shown to cause damage in 
the biomedical literature, and are not protecting the public from harmful substances. 
 
He is listed in: 
 Who's Who in America, 60th Edition (2006), 
 Who's Who in Science and Engineering, 9th Edition (2006), and 




Prevention and Reversal of PN/PAD                                   Copyright © 2019                                   RN Kostoff 
 
Acknowledgements and Author Bio                                                                                                                      422 
 
